terms
heart failure ( class l - lll )
duration of hypertension , n ( % )
type nmbr diabetes 一 no . ( % )
tofacitinib nmbr mg bid [n = nmbr |
high - density lipoprotein cholesterol mean ( mg / dl ± sd )
temporary discontinuation of study drug
death , mi , idr , st , or any timi bleeding
race and ss at baseline
high intensity
prior percutaneous coronary intervention , n ( % )
pre - randomization pci
p , subgroup *
hosji fcrhypoglycemia
apixaban vs . placebo
medication use — no . ( % )
second prior mi
subarachnoid hemorrhage
total invasive cancer
acute stent thrombosis
alteplase ( n = nmbr )
relative decrease > nmbr %
nmbrth - nmbrth percentiles
number of ( % ) females
emphysema ( % )
argentina
ccq score § §
vents / patients
number of patients with
concomitant mtx —
europe / lsrael
thromboaspiration — no . ( % )
cardiac - biomarker status — no . / total no . ( % ) $
receiving insulin therapy
pulmonary embolism ± deep vein thrombosis
abdominal or perianal fistula at baseline , n ( % )
cyclosporine ( n = nmbr )
geographic region - europe
indian ( indian subcontinent )
percutaneous coronary intervention
antiplatelet or anticoagulant therapy
lesion length , mean ( sd ) , mm
non - q wave
continued thienopyridine n = nmbr subjects
weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ]
left ventricular ejection fraction , % af history
single - vessel disease , n ( % )
geographic region — no . ( % )
pad lower extremities
bmi > nmbr kg / mnmbr ( % )
total gadolinium - enhancing lesion count , no . ( % )
fatigue
nmbr to < nmbr kg / mnmbr
st - elevation mi
azathioprine ( n = nmbr )
serum uric acid ( mg / dl )
baseline mean ( sd ) , % [mmol / mol]
cv death , ml , or stroke
atenolol ( « = nmbr nmbr )
previous antiarrhythmic treatment — no . ( % )
drugs used in diabetes , n ( % )
after pci
secukinumab
mean a ± sem ( % )
ppi but no aspirin
nmbr mg / kg ( n = nmbr )
family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % )
trend / het . test
cv death + hf hospitalization
mepolizumab , nmbr mg ( n = nmbr )
medical therapy only ( n = nmbr )
caucasian ethnicity
crcl at baseline < nmbr ml / min
elevated hscrp > nmbr mg / l , n ( % )
seizure types reported during baseline , n ( % ) a
median total cholesterol , mmol / l
mean ± sd bmi , kg / mnmbr
first mace
disease duration nmbr to bnmbr years ( n = nmbr )
history of amputation — no . ( % )
lipid - lowering medication ( % )
previous hf hospitalization , n ( % )
mean lipid values , mg / dl
prior years taking warfarin
bnp , median ( iqr ) , pg / ml
hbanmbrca , % ( mmol / mol )
latin america hr ( nmbr % cl )
current atrial fibrillation or flutter on ecg
invasive
estimated glomerular filtration
pasi score ! * *
amiodarone , n ( % )
american indian or alaska
pooled simvastatin factorial studies
implantable cardioverter - defibrillator
varespladib ( n = nmbr )
acute coronary event
ntpro - cnp ( ng / ml )
useofmedical therapyathospitaldischarge
coenzyme qnmbr , ^g / ml #
dyspnoea - mmrc grade , n ( % )
triglycerides — mmol / liter
baseline ecrcl
cardiovascular history
with placebo ( n nmbr nmbr )
cardiovascular medications
after bronchodilation
mean nmbrmwd * , m ( sd )
angiotensin - converting enzyme inhibitors / angiotensin receptor blockers
medication taken alone or in combination
etoricoxib dose
ischemic cerebrovascular disease , n ( % )
bare metal stent , n ( % )
mean age ( years ) ( s . d . )
dasnmbr ( esr ) , mean ( sd )
absolute , litres
wml load at follow - up mri
clopidogrel ( n = nmbr , nmbr )
ancestry ( % ) f
no p - blocker intake at randomisation ( n = nmbr )
valsartan / hctz , n / n ( % )
> nmbr oral agents
total chol , mg / dl
calcium channel blockers , n ( % )
bsa > nmbr % , n ( % ) t
benralizumab nmbr mg qnmbrw ( n = nmbr )
blood pressure , mean ( sd ) [range] , mm hg
atenolol n = nmbr
type of mi ( % )
mtx + non - mtx
concomitant corticosteroid use , n ( % )
estimated glomerular filtration rate ( mdrd ) , ml / min / nmbr . nmbrmnmbr
mild impairment ( nmbr to < nmbr )
years since menopause
major cvd /
medical therapy ( n = nmbr )
no . of tnfi among non - tnfi naive
use of ace inhibitor
haemorrhagic
stroke ( vs tia )
detemir / insulin glargine , %
screening prebronchodilator fevnmbr , l
stent plus placebo
coronary revascularization nmbr days after randomization
sacubitril / valsartan
no . of prior bdmards
mean prebronchodilator fevnmbr ( sd ) , % predicted
paracetamol
aspirin / other antiplatelet agents , n ( % )
randomized to receive beta carotene
bsa , % *
erosion score
peripheral arterial disease , n ( % )
primary end point , no . of events / total no . ( % )
lvdd ( mm )
draining cutaneous fistula at baseline , n ( % )
tg < nmbr , hdl > nmbr ( n = nmbr )
comorbidities other than diabetes
toast classification of qualifying stroke
rasagiline , nmbr mg / day
metabolic syndromenmbr baseline lipids , mg / dl
crude analysis , n ( % )
bypass surgery
missing — number / n ( % )
cholesterol , ( . nmbr . nmbr mmol / l ) , n ( % )
right coronary
health habits
blood pressure
homa . % b , median ( ql , qnmbr ) , %
severity of copd , ( gold nmbr ) , %
prior myocardial infarction
both ptca and cabg
major cerebrovascular
hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )
diastolic blood pressure ( mm hg ) medications
iglar dose at randomization ( u / day )
prior cv event at randomization !
mean ± sd waist circumference , cm
risk of bleeding
cv medication , % of patients
total updrs score ( range , nmbr - nmbr ) 卞
atrial fibrillation , duration — no . ( % )
known duration of diabetes , yr
nmbr % < hbanmbrc < = nmbr %
dactylitis count
previous disease :
previous dmards use , n ( % )
gly nmbr . nmbr gg b . i . d n / n ( % )
previous percutaneous coronary intervention
unfractionated heparin before randomisation
oad plus insulin
diabetes with target organ disease *
unknown type
beta - blocker — no . ( % )
cognitive functioning
( % ) nmbr - nmbr
history of hyperlipidemia ( % )
evenls per nmbr , nmbr palienl - years
fasting free fatty acids ( ^mol / liter )
treatment after admission
rarertd antocagibtcn before andorrtzafon
intestinal area involved , n ( % ) $
ethnicity ( % )
all cardiovascular
smoking in the past year
diskus only , n
jsn score , mean nmbr sd
number omega - nmbr number placeb fatty acid
high - intensity statin vs medium - or low - intensity statin at randomization
score on nih stroke scale — median ( iqr )
initiation of insulin
nmbrnd > nmbr . nmbr / < nmbr . nmbr
cad and abi < nmbr - nmbr §
pioglitazone events / n ( % )
acecoumarol , no . ( % )
cigarette users
gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr )
bmi ( kg / mnmbr ) cardiac parameters
ace inhibitor or arb at last follow - up
blood urea nitrogen ( mg / dl )
grip strength ( kg )
current smoker — no . of patients ( % )
one - third radius
psychosocial risk factors
bursitis
non - hdl - c in nmbr classes
family history ol diabetes ?
age ( years ) : nmbr - < nmbr
digital clubbing , n ( % )
death or myocardial infarction
risk reduction , %
a mini - mental state examination , omega - nmbr fatty acids vs placebo
pain vas , nmbr - nmbr mm
smoking : ex - smoker
statin treatment
pre - bronchodilator fevnmbr / fvc ratio *
prior stroke or transient ischemic attack
czp nmbr mg ( n nmbr nmbr )
microvascular eye diseased
extent of disease , %
mean ( nmbr % ci ) difference vs saxa + dapa + met
urgent coronary revascularization
caucasian simva
full analysis set
serious ae
smoking history ( ever )
uncodable
no pah therapy
standard ( n = nmbr )
patent foramen ovale
laboratory values
years , mean ( sd )
hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr )
physician ' s judgment that vka
calcium - channel blocker ( ratelowering )
left ventricular hypertrophy ( % )
randomized to aspirin use
antihypertensive , antianginal , and other cardiovascular medications
glp - nmbr receptor agonist ( other than study drug )
primary renal endpoint or death
metabolic syndrome characteristics , n ( % )
mean duration of disease , years
other oral hypoglycemic drug ( s )
> nmbr additional cv risk factorsnmbr
pancolitis
death from any cause
high - density lipoprotein cholesterol , mg / l
diabetes mellitus status
fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % )
stool frequency subscore
psap - b ( ng / ml )
no use of nmbr - asa compounds
visit nmbr ldl cholesterol strata
endothelin nmbr ( pg / ml )
normal ( egfr > nmbr )
py = nmbr . nmbr )
fibrinogen
total haq , nmbr - nmbr
mean baseline ibdq score ( sd ) § crp concentration , mg / l
dipyridamole
aspirin and other antiplatelet
positive
age [years] ( interaction : p = nmbr . nmbr )
decreased appetite
beta - blocker ( except sotalol )
geometric mean crp concentration ( mg / l )
duration of morning
hr ( enl vs lcz ) ( nmbr % cl )
rf positive — number ( % )
selected medications — no . ( % )
no peripheral revascularization ( n = nmbr , nmbr )
white / european
at least nmbr flare
time to admission , min
octave sustain
lm bifurcation not treated
radial access
history of peripheral artery disease
baseline fev , ( l )
combined trials
negative
severe dysfunction
fasting c - peptide , ng / ml
aggressive ( n = nmbr )
aldosterone blocker , %
management of event — no . ( % )
> nmbrmg / dl chd status
serum albumin , g nmbr nmbr
intraperitoneal
headache
left main artery
> nmbr to < nmbr egfr , ml / min / nmbr . nmbr mnmbr a
established
gender ( % ) male / female
chondroitin sulfate ( n = nmbr )
unstable angina ( biomarker negative )
american indian or native alaskan
symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !
age ( years ) [median ( nmbrth to nmbrth percentile ) ]
formoterol nmbr gg bid
race or ethnic group ( % )
dihydropyridine
canakinumab
lev status , n ( % )
steroids § §
normal / mild ckd
number of stent = nmbr
previous medications , n ( % )
nyha class nmbr - nmbr : no { n = llll )
tofacitinib nmbr mg twice daily n = nmbr
verapamil sr n = nmbr no . ( % )
no prior ml or stroke
stent length per lesion , mm
chf history
anti - ccp antibody positive
oral medications
no antidiabetic drug
tofacitinib nmbr mg two times a day
no . of nmbr - mg acetaminophen tablets / day
acpa positive , %
timi major / minor
severity of airflow limitation ( gold nmbr - nmbr ) , n ( % )
pooled simva
timi risk score — no . ( % ) : t
baseline dyspnea index , mean total score
number ( % ) of patients with event
atrial fibrillation onset
infarct characteristics
caucasian simva ( „ = nmbr }
ticagrelor nmbr mg nmbr yr km %
galectin - nmbr ( ng / ml )
hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index , t tests for systolic and diastolic blood and ' / nmbr tests for categorical variables . t data were missing for some patients .
nmbr mg clopidogrel load
intravenous dobutamine
family history of diabetes — no . ( % )
primary prevention subgroup
telmisartan ( n = nmbr , nmbr )
ppi use ( p = nmbr - nmbrt )
large mi
never / rarely
medication adherence
no concomitant cortcosteroid use
severity of hypertensionb
clopidogrel , %
fevnmbr percent predicted ( sd )
antidiabetic medication | |
gad positive — no . ( % ) ^
intravenous vasodilators ( % )
european trial
systemic corticosteroid use
weight , median ( interquartile range ) , kg
indacaterol nmbr ug versus placebo
crohn ’ s disease related surgery
peripheral arterial disease — no . ( % ) §
mases ( nmbr - nmbr ) , mean ( sd )
duration of coronary artery disease — yr
hbanmbrc , mean ( sd ) , % [mmol / mol]
total cholesterol ( week nmbr )
at least nmbr severe flare
baseline / concomitant therapies
chd eze / simva ( n = nmbr]
heart failure criteria met
left atrial diameter
pulmonary function tests , % of predicted
other nsaids
rheumatic heart disease
coronary angiography and intervention
time of qualifying ecg to balloon inflation ( hrs )
time from symptoms to treatment
ratio fp / sal : sal ( nmbr % ci )
coexisting conditions — no . ( % )
clopidogrel , ticlopidine , or prasugrel
crp ( mg / dl ) < nmbr . nmbr
mean ± s . d . duration of diabetes , years
russia / georgia ( n = nmbr )
fatal and nonfatal ml
hypertension ( n 二 nmbr )
cv event , years
oxidative stress
age ( yrs ) < nmbr
no . of previous anti - tnf drugs — no . ( % )
< nmbr . nmbr mmol / liter apob : apoa - l ratio
former smoker , n ( % )
less than nmbr %
hispanic ( n = nmbr )
ischemic tvr
any albuminuria — no . ( % )
baseline ics use , n ( % )
bosentan ( n = nmbr )
nitrates ( oral or topical )
left - sided disease only
third heart sound , n ( % )
other antiarrhythmics^
psa duration , years
low molecular weight ( lmw ) heparin before randomisation
interval study drug to pci
atrial fibrillation / atrial flutter , %
anmbr + ez n = nmbr
initial aspirin — no . ( % )
symbol digit score
time from qualifying event to randomization
serum hdl cholesterol ( mmol / l ) , mean ( sd )
pav , mean ( nmbr % ci )
events treatment ( nmbr )
annt or bnnh ( nmbr % ci )
geographic region , %
drug - related teaesnmbr
atorvastatin dose
ldl - cihdl - c , mean ( sd )
prior biologic therapy ( including anti - tnfs )
left ventricular ejection fraction within previous nmbr mo |
cabg or pci
ace inhibitor monotherapy
treated with cabg — no . / total no . ( % )
psoriatic arthritis pain]
erythrocyte sedimentation rate — mm / hr | |
dose of aspirin
p - val . ( nmbr )
small - artery occlusion ( lacune )
atorvastatin , n ( % )
baseline heart rate
apo b ( mg / dl ) - mean ± sd
peak procedural act — sec
extended - duration enoxaparin , n / n ( % )
total stent length
triglycerides , median ( range )
efficacy
non - stemi
mri substudy ( n = nmbr )
lv mass index ( g / mnmbr - nmbr )
all with coenzyme qnmbr ( n = nmbr , nmbr )
serum total cholesterol , mmol / l ( sd )
visits nmbrenmbr
week nmbr ( itt population )
puerperium
gold group d — no . ( % ) | |
atv nmbr mg study protocol
aml / val nmbr / nmbr mg
median albumin / creatinine ratio ( g / mg )
smoking ( a )
tirofiban ( n = nmbr )
time from acs to randomization ( median , iqr )
smoking pack - years
serum creatinine > nmbr mmol / l , n ( % )
nonaspirin antiplatelet agent
use of concomitant lipid - modifying therapy
% stenosis , as assessed by investigator
parenteral anticoagulalion before randomization
lesions bnmbr / c
median fasting insulin ( iqr ) — pu per milliliter
death or stent thrombosis
measured at home with automated device
atenolol *
neuropilin ( ng / ml )
individuals with diabetes , n = nmbr
basal insulin analogue : insulin
mean pulse pressure , mmhg ( s . d . ) “
oral hypoglycemic drug
antihypertensive treatment
patients with > nmbr exacerbations resulting in hospital admission
ranolazine ( n = nmbr , nmbr )
final timi flow grade post - ppci
duration of disease , median
ace inhibitor or arb at enrollment
psoriasis duration , yrs *
nmbr to < nmbr . nmbr %
simvastatin monotherapy ( n = nmbr , nmbr * )
timi major bleeding
small - artery occlusion
left ventricular hypertrophy — no . ( % )
laboratory findings
crp , nmol / l , median ( range )
bivariate frailty model ( statin users vs non - users )
resection performed , %
liraglutide nmbr . nmbr mg ls means ( n )
ada ifg
median change , %
sita nmbr + pio nmbr
combined estimated gfr and albuminuria status
neoplasia
venous graft
mean age , y , median ( range )
body - mass index ( kg / mj ) previous diagnosis
antihyperglycemic
duration of ra ( time from symptom onset ) , years
grouped region
nitrate — no . ( % )
shs , mean nmbr sd
oral antidiabetes monotherapya , n ( % )
patients without ra , as , or psa ( n = nmbr , nmbr )
treatmentofpulmonary embolismpriorto randomization
renin - angiotensin inhibitors
fevnmbr , litres ( post - salbutamol ) , mean ( sd )
upper respiratory tract infection nmbr ( nmbr . nmbr )
age at diagnosis , y
change in mtss ( mean )
aliskiren ( n = nmbr )
number of exacerbations in last nmbr months ,
p , all vs all
fasting plasma insulin — mu / liter
baseline albumin / creatinine ratio in nmbr classes
cvd risk factors ( age > nmbr )
former smoker ( n = nmbr )
prior use of biologics , n ( % )
amlodipine nmbrmg / v = nmbr
moderate or less airflow limitation
ethnic group — no . ( % ) '
any event
pain in extremity
hospitalized for asthma , n ( % ) *
sex : male ( n = nmbr )
apolipoprotein b^
abnormal angiogram
three or more drugs
data missing
heart failure nyha ii - iii
cerebrovascular disease , n ( % )
western europe hr ( nmbr % cl )
biologic agents
ls mean difference ± seb
factor xa inhibitor
mean bmi , kg / mnmbr ( s . d . )
anti - ischaemia agents *
exposure
mycophenolate mofetil
age when diabetes first diagnosed — yr
randomization to placebo or telmisartan
aspirin nmbr clopidogrel
chd risk equivalents , n ( % )
systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr )
clinical history
ezetimibe + simvastatin ( n = nmbr * )
duration of psoriasis , years
procedures for index event
killip class at admission — no . / total no . ( % )
other lipid parameters
tc / hdl - c ratio
ct or mr scan of the brain *
peri - or postmenopausal
indeterminate or unknown
ratet ( nmbr % cl )
> nmbr % stenosis of coronary , carotid , or lower extremity arteries
atrial fibrillation / flutter , n ( % )
hypertension — no . ( % ) hypercholesterolemia — no . ( % )
pulmonary disease
region of enrollment , n ( % ) +
baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr
statin + ezetimibe , n ( % )
ldl - c ( calculated ) *
evaluable for acrnmbr at week nmbr , n
tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr
ez / simva n = nmbr n ( % )
event rates , %
baseline nmbr - h ppg ,
nontrial ppi
cardiac resynchronization therapy
nyha class iii or iv ( n = nmbr )
oral agents use
recurrent ischemia - urgent revascularization
rheumatoid factor positive § , n ( % )
serum pnmbrnp ( ^g / liter )
investigator - reported hypoglycaemia *
diuretic — no . / total no . ( % )
interleukin - nmbr ( ng / l )
non - caucasian eze / simva ( „ = nmbr }
median ( qnmbr : qnmbr ) tgs
indacaterol nmbr ug versus indacaterol nmbr ug
score of > nmbr . nmbr — %
weight , median ( nmbrth — nmbrth percentiles ) , kg
nmbr - nmbr ( n = nmbr , nmbr )
anti - cholinergics ( short - acting ) a
north america n z nmbr
diabetes durationa < median
discontinuations
available baseline blood specimen n
quicki
ratio of women to men — %
randomization to arterial sheath insertion
p value versus placebo
history of cardiac arrhythmia
n analysed
body mass , kg
mean cdai score
placebo plus aspirin
ii - iv ( % )
previous bowel resection performed — no . of patients ( % )
left anterior descending , n ( % )
postmenopausal hormone use
femoral neck
standard control ( n = nmbr ) no . of patients ( percent )
other asian
measurements
antithrombotic / coagulant
myocardial infarction within the previous nmbr yr
receiving concomitant nsaids and / or cox - nmbr inhibitors
b digit symbol substitution , omega - nmbr fatty acids vs placebo
post - bronchodilator ratio of fevnmbr to fvc — %
statin with niacin
neither glucocorticoids nor immunosuppressive agents
anti - inflammatory drugs
i & ii : fevnmbr > nmbr % predicted
interval clopidogrel to pci
procedure
electrophysiological study — no . ( % ) weight — ibj
montelukast ( n = nmbr )
nmbr - h pmg ( mg / dl )
phenytoin
enact - nmbr trial rerandomization to natalizumab ( n = nmbr )
nmbr bmi , kg / m
baseline ldl cholesterol
iglar ( insulin glargine lnmbr u )
llv wlalil nmbr statin
number of prior csdmards , n ( % )
efficacy and safety : net adverse clinical events *
glucocorticoids and immunosuppressants
heart disease risk factors
statin use at baseline
current smoker : ex - smoker ( % )
aspirin but no ppi
nsaid use — no . / total no . ( % )
dx at presentation , n ( % )
recent surgery or trauma
left anterior descending
ezetimibe nmbr mg + statin ( n = nmbr , nmbr )
coumadin
device group
glargine
safety population , n ( % )
pef , post - bronchodilator , % predicted normal
all randomized patients ( range )
permanent
tocilizumab
"nmbr = help needed ; still independent"
non - metsyn
hemoglobin , g nmbr nmbr
level of renal impairment
soe or sue
previous stroke ortransient ischaemic attack ( % )
clopidogrel / ticlopidine
selexipag
mi type unknown ( % )
crohn ' s disease
high - sensitivity crp — mg / liter | |
prior coronary revascularization
severe teaes
any statin + other llt
arb at last follow - up
ml without st - segment elevation !
hydralazine
multivessel pci
oral anticoagulant — no . / total no . ( % )
notable abnormalities
contrast nephropathy risk score
aspirin at last follow - up
physical component
indacaterol nmbr gg qd
elderly ( > nmbr years )
odds ratio versus placebo ( nmbr % ci )
geographic region - north america
all patients with fistulas ( n = nmbr )
fevnmbr / fvc ( post - albuterol )
prior medications
location of ml
use of hormone replacement therapy ( a )
versus tiotropium nmbr . nmbr pg
prior coronary revascularization , n ( % )
duration of infusion — hr
beta - blocker at last follow - up |
rentrop score
randomisation visit ( baseline )
gastrointestinal area involved — no . / total no . ( % )
baseline pulmonary medication , n ( % )
median serum periostin , ng / mla
multiple tnfi *
diet + pravastatin ( n = nmbr )
prior coronary artery bypass graft surgery
c - peptide , median ( ql , qnmbr ) , nmol / l
enoxaparin
vorapaxar placebo nmbr - yr %
missing data
"risk reduction ( % ; nmbr % ci )"
fastest third
gemfibrozil
chanmbrdsnmbr - vasc
ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr )
( nmbr % ci] nmbr
triglycerides mean ( mg / dl ± sd )
incidence rate
urinary albumin / creatinine ratio , median mg / g ( range )
minimum stent diameter
nt - probnp pg / mla ( iqr )
body mass index ( bmi ) , kg / mnmbr
diet plus pravastatin group ( n = nmbr )
duration of clopidogrel pretreatment 一 hr median
family history of coronary artery disease
sex , n ( % ) male
cv risk factor - no . ( % )
valvular disease ( % )
no corticosteroid + no imm , n
antimalarials only
tnl ultrapositive > nmbr . nmbr pg / l , nmbr = nmbr
dactylitis count ( nmbr - nmbr ) , mean ( sd )
nasal polyps
verapamil sr n = nmbr
continued thienopyridine n ( % )
disease - progression composite outcome !
egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr , n ( % )
diarrhea
uric acid ( mg / dl )
pasi score , mean ± sd
theophylline compound
heterogeneity / trend test
disease
hispanic / latin american
isolated pulmonary embolism
"middle tertile ( range , nmbr . nmbr - nmbr . nmbr mg / dl ; mean ± sd , nmbr . nmbr ± nmbr . nmbr mg / dl )"
total cholesterol ( mg / dl ) , mean + sd , available for nmbr patients
geometric mean of baseline
baseline fvc , l
csf nmbrs - hydroxy -
mean annualized exacerbation rate
placebo no . / total ( % )
not reported / unknown
prior therapy with tnf antagonist , n ( % )
difference from baselinea
age at randomization ( years )
never used lev
single vessel coronary artery disease *
non - sulfonylurea secretagogues
index event asymptomatic or unconfirmed
baseline medical therapy
prior corticosteroid failure only
one or more blood pressure medications , n ( % )
evomab ( n = nmbr )
baseline post - bronchodilator % predicted fev , < nmbr %
cardiovascular hospitalization
crohn ' s disease activity index score]
prior use of biologic agents
relative risk reduction ( nmbr % cl )
hbanmbrc distribution
diuretic agent
patients treated with insulin
estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |
nmbr - aminosalicylic compounds — no . ( % )
iwqol - lite physical score ( arbitrary units )
bdi total score ( baseline )
estimated * creatinine clearance < nmbr mlvmin , %
low - density lipoprotein cholesterol , %
education , high school or higher
partial mayo clinic scored
prior lipid - modifying therapy
cv risk factor
mets w / o tnmbrdm
other countries
smoking history — no . ( % )
other vascular disease — no . ( % )
mean — g / dl
outcome
ccbs , ( % )
sfc nmbr / nmbr | ig bid n = nmbr
cangrelor , %
losartan n = nmbr
laba + ics
short - acting anticholinergics
> nmbr vessels with > nmbr % stenosis
concomitant antihyperglycaemic drugs , n ( % )
losmapimod
history of myocardial infarction ( % )
nmbr - nmbr with cv disease ( n = nmbr )
severely impaired
estimated creatinine clearance < nmbr ml / min *
anticyclic citrullinated peptide positive^ , n ( % )
wrist fracture
mtx exposure ( mg / week )
ischaemic , n ( % )
atenolol n = nmbr no . ( % )
vascular disordersb
adjusted mean change from baseline ( nmbr % ci ) , % [mmol / mol]
< nmbr . nmbr mmol / liter triglyceride level
previous myocardial infarction — no . ( % )
time since diagnosis of diabetesa , n ( % )
fevnmbr / fvc , % , mean ( sd ) nmbr
> nmbr . nmbrmmol / l ( n = nmbr )
serum albumin , g / dl
classification of af , no . ( % )
age at screening
change in sbp ( nmbr months )
bronchitis
left ventricular ef , mean ( sd ) , %
pdenmbr inhibitor monotherapy
ischemic heart disease , %
neither pbo + statin eze + statin
impaired fasting glucose level ( n = nmbr )
cancer ( n = nmbr )
selected clinical characteristics , n ( % )
lumbar spine
reversibility of fevnmbr ( % )
missing data — no . / total no . ( % )
insulin ( pmol / l ) t vital signs
glucose - lowering therapies
baseline heart failure severity nyha class i
selected baseline medications
endovascular — no . ( % )
aspirin - erdp ( n = nmbr , nmbr )
previous treatment with tnf antagonist — no . ( % ) §
zotarolimus - eluting
change in nt - probnp at nmbr months ( log - transformed )
low - molecular - weight
heart rate ( b . p . m . ) , mean ± sd
vorapaxar group ( n = nmbr )
glucose test
number of concomitant aeds , n ( % )
mean number of exacerbations ( per patient - year [nmbr % ci] )
use nmbr - asa compounds
glycemic drugs
balloon angioplasty — no . ( % )
prior history of cardiovascular disease , n ( % )
accp bleeding risk at inclusion , no . ( % ) f
angina pectoris — no . ( % )
history of systemic hypertension
angiography — no . ( % )
prasugrel
cardiovascular disease
prior congestive heart failure
post - bronchodilator reversibility fevnmbr ( % ) mean ( sd )
diabetes therapy , n ( % )
low - dose aspirin use at baseline yes
medication at enrollment — no . ( % )
age , yrs , median ( nmbrth , nmbrth )
no . of predictors of cardiovascular risk
mean ( s . d . ) free pcsknmbr , ng / ml
enrollment in lmwh
coronary angiography during the index hospital stay
primary pci ( n = nmbr )
versus tiotropium + olodaterol nmbr . nmbr / nmbr pg
long - acting or short - acting nitrates
cardiovascular and respiratory
hispanic ethnic group — no . ( % ) f
placebo , n ( rate )
calcium antagonists , n ( % )
egfr , ml / min / mnmbr
lipid lowering medication use
opg , ( ng / ml )
final timi flow
patient ' s global assessment of disease activity , mean ( sd )
with revascularisation
antihypertensive medication or
level nmbr immobility § | |
serum creatinine , limo nmbr nmbr
central / eastern europe / russia
role physical
hbanmbrc category , n ( % )
not reported in ecrf
beta - blockers ( all ) , n ( % )
laba users
creatinine clearance at admission ( ml / min )
egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )
other anticoagulant
severe impairment ( < nmbr )
pre - bronchodilator fevnmbr ( % predicted normal )
insulin + oad
clopidogrel ( n = nmbr )
first - generation stentt
crp , mg / l : median ( range )
least square mean ( se )
preoperative heart rate ( beats per minute )
angiography during index hospitalization
allhat - llt
prior cardiovascular event — no . ( % ) - j -
baseline killip class
score on modified rankin scale — no . ( % ) §
energy / fatigue
atrial flutter
subjects randomized
active a
rec . ischemia leading to hasp
history of cabg surgery , n ( % )
western europe and other
qualifying mi type
potassium - sparing at last follow - up
congestive heart failure , n ( % )
score distribution : < nmbr
candesartan nmbr / nmbr
planned treatment strategy
/ ’ - valuenmbr ’
parental history of myocardial infarction before nmbr yr of age ( % )
hbanmbrc distribution at baseline , n ( % )
change in haq - di ( mean ) t
normoalbuminuria at baseline ( nmbr % of patients treated )
previous deep - vein thrombosis or pulmonary embolism
placebo mean ( n )
previous coronary revascularization — no . ( % )
medical history and risk factors — no . ( % )
rankin grade
previous heart failure
ptca or pci
inflammatory disease
exacerbations
statin ( open )
glyburide ( n = nmbr )
history of cardiovascular disease — no . ( % ) ^ |
heart failure — no . ( % )
normoglycemicnmbr
fevi , % predicted , mean ( sd ) nmbr
cardiac failure , n ( % )
previous vascular disease
ethnic origin , n ( % )
abatacept monotherapy ( n = nmbr )
calcium channel antagonists , n ( % )
high potencyc
ra symptom duration — year
previous myocardial infarction ( % )
post - bronchodilator fvc ( l ) a
moderate risk
< nmbr . nmbr mm hg diastolic blood pressure
nmbr mg cohort
exercise times per week , ( minimum
other ( nmbr . nmbr % ) t
medical conditions , no . ( % )
smoking status at screening , n ( % )
low - dose rivaroxaban + aspirin ( n / n )
revascularization
hoehn and yahr stage ( range , nmbr - nmbr )
blood leukocyte count ( nmbr cells per l )
low risk and fewer symptoms ( group a )
alt and / or ast > nmbr times uln consecutive #
nmbr yr km % ( n )
history of symptomatic
time of symptom onset to balloon inflation ( hrs )
statin potency stratum , n ( % )
no dysglycaemia or mets
weight $ nmbr . nmbr kg , < nmbr . nmbr kg , n
race or ethnic group
moderate impairment ( nmbr to < nmbr )
ascvd including tia
receiving concomitant corticosteroids
laba + ics ( free or fixed - dose combination )
fc - ldl - c , friedewald - calculated
egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % )
receptor blockers , n ( % ) baseline lipid and apolipoprotein levels
hyperkalemia ( > nmbr . nmbr meq / l )
region of enrollment , no . ( % )
mean score on haq - di §
medications at randomization
nmbr , nmbr / nmbr , nmbr ( nmbr . nmbr )
history of cardiovascular disease
> nmbr yr warfarin experience
intervention in complex lesions
peak creatine kinase - mb , u / l
secondary ( change in total updrs score from baseline to final visit in phase nmbr )
leflunomide ( mean dose : nmbr . nmbr mg / day )
antithrombotic agents , n ( % )
leisure
angiotensin receptor blocker and / or ace
type of treatment , n ( % )
pancreatic cancer
mean iglar dose ± sd ( u / day )
int . p *
hawaiian / pacific
aspirin at any dose
baseline fpg ,
crp ( mg / l ) : < nmbr
large - artery atherosclerosis
antihyperglycemic medication usage
carotid
western european includinq australia , israel , and south africa
low density lipoprotein cholesterol , mg / dl * *
blood eosinophil count ( nmbr cells per l )
egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd )
placebo n = nmbr subjects
treatment with candesartan
hbanmbrc nmbr - < = nmbr %
eze / simva nmbr / nmbr mg ( n = nmbr )
pulmonary rales
loop at last follow - up
modified rankin scale score
qualifying event — no . ( % )
claudication ( fontaine class > nmbr )
steroid use at baseline , n ( % )
metabolic syndrome ( > nmbr of nmbr characteristics )
killip class
respiratory medication ( % )
concomitant lipid - lowering therapy , n ( % )
duration of tnmbrdm
egfr , ml min nmbr nmbr . nmbr m nmbr
smoking status ( % )
bare - metal stent — no . ( % )
rate / nmbr patient - years
> nmbr servings / wk ( n = nmbr )
key secondary end point : st
no . of risk factors ( % ) | |
prior antihypertensive medication , n ( % )
mean yearly decline
standard therapy
phosphorus , mmol nmbr nmbr
lipid levels — mg / dl
smoking habit , n ( % )
open triple ( n = nmbr )
no prior hf hospitalization ( n = nmbr , nmbr )
glyburide
mean ( sd ) extent of exposure , days
triple therapy use at screening , n ( % )
europe nmbr ( n = nmbr )
ankle - brachial index < nmbr . nmbr — no . ( % )
number of subjects
fasting insulin
ace - i or arb use
pfo closure group ( n = nmbr )
median ( qnmbr : qnmbr ) duration of insulin use , years
control group ( n = nmbr )
normal troponin
ind / glynmbr / nmbr pg o . d . n = nmbr
traditional chinese medicine for respiratory disease — no . ( % )
baseline copd exacerbation history , * n ( % )
european union
blood pressure - lowering treatment
ezetimibe
fish oil
cardiovascular inclusion criteriat
median duration of study - drug administration
psoriasis body surface area > nmbr %
exenatide
cardiovascular risk factors — no . / total no . ( % )
( nmbr % ci ) p value
time from symptom onset to randomization
percentage difference ( nmbr % cl )
fpg ( mmol / l ) , mean ( sd ) 、
apo anmbr ( g / l )
fibrinolysis ( n = nmbr )
ticagrelor nmbr mg vs . placebo hr ( nmbr % ci )
combined n = nmbr
simplified disease activity index
ratio of ldl to hdl
st ( arc definite only )
duration of diabetes mellitus , y
sex , male / female , %
total study population ( n = nmbr , nmbr )
sita / pio nmbr / nmbr
blood eosinophils count
who / idf ifg
cardiovascular history 一 no . ( % )
ace inhibitor at last follow - up
prior cardiac surgery , n ( % )
ischemic aetiology , n ( % )
placebo nmbr year km ( % )
vorapaxar n = nmbr
postmenopausal , never or past hormone therapy use
difference vs placebo , % [nmbr % cl] , p
urinary albumin - to - creatinine ratio^
percent change
standard care ( n = nmbr )
cerebrovascular disorders , n ( % )
ace inhibitor — no . ( % )
location of treatment center
indacaterol nmbr ug ( n = nmbr )
history of peripheral arterial disease ( % )
creatinine , mean ( sd ) , mg / dl
sfnmbr - pcs
randomization groups nmbr and nmbr
presence of honeycombing , nmbr n ( % )
very severe n z nmbr
years since pah diagnosis
partial mayo score $ | |
rosuvastain + fenofibric acid nmbr = nmbr
severity n ( % )
history of hypercholesterolemia
> nmbr years education
angiographic complications , site - reported — no . / total no . ( % )
acute coronary syndrome nmbr
asastoppedat randomization , n
mean blood pressure , mmhg ( s . d . j
"baseline lipids ; mean ± sd ( mmol / l )"
philippines
active cancer at randomization , n ( % )
current ( , nmbr cigs / day )
aspirin and ppi
screening % reversibility fevnmbr
prior pci or cabg surgery
lower - limb arterial — no . ( % )
baseline disease and quality - of - life scores
index event , %
endoscopy subscore
intended clopidogrel dose nmbr mg
placebo + mtx
celecoxib ( n = nmbr )
oral hypoglycemic agent
death , mi , idr , or st
unacceptable adverse events
tolal choleslerol - lo - hdl choleslerol ralio
median ( days )
ldl particle size ( week nmbr )
gold nmbr groups
parameter
vascular intervention
anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr )
amlodipine / vaisartan ( n = nmbr )
ldl cholesterol — mg / dl | |
week nmbr ( geometric mean , cv )
triglycerides ( week nmbr ) a
cause of heart failure
copd or asthma
latin and north america
comorbid diseasesa diabetesb
cardiac rhythm
proactive intervention ( n = nmbra )
"nmbr = minor symptoms ; no limitations"
patients ' characteristics age ( years ) , mean + sd
history of hypercholesterolemia , n ( % )
acc / aha lesion class bnmbr or c , n ( % )
enact - nmbr trial
fasting insulin — / tiu / ml §
biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl ) , na
age , mean years , [sd]
lipoprotein ( a ) ( mg / dl )
any pulmonary medication
non - study ppi use
> nmbr : obese class iii
acute dvt study
high subgroup
mean ( sd ) body mass index , kg / mnmbr
diuretic drugs
gallbladder - related aes
rivastigmine ( n = nmbr )
vitamin e
jvp > nmbrcm
family history of venous thromboembolism ( % )
post - bronchodilator fevnmbr ( % predicted * )
creatinine clearance by c - g ( ml / min )
associated with hiv infection
muscle spasms
copd severity ( gold stage )
rivaroxaban nmbr mg
baseline cardiac biomarkers elevated
mental component score ( mcs )
combined end points
death , large mi
race , white , n ( % )
elevated tg
baseline scales , median ( range )
formal education , years
tiotropium nmbr gg qd
thrombocytopenia
presence of mets
treatment at randomization — no . ( % )
other biologic agent
hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women
baseline systolic bp
angina class iii or iv prior myocardial infarction
mucolytic agent
acenocoumaroi
multiple
emotional well - being
nmbr ( fevnmbr < nmbr % pred )
rec . ischemia due worsening angina
current ( nmbr + cigs / day )
prior surgery : no
carotid stenosis
smoking history , pack - years , mean ( sd )
ever smoked ( current / former )
estimated gfr , ml min - nmbr nmbr . nmbr m - nmbr ( sd ) a
isolated systolic hypertension , n ( % ) “
feno placebo ( lsm )
no . of prior tnfi
non - fatal myocardial infarction
involved intestinal area , n ( % )
normal fasting glucose level ( n = nmbr )
saxa + dapa + met n = nmbr
joint damage outcomes ( mitt population )
discontinuations teaes
aldosterone inhibitor
adverse outcome
etoricoxib nmbr mg n = nmbr n ( % )
asia - pacific hr ( nmbr % cl )
left bundle - branch block
any prior anti - tnf treatment failure
pioglitazone pts / n ( % )
central / eastern europe and russia hr ( nmbr % cl )
copd - rosuvastatin ( n = nmbr )
abatacept / open - label abatacept
nonblack race — no . ( % ) - j -
prior ischemic stroke
ff / vi nmbr / nmbr gg ( n = nmbr , nmbr )
baseline nihss score ( % ) #
free fatty acids ( mmol / l )
laba or lama ’ versus ind / gly lsm difference ( nmbr % cl )
change from baseline in hbanmbrc ( % )
aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years )
angiogenin ( ng / ml )
"weight ; mean ± sd ( kg )"
race / ethnicity , %
etanercept ( n = nmbr )
serum creatinine — pmol / liter
prior carotid intervention
abx - facil . pci
antiplatelet — no . / total no . ( % )
other lipid - modifying drug use at study entry , n ( % )
without dm ( n = nmbrinmbr * )
potassium
difference ( tiotropium - placebo ) ml ( nmbr % ci )
any relevant infarct
baricitinib , nmbr mg daily ( n = nmbr )
ls mean % change from baseline _ se
established ascvd or > nmbr cv risk factors
fasting plasma glucose , mg / dl , mean ( sd ) b
enmbr + anmbr -
filtration rate nmbr - nmbr
placebo secukinumab nmbr mg
sf - nmbr physical component summaryjj
angiographic data
community hospital ( % )
death or absolute fvc decrease > nmbr %
indacaterol nmbr mg[n z nmbr]
other statin
median ( iqr ) age , years
estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §
homa_ % b tx difference vs pbo , median change from baseline ( se ) nmbr
tim nmbr nsk score
indication for pci
percutaneous coronary intervention or coronary artery bypass graft surgery , n ( % )
"nmbr - aminosalicylates ’ i "" i ‘"
native latin
left atrial diameter , mm ( sd )
patient history of disease
copd severity : severe / very severe
mean platelet volume , fl
in ibdq total score at week nmbr , mean [se]
baseline ezetimibe usec
ics use at screening , n ( % )
mdi / hfa , n
moderate or severe exacerbations in the previous year ( range )
mixed chronic bronchitis and emphysema
triple - vessel disease , n ( % )
mean ( sd ) crp , mg / l *
epa / aa ratio
one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr
health state index score , uk algorithm
time from onset of pain to randomization , median ( iqr ) , h
homajr tx difference vs pbo , median change from baseline ( se ) nmbr lipid parameters
ticagrelor , nmbr mg ( n = nmbr )
dpp - nmbr inhibitor therapy
median cardiac troponin t ( iqr ) — pg / ml
> nmbr ( ml ) additional angiography
sbp < nmbr mmhg and dbp < nmbr mmhg
insulin and oral hypoglycemic drugs
other antiplatelet
use of ics
mean hscrp , mg / l ( sd )
carotid revascularization
time from onset to randomization , h , mean ± sd
beta - adrenergic blocker
class l / ll heart failure
rerandomization to placebo ( n = nmbr ) f
triglycerides > nmbr mg / dl
history of cabg surgery
vomiting
thoracic cage fractures
baseline sgrq score
usa and canada
obesity ( body mass index > nmbr kg / mnmbr )
clopidogrel plus aspirin ( n = nmbr )
intent of early invasive strategy , %
mean fevnmbr , l ( sd )
heavy calcification
cardiovascular medications , %
only peripheral artery disease
inhaled anticholinergic §
nmbr - h plasma glucose during ogtt ( mmol / l )
uacra , mg / g , n ( % )
western europe and israel
sglt - nmbr inhibitors^
myocardial infarction — no . ( % )
united states
number of antidiabetes drugs at screening , n ( % )
any type , according to daily dose * *
glucocorticoids plus immunosuppressive agents
left anterior descending artery , n ( % )
albuterol reversibility , %
rivaroxaban + aspirin
anyantianginal agent
patients with diabetic nephropathy
hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se )
health - related quality of life
risk factors , %
concomitant therapy , no . ( % )
any cardiovascular disease history , n ( % )
cardiac history , %
subgroup by treatment interaction p - value
anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr )
dpi ( other than diskus ) , n
previous copd treatment , n ( % ) *
body mass index ( kg / mnmbr ) - mean ± sd
positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f
psoriasis duration , mean ± sd , years
fevi , l *
ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening
black race
lp ( a ) , mean ( sd )
previous transient ischaemic attack / ischaemic stroke previous warfarin use
calculated ldl - c in nmbr classes
rosiglitazone
without revascularsation
odds ratio
body mass index , kg / mnmbr , median ( qnmbr , qnmbr )
exenatide n = nmbr
"total score on the sgrq - c ; i ;"
elevated creatinine ( > nmbr pmol / l )
valsartan / hctz
baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l
history of currently treated hypertension , n ( % )
tg , mmol / l [mg / dl]
terminal ileum
dasnmbr - esr lda
prior tnfi , n ( % )
liraglutide nmbr . nmbr mg / day ( n = nmbr )
established ascvd
depressed and low perceived social support
limb ( sd )
emergent / urgent surgery
laboratory measurements
simva n = nmbr n ( % )
czp nmbr mg , % ( n / n )
fibrinogen ( pmol / l ) c
frailty status
basal insulin dose at run - in ( u / day )
worsening angina
use of parenteral antithrombotic
cvd or mi
screening bmi ( kg / mnmbr )
atherosclerosis^ , n ( % )
none ( cdmard - naive or past use at baseline )
tender joint count ( nmbr - nmbr )
hbanmbrc , % , n ( % ) b
ldl - c < nmbr . nmbr mmol / l
duration of last qualifying episode of atrial fibrillation > nmbr days
saxagliptin nmbr . nmbr mg ( n = nmbr , nmbr )
years [range]
potassium - sparing at enrollment
body mass index > nmbr kg / mnmbr , n ( % )
modmy al randcnxzaton
additional investigations
peri - op amiodarone : no ( n = nmbr )
ejection fraction , % nyha class , n ( % )
class i or iii aad use in nmbr months before enrollment
intravenous anticoagulant during hospitalization
high density lipoprotein cholesterol , mg / dl^
functional assessment of chronic illness
hormonal status
postmenopausal , current hormone
spironolactone ( n = nmbr )
any disease
endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors
bolus administered — no . ( % )
tofacitinib , nmbr mg ( n = nmbr )
medical history — no . / total no . ( % )
tobacco use ( % )
infliximab - naive ( n = nmbr )
week nmbr mean 士 sd
hr ( nmbr % ci ) p value for interaction *
history of congestive heart failure
events , no .
event / total
serum cholesterol — mmol / liter
pooled empagliflozin ( n = nmbr )
statin monotherapy
total comparators , patients with events / total patients
( % ) control ( nmbr )
hypertension : no ( n = nmbr )
angiotensin - converting enzyme inhibitor or angiotensin receptor blocker
bdmard - ir
estimated glomerular filtration rate
periprocedural medications — no . / total no . ( % )
"proportion of predicted normal fevnmbr value ; , §"
mellitus
amiodarone
permanently stopped study drug because of adverse events
median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol
apolipoproiein anmbr ( tng / nmbr )
metformin dose , mg
placebo no . of events / total no . ( % )
hbanmbrc nmbr % - < nmbr % ( n - nmbr )
hypoglycaemic agents
apremilast nmbr mg bid n = nmbr
duration , mean ( sd ) , years
patient global assessment of disease activity ( vas nmbr - nmbr mm )
intermittent claudication
myocardial ischaemia
arb at enrollment
rosuvastatin of patients ( rate )
recent cardioversion ( within nmbr days before randomization ) —
denosumab ( n = nmbr )
genotyping
remission , n ( % )
radius fracture
clopidogrel dose on / before pci
enoxaparin / vka
sf - nmbr score
seropositivity
interval pain onset to admission
metrex modified intention - to - treat population with an eosinophilic phenotypey
number of previous anti - tnf treatments for psoriatic arthritis
serum creatinine , mean ( sd ) , pmol / l
coronary heart disease ( % )
bmi ( kg / mnmbr ) < nmbr
abdominal aortic — no . ( % )
mean weight , kg ( sd )
severe hyperkalemiac
history of bone disease ( predefined ) , n ( % )
abrupt vessel closure
/ j - valuc ! l
> nmbr days warfarin
non - hdl - c ( mmol / l , mean )
yes , non - insulin - treated
nmbr - nmbr . nmbr kg / mnmbr
baseline lp ( a ) in nmbr classes
primary + gusto moderate or severe bleeding
dyspepsia
south asian
claudication
anticoagulant therapy
dactylitis , n ( % )
prior immunnosupressive failure but no anti - tnf failure
sf - nmbrvnmbr domain scores , mean [sd]
reversibility ( bnmbr - agonist ) , % , mean ( sd ) nmbr
icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl )
fev , at baseline
low - density lipoprotein cholesterol , mg / dl
qualifying type of atherosclerosis — no . ( % )
white : black : other
placebo estimated mean
salmeterol - fluticasone group
impaired glucose tolerance or impaired fasting glucose — no . ( % )
duration of tnmbrdm ( % )
therapy ( asa nmbr , nmbr / placebo nmbr )
antihyperglycemic oral agent therapy
gender , % of patients
planned thienopyridine at baseline
medical history
medium - or low - intensity statin
current / past
rosuvastatin n = nmbr
pulse rate ( bpm )
anti - cholinergics ( long - acting )
primary + gusto severe bleeding
mean age , years ( nmbr % ci )
vertebrobasilar infarct
alathosterol ( % )
blood oxygenation , mean ± sd
rf positive , %
sf - nmbr ( health transition score )
time since diagnosis of osteoarthritis — yr
no . of days to homa - ir testing — median ( iqr )
certolizumab group ( n = nmbr )
nmbr - nmbr / week
pnmbrynmbr inhibitor
previous cardiovascular disease !
acute and delayed reaction
atenolol strategy
nationality
bl updrs : high
history of paroxysmal atrial fibrillation , n ( % )
biomarker status
nicotine pack - years
congestive heart failure — no . ( % ) | |
fibrin - specific
≥ nmbr . nmbr to < nmbr . nmbr years
duration of hypertension ( years )
therapy ( asa nmbr / placebo nmbr )
nmbr prolonged antithrombotic pretreatment ( n = nmbr )
isolated igt
pasi < nmbr *
nmbr locf )
uacr ( mgg - nmbr )
vorapaxar placebo nmbr - yr . km % rate
change from baseline , adjusted mean ( nmbr % ci ) , %
paclitaxel - eluting
distal anastomosis ( % )
< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % )
atrial fibrillation , n ( % )
uacr , mg / mmol ( interquartile range ) b
fasting glucose , mmol / l , mean ± sd
coronary artery bypass surgery
prior cardiovascular event — no . ( % )
concomitant atorvastatin dose , mg
n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo )
etanercept
aortic stenosis , n ( % )
pretreatment / concomitant treatment
circumflex
diuretic drugs , n ( % )
baseline median ( iq range )
serum sodium — meq / liter
pacific islander
hbalc > = nmbr % ( n - nmbr )
hbanmbrc ( % ) all countries
prior diabetes
number of events / patients
coronary heart disease
mean sgrq total score ( sd )
managed medically — no . / total no . ( % )
postoperative glucocorticoid use
losartan + placebo
geographical region ( % )
serum haemoglobin anmbrc concentration ( % ) , mean ( sd )
creatinine ≥ nmbr . nmbr mg / dl
previous balloon angioplasty , n ( % )
thrombolytic treatment before randomization
apixaban
urgent cor revasc
diabetic treatments !
primary ep ( cvd / mi / ri )
cv death / mi / stroke
ticlopidine ( n = nmbr )
alt , ast , or both > nmbrx uln
qualifying nstemi , n ( % )
baseline nihss score , median ( range )
scr , gmol / l
baseline cardiovascular medication , c n ( % )
thienopyridine drug at start of open - label period
egfr ( mumin / nmbr . nmbr mnmbr )
median ( sd ) , mg / mmol
double - vessel disease , n ( % )
lipid profile
chronic obstructive pulmonary disease
treatment difference , ml
homa - ir , median ( qnmbr , qnmbr )
nmbr placebo n = nmbr
concomitant mtx use , n ( % )
atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr )
dmard | |
calculated ldl cholesterol ( week nmbr )
median ( qnmbr : qnmbr ) total daily insulin dosenmbr
hematologic
physician global assessment ( nmbr - nmbr mm vas )
ipf - related
history of major bleeding
fpg , mean ( sd ) , mmol / l
ldl - c ( bq ) ( mg / dl ) - mean ± sd
"body - mass index ; ! ; waist - to - hip ratio"
hba , % nmbrc
current tobacco abuse , n ( % )
hormone therapy
total group ( n = nmbr )
smoking pack year ( years ) fl
( nmbr % ell ' ll , * non - hdl - c
"terol ; hdl - c , high - density lipoprotein cholesterol ;"
age at first seizure , years , mean ( sd )
glomerular
median blood eosinophil count , cells per pla
cv death or first hhf
balloon angioplasty plus abciximab
lipoprotein ( a ) , median ( ql , qnmbr ) , nmol / l
osteoporosis
acute rheumatic disorders
intensive control
treatment duration , days
warfarin ( n = nmbr )
reported hypertension *
before bronchodilation
ccv history / condition at baseline
ivabradine ( n = nmbr )
"bmi ( nmbr . nmbr ; nmbr . nmbr )"
physical function ( nmbr - nmbr , short form - nmbr subscale )
prior cerebrovascular disease
reason for enrollment in active a — no . ( % )
medical characteristics
medication use at baseline — no . ( % )
age < nmbr years — no . ( % )
planned valve surgery , n ( % )
time from randomization to pci ( st - elevation mi ) , min
haq - di score ( nmbr - nmbr )
mean ( sd ) dasnmbr - nmbr ( esr ) *
randomised treatment
v alsartan / hctz , n ( % )
nmbr year or more
crcb - ( ml / min ) , mean ( s . e . )
three - vessel disease
st - segment depression > nmbr . nmbr mv on admission , %
planned treatment duration , n ( % )
z\tonastaiin
inadequate response / intolerance to prior therapy , %
change from baseline in dasnmbr - esr , meannmbr sd
cause of heart failure — no . ( % )
predominant type of heparin
western europe / australia / israel
preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria
glucose , mmol / l
aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr
retinopathy — %
pulmonary embolism
mild or moderate copd
prior ml ( before index acs )
diabetes duration ( known ) , % of patients
creatinine clearance ， : : nmbr ml / min , %
baseline hb < nmbr g nmbr nmbr n = nmbr
joint swelling
nmbrmwd decrease > nmbr m
profound thrombocytopenia ( < nmbrxnmbr / l )
body mass index , median , ( nmbrth — nmbrth percentiles ) , kg / mnmbr
associated with connective tissue disease
postbronchodilator lung function at screening
non – small - cell lung cancer
prior anti - tnf therapy — no . ( % )
all rosuva
peripheral edema
insulin - na ' ive
gender , women n , % )
mean ( sd ) swollen joint count *
diuretic drugs ( excluding antialdosterone )
hfpef ( ef n nmbr ) , ( % )
extent of disease , n ( % )
tendonitis
previous hypertension
oral contraceptives
syncope — no . ( % )
anatomic complexity characteristics
conventional treatment
left circumflex
amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl )
number of pack - years
baseline cardiac biomarkers
type nmbr diabetes duration , mean ( sd ) , years
oral study drug administered — no . / total no . ( % )
diltiazem or verapamil
major bleeding ( statin use vs non - use )
placebo secukinumab pooled
bilateral disease ( % ) ' j ' ' j '
pathological q waves
leukocytes , nmbr / nl
lipid - lowering agents ( % )
history of second prior mi
study medication — no . ( % )
laboratory data , mean ( sd )
p value ( men versus women )
former n z nmbr
insulin : glucose ratio
tnmbrdm duration ( years )
serum creatinine > nmbr pmol / l . n ( % ) |
kellgren and lawrence radiographic reading grade nmbr — no . ( % )
data missing or no drug given
gpiib / iiia receptor inhibitor
ethnic origin
supine after nmbr minutes change from baseline
omega - nmbr fatty acid ( n = nmbr )
pulmonary rales , n ( % )
< nmbr months , n ( % )
fibrinogen , g / l
right ventriculardysfunction atinclusion
nace ( primary endpoint )
micro - / macro - albuminuria , ckd and / or retinopathy
interaction : treatment by psoriasis p valuenmbr
score > nmbr % , % of patients
any aes , n ( % )
ace inhibitors or angiotensin ii
des ( % previous stenting )
comparison with placebo ( mean
mean ( s . d . ) hbalc , %
exercise
vascular territory # nmbr
native hawaiian or other pacific islander
control baseline ( n - nmbr )
rando . in na * *
estimated glomerular filtration rate - ml / min , median ( iqr ) '
nyha class within past month — no . / total no . ( % )
aspirin group
non - hdl - c ( mg / dl ) - mean ± sd
fibrinolytic for qualifying event
nmbr degree of ica stenosis 丰
calcium - channel blockers ( % )
duration of ra ( years )
min , max
estimated gfr , < nmbr ml min - nmbr nmbr . nmbr m - nmbr , n ( % ) a
ctn - l , ng / ml
chd + cerebral infarction
fenofibric acid + moderate - dose statin
highest tg tertile
days of study - drug administration ( % ) * * nmbr day
emotional role
antithrombotic therapy
periprocedural medications — no . / total no .
kim nmbr ( pg / ml )
mi or cad
d - dimer levelsatinclusion
any immunosuppressive agent
tender joint count , of nmbr
increased waist circumference
cross - damp time : < l : llhrs : min ( n = nmbr )
aspirin only ( n = nmbr , nmbr )
high risk with atherosclerotic vascular disease *
metrex overall modified intention - to - treat population ? :
basmi ( linear ) , mean ( sd )
cor revasc
"high ( > nmbr ) ( n = nmbr , nmbr ; nmbr % )"
adl subscale ( range , nmbr - nmbr ) *
baseline statin usec
unbound pcsknmbr ( nmol / l )
months from mi — median ( iqr )
enthesitis count
enalapril
history of alcohol use
initiation of dialysis , renal transplantation , or creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l )
female race / ethnicity
bsa affected , mean ± sd , %
timing of clopidogrel loading dose
week nmbr fpg , mean ( s . e . )
crohn ' s disease - related medication at baseline , n ( % )
post - menopausal ( a )
saxagliptin nmbrmg ( n z nmbr )
weight ( range ) ( kg )
monotherapy
small vessel
history of microvascular disease — no . ( % )
baseline sitosterol
hypertension and left ventricular hypertrophy
ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr
severe n z nmbr
arthritis
concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff
extensive
baseline corticosteroids *
lv hypertrophy , n ( % )
sex ( interaction : p = nmbr . nmbr )
native hawaiian / other
pain ( nmbr - nmbr mm vas )
randomized
nmbrbaseline mean
fc - ldl - c , mg / dl
patients with previous loss of response to and intolerance of infliximab *
other glp - nmbr receptor agonist
baseline hematocrit , median ( iqr )
placebo event rate ( n = nmbr ) , %
history of amputation
low - dose rivaroxaban + aspirin group
documented asymptomatic cardiac ischemiac
seropositive ( rf + ve and / or acpa + ve ) subgroup
| ? ) - blocker , %
metabolizer phenotype ( % ) §
disease location / type : terminal ileum
selexipag ( n = nmbr )
clinical presentation
patients not receiving corticosteroids at baseline
alteplase group ( n = nmbr )
obesity , % *
cardiovascular history — no . / total no . ( % )
cardiac therapy , n ( % ) d
femoral access — no . / total no . ( % )
laboratory data
other drugs
apob : apoa - nmbr ratio
length of stay ( randomization to discharge , h )
nmbr - aminosalicylates | | | |
peripheral - artery disease ( % )
severity of the disease ( gold nmbr ) , n ( % )
apixaban , nmbr . nmbr mg
coronary bypass graft
vascular disease indicator no ( n = nmbr )
laboratory values at randomization ( median and iqr )
acr , mg / mmol
tc / hdl - c
hbanmbrc at baseline , %
indication for stent
history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %
months since ra was first diagnosed , mean ( sd )
hemorrhagic stroke ( n = nmbr )
mini - mental state examination
number of stents implanted
risk score category ( points )
microvascular complications , n ( % ) ’
erosion score , median ( min , max )
fevnmbr / fvc ( post salbutamol )
type nmbr diabetes
% predicted pre - bronchodilator fevnmbr , % *
patients receiving corticosteroids at baseline
odds ratio adj ( nmbr % cl )
no statin vs statin alone vs any statin plus other llt
general and lumbar epidural
rf and acpa negativenmbr
hispanic
onsetofaf , no . ( % )
percentage with disease duration < nmbr years
doubling of creatinine †
diameter stenosis , mean ( sd ) , %
biologic naive
systemic corticosteroids , n ( % ) a
europe ( non - eu )
fasting blood glucose ( mg / dl )
fevnmbr reversibilityz ( pre / post ipratropium ) , %
mean eosinophil count , per ml
men , total ( n 二 nmbr )
rhabdomyolysis , myopathy , or myalgia with ck elevation > nmbrx uln
rf positive , n ( % )
without insulin or insulin - modifying therapy
hospitalized for heart failure during that time period
phospholipid omega - nmbr levels : < nmbr % ( n = nmbr )
clinical and laboratory measurements
current medication — no . ( % )
infliximab nmbr mg / kg
randomization - to -
low hdl cholesterol
history of chronic hf
race - non - white ( n = nmbr , nmbr )
moderate teaes
sfc nmbr / nmbr mg twice daily ( n = nmbr )
time since diagnosis of type nmbr diabetes
riva roxa ban n / n { % ) nmbr ( nmbr . nmbr )
disease and quality - of - life scores
laba / ics use at screening , n ( % )
mean change in radiographic end points
screening % predicted fevnmbr
lntensityd
steroid use at baseline
angina class at baseline
emotional status
albuminuria ( g / g )
concomitant therapy
thrombophilia
mean — mg / dl level — no . ( % )
urine albumin - to - creatinine ratio - no . ( % ) § §
mean a ± sd ( mmhg )
hdl cholesterol ( week nmbr ) a
low - dose rivaroxaban plus aspirin ( n = nmbr )
clinical criterianmbr
abatacept ( n = nmbr * )
ind nmbr gg q . d . n / n ( % )
lvef ( % ) , mean ± sd
menopausal status and use of hrt ( % ) y
renin inhibitor ( e . g . aliskerin )
urine albumin - to - creatinine ratio
total n = nmbr n ( % )
chronic heart failure
type nmbr diabetes mellitus ’
mean score on dasnmbr - nmbr ( crp ) ^
orthostatic hypotension
previous oral glucose - lowering agents , % of patients
aortic stenosis
no . of patients / total no . ( % )
any dose reduction
hazard ratio for event ( nmbr % ci )
prior implantable cardiodefibrillator , n ( % )
crp ( mg / l ) , median ( min , max )
gold nmbr groups , n ( % )
enalapril + aliskiren dm = nmbr non - dm = nmbr
ics , mg / day
psoriasis covering > nmbr % bsa , n ( % ) §
antihypertensive drug , %
mean ( sd ) post - bronchodilator fevnmbr reversibility , %
nmbr - nmbr ( severe )
stroke or pvd , ( % )
cabg > nmbr month ago
history of percutaneous coronary intervention
current or previous atrial fibrillation
ace - inhibitor use
anemia — no . ( % ) | |
low - dose corticosteroid user
upper gastrointestinal
cad history and risk factors , n ( % )
das - nmbr ( crp ) < nmbr . nmbr , n ( % )
repaired chd
gusto - defined bleeding
peripheral vasodilators
mean ( sd ) number of albuterol per day , puff
liraglutide ( n = nmbr , nmbr )
angiotensin - converting enzyme or angiotensin receptor blocker
perianal or anus
framingham nmbr - year cv risk score
native coronary - artery lesions
current drinker
placebo ls means ( n )
( % , nmbr % cl )
duration of disease , years
musculoskeletal
severe ( gold nmbr )
moderate thrombocytopenia ( < nmbrxnmbr / l )
st change > nmbr mm
received an oral aha within nmbr weeks prior to screening
stiffness subscale
egfr < nmbr , n ( % )
rec . ischemia requiring revasc
type of concomitant statin
bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ]
moderate ( nmbr risk factor )
timi risk score nmbr - nmbr
chronic obstructive pulmonary disease , n ( % )
glycopyrronium nmbr mg ( n = nmbr )
history of microvascular eye disease 本 , n ( % )
oral aminosalicylates
bmi kg - m - nmbr
mean ± sd triglycerides , mg / dl
type of des
white , n ( % )
aspirin / antiplatelet
any peripheral arterial disease
ldl cholesterol mean ( mg / dl ± sd )
index event — no . ( % )
hospital factor # nmbr
baseline tobacco use
"persistent anemia bsl hb < nmbrg i - nmbr ; yr nmbr < nmbrg i nmbr"
previously taken tnfi , %
troponin t
exacerbations in the previous year
omega - nmbr fatty acid
stroke risk score
daily insulin dose , mean ( sd ) , iu
former or never
type nmbr diabetes duration , years
ccv history / condition
microalbuminuria or proteinuria
absolute risk difference ( ci ) , % *
elevated at wk nmbr — no . ( % ) nmbr
proctosigmoiditis
mean age ( years ) race
cat total score
nmbr no . of events
intervention group ( n = nmbr )
( nmbr % cl ) interaction
apoa - nmbr , g / l
yes , insulin - treated
epa treatment ( n = nmbr )
responders of three - item end point at nmbr weeks *
systemic glucocorticoid use at randomisation
duration of tnmbrdm , y
ace inhibitors or angiotensin ii blockers
physician ' s global assessment of dis -
clopidogrel no . of patients % )
duration of crohn ' s disease ( yrs )
multivessel intervention , n ( % )
tertile nmbr
cabg surgery
crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l ) , n ( % )
fatal and nonfatal stroke
angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §
ace - i / arb , ( % )
gliclazide ( modified release ) 一 no . ( % ) ^
conventional treatment ( n = nmbr )
currentother ( notpredefined ) medical conditions
history of coronary revascularization
concomitant conventional dmard use
dual antiplatelet
digitalis
active or previous cancer
therapy at discharge
north america hr ( nmbr % cl )
"intermediate ( nmbr ) ( n = nmbr , nmbr ; nmbr % )"
male sex — no . ( % ) race — no . ( % ) ) :
primary end point kaplan - meier rate , %
all ~ cause mort / hf hosp .
haemodynamics and lv function
duration of study - drug infusion
salmeterol nmbr gg bid
p value for adjusted hr
vitamin k antagonist ( e . g . warfarin / coumarol )
a / v ( n = nmbr )
unknown
ff / vi nmbr / nmbr pg od
ivabradine group
comparison with baseline ( mean
irofiban
laba / lama
< nmbr years eze / simva
placebo ( dm - vs . dm + )
o total randomized
cabgorptca
total patients n = nmbr
left circumflex artery
lebrikizumab ( n = nmbr )
disease duration , median ( range ) years
bl updrs : low
fevnmbr % reversibility
lipoprotein ( a ) tx difference vs pbo , ls mean % change from baseline ( se )
( $ nmbr mg / dl [nmbr . nmbr mmol / l] )
very high risk
location of crohn ' s disease , %
baseline diabetes
number of vessels disease
patient history of disease n ( % )
tocilizumab ( n = nmbr )
mean ( sd ) duration of smoking , pack years
difference ( a ) vs placebo ( nmbr % cl )
nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr
demographic characteristics
ezetimibe use
subset of patients on metformin
nmbr vessels or left main
congenital shunts
eze / simva gender
methotrexate dose at baseline
neoplasia , n ( % )
mesothelin ( ng / ml )
non - smoker ( n = nmbr , nmbr )
amlodipine / valsartan nmbr / nmbr mg / v = nmbr
> nmbr . nmbr hdl cholesterol level
past or current angina pectoris
history of peripheral vascular disease
group — no . ( % )
number of treated vessels ( per patient )
ranolazine , n = inmbrinmbr
prior failure of anti - tnf therapy — no . ( % )
concomitant medications for ulcerative colitis — no . ( % )
lipid - lowering therapy
dlqi , nmbr - nmbr *
patients treated for > nmbr weeks ( % )
immunomodulatory agents
endothelin - receptor antagonists
nt - probnp , median ( iqr ) , pg / ml
hosp . for hf
alcohol use ( > nmbr drink / wk )
st - segment elevation mi
history of dyspepsia
ncep risk category at study entry , n ( % )
treated hypertension :
presence of dactylitis , n ( % )
placebo every nmbr weeks ( n = nmbr )
heart rate , mean ± sd ( b . p . m . )
post - bronchodilator fevnmbr , reversibility percentage of baseline value
intense physical activity
concomitant drugs
cholesterol absorption inhibitor ( ezetimibe )
chanmbrdsnmbr - vasc score ( median , iqr )
serum potassium — mmol / liter
nadroparin vs control
type of event — no . ( % )
stroke or tia — no . ( % )
previous major bleeding
coexisting conditions
characteristics of pulmonary embolism at inclusion
time of symptom onset to randomization ( hrs )
recurrent heart failure
all completers ( n nmbr nmbr )
qualifying hbanmbrc ( % )
medically important infectionsa
three arm
after nmbr h
fevnmbr % pred
copd assessment test ( cat ) score
aspirin use ( > nmbr mg )
moderate ( gold nmbr )
no ascvd + additional cv risk factors , n ( % )
arb / ace
hypertension serum lipid values
measured at clinic visit with usual device
average maximum cimt ( mm )
thrombophilia , no . ( % ) e
health assessment questionnaire - disability index
median ( qnmbr : qnmbr ) lp ( a ) , mg / dl
any clinical ae
mean ( sd ) feno , ppb
cdai score §
unfractionated
physical and cognitive examination : ! :
syst . bp ( mmhg )
medications at discharge or day nmbr , if earlier ( % )
drug discontinuation not due to death
congestive heart failure ( < nmbr wk )
aliskiren
physician global assessment of disease activity ( vas nmbr - nmbr mm )
baseline dlco . mmol kpa - ’ -
role emotional
baseline ( geometric mean , cv )
pah classification
days without albuterol use , * %
simva ( % )
treatment with open - label perindopril
new diabetes — no . ( % )
adjusted change from baseline mean ( s . e . )
$ nmbrand , nmbr years
fpg ( range ) ( mmol / l )
arterial graft
any established coronary artery disease
time to treatment ( min ) t
serum potassium : < nmbr . nmbrmmol / l ( n = nmbr )
hemoglobin concentration — g / liter
clopidogrel + aspirin ( n = nmbr )
previous metformin use , %
current ( % )
ecg findings at baseline — no . ( % )
concomitant therapies n ( % )
baseline therapy
hbanmbrc nmbr . nmbr to < nmbr . nmbr % ( nmbr - nmbr mmol / mol )
history of recurrent venous thromboembolism
magnetic resonance angiography
free fatty acids — mmol / liter
baseline post - bronchodilator % predicted fev , > nmbr % and no concurrent tiotropium
id genotype
major coronary
cardiac rhythm disorders
previous ischemic stroke , n ( % )
apolipoprotein b tx difference vs pbo , ls mean % change from baseline ( se )
history of macroalbuminuriat , n ( % )
high ( > nmbr risk factor )
psoriasis affecting > nmbr % of body - surface
asthma duration ( sd ) , years
glucose metabolism
glycated hemoglobin , median ( iqr )
blood pressure , mean ± sd mm hg
fpi , mean ( sd ) , pu / mlt
secondary # nmbr
nmbr . nmbr - nmbr . nmbr kg / mnmbr
primary pci no .
rectum and sigmoid colon only
radial access — no . / total no . ( % )
oral blood glucose - lowering
age nmbr + yrs
> nmbr . nmbr pmol / liter hscrp level
other ischaemic heart disease ( non - infarction )
calcium supplements
a mini - mental state examination , insulin glargine vs standard care
country : argentina ( n = nmbr )
estimated gfr — no . ( % ) nmbr
received > nmbr prior anti - tnf therapies , n
nmbr placebo ( n = nmbr nmbr )
standard care n ( % )
interval from clopidogrel loading , h
severity of copd * , n ( % )
acr deciles
change at week nmbr
europe , israel , or australia
low density lipoprotein cholesterol - mg / dltt
other dmard use
duration of hypercholesterolemia ( yr )
personal relationships
heart failure or lvef < nmbr % associated with index acs event
previous venous thromboembolism — no . ( % )
prior biologic exposure
need for urgent coronary - artery bypass grafting
egfr ( ml / min / nmbr - nmbr mz )
egfr ( mdrd ) , ml / min / nmbr . nmbr mnmbr
previous stroke , n ( % )
alpha nmbr blockers
moderate dysfunction
tnf - rnmbra ( ng / ml )
jejunum
neither ace - i nor arb use
history of vte * *
d - dimer level , mean ( sd ) , ng / mld
gfr ( ml / min per nmbr . nmbr nr )
diastolic fmmhff ' )
diabetes duration , median ( iqr ) , years
nmbr . nmbr ( nmbr nmbr . nmbr )
plaque score ( nmbr - nmbr )
prior disease
mean sd fpg , mg / dl
serum ctx ( ng / ml )
baseline triglycerides in nmbr classes
ff / vi nmbr mg / nmbr mg ( n = nmbr )
previous anti - tnf therapy , n [ % ]
dronedarone ( n = nmbr )
standard ( nmbr )
age , median ( interquartile range ) , y
one or more copd exacerbations ( n / n [ % ] )
peripheral embolism
arterial blood pressure , mm hg
co - morbidities , a n ( % )
oral hypoglycemic drugs only
p value ( on vs off omt )
mucocutaneous
any new anti - hyperglycemic rx
metsyn with ldl > nmbr . nmbr mg / dl
severe or worse airflow limitation
periprocedural anticoagulant
lsms difference ( nmbr % ci ) nmbr
age , y sex , no . ( % )
blood eosinophil
pah classification — no . ( % )
short - acting bnmbr - agonists
fevnmbr reversibility , pre - / post - albuterol , %
ischemia on cecg ( n = nmbr , nmbr )
ularitide n / n ( % )
three of seven risk factors
moderately high risk without atherosclerotic vascular disease *
randomised to canakinumab nmbr mg
ff nmbr pgod
fevnmbr post - bronchodilator , % predicted normal
migraine — no . ( % ) $
hypertension — no . / total no . ( % )
randomized to active yitamin e
low risk and more symptoms ( group b )
high risk
carotid artery diseaset
cholesterol — mmol / liter
fasting plasma glucose
daily activities
extended - duration enoxaparin ( n = nmbr )
dasnmbr - nmbr ( esr )
associated with corrected - congenital shunts
traditional nsaid use
baseline albumin : < nmbr
high - risk cvd , n ( % )
pro / pro homozygotes
sulfasalazine ( mean dose : nmbr . nmbr g / day )
> nmbr years eze / simva baseline ldl - c
< nmbr % predicted arr ( n = nmbr , nmbr )
pe associated with dvt at diagnosis
baseline hbanmbrc
renal function < nmbr egfr , ml / min / nmbr . nmbr mnmbr
blood eosinophil concentration , nmbr cells per l
less severenmbr
cardiovascular risk
prehospital ticagrelor ( n = nmbr )
symptoms of atrial fibrillation in the nmbr months before randomiza -
perindopril
tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr )
symptom onset to hospital admission
ldl - c ( measured ) *
rerapamil - sr strategy ( n = nmbr )
erosion score , mean nmbr sd
valve surgery , n ( % )
ticagrelor nmbr mg nmbr year km ( % )
north america ( plus australia and new zealand )
calcium antagonist — no . ( % )
penetrating disease , %
non - drug - eluting stent
number of exacerbations in the past nmbr months
potassium supplement
age group
congestive heart failure ( chf ) ( in past nmbr weeks )
platelet count , x nmbr mmnmbr
other supraventricular tachycardia
egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] )
mean bmi , kg / mnmbr
* * * unstable angina
rate ratio
recurrent vte ( statin use vs non - use )
saxagliptin nmbr mg ( n = nmbr , nmbr )
irregular or ulcerated ica p ) laque : [ :
extreme tortuosity
angina status — no . ( % )
p value nmbr . nmbr
nonaspirin antiplatelet
antihyperglycemictherapies , %
geographic distribution - no . ( % )
conventional synthetic dmard use at baseline
statins 一 no . ( % )
at six weeks
angiographic data and treatment :
clinical indication at the index procedure , n ( % )
mean bdi focal score ( sd )
cabg during index hospitalization
pci for index event
concomitant drug treatment
third primary ( change in updrs score / wk , wk nmbr - nmbr )
implanted pacemaker
concomitant asthma medications , n ( % )
hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol )
uacr not available
ret / abx - facil . pci
severity of copd , airflow limitation , n ( % )
claudication only
mean % predicted dlco * ( sd )
titre ( u / ml ) t
treatment before admission ( % )
overall quality of life
no baseline corticosteroids
high on - treatment platelet reactivity *
potassium ( meql ) , mean + sd , available for nmbr patients
all patients with opg n - nmbr
urinary albumin : creatinine ratio ( pg / mg ) , median ( iqr )
cardiac rhythm disorder at baseline yes
islander
left circumflex coronary artery
risk category ( points )
nihss at randomization , nmbr - nmbr
cilostazol
creatinine clearance category , ml / min , no . ( % ) b
tg > nmbr mg / dl , n ( ° / o )
chf on losartan ( % )
comorbidities , %
prior lipid - lowering agent use
iwqol - lite total score ( arbitrary units ) #
absolute change
gusto moderate / severe
ls mean difference ( se ) vs placebo
stent implanted — no . ( % )
eze / simva ( „ = nmbr }
low eosinophil subgroup ( , nmbr / ml ) ( n = nmbr )
alaska native
| interactior nmbr p
number ( s ) of features present
extent of disease — no . / total no . ( % ) § ^ |
eze / simva nmbr / nmbr mg n = nmbr
bivalirudin
two arm
metreo modified intention - to - treat population §
any blood pressure medications ( % )
p , net difference
statin users ( n = nmbr )
simplified disease activity index score ( nmbr - nmbr )
calcium channel
level — no . ( % )
no regular consumption
nmbr / nmbr , nmbr ( nmbr . nmbr )
time from randomization to pci ( non - st - elevation mi ) , h
nmbre < nmbr % , n ( % )
prior pacemaker , n ( % )
non - detectable / unknown , n ( % )
individuals without diabetes , n = nmbr , nmbr
post - fibrinolysis angioplasty ( n = nmbr )
aerobic activity
pulse pressure
laboratory measures
deep - vein thrombosis ( % )
cardiovascu lar subg roup
greater than or equal to nmbr ml / min / nmbr . nmbrmnmbr
statin , n ( % )
location of infarction
infliximab - experienced ( n = nmbr )
time since first copd diagnosis ( years )
potassium — mmol / liter
rivaroxaban ( n = nmbr )
investigator - determined myocardial infarction
time from first eval
diagnosis of heterozygous familial hypercholester
baseline crp ( mg / dl )
average of maximum far wall cimt ( mm )
hispanic ethnicity
other vasodilator
maintenance dose
thienopyridine type
perfusion defectsatinclusion
dasnmbr - esr remission
no . of panents . total no . nmbr % )
disease activity outcomes ( itt population ) week nmbr
fluticasone furoate and vilanterol ( n = nmbr )
any infarct
apolipoprotein a - i *
current smoking — no . / total no . ( % )
miami k antagonist received
rivastigmine
europa ( n = nmbrlnmbr )
lung function , mean
physician ' s global assessment of disease activity ( nmbr - nmbr mm vas ) , mean ( sd )
nmbr - nmbr ( very severe )
high - risk clinical features
second primary composite outcome
baseline % predicted fevnmbr
treatment characteristics
digoxin at last follow - up
both impaired glucose tolerance and impaired fasting glucose tolerance — no .
ez / simva < % >
"sbp indicates systolic blood pressure ; dbp , diastolic blood pressure ; aa , arachidonic acid ; epa , eicosapentaenoic acid . values for age , bmi , total cholesterol , ldl cholesterol , hdl cholesterol , sbp , dbp , aa , epa , and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups ."
# of prior bdmards
acute reaction
ulcers / gangrene
fasting plasma glucose ( mmol / l )
other teaes
alcohol intake
change from baseline ( % )
ileum only
anti - tnf - ir patients
north america plus australia and new zealand
medial - distal - diag
bw at nmbr weeks , kg +
haemoglobin ( mmol / l )
severity ofcopd ( goldnmbr ) , n ( % )
prior stroke — no . ( % )
adalimumab ( n = nmbr )
aliskiren dm = nmbr non - dm = nmbr
previous cabg ( before index acs ) *
number of patients ( % ) or mean 士 sd
severity of copd , n ( % ) ( gold nmbr ) : moderate
western friroce
"baseline lipids ; mean ± sd ( mmol / nmbr )"
baseline calcium yes
cardiac mediations
large vessel
no . of treated vessels
sinus rhythm at baseline
ipah / hpah
ccs class §
antithrombotic and anticoagulant medications
ixeqnmbrw , n = nmbr
warfarin group ( n = nmbr )
white - cell count — xnmbr_nmbr / liter
mean % predicted fvc ( sd )
only cerebrovascular disease
three or more agents
msfc timed nmbr - foot walk test , median seconds
mean ( sd ) baseline scores
patients with > nmbr % ■ nmbr ml increase in fevnmbr post - bronchodilator ( % )
meglitinide
prior tobacco use , n ( % )
graft occlusionsa
ascot - lla
cortical only
"key : tc = triglyceride ; hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose ; ncep atp * this category did not include ar to have > _ nmbr of the indicated char least - square means , except tc an note : all treatment by subgroup"
prior disease - modifying drugs resulting in inadequate response — mean no . / patient
extent of disease
candesartan group ( n = nmbr )
rivaroxaban alone ( n = nmbr )
body mass index , mean ( sd ) [range]a
baseline antihyperglycemic medications , n ( % )
fasting lipid levels , mmol / l
proximal gastrointestinal tract
diabetes mellitus ( type nmbr or nmbr )
heart failure ( hf ) , ( % )
platelet , nmbr / l
hbanmbrc < nmbr % ( n - nmbr )
spironolactone , n ( % )
b digit symbol substitution , insulin glargine vs standard care
proteinurianmbr ( g / day )
elevated blood pressure
ldl - c ( mg / dl ) < nmbr
laser or vitrectomy
total study population ( n = nmbr )
presenting diagnosis
duration of type nmbr diabetes ( years )
alt ( units / l )
severity of airflow limitation
patient ' s global assessment of disease
daily dose nmbr - nmbr mg n = nmbr
in - stent restenosis of des
baseline hbanmbrc , mean ( s . e . )
predicted normal ( % )
killip class — no . ( % ) i
prior ml or abnormal angiogram
placebo + mtx ( n = nmbr )
baseline corticosteroid use ( mg )
ind / gly nmbr / nmbr mg once daily ( n = nmbr , nmbr )
patients who received positive results on test for antibodies to infliximabt
ptca < nmbr h
verapamil - sr ( « = nmbr nmbr )
simvastatin ( nmbr / nmbr mg / d )
insulin 一 no . ( % )
duration of type nmbr diabetes mellitus ( years )
central america and south america
hip circumference — cm
rnmbr + ezio ( n = nmbr )
male sex — no . of patients ( % )
stents per lesion , n
infliximab ( n = nmbr )
dose of rosuvastatin
lvef < nmbr % , n = nmbr nmbr ) “
n - terminal pro - brain natriuretic peptide , pg / ml
bmi — mean ( sd ) ( kg / mnmbr )
vorapaxar event rate ( n = nmbr ) , %
death or nmbrmwd decrease > nmbr m
associated with transient or reversible risk factor
europe and australia
all countries
urinary protein : creatinine ratioa ( mg / mg )
serum cholesterol , median ( iqr ) , mg / dl
intermediate risk ( ri = nmbr )
cangrelor
baseline cdai score , mean ( s . d . )
major bleeding events *
baseline , mm hg
white / caucasian
"body mass index ; mean ± sd ( kg / mnmbr )"
recurrent ischemia
index event not confirmed
non - hdl cholesterol ( mg / dl )
comparison with placebo
current use of an ace inhibitor
mean total serum ige ( sd ) , iu / ml
af or atrial flutter 卞
pain subscale
ejection fraction based on local reading
cardiac and echocardiography parameters
albuterol use ( sd ) , puffs / day
white race — number ( % )
stable angina ( n - nmbr , nmbr )
weight , kg , median ( nmbrth , nmbrth )
long - term aspirin
moderately impaired
left side only
past or never
gastroesophageal reflux disease
anticoagulant — no . ( % )
region , asia / paafic
arteriosclerosis
fasting plasma glucose nmbr medan
age mean ( yrs ± sd )
chronic renal failure
peripheral artery
neither tnmbrdm nor mets
time since first af diagnosis , yrs
anti - hypertensive therapy - no . ( % )
pacemaker
infarct ion w ithin previous nmbr day s
cardiac death
interval between clinical evaluation and initiation oftreatment — no . ( % )
apolipoprotein b , mean ( sd ) , g / l
no . of participants with events ( % )
mean a ± sd , mg / dl ( mmol / nmbr )
homa - ir ( mu / l^mmol / l )
> nmbr months ( n = nmbr , nmbr )
elevated troponin ( > nmbr . nmbr mg / l ) , %
mean weight ( sd ) , kg
europe ( zone nmbr )
cox bsl onlyc
number resulting in ed visit
left ventricular systolic or diastolic dysfunction
any other llts ( other than statin )
other blood - pressure drug
both ace inhibitor and arb
tg , median ( sdy rng / cjl
statin at last follow - up
p - value ( lnteraction )
mild dysfunction or normal
recurrent infections ( > nmbr per year )
estimated glomerular filtration rate < nmbr ml / min per nmbr . nmbr mnmbr
median ( qnmbr : qnmbr ) duration of diabetes , years
nmbrlnmbrmmhg
chronic non - steroidal antiinflammatory drugs
european subcategories
placebo + nmbr mg / d of simvastatin ( n = nmbr )
median c - reactive protein — mg / dl^
use of other medications — no . ( % )
total - c : hdl - c
pre - bronchodilator fevnmbr / fvc ( % )
reversibility ( % predicted fevnmbr ) *
conversion to sinus rhythm in < nmbr days
stent implanted
median weight , kg ( iqr )
saxagliptin ( % )
salmeterol - fluticasone group ( n = nmbr )
abciximab
vein bypass graft stented
mean age ( sd ) , years
prior treatment
bivalirudin used during pci
mean ( s . d . ) ldl particle number , nmol / l
pad symptoms ( % )
number of treated lesions
infliximab ( combined nmbr mg / kg and nmbr mg / kg ) , n ( % )
high dose statin ( n = nmbr , nmbr )
any recurrent stroke
distal one - third of radius
mean mayo score ( sd )
diagnosis at presentation
median disease duration — yr
events / control group
lowest tg tertile
other antihyperglycemic agents , not listed
index stroke > nmbr days before randomization — no . ( % )
renal fmclicn : creatntoe clearance
prior mi ( n - nmbr , nmbr )
losartan plus placebo ( n = nmbr )
anti - ccp positive ( > nmbr u / ml ) , n ( % )
total occlusion , n ( % )
male sex — no . ( % ) risk factors
multiple tnfi and other bdmards §
stiffness ( min )
rosuvastatin nmbr - nmbr mg ( n = nmbr )
randomization to angiography
thienopyridine n = nmbr
treatment difference
absolute reversibility in fevnmbr , ml *
time to treatment
duration of initial anticoagulation , mean ( sd ) , mo
undetermined etiology
ace inhibitors through hospital discharge or day nmbr — %
patient ' s global assessment ( vas )
triglycerides ( mg / dl ) , mean + sd , available for nmbr patients
qualifying type of atherosclerosis , n ( % )
patient ' s preference not to take vka , only reason
probable
at least two cardiovascular risk factors
surgical technique post - randomisation characteristic * *
age group , no . ( % ) , y
disease location ( % ) *
previous oad ( % )
hdl cholesterol — mg / dl triglycerides — mg / dl
< nmbr months in - nmbr kill
antialdosterone agents
risk factors bmi ( kg / mnmbr ) , mean + sd
ex - smoker / current
at goal
history of heart failure — no . ( % )
diabetes duration subgroups
western europe ( including south africa )
randomization stratum
death , mi , idr , st or gusto severe bleeding
clopidogrel / total no . of patients % %
corticosteroid ( without imm )
creatinine ratio nmbr - nmbr
overall pad
steroids ( other )
mean ± s . d . weight , kg
amlodipine ( n = nmbr )
previous infliximab therapy — no . of patients ( % ) * *
anti - tnf - naive , n ( % )
previous acute hypersensitivity reaction to infliximab — no . of patients ( % )
non - elderly ( < nmbr years )
pravastatin ( n = nmbr >
week nmbr ( mean , sd )
factor v leiden ( % )
tender joint count ( nmbr - nmbr possible joints )
male sex — no . / total no . ( % )
insulin glargine n ( x )
time since randomization
post - bronchodilator fevnmbr ( % predicted normal ) a
vessel size , mean ( sd ) , mm
hs - crp ( median , iqr ) , mg / l
insulin - requiring
homa . ir , median ( ql , qnmbr ) , % / nmbr
baseline short - acting anticholinergics
multivitamin use ( current )
apob : apoal
cardiac stretch
hospitalization for heart failure within nmbr mo
lv ejection fraction , mean ( sd ) [range] , %
pasi score , nmbr - nmbr *
patients with event / patients analyzed
mean ( sd ) periostin , ng / ml
any blood transfusion
low molecular weight heparin
yes ( stopped for trial )
previous chronic use of antiplatelet drugs
aspirin - erdp clopidogrel no . of patients / total no .
denosumab
patients randomized
days with asthma symptoms / week
statin with fibrate
delayed - start group ( n = nmbr )
fevnmbr % predicted ( post salbutamol )
intended durat - sm of antccagubficn
baseline dmard use , n ( % )
creatinine — mg / dl urinary albumin - to - creatinine ratio §
companion : wake - up stroke
placebo events / n ( % )
cdai score < nmbr
baseline ibdq total score , mean
positive for rheumatoid factor , anti - cyclic citrullinated peptide antibodies , or both — % ff
current alcohol use , n ( % )
cardiac medications at discharge , %
medical management only
shoulder pain
hbalc , mean ( s . d . )
nmbr . nmbr mg bid
pci during index hospitalization
history of cv disease
complex lesions^
level nmbr immobility^
asia / pacific / other
calcium , mmol nmbr nmbr
race , % caucasian
mtss cfb mean ± sd
study end concentration
potassium , mean ( sd ) , meq / l
naive to antihyperglycemic agent therapy
swollen joint count , of nmbr
hemispheric tia n = nmbr
c - peptide tx difference vs pbo , median change from baseline ( se ) nmbr
severity of airflow limitation ( gold nmbr ) , n ( % )
other atherosclerotic event
retinopathy ( stage nmbr / nmbr / nmbr / nmbr )
mean — ml / min / nmbr . nmbrmnmbr
fevnmbr ( % predicted normal )
baseline total cholesterol
egfr category , n ( % )
rhabdomyolysis
any other antihyperglycaemic drugs
any risk factor for stent thrombosis
copd severity : mild / moderate
medications taken at time of randomization statins
neither n = nmbr , nmbr
exercise at least weekly ( a )
patients with previous intolerance of infliximab
mayo clinic score §
nob systolic blood pressure ( mm hg )
geographic region - other
months since first ra symptom , mean ( sd ) f
continuation ( n = nmbr )
timi - defined bleeding
glycosylated hemoglobin , %
omeprazole
in - hospital ticagrelor ( n = nmbr )
mean bmi ( nmbr % ci )
physiological measures
atrial fibrillation pattern
corticosteroid + imm
thiazide at enrollment
nasopharyngitis
established atherosclerotic
overall effect
omega - nmbr fa
ejection fraction : < nmbr % ( n = nmbr )
< nmbr mm hg heart rate
lv ejection fraction ( % )
cangrelor clopidogrel no . of events / total no . ( % )
killip at baseline
time since asthma diagnosis ( years )
nmbr placebo
carbamazepine
postmenopausal , current hormone therapy use
known duration of type nmbr diabetes ( years )
beta - blocker at enrollment
number of exacerbations nmbr months before randomisation
week nmbr hbanmbrc , mean ( s . e . )
tertile nmbr ( n = nmbr )
mean ( sd ) duration of copd , years
ci - aki risk score
risk factors for stroke , no . ( % )
esr ( mm / h ) , median ( min , max )
units per week , mean ( sd )
c - reactive protein — mg / literj
non - u . s .
acuity - defined bleeding
vedolizumab
other / multiracial
time since qualifying event
> nmbr vessels treated
statin use , n ( % )
previous coronary - artery bypass grafting
median ( min , max )
intensive control ( n = nmbr ) no . of patients ( percent )
arterial hypertension , n ( % )
ranolazine ( n = nmbr ) placebo ( n = nmbr )
large shunt
history of hypertension , n ( % )
age y , median ( range )
companion : nmbr - nmbr hours
nt - pro bnp
lipid difference ( mg / dl )
other determined etiology
baseline pasi score
mean ( sd ) total asthma symptom scores
time since pah diagnosisc ( years )
alpha receptor antagonist
esrd on losartan ( % )
stroke at entry ( vs transient ischemic attack )
medical history and risk factors ( % )
placebo monthly ( n = nmbr )
intravenous inotropes or vasopressors ( % )
overall a phase population
symptom onset to first medical contact : ambulance or emergency department
any glucocorticoid *
mean ( sd ) post - bronchodilator fevnmbr percentage predicted
insulin ( mu / ml )
creatinine clearance < nmbr ml / min
nihss at randomization
elevated serum potassium , > nmbr . nmbr mmol / l
concordant stress test abnormalities
eos serum k + , meq / l
duration of diabetes
arterial revascularization
endpoint rate
"highest tertile ( range , nmbr . nmbr - nmbr . nmbr mg / dl ; mean ± sd , nmbr . nmbr ± nmbr . nmbr mg / dl )"
p interaction women vs men
malaysia
populations :
serum creatinine , 弘 mol 儿 | |
index pci performed
retinopathy
history of nicotine use
insulin glargine n ( % ) / nmbrpy
no chd simva ( n = nmbr]
treated with insulin
previous ischemic stroke ortia
iglarlixi
previous cabg surgery
statin alone
study drug loading days ( actual ) : nmbr ( n = nmbr )
lumbar epidural
periprocedural medications
mean age , y , mean = sd
group dif . ( nmbr )
prior cardiac resynchronization therapy , n ( % )
cardiac risk
albuterol use
no . of events / total
no . of participants per nmbr patient - yr
estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr — no . / total no . ( % ) §
established atherosclerotic disease
ukraine
negative for helicobacter pylori — no . / total no . ( % )
other medical history — no . / total no . ( % )
left atrial anteroposterior diameter — mm
any established peripheral arterial disease
serum k + level and drug treatment
chronic inflammatory disease
randomization to arrival in catheterization laboratory
rituximab
hemoglobin
high risk ( receiving treatment for ) :
c - reactive protein , median ( iqr ) , mg / l
anti - tnf - naive patients
lipids , mean ( sd ) , mg / dlt
high - dose statin use at screening *
second primary ( estimated change in total updrs score from baseline to wk nmbr )
abciximab no . / total ( % )
no . of non - tnfi
current cvd / diabetes , n ( % )
cv mortality
duration of dementia symptoms , months
no pad baseline
pre ' rtous eptscde ( s } d dvt / pe
prior coronary artery bypass surgery
interaction p - valuenmbr
ipah , hpah , hiv , drug or toxin induced
< nmbr mg / dl simva ( n = nmbr]
location of disease , n ( % )
mtx ( mean dose : nmbr . nmbr mg / wk )
labs at the index acs event
black race ( n = nmbr vs nmbr )
treatment with any bp lowering drugs
placebo nmbr / nmbr
diagnosed , y
peri - op statins : no ( n = nmbr )
region , europe
copd disease severity
baseline dyslipidemia
difference in ls means ( nmbr % ci ) nmbr
male gender , n ( % )
( nmbr - nmbr - cm vas )
screening absolute reversibility fevnmbr , ml
k - m %
type of surgery
hosp . worsening hf
rest of the world
placebo no . / total no .
azathioprine / nmbr - mercaptopurine
duration of diabetes , mean ( sd ) , y
cox - nmbr selective nsaid
total ( n = nmbr , nmbr ) - -
laboratory variables
baseline anti - hyperglycemic medications
ivabradine group ( n = nmbr )
undergoing major vascular surgery
< nmbr baseline killip class
statin intensitynmbr * nmbr
multivitamin use
baseline body weight quartile
baseline fpg , mean ( s . e . )
primary pci n = nmbr
prior tnfi treatment
multiple ( > nmbr ) chd risk factors that confer a nmbr - year risk of chd > nmbr %
pctindopnl - indapamide ( n = nmbr )
history of impaired renal function
stroke of any etiology
fasting insulin ( pmol / l )
total body ( without head )
fatty acid composition
cerebral hemorrhage
pasinmbr response }
nonglycemic cardiovascular risk factors systolic blood pressure — mmhg
duration of diabetes ( months )
alpha - glucosidase inhibitors
anthropometry : mean ( sd )
white ethnicity
vascular history , %
time from qualifying myocardial infarction
nmbr — nmbr nlmw
postoperative glucocorticoid use post - randomisation characteristic * *
sinus rhythm
united states or canada
heparin , ‘ ondaparinux or brvalirudin use between rxjex event
community hospital , n ( % )
patient - reported outcome measures
> nmbr . nmbr mg / liter antiplatelet agents
ara functional class — no . ( % )
left ventricular ejection fraction
restenotic vessel
mean nmbr - year cvd risk *
^median > median
ace inhibitors / sartans
duration of hypertension , y
history of pci — no . / total no . ( % ) : t
current cigarette smoker or within past year
time to randomization from symptom onset
motor weakness
hospitalization for hf previous year , ( % )
st - segment depression < nmbr . nmbr mv , %
ab / ff nmbr / nmbr pg ( n = nmbr )
severity of airflow obstruction
tender - joint count ( of nmbr joints )
tenecteplase
median duration of symptoms ( range ) , yr
history of pci / ptca
only dvt
glucose - lowering drug
age group ( years )
renal events
blood leucocyte concentration ( nmbr cells per l )
baricitinib nmbr mg
etd ( % ) [nmbr % ci]
ranolazine ( n = nmbr )
below - knee popliteal
uacr ( mg / g )
geographic location
albuminuria
angina , n ( % )
acrnmbr response
dyslipidemianmbr
past or current
interval from randomization to angiography
enthesitis
previous treatment
non - tnf inhibitors
any blood - pressure - lowering drug 一 no . ( % )
previous stroke — no . ( % )
proximal to the splenic flexure
high eosinophil subgroup ( > nmbr / ml ) ( n = nmbr )
patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr , n
slo days
cardiovascular mortality
mnmbr subgroup
valsartan ( n = nmbr )
japan n = nmbr
modified se - adl scale
corticosteroids only
p - value interaction
undetermined , other , or cardioembolism
percentage patients reaching target
hispanic , n ( % )
modified has - bled
insulin alone
statin only , n ( % )
body - mass index categories — no . ( % ) : c
monocytes , nmbr / nl
criteria for subcortical vad ( by mri ) , %
crp mean ( mg / dl ± sd )
angiographic features
> nmbr years to < nmbr years ( n = nmbr )
pathologic q waves , n ( % )
duration of metformin therapy ( months )
baseline bmi > nmbr kg / mnmbr , n = nmbr change from baseline to nmbr weeks
lesion location
patients treated with statins ( n = nmbr )
copd exacerbations during the previous year
biasp nmbr
insulin — iu
subject characteristics
primary composite outcome
category nmbr and nmbr
race or ethnic background — no . ( % ) f
renal function subgroups
percent of patients
placebo / simvastatin
% of predicted normal value *
body - mass index ( kg / mnmbr ) , mean ( sd )
rolofylline dose
canagliflozin dose
pbo + statin nmbr
orthopaedic
geographic region — number ( % )
black race — no . / total no . ( % ) f
versus olodaterol nmbr pg
antihypertensive agents , n ( % )
baseline cardiovascular medication
alpha - blocker
modified total sharp score * *
beta - blocker use at baseline
all - cause
class nmbr or no symptoms
laboratory variables at baseline
pneumonia in past year
apixaban , nmbr mg ( n = nmbr )
chd men
calcium antagonist strategy ( cas ) ( events / n )
muscle twitching
other medication usage
qvanmbr nmbr / nmbr | ig od n = nmbr
female sex — number ( % )
heart rate , beats / min , mean ± sd
mitral insufficiency , n ( % )
from baseline ( nmbr % ci )
compression stockings
baseline triglycerides < nmbr mg / dl
apo b / apo a - l
beta - carotene ( n = nmbr , nmbr )
> nmbr years baseline ldl - c
prevalence of each metabolic syndrome criterion
sex , men / women , %
high - dose statin use , n ( % ) e
fasting glucose ( mmol / l )
fistula at baseline , n ( % )
dizziness
coronary angiography — no . ( % )
presenting signs and symptoms
moderate copdb [n z nmbr]
planned conservative therapy subgroup
sonti amenca
clopidogrel , nmbr mg *
methotrexate
hs - crp ( mg / l , median )
previously taken dmards other than methotrexate , %
non - ischaemic ( n = nmbronmbr )
progestins
fasting serum glucose ( mg / dl ) , median ( iqr )
normalized
time from hospital admission to pci , h , median ( qnmbr , qnmbr )
known t ' rc - iitoji cccndilon
ii or iii
left ventricular ejection
left ventricular ejection fraction — no . / total no . ( % )
previous loss of response to and intolerance of infliximab , n ( % ) *
reported diabetes mellitus
other / missing
severe or moderate
coronary bypass , n ( % )
new zealand
cox - nmbr selective nsaid use
heart failure cause
sbp ( mmhg ) < nmbr
past smoker , n ( % )
previous stroke — no . ( % ) concomitant treatment — no . ( % )
mean ( s . d . ) hdl cholesterol
amiodarone ( n = nmbr )
previous disease — no . ( % ) f
esrd on placebo ( % )
acute respiratory insufficiency
> nmbr % predicted arr ( n = nmbr )
associated with drug or toxin exposure
ls mean change ± sea
reversible ( % )
left atrial dimension , cm
aspirin alone ( n = nmbr ) nmbr . nmbr
diuretics ( % )
ldl cholesterohhdl cholesterol ratio
renal insufficiencynmbr
> nmbr : nmbr hrs : min ( n = nmbr )
sr ii b nmbr - cjl nmbr
csdmards + mtx ( n = nmbr )
uc duration , y , mean ( range )
ejection fraction category
high - probability ventilation / perfusion lung scanning
mmse nmbr - nmbr
use oforal glucose - lowering agent — no . ( % )
baseline sgrq total score
min - max age
baseline gfr < nmbr ml / min per nmbr . nmbr mnmbr , n ( % )
ischemic stroke
medications at discharge
multiracial , n ( % )
qnmbr : nmbr . nmbr to < nmbr . nmbr kg ( n = nmbr vs nmbr )
heart rate
self - reported disease severity , nmbr - nmbr scale *
concomitant aedsa
immunosuppressant use , %
moderately high risk
triglycerides , median ( ql , qnmbr ) , mmol / l
"nmbr = some restrictions ; no help needed"
nmbr or nmbr high - risk categories
calcium antagonist strategy ( n = nmbr nmbr )
time to balloon / needle , min *
no - diuretics group ( n = nmbr )
egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )
patients with any clinical
squamous cell carcinoma
( pg / mg )
phosphodiesterase type nmbr inhibitors
history of stroke ( % )
age ^nmbr yrs , n ( % )
cangrelor ( n = nmbr )
previous cabg ( % total )
baseline composite mayo clinic score
ticlopidine after completion of study drug
admission for hf in previous year , n ( % )
time since diagnosis — mo
left main coronary artery
other llt at randomization
other anti - hypertensives
a ngina > nmbr day s previously *
% predicted
use of antihypertensive drugs
total cholesterol ( median , iqr ) , mg / dl
hr ( nmbr % ci ) p   value
loop or thiazide diuretic : ! :
monitoring group ( n = nmbr )
ischemic coronary artery disease
blood eosinophil count > nmbr / mmnmbr at screening — no . ( % )
no known frtrontxtfufoc cond aon
mssbp / msdbp
devices for heart failure at screening visit
interleukin nmbr ( pg / ml )
priorvascular disease , %
planned thienopyridine at enrollment
background csdmard category
relative risk ( nmbr % ci ) ofprimary end point
history of gi bleeding or ulcer — no . / total no . ( % )
non - fibrin - specific
gly nmbr . nmbr mg b . i . d . n = nmbr
previous coronary angioplasty , n ( % )
mean ± sd egfr , ml / min / nmbr . nmbr mnmbr
octave induction nmbr and nmbr
single vessel coronary artery diseasenmbr
greater than or equal to nmbr %
baseline nih stroke scale — no . ( % ) ^
history of stroke or tia — no . ( % )
chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr )
albumin ( mg / dl )
lp ( a ) ( pmol / l )
st - segment depression
statin — no . / total no . ( % )
> nmbr episodes of atrial fibrillation in previous nmbr mo
ascvd as per protocol
oral antidiabetes combination therapy without insulina , n ( % )
interquartile range — yr
beta - blockers through hospital discharge or day nmbr — %
korea , republic of
corticosteroid ( without imm ) , n
index event subtype
residual perfusion defect > nmbr % on lung scan , no . ( % )
antiplatelet agent or anticoagulant
atorvastatin monotherapy ( n = nmbr * )
glycoprotein ilb / iiia inhibitor before pci]
extensive disease other
catheter access site
number of individuals
congenital heart disease
ff nmbr gg ( n = nmbr , nmbr )
time from event to randomization — days
clinical
presence of mets ( % ) a
parental history of mii
fasting serum glucose , mg / dl
treatment at randomization
glomerular filtration rate ( ml / min / nmbr . nmbrma ,
qrs duration > nmbr ms , n ( % )
median time to first exacerbation ( months [nmbr % ci] )
fasting c - peptide ( nmol / l ) c
tender joint count ( nmbr joints )
all - cause hospitalization
duration of full - dose warfarin therapy before enrollment ( mo )
severe or very severe copd
nmbrmg vs placebo
nmbrmwd , m
proportion ( nmbr % ci ) adjusted for baseline hbanmbrc , %
waist ( cm )
qualifying diagnosis
mean disease duration , y ( sd )
daily activities / social functioning
saxa nmbr . nmbr mg
rosuva nmbr mg n = nmbr
bmi group — no . ( % )
lv mass
hours from clopidogrel loading , mean ( sd )
non - ischaemic
omega nmbr allocation
adjustednmbr risk reduction losartan vs placebo ( nmbr % cl )
n - nmbr pufa
combined ( n = nmbr )
lamotrigine
maximal diameter stenosis
hispanic ethnic group , n ( % )
multivessel coronary artery disease — no . / total no . ( % )
history
patient ' s global assessment of disease activity ( nmbr - nmbr mm vas ) , mean ( sd )
"prior cardiovascular event "" ' """
no . with event / total no . { % )
ras - aldosterone inhibitor^
mean ( sd ) post - bronchodilator fevnmbr / fvc , %
non - hispanic white
ethacrynic acid
aqlq ( s ) score
patients who received negative results on test for antibodies to infliximabt
non - hdl ( mg / dl ) < nmbr
all completers
mean difference = seb
> nmbr , n ( % ) gender , n ( % )
prior use of $ nmbr systemic therapies
health assessment questionnaire ( nmbr - nmbr range )
low - molecular - weight heparin
non - hdl cholesterol ( mmol / l )
previous medication for respiratory disease — no . ( % )
characteristics of the index ml
history of heart failure
prior cardiovascular history
metabolic syndromenmbr *
consistency of effect
fondaparinux
other lipid - modifying drug 一 no . ( % )
initial timi flow
overall nmbr
absolute decrease > nmbr %
recurrent hf hospitalization
intrathoracic or intraperitoneal surgery
former or never diabetes
geographic site , %
history of high cholesterol ( a ) nmbr
history of heart failure , n ( % )
sco . ’ ita ' rojs dvt . ' pe
general health vas , nmbr - nmbr mm
placebo / open - label abatacept
prior known stenosis > nmbr %
ras antagonist , %
cancer medications
current other ( predefined ) medical conditions
center location
time from qualifying stroke to randomization
geographical region , n ( % )
priorbone disease
laba - inhaled glucocorticoid use at screening
main concomitant treatments , no . ( % )
use of rescue medication
p vs placebo
cardiac troponin t level > nmbr . nmbr pg / l
aspirin < nmbr day
native coronary
arthralgia
other bdmards ( no tnfi taken ) t , n ( % )
hmgcoa rl
egfrmdrd , ml - min - nmbr - nmbr . nmbr m - nmbr
prior angioplasty
anti - ccp antibody ( u /
mean baseline ldl - c ( mmol / l )
composite events
foot fracture
non - caucasian simva ( „ = nmbr }
tc , mean ( sd ) , rrig / dl
high risk and fewer symptoms ( group c )
type nmbr diabetes history , n ( % )
total cholesterol / hdl - c
hypertension absent
warfarin
moderate , n ( % ) a
urine acr ( mg / g )
baseline systolic blood pressure
hrnmbr and nmbr % cl
ventricular tachyarrhythmias
sulfonylurea based
medication use — no . ( % ) ^ |
bivalirudin ( n = nmbr )
p - blockers , n ( % )
acarbose 一 no . ( % )
unfractionated heparin
all patients n = nmbr
sitagliptin no . / total no .
% anti - ccp + ( > nmbr units )
septal anomaly — no . ( % )
intensified ( n 二 nmbr )
long - acting bnmbr - agonists
bodily pain
mmrc grade
alcohol consumption > once weekly
p - value for trend *
blood eosinophil count > nmbr / mmnmbr in nmbr months before screening — no . ( % )
at entry
tiotropium group ( n = nmbr )
nmbr - nmbr months ( n = nmbr )
dapagliflozin nmbr mg group ( n = nmbr )
p value ( aged > nmbr vs . < nmbr years )
valvular disease
prior angina
japan and south korea
postoperative nsaid or glucocorticoid use post - randomisation characteristic * *
all randomized patients
pack - years , mean ( sd )
epa hr events ( % )
type of myocardial infarction — no . ( % )
pciperformed for qualifying event
nonsustained ventricular tachycardia — no . ( % ) - j -
ventricular tachycardia or fibrillation
percutaneous intervention
hazard ratio for cardiovascular death , stroke , or myocardial infarction ( nmbr % ci )
hypercholesterolemia , n ( % )
diclofenac
nmbr week to nmbr month
gp llb / llla inhibitors
current , n ( % )
syndesmophyte present , n ( % )
angiographic findings | |
apixaban , nmbr mg
bypass graft
bmnmbr ( kg / mnmbr )
nmbr = no symptoms
prior brachytherapy
time since cessation of full - dose warfarin therapy
history of or current cardiac disorders , %
impaired glucose tolerance or impaired fasting glucose
severe , n ( % ) b
hospitalization for heart failure within previous nmbr mo — no . ( % )
diuretics , n ( % )
mmse ( points )
apixaban ( n = nmbr )
corticosteroid ( with or without immunosuppressants )
congestive heart failure
chf on placebo ( % )
overall hr ( nmbr % cl )
hyperlipidemia — no . ( % )
p value for trend across tertiles
nmbr - nmbr drinks / wk
> nmbr mg / dl — %
diagnosis of allergic rhinitis
refractory to such therapy — no . ( % )
lymphocytes , nmbr / + il
adjusted * or ( nmbr % ci ) p value
fevnmbr % pred . ( post - albuterol ) , %
known thrombophilia — no . ( % )
nmbr - nmbr ( mild )
simvastatin , n ( % )
age , mean ( sd ) [range] , y
copd exacerbation history , n ( % )
atio - pla
cardiac troponin t level , median ( iqr ) , pg / l
estimated glomerular filtration rate , ml / min per nmbr . nmbr mnmbr
toast classification of qualifying stroke ( % )
duration of diabetes by tertiles
on drug treatment ( % )
"triglyceride ( median ; mg / dl ) - nmbr [nmbr - nmbr percentile |"
pre - specified hr ( nmbr % cl )
cardiac medications during indexhospitalization and / or discharge
neither corticosteroid nor immunosuppressant
albumin / creatinine ratio , n ( % )
score on modified rankin scale — median ( iqr )
placebo group
discontinuations due to ae
creatinine clearance , n ( % )
multi vessel ( or left main )
infarct location
elevated hscrp
laba + ics n = nmbr
renal function , severe
high - density lipoprotein cholesterol , median , ( nmbrth — nmbrth percentiles ) , mg / dl
mean ± sd fasting insulin , uu / ml
at least nmbr / mo
atrial fibrillation — no . / total no . ( % )
ls - mean between - group difference ( nmbr % ci )
all others , n ( % )
joint swelling , effusion , or both on clinical examination — no . ( % )
median age ( nmbr % , nmbr % ) , y
history of cerebrovascular disease
laba or lama ’
metformin ( n = nmbr )
prior cabg ( before index acs )
anti - tnf - experienced patients
digoxin / digitalis glycoside
body mass index ( range ) ( kg / mnmbr )
patients with previous loss of response to infliximab
treatment group
haq - di , mean ( sd )
duration of copd ( years ) , mean ( sd )
egfr < nmbr , ml / min / mnmbr
carotid infarct
negative ( < nmbr . nmbr ) , n ( % )
endpoint week nmbr
homa - ir , mean ( sd ) ( mu / l $ mmol / l ) b
lipid and lipoprotein values ( mg / dl )
placebo no . of events / no .
for treatment of index event
mild ( > nmbr to < nmbr )
heterogeneity p value
number of stents ( per patient )
preoperative serum creatinine > nmbr pmol / l
sacubitril / valsartan ( n = nmbr )
mean ( s . d . ) apoc - ll nmbr , mg / dl
implanted cardioverter - defibrillator
swollen joint count ( n / nmbr )
postmenopausal ( % )
coronary disease
prior lev treatment
rsg nmbr mg / day
former or current smokers ( % )
topiramate
hydrochlorothiazide
toast classification of qualifying stroke , no . ( % )
class nmbr antiarrhythmic agents
age , mean nmbr sd years
concomitant methotrexate , n ( % )
corticosteroids . immunosuppressants . and antimalarials
bl mean , mg / dl ( mmol / nmbr )
history of diabetes mellitus , n ( % )
median ( iqr ) admission data
not provided
current bone disease
triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile]
stent plus abciximab
systolic blood pressure < nmbr mm hg and diastolic blood pressure < nmbr mm hg
vasoprotectives
associatedproximaldeep - veinthrombosisatdiagnosis , no . ( % )
discharge medication , n ( % )
other cardiac surgery , n ( % )
induction - trial group assignment — no . ( % )
bw , mean ( sd ) , kg
first procedure
prior af ablation , n ( % )
fevnmbr reversibilityz ( pre / post salbutamol ) , %
second - generation stent
msasss , mean ( sd )
total cholesterohhdl cholesterol ratio
primary safety end point : severe / life - threatening
nt - probnp ( pg / ml ) ( qnmbr - qnmbr )
remodeling
smoking past
cigarette smoking status
use of concomitant lipid - lowering therapy - no . ( % )
prior arrhythmias , n ( % )
thienopyridine at enrollment
coronary risk factors — no . ( % )
cardiovascular risk factors
less than nmbr year
anti - arthritic medications
some physical activity
first medical contact — no . ( % ) §
premature cad among family members
ppci in - nmbr
overall n = nmbr , nmbr
fevnmbr % predicted , post - albuterol , %
medical therapy only
aspirin and thienopyridine therapy
heart rate , mean ( sd ) , beats / min
tg , median ( interquartile range )
non - hispanic black
normal renal function
renal parameters
fasting blood glucose — mmol / liter
glycoprotein iib / iiiareceptorinhibitor
plaque ( n , % )
coronary angiography
age , mean ( min - max ) ( yrs )
evolocumab nmbr mg every nmbrweeks ( n = nmbr )
patients not receiving immunosuppressive agents at baseline
no . ( % ) with event [incidence rate per nmbr patient - y]
screening hbanmbrc ( % )
modified rankin scale — no . ( % ) |
previous cancer , n ( % )
penetrating
more than nmbr vessels stented
changes ( a ) in metabolic syndrome parameters hdl cholesterol
baseline acq - nmbr score
dm medication , n ( % ) c
left main disease
> nmbr lesions per vessel
xanthinesnmbr
tg ( mmol / l , median )
verapamil sr strategy ( n = nmbr , nmbr )
aspirin ( asa ) ( » = nmbr nmbr )
weight , mean nmbr sd kg
hispanic black
atrial fibrillation or flutter — no . ( % )
on - treatment
killip class i — no . ( % )
killip class ( interaction : p = nmbr . nmbr )
adjusted hr ( enl vs lcz ) ( nmbr % cl )
total basdai , mean ( sd )
placebo + statin ( n = nmbr , nmbr )
thrombus aspiration
marital status , married
no . of days to randomization — median ( iqr )
exacerbations in previous year
pain ( nmbr mm vas )
angiogenesis
non - fatal mi
who functional class — no . ( % ) : c
diabetic patients
type nmbr , n ( % )
abatacept nmbr / — nmbr mg / kg ( n = nmbr )
black race and ss < nmbr ( n = nmbr vs nmbr ) ■ -
baseline treatments , n ( % ) a
imm ( without corticosteroid )
mean ( sd ) number of exacerbations *
s . e .
spiralcomputedtomographyangiography
p ( losartan versus placebo )
apo b / apo a - l ratio ( mean )
mean ( s . d . ) non - hdl cholesterol
secukinumab nmbr mg
early - start group ( n = nmbr )
p interaction ( rx arm * sex )
left ventricular hypertrophy , n ( % )
af pattern
severity of copd
post - bronchodilator fev , , % predicted
copd or asthma , ( % )
body - mass index — no . ( % ) $
waist - to - hip ratio
nmbr years or older
years since myocardial infarction
with alogliptin nmbr mg ( n nmbr nmbr )
hoehn and yahr stage
elevated cardiac markers — no . ( % ) : t
scores for global and pain assessments §
documented coronary artery disease
large vessel atherosclerosis
hbalc < nmbr % ( < nmbr mmol / mol ) , n ( % )
copd severity
geometric mean
assoc , with connective tissue disease
chronic kidney disease stage : egfr ( ml / min per nmbr . nmbr mnmbr )
haq - di ( nmbr - nmbr ) , mean ( sd )
egfr crcl < nmbr ml / min / nmbr . nmbr mnmbr
baseline weight , kg
bifurcation , n ( % )
pe ( with or without dvt )
differencenmbr
dilatative , n ( % )
arterial access
serum cholesterol ( mg / l ) *
cerebral thrombosis
rosuva nmbr mg
dose of atorvastatin
mean ( sd ) weight , kg
congestive heart failure — %
no prior ms therapies
glucocorticoids only
background aha therapy at screening , n ( % )
established atherosclerotic cv disease §
angina symptoms^
pain ( vas )
stroke subtype , n ( % )
with placebo
relative risk ( nmbr % confidence interval )
r nmbr mg + fa ( « = nmbr )
previous pci or cabg
total pack - yrs
baseline trl - c by quintiles
mtx > nmbr and £ nmbr mg / week
ff / vi nmbr / nmbr | ig ( n = nmbr )
( nmbr % ell ' ll
corticosteroids and immunosuppressants only
number of vessels treated , index pci
mra ( spironolactone or eplerenone )
peripheral artery occlusive disease
baseline value
chronic cvd
established ( n = nmbr )
known thrombophilia
normal > nmbr - nmbr
estimated gfr renal function stage
tg , mmol / l ( mg / dl ) [median]
clinical characteristics
interval after index event
country , n ( % )
fractures ( site not specified )
number of previous dmards
non - hispanic
proportion of patients in corticosteroid - free clinical remission at week nmbr
pramlintide
height , inches
antithrombotic agents
ambulance , n ( % )
chd risk - no . ( % )
infusion administered — no . / total no . ( % )
non - hdl cholesterol ( week nmbr )
inhaled glucocorticoid use at screening
type of vessel involved
oral blood glucose - lowering drug nmbr ( nmbr . nmbr )
baseline pos frequency per nmbr days , median ( min , max )
mean ( sd ) mtx dose , mg / week
laboratory ae , n ( % }
use of concomitant lipid - lowering treatment
age ( y ) , median ( iqr )
heart failure , lvef < nmbr % , or both
omalizumab ( lsm )
baseline cv medications , n ( % )
nmbr or nmbr high cardiovascular risk categories
pack - years smoked
exenatide lar
concomitant treatment
score on the minnesota living with heart failure scaled
eosinophil count ( cells per pl )
disease duration ( yr ) , mean ± sd
baseline total pcsknmbr level by median
antiplatelet agents ( % )
peripheral vascular disease , n ( % )
duration of disease — yr : t
infarction nmbr - nmbr days
estimated difference ( nmbr % ci )
non - st - elevation myocardial infarction
aspirin i clopidogrel ( n = nmbr , nmbr )
pulmonary disease — no . ( % )
etn nmbr mg + mtx n = nmbr
all stroke
previous respiratory disease other than copd — no . ( % )
history of stroke or transient ischemic attack
pelvic fractures
standard care allocation
ra duration ( months ) *
other drugs — no . ( % )
atherosclerotic disease *
angiography and revascularization
unfractionated heparin ( n = nmbr )
demographic and clinical characteristics
mean lixi dose ± sd ( lg / day )
number ( % )
age subgroups
ind / gly nmbr / nmbr mg once daily ( n = nmbr )
glycated hemoglobin , mean ( sd ) , %
no . of events / no . of patients
carotid artery intervention *
hope patients with coronary - artery disease ( n = nmbr )
linagliptin / metformin
ultrasound carotid arteries
pci or cabg surgery for index event
dasnmbr - nmbr ( esr ) nmbr
cardiac therapy §
low - dose statin
oral anticoagulant , n ( % )
p - value for interaction nmbr . nmbr
> nmbr des type
placebo patients with events / total
average age ( year )
placebo + nmbr mg / d of simvastatin
baseline hb nmbrg i nmbr n = nmbr
type of end point
copd medication at study entry
emphysema
mean ( sd ) esr , mm / h *
vilanterol , n = nmbr
latin america ( n = nmbr )
third heart sound
tnfi naive
continued thienopyridine ( n = nmbr )
total intravenous loop diuretic ( mg ) median
mild to moderate
median n - terminal probnp ( iqr ) — pg / ml
degree of stenosis , % of diameter
diagnostic angiography
left ventricular hypertrophy on echo
fasting serum glucose , median ( sd ) , mg / dl
abatacept plus mtx ( n = nmbr )
baseline measurements
non - compliance
duration of pre - randomization anticoagulant therapy
bmi at baseline ( kg / mnmbr )
average maximum common and bifurcation cimt ( mm )
location
kheeatne index dvt
osteitis
nmbr - nmbr months fn = nmbr . nmbr )
glinide 一 no . ( % )
below - knee popliteal crural
pre - enrollment antihyperglycemic therapy
symptom duration
% patients with no progression
measured at clinic visit with automated device §
previous episode of heart failure
liraglutide ( n = nmbr )
hbanmbrc , % ( sd )
post - bronchodilator fevnmbr — liters
renal insufficiency
lvef within nmbr mo , %
ldl cholesterol , mmol / l , mean ± sd
history of hypertension for nmbr mo or more
fish oil ( n = nmbr )
digitalis glycoside
baseline mean
no previous dmard therapy
hbanmbrc at nmbr weeks *
glycated hemoglobin
elevated fasting glucose
no adk / e cancer
indacaterol + tiotropium ( n[nmbr )
ras % target dose
history of upper gastrointestinal event
ibdq score |
first primary ( change in updrs score / wk , wk nmbr - nmbr )
overweight ( nmbr to < nmbr kg / mnmbr )
symptom onset - to -
median ( iqr ) cholesterol ,
week nmbr mean ( se )
western europe , israel , australia , or south africa
imm + corticosteroid , n
tnmbrdm duration , y
previous myocardial infarction , n ( % )
no . ( % ) of participants
previous tnf antagonist exposure , n ( % )
pharmacotherapy
ulcerative colitis
received nmbr prior anti - tnf therapy , n
placebo n ( rate ) *
low - density lipoprotein
family history^
fvc ( % predicted )
clinical ae , n ( % }
dietary epa - dha intake ( mg / day ) *
other llt use
ada nmbr / nmbr n[nmbr
serious adverse events
change from baseline at week nmbr
medications at coronary angiography
nmbr nmbr years , n ( % )
no . of subjects
fpg , mean ( sd ) , mg / dl [mmol / l]
acrnmbr response , n / n ( % )
sfc nmbr / nmbr mg twice daily ( n = nmbr , nmbr )
geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mmnmbr
copd - placebo ( n = nmbr )
pga subscore
mafcaiancy at randorrtzaton
nmbr . nmbr mg / dl triglycerides^
antiplatelet within nmbr mo before randomization
lesion characteristics
handihaler and diskus , n
baseline dyspnea index score
creatinine clearance — no . ( % )
any oral hypoglycemic drug 一 no . ( % )
sfcnmbr / nmbr pg b . i . d . n = nmbr
infarct related artery location
pen - label empagliflozin nmbr mg ( baseline hbanmbrc > nmbr % )
other vasculars
patients who received indeterminate results on test for antibodies to infliximabt
history of diabetes requiring drugs
coronary intervention
elevated at wk nmbr — no . ( % ) !
body mass index category , no . ( % ) l
liraglutide nmbr . nmbr mg mean ( n )
habnmbrc ( mean ± sem ) , %
low risk ( nmbr - nmbr )
gfr as assessed by mdrd
history of ischemic stroke
nmbr - minute walk distance — m
male / female , %
current inhaler +
phosphate ( mmol / l )
established cardiovascular disease
smoker ( current / former )
total cholesterol - to - hdl cholesterol ratio
oral anticoagulant drugs , n ( % )
definite
abciximab - facilitated pci ( n = nmbr )
computed tomographic angiography
distribution — no . ( % )
intravenous heparin
nmbr . nmbr to < nmbr . nmbr % ( nmbr to < nmbr mmol / mol )
nmbr - month follow - up median ( iq range )
biventricular pacemaker
warfarin group
nmbr aspirin ( n = nmbr nmbr )
short form nmbr ( sf - nmbr )
individual intended study duration — no . ( % )
male nyha class
metoprolol group ( n = nmbr )
fenofibric acid
warfarin at enrollment
global ischemia
p value § ( < nmbr vs . > = nmbr years )
hf or lvef < nmbr % associated with index event
subject completion status , n ( % )
egfr — ml / min / nmbr . nmbr m * *
coronary angioplasty or stenting
death from cardiovascular causes
nmbr mg / dl ldl cholesterol | |
femur fracture
erythrocyte sedimentation rate , mm / hour
insulin sensitivity — % §
anti - tnf agent ( s )
medication after enrolment
number insulin glargine
asian ( nmbr . nmbr % )
lifestyle modifications
change from
% change , nmbr % ci )
< nmbrnwrrtn
moderate renal impairment
major diabetic eye disease , n ( % )
all participants
history of atrial fibrillation / flutter , ( % )
apixaban dose ( or matching placebo )
symptom onset
prosthetic
disease hare . no . ( % ) i
treatment by egfr stage
hormonal therapy — no . ( % )
angina pectoris , ( % )
type of stent at index procedure
blood pressure lowering medication use
gpi used during pci
lowzmedium intensity
antihypertensive therapy , n ( % )
any medication
mean — mm hg level — no . ( % )
chd simva nmbr = nmbr]
diabetic history ( years ) x
urine albumin / creatinine ratio ( mg / g )
extensive colitis or pancolitis
moderate ckd at randomization
less than the median
qualifying cv event , n ( % )
peripheral artery occlusive disease ( stage nmbr / nmbr / nmbr / nmbr / nmbr )
or placebo treatment
diabetesnmbr ( % )
continued thienopyridine ( n nmbr nmbr )
saxagliptin nmbr . nmbr mg
patients with ra , as , or psa ( n = nmbr )
chronic bronchitis ( % )
"reduction 
 in risk 
 ( nmbr % ci ) %"
moderate disease activity : > nmbr . nmbr to < nmbr . nmbr , n ( % )
age nmbr years or more
valsartan / hctz ( n = nmbr )
ics users , n ( % )
since onset
diabetes at randomization
treated with pci — no . / total no . ( % )
device group ( n = nmbr )
left main coronary artery , n ( % )
statin use at study entry , n ( % )
lipid disorder
history of atrial fibrillation , type 一 no . ( % )
total diuretic dose ( iv + oral ) on day nmbr , mg
enthesitis , n ( % )
immobazaton
digit symbol substitution
prior coronary revascularization ( pci or cabg )
hbalc , median ( ql , qnmbr ) , %
fasting cholesterol — mg / dl
idiopathic
mean ( sd ) [range]
inhaled corticosteroids
fasting insulin — pmol / liter
watchman ( n = nmbr )
apixaban , nmbr . nmbr mg ( n = nmbr )
primary renal endpoint
hgb , g / dl
normal ( > nmbr )
type of des at index procedure
nmbr vitamin e ( n = nmbr nmbr )
persistent wrf ( n = nmbr )
estonia
score on modified rankin scale ( ' % / '
atrial fibrillation or flutter ( ecg ) §
adcs - adl score *
mean sfnmbr score ( nmbr % ci )
qrs > nmbr ms , n ( % ) , available for nmbr patients
baseline high - sensitivity crp
heart rates ( beats / minutes )
insulin glargine allocation
left side of colon
left ventricular hypertrophy
non - cortical
low - density lipoprotein cholesterol , median , ( nmbrth — nmbrth percentiles ) , mg / dl
unsuccessful procedure
previous angina , n ( % )
nmbr . nmbr to nmbr . nmbr ( % )
nt - pro - bnp — pmol / liter - j -
sirukumab nmbr mg qnmbrw
baseline post - bronchodilator % predicted fev , > nmbr % and concurrent tiotropium use
euroscore additive , median ( nmbrth , nmbrth % ) §
lev - naive
clinical disease activity index score ( nmbr - nmbr )
black / african - american ( nmbr . nmbr % )
chronic coxnmbr inhibitors
no . of coronary vessels with > nmbr % diameter stenosis
history of claudication
seated sbp at nmbr weeks , mmhg +
ended > nmbr days before trial entry
rope score * *
inter p - value
risk factor profile index event
use of ace inhibitor , arb , or both — no . ( % )
clopidogrel , nmbr mg loading dose !
adverse eventy
discontinued
duration of osteoarthritis symptoms — yr
total cholesterol - mg / dl * *
peripheral revascularization ( n = nmbr )
smoking in past yr
percentage of patients using ics or ics / laba on entry
mean change ,
neither ics nor laba
combination - facilitated pci ( n = nmbr )
bifurcation
coronary heart disease death
< nmbr mg / dl eze / simva ( n = nmbr }
a / v ( n = nmbr ) v ( n = nmbr )
hypertrophic cardiomyopathy
median body mass index , kg / mnmbr ( iqr )
nmbr - year framingham chd risk ( % ) nmbr mean / sd )
ecrcl , ml / min
time from longest event to randomisation
no prior hf hospitalization
conservative
serum creatinine ( pmol / l ) , mean ( sd )
any cv history / risk factors , n ( % )
vte at day nmbr +
age of completion of highest education , years ( sd )
pfo + asa
nmbr mg / day - placebo
mtss cfb
mental component summary
low - density lipoprotein cholesterol tx difference vs pbo , ls mean % change from baseline ( se )
dihydropyridine calcium - channel blocker
germany
high sensitivity c - reactive protein ( mg / l )
azathioprine
high risk ( ri ≥ nmbr )
egfr ( ml / min per nmbr - nmbr m ' )
ez / simva nmbr mg
patients receiving immunosuppressive agents at baseline
demographics age , years , mean ( sd )
previous aorta - femoral or lower extremity bypass surgery , pta of iliac , or infrainguinal artery
fracture
clopidogrel loading dose nmbr mg
renal insufficiency — no . ( % )
caucasian eze / simva ( „ = nmbr }
tg mg / dl , median ( sd )
locafon of index dvt
baseline nihss
clinical details
limited i -
intracranial disease of major artery 寸
mean bp ( mmhg )
no chd eze / simva nmbr = nmbr }
heart rate , b . p . m . mean ± sd
estimated glomerular filtration rate - no . ( % ) : :
moderate n z nmbr
central nervous system
drug - eluting stent implanted — no . ( % )
elevated bnp ( nmbr pg / ml ) , %
verapamil - sr strategy
baseline steroids
c - reactive protein , median ( qnmbr , qnmbr )
albumin measurements^^
dactylitis
no hypertension ( n = nmbr )
history of other medical conditions , n ( % )
placebo allocation
cyclosporin
symptom onset to hospital arrival , hours
before amendment
baseline erosion
minimal important change threshold ( improvement ) a
digoxin
left ventricular ejection fraction , mean ( sd ) , %
new york heart association congestive heart failure class
haemoglobin ( g / dl ) , mean + sd , available for nmbr patients
peripheral arterial revascularization
median daily dose - iu ™
hla - bnmbr positive , n ( % )
renal function ( egfr , ml / min / nmbr . nmbr mnmbr )
ldl particle numbers ( week nmbr )
serum ldl cholesterol
all grafts
stroke thought due to atherothrombotic disease
first hhf
primary angioplasty ( n = nmbr )
atenolol strategy ( n = nmbr )
prothrombin mutation ( % )
cardiovascular risk factors and medical history
valsartan , n ( % )
qrs > nmbr msec nmbr - min walk test
immobilization at randomization , n ( % )
difference
participants n
left ventricular ejection fraction , median ( iqr ) , %
associated with corrected
ckd ( egfr < nmbrb )
lowering drugs
concomitant cardiovascular therapy ( taken > nmbr days )
post - bronchodilator fevnmbr / fvc ( % ) a
no . evenls
medical treatment
previous angina pectoris
indeterminate ! !
select lipids and lipoproteins
nmbr - year framingham chd risk
> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr ) — number / n ( % )
egfr ( ckd - epi , cystatin c ) , ml / min / nmbr . nmbr mnmbr
previous receipt of therapy against tnf - a — no . ( % )
prior to index event
race , % of patients
apo a - i , mg / dl
vessel treated , n
non - smokers receiving lipid - lowering drugs , p blockers ,
estrogen therapy
haq - di total score , mean ( sd )
high density lipoprotein cholesterol - mg / dl * *
systolic pulmonary arterial pressure , mean ( sd ) , mm hg
> qnmbr ( nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % )
das - nmbr ( crp ) , mean ( sd )
blood transfusion
partial evolving to secondarily generalized ( ic )
hscrp > nmbr to < nmbr mg / l
ra symptom duration < nmbr months — number ( % )
ldl - c < nmbr mg / dl
ace / arb medication ( % )
positive family history of type nmbr diabetes ( % )
urinary albumimcreatinine ratio
diabetes treatment
mucolytics
pooled analysis
infliximab
iduration of symptoms > nmbr min
estrogens
nmbr mg twice daily n = nmbr
major gastro - intestinal bleeding
anti - ccp antibody positive , n ( % )
egfrmdrd , ml / min / nmbr . nmbr mnmbr bsa
weight > nmbr kg , n ( % )
multiple diagnoses
cholecystitis chronic
baseline % bsa involvement
> nmbr corticosteroids or immunosuppressants
history of atrial arrhythmia , n ( % )
chronic pulmonary disease
> nmbr , obesity class nmbr
congestive heart failure ( definite )
average dose ( mg / week )
urinary albumin : creatinine ratio *
previous pci ( % total )
highest killip classiciation pre - pci
edss stratification , no . ( % )
exenatide no . of events / total no . ( % )
method used to diagnose the incident pulmonary embolism , no . ( % )
blood glucose
rf or acpa positive
congestive heart failure — no . ( % )
mean ucsd - sobq score * ( sd )
morphine use for index event / pci
albumin - to - creatinine ratio ,
region , north america
medical therapy alone
continuation
nmbr ( fevi nmbr - < nmbr % pred )
anmbrs - hydroxy -
qrs interval > nmbr msec — no . ( % )
streptokinase
haq - di improvement > nmbr . nmbr
baseline cv treatment , n ( % ) y
adalimumab croup , n / n ( % )
apob ( week nmbr )
systemic arterial hypertension , n ( % )
reversibility to salbutamol , %
overall , male : female
nmbr p value
evolocumab ( nmbr mg )
bifurcation lesion
time from onset of symptoms to randomization — days
thiazide at last follow - up
% change median baseline crp > nmbrmg / l
blood pressure systolic , mm hg
hf hospitalizations , median ( iqr )
history of carotid artery disease
history of diabetes mellitus
prior treatment historynmbr
patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +
interactionnmbr
no history of migraine
mild ( gold nmbr )
iii : fevnmbr > nmbr % - < nmbr % predicted
cat score category
baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr , nmbr
statin only
drug therapy at admission 一 no . ( % ) aspirin
fatty acid profile
residual deep - vein thrombosis , no . ( % )
unstable angina , n ( % )
completed trial
duration of symptoms , h
% predicted ” fev , at baseline , % *
aspirin dose at randomization
normoglycemia^
race / ethnicity
oral antidiabetic drugs
ef nmbr - nmbr % hfmref ( n = nmbr , nmbr % )
cerebral embolism
fevnmbr / fvc prebronchodilatort
previous use of antiplatelet drugs
laba non - users
thiazolidinedione based
chronic respiratory failure
coronary artery disease history
current prescribed medications
current weekly alcohol use ( % )
calcium ( mmol / l )
region ( pooled )
bdmard - naive
general andthoracic epidural
first co - primary outcome
cvd , mi , stroke , or recurrent ischemia - urgent revascularization , or hospitalization for unstable angina
age at enrolment , years
not available
use of antiplatelet agents^
aspirin or thienopyridines ( % )
baseline trig > nmbr millycerides g / dl
baseline anti - hypertensive usea
intent - to - treat population , n ( % )
dyslipidaemia and hypertension , n ( % )
saxa nmbr . nmbr mg ( n = nmbr )
estimated response rate and odds ratio
first loading dose
ex - smokers nmbr
atrial fibrillation ldl cholesterol level
duration of
weight ab , %
race or ethnic group — no . / total no . ( % ) f
loop at enrollment
current cigarette use , n ( % )
central europe
atopic ( based on phadiatop test )
baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr change from baseline to nmbr weeks
kccq ( nmbr months )
mean eq - nmbrd response ( nmbr % ci )
tp vs no tp
mitral insufficiency
r nmbr mg + fa
total study population
subacute ( nmbr - nmbr days )
assoc , with corrected congenital shunts
spinal fractures
multivessel disease , n ( % )
normoalbuminuria or microalbuminuria
low ( no risk factor )
hospitalisation for chf within nmbr years of randomisation
rec . ischemia due to ecg changes
event / patients ( nmbr / pt - y )
calcium - channel antagonists
angiotensin receptor
dbp , mean ( sd ) , mm hg glycaemic parameters
priorother ( predefined ) medical conditions
tnmbr lesion volume , mmnmbr
african - american / african heritage ( n = nmbr )
new anti - anginal therapy
smoking : current smoker
total cataract
no . of patients ( % )
ami nmbr mg n = nmbr
baseline lvef
change from baseline stage nmbr ckd
indacaterol group ( n = nmbr )
iv : fevnmbr < nmbr % predicted
education nmbr - nmbr years
waist circumference
hispanic — no . ( % )
> nmbr . nmbr ml / min / nmbr . nmbr mnmbr
rituximab , n = nmbr
stroke , n ( % )
family history of premature
change in bp , mm hg
nonfatal ischemic stroke
pci delay due to low risk
prior percutaneous coronary intervention
oral anticoagulant agent
alcohol intake ( a )
hbanmbrc subgroups
history of atherosclerotic vascular disease — no . ( % ) §
renal function : creatinine clearance
mercaptopurine
transient monocular blindness
nyha functional class , n ( % )
entire cohort gender
inhaled §
patient global assessment of pain ( vas nmbr - nmbr mm )
rituximab ( nmbrxnmbr mg ) + mtx ( n = nmbr )
peripheral artery revascularization without amputation
other cause , n ( % )
immunosuppressants and antimalarials only
* * positive stress test
aspirin use at baseline
randomisation scheme
ala carriers
arterial hypertension — no . ( % )
bmi ( median , iqr ) , kg / mnmbr
alternative disability
non - hdl cholesterol / apob ( ratio )
other risk factors
hf hospitalization or cardiovascular death
no revascularization for index acs event
p - value for variance
apo b , mean ( sd ) , mg / dl
at ldl - c ( bq ) goal * at baseline - no . ( % )
missing data initial diagnosis — no .
aspirin at enrollment
prespecified analysis
k ( rate )
r | r ' ' ' ( nmbr % ci )
glyburide dose duringthe study ( mg )
ptca / cabg
score , %
seizure types reported during baseline , b n ( % )
biologic therapeutic failure
simva ( „ = nmbr }
partial mayo score , mean ( sd )
selected clinical characteristics — no . / total no . ( % )
. nmbr . nmbr ml / s / mnmbr ( nmbr ml / min / nmbr . nmbr mnmbr ) , n ( % )
prior use of conventional dmards only ( biologic - nai ' ve ) , n ( % )
family history , n ( % )
patients with diabetes mellitus
thiazolidinedione ( includes pioglitazone )
corticosteroids and antimalarials only
total pack - years mean ( sd )
medications at study entry — no . / total no . ( % )
gold iii - iv
reason for enrollment in active a
asia / australia / new zealand
octave induction nmbr
tachyarrhythmias , n ( % )
europe n z nmbr
"atrial fibrillation alone ) ;"
supraventricular tachyarrhythmias ( incl . atrial
previous cerebrovascular event
stroke — no . ( % )
bronchodilator response , ml
nmbr ( fevi ^nmbr % pred )
mental component
apo a - l ( g / l )
veflonzumao
pfo with large shunt and atrial septal aneurysm
classification of index venous thromboembolism — no . ( % )
fevnmbr at baseline
incidence rate per nmbr person - years
time of randomization ( interaction : p = nmbr . nmbr )
chronic renal failure , n ( % )
both deep - vein thrombosis and pulmonary embolism
myocardial infarction without st - segment elevation — no . ( % )
pooled eze / simva
other sglt - nmbr inhibitor
clavicle fracture
ecg abnormality ( resting ) , %
musculoskeletal stiffness
psoriatic arthritis , %
medication prior to admission , ( % )
death / st
bdi focal score
time to randomisation [hours] ( interaction : p = nmbr . nmbr )
laboratory examination
placebo patients with events
organ system involvement , no . ( % )
enalapril lcznmbr ( n = nmbr ) ( n = nmbr )
high - dose statin
peripheral
ldl cholesicrol ( minol / l )
hispanic / latino ethnicity , n ( % )
nmbr - nmbr drinks
aborted cardiac arrest
baseline crp < nmbrmg / l
relative risk reduction ( nmbr % cl ) percent
unprotected left main stented
catheterization performed for qualifying event
fraction ( % )
nmbr % ci for difference
index event to randomization , median ( iqr ) , h
inclusion criteria — no . ( % )
normal hscrp
^nmbr - cell function — % §
previous tnf - antagonist use , n ( % )
depressed only
acute infection without septic shock
mtss units
previous statin use
mean ( s . d . ) calculated ldl cholesterol
nmbr % confidence interval
type of concomitant statin by daily dose
statin with ezetimibe
history of ml or ischemic stroke
within nmbr h
placebo n = nmbr n ( % )
nyha class not reported
neither uh or lmw heparin
fpg tx difference vs pbo , median change from baseline ( se ) nmbr
iglarlixi ( fixed - ratio combination )
previous congestive heart failure
periostin ( ng / ml )
belimumab nmbr mg sc ( n nmbr )
glycatedhemoglobin category , %
canvas - r
waist circumference , cm mean ( sd )
tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr )
africa , asia , or the middle east
history of gestational diabetes mellitus — no . ( % of women )
non - black race ( n = nmbr vs nmbr )
community hospital
not - japan n = nmbr , nmbr
stage > nmbr chronic kidney disease ( % )
nmbr - hr plasma glucose — mg / dl
not at goal
concomitant aminosalicylates , n [ % ] concomitant corticosteroids , n [ % ] mayo score , mean [sd]
baseline fecal caicrctectin
hospitalization for unstable angina
patients having exacerbation
regular alcohol consumption per week , no . ( % )
"improving anemia bsl hb < nmbrg i - nmbr ; yr nmbr > nmbrg i - nmbr"
qualifying peripheral arterial disease
previous bypass surgery , n ( % )
anthropometric characteristics
baseline fevnmbr , l *
nmbr - lead ecg heart rate , beats / min
aspirin + dipyridamole ( n = nmbr )
patients entering pt period n = nmbr
surgical technique
psoriatic arthropathy
with alogliptin nmbr mg
revascularisation but no antiplatelets , lipid - lowering agents , or p blockers
pfo with large shunt without atrial septal aneurysm
clinical and patient - reported characteristics at baseline and randomization
or ( unadjusted )
unknown or missing
reported high cholesterol ' !
syndecan - nmbr ( ng / ml )
long - acting
use of antiarrhythmic agent
egfr using cg / mdrd formulae , % of patients
baseline body mass index
swollen - joint count ( of nmbr joints )
region , n ( % )
> nmbr - nmbr mg / week
hypertensionnmbr ( % )
psa - modified total shs
minor ischaemic stroke
annualized rate ind / gly sfc
sulfasalazine
mean change at week nmbr
acpa positive ( > nmbr iu / ml ) , n ( % )
history of strokenmbr
long - term warfarin ( n - nmbr )
crp ( mg / l ) , median ± sd
obese ( > nmbr kg / mnmbr )
facit - fatigue . mean nmbrsd ( range nmbr - nmbr )
infarct location ( interactsn $ : p = nmbr . nmbr )
not hospitalized for heart failure in the year prior to study enrollment
calcification , n ( % )
all ischemic stroke
rosuvastatin , n ( % )
hormone replacement therapy use
older than nmbr years
rolofylline
apo a - nmbr , mean ( sd ) , mg / dl
long - term antiplatelet therapy
prior bypass graft surgery
bone erosion ( judged by physician ) , n ( % )
triglyceride ( mm
cigarettesmoking , %
pentraxin - nmbr ( ng / ml )
tnfi exposed
history of atrial fibrillation , n ( % )
asa or antiplatelet agent
ischemic stroke ( vs . tia )
men : women ( % )
patients not treated with statins ( n = nmbr )
severe renal impairment
om nmbr mg / aml nmbr mg / hctz nmbr mg
history of atrial fibrillation
corticosteroid use at baseline
sedentary
no . of patients ( indacaterol / placebo )
insulin plus oral
> nmbr . nmbr , n ( % )
ics use , %
age category ( years ) , n ( % )
atherosclerotic disease ( % )
copd duration , y
thrombolytic therapy
acpa positive , n ( % )
baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr , nmbr change from baseline to nmbr weeks
acei vs . non - acei
risk factors for atherosclerosis
bifurcation lesion with side branch $ nmbr . nmbr mm stented
fevi , % predicted *
heart rate at rest in the supine position ( beats / min )
feno nmbr mg / eze nmbr mg ( n = nmbr )
mean ( s . d . ) total pcsknmbr , ng / ml
baseline cdai score , mean ( sd )
severity of copd , combined assessment , n ( % )
ambulance ( % )
estimated means and difference
concomitant medication ( % )
qualifying atherosclerosis
ada impaired fasting glucose
death , q wave mi or ischemia - driven revasc
stented vessels
diabetes duration , n ( % )
tender - joint count , of nmbr joints examined
verapamil sr
thiazolidinedione 一 no . ( % )
difference , % median
edema , ( % )
medications on admission , %
rf positive ( > nmbr iu / ml ) , n ( % )
worsening heart failure
previous limb or foot amputation
alcohol consumption ( % )
uacr , mgg nmbr ( gm )
om nmbr / aml nmbr /
hypertension history
swollen - joint count , of nmbr joints examined
racial group , n ( % )
nmbr to < nmbr ml per nmbr - nmbr mnmbr
risk factors
deep vein thrombosis only
within last nmbr d
egfr at baseline , nmbr ml / min ( % ) b
low - density lipoprotein cholesterol , mean ( sd ) , mmol / l
intermediate
duration of hypertension ( months )
wapnmbrc ( ng / ml )
left circumflex artery , n ( % )
fpg , median ( ql , qnmbr ) , mmol / l
ischaemic cause
total cholesterol > nmbr mg / dl
intention - to - treat
enoxaparin / vka n / n ( % ) nmbr / nmbr ( nmbr . nmbr )
in - stent restenosis
high risk without atherosclerotic vascular disease +
priorother ( not predefined ) medical conditions
reteplase / abciximab - facilitated pci ( n = nmbr )
established atherosclerotic disease , n ( % )
concomitant drugs , %
after amendment ( % )
antianginal medications
eular good response
ls means difference ( nmbr % ci ) nmbr
prior stroke ( before index event )
interval from onset of symptoms
low risk ( ri = nmbr - nmbr )
patients with prior copd - related
duration of ra , mean ( min - max ) ( yrs )
myocardial infarction / cabg / pci < nmbr years
dilatative
ncep atp iii risk factors
change from baseline , adjusted mean ( nmbr % ci )
antiarrhythmic therapy
mean ( sd ) tender joint count *
• ? sd ml / min
renal function ( egfr , ml / min / nmbr . nmbr mnmbr , according to mdrd ) , n ( % )
serum creatinine
"first - recorded event ; no . ( and % ) of patients"
fevi , l , mean ( sd ) nmbr
male / female
unknown ( none of the above )
baseline creatinine clearance
drug - eluting stent — no . ( % )
mean disease duration , years
spacer use during the study
non - end - stage renal dysfunction
duration of epilepsy , years , mean ( sd )
blood pressure control
medications through day nmbr
nyha class ii ( n = nmbrlnmbr )
nadroparin
past smoking
nmbr - min walk distance ( m )
biologics user
other medical history — no . ( % )
blood pressure ( % )
sfc nmbr mg / nmbr mg
cardioversion in previous nmbr wk
nmbr - nmbr ( low risk )
hypercholesterolemia ( > nmbr mg / dl )
use of medication at baseline — no . ( % )
revascularization during index hospitalization , %
gender , %
brv dosage , mg / d
not rando . in na *
age , median ( iqr ) , years
oral antidiabetic drugs / insulin ( % / % )
risk factors specified as inclusion criteria — no . ( % ) f
asian or pacific islander
reversibility : > nmbr - < nmbr %
average daily dose ( % of target ) *
target - vessel revascularization
severity of copd — no . ( % ) f
lvef , % , median ( iqr )
fevnmbr / fvc , post - albuterol , %
esrd saxa nmbr . nmbr mg ( n = nmbr )
time since diagnosis of pah — yrf
right coronary artery , n ( % )
younger patients ( agednmbr years )
fvc ( l ) proportion taking pulmonary medications ( % ) b
vein graft stented
qualifying stroke
difference vs . pbof mean ( s . e . ) t
oral hypoglycaemics only
baseline history of vascular disease ( % )
prednisone - equivalent dose — mg
aspirin alone group no of events / total n ( % )
known thrombophilic condition — no . ( % )
blood eosinophil proportion ( % )
( a ) demographics
cox bsl + yr nmbr hbd
direct thrombin inhibitors
body - mass index - kg / mnmbr , median ( iqr )
acute coronary syndrome
waist circumference , cm ( sd )
moderate impairment ( egfr nmbr - nmbr )
use of supplemental oxygen , n ( % )
unadjusted or ( nmbr % ci ) p value
rarely / never
st - elevation myocardial infarction
woscops
age ( yrs ) , mean *
non - ischaemic cardiomyopathy
history of myocardial infarction , n ( % )
cardiac catheterization
estimated glomerular filtration rate , n ( % )
no aspirin or ppi
inadequate response
drinking , n ( % )
non - ics +
endovascular
sbp ( mmhg ) , mean ± sd
hormone - refractory prostate carcinoma
drug - eluting stent implanted ( at least one )
pah origin / cause
experience
chinese subgroup
history of cardiovascular events
disease duration : < baseline mean
physician ' s global assessment . mean nmbr sd
glycated hemoglobin < median
% stenosis , as assessed by core laboratory
upper respiratory tract infection
antibiotics * *
normoalbuminuria — no . / total no . ( % )
aggressive ( nmbr )
patients with specific disease characteristics
work and school
activity ( nmbr - nmbr vas )
age ( yrs ) nmbr - nmbr
afcaps /
clinical presentation of vte at initial diagnosis — no . ( % )
aspirin < nmbr hours
glucosamine ( n = nmbr )
neither ace inhibitor nor arb
previous coronary intervention
time since diagnosis of diabetes — no . ( % )
egfr ( ckd - epi , cystatinc ) , ml / min / nmbr . nmbr mnmbr , n ( % )
dyslipidaemia and hypertensiont
presence of erosions , n ( % )
sitting pulse , bpma
post - cabg
cigarette smoking , mean pack - years ( sd )
> nmbr - nmbr ( moderate risk )
triglycerides tx difference vs pbo , ls mean % change from baseline ( se )
nmbr - nmbr / nmbr - nmbr mm hg
body mass indexa < median
dmard user
admission for hf in previous year
duplex ultrasonography
all of the colon
nmbr - nmbr - nmbr , obesity class nmbr
coronary artery disease — no . / total no . ( % )
"body mass index ; mean + sd ( kg / m )"
> nmbr previous venous thromboembolisms ( % )
remission at maintenance - trial entry — no . ( % )
improved
treatment stratum^ :
red blood cell counting , nmbr / l
nmbr - wk kaplan - meier rate , %
continuous variables , mean ( sd )
intensified nmbr months ( n - nmbr )
elevated troponin
smoking history : current smoker
jbs - nmbr primary prevention onlynmbr
( se]tf hdl - c
baseline hs - crp tertiles ( mg / i]
not reported
diabetes and currently on an oral hypoglycaemic agent orinsulin
standard care n ( % ) / nmbrpy
apremilast
anterior myocardial infarction — no . ( % )
oxcarbazepine
mildly impaired
incidence [n / n ( rate per nmbr person - years ) ]
blood pressure at target level ( % ) §
egfrmdrd ， ml - min - nmbr - nmbr . nmbr m_nmbr
benign prostatic hyperplasia
> nmbr erosion , n ( % )
body - mass index > nmbr
alcohol consumption , n ( % )
rhabdomyolysis or myopathy
treatment arm
concomitant therapies at hospital discharge
hbanmbrc in patients with baseline hbanmbrc > nmbr % ( > nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )
specific risk of bleeding^
number resulting in emergency department visit
elevated troponin ( > nmbr . nmbr pg / l )
hi ) ah ( % )
number of exacerbations
cpk > nmbr times uln
glucosamine + chondroitin sulfate ( n = nmbr )
serum trap - nmbrb ( u / liter )
sex ( male ) ethnic origin
no corticosteroids or immunosuppressants
lvef within nmbr months , %
ls mean change from baselinenmbr
uric acid ( mg / dl ) creatinine clearance ( ml / min per nmbr . nmbr mnmbr )
weight — kg ( median )
non - black
myocardial infarction
duration of assigned regimen before surgery
asian / black / white / hispanic / other ( % ) clinical parameters
> nmbr mg / dl eze / simva nmbr = nmbr }
risk factors for pad
baseline hemoglobin , median ( iqr , g / dl )
insulin , iu / ml , median ( qnmbr , qnmbr )
prior percutaneous coronary intervention — no . ( % )
other bdmard §
icd therapy ( n =
apo a - l ( mg / dl ) - mean ± sd
with alogliptin nmbr . nmbr mg ( n nmbr nmbr )
symptomatic pad of lower extremities *
pfor heterogeneity
severe impairment ( egfr < nmbr )
previous use of amiodarone
levetiracetam
peri - op beta - blockers : no ( n = nmbr )
patient global assessment ( nmbr - nmbr mm vas )
background treatment , n ( % )
high titre ( > nmbr times of uln ) , n ( % )
no corticosteroid , no imm
greater than or equal to nmbr mm hg
antiarrhythmic agent
white not of hispanic origin
cause of dvt or pe — no . ( % )
sulfonylurea — no . ( % )
mean preoperative abpi of the index
met criterion at finalt
orthopnea , ( % )
total mortality
pace , no . ( nmbr )
non - caucasian simva
high periostin subgroup ( > nmbr ng / ml ) ( n = nmbr )
overall population
all randomized women
respiratory - related^
treated vessel - native coronary
< nmbr . nmbr mmol / liter estimated gfr
prior ms treatment with ifn - beta or
no hemoconcentration hemoconcentration
clopidogrel , nmbr - mg loading dose
body weight ( kg ) , mean ( s . d . )
dasnmbr ( c - reactive protein )
"blood pressure ; pbo y patients with diabe teristics ( ncep atp i"
patients with normoalbuminuria at baseline
stenting plus medical therapy ( n = nmbr )
mean - sd change in pre - bronchodilator fevnmbr , l
change from baseline in % predicted fevnmbr
patients with uncomplicated events ( p = o - nmbr 十 )
post - bronchodilator percent of predicted fevnmbr , % ( sd )
comparison with baseline
previous ml ( interaction : p = nmbr . nmbr )
cardiac glycosides
previously taken any other dmards , n ( % )
crp ( normal range : nmbr - nmbr . nmbr ) , mg / dl , mean ( sd )
modified rankin score
a a ( nmbr ( % )
mean involved bsa , % ( nmbr % ci )
other defined
without ( n = nmbr nmbr )
treatment with drugeluting stent
nmbr - nmbr ( moderate )
angiography
sbp / dbp $ nmbr / $ nmbr mmhg
non - extensive
electrocardiographic findings — no . ( % )
beta receptor antagonist
baseline triglycerides by quintiles
median albumin - to - creatinine ratio ( interquartile range )
< nmbr regardless of historical count
stent type
nmbr vessel pci
body mass index subgroups
pioglitazone
b - agonists ( long - acting ) a
tg ( mg / dl ) , median ± sd
risk factors for recurrent vte — no . ( % ) f
caucasian eze / simva
nmbr - < nmbr mvmin
pioglitazone ( n = nmbr , nmbr )
time from onset to medication , h , mean ± sd
baseline insulin daily dose / kg
mean — ml / min / nmbr . nmbr mnmbr of body - surface area
telmisartan group ( n = nmbr )
total cholesterol ( mmo nmbr / nmbr )
african - latin american
more than nmbr lesions per vessel
fpg , mg / dl ( mmol / l )
> = nmbr % and < nmbr % ( > = nmbrand < nmbr mmol / mol )
no . of events / total no . ( % )
ind nmbr mg q . d . n = nmbr
smoking history : ex - smoker
troponin level
duration of copd — days^
other antiplatelet agents , n ( % )
thienopyridine at randomization
bmi ( kg / mnmbr ) cardiovascular history
controllednmbr — no . ( % )
sulfonylurea derivatives
score nmbr - nmbr
radial access site
use of parenteral antithrombotic agents — no . ( % )
immunosuppressant ( with or without corticosteroid )
ml with st - segment elevation
remission in overall population
v / hctz
pulse ( beats / min ) cholesterol ( mmol / l )
number of participants
beta - carotene
hemispheric stroke n = nmbr
pci for index mi ( % )
absolute fvc decrease > nmbr %
hemoglobin ( gl ' )
"low ( nmbr - nmbr ) ( n = nmbr , nmbr ; nmbr % )"
> nmbr % and < nmbr % predicted arr ( n = nmbr , nmbr )
duration from hospital admission to pci , h ( median , iqr )
prednisone
enalapril dm = nmbr non - dm = nmbr
entire cohort
intravenous loop diuretics !
peripheral revascularization
no ischemia ( n = nmbr , nmbr )
fp / sal nmbr / nmbr pg ( n = nmbr )
antithrombotic use
p lace of randomization ( interaction : p = nmbr . nmbr )
km event rate ( % )
revascularisation + antiplatelets + lipid - lowering agents + p blockers
betanmbr selective
iii and iv ejection fraction
antiarrhythmic drug
median time since diagnosis * ( range ) , yr
bmi , kg / mnmbr uac , no . ( % )
high - density lipoprotein cholesterol , mean ( sd ) , mmol / l
serum potassium ( mmol / l )
gissi prevention nmbr / nmbr - nmbr / nmbr
nyha class nmbr or higher
concomitant medication — no . ( % )
history of major cardiovascular disease , n ( % )
versus tiotropium nmbr pg
nyha functional class at screening
time from most recent qualifying
use of loop diuretics , n ( % )
glycemia , mg / dl
duration of asthma , years
bisphosphonates
cardiovascular disease history
no pci or cabg — no . ( % )
any statin ( with / without llt )
associated with drug / toxin
non - diabetic patients
baseline hbanmbrc in nmbr classes
coronary artery disease — no . ( % ) : ! :
patients with egfr nmbr > nmbr to < nmbr ml / min / nmbr . nmbrmnmbr , n
baseline corticosteroidst ( mean dose : nmbr . nmbr mg / day ) , n ( % )
vka , only reason
reported in ecrf
evidence or thombus , n ( % )
prior aortocoronary bypass surgery 一 no . ( % )
regional anaesthesia
events / n
anti - coagulants - no . ( % )
other antihypertensive
thrombus - containing lesion
sgrq total score ( week
americas ( n = nmbr )
"placebo - adjusted mean difference in % hbanmbrc ( nmbr % ci ; [ p value] )"
serum total cholesterol ( mmol / l ) , mean ( sd )
creatinine level
heart rate , mean ( sd ) [range] , beats / min
cv death / mi / stroke / ucr
irbesartan
time from acs to randomization
time intervals , h
history of stroke or tia
medications at timing of randomization , n ( % )
cv death or hf hospitalization n
cvd events
nmbr - point mace
low - dose aspirin use
"moderate / severe exacerbations , itt population ; n ( % )"
lp ( a ) §
hbanmbrc levels
weekly
> nmbr ( high risk )
percentage of time in therapeutic inr range , mean ( sd )
> nmbr prior myocardial infarction — no . ( % )
threatened abrupt vessel closure
prior therapy , %
duration of pci ( min ) , median n ( iqr )
age > nmbr y , n ( % )
van der heijde mtss , mean ( sd )
form / bud
no . of patients ind / gly sfc
missing hb at yr nmbr
within nmbr h after
left ventricular ejection fraction < nmbr %
mestizos
ankle - brachial index < nmbr . nmbr
p - value ( anova )
patients with > nmbr exacerbations resulting in emergency department visit
difference in change
established atherosclerotic cardiovascular disease
other vascular disease
black race and ss > nmbr ( n = nmbr vs nmbr )
qualifying mi : stemi
coenzyme qnmbr
history of a transient ischaemic attack
known tiromtcch * c ccndifeon
total patients
periprocedural medications , n ( % ) clopidogrel , nmbr mg *
swollen joint count ( nmbr - nmbr possible joints )
prior amputation
weight , kg , median ( range )
arterial area ( mmnmbr )
statin + fibrate or
presence of enthesitis , n ( % )
nyha class ( when patient was last in stable condition before admission ) , %
history of second prior mi , n ( % )
ischaemic ( n = nmbrlnmbr )
sbp > nmbr mmhg and / or dbp > nmbr mmhg
caucasian , n ( % )
use of cardiac medication *
pioglitazone ( n = nmbr )
hdl cholesterol < nmbr ( men ) or < nmbr mg / dl ( women )
cardiac valvular disease
randomized to receive vitamin e
indication for index procedure
total c ( mmol / l , mean )
left ventricular ejection fraction — %
non - reversible ( % )
peripheral neuropathy
acuity major
standard therapyy ( n = nmbr )
acqnmbr score
baseline cardiovascular disease
myalgia
time since as diagnosis , mean ( sd ) years
albumin / creatinine ratio - mg / mmol , median ( iqr )
change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr
venous insufficiency
pdqol scale
baseline nmbr - asa
current medication , n ( % )
baseline pulmonary medication
median ( range )
mean ( sd ) aqlq
humerus fracture
high - density lipoprotein cholesterol tx difference vs pbo , ls mean % change from baseline ( se )
clopidogrel pretreatment duration
lower than normal range — % ^
months ( log - transformed )
saba reversibility
previous stroke or tia
high disease activity : > nmbr . nmbr , n ( % )
alcohol use ( % )
americas , excluding us
acitretin
stratification variables
factor v leiden or prothrombin mutation
simplified disease activity index score
diabetic kidney disease
prior coronary artery disease yes
intravenous nitrates
toast classification
£ nmbr . nmbr % * *
yes previous revascularization
no . / nmbr person - yr
p - blocker intake at randomisation ( n = nmbro )
> l : nmbrhrs : min ( n = nmbr )
oral glucocorticoid use at baseline — no . ( % ) : t
adjusted mean change
age at completion of highest level of
age group 一 ％
combined macro + micro
race / ethnicity chinese
history of more than nmbr prior mi ( % )
physical activity §
systolic blood pressure , mm hg < nmbr
diagnoses / risk factors , n ( % )
medication effects
insulin glargine
mean age , years ( sd )
diuretic thiazide
paclitaxel
total back pain , mean ( sd )
previous intolerance of infliximab , n ( % ) *
uae ( p , g / min )
any statin versus no statin at randomization
adalimumab group ( n = nmbr ) t
hgb , g / dl < nmbr men , < nmbr women
fracture during follow - up
biguanides
> nmbr . nmbr kg / mnmbr hypertension :
"values are expressed as percentages unless otherwise indicated . bmi , body mass index ; cabg , coronary artery bypass ischemic attack ; nsaids , nonsteroidal anti - inflammatory drugs , sbp , systolic bp ; dbp , diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications ."
aminosalicylates
prediabetes — no . ( % ) nmbr
history of pci with stenting
brain volume , cmnmbr
swollen joint count ( nmbr - nmbr )
no . of strokes ( % )
demographic and medical variables
australia / nz
no . of events / patients
chd history , n ( % )
jsn score ( nmbr - nmbr )
ascvdor > nmbr cv risk factors
previous transient ischemic attack
number of stent = l or nmbr or nmbr
ischemic stroke with hemnrrhnaic cnnversinn
chronic stable angina
fenofibric acid + low - dose statin
daily iglar dose at week nmbr ( u )
anticholinergic
contrast volume
rituximab ( nmbrxnmbr mg ) + mtx
> nmbr mg / dl simva nmbr = nmbr]
glucagon - like peptide - nmbr agonist
acrnmbr response at week nmbr , n ( % )
alcohol intake ( + ) ( % )
# of prior tnfi among non - tnfi naive
remission
triglycerides ( median , iqr ) , mg / dl
total antihypertensive use
anmbrc distribution ( % )
middle third
symptom score ( sd )
atorvastatin factorial study
former / non - drinker
electrocardiographic findings at randomization
lumbar spine bmd t - score
multiple ( nmbr + ) chd risk
hyperlipidemia , n ( % )
place of randomization
beta - blocker % target dose
left circumflex , n ( % )
ranolazine vs . placebo km failure rate
biomarker high ( periostin > nmbrng / ml or blood eosinophils > nmbrcells per pl ) , na
at or above the median
indacaterol - glycopyrronium group ( n = nmbr )
infarct on brain imaging 丰
baseline laboratory values , median ( iqr ) d
timi major or minor bleeding
olodaterol nmbr mg ( n = nmbr )
race / ethnicity white
tnfi ( no other bdmard taken ) t , n ( % )
patients treated
distribution time
previous treatment failure — no . ( % ) § * *
median body weight — kg
raas inhibitor use
previous cardiovascular event at randomization
aspirin alone ( n = nmbr )
wml load at baseline mri
clopidogrel plus aspirin
alanine aminotransferase or aspartate aminotransferase > nmbrx upper limit of normal ( n = nmbr )
non - endstage renal dysfunction *
active inflammatory bowel disease
current alcohol use — no . / total no . ( % )
complex partial ( ib )
saxagliptin ( n = nmbr , nmbr )
low subgroup
high - dose statin pretreatment ( n = nmbr )
common study baseline
lm bifurcation treated
renal impairment , n ( % )
> nmbr failure
coronary revascularization procedure
intensified baseline ( n - nmbr )
time from onset of qualifying stroke to randomization
statin non - users ( n = nmbr )
barc nmbr - nmbr
laba use , % patients
enoxaparin ( n = nmbr )
who / idf impaired fasting glucose
dip involvement , ! n ( % )
copd severity ( gold nmbr )
erosion score ( nmbr - nmbr )
st - segment depression > nmbr . nmbr mv
fasting tgs §
total cataract extraction
nmbr mg / day early - start
nmbr - nmbr with cv risk but not disease ( n = nmbr )
oral treprostinil ( n = nmbr )
acute ( < nmbr hr )
total ldl - c *
obese patients , ! n ( % )
baseline aspirin dose < nmbr mg
immunologic
high - dose aspirin
a - glucosidase inhibitor
history of stroke , n ( % )
crusade bleeding score
% with haq - di decrease > nmbr . nmbr
= nmbr ’ )
simple partial ( ia )
monitoring ( n = nmbr )
crp median ( se ) , rng / l
no . of previous venous thromboembolic events
d / mi / idr / st
smoking ( % ) laboratory parameters
female sex , n ( % ) race , n ( % )
hypertension , treated
no . in the nmbr mo before screening
severity of copd , n ( % ) *
reduced ef
disease duration , years : median ( range )
absent ( < nmbr mg / dl )
sgrq total score * *
black race , n ( % )
indication for index pci
forearm fracture
clinical copd phenotype^
symptoms and feelings
extent of index event
gold stage — no . ( % ) * *
drugs used in diabetes
baseline short - acting anticholinergics , n ( % )
stent plus medical therapy
significant worsening in kccq clinical score ( > nmbr ) at nmbr monthsnmbr
diet + pravastatin
doubling of serum creatinine
before index acs event
global ischemia ( % ) * *
il - nmbr , ng / l
> nmbr . nmbr to < nmbr . nmbr mu / l $ mmol / l
glycoprotein llb / llla inhibitors
statin intolerancenmbr , n ( % )
ccsc at nmbr month before enrollment
fevi aucnmbr - nmbrl
total , adjusted weight of nmbr . nmbr for gastrointestinal bleeding
indacaterol n = nmbr
cv risk factors , % of patients
egfr , median ( sd ) , ml / min
% rf +
moderate or severe copd exacerbations
beta - blocker use at randomization
hscrp > nmbr mg / l
exacerbation rate in the previous year ( range )
bdp / ff / g ( n = nmbr )
high density lipoprotein ( mg / dl )
dose ( n )
hormone replacement therapy
europe ( eu )
events / statin group
site of disease — no . ( % )
proximal - mainleft
pharmaco - invasive n = nmbr
nmbr % c . i .
metformin : no / yes , %
laba or lamab n = nmbr
physical role
colorectal cancer
estimated odds ratio
secukinumab intravenous nmbr mg ( n = nmbr )
clopidogrel dose
ex - smoker / smoker , %
moderate ( > nmbr to < nmbr )
stroke of undetermined cause
screening visit
medications before admission
antiplatelet therapy dual
fenofibric acid nmbr = nmbr
asia / pacific ( % )
number of patients with fractures
before amendment ( % )
( haq - di , nmbr - nmbr )
race or ethnic group — no . f
loss of response : ! : : ! :
post - bronchodilator fevnmbr — % of predicted value
medical history duration of heart failure ( years ) primary cause of heart failure
major cardiovascular
bmi > nmbr ( % )
high risk ( nmbr - nmbr )
seronegative ( rf - ve and acpa - ve ) subgroup
functional outcome ( mrs nmbr - nmbr )
previous balloon angioplasty
mean number of exacerbations in previous nmbr months ( sd )
duration from clopidogrel / placebo to pci , min ( median , iqr )
( ci ) b
hispanic ethnic group — no . / total no . ( % ) ‘ j ‘
age , y . o .
serum triglycerides , mg / dle
post - acute ischemic stroke
death / mi / idr / st / gusto - defined moderate or severe bleeding
use of rescue albuterol , puffs / day *
intent of conservative strategy , %
"> < nmbr . nmbr , < nmbr . nmbr , r < mmse = mini - mental ;"
estimated gfr
stenosis > nmbr %
nmbr - year rates in placebo groups
previously on acei + arb
peripheral artery disease details
egfr ( median , iqr ) , ml / min / nmbr , nmbrmnmbr
dipeptidyl peptidase - nmbr inhibitor
body mass indexnmbr
traditional nsaid
menopausal status and use of ht
standard care
non - european trial
patient ' s assessment of pain ( nmbr - nmbr vas )
tdi total score ( week nmbr
p , treatment - by - region interaction
insulin only
catscorecategory , n ( % )
anacetrapib ( n = nmbr , nmbr )
control nmbr months ( n - nmbr )
no immomtedion
delayed reaction
disease site — no . of patients ( % ) |
nmbr . nmbr - < nmbr
sgrq total score ( units ) : ! :
qualifying myocardial infarction
psoriasis
no glucocorticoids or immunosuppressants
mean ± s . d . hbanmbrc
time from last dose of pnmbrynmbr inhibitor , days
snmbr gallop , n ( % )
any condition
sitagliptin n = nmbr
mean weight , kg , mean = sd
abciximab ( n = nmbr )
antiplatelet — no . ( % )
ischemic heart disease indicator no ( n = nmbrl )
ifg / prediabetes^
no . of target vessels
adjusted mean ± se ( nmbr % ci )
albuminuria < nmbr gram / gram cr
nyha lll - iv
chronic kidney disease , n ( % )
patients with fistulas at baseline
standard control
cvd , mi , stroke , or recurrent ischemia - urgent revascularization
white race , %
> nmbr / tmol / liter — no . ( % )
renin inhibitors
not localized
ischemic stroke without hemorrhagic conversior
constitutional
smoking status , n ( % ) former
crp ( mg / dl ) * *
ularitide ( n = nmbr )
vorapaxar placebo nmbr - yr . km %
cv death , ml , ischemic stroke , hosp . for hf , cor . revasc . , ua
prior anti - tnf therapy
reinfarction
sgrq total score
first primary composite outcome
score on modified mini - mental state examination — median ( iqr )
hormone replacement
composite endpoint of doubling of serum creatinine , esrd ,
exercise ( % )
history of ischemic heart disease — no . ( % )
statin therapy
stratified analyses
seated sbp at nmbr weeks , mmhg + * *
former / current smoker , n ( % )
( sd ) , mg / dl
primary trial end point
fasting blood glucose
number ( % ) reporting migraine on nmbr - month questionnaire
concomitant corticosteroid use
elevated bun ( > nmbr . nmbr meq / l )
slowest third
clinical features of hf
tertile nmbr index pci performed
risk factor ( predefined ) for falling at screening , n ( % )
left ventricular dysfunction
serum cholesterol , mg / dld
acs treatment
< nmbr ml / min / nmbr . nmbr mnmbr nt - pro - bnp
prednisone use , %
actual treatment strategy
other antiplatelet agent 一 no . ( % )
% change from baseline ls means ( se )
use of blood pressure lowering medication *
multivessel disease 一 no . ( % )
patients using concurrent tiotropium
time since copd diagnosis ( yrs )
use of medications for pah — no . ( % )
ace - i or arb use at baseline
medical history of diabetic retinopathy §
anmbr + ez n = nmbr anmbr n = nmbr
anti - tnf - naive patientsnmbr
total patients , n
heterogeneity test
infarction , date not reported
rates per nmbr patient - years
% difference , nmbr % ci )
tofacitinib nmbr mg bid
smoking index — pack - yr §
body weight ( kg ) , n ( % )
spironolactone
non - frail
nmbr vitamin e
low potencyc
osteopontin ( ng / ml )
pvaluefor any mi versus no mi
prerandomization statin therapy
multivessel cad , n ( % )
glomerular filtration rate §
nmbr mg sirukumab every nmbr weeks ( n = nmbr )
baseline lvef , %
hypertension ( % ) : t
previous loss of response to infliximab , n ( % ) *
number of treated vessels
extracranial carotid stenosis , n ( % )
coronary artery disease , n ( % )
telmisartan
physician
black and other
diclofenac nmbr mg ( n nmbr nmbr ) , . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .
smokers ( at baseline )
baseline use of hormone therapy ( % )
high hdl - c ( for men ≥ nmbr   mg / dl / for women ≥ nmbr   mg / dl )
myocardial infarction or angina
exposed ( n = nmbr )
primary composite end point
fasting insulin ( giu / ml )
met criterion at final ( n [ % ] )
mean ( sd ) bmi ( kg / mnmbr )
mean body weight ( sd ) , kg
lean ( < nmbr kg / mnmbr )
previous treatment with a laba and / or lama , n ( % ) c
new des ( n = nmbr )
homa - ir index — median ( iqr )
timi risk score ( interaction : p = nmbr . nmbr )
prior use of systemic
all randomized
obesity ( % ) §
diabetes therapy
balloon angioplasty
ibdq domain scores , mean [sd]
rosiglitazone ( n = nmbr )
smoking ( ever )
patella fracture
screening
medical history and risk factors
ineffective therapy
risk group
hdl - c ( mg / dl ) - mean ± sd
very severe ( gold nmbr )
glycated hemoglobin , n ( % )
antihypertensive therapy — no . ( % )
non - ischaemic cause
low periostin subgroup ( , nmbr ng / ml ) ( n = nmbr )
infarct location — no . / total no . ( % )
enrollment by region , no . ( % )
fixed triple ( n = nmbr )
multivessel stenting
estimated creatinine clearance < nmbr rmb ' mint
event rate
fevnmbr , litres ( pre salbutamol ) , mean ( sd )
gpifeellla inhibitor use before angography
gender , female , n ( % )
latin america or south africa
patients with complicated events ( p = nmbr - nmbr 十 )
triglycerides $ nmbr mg / dl ( nmbr . nmbr mmol / l )
patients with > nmbr exacerbations resulting in ed visit
use of statins
time between cessation of full - dose warfarin therapy and enrollment ( mo )
egfr nmbr - nmbr
egfr > = nmbrml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )
peri - op ace - inhibitors / arbs : no ( n = nmbr )
cangrelor ( n = nmbr ) n / n ( % )
baseline fevnmbr % predicted
age ( range ) ( years )
mean — yr age group — no . ( % )
history of atrial fibrillation or flutter treatment at randomisation
previous stenting ( % previous pci )
bivalirudin only
medical history ( % )
clopidogrel given before procedure
ezetimibe + simvastatin ( n = nmbr , nmbr * )
aliskiren / valsartan ( n = nmbr )
urinary protein - to - creatinine ratio | |
cerebrovascular accident
male sex — no . ( % ) weight — no . ( % )
weight — no . ( % )
nmbr non - mtx
fasting triglycerides — mg / dl
concomitant csdmards other than methotrexate , n ( % )
( b ) concomitant respiratory medications [n ( % ) ]
copd population ( n = nmbr )
ibdq score , mean ( sd )
lifestyle
disease location , %
haq - di , number ( % )
cardiac pacemaker — no . ( % )
patient ' s preference not to take
tofacitinib , nmbr mg twice daily
diet + pravastatin group
glycated hemoglobin level
asthma population ( n = nmbr )
albumin creatinine ratio
apolipoproiein b ( mij / nmbr )
aliskiren ( dm - vs . dm + )
regadenoson
change in erosion score ( mean )
fecal calprotectin — pg / g * *
infarction before age nmbr ( a )
patients , no . / total no . ( % )
prior biologic use
time since diagnosis of type nmbr diabetes - no . ( % )
metabolic syndrome visit nmbr low - density lipoprotein cholesterol strata
nonbiologic disease - modifying drug other than methotrexate : :
moderate risk ( nmbr - nmbr )
csf a ( nmbr ( pm )
combination - facilitated pci ( % )
time since psa diagnosis ( years ) , mean ( sd )
deep - vein thrombosis
> nmbr to < nmbr - nmbr mg / week
aspirin alone ( n / n )
prior treatment — %
homa - ir ( % ) b
duration of diabetes , median ( iqr )
interquartile range height — cm
mild thrombocytopenia ( < nmbrx nmbr / l )
reversibility ( anticholinergic ) , % , mean ( sd ) $
number of exacerbation in the previous nmbr months , n ( % )
established cvd ( age > nmbr )
crci > nmbr - < nmbr
who functional class ii / iii
( n nmbr nmbr )
cigarette smoking in the past year
candesartan
previous pci / cabg , n ( % )
coronary angiography during the index hospitalization
baseline free pcsknmbr level by median
( se]tf total - c
continued thienopyridine %
before pci
glomerular filtration rate , nmbr ml / min / nmbr . nmbr mnmbr
elevated troponin t ( > nmbr . nmbr / xg / l )
rivaroxaban
prior history ml or stroke
atorvastatin nmbr mg ( n = nmbr , nmbr )
alcohol , % with > nmbr drink / d
western europe and lebanon
body mass index , kg / mnmbr ( sd )
current smoker ( > nmbr cigarettes / day ) — no . ( % )
atorvastatin nmbr mg ( n = nmbr )
unstable angina > nmbr mo ago
amlodipine / valsartan nmbr / nmbr vs nmbr / nmbr mg
mean ( s . d . ) apob , mg / dl
tobacco use — no . ( % )
previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis
dapagliflozin nmbr mg / day ( n = nmbr )
edema , peripheral
peripheral vascular disease
angina ( past nmbr weeks )
drug - eluting stent implanted
rhabdomyolysis ( n = nmbr )
hospitalizations , n
baseline heart failure severity amongthose with priorheartfailure , %
patients with end point
us resident
less than nmbr mm hg
p value for mra vs no mra
insulin - treated diabetes
nmbrrrmnl )
metastatic disease
no stroke n = nmbr nmbr
physical component score ( pcs )
bmi > nmbr — no . ( % ) f
oral contraceptive pills — no . / total no . ( % )
renal function , moderate
nmbr - yr risk of coronary heart disease ( % ) ^ |
llt other than statin at randomization
other antihypertensive agents
ace inhibitor at enrollment
b - agonists ( short - acting ) a
egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )
hemoglobin anmbrc , mean ( sd ) , % b
duration of ulcerative colitis
positive for rheumatoid factor — no . ( % ) : t
euroscore logistic , median ( nmbrth , nmbrth % ) £
simvastatin nmbr mg plus fenofibrate nmbr mg ( n = nmbr /
age — mean ( sd ) ( years )
cerebrovascular or peripheral arterial disease , n ( % )
low feno subgroup ( , nmbr . nmbr ppb ) ( n = nmbr )
blood - pressure medications at randomization — no . / total no . ( % )
index event , n ( % )
other or missing data
number of copd exacerbations in the previous year , n ( % )
rivaroxaban plus aspirin ( n = nmbr )
diuretics * *
one vessel
intended duration of anticoagulation
non - stenotic vessels , n ( % )
gusto severe
> nmbr . nmbr bpm current smoker
patients with any clinical event
previous diabetes
mmrc dyspnea scale , n ( % )
brv nmbr mg / day ( n = nmbr )
urinary tract infection
baseline bmi > nmbr kg / mnmbr , n = nmbr , nmbr
hospitalization for heart failure
any history of congestive heart failure
time from study drug administration to coronary revascularization , median ( iqr ) , h
heart failure ( class i — iii )
c - reactive protein — mg / liter * *
liraglutide nmbr . nmbr mg , n = nmbr , nmbr
placebo nmbr yr km %
prebronchodilator fevnmbr ( % predicted normal ) t
rest of world
mean age ( sd ) , y
low - molecular weight heparin or intravenous unfractionated heparin
nmbr early intervention ( n = nmbr )
no statin ( + / - llt )
treatment satisfaction
pathologic q waves — no . ( % )
total periventricular wml score , mean ( sd )
laboratory values at admission ( median and iqr )
corticosteroid use , nmbr n ( % )
use of inhaled glucocorticoids at screening — no . ( % )
comorbidity score , mean ( sd ) t
non - smokers ( at baseline )
tender joint count ( n / nmbr )
total intravenous loop diuretics , mg
atorvastatin nmbr mg + ezetimibe nmbr mg ( n = nmbr )
angiotensin ll - receptor antagonist — no . ( % )
mean serum glucose , mg / dl , mean = sd
gold stage ( % ) f
non - hdl - c / hdl - c
multivessel ( two vessel , three vessel , or left main )
body weight index ( kg / mnmbr )
triglycerides , mmoltnmbr ( gm * )
procalcitonin ( ng / ml )
fasting blood glucose > nmbr mg / dl
category nmbr
type of event
quality of life
diagnosis ( y ) , mean ( sd )
persistent or permanent immobilization
modified rankin scale at screening , nmbr - nmbr
placebo nmbr . nmbr pt yrs
diet controlled or no
body weight
cvd , mi , or stroke
no . of patients / no . of events
intravenous study drug administered — no . ( % )
number of females n ( % )
> nmbr . nmbr % and ≤ nmbr . nmbr %
treatment with statins
prior heart failure , n ( % )
systemic symptoms
persistent or paroxysmal
metabolic syndrome w / o tnmbrdm
stroke — no . / total no . ( % )
nice primary prevention onlyb
cv death , mi , ischemic stroke , hospitalization for hf , coronary revascularization , ua
change from pre - to
any lipid - lowering agent
abatacept
indacaterol - glycopyrronium group
warfarin naive
prior or new diabetes
tender and swollen joints — mean no . : :
systolic blood pressure > nmbr mm hg or diastolic blood pressure > nmbr mm hg
rolofylline ( n = nmbr , nmbr )
total stent length ( mm ) , mean ± sd
swollen joint count ( nmbr joints )
mean nmbr sd
previously taken methotrexate , %
gusto moderate
procedure * *
hormone replacement ! !
other cardiovascular risk factors
severe copdc [n z nmbr]
cardiac biomarker status !
nmbr - mercaptopurine
patient presentation
baseline serum k + , meq / l
other sulfonylurea 一 no . ( % )
hctz * ( n = nmbr )
cardiometabolic syndrome , ^n ( % )
carotid artery — no . ( % )
cardiac valve surgery : no ( n = nmbr )
other cause
beyond popliteal pedal
> nmbr cv risk factors 咐 or established atherosclerotic cv disease
oral anticoagulant drugs
fracture history ( predefined ) , n ( % )
any coronary revascularization
ex - / current smoker
vorapaxar nmbr - y
fluindione , no . ( % )
current n z nmbr
concomitant oral corticosteroids , n ( % ) * *
anaesthesia / analgesia
local eosinophil count ( cells per pl ) t
age ( years ) , mean ( s . d . )
ethnic group ( % )
physician ' s global assessment ( vas )
antihypertensive drugs
median age — yr §
cad and / or crvd ( % )
chronic obstructive lung disease
exercise category ( % )
prior congestive heart failure yes
secondary prevention subgroup
aspirin nmbr mg ( n = nmbr )
night - time awakenings / week
non - hdl - c , mean ( sd ) , rng / dl
laa closure ( n - nmbr )
p - value * ' '
known prothrombotic genotype
> nmbr concomitant medication
function subscale
high risk and more symptoms ( group d )
white ( nmbr . nmbr % )
osteoarthritis
age ( y ) , median ( nmbrth to nmbrth percentiles )
history of microalbuminuria — no . ( % )
tender joint count ( nmbr joints ) , mean ( sd )
nmbr mg / day delayed - start
documented symptomatic chdb
c - reactive protein
ejection fraction , percent ( sd )
previous pneumonia
dasnmbr - esr remission , %
budesonide — no . ( % )
linagliptin , patients with events / total patients
middle tg tertile
"density lipoprotein ; csf ="
hscrp , median ( min , max ) , mg / l
concomitant medication after randomisation
non - black ( n = nmbr )
dmard or corticosteroid
non - epa number of <
hbalc tx difference vs pbo , median change from baseline ( se ) nmbr
trough fevi l
eq - nmbrd ( visual analog score )
antihypertensive medication , open - label , no . ( % )
mer ’ s disease assessment
baseline ldl - c strata , n ( ° / o )
with alogliptin nmbr . nmbr mg
anacetrapib ( n = nmbr )
secondary dvt . ' fe
with laba , n ( % ) pretreatment
basal insulin analogue dose * ( coefficient
theophyllines
angina class iii or iv — no . ( % )
n ( nmbryr km event rate , % )
age — year ( median )
tnt and ideal ( pooled )
cabg or ptca / pci
ex - smoker ( n z nmbr )
event rate ( % ) of primary endpoints
insulin - dependent diabetes
malignancy at randomization
short - acting
serum potassium , meq / l
rest of world n z nmbr
never smoked , n ( % )
seizure worry
placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years )
rest - of - world ( n = nmbr )
no use ofdiabetes drugs — no . ( % )
no estimate
baseline ( n )
pci > nmbr month ago
swollen joint count ( nmbr joints ) , mean ( sd )
> nmbr years nmbr / nmbr ( nmbr . nmbr )
time in therapeutic range before inclusion
initial diagnosis — no . ( % )
angiotension converting enzyme - inhibitor
xanthines
management distribution medical treatment
pharmaco - invasive ( n = nmbr )
estrogen - containing hormones
uac nmbr - nmbr mg / g
nmbr % < hbanmbrc < = nmbr % ( n nmbr nmbr )
mean ( s . d . ) measured ldl cholesterol
history of hypertension — no . ( % )
prior cv history , n ( % )
time to end - of - study ivus , median ( iqr ) , days
steroids ( inhaled ) a
> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % )
previous angioplasty , n ( % )
time since diagnosis of diabetes
uric acid tertile nmbr ( nmbr . nmbr to < nmbr . nmbr mg / dl )
major hypoglycemia
prosper
dyspnea at rest ( nyha iv ) , ( % )
czech republic
gusto moderate or severe bleeding
baseline cdai ,
% change from baseline , mean ( s . e . )
enalapril + aliskiren ( n = nmbr )
non - calcium antagonist strategy ( n = nmbr nmbr )
ankle fracture
number standard care
digitalis , n ( % )
warfarin at last follow - up
pci data
end of follow - up
handihaler only , n
certolizumab pegol ( n = nmbr )
mean — ml / min / nmbr . nmbr mnmbr level — no . ( % )
egfr via mdrd ( ml / min / nmbr . nmbrmnmbr )
core laboratory percent stenosis
native american / alaskan
mean cdai score ( sd )
insulin glargine vs standard care least - squares mean ( nmbr % cl )
difference in ls meannmbr ( nmbr % cl )
prior diagnosis - no . ( % )
moderate - dose statin
tnf - alpha ( pg / ml )
antithrombotic drug use at time of event
jbs - nmbr secondary prevention onlynmbr
full cohort
c - peptide
immobilization
death , mi , idr , st , or gusto moderate / severe bleeding
thienopyridine ( n = nmbr )
nmbr - year framingham chd risk , %
etoricoxib
previous coronary artery disease , n ( % )
elevated cardiac markers
ifx + aza ( n = nmbr )
open - label clopidogrel after completion of study drug
baseline low - density lipoprotein cholesterol ( mg / dl )
symptom onset to randomization
stricturing
insulin tx difference vs pbo , median change from baseline ( se ) nmbr
duration of rheumatoid arthritis ( years )
beta - blocker — no . / total no . ( % )
second loading dose
trochanter
low perceived social support only
white / other
treatment groups [n / nb ( % ) ]
cardiovascular medication usage
non - calcium antagonist strategy ( ncas ) ( events / n )
simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr )
baseline bmi > nmbr kg / mnmbr , n = nmbr
n / n nmbr / nmbr
not - japan
previous cardiovascular events
trigl yeerides * ( m mol / l )
total cholesterol : hdl - c ratio
proadm ( ng / ml )
interact !
older des ( n = nmbr )
second co - primary outcome
pe ± dvt
previous warfarin use , no . ( % )
nice secondary prevention onlyb
ankle / brachial index
non - caucasian eze / simva
use of compression stockings , no . ( % )
prior angiography showing stenosis > nmbr % , n = nmbr °
previous use of antiarrhythmic drugs
location , n ( % )
associated with ctd
clopidogrel ( n = nmbr ) n / n ( % )
physical exam oedema
triglyceride ( mmol / l ) * blood pressure
valproate
ls - mean change from baseline ( nmbr % ci )
"median age ( iqr ; years )"
cardiac medications during index hospital stay and / or discharge
cardiac medications during index hospitalization , %
no ipst ( n = nmbr , nmbr )
non high dose statin ( n = nmbr , nmbr )
gall bladder adverse event ( n = nmbr )
elevated crp ( > ulnt ) , n ( % )
liraglutide
type of drug - eluting stent , n ( % )
ratio of fevnmbr to fvc
infarct localization , n ( % )
racial category *
inhaled jnmbr - agonist §
nonwhite race — no . ( % ) ejection fraction
theophylline use at screening
history of omalizumab treatment
symptom onset to arrival in catheterization laboratory
omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl )
tnfi and other bdmardst , n ( % )
atenolol strategy ( n = nmbr , nmbr )
left atrial diameter : < nmbr mm ( n = nmbr )
ethnic group
baseline bmi > nmbr kg / mnmbr , n = nmbr , nmbr change from baseline to nmbr weeks
rf ( iu / ml )
coronary heart disease risk equivalents , n ( % ) c
medical history of hypertension
mepolizumab group
microalbuminuria or macroalbuminuria
baseline ldl - c > nmbr mg / dl
combination therapy * *
uac > nmbr mg / g
health assessment questionnaire score
age at onset , y
antidiabetes drug usage [ % ( n ) ]
ibdq total score , mean [sd]
fenofibric
era and pdenmbr inhibitors
allogliptin
current smoker ( n = nmbr , nmbr )
weight ( kg ) , mean ( s . d . )
previous stroke or tia ( % )
average of maximum common carotid cimt ( mm )
new or suspected thrombus
lacosamide
natalizumab ( n = nmbr ) f
family history of coronary disease
multivessel cad ( % )
long - acting bronchodilator use at screening
fevnmbr / fvc ratio , % ( sd )
mild impairment ( egfr nmbr - nmbr )
all randomly assigned
diet and exercise
diabetesduration , mean ( sd ) , y
median feno , ppba
non - detectable / unknown
primary enrollment diagnoses , n ( % )
low hdl - c ( for men < nmbr   mg / dl / for women < nmbr   mg / dl )
mean body mass index ( sd ) , kg / mnmbr
ace inhibitor or angiotensin ii receptor
diet diet + pravastatin
unspecified
atherosclerotic cardiovascular disease
dilated cardiomyopathy
participation in phase a
region of enrollment
white race , n ( % )
after amendment
laba + ics versus indzgly lsm difference ( nmbr % cl )
number of patients > nmbr years ( % )
hypoglycemia
gold stage [n ( % ) ]
not treated
motor subscale ( range , nmbr - nmbr )
feno + eze
total group
asthma control test score at baseline
lipid values , mmol / l
esr , nmbr - nmbr mm / hour
europe and canada
total mayo score $ | |
egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr )
as - needed inhalations / day
warfarin , no . ( % )
habitual fish intake : < nmbr servings / wk ( n = nmbr )
number resulting in hospital admission
infarction > nmbr days previously
pasi score ( nmbr - nmbr ) t , mean ( sd )
index mi ( n - nmbr , nmbr )
> nmbr % coronary stenosis
mean ( s . d . ) egfr , ml / min / nmbr . nmbr mnmbr
triglycerides , mmol / l , mean ± sd
losartan + lisinopril
male , n / n ( % )
isolated deep - vein thrombosis
esrd or death
tiotropium nmbr . nmbr mg
other major risk factors
csf lathosterol ( | jlg / cll )
diagnosis at presentation — no . ( % )
number of concomitant csdmards , n ( % )
radiographic characteristics at baseline and randomization
"probability "" of event %"
d - dimer ( ng / ml )
insulin , median ( ql , qnmbr ) , pmol / l
cerebrovascular
methotrexate use at randomisation
method of identification ofstenosis ( % )
treatment of the index ml
saba puffs per day at baseline
joint space narrowing score
evolocumab nmbr mg monthly ( n = nmbr )
intent - to - treatb
ace - i or angiotensin receptor blocker
body mass index > nmbr — no . ( % ) f
mean change , % ( se )
prebronchodilator fevnmbr / fvc
less than nmbr ml / min / nmbr . nmbrmnmbr
previous tia or stroke
non - ischaemic aetiology
stroke n = nmbr
crp concentration > nmbr mg / l , n ( % ) \
european quality of life - nmbr dimensions - nmbr level ( eq - nmbrd )
major clinical response
mean ham - d score ( nmbr % ci )
bowel function
laa ostium
bnp o nmbr pg / ml or nt pro - bnp o nmbr pg / ml , n ( % )
laa length
patient ' s preference not to take vka , only reason * *
risk factors and immobility level , n ( % )
pasi score > nmbr *
cardiac history
drug - eluting stent , n ( % )
copd — no . ( % ) medication use
interquartile range
acute stroke of other determined cause
"severe exacerbations , itt population ; n ( % )"
europe nmbr
male gender ( % )
no . of vessels
n - nmbr fatty acids - placebo lsm ( nmbr % cl )
rheumatoid arthritis
> nmbr % focal seizure frequency responders
medication within nmbr days before enrolment
sex ( male ) - no . ( % )
worsened
digoxin at enrollment
prostate cancer
pre - bronchodilator fvc ( l )
creatinine clearance
no . of treated lesions
cholecystectomy ( n = nmbr )
# of prior non - tnfi bdmards *
immunosuppressive agents only
enalapril ( n = nmbr )
deep - vein thrombosis or pulmonary embolism — no . ( % )
age - years , median ( iqr )
total no . of patients
n - nmbr fatty acids ( n = nmbr )
baseline cv treatment
selena - sledai ( range u - nmbrunmbr ) t
bnp > nmbr pg / ml , n = nmbr
ms & ng
global assessment of disease status score
all patients ( n = nmbr )
isolated impaired glucose tolerance — no .
angiographic extent of disease
type of concomitant statin by daily dose - no . ( % )
postoperative nsaid or glucocorticoid use
airflow reversibility — no . ( % ) |
devices
age at enrollment ( years )
mean ( sd ) disease duration , years
race - white ( n = nmbr , nmbr )
fluticasone furoate , n = nmbr
baseline hbanmbrc , n ( % )
aldosterone antagonists ( e . g . spironolactone )
pci duration in min ( median , iqr )
age > nmbr years , n ( % )
active cancer — no . ( % )
insulina , n ( % )
skull , and facial bone fractures
nmbr - aminosalicylates {
hemorrhagic stroke
immy ( without corticosteroid ) , n
renal function , normal - mild
log rank p - value
prior myocardial infarction , n ( % )
high - density lipoprotein
antibodies to infliximab , n ( % ) * *
safety : non - cabg - related bleeding
diabetes mellitus — no . ( % )
mmrc grade , n ( % )
inspiratory capacity ( l )
hf , lvd , or both
percent of predicted fevnmbr
ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % )
diuretics group ( n = nmbr )
prior aortocoronary bypass surgery
neutrophils , nmbr / nl
antiplatelet or anti - inflammatory drugs
presentation of index event
statin at enrollment
ethnicitya hispanic or latino
waist circumference snmbr ( men ) or > nmbr cm ( women )
baseline mssbp / msdbp , mm hg
hispanic american
hba]c ( mmol / mol )
men / women
pbo ( nnmbr nmbr )
creatinine clearance < nmbr ml / min ( % )
total comparators ( n = nmbr )
heart rate ( b . p . m . )
smoking history , n ( % )
disease duration , mean yr ( sd )
high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr )
hbanmbrc in patients with baseline hbanmbrc < nmbr % ( < nmbr mmol / l ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )
overall event rate
prior biologic therapeutic failures , n ( % )
losartan plus lisinopril ( n = nmbr )
us site of enrollment
killip class lll - iv
coronary artery osteochondrosis
time from onset of pain to randomization , median ( nmbrth — nmbrth percentiles ) , n
subset of patients not on metformin
no persistent wrf ( n = nmbr , nmbr )
clopidogrel plus aspirin % / yr
percutaneous coronary revascularization
plus metformin
calcium - channel inhibitor
uacra , mg / g , gmean = gcv
cure trial
ratio ( nmbr % ci ) *
baseline pre - bronchodilator fevnmbr , l
physical component summary
placebo croup , n / n ( % )
smoking status at screening
copd medication taken for at least nmbr months before st
st - segment - elevation myocardial infarction — no . ( % )
ada nmbr / nmbr ( n[nmbr )
previous segmental resection — no . ( % )
older patients ( aged > nmbr years )
pre - operative cardiac medications *
other forms of
mean ( s . d . ) hbalc , mmol / mol
number of ( % ) patients > nmbr years
ck - mb , ng / ml
prior cardiovascular disease
current / past smoker
on - pump time : < l : nmbrhrs : min ( n = nmbr )
diuretic — no . ( % ) surgery
< nmbr ml / min / nmbr . nmbr mnmbr , n ( % )
types of fibrinolytic agent
u » c » ( mg / g )
anticoagulant group ( n = nmbr )
< nmbr yr of education — no . ( % )
non - colorectal cancer
all bleeding
hbalc ( % ) , mean ( sd ) ^
simvastatin nmbr mg ( n = nmbr , nmbr )
losmapimod ( n = nmbr )
number of e
region , europe union
hydochlorothiazide ( n = nmbr )
continued treatment study
death / q - wave mi / idr
p value for trend
time since diagnosis of heart failure
mean ( s . d . ) ldl particle size , nm
single vessel pci
pfo with mild - to - moderate shunt and atrial septal aneurysm
obesity ( bmi > nmbr kg / mnmbr ) , %
colon only
lp ( a ) ( week nmbr )
n - nmbr pufa events / patients ( % )
arthritis type *
aml / val , nmbr / nmbr mg rr = nmbr *
in emergency department before ambulance transfer
gold d
saaca
ecg
之 nmbr
total ( n = nmbr )
race , %
race — no . ( % ) |
% nmbr - nmbr
severe
pbo , n = nmbr
bnp
male sex , ( % )
females , %
< nmbr mm
snmbr %
age ' ^nmbr yrs
atvnmbr mg ( n = nmbr )
female , no . ( % )
> nmbr mo
male sex — %
lvh
stent
acrnmbr
diet
cg / ld
age ( years ) *
nonsmoker
ics use
no ( % )
lips
≤ nmbr
ocs
tg < = nmbr . nmbr
vka
rate * ( n )
statin ( n - nmbr )
« snmbr - nmbr
nmbr to < nmbrmmhg
males ( % )
三 nmbr to < nmbr
cough
> median
smoking *
etd ( nmbr % ci )
% ( se )
pm , n ( % )
placebo , n ( % )
n ( % )
> nmbr beds
number
male , no ( % )
> nmbr years ( n = nmbr )
femaleb
< nmbr hr
> nmbr to < nmbr mm hg
deaths
uvb
asian ( n — nmbr )
bms
p - int
l ’ - value ’
abnormal
placebo
crt
sex :
icd
cabg
≤ median
nmbr - nmbr ft
lad
nmbr yrs
hs - crp
no prior llt
range
phi ( n = nmbr )
> nmbr h
women ( n = nmbr )
> nmbr - < nmbr years
men ( % )
> nmbr ug / g
cdai
age nmbr
age > = nmbr years
hbalc < median
arr ( nmbr % ci )
msdbp
ato nmbr mg ( n = nmbr )
redon
daily
placebo n / n ( % )
statin ( n = nmbr )
white
blockers
idr
p - valuec
nmbr ( > nmbr % )
≥ nmbr . nmbr years
men , %
anmbr n = nmbr
p valued
study
> nmbr % nmbr
no pci
igm
ex - smoker
etn , no
rales , n ( % )
pooled
total
female sex ( % )
acs
nmbr . nmbr min
motor
apo bt
age , years
asian , n ( % )
age < nmbr yr
hr nmbr % cl
sal nmbr mg
frail
> lnmbr years
iv ( n z nmbr )
( nmbr % cl )
* p value
arb
oad
fema le
nmbr enmbr years
black ( n = nmbr )
missing
single
events ( % )
> nmbr kg
s
< nmbr ng / ml
rr ( nmbr % ci )
result
age > nmbr years , %
patients n
placebo [n = nmbr |
nmbr % cl
nmbr nmbr
> nmbr %
hbak < median
yes
> nmbr yr sex
< nmbr
> = nmbr years
nmbr mg / g
ascvd , n ( % )
lgm ( n = nmbr )
mace
neither
> = nmbrkg
( se ) t *
esrd
placebo n[nmbr
death
mtx
loop
japanese
chda
> nmbr lb
age ( years ) +
l ( % )
chadsnmbr
( n = nmbr )
new om
nmbr % nmbr
former , n ( % )
b lack
median
nmbr — < nmbr years
hdl - cd
low
> nmbr ( n — nmbr )
rr *
iii / iv
pla
hr
placebo ,
bmi < nmbr
nmbr . nmbr yrs
plac
women , n ( % )
other , n ( % )
lmwh
mexico
lcznmbr ( n = nmbr )
nmbr % cit
black ( n — nmbr )
< nmbr yr
< nmbr » < nmbry
hba „ ( % )
htn
p for i
af
# nmbr year
beta - blocker use
naive ( n = nmbr )
changenmbr
< lnmbr years
treated
tnmbrd
mtx n = nmbr
white ( n — nmbr )
pasi *
aged ^nmbr years
> nmbr - < nmbr mmhg
copd ( n = nmbr )
nmbrto < nmbrmmhg
nmbr +
< nmbrkg
< nmbr ( n — nmbr )
bmi > nmbr
lsm ( nmbr % ci )
dd
x / n
age yrs
diet alone
sfc ( n [nmbr )
> nmbr / > nmbr mm hg
former
< nmbr ft
■ nmbr years
nmbr - nmbr years
p value *
beta blocker
< nmbr years ( n = nmbr )
beta - blocker , %
race ( % ) $
fibrate
primary pci
egfr
colon
n
arb , n ( % )
aphasia
heparin
white , %
low ’
f emale
igm ( n = nmbr )
> nmbr nmbr
< nmbr mg
ics : yes
< nmbr ml
placebo ( n = nmbr
unprovoked
strategy
asia ( n = nmbr )
region , %
cse] +
age > nmbr y * *
i % nmbr
mca
taci ( n = nmbr )
hdl - c
medium
placebo ( n = nmbr )
women men
both
rca , n ( % )
events
patients , n
italy
, nmbr
> nmbr - nmbr years
snmbr
chf
^ - blockers
nmbr ( n = nmbr )
ale
p valuea
age ( yrs )
≤ nmbr %
nmbrmg
placebo n = nmbr
anemia
eze
mean *
atv nmbr mg
ef nmbr - nmbr %
open — no . ( % )
oriental
\nmbr %
anakinra
of patients
arb , %
sex , men ( % )
sedbp
£ nmbr kg
japan
> nmbr hrs
female ( % )
hbak > median
aspirin , n ( % )
other — no . ( % )
male ( n z nmbr )
dm absent
vora
* nmbr to < nmbry
male
never smoking
female sex — no . ( % )
( gm )
st +
≥ nmbr to < nmbr %
aqe inmbr
n / pyr
< nmbr kg
apobe
age : > nmbr years
crci > nmbr
nmbr mg bid
psa ( n = nmbr )
ldl *
pin /
overall
( se]tf
oa
grade nmbr
off omt
gold a
no ascvd
mean bmi
female sex
serum
othersc
eze nmbr mg
crt - p
itherchdt
dm present
non - smoker
> = nmbr - < nmbr mmhg
nmbr or nmbr days
group d
age , nmbr years
placebo pts / n ( % )
= snmbr
nmbr - nmbr min
ii ( n = nmbr )
rectum
age , yrs *
total *
, nmbr ( n = nmbr )
< nmbr . nmbr %
cana nmbrmg ( n = nmbr )
mae
nmbr % - nmbr %
^nmbr - nmbr
on omt
race — no . ( % )
age : < nmbr years
hdl - cy
≥ nmbr %
africa
cardiac
feno nmbr mg ( n = nmbr )
lvef < nmbr %
pa
hr ( nmbr % ci )
nsaid
pe
white ( n = nmbr )
placebo n ( % )
egfr > nmbr
other *
> nmbr . nmbr yrs
past
< nmbr mm hg
> nmbr % to < nmbr %
known chd
sex , n ( % )
nnt
all ( n = nmbrf )
tia
nmbr / nmbr mg
mmse < nmbr
> nmbr - nmbr kg
< nmbr . nmbr bpm
placebo ( n z nmbr )
locf )
< nmbr days
erosion
smokers , %
weight
iiiv
( i - blocker
dasnmbr
all ( n = nmbr )
placebo , n = nmbr
no htn
sex , no . ( % )
race ( % )
vitality
us
pain
age — y £
< nmbr week
hbalc , %
open
> nmbr y
avm ( n = nmbr )
mild
ami nmbr mg
nmbr mg / day
ever - smoker
no . ( % )
lateral
placebo , n / n ( % )
region — no . ( % )
age ^nmbr
pvd
> nmbr mm hg
romania
nmbr < - nmbr
< nmbr mg / dl
patients
n / n ( % )
> = median
> nmbr ( n = nmbr )
nmbr — nmbr years
> nmbr % and < nmbr %
cancer
macce
£ nmbr to < nmbr years
or nmbr % ci
> i
any use
never
p - blocker
age > nmbr
period i
nmbr to < nmbr hr
swollen
rrr ( nmbr % cl )
≤ nmbr . nmbr %
hscrp
nmbr % ci
second ( n = nmbr )
chd death
pbo ( n = nmbr )
mean — kg
ab nmbr pg ( n = nmbr )
p +
yes *
age
ageadj
aqc < nmbr
rr^ ( nmbr % ci )
nmbr mmhg
nmbr - nmbr mo
> nmbr mg / dl
age - years
statin usage
age nmbr y
race — no . ( % ) 卞
> nmbr / day
des
< median
nmbr - < nmbr yrs
taiwan
nmbr - nmbr yrs
some
≥ nmbr years
> nmbr to < nmbr years
female , no ( % )
cabg — no . ( % )
women - no . ( % )
paci
anmbrc
age :
vldl
lvef ( % )
nmbr - nmbr hr
mi
ls mean
n *
ldl
risk *
present
age > nmbr y , %
sex
bid
pci
statin use
monthnmbr
primary
placebo ( n = nmbro )
< nmbr years
niacini
dm
nmbr to < nmbr yr
edge
spoke
bmi < = nmbr
epa ( n = nmbr )
mean ( sd )
cdmard
sd
nmbr mo to nmbr yr
pfor
nmbr - < nmbr %
alert
lvef
$ nmbr
apo - b
cohort
ali
ace
woman
apob
nmbr to < nmbr mm hg
£ median
ckd
or ( nmbr % cl )
af alone
region ,
nsclc
other ( n , % )
monthly
beta - blockers
race , n ( % )
australasia
fp nmbr mg
mean ( se )
iii - iv
nmbr or nmbr
or [nmbr % ci]
asian
itt
id ( n = nmbr )
state
anmbr
hub
> nmbr hr
lsm ( nmbr % cl )
pci , n ( % )
no . ( % ) *
≥ nmbr to < nmbr years
wssng
f
fp ( n [nmbr )
» nmbr yr
mean — yr
prior dm
pre - h
acid
hctz
rnmbr
korean
placebo %
. nmbr
age < median
nste - acs
age £ nmbr
w
p - value *
stent ( n = nmbr )
> nmbrh
value *
sso - nmbr
id
iorii ( n z nmbr )
belgium
hbalca median
use
male sex ( % )
> nmbr yrs sex :
female ( n z nmbr )
pci ( % )
or ( nmbr % ci )
( e - blocker
nsteacs
other '
bmi^
smoking
race n ( % )
risk
homa
africa *
sex ( % )
jvp , ( % )
rnmbr ( n = nmbr )
py = nmbr )
a - blocker
p blocker
hba , c ( % )
r nmbr mg
female sex , n ( % )
> nmbr
> nmbr to < nmbr
rales , ( % )
tion — no . ( % )
p trend
ada , no
macce ( % )
nonwhite
pt
apo b *
% ( nmbr % ci )
^ - blocker
no betablocker use
age , ( years )
> nmbr type
female
us ( n = nmbr )
tzd
nmbr - < nmbr
peace ( n = nmbr )
< nmbr lb
< nmbr mg / g
non - mtx
age , year
py *
feno
mental
smokers
> nmbr ft
women , %
mssbp
uac =
acei
usa
class > nmbr
europe ii
"/ ’ - value """
sabaa
prior mi
no statin
cv death
age > = nmbr
nmbr §
alone
r
ultra
paci ( n = nmbr )
age < nmbr
stage nmbr
laba alone
eze nmbr mg ( n = nmbr )
no prior ml
nmbr ( < nmbr % )
statin
nnmbr yrs
male ( n = nmbr )
psa
nmbr / nmbr
region - no . ( % )
placebo ( n = nmbrl )
otherz
nmbr years
nmbr yr
asp
aqe < nmbr
n = nmbr
fh ii
overallb
nitrate
age > nmbr y
black
new dm
< nmbr mon ( n = nmbr )
lower
age , mean
dvt
m
black , n ( % )
obesity
women
nmbr mg
il - nmbr
< nmbr y ( n = nmbr )
placebo r %
mg / dl
ml c
tg +
sotalol
cdai < nmbrt
nmbr ( nmbr % )
mmse > nmbr
tg §
v ( n = nmbr )
= nmbr
p
race , no . ( % )
fa nmbr mg
none
no smoking
usa ( n = nmbr )
rate *
gender
male ( n - nmbr )
austria
$ nmbr years
fh nmbr
no ?
dd ( n = nmbr )
lu / kg
no ststm
st -
p - valuea
yes ( n = nmbr )
abi < nmbr . nmbr
iv
sama
latvia
mra
asian *
bm i < nmbr
age > nmbr yrs
chf ( % )
ef , %
vi nmbr mg ( n = nmbr )
< nmbr % ( n = nmbr )
hbaic ( % )
tjc
cvd
> nmbr ml
nmbr to < nmbr
obese
gold , n ( % )
age $ nmbr yrs
placebo ( % )
rr ( nmbr % cl )
« nmbr - nmbr
whitea
age > : nmbr
stroke
median ( iqr )
sjc
< nmbr h
pbo
nmbr - nmbr yr
< nmbr %
chadsnmbr^
p blockers
£ nmbr years
> nmbr / week
nmbr - < nmbr y
non - c
group a
< nmbr - nmbr
ldu - c
$ nmbr ( n = nmbr )
≥ nmbr mg / dl
> nmbr % ( n = nmbr )
rca
age , n ( % )
nyha ii
nmbr . nmbr
£ nmbr yo ( n = nmbr )
ni
noneh
» nmbry
saba §
cabg , n ( % )
nitrates
sita nmbr
anmbr + eznmbr
male sex , %
laaca
> nmbr mmhg
age > nmbr yr
bmi
stemi ( % )
cabg ( % )
european
pvalue
lll - iv
bmi > = nmbr
onmbr
fp ( n = nmbr )
crt - d
severity
normal
age > nmbr yrs , %
patients ( n )
hr , nmbr % cl
sdai < nmbr t
no *
age years
row
beta blockers
lvmi ( nmbr
care
egfr -
prior om
n %
early ( n = nmbr )
nmbr to < nmbr cells
mm hg
any death
> nmbr < nmbr
cl nmbr %
poci ( n = nmbr )
pbo n ( % )
$ nmbr years ( n = nmbr )
all patients
laba '
< nmbr ( n = nmbr )
smoking , %
male , %
level nmbr
placebo , n = inmbr
< nmbr mmhg
no psa
nmbrenmbr
placebo [n z nmbr]
ls mean ( se )
prior stemi
betablocker use
aml nmbr /
acr
\nmbr
homa > median
p - blocker yes
> = nmbr mmhg
no dm ( n = nmbr )
otherx
age — yrf
fragile
no beta - blocker use
n o
asa > nmbr mg
mra , ( % )
india
gold nmbr
csf
nmbr mo
sites
aspirin ( n = nmbr )
< nmbr days ( n = nmbr )
first ( n = nmbr )
age > nmbr , y
sesbp
( se]t *
value
ics usage
> nmbr to < nmbr yr
< nmbr beds
ptca
≥ nmbr bpm ( n = nmbr )
no beta - blocker
age < nmbr y
fa nmbr mg ( « = nmbr )
p value 十
spinal
arr
acm
age > nmbr yrs *
orc ( nmbr % cl )
saba
in - h
males
female , n ( % )
brachial
month nmbr
nmbryr
age ( yr )
italy ( n = nmbr )
nmbr - nmbr
hiv
ale < nmbr
chd * , n ( % )
region
iglar
arbs
age in years
l / ll
> nmbr yrs
tg ’
age < nmbryrs
ff nmbr pg ( n = nmbr )
pad
arr ( nmbr % cl )
americas
st
hctz *
> nmbr . nmbr mm hg
placebo ( n - nmbr )
gold ii
lama
chd
median , iqr
cv death n
ldl , - c
p - value
edge ii
nmbr kg
both ( % )
ml
cana nmbr mg ( n = nmbr )
cad
all
age > nmbr years
sa
racea
male sex , n ( % )
others
reqion
m / f
cat > nmbr
atv n ( % )
< nmbry
> nmbr days
ebria
other
no pa
poland
prior pci
b - blocker
( n = nmbr ,
abi # nmbr . nmbr
oradj ( nmbr % cl )
labaa
hr nmbr % ci
minor
ufh
dm ( n = nmbr )
never smoked
copd
v total ( n = nmbr )
egfr < nmbr
other !
hba < median
event ( % )
general
≤ nmbr ug / g
rr ( nmbr % ci ) *
yes ( % )
post - mi
laba
, nmbr years ( n = nmbr )
sdai
> nmbr mg
p value
stemi
< nmbr ( n z nmbr )
age > nmbr , %
area
male sex — no . ( % )
teaes
sex — no . ( % )
age , y
male ( % )
cvd death
chinese
nstemi
qmi
nmbr - nmbrh
apo b
> nmbr mm ( n = nmbr )
female sex , %
all n = nmbr
abi
any statin
tg > nmbr . nmbr
nmbry
race — no . ( % ) : c
e
angina
ns
age , yr
oretal
no smo king
women , n ( % ) *
p value c
mets
pbo ( n = nmbr ) vs
race — no . ( % ) f
lipid
females
nmbrmg ( n = nmbr )
ada , yes
placebo [n = nmbr]
< nmbr mo
$ nmbr %
> = nmbr . nmbr
< nmbr min
no .
hbaic — %
n .
russia
race *
< nmbr hrs
hps
patients ( ft )
prior stent
nmbr — < nmbr
all ( n = nmbr * )
asa < nmbr mg
< nmbr year
stage nmbrb
iv nitrates
pio nmbr
beta - blocker !
femoral
australia
placeboa
pint
hdl
, nmbr / week
> nmbr y ( n = nmbr )
phi ( n - nmbr )
iii & iv
aqe ^nmbr
region ( % )
nmbr to < nmbr kg
< nmbr y
age # nmbr yrs
placebo ( n nmbr )
anemia ( % )
pbo ( nnmbr )
ckdc , n ( % )
provoked
race
mtx ( n = nmbr )
> nmbr years
upper
mean a ± sdt
no prior mi
mean ± sd
female ( n — nmbr )
tics — no . ( % )
apo a - i
ascvd
glipizide
years
stage nmbra
asian ( n = nmbr )
ics alone
i / ii
%
lesions
total c
> nmbr mon ( n = nmbr )
nstemi ( % )
ppci ( n = nmbr )
women , no . ( % )
no ipst
( n = ms )
uti
obesityj
asia
p [int]
rarely
tc
qd
age , yrs
age ( year )
age , years *
> nmbr mm
europe
≥ nmbr
nmbr min
statins
canvas
niacin
study nmbr
graft , n ( % )
c
ipst ( n = nmbr )
f * >
high , %
ml )
male sex 一 no . ( % )
£ nmbr %
no po
y es
ff - blocker
no prior stemi
< nmbr . nmbr years
african
fibrates
canada
nmbr mg ( n = nmbr )
venous
nmbr - < nmbr ( % )
total n = nmbr
mate
i
met ( n = nmbr )
nausea
other chd
lda , %
ics : no
aspirin
age ( years )
rrr
nmbr - nmbr days
hr ( nmbr % cl )
etn , yes
> nmbr and < nmbr %
male sex — no . ( % ) f
n nmbr
ipst
age > = nmbr yrs
m being
oral
race , zz ( % )
> nmbr - < nmbr
tgt
sfc ( n = nmbr )
prior llt
> = nmbr y
"p - value """
non - white
ldl - c
( nmbr % ci]h
gold b
men , n ( % )
hbalc ( % )
never smoker
men
≥ nmbr mg / g
≥ nmbr ng / ml
no psa ( n = nmbr )
nmbr - i
low , %
haq
beta - blocker
urti
renal
lama +
( sem )
primary *
no mi
age < nmbr yrs
statini
n_
metsyn
< nmbr / < nmbr mm hg
no use
> nmbr . nmbr %
tvr
laa
om nmbr /
arm
r nmbr mg ( « = nmbr )
female , %
cancer §
hbalc > median
men ( n = nmbr )
crcl < nmbr
chd , n ( % )
age — yr
gold c
mean = sd
avr
epa
lnmbr
treatment
< nmbr yo ( n = nmbr )
wegu
hbanmbrc
( se] +
cards
nmbr mg / dl
hdl *
year nmbr
p - blockers
< nmbr yrs
( se]t
no prior pci
nmbr . nmbr %
diet ( n 二 nmbr )
pnorpci
hr ( nmbr % cl ) *
iu
^median
> nmbr min
nmbr to < nmbr mo
> = nmbr yea ' s
median — yr
nnmbr
nmbr to < nmbr years
no des
> nmbr mg / g
> nmbr . nmbr
hrqol
p values
no acs
othernmbr
> nmbr to nmbr years
cat < nmbr
age > nmbr yr 十
smoker
oads , n ( % )
paod
nmbr or more
site
> = nmbr years ( n = nmbr )
ifg
cancer * *
race — no . ( % ) ' (
aged < nmbr years
( ri = nmbr )
x / n *
s £ nmbr
aml
age ( years ) :
htn hx
lvef > nmbr %
non - dm
group b
total hip
obesity t
b
no
total , n = nmbr
race - no . ( % )
< nmbrh
< nmbr . nmbr
r nmbr mg ( n = nmbr )
ics # #
off pump
china
abi > nmbr . nmbr
male , n ( % )
female ( n = nmbr )
age , ya
adl
ii - iv
any
ff nmbr | ig ( n = nmbr )
crp
nste - mi
n =
korea
ckd , n ( % ) t
icd , n ( % )
poba , n ( % )
no aspirin
yes , n ( % )
placebo nmbr
no chd
sfc
asthma
[nmbr % cl]
nmbr to < nmbr ( % )
lvef , %
> = nmbr
ynmbr
age < nmbr years
n / n
racenmbr
placebo ( n[nmbr )
vdhmtss
poci
> nmbr . nmbr min
placebo ( n = nmbr * )
aicd , ( % )
hscrp §
nmbr
major
prior
ccb
male - no . ( % )
b - blockers
placebo ( lsm )
median — vr
ileum
no ( n = nmbr )
> nmbr - nmbr
no statin use
absent
age $ nmbr years § *
ics
laci
< nmbr bpm ( n = nmbr )
% pred
prior ml
> nmbr yr
on nmbr
tg
> = nmbr kg
on pump
tnmbrdm
others , n ( % )
mean
high
hazard
p valuey
cana nmbr mg
age ( y )
( nmbr % ci )
age ( yij
ssi - nmbr
« = nmbr
ucr
tender
p *
iii ( n z nmbr )
cyclo
hbalc < medan
non - hdl
sodium
£ nmbr
simva
laci ( n = nmbr )
puva
icsa
ua
hr ( nmbr % ci ) “
asa
ng
patient
rr
race ( % ) ) '
> nmbr to nmbr
ii
otherb
ldl - cz
( a blocker
event
iii
^nmbr
ef < nmbr %
israel
glinide
brazil
nmbr to < nmbrkg
pasi^i
indian
europe i
male sex
, nmbr years
ifx ( n = nmbr )
week nmbr
right
tg *
samanmbr
high *
hope ( n = nmbr )
active ( n = nmbr )
> nmbr , < nmbr
group c
ex - smokers
male sex , no . ( % )
with ( n = nmbr )
poor
radial
nnmbr / nnmbr
ef > nmbr %
stalin
> = nmbr yr
sfc ( n[nmbr )
race , n ( % ) b
ra
sal nmbr pg ( n = nmbr )
pci — no . ( % )
hrt
fp ( n[nmbr )
mtss
nmbre < nmbr %
yes '
ratio
sal ( n = nmbr )
nyhaii
women — no . ( % )
smoking status , no . ( % )
smoking status , n ( % )
smoking status — no . ( % )
systolic bp , mm hg
systolic bp ( mm hg )
diastolic ( mmhg )
systolic — mm hg
diastolic ( mm hg )
systolic bp ( mmhg )
systolic ( mm hg )
diastolic bp , mm hg
systolic ( mmhg )
diastolic bp ( mmhg )
diastolic — mm hg
diastolic bp ( mm hg )
dasnmbr ( esr )
dasnmbr - crp §
dasnmbr - hscrp
dasnmbr ( crp )
dasnmbr - crp
dasnmbr - esr
unadjusted
unadjusted hr
unadjusted irr
adjusted
unadjusted hr .
ejection fraction
lv ejection fraction
apolipoprotein anmbr ( g / l )
apolipoprotein anmbr ( mg / dl )
fpg , mmol / l
fpg ( mmol / l )
tg ( mmol / l ) c
na ( mmol / l )
k ( mmol / l )
ldl ( mmol / l )
bun , mmol / l
tc ( mmol / l )
tg ( mmol / l )
ffa ( mmol / l )
fpg , mmol / lt
mdg ( mmol / l )
ppg , mmol / l
hdl ( mmol / l )
mssbp , mm hg
dbp ( mmhg )
sbp ( mm hg )
sbp , mmhg
dbp , mm hg
sbp ( mmhg )
dbp , mmhg
msdbp , mm hg
msdbp , mm hga
mssbp , mm hga
sbp , mm hg
dbp ( mm hg )
map ( mmhg )
cvd subjects
all subjects
mrf subjects
c - reactive protein ( mg / l )
c - reactive protein ( mg / dl )
c - reactive protein , mg / l
c - reactive protein , * mg / l
c - reactive protein ( mg / dl_ )
body - mass index ( kg / mnmbr ) t
body mass index - kg / mnmbrt
body mass index ( kg / mnmbr ) ,
body mass index , kg / mnmbr
body mass index ( kg / nr )
body mass index ( kg / mnmbr )
body - mass index ( kg / mnmbr )
bodymass index ( kg / mnmbr )
body mass index ( kg / mnmbr ) * '
body mass index , * kg / mnmbr
comorbidities , n ( % ) a
comorbidites , n ( % )
controls ( n = nmbr )
control ( n z nmbr )
control ( nznmbr )
control ( n = nmbr )
control ( n - nmbr )
african - american
african american
african americans
african america
history of hypertension ( n = nmbr )
no history of hypertension ( n = nmbr )
egfr ( ml / min )
egfr , ml / min
- ics / + laba n z nmbr
+ ics / + laba nz nmbr
baseline mean ( se )
baseline ( mean , sd )
baseline , mean ( sd )
no current smoking
current smoker , %
current smokers
current smokers ( % )
current smoker ( % )
current smoker
current non - smoker
current smoking
current smokers , %
current smokers *
current smoking *
current nonsmoker
current smoker ,
current smoker yes
current nonsmokers
prior ptca or pci
prior ptca / pci
interactior p - value
interaction p - value
interaction p value 中
interaction p value §
interaction p value
duration of copd ( yr )
duration of copd , y
duration of copd — yr
duration of copd , yr
duration of copd , years
duration of pd , y
duration of copd ,
duration of copd ( years )
multivariate p - value
univariate p - value
group b ( n = nmbr )
group c ( n = nmbr )
group a ( n = nmbr )
rage ( ng / ml )
ltbr ( ng / ml )
pigr ( ng / ml )
vegfr ( ng / ml )
imt ( nmbr )
imt ( mm )
haq - di *
haq - di
haq - di * *
non - fatal stroke
nonfatal stroke
antiplatelet or anticoagulant
antiplatelets or anticoagulants
hypercholesterolemia — no . ( % ) *
hypercholesterolemia — no . ( % )
hypercholesterolemia 一 no . ( % )
pre - menopausal without hormone replacement
post - menopausal with hormone replacement
pre - menopausal with hormone replacement
post - menopausal without hormone replacement
bumetanide
budesonide
nmbr - hour madbp , mm hg
nmbr - hour masbp , mm hg
no prior heart failure
prior heart failure
prior cancer
no prior cancer
nmbr to < nmbr ( n = nmbr )
$ nmbr to , nmbr ( n = nmbr )
nmbr to < nmbr ( n z nmbr )
ace - i or arb
no ace - i / arb
ace - lorarb
ace - i / arb
acei or arb
ace - l / arbs
aceis / arbs
acei / arb
triglycerides
triglyceride a
triglycerides *
triglycerides * *
triglyceride
fluvastatin ( n = nmbr )
simvastatin ( n = nmbr )
rosuvastatin ( n = nmbr )
diabetic yes
diabetes
antidiabetic
diabetesnmbr
nondiabetic
prediabetes , %
diabetic no
non - diabetic
diabetes ( % )
diuretics
diuretic use
diabeticnmbr
diabetesf
diabetes , %
prediabeticb
diureticff
n o diabetes
diabetes *
dabetes
non - diabetes
non - diabetics
diabetics
diuretic
no diabetes
diurciic
diabetic
diabeticb
stage nmbra : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr
stage nmbrb : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr
pm pef ( sd ) , l / min
am pef ( sd ) , l / min
fevnmbr : fvc ratio
"fevnmbr : fvc ratio ;"
fevnmbr / fvc ratio *
egfr , * ml / min / nmbr . nmbr mnmbr
egfr , ml / min / nmbr . nmbr mnmbr
egfr ( ml / min / nmbr . nmbrmnmbr )
egfr ( ml / min / nmbr . nmbr mnmbr )
egfr ( ml / min / nmbr . nmbr mnmbr ) §
dyslipidaemiat
dyslipidaemia
dyslipidaemia 本
dyslipidemia
nmbr st < nmbr . nmbr
nmbr / nmbr ( nmbr )
nmbr ( nmbr , nmbr )
nmbr ( nmbr . nmbr % )
nmbr ( nmbre < nmbr % )
> nmbr - nmbr - nmbr
nmbrrd > nmbr . nmbr
nmbr - nmbr . nmbr
nmbr ( nmbr . nmbr )
nmbr . nmbr % ( nmbr )
nmbr - < nmbr . nmbr
oral hypoglycemic
oral hypoglycemics
north america ( % )
south america ( % )
sitagliptin nmbr mg n = nmbr
sitagliptin nmbrmg n = nmbr
disease activity]
disease activity
ease activity]
class i
class ia
class iii
class ii
class ib
class ic
class iv
nt - probnp , pg / mlt
nt - probnp ( pg / ml ) h
nt - probnp ( pg / ml )
nt - probnp — pg / ml * *
nt - probnp , pg / ml
drug - eluting stent
drug eluting stent
race : non - white
race , nonwhite
race - non - white
race nonwhitet
race , % nonwhite
race , non - white
smoking status *
smokinq status
smoking status
nyha iii or iv
nyhaiiioriv
csf cholesterol
hdl - cholesterol
vldl cholesterol
ldl cholesterolt
ldl - cholesterol (
hdl cholesterol §
ldl cholesterol
tolal choleslerol
total cholesterol *
hdl cholesterol *
total cholesterol , %
total cholesterol
hdl choleslerol
ldl choleslerol
aldl cholesterol
hdl cholesterol
ldl - cholesterol
medical therapy
medical therapies
topical therapy
hbanmbrc ( n )
> nmbr , no . ( % )
> nmbr h , n ( % )
> nmbr days ( % )
< nmbr h , n ( % )
< nmbr % , n ( % )
> nmbr ( % )
anmbrc ( % )
> nmbry , no . ( % )
hbanmbrc , %
hbanmbrc , % §
> nmbr % , n ( % )
hbanmbrc ( % )
> nmbr yr — no . ( % )
< nmbr vr — no . ( % )
$ nmbr % , n ( % )
> nmbr , n ( % )
< nmbr { % )
< nmbr y , n ( % )
^nmbr y , n ( % )
aabnmbr ( % )
< nmbr yr — no . ( % )
< nmbr ( % )
> = nmbr * ( % )
> nmbr yr ( % )
> = nmbr ( % )
> nmbr y , n ( % )
> nmbr y , no . ( % )
< nmbr days ( % )
> nmbr y . n ( % )
< nmbr , n ( % )
£ median ( nmbr )
> median ( nmbr % )
> median ( nmbr kg )
> median ( nmbr mm )
> median ( nmbr )
< median ( nmbr kg )
women < nmbr years
women > nmbr years
diclofenac ( n = nmbr , nmbr )
diclofenac ( n = nmbr nmbr )
previous mi — no . ( % )
previous vte — no . ( % )
previous chf — no . ( % )
bl h / y : bilateral
bl h / y : unilateral
diabetes status
diabetic status
mean ( sd ) age in years
mean ( sd ) age , yr
mean ( sd ) age , years
mean ( sd ) age ( years )
no symptoms
symptoms
age at randomization
age at randomisation
vadas score *
mmse score *
mean acrn
rope score
cat score
sss score
gds score *
mmse score
edss score
chads score
mean score
mhis score
cat scoreff
kccq score
aqlq score
accp score
baseline sbp ( mm hg )
baseline dbp ( mm hg )
itt population
mitt population
tiotropium + placebo ( n[nmbr )
tiotropium + placeb ( n[nmbr )
myocardial infarction , n ( % )
myocardial infarction , ( % )
sinusitis
synovitis
no history of tia / stroke
history of tia or stroke
history of tia / stroke
heart rate ( beats per min )
heart rate , beats / min
heart rate , beats per min
heart rate — beats / min
heart rate ( beats / min )
heart rate ( beats per minute )
pga , nmbr - nmbr
tjc , nmbr - nmbr
sjc , nmbr - nmbr
ptga , nmbr - nmbr
region latin american
region , latin america
calcium - channel blockers
calcium channel blockers
calcium - channel blocker
calcium channel blocker
calcium - channel blockerf
baseline median [mg / l]
baseline median , mg / dl
baseline mean , mg / dl
baseline mean ( mg / dl]
baseline median , mg / l
baseline mean mtss
baseline mean 士 sd
glucocorticoids
glucocorticoid
glucocorticoids *
esr ( mm / h )
esr , mm / hour
esr — mm / hr
"esr ( mm / hour )git config --global user.name ""Your Name"""
ns cardiac cisease
cardiac disease
no cardiac disease
education < nmbr years
education > nmbr years
triglyceride ( mmol / l )
triglyceride ( mmol / l ) t
triglyceride , mmol / l
triglycerides ( mmol / l ) :
triglycerides ( mmol / l )
triglycerides , mg / l
triglycerides , mmol / l §
triglycerides * ( mg / dl )
triglycerides , mg / dl
triglyceride ( mg / dl ) d
triglycerides — mg / dl
triglycerides ( mg / dl )
triglycerides , mg / dl^
triglycerides , mmol / l
triglyceride ( mg / dl )
triglycerides , mmol / lf
patients without diabetesb
patients with diabetesb
no prior heart failure ( n = nmbr , nmbr )
prior heart failure ( n = nmbr , nmbr )
prior lev use
prior asa use
postmenopausal ,
postmenopausal
premenopausal
hs - crp ( mg / l )
apob , mg / dl
fpg , mg / dl
bnp ( pg / ml )
fpg ( mg / dl )
hs - crp , mg / l
bun , mg / dl
crp — mg / l
crp ( ng / ml )
hscrp , mg / l
apob , g / l
bun ( mg / dl )
tgs ( mg / dl )
hdl ( mg / dl )
ppg , mg / dl
bnp , pg / ml
apo b ( g / l )
crp ( mg / dl )
apoal , mg / dl
mpo ( ng / ml )
hscrp ( mg / l )
hscrp , mg / dl
hscrp ( mg / l ) c
apo b , mg / dl
hscrp ( nmol / l )
troy ( ng / ml )
apob ( mg / dl )
bnp ( pg / ml ) h
crp , mg / l
bnp , pg / mlt
triglycerides nmbr , d third
triglycerides nmbrst third
triglycerides nmbrnd third
no multivessel disease
multivessel disease
fastng plasma glucose < median
fascng plasma glucose a medan
fasting plasma glucose < median
caucasian , %
caucasian ( % )
caucasiana ( % )
concomitant cardiovascular therapies — no . ( % )
concomitant cardiovascular therapy — no . ( % )
dissatisfied with / stopped $ nmbr prior systemic therapies because of side effects
dissatisfied with / stopped $ nmbr prior systemic therapy because of side effects
linagliptin ( n z nmbr )
vildagliptin ( n = nmbr )
linagliptin ( n = nmbr )
sitagliptin ( n = nmbr )
smoking — current
smoking , % current
current smoking — no . ( % )
current smoking , n ( % )
current smoker 一 no . ( % )
current smokers , n ( % )
current smoker — no . ( % )
current smoker , n ( % )
current smoker , no ( % )
without tnmbrdm n = nmbr
with tnmbrdm n = nmbr
val / hctz ( n = nmbr )
v / hctz ( n = nmbr )
aml / hctz ( n = nmbr )
ind / gly
indzgly
gdf - nmbr ( ng / ml )
mmp - nmbr ( ng / ml )
st - nmbr ( ng / ml )
mmp - nmbr ( ng / ml ) *
il - nmbr ( pg / ml )
diabetes , n ( % )
diabetes — no . ( % )
diabetes , no . ( % )
diabetes , * n ( % )
prediabetes , n ( % )
unstable angina — no . ( % )
stable angina — no . ( % )
anmbrc < nmbr . nmbr % ( median )
anmbr = nmbr . nmbr % ( median )
hazard ratio ( nmbr % cl )
hazard ratio ( nmbr % ci ) *
hazard ratio ( nmbr % ci )
hazard ratio * ( nmbr % ci )
hazard ratiof ( nmbr % ci )
lipid - lowering agent §
lipid - lowering agents
lipid - lowering agent
zotarolimus
zotarolimust
pci orcabg
prior cabg
no prior cabg
pnorcabg
diastolic blood pressure , mm hg , median ( range )
systolic blood pressure , mm hg , median ( range )
very severe
more severe^
less severe
more severe
cholesterol ( mg / dl )
cholesterol — mg / dl
treatment difference ( nmbr % cl )
treatment difference ( nmbr % ci )
insulin
insulina
> median ( nmbr ) — number / n ( % )
< median ( nmbr ) — number / n ( % )
baseline mssbp ( mmhg ) , mean ± sd
baseline msdbp ( mmhg ) , mean ± sd
age range ( years )
age range , years
inflammation
inflammatory
hispanic or latino
hispanic / latino
< nmbr cells / pl
> nmbr cells / pl
american indian
american indian /
with an sfua
without an sfua
men , > nmbr cm
men , < nmbr cm
women , < nmbr cm
women , > nmbr cm
sulphonylureas
sulphonylurea
on sulfonylurea
sulfonylureaa
sulfonylurea
pbo + mtx
czp + mtx
caucasians
caucasian
noncaucasian
non - caucasian
ldl cholesterol ( mg / dl ) , mean + sd , available for nmbr patients
hdl cholesterol ( mg / dl ) , mean + sd , available for nmbr patients
previous or current use of im or cs : no
previous or current use of im and cs : no
nmbr to < nmbr ml / min / nmbr . nmbrmnmbr
nmbr to o nmbr ml / min / nmbr . nmbr mnmbr
nmbr to onmbr ml / min / nmbr . nmbr mnmbr
≥ nmbr to < nmbr ml / min / nmbr . nmbr mnmbr
nmbr to < nmbr ml / min / nmbr . nmbr mnmbr
without psoriasis ( zi = nmbr )
with psoriasis ( n = nmbr )
with psoriasis ( zi = nmbr )
placebo events / patients ( % )
placebo , events / patients ( % )
ldl - cholesterol ( mg / dl )
ldl cholesterol , mg / dl
hdl cholesterol ( mg / dl )
ldl cholesterol — mg / dl
i idl cholesterol ( mg / dl )
hdl cholesterol — mg / dl
hdl cholesterol , mg / dl
ldl cholesterol ( mg / dl )
hdl - cholesterol ( mg / dl )
baseline ldl - c
baseline ldl - c :
who fc ii symptoms at baseline
who fc iii symptoms at baseline
nmbr . nmbr - < nmbr . nmbr
> nmbr - nmbr - nmbr - nmbr
nmbr - nmbr - nmbr - nmbr
nmbr . nmbr to nmbr . nmbr %
> nmbr . nmbr - < nmbr . nmbr
nmbr . nmbr - nmbr . nmbr
nmbr . nmbr + nmbr . nmbr
nmbr nmbr ( nmbr . nmbr )
nmbr . nmbr - < nmbr . nmbr %
nmbr , nmbr ( nmbr . nmbr )
nmbr , nmbr - < nmbr . nmbr
nmbr / nmbr ( nmbr . nmbr )
nmbr . nmbr to nmbr . nmbr
> nmbr . nmbr to < nmbr . nmbr
nmbr . nmbr ( nmbr . nmbr )
> nmbr . nmbrto < nmbr . nmbr %
nmbr . nmbr % - nmbr . nmbr %
no mra at baseline
mra at baseline
ss at baseline
mmrc at baseline
pad at baseline
nihss at baseline
aspirin dose
aspirin alone
aspirin use
arrhythmia
arrhythmia !
arrhythmias
hypertensive
hypertensiont
hypertension , n ( % )
hypertension 本
hypotension
hypertension , * n ( % )
hyper - tension
hypertension
hypertension , %
hypertension ( % )
hypertension , ( % )
no hypertension
hyperlension
hypertension *
hypertensive , n ( % )
hypertension §
hypertension !
unstable angina *
unstable angina age
unstable angina §
unstable anginad
unstableangina
stable angina
unstable anginat
unstable angina
arb monotherapy
era monotherapy
cardioembolism
cardioembolic
age category >
bmi category
age category
aspirin or other antiplatelet agents
aspirin or other antiplatelet agent
mean ( sd ) pga vas *
mean ( sd ) ptga vas *
mean ( sd ) pain vas *
previous ml ( before index acs )
previous pci ( before index acs )
fibula fracture
tibia fracture
weight in kg , mean ( sd )
weight , kg , mean ( sd )
weight , kg : mean ( sd )
weight ( kg ) , mean ( sd )
weight ( kg ) , mean ± sd
serum creatinine , umol / lf
serum creatinine , gmol / l |
serum creatinine ( gmol / )
serum creatinine ( mmol / l )
serum creatinine , ^mol / l
> nmbr years eze / simva ( „ = nmbr }
< nmbr years eze / simva ( n = nmbr }
im use : no
cs use : no
stent diameter < nmbr mm
stent diameter $ nmbr mm
overall ( n = nmbr , nmbr )
overall ( n = nmbr vs nmbr )
leukotriene receptor antagonists
leukotriene - receptor antagonist
high - sensitivity c - reactive protein , mg / ltt
high - sensitivityc - reactive protein , mg / l
etn + mtx ( n = nmbr )
hcq + mtx ( n = nmbr )
ssz + mtx ( n = nmbr )
lef + mtx ( n = nmbr )
> nmbr drinks
nmbr drinks
glucose ( mg / dl )
glucose — mg / dl
thienopyridine
+ thienopyridine
no thienopyridine
- thienopyridine
acholesterol ( % )
cholesterol ( % )
< nmbr . nmbr mg / dl
> nmbr . nmbr mg / mmol
> nmbr . nmbr - g / l
nmbr - nmbr mg / g
nmbr nmbr mg / dl
≥ nmbr to < nmbr mg / g
> nmbr . nmbr mg / l
> nmbr . nmbr mmol / l
≥ nmbr to < nmbr mg / dl
< nmbr . nmbr mmol / l
< nmbr . nmbr mg / mmol
> nmbr & < nmbr mg / dl
> nmbr and < nmbr mg / dl
> nmbr to nmbr mg / g
> nmbr but < nmbr mg / dl
< nmbr . nmbr ng / ml
> nmbr + nmbr mmol / l
nmbr - nmbr mg / dl
. nmbr . nmbr mg / mmol
< nmbr - nmbr mmol / l
, nmbr . nmbr mg / mmol
nmbr to nmbr mg / g
nmbr to < nmbr mg / dl
> nmbr . nmbr mg / dl
> nmbr , < nmbr mg / dl
< nmbr . nmbr l - g / l
> nmbr . nmbr ng / ml
> nmbr ' nmbr mmol / l
> nmbr - nmbr mmol / l
< nmbr . nmbrmg / l
cerebral vascular disease
cerebrovascular disease
linagliptin
vildagliptin
sitagliptin
saxagliptin
mean ( s . e . )
mean ( s . e . ) t
mean ( s . d . )
mean bmi , kg / mnmbr ( sd )
mean bmi ( kg / mnmbr ) ( sd )
tiotropium ( nznmbr )
tiotropium ( n z nmbr )
tiotropium ( n = nmbr )
gastroduodenum
gastroduodenal
primary endpoint
"primary end point """
primary end point
dyslipidemia — no . ( % )
dyslipidemia — no . ( % ) |
tjc ( nmbr - nmbr ) , mean ( sd )
sjc ( nmbr - nmbr ) , mean ( sd )
non cv mortality
non - cv mortality
patients with prevalent kidney disease at baseline
patients without prevalent kidney disease at baseline
mean ( s . d . ) age , years
mean ± s . d . age , years
nmbr mg / day early - start - delayed - start
nmbr mg / day early - start - delayed start
£ nmbr kg / mnmbr
anmbr kg / mnmbr
< nmbr kg / m nmbr
> nmbrkg / mnmbr
< nmbrkg / mnmbr
snmbr kg / mnmbr
< nmbr kg / mnmbr
≥ nmbr kg / mnmbr
> nmbr kg / mnmbr
hypokalemia ‡   ( potassium < nmbr . nmbr mmol / l )
hyperkalemia ‡   ( potassium ≥ nmbr . nmbr mmol / l )
heparin only
aspirin only
mitral regurgitation , n ( % )
mitral regurgitation , ( % )
< nmbr years n z nmbr
> nmbr years n z nmbr
age < nmbr y ( n = nmbr )
age ' nmbr y ( n nmbr )
age > nmbr y ( n = nmbr )
ace inhibitor , %
ace inhibitor
ace inhibitors
tnf inhibitors
tnf inhibitor
ace inhibitor yes
body - mass index : ! :
"body - mass index ; ! ;"
change from baseline to eos , uu / ml
change from baseline to eos , mg / dl
right coronary artery
r ight coronar y artery
duration of tnmbrdm > nmbr years
duration of tnmbrdm < nmbr years
time to randomization
time of randomization
p value ( cangrelor versus clopidogrel in men )
p value ( cangrelor versus clopidogrel in women )
weight ( kg )
weight , kg *
height — cm
w eight ( k g )
weight , lbs
weight , kg
height , cm
weight 一 kg
height ( cm )
weight — kg
weight - kg
height , cm *
ldl - c , mmol / l ( mg / dl )
hdl - c , mmol / l ( mg / dl )
body - mass index ) -
body mass index , %
body - mass indexj
body - mass indexf
"body - mass index ) """
body - mass index )
body - mass index *
body - mass index §
body mass index *
body - mass index $
body mass indexc
body mass index +
body mass index
body mass index :
body - mass index
family history of premature chd
family history of premature chdj
abatacept nmbr mg / kg ( n = nmbr )
abatacept ~ nmbr mg / kg ( n = nmbr )
prior tnf antagonist failure - no
prior tnf antagonist failure - yes
previous cabg
previous mi
previous ptca
previous pci
previous hf
previous tia
previous ml
previous chf
previous cad
previous ami
previously
previous
w event ( rate )
n event ( rate )
type nmbr diabetes ( n = nmbr , nmbr )
no type nmbr diabetes ( n = nmbr , nmbr )
family history of vte
family history of cad
with p blockers
without p blockers
triglycerides < nmbr - nmbr mmol / l
triglycerides > nmbr - nmbr mmol / l
non - hdl - c , mg / dl
non - hdl - c ( mg / dl )
lipid - lowering medications^
lipid - lowering medications
lipid - lowering medication
history of cad
no history of af
history of pci
history of copd
history pci
history of mi
history of vte
history of chf
history of chd
history of cabg
no history of chf
history of pad
history of ml
history of hf
history of af
lesion length $ nmbr mm
lesion length > nmbr mm
male gender
female gender
ratio of hrs ( nmbr % cl ) , p for sex interaction
ratio of hrs ( nmbr % ci ) , p for sex interaction
statins / ezetimibe
statin or ezetimibe
> median ( nmbr . nmbr ) — number / n ( % )
< median ( nmbr . nmbr ) — number / n ( % )
renal impairment
renal impairmentt
antiplatelet drugs
antiplatelet drug
chanmbrdsnmbr - vasc $ nmbr
chanmbrdsnmbr - vasc # nmbr
chanmbrdsnmbr - vasc > nmbr
reversibility to
reversibility ( % ) t
reversibility *
reversibility
reversibility , %
reversibility ( % )
reversibility %
present ( £ nmbr mg / dl )
present ( > nmbr mg / dl )
hbanmbrc < = nmbr %
hbanmbrc < nmbr %
hbanmbrc > nmbr %
hbanmbrc > = nmbr %
metformin 一 no . ( % )
metformin — no . ( % )
women / men [ % ]
women / men , %
nmbr . nmbr to # nmbr . nmbr mg / mmol
nmbr . nmbr - < nmbr . nmbr mg / mmol
baseline tav - > = median ( n = nmbr , nmbr )
baseline pav - > = median ( n = nmbr , nmbr )
baseline tav - < median ( n = nmbr , nmbr )
baseline pav - < median ( n = nmbr , nmbr )
ifg / igt
ifg and igt
< nmbr % ( < nmbr mmol / mol )
> nmbr % ( > nmbr mmol / mol )
> = nmbr % ( nmbr mmol / mol )
< nmbr % ( nmbr mmol / mol )
no mi ( n - nmbr , nmbr )
pad ( n - nmbr , nmbr )
no mvd ( n - nmbr , nmbr )
acs ( n - nmbr , nmbr )
mvd ( n - nmbr , nmbr )
any mi ( n - nmbr , nmbr )
no pad ( n - nmbr , nmbr )
total cholesterol > nmbr - nmbr mmol / lt
total cholesterol < nmbr nmbr mmol / lt
total cholesterol < nmbr - nmbr mmol / lt
total cholesterol > nmbr ' nmbr mmol / lt
body mass index , mean ( sd )
body mass index , mean ( sd ) t
body massindex , mean ( sd ) a
body - mass index , mean ( sd )
body mass index , mean ( sd ) d
change from baseline *
change from baseline
% change from baseline
rectal bleeding subscore {
rectal bleeding subscore
ldl - c ( mmol / l )
ldl - c , mmol / l
hdl - c , mmol / l
hdl - c ( mmol / l )
ldl - c * ( mmol / l )
insulin - dependent
insulin dependentc
antihypertensive therapy
anti - hypertensive therapy
ace inhibitors or angiotensin - receptor blockers^
ace inhibitor or angiotensin receptor blocker
ace inhibitor or angiotensin ii receptor blocker
ace inhibitors or angiotensin receptor blockers
diabetes duration , years
diabetes duration ( years )
age ( years ) mean ± sd
age , y , mean ( sd )
cdai , mean ( sd )
age , years ( sd )
age , years , mean + sd
age , yr mean ( sd )
age , mean ( sd )
bmi , mean ( sd )
age ( years ) mean ( sd )
age ( years ) ( mean , sd )
tc , mean ( sd )
bmi , mean ( sd ) b
ibdq , mean ± sd
age ( years ) , mean ± sd
age , y , mean ± sd
age , years , mean ( sd )
bmi , mean ± sd
age , yr , mean ( sd )
sdai , mean ( sd )
age , mean ± sd
age ( yrs ) , mean ± sd
age ( years ) , mean ( sd )
age , years , mean ± sd
age , mean yr ( sd )
basfi , mean ( sd )
age in years , mean ( sd )
age ( years ) - mean ± sd
age , yrs , mean ( sd )
one of the above
two of the above
all of the above
none of the above
any of the above
asian or oriental
asian / oriental
no . of stents
no . of events
no . of patients
serum creatinine — mg / dl §
serum creatinine ( mg / dl )
serum creatinine — mg / dl
serum creatinine , mg / dlb
serum creatinine , mg / dl
no diabetes ( n - nmbr , nmbr )
diabetes ( n - nmbr , nmbr )
final median , mg / l
final mean , mg / dl
nonwhite race !
nonwhite race
white race
non - white race
non - white raceb
> nmbr egfr , ml / min / nmbr . nmbr mnmbr
> nmbr egfr , ml / min / nmbr . nmbr mnmbr a
current cigarette smoker
current cigarette smoking
at home systolic pressure > nmbr mm hg
at home diastolic pressure < nmbr mm hg
at home diastolic pressure > nmbr mm hg
at home systolic pressure < nmbr mm hg
hx stroke / tia
stroke or tia
stroke ortiab
stroke / tia
no stroke / tia
clinical history — no . ( % )
clinical history , no . ( % )
clinical history , n ( % )
combination therapy ( n = nmbr )
combination therapy , n = nmbr
anmbrc at baseline < nmbr . nmbr %
anmbrc at baseline ≥ nmbr . nmbr %
native american
latin american
latin america
liraglutide nmbr . nmbr mg ,
liraglutide nmbr . nmbr mg
medical history , no . ( % )
medical history — no . ( % )
medical history , n ( % )
diabetes mellitus :
diabetes mellitus
no diabetes mellitus
diabetes mellitus , n ( % )
diabetes mellitus !
diabetes mellitus , § n ( % )
diabetes mellitus , %
diabetes mellitus ( % )
diabetes mellitus , ( % )
since diagnosis
index diagnosis
> nmbr months , mean ( sd )
< nmbr months , mean ( sd )
placebo ( n = nmbr nmbr )
placebo ( n = nmbr , nmbr )
placebo ( n - nmbr . nmbr )
placebo ( n nmbr nmbr )
second mi
no second mi
controlled
coronary
country
controlld
uncontrolled
control
diabetes status , n ( % )
diabetes status , no . ( % )
ezetimibe nmbr mg ( n = nmbr * )
ezetimibe nmbr mg ( n = nmbr )
chadsnmbr score
chadsnmbr score *
chadsnmbr scoreb
age , mean = sd , years
age , mean ± sd ( year )
age , mean ± sd years
age , mean ( sd ) years
age , mean ( sd ) , years
age , mean ( sd ) , y
age , mean ( sd ) , yrs
age , mean ± sd , years
aiirocumab ( n = nmbr )
alirocumab ( n = nmbr )
< nmbr enroll
> nmbr enroll
dasnmbr - crp , ls mean change from baseline ( se ) ¥
dasnmbr - crp , ls mean change from baseline ( se ) §
anacetrapib nmbr mg ( n = nmbr )
anacetrapib nmbrmg ( n = nmbr )
anacetrapib nmbr mg ( n - nmbr )
current
currently
total stent length - mm
total stent length , mm
body mass index > nmbr kg / mnmbr *
body mass index < nmbr kg / mnmbr
p inleraclion
p nmbr interaction
p for interaction
pfor interaction
p interaction
pinteraction
p , interaction !
p for interaction *
interaction p
age - interaction
interaction - p
p - interaction
p . interaction
p : interaction
p - interactio n
angiotensin receptor blockers
angiotensin receptor blocker yes
angiotensin ii receptor blocker
angiotensin - receptor blocker
angiotensin receptor blocker
angiotensin ll - receptor blocker
creatinine — mg / dl
creatinine , mg / dl_
creatinine ( mg / dl )
creatinine , mg / dl
baseline post - bronchodilator % predicted fev , > nmbr % and no prior ics use
baseline post - bronchodilator % predicted fev , > nmbr % and prior ics use
fevnmbr ( % predicted )
fevnmbr , % predicted
fevnmbr , % predicteda
fevnmbr % predicted
fevnmbr , l *
fevnmbr , l
fevnmbr , la
fevnmbr ( l )
mean sitting sbp ( mmhg )
mean sitting dbp ( mmhg )
potassium ( mmol / l )
potassium ( meq / l )
potassium , mmol / l
£ nmbr ( men ) / £ nmbr ( women )
< nmbr ( men ) / < nmbr ( women )
creat clearance < nmbr ml / min
creat clearance > nmbr ml / min
pre - bronchodilator
prebronchodilator
post - bronchodilator
postbronchodilator
heritable
variable
apolipoprotein b ( mg / dl )
apolipoprotein b ( g / l )
tiotropiumc
tiotropium
no prior statin use
prior statin use
nyha iv , n ( % )
nyha ii , n ( % )
nyha iii , n ( % )
metabolic syndrome
metabolic syndrome ,
metabolic syndrome *
tiotropium nmbr mg
tiotropium nmbrmg
tiotropium nmbr m g
pitavastatin nmbr mg
pravastatin nmbr mg
rosuvastatin nmbr mg
simvastatin nmbr mg
atorvastatin nmbr mg
fluvastatin nmbr mg
lovastatin nmbr mg
stage nmbrb : nmbr - nmbr ml / min / nmbr . nmbr mnmbr
stage nmbra : nmbr - nmbr ml / min / nmbr . nmbr mnmbr
stage nmbr : nmbr - nmbr ml / min / nmbr . nmbr mnmbr
readmission ( n = nmbr )
no readmission ( n = nmbr )
nyha class iii
nyha class iv
nyha class
nyha class ii
nyha class > ii
nyha class i
no prior cv event
prior lgi event
prior ugi event
no prior ugi event
prior cv event
major cv event
no prior lgi event
prior peripheralarterialdisease
prior peripheral arterial disease
pre - bronchodilator fevnmbr ( l )
post - bronchodilator fevnmbr , l
post - bronchodilator fevnmbr , l *
postbronchodilator fevnmbr , l
prebronchodilator fevnmbr ( l ) t
post - bronchodilator fevnmbr ( l ) a
post - bronchodilator fevnmbr ( l ) *
prebronchodilator fevnmbr ( l )
prebronchodilator fevnmbr , l
post - bronchodilator fevnmbr ( l )
pre - bronchodilator fevnmbr , l *
amlodipine / valsartan nmbr / nmbr mg ( n = nmbr )
amlodipine / valsartan nmbr / nmbr mg ( n = nmbri )
noncardiovascular
cardiovascular
etoricoxib ( n = nmbr , nmbr )
etoricoxib ( n = nmbr nmbr )
no previous cv event
previous cv event
asa use at baseline , n ( % )
ics use at baseline , n ( % )
ics users at baseline , n ( % )
icsusers atbaseline , n ( % )
mean fvc ± sd
mean dlco ± sd
saphenous vein graft
saphenous - vein graft
hypercholesterolemia
hypercholesterolemia *
hypercholesterolemiat
hypercholesterolaemia
one tnfi and
one tnfi *
with stent^l
with stent
without stent
postmenopausal and current hrt
postmenopausal and current ht
postmenopausal , current hrt
end point
endpoint
end points
endpointc
telmisartan ( n = nmbr )
irbesartan ( n = nmbr )
olmesartan ( n = nmbr )
duration of rheumatoid arthritis , year
duration of rheumatoid arthritis — yr
dyslipidaemia , n ( % )
dyslipidemia , n ( % )
heart failure nmbr mo before admission
heart failure nmbr month before admission
"no anemia bsl hb > nmbrg i - nmbr ; yr nmbr > nmbrg i - nmbr"
"new anemia bsl hb > nmbrg i - nmbr ; yr nmbr < nmbrg i - nmbr"
no previous myocardial infarction
previous myocardial infarction
peripheral artery disease
peripheral arterial disease
peripheral - artery disease
peripheral artery disease *
peripheral artery diseasef
history of pvd , n ( % )
history of chd , n ( % )
history of mi , n ( % )
history of chf , n ( % )
history of tia , n ( % )
history of pci , n ( % )
history of cabg , n ( % )
white race — no . / total no . ( % ) $
white race — no . / total no . ( % ) f
aspirin nmbr
aspirin nmbr mg
total cholesterol , mmol / l
total cholesterol ( mmol / l )
total cholesterol , mmol / l 本
total cholesterol ( mmol / l ) :
no myocardial infarction at presentation ( n = nmbr )
myocardial infarction at presentation ( n = nmbr )
< nmbr mmol / l
> nmbr mmol / l
black / african american
black or african - american
black / african - american
black or african american
black or african america
black / african american *
saxagliptin nmbr . nmbr mg ( n = nmbr )
saxagliptin nmbr . nmbr mg ( n z nmbr )
bmi ( kg / mnmbr ) , mean ± sd
bmi ( kg / mnmbr ) mean ± sd
bmi ( kg / mnmbr ) , mean ( sd )
bmi , kg / mnmbr , mean + sd
bmi , kg / mnmbr , mean ( sd )
bmi , kg / mnmbr , mean ± sd
bmi in kg / mnmbr , mean ( sd )
bmi ( kg / mnmbr ) mean ( sd )
> nmbr years , n ( % )
< nmbr years , n ( % )
hazard ratio or differencenmbr * ( nmbr % cl ) p - value
hazard ratio or differencenmbr ( nmbr % cl ) p - value
history of hypertension ( a ) c
history of hypertension ( % )
women ( n = nmbr ) , n / n ( % )
men ( n = nmbr ) , n / n ( % )
aldosterone antagonists
aldosterone antagonist
diastolic blood pressure , mm hg , mean ± sd
diastolic blood pressure ( mm hg ) , mean ( sd )
systolic blood pressure , mm hg , mean ± sd
systolic blood pressure ( mm hg ) , mean ( sd )
systolic blood pressure , mm hg , mean ( sd )
diastolic blood pressure , mm hg , mean ( sd )
length of stent > median
length of stent < median
£ median ( nmbr . nmbr )
< median ( nmbr . nmbr )
> median ( nmbr . nmbr )
with previous surgery
without previous surgery
corticosteroids
corticosteroid use
no corticosteroid
corticosteroidsa
corticosteroid
full population
full po pulatio n
no epa group n = nmbr
epa group n = nmbr
coronary artery disease — %
coronary artery disease ( % )
olodaterol nmbr m g
olodaterol nmbr mg
baseline : > nmbr . nmbr meq / l eos : < nmbr . nmbr meq / l
baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l
digoxin , ( % )
digoxin , n ( % )
vitamin k antagonists
vitamin k antagonist
off omt ( n = nmbr )
on omt ( n = nmbr )
ticlopidine
ticlopidin
type nmbr diabetes , n ( % )
type nmbr diabetes , n ( % ) d
laba use at screening , n ( % )
lama use at screening , n ( % )
dasnmbr - nmbr ( esr ) < nmbr . nmbr *
dasnmbr - nmbr ( esr ) < nmbr . nmbrt
modified acc / aha lesion class bnmbr / c
modified acc - aha lesion class bnmbr or c
modified acc / aha lesion class bnmbr or cj
modified acc or aha lesion class bnmbr or c
mtss ( nmbr - nmbr )
vas ( nmbr - nmbr )
oad only
diet only
past only
cabg only
dvt only
ptca only
ics only
< nmbr ml / min per nmbr - nmbr mnmbr
> nmbr ml / min per nmbr - nmbr mnmbr
gold stage
gold stage , %
gold stage ii
gold stage iv
gold stage iii
gold stage #
austrafca and new zealand
australia / new zealand
australia and new zealand
simvastatin
pravastatin
subjects $ nmbr years of age , n ( % )
subjects , nmbr years of age , n ( % )
previous mi , n ( % )
previous ami , n ( % )
previous cabg , n ( % )
previous pci , n ( % )
nmbr - nmbr vr — no . ( % )
nmbr - nmbr yr — no . ( % )
nmbr = nmbr yr — no . ( % )
ldl cholesterol , mmol / l 丰
hdl cholesterol , mmol / 冲
hdl cholesterol ( mmol / l )
ldl - cholesterol ( mmol / )
hdl cholesterol ( mmol / l ) :
hdl cholesterol , mmol / l
kdl cholesterol ( mmol / )
ldl - cholesterol ( mmol / l )
hdl cholesterol , ( mmol / l )
ldl cholesterol ( mmol / l ) :
hdl cholesterol , mmol / l *
ldl cholesterol ( mmol / l )
ldl cholesterol , mmol / l
ldl cholesterol , mmol / l *
hdl - cholesterol ( mmol / l )
no renal dysfunction
renal dysfunction
renal function
prebronchodilator fevnmbr , % predicted
postbronchodilator fevnmbr , % predicted
post - bronchodilator fevnmbr , % predicted
< qnmbr ( nmbr . nmbr ) — number / n ( % )
> qnmbr ( nmbr . nmbr ) — number / n ( % )
p valuenmbr
p value * nmbr
eze / simva - nmbryr km rale ( % )
pbo / simva - nmbryr km rale ( % )
age , median ( iqr )
bmi , median ( iqr )
inter .
intense
< nmbr . nmbr kg / mnmbr
nmbr - nmbr kg / mnmbr
> nmbr . nmbr kg / mnmbr
thiazide
thiazides
antiplatelet agents
antiplatelet agent
hemoglobin , g / dl
haemoglobin ( g / dl )
haemoglobin ( g / l )
hemoglobin ( g / dl )
hemoglobin ( gm / dl )
hemoglobin , mg / dl
hemoglobin , g / l
haemoglobin , mg / dl
hemoglobin — g / dl
hemoglobin , g / dlf
usual care ( n = nmbrla )
usual care ( n = nmbra )
usual care ( n = nmbr )
ace - inhibitors , n ( % )
ace inhibitor , n ( % )
total ho population ( n = nmbr )
total population ( n = nmbr )
mean age , years
mean age ( years )
mean age , yrs
mean age ( yrs )
mean age — yr
waist - to - hip , female
waist - to - hip , male
at index acs event
index acs event
chronic bronchitis !
chronic bronchitis
post - bronchodilation fevnmbr
pre - bronchodilation fevnmbr
pre - bronchodilator fevnmbr
lama use at screening
laba use at screening
exetimibe / simvastatin
ezetimibe / simvastatin
cv death , ml , ischemic stroke
cv death , mi , ischemic stroke
cv death , mi , or ischemic stroke
proton pump inhibitors
proton - pump inhibitors
proton - pump inhibitor
proton pump inhibitor use
duration of tnmbrdm ( years )
duration of tnmbrdm , years
duration of tnmbrd ( years )
anti platelet therapy
anti - platelet therapy
no antiplatelet therapy
antiplatelet therapy
antiplatelet therapy §
diastolic blood pressurea , mmhg
systolic blood pressure — mm hg
diastolic blood pressure ( mm hg )
systolic blood pressure , mm hg
systolic blood pressure ( mmhg )
diastolic blood pressure ( mm hg ) :
systolic blood pressurea , mm hg
diastolic blood pressure , mm hg
systolic blood pressure ( mm hg )
diastolic blood pressure , mmhg
diastolic blood pressure - mmhg
diastolic blood pressure ( mmhg )
systolic blood pressure - mmhg
systolic blood pressure , mmhg
diastolic blood pressure — mm hg
mineralocorticoid receptor antagonist
mineralocorticoid receptor antagonists
diet group ( n = nmbr )
stent group ( n = nmbr )
haq - di scoreff
haq - di scored
haq - di score
sirolimus
everolimus
ambulance
in ambulance
p value for heterogeneity
pvalue for heterogeneity
race , while
racea white
nmbr . nmbr - nmbr . nmbr mg / l
nmbr . nmbr - nmbr . nmbr mmol / l
macroalbuminuria , n ( % )
microalbuminuria , n ( % )
womac score
total score
lacunar
vascular
dbp , mm hg , mean ± sdc
sbp , mm hg , mean ± sdc
sbp , mm hg , mean + sdc
mean dlqi score ( nmbr % ci )
mean pasi score ( nmbr % ci )
tc , mmol / l ( mg / dl )
fpg , mmol / l ( mg / dl )
body weight , mean ± sd , kg
body weight , mean = sd , kg
race / ethnicity n ( % )
race / ethnicity , n ( % )
race / ethnicity , no . ( % )
race or ethnicity , n ( % )
arial flutter or fibrillation
atrial flutter / fibrillation
current smoker ( n z nmbr )
current smoker ( n = nmbr )
waist circumference , mean ( sd ) , cm
waist circumference , mean ( sd ) , in
empagliflozin
dapagliflozint
canagliflozin
coronary - artery bypass grafting
coronary artery bypass grafting
coronary artery bypass graft
sex : male
sex , male
sex , % female
sexa male
sex : female
sex , female
sex ( female )
dbp , mean ( sd ) , mm hg
sbp , mean ( sd ) , mmhg
dbp , mean ( sd ) , mmhg
sbp , mean ( sd ) , mm hg
sbp , mean = sd , mmhg
contrast volume ( ml )
contrast volume , ml
crp — mg / liter^
hscrp — mg / liter
omega - nmbr fa intake nmbrnd third
omega - nmbr fa intake nmbrst third
omega - nmbr fa intake nmbr , d third
mean ( sd ) pre - bronchodilator
mean ( sd ) post - bronchodilator
former smoking
former smoker
egfr > nmbr ml / min / nmbr . nmbr mnmbr
egfr > nmbr ml / min / nmbr - nmbr mnmbr
egfr < nmbr ml / min / nmbr . nmbr mnmbr
egfr > nmbr ( ml / min / nmbr . nmbr mnmbr )
egfr < nmbr ml / min / nmbr - nmbr mnmbr
egfr > nmbr ml / min / nmbr . nmbrmnmbr
egfr < nmbr ( ml / min / nmbr . nmbr mnmbr )
egfr < nmbr ml / min / nmbr . nmbr mnmbr *
egfr £ nmbr ml / min / nmbr . nmbrmnmbr
egfr < nmbr ml / min / nmbr . nmbr mnmbr §
egfr < nmbr ml / min / nmbr . nmbrmnmbr
primary outcomes
primary outcome !
primary outcome
nmbr vessel
nmbr vessels
non - st - segment elevation mi
non - st - segment elevation acs
rate ratio ( nmbr % ci )
rate ratio ( nmbr % cl )
extensive colitisy
extensive colitis
lipid - lowering therapy — no . ( % )
lipid - lowering therapy - no . ( % )
patients with at least one concomitant disease *
patients with at least one concomitant disease | |
hyperlipidemia ( % ) §
hyperlipidemia , %
hyperlipidaemia ( % )
hyperlipidemia ( % )
diagnosed diabetes ( n = nmbr )
undiagnosed diabetes ( n = nmbr )
salmeterol ( n[nmbr )
salmeterol ( n [nmbr )
physician ' s judgment that vka inappropriate]
physician ' s judgment that vka inappropriate
female simva
male simva
western europe ( n = nmbr )
eastern europe ( n = nmbr )
elevated creatine kinase - mb ( > nmbr u / l )
elevated creatine kinase mb ( > nmbr u / l )
current tobacco use
no current tobacco use
bare metal
bare - metal
corticosteroid or azathioprine / nmbr - mercaptopurine
corticosteroid - azathioprine / nmbr - mercaptopurine
dapagliflozin nmbr mg
dapagliflozin nmbrmg
empagliflozin nmbr mg
ertugliflozin nmbr mg
ics / lama
ics / laba
ics + laba
duration of disease — yr
duration of disease — mo
eze + statin
pbo + statin
ze + statin
coronary endpoint
coronary end point
patients with baseline crp concentration £ nmbr mg / l
patients with baseline crp concentration < nmbr mg / l
none 一 no . ( % )
score , no . ( % )
score 一 no . ( % )
female simva ( „ = nmbr }
male simva ( „ = nmbr }
aspirin — no . ( % )
aspirin 一 no . ( % )
adas — cog score
adas - cog score *
troponin nmbr at baseline *
troponin nmbr at baseline
lower limb fracture
upper limb fractures
upper limb fracture
lower limb fractures
inflix , yes
inflix , no
east europe
e . europe
western europe
w . europe
eastern europe
w est europe
eastern european
general health
mental health
canakinumab dose ( per mo )
canakinumab dose ( per month )
age ( years ) : < nmbr
age ( years ) : > nmbr
chd status §
chd status
rheumatoid factor positive
rheumatoid factor - positive
priorheartfailure , %
prior heart failure yes
prior heart failure , %
gender , male
gender male
metabolic syndrome * n = nmbr
metabolic syndrome ( n = nmbr )
nonmetabolic syndrome ( n = nmbr )
bmi ( kg / mnmbr )
bmi , kg / mnmbr
bmi , kg / mnmbr , n
bmi ( kg / mnmbr ) *
baseline bmi < nmbr kg / mnmbr
baseline bmi > nmbr kg / mnmbr
duration of assigned regimen before surgery post - randomisation characteristic *
duration of assigned regimen before surgery post - randomisation characteristic * *
asa use at baseline
no asa use at baseline
ics use at baseline
female eze / simva ( „ = nmbr }
male eze / simva ( „ = nmbr }
body mass index , kg / mnmbr , mean + sd
body mass index , kg / mnmbr , mean ( sd )
body mass index , kg / mnmbr , mean ± sd
abdominal obesity *
abdominal obesity
cohort nmbr ( n = nmbr )
cohort nmbr ( n = nmbr ) f
age , median ( nmbrth - nmbrth percentiles ) , y
age , median ( nmbrth — nmbrth percentiles ) , y
baseline hbanmbrc , %
baseline hbanmbrc ( % )
no aminosalicylates , n
aminosalicylates * *
aminosalicylates , n
vildagliptin nmbr mg qd
vildagliptin nmbr mg bid
< nmbr kg / mnmbr ( n — nmbr )
> nmbr kg / mnmbr ( n — nmbr )
baseline ldl - c > nmbr . nmbr to < nmbr . nmbr mmol / lc
baseline ldl - c nmbr . nmbr to < nmbr . nmbr mmol / lc
methotrexate use
methotrexate user
bare metal stent
bare - metal stent
other ( n = nmbr )
other ( n — nmbr )
amputationsa
amputation
p — value for interaction
p - value for interaction *
p value for interactiont
p value for interaction
p - value for interaction
p value for interaction^
p value fo interactio
waisthip ratio
waist - hip ratio
tnglycendes < median
tngtycerides a median
tngtycendes a median
tngtycerides < median
furosemide
torsemide
drinker ( % ) a
drinker ( % )
uncertain
uncerlain
mean diastolic blood pressure , mm hg
mean systolic blood pressure , mm hg
maximum cimt < median
maximum cimt a med an
at clinic diastolic pressure > nmbr mm hg
at clinic systolic pressure > nmbr mm hg
at clinic systolic pressure < nmbr mm hg
at clinic diastolic pressure < nmbr mm hg
thiazolidinediones
thiazolidinedioneb
thiazolidinedione no
thiazolidinedione
thiazolidinedione yes
crcl < nmbr ml / min
crcl > nmbr ml / min
ecrcl < nmbr ml / min
stroke or transient ischemic attack
stroke / transient ischemic attack
hdl cholesterol , mmol / l , women , mean ± sd
hdl cholesterol , mmol / l , men , mean ± sd
disease duration > nmbr years ( n = nmbr )
disease duration b nmbr years ( n = nmbr )
bmi ( kg / rrr )
bmi ( kg / m )
anterior ( n , % )
inferior ( n , % )
blood pressure — mm hg
blood pressure , mm hg
blood pressure — mmhg
blood pressure , mm
blood pressure ( mm hg )
blood pressure ( mmhg )
blood pressure , mmhg
non - st - elevation mi
non - st — elevation mi
non - st - elevation ml
nmbr - nmbr . nmbr : overweight
nmbr - nmbr - nmbr , overweight
intention - to - treat with st - segment - elevation myocardial infarction
intention - to - treat without st - segment - elevation myocardial infarction
no history of cancer
history of cancer
antidiabetic agent
antidiabetic agents
age > = nmbr years old
age < nmbr years old
ics use at baseline : no
ics use at baseline : yes
crp $ nmbr mg / l , n
crp < nmbr mg / l , n
stent thrombosis *
stent thrombosis
high - dosage ics plus laba with baseline blood eosinophils > nmbr cells per pl ( n = nmbr )
high - dosage ics plus laba with baseline blood eosinophils anmbr cells per pl ( n = nmbr )
high - dosage ics plus laba with baseline blood eosinophils < nmbr cells per pl ( n = nmbr )
not hispanic or latino ( n = nmbr )
not hispanic or latino ( n — nmbr )
< nmbr mg / dl simva
> nmbr mg / dl simva
cardiovasculardeath
cardiovascular death !
cardiovascular death
mean body - mass index , kg / mnmbr
mean body mass index , kg / mnmbr
mean body mass index ( kg / mnmbr ) *
mean body mass index ( kg / mnmbr )
anmbr + enmbr ( n = nmbr )
anmbr / nmbr ( n = nmbr )
nmbr - nmbr ( n = nmbr )
mean sd nmbr - h asbp , mm hg
mean ± sd nmbr - h adbp , mm hg
egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr
egfr nmbr – nmbr ml / min / nmbr . nmbr mnmbr
egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr
nmbr - nmbr / month
nmbr - nmbr months
with corticosteroid treatment < nmbr
with corticosteroid treatment > nmbr
postmenopausal , no hrt
postmenopausal and no ht
poslmenopausal , no ht
postmenopausal and no hrt
poslmenopausal , ht
depression
depression^
no depression
concomitant medications
concomitant medication
nmbr blocker
( nmbr - blockers
nmbr blockers
( nmbr blocker
/ nmbr - blockers
, nmbr - blockers
no prior stroke / tia
prior stroke / tia
prior stroke or tia
cv entry criteria
entry criteria
fevnmbr / fvc , % a
fevnmbr / fvc , % *
placebo , % > ( n / n )
placebo , % ( n / n )
mayo < nmbr , n
mayo $ nmbr , n
weight in kg , median ( iqr )
weight - kg , median ( iqr )
weight ( kg ) , median ( iqr )
prior myocardial infarction — no . ( % )
prior myocardial infarction 一 no . ( % )
baseline ics use : no
baseline ics use : yes
tg , median ( min , max )
mtss , median ( min , max )
jsn , median ( min , max )
all - cause mortality or hf hospitalization
all - cause mortality or hf hospitalization^
fbs < nmbr mg / dl
fbs > = nmbr mg / dl
amlodipine / valsartan nmbr / nmbr mg
amlodipine / wlsartan inmbr / nmbr mg
all - cause mortality
all cause mortality
renal insufficiency / failure
renal insufficiency or failure
anticoagulants
anti - coagulants
anticoagulant
oral corticosteroids
oral corticosteroid
prior lower gi clinical event
prior upper gi clinical event
complex anatomy ( n - nmbr , nmbr )
noncomplex anatomy ( n - nmbr , nmbr )
all cana
all cancer
ace inhibitors / arb
ace inhibitor or arb
ace inhibitors and arb
ace inhibitors or arb
ace inhibitors or arbs
ace inhibitors / arbs
physician ' s global assessment
physician ' s global assessment !
previous or current im use : no
previous or current cs use : no
nyha class , n ( % ) i
nyha class , n ( % )
nyha class , n ( % ) ii
nyha class , ( % )
baseline heart rate ( beat / min )
baseline heart rate ( beats / min )
concomitant medications , %
concomitant medication | |
metabolic syndrome , ! n ( % )
metabolic syndrome , n ( % )
body weight ( kg )
body weight , %
body weight , kg
body weight — kg
bodyweight ( kg )
body weighta , kg
fev_ ( l ) :
fvc , l
"fvc ( l ) ;"
fvc ( l ) *
fvc ( l )
no fracture history
fracture history
nmbr to < nmbr ml / min
> nmbr to < nmbr ml / min
nmbr - < nmbr ml / min
nmbr - nmbr ml / min
met criterion at blt ( n [ % ] )
met criterion at bl ( n [ % ] )
( % ) ( nmbr . nmbr )
( % ) ( nmbr - nmbr )
post - bronchodilator fevnmbr reversibility , % a
postbronchodilator fevnmbr reversibility , %
post - bronchodilator fevnmbr reversibility , %
cigarette smoking
cigarette smoker
daily dose nmbr mg n = nmbr
daily dose > nmbr mg n = nmbr
female ( n = nmbr , nmbr )
male ( n = nmbr , nmbr )
hemoglobin ( g rnmbr )
hemoglobin ( g nmbr ! )
with lipid - lowering agents
without lipid - lowering agents
macroalbuminuria
macroalbuminuriaf
microalbuminuria
macro - albuminuria
micro - albuminuria
egfr ( ml / min per nmbr - nmbr mnmbr )
egfr ( ml / min per nmbr - nmbr mnmbr ) t
macroalbuminuria — no . / total no . ( % )
microalbuminuria — no . / total no . ( % )
chd simva
no chd simva
> nmbr . nmbr mu / l $ mmol / l
< nmbr . nmbr mu / l $ mmol / l
stage nmbra : > = nmbr and < nmbr
stage nmbrb : > = nmbr and < nmbr
canakinumab , hscrp > nmbr - nmbr mg / l at nmbr months ( n = nmbr )
canakinumab , hscrp < nmbr - nmbr mg / l at nmbr months ( n = nmbr )
post - bronchodilator screening fevnmbr ml
pre - bronchodilator screening fevnmbr ml
"duration of hypercholesterolaemia ; mean ± sd ( year )"
"duration of hypercholesterolemia ; mean ± sd ( years )"
< nmbr with no historical count > nmbr
< nmbr with historical count > nmbr
baseline hbalc > nmbr . nmbr % ( nmbr mmol / mol ) nmbr
baseline hbalc < nmbr . nmbr % ( nmbr mmol / mol ) nmbr
difference from placebo ( nmbr % ci )
difference from placebo * ( nmbr % ci )
central eosinophil count ( cells per pl )
central eosinophil count ( cells per pl ) t
other anti - platelet agents
other antiplatelet agents
other forms of atherosclerosis^
other forms of atherosclerosis ’
race or ethnic group , no . ( % )
race or ethnic group — no . ( % ) f
prior smoker
prior stroke
no prior stroke
gender , n ( % )
gender , no . ( % )
coronary heart disease , n ( % ) b
coronary heart disease , n ( % ) t
mean ± s . d . fpg
mean ( s . d . ) fpg
troponin i ( pg / ml )
troponin t ( pg / ml )
> nmbr ml / min / nmbr . nmbrmnmbr
≥ nmbr ml / min / nmbr . nmbr mnmbr
< nmbr ml / min / nmbr . nmbrmnmbr
< nmbr ml / min / nmbr . nmbr mnmbr
> nmbr ml / min / nmbr . nmbr mnmbr
ischemia - driven revascularization
ischemia driven revascularization
timi minor
timi major
history of major microvascular disease , n ( % )
history of major macrovascular disease , n ( % )
pre - bronchodilation fvc
post - bronchodilation fvc
nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr )
nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr )
nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr )
history of macrovascular disease ( % )
history of microvascular disease ( % )
patient characteristics
patients ' characteristics
treatment with anti - platelet drugs
treatment with antiplatelet drugs
concomitant medications , * n ( % )
concomitant medication , n ( % )
concomitant medications , n ( % )
fpg , mean ( sd ) , mg / dl
fpg , mean ( sd ) , mg / dlt
one - vessel disease
two - vessel disease
ethnicity
ethnicity ,
ind / glyb n = nmbr
ind / gly n = nmbr
non - hispanic / latino
not hispanic or latino
not hispanic / latino
north american
north america
south africa
south american
sou ti africa
south america
northamerica
bloodpressure , mean ( sd ) , m m hg
blood pressure , mean ( sd ) , mm hg
tiotropium / olodaterol nmbr . nmbr / nmbr mg
tiotropium + olodaterol nmbr . nmbr / nmbr mg
tiotropium + olodaterol nmbr . nmbr / nmbr pg
diastolic bp , mmhg ( sd )
systolic bp , mmhg ( sd )
postamendment
preamendment
fasting glucose — mg / dl
fasting glucose ( mg / dl )
fasting glucose ( mg / dl ) ,
mean systolic bp , mmhg , mean = sd
mean diastolic bp , mmhg , mean = sd
number of prior aeds , n ( % ) b
number of prior aeds , n ( % )
mean ( sd ) sdai *
mean ( sd ) cdai *
age > nmbr yearsnmbr
age < nmbr yearsnmbr
baseline systolic blood pressure ( mm hg )
baseline diastolic blood pressure ( mm hg )
adp antagonist
tnf antagonist
comorbidities
co - morbidities
vildagliptin nmbr mg bid n = nmbr
vildagliptin nmbr mg qd n = nmbr
migraine with aura
migraine without aura
previous cancer
previous cancerc
lipid - lowering drugs
lipid - lowerinq druq
lipid - lowering drug
des type
acs type
fevnmbr ( post - albuterol ) , l
fevnmbr , pre - albuterol , l
fevnmbr ( pre - albuterol ) , l
fevnmbr , post - albuterol , l
p blockers ( % )
p - blocker ( % )
severe or very severe
severe / very severea
difference ( nmbr % cl )
difference ( nmbr % ci ) *
nmbr months
nmbr mentis
nmbr mortis
> nmbr months
< nmbr months
nmbr montlts
seated sbp , mean ( sd ) , mmhg
seated dbp , mean ( sd ) , mmhg
alcohol abuse
alcohol use
> nmbr microg / l
< nmbr microg / l
tobacco abuse
tobacco use
hospital stay ( days )
hospital stay , days
fevnmbr — % of predicted value
fevnmbr ( % of predicted value )
maternal history , n ( % )
paternal history , n ( % )
plp - c , mean ( sd ) , mg / dl
ldl - c , mean ( sd ) , mg / dl
hdl - c , mean ( sd ) , mg / dl
nmbr drinks / wk
> nmbr drinks / week
nmbr + drinks / wk
> nmbr drinks / wk
prior hypertension yes
prior hypertensiona yes
drug - related ae *
drug - related teaes *
subgroup p valuef
subgroup p value 本
white ethnic origin
while ethnic origin
> nmbr yr since menopause
< nmbr yr since menopause
ls mean difference ( nmbr % ci )
( mean difference , nmbr % ci )
( mean % difference , nmbr % ci )
reversibility : < nmbr %
reversibility : > nmbr %
male eze / simva
all ez / simva
female eze / simva
glycated hemoglobin - % ’
glycated hemoglobin , %
glycated hemoglobin ( % )
glycated hemoglobin — %
glycated haemoglobin ( % )
anmbrc ( mmol / mol )
hbanmbrc , mmol / mol
hbanmbrc ( mmol / mol )
arterial hypertension *
arterial hypertension
intervention
interruption
waist circumference ( cm )
waist circumference — cm
waist circumference , ( cm )
waist circumference , cm
dbp ( mm hg ) , median ( iqr )
sbp ( mm hg ) , median ( iqr )
total cholesterol , mg / dl
total cholesterol — mg / dl
total cholesterol ( mg / dl )
toial cholcsierol ( mg / dl )
total cholesterol , mg / dl^
no change
% change
> nmbr ml / min
£ nmbr ml / min
< nmbr ml / min
smoking history ( pack - years )
smoking history , pack - years
smoking history ( pack - yr )
dm + ( aliskiren vs . placebo )
dm - ( aliskiren vs . placebo )
without beta blocker
with beta blocker
timi risk score !
timi risk score
timi risk score , %
angiotensin - converting enzyme inhibitor
angiotensin - converting - enzyme inhibitor
total asthma symptom score
total asthma symptom score :
diastolic bp , mmhg , mean ± sd
systolic bp , mmhg , mean ± sd
uric acid fertile nmbr ( > nmbr . nmbr mg / dl )
uric acid tertile nmbr ( < nmbr . nmbr mg / dl )
uric acid tertile nmbr ( > nmbr . nmbr mg / dl )
> nmbr . nmbr mmol / liter
> nmbr . nmbr mg / liter
< nmbr . nmbr mg / liter
< nmbr . nmbr mmol / liter
< nmbr . nmbr pmol / liter
age ( years ) - < median ( n = nmbr , nmbr )
age ( years ) - > = median ( n = nmbr , nmbr )
macrovascular disease , n ( % )
microvascular disease , n ( % )
vorapaxar ( n = nmbr . nmbr )
vorapaxar ( n = nmbr nmbr )
vorapaxar ( n = nmbr , nmbr )
risk difference
lsm difference
aspirin ( n = nmbr , nmbr )
aspirin ( n = nmbr nmbr )
rosuvastatin
rosuvastatin +
metformin use
no metformin use
copd severity , n ( % ) a
copd severity , n ( % )
copd severity , n ( % ) *
prior revascularization
pci revascularization
ldl - c : hdl - c
ldl - c / hdl - c
ldl - c / hdl - cx
oral agents
two agents
ras agents
mean ( sd ) fevnmbr ( l ) pre - bronchodilator
mean ( sd ) fevnmbr ( l ) post - bronchodilator
< nmbr years simva ( n = nmbr }
> nmbr years simva ( „ = nmbr }
bmi > nmbr kg / mnmbr
bmi < nmbr kg / mnmbr
bmi , xnmbr kg / mnmbr
bmi < nmbrkg / mnmbr
bmi > = nmbrkg / mnmbr
bmi , median ( sd ) , kg / mnmbr
bmi , mean ( sd ) , kg / mnmbr
physical function
physical functioning
ldl - c ( mg / dl )
hdl - c ( mg / dl )
hdl - c , mg / dl
ldl - c , mg / dl
regular aspirin use
no regular aspirin use
> nmbr beats / min
< nmbr beats / min
antiplatelets
antiplatelet
characteristics
characteristic
hypokalemia
hvookalemia
hyperkalemiab
hungary
surgery
baseline uacr < nmbr mg / g
baseline uacr > nmbr mg / g
insulin plus nmbr oral agent
insulin plus > nmbr oral agent
long - acting nitrates
long acting nitratef
long - acting nitrate
ischaemic aetiology
ischemic aetiology
systolic blood pressure , mean ( sd ) , mm hga
systolic blood pressure , mean ( sd ) , mm hg
hscrp < nmbr . nmbr mg / l
hscrp > nmbr . nmbr mg / l
hscrp > nmbr . nmbr mga .
hs - crp > nmbr . nmbr mg / l
hs - crp < nmbr . nmbr mg / l
hs - crp < nmbr . nmbr g / l
creatinine clearance , ml / min
creatine clearance , ml / min
creatinine clearance ( ml / min )
total cholesterolnmbr < nmbr mg / dl
total cholesterolnmbr > nmbr mg / dl
rosuvastatin , n ( rate )
rosuvastatin n ( rate ) *
rosuvastatin n ( rate )
tiotropium / olodaterol nmbr / nmbr mg
tiotropium + olodaterol nmbr / nmbr mg
tiotropium + olodaterol nmbr / nmbr pg
diastolic blood pressure
diastolic blood pressure ,
systolic blood pressure
systolic blood pressure ,
cardiac failure *
cardiac failure §
cardiac failure
major cardiovascular event
major cardiovascular event *
major cardiovascular events
no concomitant immunosuppressive and / or prior anti - tnf use
concomitant immunosuppressive and / or prior anti - tnf use
triglycerides - mg / dl * *
triglycerides ( mg / dl ) * *
nmbr - nmbr months , n ( % )
nmbr - < nmbr months , n ( % )
received nmbr prior biologic therapies , n
received nmbr prior biologic therapy , n
immunosuppressants onlyff
immunosuppressants only
mtx > nmbr mg / week
mtx £ nmbr mg / week
active smoking
active smoker
cardiovascular risk factors , no . ( % )
cardiovascular risk factors , n ( % )
demographic
demographics
demography
no stroke ( n = nmbr )
any stroke ( n = nmbr )
left main
back pain
neck pain
rest pain
< nmbr mg / dl eze / simva
> nmbr mg / dl eze / simva
no st depression or elevation
st depression or elevation
medication use at baseline , n ( % )
medications at baseline , n ( % )
history of atrial fibrillation or fl utter
history of atrial fibrillation / flutter
statin without other llt
statin with other llt
< qnmbr ( nmbr ) — number / n ( % )
> qnmbr ( nmbr ) — number / n ( % )
time from qualifying mi , %
time from qualifying mi , yrs
prior history of ml or ischemic stroke
prior history of mi or ischaemic stroke
hazard ratio ( nmbr % confi dence interval )
hazard ratio ( nmbr % confidence interval )
hazard ratio ( nmbr % confidence interval ) *
with antiplatelets
without antiplatelets
range , ( min , max )
range : min , max
range ( min , max )
aml nmbr mg / hctz nmbr mg
om nmbr mg / hctz nmbr mg
insulin therapy
noninsulin therapy
mean ± sd , n
mean ± sd ( yr )
mean ± sd ( n )
stage nmbr : > nmbr ml / min / nmbr . nmbr mnmbr
stage nmbr : < nmbr ml / min / nmbr . nmbr mnmbr
median ( qnmbr , qnmbr )
median ( qnmbr : qnmbr )
bmi category ( % )
age category ( % )
supplementary oxygen
supplemental oxygen
fvc ( liters )
fvc — liters
> nmbr years of age
< nmbr years of age
$ nmbr exacerbations
nmbr exacerbation
> nmbr exacerbations
nmbr exacerbations
history of mi ( n = nmbr , nmbr )
no history of mi ( n = nmbr , nmbr )
vka therapy
dual therapy
egfr , mean ( sd ) , ml / min / nmbr . nmbr mnmbr
egfr , mean = sd , ml / min / nmbr . nmbr mnmbr
nt - probnp ， pmol / h
nt - probnp , pmol / l^
nt - probnp , pmol / l
antihypertensive
antihypertensives
gender , n ( % ) male
gender , n [ % ] male
ldl - c ( mmol / l , mean )
hdl - c ( mmol / l , mean )
all patients ( « = nmbr nmbr )
all patients ( n = nmbr , nmbr )
eastern europe ( % )
western europe ( % )
om nmbrmg / aml nmbr mg
om nmbr mg / aml nmbr mg
ischaemic heart disease
ischemic heart disease
hbanmbrc , mean ( sd ) , %
hbanmbrc , mean = sd , %
hbanmbrc , median ( sd ) , %
asia pacific
asia - pacific
asia / pacific
previous coronary revascularization
previous coronary revascularisation
corticosteroid use at baseline - no
corticosteroid use at baseline - yes
fevnmbr reversibility , % *
fevnmbr reversibility , % b
serum triglycerides — mmol / liter
serum triglycerides — pmol / liter
angina pectoris
angina pectoris 本
angina pectoris *
angina pectorisf
alc > = nmbr . nmbr %
alc < nmbr . nmbr %
major bleeding
minor bleeding
a from baselineb
a from baseline
bmi : < nmbr . nmbr kg / mnmbr
bmi : > nmbr . nmbr kg / mnmbr
mayo score , mean ( sd )
mayo score ( mean ± sd )
total ( n = nmbr nmbr )
total , n = nmbr nmbr
total ( n = nmbr , nmbr )
> median ( nmbr . nmbr years ) — number / n ( % )
< median ( nmbr . nmbr years ) — number / n ( % )
difference vs placebo * *
difference vs placebo '
difference vs . placebo
difference vs placebo
avm % △ ( se )
met % △ ( se )
chronic kidney diseased
chronic kidney disease
estimated difference %
estimated difference
u . s . site
u . s . sites
history of diabetes ( n = nmbr )
no history of diabetes ( n = nmbr )
< nmbr months , median ( min , max )
> nmbr months , median ( min , max )
posterior circulation
anterior circulation
insulin yes
insulin use
insulin based
non - black race and ss > nmbr ( n = nmbr vs nmbr )
non - black race and ss < nmbr ( n = nmbr vs nmbr )
family history of diabetes ( % ) *
family history of diabetes ( - )
family history of diabetes ( + )
duration of diabetes , years
duration ofdiabetes — yr
duration of diabetes ( years )
duration of diabetes — yr
duration of diabetes , yrs
duration of diabetes ( y )
duration of diabetes ( years ) t
duration diabetes ( years )
at index event
index event
moderate ckd
moderate ’
moderatey
no moderate ckd
moderate
weight < nmbr . nmbr kg , n
weight $ nmbr . nmbr kg , n
history of microvascular disease
history of macrovascular disease
disease duration , years
disease duration ( years )
disease duration ( yr )
glycated hemoglobin , nonstandardized level — %
glycated hemoglobin , standardized level — %
baseline characteristics
baseline characteristic
patients without chronic
patients with chronic
baseline egfr < nmbr ml / min / nmbr . nmbr mnmbr
baseline egfr < nmbr ml / min / nmbr . nmbr mnmbrc
baseline egfr > nmbr ml / min / nmbr . nmbr mnmbr
ldl - c , mean ( sd )
tchdl - c , mean ( sd )
hdl - c , mean ( sd )
symptomatic pad
symptomatic padt
statin during admission
no statin during admission
rosuvastatin events / patients ( % )
rosuvastatin , events / patients ( % )
average weekly mtx dose ( mg / week )
average weekly mtx dose ( mg / week ) t
all teaes *
all teaes
mild teaes
sbp , mean ± sd ( mmhg )
dbp , mean ± sd ( mmhg )
death ( all - cause )
death ( all cause )
qnmbr : > nmbr . nmbr kg ( n = nmbrvsnmbr )
qnmbr : < nmbr . nmbr kg ( n = nmbrvsnmbr )
"> = nmbr years ( placebo n = nmbr , nmbr ; saxagliptin n = nmbr , nmbr )"
"< nmbr years ( placebo n = nmbr , nmbr ; saxagliptin n = nmbr , nmbr )"
without psoriasis ( zi = nmbr , nmbr )
without psoriasis ( n = nmbr , nmbr )
heart rate > nmbr bpm
heart rate < nmbr bpm
inferior
non - anterior
nonanterior
not anterior
anterior
hyperlipidaemia
hyperlipidemia
hyperlipidemia^
left - sided colitisz
left sided colitis
left - sided colitis
nadroparin ( n = nmbr )
no nadroparin ( n = nmbr )
social functioning
social function
eze / simva
ez / simva
aniagonisi
antagonist
all - cause death n
all - cause death
family history of cancera
family history of cancerf
indacaterol nmbr mg
indacaterol nmbr pg
p , regional difference
p , regional difference *
liraglutide nmbr . nmbr mg , n = nmbr
liraglutide nmbr . nmbr mg n = nmbr
liraglutide nmbr - nmbr mg ( n = nmbr )
liraglutide nmbr . nmbr mg ( n = nmbr )
fevnmbr pre - bronchodilator
fevnmbr post - bronchodilator
ace inhibitors / arbs , n ( % )
ace - inhibitors / arbs , n ( % )
increase creatinine , < nmbr . nmbr mg / dl
increase creatinine , > nmbr . nmbr mg / dl
> nmbr . nmbr ( % )
< nmbr . nmbr ( % )
baseline lipid and lipoprotein values
baseline lipid / lipoprotem values
baseline lipid / lipoprotein values
previous stroke *
previous stroke
hypertension — no . ( % )
hypertension — no . ( % ) |
overall ( n = unmbr )
overall ( n = nmbr )
history of diabetes :
history of diabetes
beta - blockers , n ( % )
beta - blockers , ( % )
history of hypertension *
history of hypertension
ischemic heart disease , ( % )
ischemic heart disease , n ( % )
ischaemic heart disease , n ( % )
patients receiving enl , no . ( % )
patients receiving lcz , no . ( % )
urinary albumin : creatinine ratioa ( mg / g )
urinary albumin : creatinine ratio ( mg / g )
indian ( american ) or alaska native
indian ( american ) or alaskan native
saxagliptin nmbr mg
saxagliptin nmbrmg
mssbp < nmbrmmhg
mssbp > nmbrmmhg
infarct localisation
infarct localization
placebo group ( n = nmbr )
placebo group ( n = nmbr ) f
sjc ( nmbr joints )
sjc ( / nmbr joints )
tjc ( / nmbr joints )
tjc ( nmbr joints )
oral anticoagulants
oral anticoagulant
ischemia
ischaemic
disease characteristics
disease characteristics *
nyha functional class
ara functional class
teaes ( > nmbr % in any treatment group ) *
teaes ( > nmbr % in any treatment group )
history myocardial infarction
history of myocardial infarction
acq - nmbr score *
npi - nmbr score *
acq - nmbr scoret
nmbr - h ppg ( mmol / l )
nmbr - h ppg ( mmol / l ) *
nmbr - h pg ( mmol / l )
fvc post - bronchodilator
fvc pre - bronchodilator
baseline su dose < nmbr / nmbr maximal
baseline su dose > nmbr / nmbr maximal
mean sd ldl - c , mg / dl
mean sd hdl - c , mg / dl
laa closure
pfo closure
cdai < nmbr . nmbr *
sdai < nmbr . nmbr *
nyha class — no . ( % ) $
nyha class — no . ( % )
drug - eluting
drug eluting
homa - p
homa - ir
no . of patients with psa
no . of patients with ra
no . of patients with as
ng ( n = nmbr , nmbr )
no ( n = nmbr , nmbr )
nmbr ( n = nmbr , nmbr )
sf - nmbrvnmbr mcs , mean [sd]
sf - nmbrvnmbr pcs , mean [sd]
regular ppi use
no regular ppi use
hospitalization for acs
hospitalization for
hospitalization for hf
pbo + mtx to mtx
czp + mtx to mtx
tg , mg / dl , mean ± sd
tc , mg / dl , mean ± sd
tc , mg / dl , mean + sd
aiirocumab
alirocumab
hispanic or latino ethnic groupf
hispanic or latino ethnic group !
hispanic or latino ethnic groupb
hispanic or latino ethnic group *
prior aspirin
no prior aspirin
medication , n ( % )
medications , n ( % )
medication — no . ( % )
medications . no . ( % )
medications , no . ( % )
eze + statin n = nmbr
pbo + statin n = nmbr
incidence *
incidence , %
incidencea
asia , pacific and other
asia pacific or other
asia pacific and other
apo b : apo a - i ratio
apob : apoal ratio
apob : apoa - l ratio
saxa + met n = nmbr
dapa + met n = nmbr
patients with uncomplicated events
patients with complicated events
sf - nmbr mcs , mean ± sd
sf - nmbr pcs , mean ± sd
systolic blood pressure subgroups
diastolic blood pressure subgroups
losartan , n / n ( % )
valsartan , n / n ( % )
persistent
persistent af
ukpds nmbr - year risk score < nmbr %
ukpds nmbr - year risk score > nmbr %
sirolimus - eluting
everolimus - eluting
immunosuppressants
immunosuppressant^^
hdl - c , mg / dl , mean ± sd
ldl - c , mg / dl , mean + sd
ldl - c , mg / dl , mean ± sd
hdl - c , mg / dl , mean + sd
medication use
medication
education *
medications *
medications
sgrq total score * ( units )
sgrq total score , units
sgrq total score ( units )
weight , median ( sd ) , kg
weight , mean ( sd ) kg
weight , median ( iqr ) , kg
weight , mean ( sd ) , kg
diclofenac nmbr mg ( n nmbr nmbr ) , . . . n . . ( . % . . ) . . . . . . . . . . . .
diclofenac nmbr mg ( n nmbr nmbr ) , . . . n . . ( . % . . ) . . . . . . . . . . .
total no .
total body
ind / gly ( n = nmbr )
ind + pbo ( n = nmbr )
ind + gly ( n = nmbr )
score of $ nmbr , no . ( % )
score of # nmbr , no . ( % )
body - mass index ( kg / m ' )
body - mass index ( kg / m - ) !
body - mass index ( kg / m - )
"time to treatment initiation ( min ;"
time to treatment initiation ( min )
patients with microalbuminuria at baseline
patients with macroalbuminuria at baseline
atrial fibrillation !
atrial fibrillation , %
atrial fibrillation
atrial fibrillation ( % )
prior tnf antagonist treatment - no
prior tnf antagonist treatment - yes
pt baseline ( week nmbr )
db baseline ( week nmbr )
odds ratio ( nmbr % ci )
odds ratio ( nmbr % cl )
ethnicity , n ( % )
ethnicity , no . ( % )
ethnicity - no . ( % )
pacemaker , n ( % )
pacemaker , ( % )
physical examination
physical examinations
ileum and colon
ileum or colon
killip class > ii ( % )
killip class , n ( % )
qrs < nmbr msec
qrs > nmbr ms *
hbanmbrc , % , mean ( sd ) b
hbanmbrc , % , mean ( sd )
hbanmbrc , % , mean ± sd
< nmbr % blood eosinophils at baseline
> nmbr % blood eosinophils at baseline
czp nmbr mg ( n nmbr )
czp nmbr mg ( nnmbr )
age ( median , iqr ) , y
age , median ( iqr ) , y
atrial fibrillation / flutter
atrial fibrillation or flutter
metformin
no metformin
q wave
q wave mi
q - wave mi
hand fracture
hip fracture
canagliflozin ( n = nmbr )
empagliflozin ( n = nmbr )
smoking history
smoking history ,
post - bronchodilator fevnmbr / fvc , %
postbronchodilator fevnmbr / fvc , %
smoker ( % )
smoker ( % ) a
ast , u / l
alt , u / l
non - hdl - c , mmol / l
non - hdl - c ( mmol / l )
menopause and ht
menopause and hrt
minimum - maximum
minimum : maximum
patients < nmbr %
patients > nmbr %
women ( n = nmbr vs nmbr )
men ( n = nmbr vs nmbr )
men ( n = nmbr nmbr )
diastolic — mean ( sd ) ( mm hg )
systolic — mean ( sd ) ( mm hg )
active cancer
no active cancer
ac tve cancer
physical activity , kcal / wk
physical activity , kcal / wk *
loop or thiazide diuretic
loop or thiazide diuretic #
alcohol use , drinks / wk
alcohol use , drinks / wk *
total population
total population n
interruption ( n = nmbr )
intervention ( n = nmbr )
non - st - segment elevation myocardial infarction
non — st - segment — elevation myocardial infarction
% risk reduction ( nmbr % ci )
risk reduction ( nmbr % cl )
use of beta - blocker
use of beta - blockers
hf hospitalization
hf hospitalization n
hospitalization
r elative risk ( nmbr % ci )
relative risk ( nmbr % ci )
relative risk ( nmbr % cl )
> nmbr . nmbr ( n — nmbr )
< nmbr . nmbr ( n — nmbr )
mi > nmbr months *
mi < nmbr months *
> nmbr months — number / n ( % )
< nmbr months — number / n ( % )
all n = nmbr , nmbr
all n = nmbr nmbr
any clinical or lesion rf for st
no clinical or lesion rfs for st
neuropathy
nephropathy
hbanmbrc > nmbr % ( n nmbr nmbr )
hbanmbrc < = nmbr % ( n nmbr nmbr )
am △ 士 s . e .
ama 士 s . e .
im or cs use : no
im and cs use : no
hdlnmbr - c
ldlnmbr - c
at randomization
randomization
to randomization
> nmbr years simva
< nmbr years simva
simvastatin nmbr mg ( n = nmbr ) *
simvastatin nmbr mg ( n = nmbr )
hispanic or latino ( n — nmbr )
hispanic or latino ( n = nmbr )
copd exacerbation : yes
copd exacerbation : no
hdl cholesterol > nmbr - nmbr mmol / l
ldl cholesterol < nmbr - nmbr mmol / l
ldl cholesterol > nmbr - nmbr mmol / l
hdl cholesterol < nmbr - nmbr mmol / l
sex , female , n ( % )
sex ( male ) , n ( % )
sex , male , n ( % )
sex , male , no . ( % )
adjusted p - value for interaction
unadjusted p - value for interaction
no chd eze / simva
chd eze / simva
aspirin use ( p = nmbr - nmbrt )
aspirin use ( p = nmbr - nmbr 十 )
dapagliflozin nmbr mg ( n = nmbr )
ertugliflozin nmbr mg ( n = nmbr )
empagliflozin nmbr mg ( n = nmbr )
prior coronary artery bypass grafting
prior coronary artery bypass graft
cholesterol ( mmol / l )
cholesterol , mmol / l
fevnmbr , litres ( pre ipratropium ) , mean ( sd )
fevnmbr , litres ( post ipratropium ) , mean ( sd )
insulin ( pmol / l )
insulin , pmol / l
proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - < median ( n = nmbr , nmbr )
proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - > = median ( n = nmbr , nmbr )
( mmol / l]
mmol / mol
mmol / l
wc ( cm )
rr ( cl )
patient ' s global assessment
patient ' s global assessment !
patient ' s global assessment of
no epa group no . of events ( % )
epa group no . of events ( % )
nitrates , ( % )
nitrates , n ( % )
cox hr ( nmbr % ci )
cmh rr ( nmbr % ci )
coronary revascularization
coronary revascularisation
n - nmbr pufa ( n = nmbr )
n - nmbr - pufa ( n = nmbr )
antihypertensive agents
antihypertensive agents *
mean ( sd ) , y
mean ( sd ) bmi
non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = nmbr , nmbr )
non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = nmbr , nmbr )
aldosterone blocker
aldosterone blockers
adjusted hr ( nmbr % ci )
adjusted hr ( nmbr % cl )
cohort nmbr ( uacr < nmbr . nmbr mg / g )
cohort nmbr ( uacr > nmbr . nmbr mg / g )
no extensive colitis , n
extensive colitis , n
prior migraine
prior migraine *
primary endpoint death / mi / idr / st
primary end point : death / mi / idr / st
difference from placebo
difference from placeboa
difference from placebo ¥
standing after nmbr minute change from baseline
standing after nmbr minutes change from baseline
american indian or alaskan native
american indian / alaska native
american indian or alaska native
multiracial
multi - racial
aqlq ( s ) + nmbr scored
aqlq ( s ) + nmbr scorets
antiarrhythmic
anti arrhythmic
ct findings
ecg findings
lipoprotein ( a ) ( nmol / l )
lipoprotein ( a ) ( mmol / l )
baseline . mean _ sd , mg / dl
baseline . mean _ sd . mg / mg
baseline . mean _ sd . mg / dl
≤ nmbr u / kg / day
> nmbr u / kg / day
valsartan
bosentan
losartan
history of stroke
history of stroke *
patients without syndesmophytes at baseline
patients with syndesmophytes at baseline
lipid - lowering
lipid lowering
stratum ii
stratum i
aaponmbr at rest , mm hg
paonmbr at rest , mm hg
mean ( s . d . ) systolic blood pressure , mm hg
mean ( s . d . ) diastolic blood pressure , mm hg
> nmbr to < nmbr h , n ( % )
nmbr to < nmbr h , n ( % )
coronary artery disease^
coronaiy artery disease
coronary artery disease
> o - nmbr - i - i
> o - nmbr - ii
egfr , ml / min / nmbr . nmbr mnmbr , mean ( sd )
egfr , ml / min / nmbr . nmbr mnmbr , mean ± sd
baseline fevnmbr
baseline fevnmbr #
nmbr ( n nmbr nmbr )
nmbr mg ( n nmbr nmbr )
respiratory rate , breaths / min
respiratory rate ( breaths / min )
karnofsky score < nmbr
karnofsky score 竺 nmbr
ldl - csmedian
ldl - c > median
non - hdl - c *
non - hdl - c
duration of pci — min
duration of pci , min
mean ( s . d . ) bmi , kg / mnmbr
mean ± s . d . bmi , kg / mnmbr
baselinec
( baseline )
baselineb
baseline ,
baseline
< nmbr . nmbr % ( nmbr mmol / mol )
≥ nmbr . nmbr % ( ≥ nmbr mmol / mol )
inferior ( % )
anterior { % )
age group , no . ( % )
age group , n ( % )
qualifying mi < nmbr yrs prior
qualifying mi $ nmbr yrs prior
hawaiian / pacific islander
hawaiian pacific islander
bl mean ( mmhg )
bl mean ( cm )
no or unknown
no / unknown
loop diuretic
loop diuretics
non diuretics
esam ( ng / ml )
ngal ( ng / ml )
fevnmbr / fvc
fevnmbr / fvc %
history of diabetes ( a )
history of diabetes ( % )
age : < nmbr years ( n = nmbr )
age < nmbr years ( n = nmbr )
age , years , mean ( range )
age , years : median ( range )
metabolic syndrome ( % ) b
metabolic syndrome ( % )
peripheral artery disease — no . ( % )
peripheral - artery disease — no . ( % )
aiorvasiaiin
atorvastatin
epa ( mol % )
aa , mol %
epa , mol %
cardiovasculardeath / myocardial infarction / stroke
cardiovascular death / myocardial infarction / stroke
m o nito ring treatment
monitoring treatment
baseline focal seizure frequency / nmbr days , median ( qnmbr , qnmbr )
baseline focal seizure frequency / nmbr days , median ( qnmbr - qnmbr )
thiazide diuretics
thiazide diuretic
diabetes present nmbr ( nmbr . nmbr )
diabetes absent nmbr ( nmbr . nmbr )
baseline medication
baseline cv medications
baseline medications
calcium aniagonisi
calcium antagonist
calcium antagonists
at qualifying event
qualifying event
nmbr - nmbr . nmbr : obese class ii
nmbr - nmbr . nmbr : obese class i
white race — no . ( % ) f
white race — no . ( % ) : t
white race — no . ( % ) :
ileocolon
lleocolon
tiotropium nmbrmg ( n = nmbr
tiotropium nmbr mg ( n = nmbr )
multi - vessel coronary artery disease
multivessel coronary artery disease
mean ± sd msdbp , mm hg
mean sd mssbp , mm hg
mean age , y ( sd )
mean age ( y ) ( sd )
age in nmbr classes
egfr in nmbr classes
heart rate , bpm
heart rate — bpm
heart rate ( bpm )
biguanide ( metformin )
biguanides ( metformin )
naive : no
naive : yes
no steroids ( n = nmbr vs nmbr )
steroids ( n = nmbr vs nmbr )
secondary ' outcomes
secondary outcomes
clopidogrel
clopiodogrel
antiplatelet - onl group ( n = nmbr )
antiplatelet - only group ( n = nmbr )
myopathyt
myopathy
baseline hdl - c in nmbr classes
baseline trl - c in nmbr classes
with diabetes
without diabetes
treated vessel
treated vessel !
estimated glomerular filtration rate - ml / min / nmbr . nmbrmnmbrtt
estimated glomerular filtration rate ( ml / min / nmbr . nmbrmnmbr )
inferior or posterior
inferior / posterior
weight > nmbr kg
weight < nmbr kg
systolic ( mean , sd )
diastolic ( mean , sd )
tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr
tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr
patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr at baseline
patients with egfr < nmbr ml / min / nmbr . nmbrmnmbr at baseline
baseline hbanmbrc > nmbr . nmbr %
baseline hbanmbrc < nmbr . nmbr %
nmbr . nmbr - nmbr . nmbr % f
nmbr . nmbr - nmbr . nmbr % t
number of stents
number of patients
tjc ( nmbr joints ) , mean ( sd )
sjc ( nmbr joints ) , mean ( sd )
body mass index , median ( iqr ) b
body mass index , median ( iqr )
all other
all others
secondary *
secondary pci
no . of prior aeds , n ( % )
no . of prior aeds , c n ( % )
( mean change , nmbr % ci )
( mean % change , nmbr % ci )
hazard ratiof
hazard ratio
prior myocardial infarction yes
prior myocardial infarction , %
dpp - nmbr inhibitor
dpp - nmbr inhibitors
ldl - c / hdl - c ratio
ldl - c : hdl - c ratio
modified has - bled $ nmbr
modified has - bled < nmbr
subgroup
subgroups
old stroke *
new stroke *
low risk
lower risk
high - intensity statin
high - intensity statin *
no high - intensity statin
smoker , ! n ( % )
smokers , n ( % )
ics use yes / no , %
ics use , yes / no %
ics use , yes / no , %
present smokerc
present smoker
p - value ( int )
p value ( int )
alteplase
reteplase
western europe / australia
western europe and australia
geographical region
geographic region
tiotropium nmbr mg respimat ® ( n z nmbr )
tiotropium nmbr mg respimat ® ( n = nmbr )
body - mass index > nmbr , n ( % )
body mass index > nmbr , n ( % )
pbo + mtx n = nmbr
czp + mtx n = nmbr
ef < nmbr % hfref ( n = nmbr , nmbr % )
ef > nmbr % hfpef ( n = nmbr , nmbr % )
macroalbuminuria at baseline ( nmbr % of patients treated )
microalbuminuria at baseline ( nmbr % of patients treated )
any coronary artery disease
only coronary artery disease
estimated gfr < nmbr ml / min / nmbr . nmbr mnmbr
estimated gfr > nmbr ml / min / nmbr . nmbr mnmbr
female patients , n ( % )
male patients , n ( % )
history , pack - years
history ( pack - years )
duration of diabetes > nmbr years
duration of diabetes < nmbr years
structural heart disease §
structural heart disease
no family history of chd ( n = nmbr , nmbr )
family history of chd ( n = nmbr , nmbr )
subcortical wml load diameter , mm , mean ( sd )
subcortical wml load diameter , mm , , mean ( sd )
etoricoxib nmbr mg ( n nmbr nmbr ) , . . . n . . . ( . % . . ) . . . . . . . . . . .
etoricoxib nmbr mg ( n nmbr nmbr ) , . . . n . . ( . % . . ) . . . . . . . . . . .
glycoprotein iib / iiia inhibitor
glycoprotein iib / iiia inhibitors
with acei / arb
without acei / arb
corticosteroid or immunosuppressant
corticosteroids and immunosuppressants
corticosteroid and immunosuppressant
egfr < nmbr ml / min
egfr > nmbr ml / min
st - segment — elevation myocardial infarction
st - segment elevation myocardial infarction
patients with psoriasis ( n = nmbr )
patients without psoriasis ( n = nmbr )
egfr < nmbr ml / min / nmbr . nmbr mz
egfr > nmbr ml / min / nmbr . nmbr mz
age > nmbr years ( median )
age < nmbr years ( median )
no . pts
no . men
nmbr mg qw nmbr . nmbr pt yrs
nmbr mg biw nmbr . nmbr pt yrs
fasting plasma glucose ( mg / dl )
fasting plasma glucose — mg / dl
antidiabetic medications
antidiabetic medication
ldl - c ( median , iqr ) , mg / dl
hdl - c ( median , iqr ) , mg / dl
nonischemic cardiomyopathy
ischaemic cardiomyopathy
ischemic cardiomyopathy
no ilb / iiia inhibitors
ilb / iiia inhibitors
nontatal ml
nonfatal ml
no of events women men *
no of events womenmen *
demographic features
demographic feature
non - epa ( n = nmbr )
non - us ( n = nmbr )
heart failure *
heart failure
heart failurea
acetylsalicylic acid
acetyl - salicylic acid
difference ( % )
difference ( se )
exercise > once weekly
exercise > once weekly ?
nmbr - nmbr days ( % )
nmbr - nmbr yr ( % )
number stent > nmbr
"number ste "" t > nmbr"
most common concomitant aeds , d n ( % )
most common concomitant aeds , n ( % )
> nmbr % to < nmbr % ( > nmbr to nmbr mmol / mol )
> nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol )
baricitinib nmbr mg ( n = nmbr )
baricitinib nmbr mg qd ( n = nmbr )
alcohol consumption
alcohol consumption !
sri response , %
acr response , %
endpoint / baseline
endpoint / baselinec
ranozaline
ranolazine
left anterior descending coronary artery
l eft anterior descending coronary artery
renal subgroup
female subgroup
ss < nmbr ( n = nmbrvsnmbr )
ss > nmbr ( n = nmbrvs nmbr )
transient ischemic attack
transient ischaemic attack
nmbr mg ew n = nmbr
nmbr mg eow n = nmbr
phgada ( mm )
ptgada ( mm )
patient ' s assessment of pain !
patient ' s assessment of pain
lama ( only monotherapy )
laba ( only monotherapy )
insulin glargine ( n = nmbr )
insulin glargine ( n = nmbrll )
secukinumab , nmbr mg ( n = nmbr )
secukinumab nmbr mg ( n = nmbr )
paroxysmal
paroxysmal af
history of major microvascular disease — no . ( % )
history of major macrovascular disease — no . ( % )
non - hdl cholesterol
non - hdl choleslerol
insulin treated
insulin - treated
msdbp , mmhg ( sd )
mssbp , mmhg ( sd )
no prior statin ( n = nmbr , nmbr )
prior statin ( n = nmbr , nmbr )
fevnmbr ( liters )
fevnmbr — liters
systolic
diastolic
czp + mtx^mtx
pbo + mtx^mtx
history of paroxysmal af
no history of paroxysmal af
stage nmbr : > = nmbr
stage nmbr : < nmbr
ato nmbr mg and sim nmbr^nmbr mg ( n = nmbr )
ato nmbr mg and sim nmbr - nmbr mg ( n = nmbr )
-------------------------------Week 54-----------------------------------
------------------------------Week 30------------------------------
-------------Week 30------------------------------ --------------------
------------Week 54-----------------
- <—■ bb—-►
- HDL Cholesterol
- LDL Cholesterol
- Median fasting serum glucose (mg/dL) (IQR)
- Median pulse pressure (mm Hg) (IQR)
- Median TG (IQR)
- Median urine ACR (mg/g) (IQR)
- recurrent VTE during overall study period
- Triglycerides
"-[The null hypothesis is that there are no differences among subgroups; for age and time since randomization, the inter-"
"-°-287; wom-"
-0-0331 (-0-2776too 2115)
-0-29 (95% Cl -0-52 to -0-06)
-0-50 (95% Cl -0-81 to -0-27)
-0.54 (95%CI: -0.74, -0.34, n=185)
-0.93 (95%CI: -1.12, -0.73, n=178) A -0.39%, *p=0.007
-1 Placebo
-2 < FLEX FN F- score
-2.0 < LS T-score
-2.2 (-3.5, -C).9r
-2.5 < FLEX FN F-score < -2
-2.5 < LS T-score < —2.0
-23.7 (0.9)*ll
-44.2 (95%CI: -53.8, -34.6, n=60)
-45.4 ± lNO^
-45.8 ± 1.44§tI
-48.1 (95%CI: -56.7, -39.5, n=68) *p=0.523
-5.65 to -3 cm
-7-2 (95% Cl -10-8 to -3-5)
-7-6 (95% Cl-11-2 to 4-0)
-B-i-
-B-i—
-bI-
-F2.88 (-I-0.16)
-ICS/+ LABA n Z 597
-major bleed
-O-OO95 (-0-0348 to 0-0159)
-O.OS
-O8O (-1-lOto -0-50)
-Oil
— no. (%)
—2.0 < FN T-score
—2.5 < FN T-score < —2.0
—b-H—
! Amlodipine
# of prior bDMARDs
# of prior non-TNFi bDMARDs*
# of prior TNFi among non-TNFi naive
# PTS
#1 year
#100 kg
$ 10 years (N = 586)
$ 2 exacerbations
$ 65 years (n = 454)
$ Race was determined by the investigator during the patient's interview.
$10 years
$3and,10 years
%-Point difference (95% CI)c
% (95% CI)
% (SE)
% \mean ± SD
% anti-CCP+ (>60 units)
% Asthma control days{,#
% bronchial reversibility (SD)
% change (mean ± SE)
% change (mean±SE)
% change (meanlSE)
% change (meantSE)
"% change (median; Q1, Q3)"
% change from baseline LS means (SE)
% change from baseline to Week 24
% change from baseline, mean (s.e.)
% change median Baseline CRP >2mg/L
% change, 95% CI)
% difference, 95% CI)
% FHG
% HbA1c (mmol/mol)
% improvement in dactylitis score at week 24, N
% improvement in enthesitis score at week 24, N
% of patients 22.2    22.5
% of predicted
% of predicted normal value*
% Patients
% PHG
% Predicted
% predicted FEV,
% predicted FEV^
% predicted FEV1
% Predicted FEV1
% predicted post-bronchodilator FEV, (SD) ml
% Predicted post-bronchodilator FEV1, mean (SD), L
% predicted pre-BD
% predicted pre-bronchodilator FEV1, %*
% Predicted prebronchodilator FEV1, mean (SD), L
% predicted value (SD)
% predicted” FEV, at baseline, %*
% Reduction
% Reversibility
% Reversibility in FEV^ at
% RF+
% Risk Reduction (95% Cl)
% risk reduction (95%CI)
% Stenosis (core lab)
% Stenosis (investigator)
% Stenosis, as assessed by core laboratory
% Stenosis, as assessed by investigator
% to goal
% With HAQ-DI decrease >0.22
%/year
%/yr
& Median
($100 mg/dL [5.6 mmol/L])
($110 mg/dL [6.1 mmol/L])
($90 ml/min per 1.73 m2)
(% of group)
(% of Target)∗
(%) Control (45002)
(%) Control (45054)
(%),28 mean (SD)
(%, 95% Cl)
(,60 ml/min per 1.73 m2)
(:> blockers
(_> 1.7 mmol/L) HDL-C women:< 50 mg/dL (< 1.3 mmol/L) men: < 40 mg/dL
(< 1.0 mmol/L)
(<5 mg/L)
(<60 ml/minute)*
(≥5 mg/L)
(0-10-cm VAS)
(156 patients)
(158 patients)
(21 patients)
(217 subjects)
(219 subjects)
(22 patients)
(3-Blocker
(3-blockers
(3-sitosterol (p.mol/L)
(3 blocker
(60-89 ml/min per 1.73 m2)
"(88.5%); values were not collected for 113 patients (11.5%) who were enrolled"
(95% CI)
(95% CI)    P Value
"(95% CI);"
(95% CI)a
(95% CI)b
(95% CI)c
(95% CI] 1
(95% Cl)
(95% Cl) Interaction
(95% ell'll
(95% ell'll,* Non-HDL-C
(95%CI]h
(96% Cl)
(a blocker
(a) AZA treatment (ref)
(a) BMI subgroups
(a) Demographics
(b) Age subgroups
(b) AZA treatment (ref)
(b) Concomitant respiratory medications [N (%)]
(baseline)
(c) ' ' KZA treatment (ref)
(cells per pL)t
(CI)b
(cm)
(composite endpoint)
(d) AZA treatment (ref)
(e-blocker
(e) AZA treatment (ref)
(Fxs)
(GM)
(HAQ-DI, 0-3)
(i-Blocker
(ID
(incl. uncertain)
(including hypertension)
(Interquartile range) (mm)
(IQR)
(IQR) — days
(L)t
(mean % change, 95% CI)
(mean % difference, 95% CI)
(mean +. SD)
(mean ± SD)
(mean change, 95% CI)
(mean difference, 95% CI)
(median, h)
(mg/dL ± SD)
(mg/dl)
(mg/dL)
(min)*
(minimum-maximum) focal seizure fre- quency/28 days at baseline
(mmol/L)
(mmol/L]
(mU/L$mmol/L)b
(n = 325)    (n = 649)
(n = 335)    (n = 666)
(n = 335)    (n = 667)
"(N = 58)""'    (N = 46)"
(n = MS)
(n=152) (n=151)
(n=171) (n=156)
(n=1l2)
(n=205) (n=213)
(n=211) (n=203)
(n=241) (n=242)
(n=28) (n=32)
(n=285)    (n=561)
(n=30) (n=39)
(n=36) (n=29)
(n=38) (n=29)
(n=42) (n=50)
(n=68) (n=73)
(n=69) (n=84)
(n=79) (n=79)
(n=82) (n=84)
(n=l44)
(NE, NE)
(ngml '') Total mean IPSS score
(NYHA grade III or IV)
(Ofl)
(pg/mg)
(Phase 2 dose-finding trial)
(points)
(range)
(Ref)
(ri = 149)
(ri = 622)
(SCALE Diabetes)
(SCALE Obesity and Prediabetes)
(SD)
(SD) l/min ACQ-5 score, mean (SD)
(SD),mg/dL
(SE)
(SE)t*
(SE]+
(SE]t
(SE]t*
(SE]tf
(SE]tf HDL-C
(SE]tf Total-C
(SEM)
(subgroup)
(tiotropium n = 105, placebo n
"(tiotropium n = 86; placebo n ="
(Tiotropium n=82 Non-tiotropium n=322)
(Tiotropium n=83 Non-tiotropium n=322)
(Tiotropium n=86 Non-tiotropium n=327)
(Tiotropium n=90 Non-tiotropium n=333)
(Tiotropium n=93 Non-tiotropium n=3 16
(Tiotropium n=95 Non-tiotropium n=326)
(total SES-CD score at
(Week)
(women only)
(years)
(yes/no)
* data are expr
* Eligibility risk factors, n (%)*
"* Hypercholesterolemia was defined as a low-density lipoprotein cholesterol level at enrollment of more than 130 mg per deciliter (3.4 mmol per liter) after an overnight fast. † Nonsustained ventricular tachycardia was defined as 3 or more consecutive ventricular beats at a heart rate of more than 100 beats per minute. ‡ To convert weight to kilograms, divide by 2.2. § To convert values for creatinine to micromoles per liter, multiply by 88.4. ¶Data for follow-up medication were available for 2500 patients (amiodarone, 840; placebo, 838; and ICD, 822). ACE de-notes angiotensin-converting enzyme, and ARB angiotensin II–receptor blocker. ¿ P<0.001 for the comparison among the groups"
* Non-Black*
* Nonfatal Ml
* P value
* Patient characterization data are reproduced from Morrow et al. (16).
* Plus-minus values are means 士SD. Race or ethnic group was self-determined. The body-mass index is the weight in kilograms divided by
* Plus-minus values are means ±SD. There were no significant differences (at
* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. The body-mass index is the weight in kilograms divided by the square of the height in meters. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ACE denotes angiotensin-converting enzyme, CABG coronary-artery bypass grafting, NT-proBNP N-terminal pro-B–type natriuretic peptide, NYHA New York Heart Association, and PCI percutaneous coro-nary intervention. † Race was reported by the investigators. ‡ One patient in NYHA class I was mistakenly included in the placebo group. § This category includes any angina-like symptoms at any time in the past, with no confirmation of diagnosis of coro-nary heart disease required. ¶ Possible scores range from 0 to 105, with lower scores indicating a better quality of life. ∥ Anemia was defined by World Health Organization criteria as a hemoglobin level of less than 13 g per deciliter in men and less than 12 g per deciliter in women. ** NT-proBNP levels are influenced by a variety of factors, including age, sex, body-mass index, and renal function. No clinically useful normal range has been established. †† Some patients were taking both loop and thiazide diuretics.
* The P‐value is from the test statistic for testing the interaction between the treatment group and Diabetes group.
** Positive stress test
*** Unstable angina
*Atherosclerotic coronary heart disease, ischaemic stroke or peripheral arterial disease. †n/N = number of people in phase 3 studies only. ‡High‐intensity statins were defined as atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg or simvastatin 80 mg daily.
*CI denotes confidence interval.
*Data are expressed as median ± SD, except
"*Data are given as percentage of subjects unless otherwise specified. PTCA indicates percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft; ACE, angiotensin-converting enzyme; BMI, body mass index (calculated as weight in kilograms divided by square of height in meters); HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; and FPI, fasting plasma insulin. tTo convert cholesterol values to micromoles per liter, multiply by 0.0259. To convert triglycerides to micromoles per liter, multiply by 0.0113. To convert FPG to micromoles per liter, multiply by 0.0555. To convert FPI to picomoles per liter, multiply by 6.945."
*Data reported as n (%) or median (quartiles 1, 3).
"*Determined by investigator to be possibly, probably or definitely related to study drug tMyopathy defined as CPK > 10 x ULN with associated muscle symptoms with no other plausible etiology ^Consecutive defined as two or more measurements at least one week apart or one measurement < 2 days after the last dose of study drug (presumed consecutive) §Two patients had incomplete data to assess CHD status SIMVA = simvastatin; EZE = ezetimibe; AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; ULN = upper limit of normal"
*Interquartile range
*Other - Europe (n=12), Australia (n=7) and India (n=134) - the data from these regions were collapsed due to the small numbers
"*p < 0.0001 for EZE/SIMVA (pooled across doses) vs. SIMVA (pooled across doses) for the entire cohort Data are presented as least squares mean ± standard error (†median ± SE for TG) for the entire cohort and also for each selected subgroup SIMVA = simvastatin; EZE = ezetimibe; TC = total cholesterol; TG = triglycerides; HDL-C = high-density lipoprotein-cholesterol; Non-HDL-C = non-high-density lipoprotein cholesterol; Apo = apolipoprotein"
"*p < 0.05 for between-treatment difference with same dose of simvastatin for entire cohort Data are expressed as least squares mean ± standard error SIMVA = simvastatin; EZE = ezetimibe; CHD = coronary heart disease"
*P for heterogeneity of treatment effect between tertiles >0.8.
*Per 1000 participant years. Composite of first occurrence death (all cause), nonfatal Ml, or nonfatal stroke. Cardiovascular death excluding those classified as “unable to determine.”
*Rate is number of events per 100 patient-years of follow-up. fThe p value for number of patients from log-rank, for total number of hospitalizations from permutation test. ^By treatment comparing the
*Reported by physicians. †Data are median (IQR). All data are mean (SD) or number (%) unless otherwise indicated.
"*Risk reduction, 95 percent confidence interval (CI), and P value are derived from Cox models.
For risk reductions, negative numbers indicate an increase in risk. †Diabetes and hypertension were defined by clinical history. ‡A family history was defined as having one or more first-degree relatives with either myocardial infarction or sudden death before the age of 55. §HDL cholesterol levels are shown according to the median value (31.5 mg per deciliter [0.8 mmol per liter]). ¶Triglyceride levels are shown according to the median value (151 mg per deciliter [1.7 mmol per liter]).
¿LDL cholesterol levels are shown according to the median value (112 mg per deciliter [2.9 mmol per liter]) and according to the values that divide the subjects into three equal groups (<104, 104 to 121, and >121 mg per deciliter [<2.7, 2.7 to 3.1, and >3.1 mmol per liter])."
"*Subgroups were defined on the basis of variables assessed before randomization. The lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization. To convert values for cholesterol to millimoles per liter, multiply by 0.02586; to convert values for triglycerides to millimoles per liter, multiply by 0.01129. CI denotes confidence interval, LDL low-density lipoprotein, and HDL high-density lipoprotein. Tests for heterogeneity of treatment effect were undertaken across each of the subgroups. In addition, we performed tests for interaction between treatment and the following continuous base-line variables: age; total, LDL, and HDL cholesterol; and triglyceride levels. There was no evidence of significant heterogeneity of treat-ment effect in any prespecified subgroup (P»0.08). †Data were missing for three patients, two in the placebo group and one in the pravastatin group."
"*The 2 substrata with baseline (BL) LDL cholesterol  100 to  130 mg/dl and  130 to  160 mg/dl were combined to make 1 group with BL LDL cholesterol  100 to  160 mg/dl because of small numbers of patients included in the substrata with  130 to  160 mg/dl. †BL HDL cholesterol cutoffs were  40 or  40 mg/dl for men and  50 or  50 mg/dl for women. Bars indicate SE. BMI   body mass index; E   ezetimibe 10 mg; HDL-C   HDL cholesterol; LDL-C   LDL cholesterol; TG   triglycerides"
, 10 years (N = 1480)
, 65 years (n = 1613)
, n/N (%)
,0-blocker
,0-Blockers
,1/week
,2 step
,3 years
,3.4 mg/mmol
. 1.0 mL/s/m2(60 mL/min/ 1.73 m2), n (%)
.100 kg
.100 kg MTX use
.3 step or incident vitrectomy or photocoagulation
.33.9 mg/mmol
/\ge category
"/’-value"""
/’-value1’
/’interaction
/3-Blocker
/3-blockers
/J-valuc!l
/pl 655 631
: MI, Previous PCI and Chronic Obstructive Pulmonary Disease.
? f? n
[}ifrerence vs. placebo, % (95% Cl)
[2.6 mmol/L])
[95% CI]*
[95% Cl]
[cm(female)/cm(male)]
[cm{female)/cm{male)]
[kg/m^]
[Min, Max]
[no/yes] (%)
[SD]
[zi = 2334] 9334 (50.7)
[zi = 2782] 2188 (78.6)
[zi = 52] 44 (84.6)
[zi = 70] 281 (56.8)
\BL-SC n/N
^-blocker
^-Blocker
^-blockers
^≥2% incidence in any treatment group in the overall safety population.
^10 days
^12 months
^135 mm Hg
^30 mg/g, n (%)
^6 hrs
^60 mL/min
^75 y, n (%)
^8-cell function — %§
^median >median
^Numbers do not always sum to group totals due to missing information for some variables. fBody mass index was calculated as weight in kilograms divided by the square of height in meters. ^Hypertension was defined as a self-reported systolic blood pressure >140 mm Hg, a diastolic blood pressure >90 mm Hg, or physician-diagnosed hypertension. §Hyperlipidemia was defined as a self-reported total cholesterol >240 mg/dL (6.2 mmol/L) or physician-diagnosed high cholesterol. ||Diabetes was defined by self-report.
|    Interactior 1    P
|:S blocker
|?)-Blocker, %
|?>-Blocker (n, %)
■335 years
“Off”
“On” with troublesome dyskinesia
“On” without troublesome dyskinesia
“Relative risk of outcome in ACEI group iw control group. bBaseline variables for models included: logarithm of age, reciprocal of serum creatinine, SBP, UP excretion, treatment assignment and terms for studies 2, 5 10 and 11 (see footnotes of Table 1). Other baseline variables considered for analysis (P < 0.2 in univariate analysis) included DP mean arterial pressure, type of antihypertensive regimen in the control group, planned duration of follow-up, whether or not the investigators were blinded, whether or not dietary advice was given and the year of publication.
£ 47 min
£ 62.5 yrs
£ 74.5 min
£ Median
£ median (2.8)
£ median (64)
£1.58 mmol/L
£100 mg/dl
£150 mg/dl
£3% BSA psoriasis, no. (%)
£30 kg/m2
£34 kg/m2
£40 (men)/ £50 (women)
£60 mL/min
£65 to <75 years
£65 years
£65 yo (N=2739)
£75 years
£75 yr
£80 m b'm in
£90 kg
£90 ml/minute
£l 00 kg
+ICS/+ LABA n Z 945
+ICS/+ LABA nZ 945
<-2.5 - VFx
<-2.5 + VFx
<-5.65 cm
< 0.04 ng/ml
< 0.6 tng>clL
< 1 year
< 1 years
< 10 years
< 100 mg
< 150 cells/pl
< 150 cells/ul    623    654
< 160 mg/dL
< 160 mg/dL EZE/SIMVA
< 160 mg/dL EZE/SIMVA (n = 337)
< 160 mg/dL EZE/SIMVA (n = 337}
< 160 mg/dL SIMVA
< 160 mg/dL SIMVA (n = 320)
< 160 mg/dL SIMVA (n = 320]
< 180 min
< 1st quartile
< 2 years
< 20 mgday P.Eq.
< 21 mm
< 24 hr
< 25 kg/m2
< 3.4 mg/mmol
< 30 kg/m2
< 30 ml/min
< 30 mL/min
< 30 mm
< 30 years
< 47 min
< 5 years
< 5 yr since menopause
< 6 month n = 426
< 6 month n=417
< 60 Kg
< 60 L/min
< 60 yr
< 62.5 yrs
< 65 years
< 65 years (%)
< 65 Years EZE/SIMVA
< 65 Years EZE/SIMVA (n = 917)
< 65 Years EZE/SIMVA (n = 917}
< 65 Years SIMVA
< 65 Years SIMVA (n = 948)
< 65 Years SIMVA (n = 948}
< 65 years, n (%)
< 65 yr
< 65 yrs
< 74.5 min
< 75 mg
< 75 years
< 75 Years
< 75 yr
< 80 mg/dl
< Median
< median (4.5)
< Median (81 kg)
< median 151.13
<= 75 yr
<=€0 kg
<=1 year, n (%)
<=100 kg
<=60 kg
<0% predicted ARR (n = 18,524)
<0.00 ld
<0.03 l-g/L
<0.04 ng/ml
<0.94 mmol/L
<1-35 mmol/L
<1-42 mmol/L
<1 mg/L (n = 1278)
<1 week
<1 year
<1 years
<1 yr
<1.05 mmol/liter
<1.05 mmol/liter Triglyceride level
<1.0mg/l
<1.30 mmol/l
<1.5 mg/dl
<1.5 ng/ml (n = 304)
<1.6 mg/dl
<1.9 ng/L (n=131) n (%)
<1.9 ng/L (n=251)
<10 days
<10 days (%)
<10 mm Hg
<10 years
<10 yr
<100 kg
<100 mg
<100 mg/dl
<100 mg/dL
<100 mg/dl*
<100 mm Hg
<104 mg/dl
<112 mg/dl
<12 months
<120 mm Hg
<120/<75 mm Hg
<122.5 mm Hg
<122.5 mm Hg Diastolic blood pressure
<125 mm Hg
<126 mg/dL
<129 min
<13.1 years
<130 mg/dL
<130 mm Hg
<130 mm Hg— no. (%)
<130/80 mm Hg+
<130/80 mmHg, LDL-C <100 mg/dL
<133 mg/dl
<133.83 mm Hg
<135 mg/dl
<135 mm Hg
<136 mm Hg
<140 mg/dl
<140 ml
<140 mm Hg
<140 mmHg
<140/90 mm Hg
<15 enroll
<15 ml/s
<150 cells/mm^
<150 mg/dl
<150 mg/dL
<150 regardless of historical count
<150 with historical count >300
<150 with no historical count >300
<1500 mg
<151 mg/dl
<160 mm Hg
<18 kg/m2
<18 mg/dL
<18 mon (N=4097)
<180 mm Hg
<1year
<2 and no moderate or severe deformity (N = 6803)
<2 days
<2 mg/liter
<2 mo
<2 months
<2 years
<2% Blood Eosinophils at Baseline
<2.12 mmol/liter
<2.12 mmol/liter Estimated GFR
<2.59 mmol/l
<2.59 mmol/L
<20 mg
<20 mg/d PEq
<20 mg/day
<20 mm Hg
<200 lb
<200 mg/dl
<21 kg/m2
<213 mg/dl
<24 h, n (%)
<24 kg/m2
<24, kg/m2
<242 ng/mL
<25 — no. {%)
<25 kg/m2
<25 kg/m2 ( n = 93)
<25 ppb
<25.0 kg/m2
<250 microg/l
<25kg/m2
<26 mm Hg
<27.2 kg/m2
<277.6 pmol/liter
<28 kg/m2
<2xULN
<3 — no. (%)
<3 days
<3 hr
<3 mm
<3 mo
<3 months
<3 Months
<3 Months In - 1 Kill
<3 months, n (%)
<3 no. (%)
<3.0 mmol/liter
<3.12 mmol/liter
<3.12 mmol/liter ApoB:ApoA-l ratio
<3.36 mmol/l
<3.4   mmol/l
<3.4 mmol/L
<30    kg/m2
<30 CrCl
<30 days (n = 7181)
<30 kg, mJ (reference)
<30 kg/m 2
<30 kg/m^
<30 kg/m2
<30 kg/m2 (n — 274)
<30 kg/mA2
<30 ky/nr
<30 mg dL (reference)
<30 mg/dL
<30 mg/g
<30 mg/g, n (%)
<30 ml/min
<30 mL/min
<30 mL/min per 1-73 m2
<30 mL/min/1.73 m2
<30 mL/min/1.73ni-
<30 ml/minute
<30% predicted
<300 cells/pL
<30mLmin) 1
<31.5 mg/dl
<325 meters
<35 mg/dl
<35 years
<39 mg/dl
<3mo,n (%)
<4-01 mmol/L
<4-1 mmol/L
<4 hr
<4 mmol/L
<4 months, mean (SD)
<4 months, median (min, max)
<4.0 mU/L-mmol/L
<4.0 mU/L$mmol/L
<40 (men) / <50 (women)
<40 mg/dl
<40 mg/dL (<1.04 mmol/L)
<40 mm
<45 mL/min/1,73m2
<45 ml/min/1.73 m2
<5 years
<5 yr
<5 yr of education — no. (%)
<5 yrs
<5.0 mg/liter
<5.18 mmol/l
<5.5 mmol/liter
<5.8 mg/liter
<50 CrCl, n (%)
<50 kg
<50 ml/min
<50 ml/min — %
<50 mL/min (n=3374)
<50 years
<50 yr
<50 yrs
<508 ng/mL
<50nWrrtn
<51 ml/min/1.73 m2
<51 ml/min/1.73 m2 NT-pro-BNP
<54 mg/dl
<55 vr — no. (%)
<55 y, n (%)
<55 years (n=824)
<55 yr
<6-21 mmol/L
<6 hr
<6 hrs
<6 mg/L
<6 mo
<6 months—number/N (%)
<6 weeks
<60 kg
<60 Kg
<60 kg'i'
<60 mi/min
"<60 mL min’1 1.73 m""2"
<60 ml/min
<60 mL/min
<60 ml/min per 1.73 m2, n (%)
<60 ml/min/1,73 m^
<60 ml/min/1.73 m^
<60 ml/min/1.73 m^ — no. {%)
<60 ml/min/1.73 m2
<60 mL/min/1.73 m2
<60 ml/min/1.73 m2— no. (%)
<60 ml/min/1.73 m2 — no. (%)
<60 mL/min/1.73 m2, n (%)
<60 ml/min/1.73m2
<60 mL/min/1.73m2
<60 mLYmin
<60 years
<60 yr
<60 yr— no. {%)
<60kg
<65 y (n=422)
<65 y (n=433)
<65 y (N=5497, 26.0%)
<65 y ears
<65 y, n (%)
<65 years
<65 Years
<65 years (n=1757)
<65 years (n=4031)
"<65 years (placebo n =3,941; saxagliptin n =3,990)"
<65 years n Z 1761
<65 years of age
<65 Years of Age
<65 years, n (%)
<65 yo (N=2306)
<65 yr
<65 yr — no. (%)
<65 yr(n = 367)
<65 yrs
<65 yrs of age (n = 3,239)
<66 yr
<67 mg/dl
<69 yr
<7 years
<7.9 mmol/liter
<70 kg
<70 yr
<70 yrs
<73 mm Hg
<73 mm Hg Heart rate
<75 Baseline Killip class
<75 beats/min
<75 mm Hg
<75 y (n=8932)
<75 yea's
<75 years
<75 Years
"<75 years (placebo n =7,051; saxagliptin n =7,111)"
<75 yr
<75 Yr
<75 yr — no. (%)
<75 yr (N = 5337)
<75.5 bpm
<77 bpm (n=3144)
<77 yr
<8 days
<8 years
<8% (<64 mmol/mol)
<8% (64 mmol/mol)
<8.0% (64 mmol/mol)
<8.5 mg/dL
<80 kg
<80 kg, n (%)
<80kg
<82.0 kg
<85 mg/dl
<850 beds
<9 months
<9 yr
<9 yr— no. {%)
<9.0% ( <75 mmol/mol)
<90 kg
<90 ml/minute)
<90 mmHg
<950 ft
<97 mg/dL
<99 cm
<l0 years
<Mean
<median
<Median (0.37 years)—number/N (%)
<Median (0.5)—number/N (%)
<Median (1.375)—number/N (%)
<Median (4.5)—number/N (%)
<Median (5.4)—number/N (%)
<median (54 Year-old)
<Median (62)—number/N (%)
<Median (7 days)
<Median {7 days)
<Median prednisone dose,n (%)
<Q1 (0)—number/N (%)
<Q1 (1.5)—number/N (%)
<Q1 (2)—number/N (%)
★Reported by physicians. tData are median (IQR). All data are mean (SD) or number (%) unless otherwise indicated.
卞at discharge.
赛 65 years
≤  Median
≥ 2 years
"= calcium channel blocker;BMI = body"
= cerebrospinal fluid.
"= ezetimibe; TC = triglycerides; HDL-C = lg/dL L> 7.0 mmol/L]). To qualify as having"
"= International Prostate Symptom Score;"
"= placebo; EZE :tes (FC J>126 rr 1 definition)."
"= placebo; EZE = ezetimibe; erol; Apo = apolipoprotein; metabolic syndrome, patients were eans and percentage changes are"
≤ 58 mmol/mol (7.5%), N (%)
≥ 64 mmol/mol (8.0%), N (%)
≥1 AE
≥1 SAE
≥1 TEAE
≤1 U/kg/day
≤1 year
≥10 years
≥10.0% (≥86 mmol/mol)
≥100 to <130 mg/dL
≥126 to <150 mg/dL
≥13.1 to <19.3 years
≥130 to <160 mg/dL
≥133 to <165 mg/dL
≥150 mg/dL
≥150 to <200 mg/dL
≥150 to <220 mg/dL
≥160 mg/dL
≥160 to <190 mg/dL
≥165 to <226 mg/dL
≥18 to <25 mg/dL
≥19.3 years
≥190 mg/dL
≥200 mg/dL
≥220 to <300 mg/dL
≥226 mg/dL
≥24, kg/m2
≥242 ng/mL
≥25 to <32 mg/dL
≥28 kg/m2
≥30 kg/m2
≥30 mg/dL
≥30 to <300 mg/g
≥30 to <45 mL/min/1.73 m2
≥30 to <50 mg/dL
≥300 mg/g
≥32 to <43 mg/dL
≥35 kg/m2
≤40 years
≥43 mg/dL
≥45 to <60 mL/min/1.73 m2
≥5 years
≤5 years
≥50 mg/dL
≤500 ug/g
≥508 ng/mL
≤6 mg/L
≥60 mL/min/1.73 m2
≥60 to <90 mL/min/1.73 m2
≥60 years
≥65 to <75 years
≥65 years
≥65 Years
≥7.5% and <9.0%
≥75 yearsa
≥75a(N=38)
≥75a(N=41)
≥75a(N=47)
≥77 bpm (n=3357)
≥80 mL/min
≥9.0% and ≤10.5%
≥90 mL/min/1.73 m2
≥97 to <133 mg/dL
=sia
>-2.5 - VFx
>-2.5 + VFx
>-2.5 and <-1.0
>-3 cm
>  Median
"> < 0.05,    < 0.01, r< MMSE = Mini-Mental ;"
> 1 Concomitant medication
> 1 med at baseline Cardiac disorder*
> 10 years
> 10 years vs. ≤ 2 years
> 100 mg
> 130 mmHg
> 15 yrs
> 160 mg/dL EZE/SIMVA
> 160 mg/dL EZE/SIMVA („ = 899)
> 160 mg/dL EZE/SIMVA 0 = 899}
> 160 mg/dL SIMVA
> 160 mg/dL SIMVA („ = 914)
> 160 mg/dL SIMVA 0 = 914]
> 160mg/dL CHD status
> 1st and < 2nd quartile
> 2 to ≤ 5 years vs. ≤ 2 years
> 2 years
> 24 hr
> 2nd and < 3rd quartile
> 3 days
> 3.5 vs. 2.1 to ≤ 3.5
> 30 kg/m2
> 30 kg/m2 Smokers
> 300 cells/pl
> 300 cells/ul
> 33.9 mg/mmol
> 3rd quartile
> 40 and ≤ 60 vs. ≤ 40
> 40 to ≤ 60 vs. ≤ 40
> 40 years vs. ≤ 40 years
> 47 min
> 5 and < 10 years
> 5 to S 15 yrs
> 5 to ≤ 10 years vs. ≤ 2 years
> 5 years
> 5 years vs. ≤ 5 years
> 5 yr since menopause
> 50 years
> 55 years
> 6 month n = 367
> 60 and ≤ 80 vs. ≤ 40
> 60 and ≤ 80 vs ≤ 40
> 60 mL/min
> 60 to ≤ 80 vs. ≤ 40
> 60 years
> 60 years 47 / 1425 (7.4)
> 62.5 yrs
> 65 years
> 65 years (%)
> 65 years Baseline LDL-C
> 65 Years EZE/SIMVA („ = 319}
> 65 Years EZE/SIMVA (n = 319)
> 65 Years EZE/SIMVA Baseline LDL-C
> 65 years old
> 65 Years SIMVA
> 65 Years SIMVA („ = 286}
> 65 Years SIMVA (n = 286)
> 65 years, n (%)
> 65 yr
> 7 years
> 720 min
> 74.5 min
> 75 mg
> 75 years
> 75 years BMI
> 75 years, n (%)
> 75 yr
> 8 % and <9 %
> 8.0% and ≤ 9.0%
> 80 mL min)1
> 80 vs. ≤ 40
> 9 % and <10 %
> 9.0% and ≤ 10.0%
> 90 mL/min/1.73 m2
> IS years
> l0 years
> Median
> median (2.8)
> Median (21 mm)
> Median (30 mm)
> median (4.5)
> Median (60%)
> median (64)
> Median (81 kg)
> median 151.13
> 58–< 64 mmol/mol (7.5–8.0%), N (%)
>= 35 kg/m2
>= 60 L/min
>= 60 l_/min
>= 60 yr
>= 75 years
>= 75 Years
>= 75 yr
>= 80 mL/mln
>= Median
>=1.9 to <10 ng/L (n=2033) n (%)
>=10 day s Initial Heparin Treatment Duration
>=10 days
>=10 to <26 ng/L (n=656) n (%)
>=10 years
>=100 kg
>=100 mmHg
>=140 mmHg
>=140 mmHq
>=26 ng/L (n=375) n (%)
>=26 ng/L (n=617)
>=30 kg/mA2
>=300 mg/g
>=325 meters
>=5 years and < 10 years
>=60 Kg
>=60^ Initial Heparin Treatment Duration
>=60kg
>=65 yea's
>=65 years
>=65 years (n=2474)
">=65 years (placebo n =4,271; saxagliptin n =4,290)"
>=75 years
>=75 Years
">=75 years (placebo n = 1,161; saxagliptin n =1,169)"
>=8% and <9% (>=64and <75 mmol/mol)
>=9% (75 mmol/mol)
>=9.0% ( >=75 mmol/mol)
>=90-<100 mmHg
>=90 ml/min/1.73m2
>=medan (54 Year-old)
>=Median (7 days)
>=Medion (7 days)
>0 to <12-5 mg/week
>0% and <1% predicted ARR (n = 8,943)
>0.03 -g/L
>0.04 ng/ml
>0.76 HDL cholesterol level
>0.94 mmol/L
>1-42 mmol/L
>1-5 years
>1 AEs
>1 AEs leading to discontinuation
>1 Antihypertensive medication, No. (%)
>1 Corticosteroids or immunosuppressants
>1 DES type
>1 drug-related
>1 drug-related AEs*
>1 erosion, n (%)
>1 exacerbation in prev 12 m (n=294)
>1 exacerbation in prev 12 m (n=316)
>1 exacerbation in prev 12 m (n=333)
>1 exacerbation in prev 12 m (n=443)
>1 failure
>1 Failure
>1 Glucose-lowering medication. No. (%)
>1 oral antidiabetic medication
>1 Prior myocardial infarction — no. (%)
>1 serious AEs
>1 to <=5 years, n (%)
>1 to <2 h, n (%)
>1 to 5 years
>1 to 5 years
>1 type
>1 U/kg/day
>1 year
>1 yr
>1 yr, n (%)
>1% predicted ARR (n = 472)
>1.05 mmol/liter
>1.30 mmol/l
>1.5 mg/dl
>1.5 ng/ml (n = 257)
>1.58 mmol/L
>1.6 mg/dl
>1/3 lung fields
>1/day
>1:11 hrs:min (n=739)
>1+35 mmol/L
>10-14 (moderate risk)
>10 DA of capillary nonperfusion in the eyec
>10 days
>10 years
>10 years to <20 years
>10 yr
>10 years
>100 & <130 mg/dl
>100 and <130 mg/dl
>100 but <130 mg/dl
>100 kg
>100 mg
>100 mg/dl
>100 ng/L
>1000b (109b to 121a)
>1000b (124b to 156a)
>1000b (259b to 382a)
>101 mg/dl
>110 cm
>12-5 mg/week
>12 months
>12 Months
>12 Months (n = 1,746)
>12 years
>12 years education
>121 mg/dl
>122.5 mm Hg
>1275 ft
>129 min
>12months
>12months, n (%)
>13.5 mm
>130 & <160 mg/dl
>130 ^mol/liter — no. (%)
>130 and <160 mg/dl
>130 mg/dl
〉130 ml/min per 1.73 m2, n (%)
>130 to <140 mm Hg
>130/tmol/liter— no. (%)
>135 to <150 mm Hg
>136 mm Hg
>14 (high risk)
>140-<160 mmHg
>140 (ml) Additional angiography
>140 mg/dl
>140 ml
>140 mm Hg
>140 mm Hg — no. (%)
>140 mmHg
>140/>90 mm Hg
>15 drinks
>15 drinks/wk
>15 enroll
>15 min
>15 ml/s
>15 years
>15 yr
>150 at screening
>150 mg/dl
>150 mg/dL
>150 mg/dl — %
>150 mm Hg
>150 per pL at screening
>150 to <300 cells/mm^
>150 to <300 cells/mm’
>1500 and <2000
>1500 mg
>160 mm Hg
>164.34 mm Hg
>18 mon (N=948)
>180 mm Hg
>2 and/or >1 moderate or severe deformity, or both (N = 759)
>2 Antihypertensive Medications
>2 CHD risk factors
>2 CV risk factors^ or established atherosclerotic CV disease
>2 CV risk factors咐 or established atherosclerotic CV disease
>2 days
>2 drinks/week
>2 episodes of atrial fibrillation in previous 6 mo
>2 exacerbations
>2 Exacerbations
>2 h, n (%)
>2 hr
>2 lesions per vessel
>2 mg/liter
>2 mo
>2 months
>2 OADs
>2 Previous venous thromboembolisms (%)
>2 servings/wk (n=127)
>2 symptom days per week
>2 vessels treated
>2 vessels with >50% stenosis
〉2 years
>2 years
>2 yr
>2% Blood Eosinophils at Baseline
>2(1) drinks/day if male(female)
>2(n=15l6)
>2.12 mmol/liter
>2.59 mmol/L
>2/3 lung fields
>20 mg
>20 mg/d PEq
>20 mg/day
>20 mm Hg
>20 ng/L
>20 years
>20 yrs
>200 lb
>200 mg/dl
>200 mg/dl — %
>2000 and <3000
>21 kg/m2
>23-^25 kg/m’
>23-s25 kg/m’
>24 kg/m2
>25-<30kg/m2 (n = 327)
>25-<s27 kg/m’
>25-s27 kg/m’
>25 kg/m2
>25 to <50 ppb
>25 years
>250 microg/l
>25kg/m2
>27-^30 kg/m’
>27-s30 kg/m’
>27.2 kg/m2 Hypertension:
>277.6 pmol/liter
>277.6 pmol/liter hsCRP level
>2to<59 ULN
>3 additional CV risk factors11
>3 diseased vessels
>3 drinks/dav
>3 hr
>3 mg/L (n = 2139)
>3 mm
>3 oral agents
>3.0 mg/l
>3.0 mmol/liter
>3.12 mmol/liter
>3.4 mmol/l
>3.4 mmol/L
>3.5 vs. > 2.1 and ≤ 3.5
>30 — no. {%)
>30 —no. {%)
>30 (moderate or high bleeding risk), No./total (%)
>30 days
>30 days to 1 year (n = 6501)
>30 kg nr
>30 kg/m^
>30 kg/m^ (obesity)
>30 kg/m’
>30 kg/m2
>30 kg/m2 (n — 221)
>30 kg/m2 (n = 155)
>30 ky/nr
>30 mg/g
>30 min
>30 to <45 mL/min/L73nr
>30 to <50 ml/min
>30 to <60 eGFR, mL/min/1.73 m2 a
>30 to <60 mg dL
>30 to <60ml/min/1.73m2
>30 to <700 IU/L
>30 to 300 mg/g
>30% and <50%
>30% predicted to <50% predicted
>30, No. (%)
>30.0 kg/m2
>300 cells/mm^
>300 in previous
>300 mg/g
>300 per pL in 12 months before screening
>33 mm Hg
>35 kg/nr
>4'01 mmol/L
>4-1 mmol/L
>4 hr
>4 mmol/L
>4 months, mean (SD)
>4 months, median (min, max)
>4 y Pathogenesis, n (%)
>4.0 to <5.5 mU/L-mmol/L
>4.0 to <5.5 mU/L$mmol/L
>4.13 mmol/l
>4.18mmol/L (n=730)
>4/week
>40 and <50%
>40 mg/dl
>40 mm
>40 mm Hg
>40 years
>40, obesity class 3
>40: obese class III
>42 mm (n=555)
>43 mg/dl
>45 ml/min/1.73 m2
>45 to <60 mL/min/L73nr
>5-<15 years
>5-10 years
>5 - <15 years
>5 to <10 years
>5 to <15 yr
>5 to 10 years
>5 to 10 years
>5 years
>5 years, n (%)
>5 yr
>5.0 mg/liter
>5.5 mmol/liter
>5.5 to <8.5 mU/L-mmol/L
>5.5 to <8.5 mU/L$mmol/L
>5.8 mg/liter
>5.8 mg/liter Antiplatelet agents
>50-100 kg
>50-60 yr
>50 ml/min
>50 mL/min
>50 ml/min/1.73 m2
>50 ng/L
>50 ppb
>50 to <80 ml/min
>50 yr
>50% coronary stenosis
>50% predicted
>50% responder rate, n (%)
>50% stenosis of coronary, carotid, or lower extremity arteries
>50% stenosis of major artery, n (%)
>503 ug/g
>51 ml/min/1.73 m2
>55 y, n (%)
>55 years to <65 years (n=2819)
>59ULN
>5yearstos IS years
>6-21 mmol/L
>6 hr
>6 hrs
>6 mg/L
>6 mo
>6 month n = 368
>6 months
>6 months—number/N (%)
>6 weeks
>6.21 mmol/l
>60-67 years
>60 CrCl
>60 eGFR, mL/min/1.73 m2
>60 kg
>60 kg Body Weight at Randomization
>60 mg/dL (>1.55 mmol/L)++
>60 mi/min
>60 ml/min
>60 mL/min
>60 ml/min/1.73 m2
>60 ml/min/1.73 m2— no. (%)
>60 mL/niin/L73ni-
>60 mLYmin
>60 to <90 eGFR, mL/min/1.73 m2 a
>60 to <90 mg dL
>60 to <90 ml/min/1.73 m^
>60 to <90iiil/iiim/1.73 m2
>60 years
>60 years 47/1425(7.4)
>60 yr
>60.0 ml/min/1.73 m2
>64 yr
>65 mm Hg
>65 to <75 years
>65 to <75 yr
>65 y (n=125)
>65 y (n=127)
>65 y, n (%)
>65 y, No. (%)
>65 years
>65 years (n=1263)
>65 years n Z 1330
>65 years of age
>65 Years of Age
>65 years of age, n (%)
>65 years to <75 years (n=3523)
>65 years, n (%)
>65 yr
>65 yr — no. (%)
>65 yr (%)
>65 yr (n = 212)
>65 yr From the United States
>65 yrs
>65 yrs of age (n = 3,116)
>65 yrs Sex:
>65, n (%) Gender, n (%)
>65y,No. (%)
>66 mg/dl
>67 to <84 mg/dl
>67 years
>69 yr
>7 years
>7.5 mg/day, %
>7.9 mmol/liter
>70-90 kg
>70-96 kg
>70 & <100 mg/dl
>70 and < 100 mg/dl
>70 but <100 mg/dl
>70 y, n (%)
>70 years
>70 years (n=556)
>70 years, n (%)
>70 yr
>70 yr— no. {%)
>70 yr — no. (%)
>70 yrs
>700 IU/L
>73 mm Hg
>75 (n, %) Weight, kg
>75 beats/min
>75 y (n=18)
>75 y (n=19)
>75 y (n=2010)
>75 y (N=8474, 40.2%)
>75 y. n (%)
>75 years
>75 years (n=1066)
>75 years or <50 CrCl, n (%)
>75 years, n (%)
>75 yr
>75 yr— no. (%)
>75 yr— no. {%)
>75 yr — no. (%)
>75 yr —%
>75 yr (N = 2471)
>75 yrs
>75.5 bpm
>75.5 bpm Current smoker
>77 bpm (n=3357)
>77 yr
>77 yr Sex
>8% to <9% (>64 to <75 mmol/mol)
>8% to <9% (>64 to 5 mmol/mol)
>8%, n (% of patients)
>8.5 mg/dL
>8.5 mU/L- mmol/L
>8.5 mU/L$ mmol/L
>80 (n, %) CHADS2 score
>80 kg
>80 kg— no. (%)
>80 ml/min
>80 mL/min
>80 mL/min (n=3880)
>80, < 100 mg/dl
>80, <100 mg/dl
>80kg
>82.0-97.3 kg
>84 mg/dl Baseline high-sensitivity CRP
>85 mm Hg
>85 years
>850 beds
>87 bpm (n=13l8)
>9 months
>9 yr
>9 yr— no. {%)
>9% (>75 mmol/mol)
>90 days (%)
>90 eGFR, mL/min/1.73 m2 a
>90 kg
>90 mg dL
>90 mL min-1 1.73 m'2
>90 mL/min per 1-73 m2
>90 mL/min per 1.73 m^
>90 ml/min/1.73
>90 ml/min/1.73 m^
>90 ml/min/1.73 m2
>90 mL/min/1.73m2
>90ml/min/1.73
>96 kg
>97.3 kg
>99-110 cm
>II
>l:36hrs:min (n=742)
>lto £2 symptom days per week
>lto<2 (n=951)
>lto<2 (n=963)
>Mean
>median
>Median
>Median (0.37 years)—number/N (%)
>Median (0.5)—number/N (%)
>Median (1.375)—number/N (%)
>Median (4.5)—number/N (%)
>Median (5.4)—number/N (%)
>Median (62)—number/N (%)
>o-9-i-i
>o-9-ii
>Q1 (0)-Q2 (0.5)—number/N (%)
>Q1 (1.5)-Q2 (4.5)—number/N (%)
>Q1 (2)-Q2 (4.5)—number/N (%)
>Q2 (0.5)-Q3 (5)—number/N (%)
>Q2 (4.5)-Q3 (8.5)—number/N (%)
>Q3 (5)—number/N (%)
>Q3 (8.5)—number/N (%)
>ULNand<20 ng/L
>Year 1
± SD.
±standard deviation. Triglyceride
«60 kg
»65 yr
»75 years
§ Classes on the Canadian Cardiovascular Society (CCS) scale range from I to IV,
"†Includes patients originally randomized to placebo who were switched to secukinumab per the study designs. ‡AEs that occurred in at least 2.0% of the patients in the Any secukinumab group during the 16‐week placebo‐controlled period and events with an EAIR of at least 5.0 cases per 100 patient‐years in the Any secukinumab group during the entire treatment period. Events listed according to preferred term in the Medical Dictionary for Regulatory Activities (MedDRA version 17.0), sorted in descending order of EAIR in the Any secukinumab group for the entire treatment period. The entire treatment period for safety data was from baseline to Week 52 visit of the last patient enrolled in these studies. AE, adverse event; AS, ankylosing spondylitis; EAIR, Exposure adjusted incidence rates; N, number of randomized patients; SAE, serious adverse event; URTI, upper respiratory tract infection."
• 1: Death from any cause, major coronary event, or nonfatal stroke
• Any MI
• Any stroke
• Death from any cause
• Death from coronary heart disease
• Death from CV causes, major coronary event, or nonfatal stroke
• Hemorrhagic stroke
• Hospitalization for unstable angina
• II: Death from coronary heart disease, nonfatal MI, coronary revascularization > 30 days
• III: Death from CV causes, nonfatal MI, hospitalization for UA, all revascularization > 30 days, nonfatal stroke
• Ischemic stroke
• Ml with ST-segment elevation
• Ml without ST-segment elevation
• Unstable angina
• Urgent coronaiy revascularization > 30 days
•?SD ml/min
•j. The body-mass index is the weight in kilograms divided by the square of the
0-10 (low risk)
0-10 (mild)
0-12 hours
0-15 min
0-30 min
0-32 (O18-O-55)
0-33 (95% Cl 0-23 to 0-49)
0-45 (O-35-O-58)
0-46 (O-37-O-58)
0-5 days
0-5 mm
0-52 (O-3O-O-91)
0-55 (95% Cl 0-38 to 0-81)
0-56 (O-23-I-41)
0-59 (O-32-I-O6)
0-59 fO-42 0-82^
0-60 (O-4O-O-91)
0-65 (O-4S-O-87)
0-67 (O-51-O-87)
0-68 (O-52-O-89)
0-69 (O-5O-O-94)
0-72 (O-66-O-8O)
0-72 (O-6I-O-85)
0-73 (O-53-1-OO)
0-74 (O-61-O-91)
0-74 (O-63-O-86)
0-76 (O-7O-O-83)
0-77 (O-65-O-91)
0-80 (O-67-O-95)
0-81 (O-51-I-28)
0-83 fO-74-O-Q^I
0-87 {O-75-1-O1)
0-92 (O7O-I-I9)
0-95 (s1-14)t
0-96 (s1-16)t
0-97 (O-7S-I-21)
0-Blocker
0—5 days
0 (or 1, if female only)
0 63 fO 39-1 01)
0 86 (O-69-I-O8)
0 drinks
0 drinks/wk
0 exacerbations
0 or 1
0 or 1 — no./total no. (%)
0 or 1, n (%)
0 or 1, No./total No. (%)
0 to <1 h, n (%)
0 to <2 hr
0 to 1 symptom days per week
0 vessel
0.098 (0.004-0.i9i)
0.125 mg
0.15 (0.02, 1.28) PTY=111
0.250 mg
0.375 mg
0.4 VS 0.6
0.47 95%CI: 0.23-0.98 P =0.043
0.5 mg
0.5 mg (N = 824)
0.5 mg (N = 826)
0.500 mg
0.62 (0.43, 0.89) PTY=2364
0.64 (0.45, 0.92) PTY = 2439
0.67 {0.49, 0.91) PTY = 2680
0.68 (0.49, 0.95) PTY=2036
0.69 (0.50, 0.94) PTY= 2788
0.7(0.4-l.l)
0.73 (0.55, 0.97) PTY = 3225
0.75 (95% CI 0.61 to 0.93) P =0.008
0.76 {0.46, 1.26} PTY=1301
0.77 {0.41,1.44) PTY = 548
0.79 (95% CI 0.53 to 1.18)
0.8 vs 1.3
0.81 (0.52, 1.26) PTY = 898
0.87 (0.55, 1.36) PTY = 972
0.89 (0.46, 1.74) PTY = 657
0.90 (95% CI 0.60 to 1.33)
0.95 (95% Cl 0.80 to 1.11) P =0.50
0.97 (0.88-1.OS)
0.97to.86. I.IOt
0.i23 (0.04i-0.205)
0=no symptoms
0119 (O-O65-O-173)
0134 (O-O88-O-179)
0134 (OO86-O.181)
048 (O-28-O-81)
08 IX
0tob 12 months
0tob 12 months, n (%)
0tol(n=1082)
0tol(n=1102)
1-14 drinks
1-14 drinks/wk
1-2 years
1-2 yr
1-2 yrs
1-3 drinks/dav
1-3/month
1-3/week
1-4/week (n = 3603)
1-5 years
1-5 yr
1-5/day
1-6 months
1-6/week
1——BH—I
1—e-H
1—eM
1    Placebo n=238
1 ($90 ml/min)
1 (4 SI
1 (except for female alone)
1 (FEVi ^80% pred)
1 (ref)
1 Abciximab (n = 1012)
1 Amlodipine- Chlorthalidone
1 Antihypertensive Medication
1 Aspirin (n = 19 934)
1 Baricitinib 2 mg ■ Baricitinib 4 mg
1 Chlorthalidone
1 Chlorthalidone (n = 15255)
1 Chlorthalidone Amlodipine
1 Cl)
1 day L
1 Degree of ICA stenosis丰
1 e5 years
1 Early Intervention (n = 203)
1 event, 0.1 per 100 py (0.0-0.4)
1 exacerbation
1 Exacerbation
1 exacerbation in prev 12 m (n=1238)
1 exacerbation in prev 12 m (n=1279)
1 exacerbation in prev 12 m (n=1299)
1 exacerbation in prev 12 m (n=1708)
1 exacerbations
1 IS ( 3.2)
1 Lisinopril
1 Lisinopril- Chlorthalidone
1 Low (n = 1024)
1 med at baseline
1 mg (288, 24.5%)
1 mg a
1 mg/day
1 mg/day - placebo
1 mg/day delayed-start
1 mg/day early-start
1 mg/day early-start - delayed-start
1 month L
1 n qi
1 n/N
1 No. of Events
1 OAD
1 OAM
1 or 2
1 or more
1 oral antidiabetic medication
1 P Value
1 Parameter
1 Placebo
1 Placebo (n = 19 942)
1 prior TNF antagonist failure, n (%)b
1 Prolonged Antithrombotic Pretreatment (n = 207)
1 st < 2.7
1 Standard (n = 1002)
1 t    i
1 to 2 years
1 to 3 mg/L (n = 1963)
1 vessel
1 Vitamin E
1 Vitamin E (n = 19 937)
1 week to 1 month
1 year mean change from baseline
1 year or more
1.0-2.9 mg/l
1.0 (Reference)
1.0 (referent)
1.0 mg
1.0 mg (N = 822)
1.0 mg (N = 825)
1.00 (ref.)
1.00 (reference)
1.00 (Reference)
1.14 (95% CI 0.77 to 1.68)
1.14f0.87, 1.5H
1.2 (fi.6)
1.3 vs 1.3
1.4 vs 1.0
1.5 VS 2.3
1.6 vs 1.9
1.7% vs. 3.8%
1.9-<10 ng/L (n=1917)
"1=minor symptoms; no limitations"
10-<15 yrs
10-<26 ng/L (n=1023)
10-Year Framingham CHD risk
10-Year Framingham CHD risk (%)28 mean /SD)
10-year Framingham CHD risk, %
10-year risk for CHD
10-Year risk of CHD, %#
10-Year risk of CHD, %# <5.0
10-Yr Rate/100 Participants
10-yr risk of coronary heart disease (%)^|
10 μg (n=207)
10 μg (n=217)
10 mg
10 mg (N = 1127)
10 mg (n = 120)
10 mg (n = 74)
10 mg (n 5 74)
10 mg (n=80)
10 mg empagliflozin
10 mg/d (n = 333)
10 mg/kg
10 ml/min
10 to <19 mm Hg
10 to <20 mm Hg
10 years or more
10 yrs
10% (-Ito 20)
10% (Oto 19)
10% participants
10.0 per 100 py
10.8 per 100 py
10/10 mg
10/20 mg
10/40 mg
10/80 mg
100-125 mg/dl*
100 mg
100 mg (n = 74)
100 mg + MTX
100 mg sirukumab every 2 weeks (n=292)
100 mg/50 mgb
100 ml (70 to 140) (n=301/253)
100 to <140 mm Hg
100/50 mga(n = 72)
1000 mg/day
100to<140mmHg
104-121 mg/dl
106-115 mg/dl
108 (mono)
10mg
11-20 (moderate)
11-20/day
11-30 days (%)
11 Cl)
11% (-Ito 22)
11% (Ito 20)
11% (Oto 21)
11.4 per 100 py
11.9 per 100 py
110 mg dabigatran
110 mg dabigatran (n=6014)
110 ml (80 to 140) (n=283/267)
115 (95% Cl 23 to 207)
116-125 mg/dl
118 < SBP < 128mmHg n = 373
118b (58b to >1000a)
12-17 years
12-17 yr
12-24 Hours
12-lead ECG heart rate, beats/min
12-wk Kaplan-Meier Rate, %
12 Carotid artery sites
12 Cl)
12 LOCF)
12 mo
12 mo, mean (SD)x
12 months
12 montlts
12% (Ito 22)
12.5 per 100 py
120-129/75-84 mm Hg
120 ml (90 to 150) (n=300/324)
120 ml (90 to 160) (n-242/236)
120 ml (90 to 160) (n=233/237)§
1200 mg (n = 201)
1200mg vs Placebo
121 to 139 mm Hg
125 to <140 mm Hg
128< SBP< 138 mmHg n = 403
128< SBP< 138 mmHg n=403
130-139/85-89 mm Hg
130 mg (N = 209)
130 mg (N = 245)
130 ml (100 to 160) (n=263/268)
130 ml (100 to 160) (n=272/267)
130 ml (90 to 160) (n=247/237)
130 ml (90 to 170) (n=205/180)
130 to <140 mm Hg — no. {%)
133-230 mg/dl
133 events,
133.83 to <149.34 mmHg
135-173 mg/dl
13O-I49 mm Hg
14.1 per 100 py
14.1 per 100 pyr
14.4 per 100 py
14.7% vs. 18.2%
140 events,
140 ml (100 to 170) (n=229/251)
140 ml (110 to 170) (n=331/285)
140 to <160 mm Hg
140 to<160mmHg
143 [106-198JS
143 f6q%)
148.0 (95%CI: 140.5, 155.6, n=60)
149.34 to <164.34 mm Hg
15-<20 yrs
15-year predicted risk (%) of
15 mg
15 mg (n=95)
15 min/time)
15 to <25 years
15+ drinks/wk
150 mg
150 mg (n=1094)
150 mg (N=110)
150 mg (N=125)
150 mg (N=72)
150 mg (N=87)
150 mg (n=92)
150 mg dabigatran
150 mg dabigatran (n=6076)
150 to < 300 cel
150 to < 300 cells
150 mg
150mg
150mg (n=80)
151.7 (95%CI: 143.5, 159.9, n=68)
154.4i11.9 (n=323)
159 (23.8%), 144 (20.8%), 9.3 per 100 7.9 per pyr 100 pyr
15mg
16.2 per 100 13.6 per 100 pyr pyr
16.8 per 100 py
160 mg
160 to <180 mm Hg
164 (95% Cl 71 to 257)
165.9i10.3 (n=573)
166 (24.9%), 147 (21.2%), 8.1 per 100 6.8 per pyr 100 pyr
1689 (10.9) (Continued )
1697 (only 1 distal)
16O/17O8 (9-4%)
17.5 per 100 py
17.6% vs. 25.6%
1700 mg/day
173 f3l%1
174 (1S.S)
175<8S)n 88(9.8)
179 events,
18-39 yr
18-40 years
18-64 yr
18 - <40 years
18 -24.9 kg/m2
18 (9.5%), 3.2 per 100 pyr
18 9.51 (0.43) [80 (4.7)] -0.64 (-0.99 to -0.29) [-7.0 (-10.8 to -3.2)] -0.82 (0.18) [-9.0 (2.0)]
18 to <40 years
18 to <65 years
180-360 min
189b (71b to 291a)
19 to <33 mm Hg
19.4 per 100 pyr
1st Tertile (<=87 mg/dL [<= 2.3 mmol/L])b
1st: 0-96.55 pmol/L
1Yr
2-10 years
2-3 days
2-5 years
2-5 yrs
2-gi
2-h PG (mmol/L)
2-h plasma glucose during OGTT (mmol/L)
2-h PMG (mg/dL)
2-h PMG (mmol/L)
2-h PMG, mmol/L (mean ± SD)
2-h postprandial C-peptide (ng/mL)
2-h postprandial insulin (mIU/mL)
2-h postprandial proinsulin (pmol/L)
2-h PPG (mmol/L)
2-h PPG (mmol/l)*
2-hour postload glucose,
2-hour PPG, mmol/L
2-Hr plasma glucose — mg/dl
2-y Kaplan-Meier rate (95% CI)
2 — no./total no. (%)
2 (60 to < 90 ml/min)
2 (FEVi 50-<80% pred)
2 5 to <30 kg/m2
2 BMI, kg/m
2 exacerbations
2 hr after glucose challenge
2 mg
2 mg (293, 25.0%)
2 mg/day
2 mg/day - placebo
2 mg/day delayed-start
2 mg/day early-start
2 mg/day early-start - delayed-start
2 mg/day early-start - delayed start
2 non-MTX
2 OADs
2 or 3
2 or 3 d/mo
2 or 3 d/wk
2 or 3 days
2 or 3 high-risk categories
2 or 3 high cardiovascular risk categories
2 or 3 step
2 or more
2 prior TNF antagonist failures, n (%)b
2 vessels
2 yr KM % (n)
2 yr. KM Rate
2, No./total No. (%)
2.0 (NE, NE)
2.0 vs 1.5
2.1 range 0-5
2.2, range 0-5
2.3 vs 2.7
2.5 mg (n = 113)
2.5 mg (n=82)
2.5 mg BID
2.59-3.35 mmol/l
2.5mg
2.6 per 100 py
2.6 vs 2.0
2.6 vs 3.1
2.7% VI. 2.9%
2.7% vs. 2.9%
2.8% vs. 5.2%
2.9 VS 1.9
"2=some restrictions; no help needed"
20 9.64 (0.52) [82 (5.7)] 0.18 (-0.19 to 0.54) [2.0 (-2.1 to 5.9)]
20 I-26-81AI
20 mg
20 mg (N = 1107)
20 mg (n = 115)
20 mg (n = 75)
20 mg (n 5 75)
20 mg (n=82)
20 mg twice daily n=169
20 mg, rosuvastatin 5 mg.
20 to <40 mm Hg
20.6 (ll.35)
200/100 mg (n = 331)
206 mgrdL
20mg
21-30 (severe)
21-35 mmol/L
21-42 mmol/L
210 (31.5%), 194 (28.0%), 12.3 per    10.6 per 100 pyr    100 pyr
213-250 mg/dl
2140 mm Hg
2160 mmHg
22 vessel PCI
224 kg/m2
225 years
23.0 per 100 py
23.7% VI, 26.3%
23.7% vs. 26.3%
2300 mg/g, n (%)
238b (78b to 223a)
24-01 mmol/L
24-Hour maDBP, mm Hg
24-Hour maSBP, mm Hg
24 months
24.5% vs. 33.7%
2400 mg (n = 196)
2400mg vs Placebo
25-29.9 kg/m2
25 - <30 kg/m2
25 - 29.9 kg/m2
25 (OH) vitamin D (ng/mL)
25 μg BID (N=185)
25 μg BID (N=200)
25 μg BID (N=231)
25 μg BID (N=245)
25 μg BID (N=47)
25 mg
25 mg empagliflozin
25 to <30 — no. {%)
25 to <30 kg/m2
25 yrs
25.0-29.9 kg/m2
25<BMI<30
250 mg
250 years
251 events,
2553 (io-6%)
25mg
25th-75th Percentiles
25th—75th Percentiles
26-21 mmol/L
26 to <43 mm Hg
260 years
265 years
2690 C.T
27-29-9, overweight
27-29.9: overweight
271b (81b to 199a)
275 Yr
280rrMnl)
29-33 kg/m2
29 (16.7%), 4.8 per 100 pyr
29.1 per 100 py
290 kg
2922 A.G
2baseline mean
2hr prandial glucose'*’
2i9 (2i.2)
2l.8 (l2.5l)
2l60mmHg
2nd >2.7/<7.5
2nd Tertile (>87 to <=120 mg/dL [>2.3 to <=3.1 mmol/L])c
2nd: 96.56-125.77 pmol/L
2or3
2S.4±S.9
2S.6±S.9
3-<6 months, n (%)
3-<6mo,n (%)
3-6 — no./total no. (%)
3-6 hr
3-6 mo
3-6 months
3-6 Months fn = 1.009)
3-6, No./totalNo. (%)
3-Blocker
3-Month Follow-Up Median (IQ Range)
3-point MACE
3-polnt MACE
3-yr KM Mortality Rate
3-yr%
3–6 months
3–6 Months
3 (30 to < 60 ml/min)
3 (FEVi 30-<50% pred)
3 (moderate disease)
3 (Moderate disease)
3 blocker
3 blocker before admission
3 blockers
3 coenzyme Q10 subgroups for time to first hospitalization (number of patients variable).
3 mo-2 y
3 months
3 mortis
3 or more
3 prior TNF antagonist failures, n (%)b
3 vessels or left main
3 year mean change from baseline
3.0 VS 3.2
3.2 VS 2.7
3.2 vs 3.2
3.3 vs 2.6
3.3 vs 3.1
3.36-4.12 mmol/l
3.4 - < 33.9 mg/mmol
3.4 to #33.9 mg/mmol
3.5 per 100 py
3.6 per 100 py
3.6 vs 2.9
3.6 vs 3.9
3.6 vs 4.3
3.8 per 100 py
3.8 vs 3.5
3.9 (LO-7.5)
3.9 (LO-7.7)
3.9 per 100 py
"3=help needed; still independent"
30−300 mg/g
30-300 mg/g
30-34-9, obesity class 1
30-34.9: obese class I
30-44 yr
30-49 ml/min
30-49 ml/min/1.73 m2
30-50 mL min)1
30-50 mL/min
30-50 mL/rain
30-60 CrCl
30–≤50 mL/min
30 - <35 kg/m2
30 - <50 mL/min
30 - <60 mL/min
30 (15.8%), 5.0 per 100 pyr
30 days composite of death/new MI/urgent revascularization and definite ST
30 days definite ST
30 days new MI
30 days new MI or definite acute ST
30 days stroke (ischemic)
30 days until end of study (Landmark analysis)
30 days urgent revascularization
30 kg/m2 or more
30 mg
30 mg (n = 74)
30 mg (n 5 74)
30 mg QD (n = 140)
30 mg twice daily n=167
30 mg/g
30 months
30 to <35 kg/m2
30 to <40 years
30 to <50 ml/min
30 to <50 mL/min
30 to <50 mUmin
30 to <60 mL per 1-73 m2
30 to <60 ml/min
30 to <60 mL/min per 1.73 m^
30 to <60 ml/min/1.73 m2
30 to <60 ml/minute
30 to 300 mg/g
30 to less than 60
30 to o 60 mL/min/1.73 m2
30 wk
30.0-44.9 ml/min/1.73 m2
300 mg
300 mg (n = 72)
300 mg (n=1132)
300 mg clopidogrel load
300 mg LD
300 mg Q4W
300 mg
300mg (n=81)
300Q4W (n = 146)
30e< 50%, n (%)
31-40 (very severe)
31-90 days (%)
31.6 vs 46.7
312b (94b to 237a)
316 events,
325 mg
33 events[1.1]
33.1 per 100 py
33.8i6.4 (n=564)
33.9i6.4 (n=572)
33.l (7.l)
33S f21)
35-39-9, obesity class 2
35-39.9: obese class II
35 to <43 mg/dl
35 to <50 years
35% Cl
35.1 per 100 py
35.8 per 100 py
361-720 min
361 events[13.7]
365b (87b to 167a)
37 events[1.2]
37.3 per 100 py
382 events,
39.5 per 100 py
3MS score†
3rd >7.5
3rd Tertile (>120 mg/dL [>3.1 mmol/L])d
3rd: 125.89-154.80 pmol/L
4-5(<30 ml/min)
4-6 — no. (%)
4-8 days
4-point MACE
4-point MACE (3-point MACE plus hospitalization for unstable angina)
4‐point reduction in SELENA–SLEDAI score, %
4-year cumulative incidence, % (CI)
4-year rates in placebo groups
4 (FEV1 <30% pred)
4 (severe disease)
4 (Severe disease)
4 mg
4 mg a
4 or more
4 TCZ+MTX
4 TCZ+MTX MTX
4 week
4 yrs L
4.0 per 100 py
4.1 vs 4.1
4.1 vs 5.9
4.1% vs. 5.1%
4.3 vs 4.2
4.4 vs 3.7
4.4±20.lf
4.5 per 100 py
4.5 vs 4.1
4.5 vs 4.6
4.7 vs 4.7
4.8 per 100 py
4.9 vs 2.8
40-59 yr
40-60 with CV Disease (n=1761)
40-60, CV disease (n=1,761)
40 - <50 years
40 (21.1%), 8.0 per 100 pyr
40 mg
40 mg (n=79)
40 mg eow N = 161
40 mg eow n =99
40 mg ew n = 150
40 mg ew n =107
40 to <50 years
40 to <65 years
400/200 mg (n = 331)
41-64 years
41 (19.3%), 6.4 per 100 pyr
41 8.35 (0.30) [68 (3.3)] -0.68 (-0.85 to -0.51) [-7.4 (-9.3 to -5.6)] -0.64 (0.12) [-7.0 (1.3)]
410/week (n=371)
42 7.44 (0.34) [58 (3.7)] -0.42 (-0.63 to -0.21) [-4.6 (-6.9 to -2.3)]
42 years
420/day
43 to <65 mm Hg
430 min twice/week
438 events[17.0]
44.6±ii.5
44.8 vs 39.4
45-54 years
45-54 yr
45-54 yr(%)
45-64 yr
45-73 (men)
45 mg
45 to <60 mL/min/1,73m2
45.0-59.9 ml/min/1.73 m2
45.0±ii.6
45.i±ii.6
46 8.37 (0.27) [68 (3.0)] -0.04 (-0.20 to 0.13) [-0.4 (-2.2 to 1.4)]
47 (49 Cl)
47 min
48 (25.3%), 9.6 per 100 pyr
48.5 vs 41.4
48.6 vs 46.2
489 events,
49 7.32 (0.54) [56 (5.9)] -0.79 (-1.00 to -0.57) [-8.6 (-10.9 to -6.2)] -0.36 (0.11) [-3.9 (1.2)]
49.1 (io.i)
"4S=Scandinavian Simvastatin Survival Study.13 WOSCOPS=West of Scotland Coronary Prevention Study.14 CARE=Cholesterol And Recurrent Events.15 Post-CABG=Post-Coronary Artery Bypass Graft.16 AFCAPS/TexCAPS=Air Force/Texas Coronary Atherosclerosis Prevention Study.17 LIPID=Long-term Intervention with Pravastatin in Ischaemic Disease.18 GISSI Prevention=Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico.19 LIPS=Lescol Intervention Prevention Study.20 HPS=Heart Protection Study.21 PROSPER=PROspective Study of Pravastatin in the Elderly at Risk.22 ALLHAT-LLT=Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.23 ASCOT-LLA=Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm.24 ALERT=Assessment of Lescol in Renal Transplantation.25 CARDS=Collaborative Atorvastatin Diabetes Study.26 S=simvastatin.
L=lovastatin. P=pravastatin. F=ﬂuvastatin. A=atorvastatin. *Mean duration of follow-up based on survival times within each trial. Overall mean is weighted by trial-speciﬁc variances of logrank (o–e) for major vascular events. †All trials included dietary intervention: WOSCOPS, GISSI Prevention, LIPID, 4S, LIPS, and HPS provided dietary advice; AFCAPS/TexCAPS, Post-CABG, CARE, ALLHAT, ALERT, CARDS, and PROSPER used American Heart Association (AHA) Step 1 diet and CARE intensiﬁed to Step 2 diet if LDL cholesterol  4·5 mmol/L (175 mg/dL). ‡Other CHD includes patients with a history of other symptomatic CHD but excludes those with a history of MI (as already counted in MI column). §Other vascular includes history of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, and peripheral artery disease. ¶None includes individuals without a history of MI, symptomatic CHD, intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, or peripheral artery disease"
4th: 154.81 -400 pmol/L
5-<10 yrs
5-7/week (n = 684)    8-10/week (n = 314)
5-Aminosalicylates{
5-aminosalicylates|| ||
"5-Aminosalicylates’i""i‘"
5-Aminosalicylic compounds — no. (%)
5-ASA compounds, n (%)
5 μg (n=208)
5 μg (n=209)
5 231 mg/dl
5 75 years, n (%)
5 mentis
5 mg
5 mg ( n = 117)
5 mg BID
5 mg/kg
5 to <15 years
5 years
5.0 (3.O-7.O)
5.0±l.l
5.1 per 100 py
5.18-6.20 mmol/l
5.3 per 100 py
5.4 per 100 py
5.4 vs 3.4
5.4% vs. 7.8%
5.5-8.5 mm
5.5 or more
5.5 VS 5.2
5=70 yr — no. (%)
50-<80 ml/min
50-<80 mVmin
50-59 yr
50-64 years
50-67 years
50-79 ml/min
"50-80 mL min""1"
50-99 kg
50–<80 mL/min
50—80 nlMW
50 - <100 kg
50 - <65 years
50 - <80mL/min
50 μg BID (N=178)
50 μg BID (N=193)
50 μg BID (N=239)
50 μg BID (N=254)
50 μg BID (N=38)
50 mg
50 mg (n=1089)
50 mg (n=92)
50 mg + MTX
50 mg sirukumab every 4 weeks (n=292)
50 to <100 kg
50 to <60 m Um in
50 to <65 years
50 to <80 ml/min
50 to <80 mL/min
50 to <80 mL/min (n=10 697)
50 to 69 y, n (%)
50 mg
50% decrease in WOMAC pain score
50.3 vs 40.6
50.8 ±b.b
50mg
50mg/100 mgc
5112 mg/dl
5151 mg/dl LDL cholesterol ||
5174 mg/dl
523 kg/m’
5251 mg/dl
531.5 mg/dl Triglycerides^
539 mg/dl
54 to <66 mg/dl
55-64 years
55-64 yr
55-64 yr — no. (%)
55-64 yr(%)
55-73 (women)
56 wk
56.0 (I0.S)
56.0 vs 48.5
565 years
566 yr
57 (26.9%), 11.2 per 100 pyr
570 kg
570 yr
58%, n (% of patients)
58.2 (1 l.l)
581(14.1 )/532Z(1Ze)
595 tQ-fi'i
5fe Black*
5ii (49.2)
5l (l5)
5l.5 (l0.5)
5mg
5mg (n=93)
6-10/day
6-12 months
6-12 Months (n = 886)
6-12 months, n (%)
6-mercaptopurine
6-Mercaptopurine
6-mercaptopurine/azathioprine
6-min walk distance (m)
6-min walk distance m
6-min walk distance, ft
6-Minute walk distance — m
6-UP and/or AZA at baseline
6-y Incidence Rate (SE) per 100 Participants
6-y Rate per 100 Persons (SE), n
6-Year KM %
6–12 months
6–12 Months
6 days
6 mg/kgf (N = 209)
6 mg/kgf (N = 249)
6 mo
6 mo to 2 yr
6 months
6 mq/kq*
6.0 per 100 py
6.0% vs. 7.6%
6.2 per 100 py
6.2% vs. 11.0%
6.3 per 100 py
6.3 vs 6.3
6.4 vs 7.6
6.5 (G.l)
6.8 VS 7.4
6.9 per 100 py
60-80 with CV Disease (n=4096)
60-80 with CV Risk but not Disease (n=2285)
60-80, CV disease (n=4,096)
60-80, risk, not disease (n=2,285)
60-90 ml/min/1.73m2
60 mg
60 mg cohort
60 mg QD (n = 158)
60 ml (20 to 90) (n=213/242)
60 ml (30 to 90) (n=304/306)
60 ml (30 to 90) (n=321/290)
60 to <100 kg
60 to <70 yr
60 to <70 yr — no. {%)
60 to <90 kg
60 to <90 mL min’1 1.73 m'2
60 to <90 mL per 1-73 m2
60 to <90 mL/min per 1.73 m^
60 to <90 ml/min/1-73
60 to <90 mL/min/1,73m2
60 to <90 ml/min/1.73 m^
60 to <90 ml/min/1.73 m2
60 to <90 mL/min/1.73m2
60 to <90 ml/minute
60 to <90kg
60 to 130 ml/min per 1.73 m2, n (%)
60 to less than 90
60 to o90 mL/min/1.73 m2
60.4 vs 41.4
600 mg
600 mg clopidogrel load
61-65 yr
61.4 vs 48.4
61.9 (lO.I)
62.5 yrs
629 (6i.i)
63.3 vs 48.8
63.3 vs 49.6
64.0 vs 54.3
65-<75 years
65-69 vr — no. (%)
65-69 yr
65-74 years
65-74 yr
65-75 years
65-89 yr
65—<75 years
65—75 years
65 - <75 years
65 to <75 years
65 to <75 yr
65 to <75 yr — no. (%)
65 to 74 y (N=7134, 33.8%)
65 to 75 yr
65 years or older
65 years, n (%)
65 yrs or more
65.2 vs 49.3
65+, No. (%)
68.8 vs 53.0
6mo
6moto<1 yr, n (%)
6MW Distance, m
6MWD decrease >50 m
6MWD, m
6MWT (m)
7 (7 SI
7 days
7 events, 0.1 per 100 py (0.0-0.2)
7.0% vs. 6.3%
7.1 per 100 py
7.2 (95%CI: 7.1,7.4, n=178)
7.3 (95%CI: 7.2, 7.4, n=185)
7.4 per 100 py
7.5% or more
7.6 VS 5.7
7.7 per 100 py
7.7% vs. 8.2%
7.8% vs. 8.2%
70-74 yr
70 (33.0%), 13.8 per 100 pyr
70 ml (30 to 110) (n=271/260)
70 ml (30 to 110) (n=302/289)
70 ml (40 to 110) (n=335/350)
70 to <72 bpm (n=987)
70 to <90 kg
70.9 vs 55.3
72 to <75 bpm (n=1364)
72/134 (53.7) (continued)
74.5 min
75-81 years
75-84 y, n (%)
75—<85 years
75 mg
75 to <80 bpm (n=1545)
75 to <85 mm Hg
75 Years (n=2010)
75 years or older
759(12J)Z728(11.e
75mg (n = 77)
75Q2W (n = 37)
8-30 days
8-9 days
8—9 days
8 TCZ+MTX
8 week
8% < HbA1c <= 9%
8% < HbA1c <= 9% (n 5 158)
8% < HbA1c <= 9% (n 5 161)
8.0 to <9.0% (64 to <75 mmol/mol)
8.1 per 100 py
8.2 per 100 py
8.3 ± O.lt
8.6 per 100 py
8.8 vs 8.5
80 mg
80 ml (40 to 130) (n=226/199)
80 ml (50 to 120) (n=290/289)
80 ml (60 to 110) (n=352/322)
80 to <87 bpm (n=1287)
80±ll
83.4 ± l.Ot
84 events,
85 to <101 mg/dl
87 nil
87.l (2l.3)
8TCZ
9-12 years
9-13.5 mm
9 to <12 mo
9% (Oto 17)
9% (Oto 18)
9.'^/5t7C}    u
9.0 to <10.0% (75 to <86 mmol/mol)
9.0% vs. 9.1%
9.1 per 100 py
9.3 vs 9.0
9.6 ± O.lt
9.6 per 100 py
9.7 per 100 py
9.9% vs. 16.5%
90-Day CCE
90-Day Mortality
90 mg
90 mg cohort
90 mg/12 wk (N = 132)
90 mg/8 wk (N = 132)
90 ml (50 to 120) (n=199/219)
90 ml (50 to 130) (n=259/260)
90 ml (60 to 120) (n=244/274)
90 ml (60 to 120) (n=261/258)
90 or greater
91.9i7.1 (n=342)
924b (87b to 107a)
95-105 mg/dl
95% C.I.
95% CI
95% CI 0.59-1.02
95% CI for difference
95% CI2
95% CIt
95% Cl
95% Clf
95% confidence interval
95%CI
950-1275 ft
97.9i8.3 (n=565)
98 (14.7%), 78 (11.2%), 4.9 per 100 3.8 per pyr 100 pyr
98.8i7.1 (n=573)a
A
a-blocker
a-Blocker
a-Blockers
α-glucosidase inhibitor
a-Glucosidase inhibitor
a-Glucosidase inhibitors
a-Glucosidase inhibitors'1
a 75 years
A A (340 (%)
A Cardiovascular Death or Hospitalization for Heart Failure
A Compared w
A Compared wi
A decrease of >100 points in the CDAI score
a Excludes two randomized patients with unknown diabetes status at baseline.
A from baseline
A from baselineb
a Median
A Mini-Mental State Examination, insulin glargine vs standard care
A Mini-Mental State Examination, omega-3 fatty acids vs placebo
a New Vertebral Fractures (mFAS)
A ngina >7 day s previously *
A Prebronchodilator FEVl (% predicted)
A Reslizumab 0.3 mg/kg n/N
A Severe Hypoglycemia
A Stroke
A vs. C
a) Those receiving no inhaled pre-treatment maintenance medication
a, no VhD (n=14 162)
A. ACR 20
A. Beuralizuinab 30 ing Q4W
A. Overall and subgroups bv statin potency    --
A. Primary Composite Outcome
A/AML (n = 119)
A/AML (n = 142)
A/AML (n = 76)
A/AML (n = 96)
A/C
A/Ga
A/V (n=200)
A/V (n=574)    V (n=565)
A/V(n=17)    V (n=14)
A/V(n=63)    V (n=51)
A: Worldwide Black and Non-Black Patients
A10 + E10 (n = 526)
A10 vs placebo
A10=6.4% (Median)
A1C
A1C (%)
A1C (mmol/mol)
A1C [n (%)]
A1c < Median
A1C <6.5%
A1C <7.0%
A1C >= Median
A1C at baseline <9.0%
A1C at baseline ≥9.0%
A1C distribution (%)
A1C, %
A1C, % (mmol/mol)
A1C<6.4% (Median)
A20/40 (n = 527)
A24S-hydroxy-
a30 kg/m2
A40 + EZ n = 136    A80 n = 140
A40 + EZ n = 225
A40 + EZ n = 89
A40 + EZ10
A40 + EZ10    A80 (n = 61)    (n = 66)
A40 + EZ10    A80 (n = 67)    (n = 68)
A40 + EZIO    A80 (n = 149)    (n = 145)
A7C >8.5-9.0%
A7C >9.0%
A7C >S.0-S.5%
A80 n = 222
A80 n = 82
A9.2±1A.6
AA
AA, mol%
Aa/G
AAb42 (%)
AaPo2 at rest, mm Hg
AB 400 pg(N=720)
AB/FF 400/12 pg (N = 720)
Abaloparatide-SC, n (%)
Abatacept
Abatacept (n=213*)
Abatacept ~10 mg/kg (n = 128)
Abatacept ~10 mg/kg (n = 139)
Abatacept 10/10 (n = 99)
Abatacept 3 mg/kg (n = 130)
Abatacept 3 mg/kg (n = 70)
Abatacept 30/—10 mg/kg (n = 141)
Abatacept 30/—10 mg/kg (n = 65)
Abatacept 30/10 (n = 99)
Abatacept monotherapy (n=116)
Abatacept plus MTX (n=119)
Abatacept/open-label abatacept
Abatacept‡
"Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DM, diabetes mellitus; HbA1c, hemoglobin A1c; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A. aSome subjects took more than 1 oral anti-DM drug in addition to metformin, and thus the total number of concomitant oral anti-DM drugs in the columns exceed the “n” values in the colesevelam hydrochloride and placebo group headings. bSulfonylureas include chlorpropamide, glibenclamide, glimepiride, glipizide, and tolazamide. cThiazolidinediones include pioglitazone, pioglitazone hydrochloride, rosiglitazone, and rosiglitazone maleate. d -Glucosidase inhibitors include acarbose or miglitol."
"Abbreviations: ACE, angiotensin-converting enzyme; IQR, interquartile range; Ml, myocardial infarction. SI conversion: To convert creatinine clearance to mL/s, multiply by 0.0167. *Data are expressed as No./total (%) unless otherwise specified. fEstimated using Cockroft-Gault equation. tThe TIMI risk score was used to categorize patients at low (0-2), intermediate (3-4), and high (5-7) risk.4"
"Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; bpm, beats per minute; CCB, calcium channel blocker; MSDBP, mean sitting diastolic blood pressure; MSSBP, mean sitting systolic blood pressure. Values are No. (%) unless otherwise indicated. aMean ± SD. bMore severe, >160 and <180 mm Hg/>100 and <110 mm Hg; less severe, >140 and <160 mm Hg/>90 and <100 mm Hg. Blood pressure at baseline is with monotherapy (ie, before switch to amlodipine/valsar-tan therapy)."
"Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; NSAIDs, nonsteroidal anti-inflammatory drugs; PCI, percutaneous coronary interventions. *Values expressed as number (percentage) unless otherwise indicated. Percentages may not equal 100 due to rounding. fHistory of or currently taking antidiabetic or lipid-lowering medications. ^History of or currently have elevated serum creatinine level but less than 4 mg/dl_ (<354 pmol/L). §Patients with a history of skin, prostate, and other cancers with long survival expectancy were not excluded. ||lnsulin and/or oral hypoglycemics. IlData for women only (n = 5850 for calcium antagonist strategy and n = 5920 for non-calcium antagonist strategy)."
"Abbreviations: CHD, coronary heart disease; Cl, confidence interval; Ml, myocardial infarction; RR, relative risk. ^Defined as a composite end point comprising the first of any of these events: nonfatal Ml, nonfatal stroke, or cardiovascular death. tP value for interaction <.05 for major cardiovascular event. No other interactions are significant. ^Calculated as weight in kilograms divided by the square of height in meters. §Hypertension was defined as a self-reported systolic blood pressure >140 mm Hg, a diastolic blood pressure >90 mm Hg, or physician-diagnosed hypertension. ||Hyperlipidemia was defined as a self-reported total cholesterol >240 mg/dl_ (6.2 mmol/L) or physician-diagnosed high cholesterol. ^Diabetes defined by self-report. #Calculated using the Framingham risk score among 28 345 women who provided a blood sample at baseline."
"Abbreviations: DA, disc area; E-ETDRS, electronic Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; OCT, optical coherence tomography."
"Abbreviations: eGFR = estimated glomerular filtration rate; IMT = intimal medial thickness; LV = left ventricular.
*
Two-sample comparison t-tests were calculated based on log-transformed variables.
**
Geometric mean with 95% confidence interval in parenthesis."
"Abbreviations: TEAE, treatment-emergent adverse event; GLY, glycopyrrolate inhalation solution; BID, twice daily."
Abciximab
ABCIXIMAB
Abciximab-Facilitated PCI
Abciximab-Facilitated PCI (n = 818)
Abciximab-Facilitated PCI (N = 818)
Abciximab (n = 401)
Abciximab (N=1079)
ABCIXIMAB (N=149)
ABCIXIMAB (N=2411)
Abciximab (n=377)
Abciximab (n=401)
Abciximab (n=630)
Abciximab (n=635)
Abciximab No./total (%)
Abciximab vs. Primary
Abdominal aortic — no. (%)
Abdominal Obesity
Abdominal obesity*
Abdominal or perianal fistula at baseline, n (%)
ABI
ABI #0.90
ABI <0.85
ABI <0.9
ABI >1.3
ABI >1.4
ABL-SC mean
ABL-SC n/N
Abnormal
Abnormal angiogram
Aborted cardiac arrest
About 100 mg/L or more
About 20 mg/L
About 50 mg/L
Abrupt vessel closure
Absence
Absent
Absent (<100 mg/dL)
Absent (<110 mg/dL)
Absolute  Change
Absolute (L)
Absolute decline in FVC >10% predicted
Absolute decline in FVC >10% predicted or death, n (%)
Absolute decline in FVC >5% predicted
Absolute decline in FVC >5% predicted or death, n (%)
Absolute decrease >10%
Absolute decrease >5%
Absolute difference estimate vs placebo (95% CI)
Absolute FVC decrease >10%
Absolute reversibility in FEV1, mL*
Absolute risk difference (95% Cl)
Absolute Risk Difference (CI), %*
Absolute Risk Reduction (95% CI), %/y
Absolute Risk Reduction (95% Cl)*
Absolute risk reductions
Absolute time spent “on” with troublesome dyskinesia, h/day
Absolute time spent “on” without troublesome dyskinesia, h/day
Absolute time spent “on”, h/day
Absolute, litres
Absolutedifferenceestimate vs placebo(95% CI)
Abx-Facil. PCI
Ac tve cancer
Acarbose 一 no. (%)
ACC/AHA lesion class B2 or C, n (%)
Access site
ACCORD ACR <3-4
ACCORD ACR >3-4
ACCORD primary, n (%)
ACCP bleeding risk at inclusion, No. (%)f
ACCP score
ACD
ACE
ACE-I (n, %)
ACE-I or angiotensin receptor blocker
ACE-I or ARB
ACE‐I or ARB
ACE-I or ARB Use
ACE-I or ARB use at baseline
ACE-I or ARB, % (n)
ACE-I/ARB
ACE-I/ARB, (%)
ACE-Inhibitor or ARB (%)
ACE-inhibitor use
ACE-inhibitors
ACE-inhibitors, n (%)
ACE-inhibitors/ARBs, n (%)
ACE-l/ARBs
ACE-lorARB
"ACE = angiotensin-converting enzyme; CABG = coronary artery bypass graft; CCSC = Canadian Cardiovascular Society classification; MI = myocardial infarction; PCI = percutaneous coronary"
AcE inhibitor
ACE inhibitor
ACE inhibitor— no. (%)
ACE inhibitor /ARB
ACE inhibitor and/or ARB
ACE inhibitor at enrollment
ACE inhibitor at last follow-up
ACE inhibitor monotherapy
ACE inhibitor or angiotensin-receptor blocker — no./total no. (%)
ACE inhibitor or angiotensin II receptor
ACE inhibitor or angiotensin II receptor blocker
ACE inhibitor or angiotensin receptor blocker
ACE inhibitor or ARB
ACE inhibitor or ARB at enrollment
ACE inhibitor or ARB at last follow-up
ACE Inhibitor or ARB Use
ACE inhibitor treatment
Ace inhibitor use (%)
ACE inhibitor Yes
ACE inhibitor, %
AcE inhibitor, ARB, or both
ACE inhibitor, n (%)
ACE inhibitor/ARB
ACE inhibitor/ARB therapy
ACE inhibitor/ARB, %
ACE inhibitors
ACE Inhibitors
ACE inhibitors and ARB
ACE inhibitors or angiotensin-receptor blockers
ACE inhibitors or angiotensin-receptor blockers^
ACE inhibitors or angiotensin II
ACE inhibitors or angiotensin II blockers
ACE inhibitors or Angiotensin Receptor Blockers
ACE inhibitors or ARB
ACE inhibitors or ARBs
ACE inhibitors through hospital discharge or day 7 — %
ACE inhibitors/ARB
ACE inhibitors/ARBs
ACE inhibitors/ARBs, n (%)
ACE inhibitors/sartans
ACE or ARB
ACE/ARB
ACE/ARB medication (%)
ACE/ARB use
ACE/ARB users
ACE=angiotensin-converting enzyme. ARB=angiotensin receptor blockers.
Acecoumarol, No. (%)
ACEI
ACEI and/or ARB
ACEi or ARB
ACEI or ARB
ACEi vs. non-ACEi
ACEi, n (%)
ACEi/ARB
ACEI/ARB
ACEi/ARB therapy, n (%)
ACEIs
"ACEIs, angiotensin-converting enzyme inhibitors; C, candesartan; DES, drug-eluting stent; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NC, non-candesartan."
ACEIs, n (%)
ACEIs/ARBs
Acenocoumaroi
Acetaminophen
Acetyl-salicylic acid
Acetylsalicylic acid
ACholesterol (%)
Acid
Acitretin
Aclidinium 400 pg
Aclidinium 400 pg vs placebo
Aclidinium 400 μg (n = 269)a
Aclidinium 400 μg (n = 337)a
Aclidinium 400 μg (n = 583)b
Aclidinium 400 μg (n = 720)
Aclidinium 400 μg BID (n = 22)
Aclidinium 400 μg BID (n = 223)
Aclidinium 400 μg BID (n = 296)
Aclidinium 400 μg BID (n = 42)
Aclidinium 400 μg BID (n = 583)
Aclidinium/formoterol 400/12 pg twice daily
ACM
ACPA positive
ACPA positive (>7 IU/mL), n (%)
ACPA positive, %
ACPA positive, n (%)
ACPA positive, no. (%)
ACQ-5 score
ACQ-5 score'!'
ACQ-6 score
ACQ-6 score*
ACQ-6 score, mean (SD)e
ACQ-6 score本
ACQ-6 scoret
ACQ-7 total score∗
ACQ score, mean
ACQ5 score
ACQ6 score, mean (SD)
ACR
ACR (mg/g), mean (SD)
ACR > 30 mg/g
ACR Deciles
ACR functional class, n (%)
ACR response by baseline MTX use, no./total no. (%) ACR20
ACR response by baseline weight,
ACR response, %
ACR response, % ACR20
ACR, mg/mmol
ACR20
ACR20 response
ACR20 response at week 16, n (%)
ACR20 response, n/N (%)
ACR20 Week 12 Responders, (n = 72)
ACR50
ACR50 response
ACR50 response, n/N (%)
ACR70
ACR70 response
ACR70 response, n/N (%)
ACR90
ACS
ACS (n - 4,584)
ACS (n = 4,584)
ACS Event
ACS management, no. (%)
ACS presentation
ACS treatment
ACS type
ACT-2
ACT total score ≥ 20
ACT total score ≥ 20 and/or improvement from baseline ≥ 3
ACT.1
action tested is between the continuous variable and treatment.
Active
Active-Control Study
Active (n=5569)
ACTIVE A
Active Canakinumab (n = 1,249)
Active Canakinumab (n = 5,467)
Active cancer
Active Cancer
Active cancer — no. (%)
Active cancer at any timeb
Active cancer at baseline
Active Cancer at Randomisation
Active Cancer at Randomization
Active cancer at randomization, n (%)
Active comparatorb
Active inflammatory bowel disease
Active or previous cancer
Active PSO wi111 BSA > 3%, n (.%y
Active smoker
Active smokers
Active smoking
Active treatment
Active vs placebo
Active versus placebo
Activities of Daily Living UPDRS subscore (baseline), mean (SD)
Activity
Activity (0-100 VAS)
activity (range 0-100), mean ± SD
Activity limitation
Actual (L)
Actual or estimated weight, kg
Actual treatment strategy
ACUITY-bleeding major/minor
ACUITY-defined bleeding
ACUITY major
ACUITY Major
ACUITY major or
ACUITY minor
Acute (<24 hr)
Acute and delayed reaction
Acute coronary event
Acute coronary syndrome
Acute coronary syndrome 3025
Acute DVT Study
Acute Increase in Serum Creatinine
Acute infection without septic shock
Acute medication intake (days/month)
Acute reaction
Acute Reperfusion
Acute respiratory insufficiency
Acute rheumatic disorders
Acute stent thrombosis
Acute Stent Thrombosis (definite or probable)
Acute stroke of other determined cause
ADA 160/80 (N[130)
ADA 160/80 N[130
ADA 80/40 (N[130)
ADA 80/40 N[130
ADA IFG
ADA Impaired Fasting Glucose
ADA, no
ADA, yes
Adalimumab
Adalimumab (n = 480)
Adalimumab (n = 70)
Adalimumab (n = 966)
Adalimumab (n=330)
Adalimumab Croup, n/n (%)
Adalimumab Group (n = 159)t
Adamantane derivatives
ADAS-cog score*
ADAS—cog score
ADCS-ADL score*
Add-on to MET
Add-on to MET + SU19
Add-on to MET+SU
Add-on to MET18
Additional angiography
Additional antihypertensive subgroup
Additional endpoints
Additional heparin
Additional investigations
Additional radiographic findings at week 24
Additional subgroup analyses
ADHERE
Adherence >80%
Adherence to study regimen — no. (%)
Adherence to study regimen — no. (%)ff
Adiusted Hazard Ratio*
Adj. HR (95% Cl)a
Adjudicated MACE5
Adjusted
Adjusted    1 OR (95% Cl)
Adjusted change from baseline
Adjusted change from baseline Mean (s.e.)
Adjusted exacerbation rate (per patient peryear)
Adjusted exacerbation rate {per patient peryear)
Adjusted for all baseline variables and interaction between ACEI and baseline UPb
Adjusted for all baseline variables, interaction between ACEI and baseline UP, and declines in SBP and UP
Adjusted for all baseline variables6
Adjusted hazard ratio (95% CI)†
Adjusted Hazard Ratio (95% Cl)*
Adjusted hazard ratio ≠ (95% CI)
Adjusted Hazard Ratio*
Adjusted Hazard Ratio§(95% CI)
Adjusted Hazard Ratio‡(95% CI)
Adjusted HR (95% CI)
Adjusted HR (95% CI)* Compared With No Diabetes at BL or at Year 2
Adjusted HR (95% CI)* Comparing IDM With BL
Adjusted HR (95% Cl)
Adjusted HR (ENL vs LCZ) (95% Cl)
Adjusted HR Losartan vs Atenolol*
Adjusted HR* (95% CI)
Adjusted HR* (95% CL) pValue
"Adjusted HR; 95% CI"
Adjusted mean (SE)
Adjusted mean (SE) FEVi AUCo_3, mL
Adjusted mean (SE) trough FEVi, mL
Adjusted mean _ SE change from baseline
Adjusted mean ± SE change from baseline
Adjusted mean change
adjusted mean change (kg)
Adjusted mean change from baseline
Adjusted mean change from baseline (95% CI), % [mmol/mol]
Adjusted mean change from baseline (SE)
Adjusted mean difference (95% CI)
Adjusted mean±SE (95% CI)
Adjusted modelc HR, 95% CI, P value
Adjusted OR (95% CI)b
Adjusted OR (95% CI)c
Adjusted OR (95% Cl)
Adjusted P-value for Interaction
Adjusted Rate of FEV1 Decline (SE), ml/yr
Adjusted rate of hospitalized pneumonia events (per patient-year), mean (95% CI)
Adjusted rate of pneumonia events (per patient-year), mean (95% CI)
Adjusted* OR (95% CI) P Value
Adjusted* HR
Adjusted∗ mean (SE) (mL)
Adjusted∗ mean of difference (SE) (mL)
Adjusted⁎Hazard Ratio (95% CI)
Adjusted3 Risk Reduction Losartan vs Placebo (95% Cl)
AdjustedaHR
AdjustedaOR
Adjustedb,c Beta (SE)
ADL
ADL subscale (range, 0-52)*
Administration of study-drug bolus — no./total no. (%)
Administration of study drug (%)
Admission for HF in previous year
Admission for HF in previous year, n (%)
Admission GRACE score
Adolescents (aged 12-17 y), No. (%)
ADP Antagonist
Adults (aged ≥ 18 y), No. (%)
Advanced, n (%)
Adverse event
Adverse events (any grade)
Adverse events leading to premature treatment discontinuation
Adverse eventy
Adverse outcome
Ae' (per cm/s)
AE/A ratio (per 0.1 unit)
AE/e' ratio (per 1 unit)
AED inducer status
Aerobic Activity
Aerobic exercise
AEs in ≥2 Japanese patients in a study arm, n (%)§
AEs leading to
AEs leading to discontinuation of study drugb
AEs leading to dose reduction of study drugb
AEs related to
AEs*
Aetiology of PAH
AF
AF alone
AF alone refers to atrial fi-brillation without coexisting cardiovascular conditions but with left atrial dilatation. ACE denotes angiotensin-con-verting enzyme, HF heart failure, and LVD left ventricular dysfunction.
AF duration, n (%)
AF first diagnosis >2 years, n (%)
AF on baseline ECG, n (%)
AF or atrial flutter!
AF or atrial flutter卞
AF pattern
AF Pattern
AF type
AF Type
AF type — no. (%)
AFCAPS/
Affected body-surface area >3% — no. {%)
Africa
Africa ! Near East
Africa or Near East
Africa*
Africa, Asia, or the Middle East
African
African-American
African-American / African Heritage (n=129)
African-American/African heritage (n=129)
African-Latin American
African America
African American
African American N = 228
African American, n (%)
African American/black
African Americans
African descent
after 48 h
After amendment
After Amendment (%)
After bronchodilation
After bronchodilator use
After PCI
AG
AG+GG
Aga Group
Age
AGE
age-interaction
Age— yr
Age—mean (SD) (years)
Age—year (median)
Age ' 70 y (n 1220)
Age '^75 yrs
Age - mean (sd) years
Age - years
Age - years, Median (IQR)
Age — y, meantSD
Age — y£
Age — yr
Age — yr Age group — no. (%)
Age — yr Race — no. (%)f
Age — yrf
Age —yr
Age #75 yrs
Age $65 years§*
Age $65 yrs
Age $75 yrs
Age &65
Age ( years)
Age (median [IQR]), y
Age (median, IQR), y
Age (median, years)
Age (p=O-53)
Age (per 5 years)
Age (range) (years)
Age (SD), y
Age (y)
Age (y) [mean - SD]
Age (y)∗
Age (y), mean (range)
Age (y), mean (SD)
Age (y), median (25th to 75th percentiles)
Age (y), median (IQR)
Age (y), median (min, max)
Age (y), median (min, max}
Age (year)
Age (year), mean±SD
Age (years (s.d.))
Age (years)
Age (Years)
Age (years) - < Median (n=195, 206)
Age (years) - >= Median (n=228, 217)
Age (years) - mean ± SD
Age (years) (mean ± SD)
Age (years) (mean, SD)
Age (years) [median (25th to 75th percentile)]
Age (years) Mean (SD)
Age (years) mean ± SD
Age (years)*
Age (years), mean (s.d.)
age (years), mean (sD)
Age (years), mean (SD)
Age (years), mean _ SD
Age (years), mean ± s.d.
Age (years), mean ± SD
Age (years), mean±SD
Age (years), Mean±SD
Age (years), median (range)
Age (years):
Age (years): <65
Age (years): >75
Age (years): 65-<75
Age (years): mean ± SD
Age (years)+
Age (years)a
"Age (years; SD)"
Age (yij
Age (yr)
Age (yr)*
age (yr), mean (SD)
Age (yr), mean (SD) BMD T-score, mean (SD)
Age (yrs)
Age (yrs) <51
Age (yrs) 18-40
Age (yrs), mean *
Age (yrs), mean ± SD
Age ,65 years
Age [year], mean ± SDa
Age [years]
Age [years] (Interaction: p=0.55)
Age [years], median (range)
Age ^65
Age ^75 yrs, n (%)
Age £75
Age £75 years (ITT) (n=154)
Age £75 years (ITT) (n=171)
Age < 65
age < 65 years
Age < 65 Years
age < 65 years old
Age < 65 yrs
Age < 75
Age < 75 years
Age < 85
Age < Median
Age <51 Gd Lesion >1 N=72
Age <51 Gd Lesion=0 N=143
Age <60 years
Age <60 years and BMI <24 kg/m2
Age <60 years and BMI ≥24 kg/m2
Age <60 yr
Age <65
Age <65 vears n = 1401
Age <65 vears n=1159
Age <65 y
Age <65 years
Age <65 years — no. (%)
Age <65 years (ITT) (n=1178)
Age <65 years (ITT) (n=895)
Age <65 years (n=1192)
Age <65 years (n=124, 66)
Age <65 years (n=132, 67)
Age <65 years (n=4031)
Age <65 years (n=899)
Age <65 years (n=905)
Age <65 years, n (%)
Age <65 yr
Age <65 yr or >65 yr
Age <65 yrs
Age <65: QVAI49-SFC
Age <65years
Age <65yrs
Age <68 years3
Age <69 years (median)
Age <70 years (median)
Age <75
Age <75 y
Age <75 y (n=8932)
Age <75 Years (n=
Age <75 Years (n=8932)
Age <75 yr or >75 yr
Age <75 yrs
Age <Median
Age ≥60 years and BMI <24 kg/m2
Age ≥60 years and BMI ≥24 kg/m2
Age ≥65 years
Age ≥65 years, n (%)
Age ≥75 years
Age ≥75 yearsa
Age >
Age >- Median
Age > 65
Age > 65 years
Age > 65 Years
Age > 70
Age > 75
Age > 75 years
Age > 75 years, n(%)
Age > 75 yr
Age > 75 yr 十
Age > 85
age >= 65 years
Age >= 65 yrs
Age >=75
Age >51 Gd Lesion >1 N=37
Age >51 Gd Lesion=0 N=187
Age >60 years
Age >60 yr (%)
Age >60 yr and elevated biomarkers
Age >60 yr and ST-segment changes
Age >60 yr, elevated biomarkers, and ST-segment changes
Age >65 (years)t
Age >65 vears n = 318
Age >65 vears n=258
Age >65 y
Age >65 y (%)
Age >65 y*
Age >65 y, %
Age >65 y, n (%)
Age >65 years
Age >65 years, %
Age >65 years, n (%)
Age >65 yr
Age >65 yr — no. (%)
Age >65 yr, no. (%)
Age >65 yrs
Age >65 yrs, %
Age >65, %
Age >65: QVAI49-SFC
Age >68 years3
Age >69 years (median)
Age >70 y
Age >70 y (n=802)
Age >70 y(n=802)
Age >70 years
Age >70 years (median)
Age >70 years, n (%)
Age >70 yr
Age >70 yrs
Age >75
Age >75 y
Age >75 y (n = 2194)
Age >75 y (n = 2206)
Age >75 y (n=2010)
Age >75 y**
Age >75 y, %
Age >75 y, n (%)
Age >75 y, n/N (%)
Age >75 years
Age >75 years (ITT) (n=217)
Age >75 years (n=174)
Age >75 Years (n=2010)
Age >75 years (n=222)
Age >75 years, n (%)
Age >75 yr
Age >75 yr — no. (%)
Age >75 yrs
Age >75 yrs*
Age >75 yrs, n (%)
Age >75, y
Age ± SD (yrs)
Age 2 65 y
Age 265
Age 265years
Age 275 y
Age 275 years (n=156)
Age 3*60 yr
Age 50-59 yr, elevated biomarkers, and previous vascular
Age 55-54 y (n = 4943)
Age 55-64 y (n = 4968)
Age 55 64 y
AGE 65-74
Age 65-74 y (n = 3968)
Age 65-74 y (n = 3979)
Age 65-74 years (ITT) (n=538)
Age 65-74 years (ITT) (n=542)
Age 65-74 years (ITT) (n=728)
Age 65-74 years (n=542)
Age 65-74 years (n=551)
Age 65-74 years (n=737)
Age 65-75
Age 65+
Age 65+ y
Age 65+ years
Age 65+yrs
Age 75 years or more
Age a 65
Age at asthma diagnosis years
Age at baseline (years)
Age at baseline in years, mean (SD)
Age at completion of highest level of
Age at diagnosis <18 years
Age at diagnosis of LN, years
Age at diagnosis of SLE, years
Age at diagnosis s18 years
Age at diagnosis, y
Age at disease onset, n (%)*
Age at disease onset, years*
Age at enrollment (years)
Age at enrollment (years), mean (SD)
Age at enrolment, years
Age at entry (years)
Age at first seizure, years, mean (SD)
Age at lipid randomization (y)
Age at menopause (yr)
Age at onset, y
Age at randomisation
Age at Randomization
Age at randomization (years)
Age at screening
Age at time of first seizure,
Age b55 y (n = 1782)
Age b55 y (n = 1791)
Age categories
Age categories (y), n (%)
Age categories, n (%)
Age category
Age category (%)
Age category (years), n (%)
Age category >
Age category, n (%)
Age category, n (%) < 65 years
Age category, n (%):
Age cohort, no. (%)
Age distribution
Age distribution, n (%)
Age distribution, years, n (%)
Age Groiro: <18 years
Age group
Age Group
Age group — no. (%)
Age group (≥75 years)—No. (%)
Age group (≥75)—No. (%)
Age group (y)
Age group (years)
Age group 一％
Age group 1
Age group 2
Age group, n (%)
Age group, no. (%)
Age group, no. (%), y
Age Groups
Age groups, n (%)
Age in 2 classes
Age in 3 classes
Age in years
Age in years, mean
Age in years, mean (SD)
Age in years, median (IQR)
Age is >60 vrs, positive biomarkers, and no si.gni.fi.canr ECG changes
Age is >60 vrs, significant ECG changes, and no positive bi.omark.ers
Age is >60 vrs, significant ECG changes, and positive biomarkers
Age mean (yrs ± SD)
Age Mean age, years Sex
Age of asthma onset, years
Age of completion of highest education, years (SD)
Age of onset
Age of onset <40 years (n = 658)
Age of onset 40 years (n = 273)
Age range
Age range (years)
Age range, y
Age range, years
Age s*60 yr
Age s65 years (n=41, 21)
Age S65 years (n=41,19)
Age s75
Age subgroup, y
Age subgroups
Age when diabetes first diagnosed — yr
Age when diabetes first diagnosed (years), mean (SD)
Age y, median (range)
Age years
Age years Geographic region
Age yr, range
Age yrs
Age*
Age, (years)
Age, mean
Age, mean (min-max) (yrs)
Age, mean (range) years
Age, mean (s.e.)
Age, mean (SD)
Age, mean (SD) (years)
Age, mean (SD) [range], y
Age, mean (SD) years
Age, mean (sd) years, n (%)
Age, mean (SD), y
Age, mean (SD), y Ethnicity, No. (%)
Age, mean (SD), years
Age, mean (SD), yearsa
Age, mean (SD), yr
Age, mean (SD), yrs
Age, mean = SD, years
Age, mean ± SD (year)
Age, mean ± SD years
Age, mean ± SD, y
Age, mean ± SD, years
Age, mean 6 SD years
Age, mean years (SD)
Age, mean years (SD)’ Gender, n (%)
Age, mean years, [SD]
Age, mean yr
Age, mean yr (SD)
Age, mean, years (± SD)
Age, mean, yrs (SD)
Age, mean±SD
Age, mean±SD, y
Age, median (25th-75th percentiles), y
Age, median (25th—75th percentiles), y
Age, median (25th, 75th), y
Age, median (interquartile range), y
Age, median (IQR)
Age, median (IQR), y
Age, median (IQR), years
Age, median (range) (years)
Age, median years
Age, n (%)
Age, X
Age, y
Age, y (25th, 75th percentiles)
Age, y (mean ± s.d.)
Age, y (mean ± SD)
Age, y (mean±SD)
Age, y (SD)
Age, y <65
Age, y Gender, n (%)
Age, y Mean (SD)
Age, y Sex, No. (%)
Age, y, mean (SD)
Age, y, mean ± SD
Age, y, mean±SD
Age, y.o.
"Age, y; median (Q1–Q3)"
Age, ya
Age, year
Age, year (median)
Age, years
Age, years (mean _+ SD) Sex, n (%):
Age, years (mean = SD)
Age, years (mean ± SD)
Age, years (mean 6 SD)
Age, years (SD)
Age, years mean (s.d.)
Age, years Mean (SD)
Age, years Mean±SD
Age, years*
Age, years, mean (range)
Age, years, mean (sd)
Age, years, mean (SD)
Age, years, mean + SD
Age, years, mean ± SD
Age, years: median (range)
"Age, years; mean (SD)"
Age, years^
Age, years“
Age, years1'
Age, yf 45-54
Age, yr
Age, yr Mean (SD)
Age, yr, mean (SD)
Age, yr, n (%)
Age, yrs
Age, yrs (mean ± SD)
Age, yrs*
Age, yrs, mean (SD)
Age, yrs, median (25th, 75th)
Age, yrs, median (IQR)
Age, yt
Age,years Geographical distribution of patients
Age. y
Age. years
Age........ y (n = 1791)
Age/GD lesion
Age:
Age: <65 years
Age: <70 years (n=960)
Age: >65 years
Age\\yr
Age<65
AGE<65
Age<65 years old
Age<75
Age ≥65 y, n (%)
Age>:65
Age>= 65 years old
Age>=65
AGE>=75
Age>75
Agea
AgeadJ
Aged ^65 years
Aged <65 years
Aged ≥65 years
Aged 65 y or older, n (%)
Aged a 65 years
AgeT, y
Aggressive (2)
Aggressive (7)
Aggressive (N = 252)
AGI
AHA status at screeningb, n (%)
ai10
AICD, (%)
Aii participants (n = 8162)
Aii Patients (n = 6886)
Aiirocumab
Aiirocumab (n = 209)
Ain, No. (%)**
Ain, No. (%)“*
Aiorvasiaiin
AIR (n = 221)
AIR + IG (n = 115)
Airflow reversibility — no. (%)|
Airway compromise
Airway reversibility, %
Airway reversibility, mean, %
Ala carriers
Alanine aminotransferase increased
Alanine aminotransferase or aspartate aminotransferase >3x upper limit of normal (N=432)
Alanine aminotransferase, U/L
Alaska Native
ALathosterol (%)
ALAV (per ml)
Albiglutide (n=4731)
Albiglutide Events/patients (%
"Albumin-to-creatinine ratio'i""/"
Albumin-to-creatinine ratio (ACR)
Albumin-to-creatinine ratio,
Albumin (mg/dL)
Albumin creatinine ratio
Albumin measurements^^
Albumin, g/dl
Albumin/creatinine ratio - mg/mmol, Median (IQR)
Albumin/creatinine ratio, n(%)
Albuminuria
albuminuria (ACR >30 m.g/g) at baseline to normoalbuminuria
Albuminuria (g/g)
Albuminuria < 1 gram/gram Cr
Albuminuria and previous maerovaseular disease plus established renal disease (eGFR 45-75 mL/min/L73 in- with an UACR >200 mg/g or eGFR 15 -<45 mL/inin/L73 in- with any UACR mg/g)
Albuminuria and previous maerovaseular disease without established renal disease
Albuminuria progression
Albuminuria_P_interaction
Albuterol reversibility, %
Albuterol Use
Albuterol use (SD), puffs/day
AlC (%)
AlC (mmol/mol)
AlC <7.0% at baseline, n (%)
AlC <7.5%
AlC >7.5-8.0%
AlC at week 26 (%)
AlC at weekO (%)
AlC group (%)
Alc<6.4%
Alc>=6.4%
Alcohol
Alcohol <= 2/wk
Alcohol > 2/wk
Alcohol >2 drinks per week
Alcohol abuse
Alcohol consumption
Alcohol consumption (%)
Alcohol consumption (%) <1 drink/dav
Alcohol consumption (yes) (n)
Alcohol consumption > once weekly
Alcohol consumption at baseline
Alcohol consumption!
Alcohol consumption*
Alcohol consumption, n (%)
Alcohol consumption, no. (%)
Alcohol drinker
Alcohol drinker, n (%)
Alcohol intake
Alcohol intake (+) (%)
Alcohol intake (A)
Alcohol intake Never/rarely
Alcohol use
Alcohol Use
Alcohol use (%)
Alcohol use (%,>1/day)
Alcohol use (> 1 drink/wk)
Alcohol use, drinks/wk
Alcohol use, drinks/wk*
Alcohol use, n (%)
Alcohol Use, n (%)
Alcohol useb
Alcohol usef, n (%)
Alcohol users, n (%)
Alcohol, % with >1 drink/d
Alcohol^
ALDL cholesterol
Aldosterone antagonist
Aldosterone antagonists
Aldosterone antagonists (e.g. spironolactone)
Aldosterone blocker
Aldosterone blocker, %
Aldosterone blockers
Aldosterone inhibitor
Aldosterone receptor antagonists
Aldosterone Use
Ale
Ale <7
Alendronate
Alendronate (n = 1841)
Alendronate (n = 2567)
Alendronate (n=1022)
ALERT
Algorithm 1
Algorithm 2
ALI
Alirocumab
Alirocumab (n = 167)
Alirocumab (n = 287)
Alirocumab (n = 294)
Alirocumab (n = 323)
Alirocumab (n = 49)
Alirocumab (n = 51)
Alirocumab (N=9462)
Alirocumab 150 mg Q2W
Alirocumab 75/150 mg
Alirocumab n = 2344
Alirocumab n = 996
Aliskiren
Aliskiren (DM-vs. DM+)
Aliskiren (n = 170)
Aliskiren (n = 1713)
Aliskiren (n = 55)
Aliskiren (n = 627)
Aliskiren (n=4274)
Aliskiren (n=567)
Aliskiren DM = 627 Non-DM = 1713
Aliskiren/Valsartan (n=574)
Alive (n=1649)
All
ALL
All-baricitinib rA (n=3492)*
All-causa mortality
All-cause
All-cause death
All-cause death    n
All-cause death/stroke/SEE
All-cause hospitalization
All-cause mortalitv
All-cause mortality
All-Cause Mortality
All-cause mortality (n=240)
All-cause mortality (no. of events)
All-cause mortality (per 100 person-years)
All-cause mortality at 1 year
All-cause mortality or HF hospitalization
All-cause mortality or HF hospitalization^
All (n = 2,530)
All (n = 332)
All (N = 4628) 71.6±9.0
All (n = 734)
All (n=1556*)
All (n=3405f)
All Bleed
All Bleeding
All CANA
All Canakinumab
All cancer
All cardiovascular
All cause mortality
All cause mortality or hosp. for worsening HF hs-CRP <2.0 mg/L
All completers
All completers (n 5 327)
All completers (n 5 333)
All countries
All death
All Diabetesd
All Doses
All doses (n=3315)
All dulaglutide 1.5 mg + insulin lispro / insulin glargine (N = 445)
All EZ/simva
All grafts
All Ischemic Stroke
All ITT Sutajects
All major cardiovascular events
All men
All Men
All Mis
All Mis*
All MN-naïve patients
All N=12 410
All N=14,671
All N=4487
All non-MN
All noncompleters
All of the above
All of the colon
All other
All Other
All others
All Others
All Others ETeed for 30 mg Edoxaban Dose at
All others, n (%)
All participants
All Participants
All Participants (N = 402)
All participants History of CABG
All participants* (N=120/115)
All participants* (N=381/380)
All participants, mm Hg: SBP, mean (SD)
All participants^^ (N=341/341)
All participantsa
All participantst (N=341/341)
All patients
All Patients
All patients (« = 22 192)
All Patients (N = 1156)
All Patients (N = 30,449)
All Patients (N = 310)
All Patients (N = 318)
All Patients (N = 323)
All Patients (N = 3362)
All patients (N = 508)
All Patients (N = 508)
All Patients (N = 5518)
All patients (n = 854)
All patients (N 5 3444)
All patients (n = 1161)b
All patients (n=1204)
All patients (n=1306)
All patients (P<0.0001)
All patients (P=0.08)
All patients (P=0.22)
All patients (P=0.42)
All patients (P=0.98)
All patients N =10 372
All patients n=868
All patients on maximally tolerated statin ± other LLT
All patients with fistulas (n = 117)
All Patients With OPG n-1447
All patients, N =
All patientsb
All randomized
All Randomized
All randomized All-cause mortality
All randomized All-cause mortality or hospitalization for worsening HF^
All randomized Coronary end point
All randomized patients
All randomized patients (range)
All randomized women
All randomly assigned
All recurrent strokes
All Responders, (n = 240)
All Responders, (n = 244)
All rosuva
All stroke
All Stroke
All strokes
All strokes*
All Strokes, n (%)
All subjects
All Subjects
All subjects - N
All TEAEs
All TEAEs*
All treatments
All trials
All With Coenzyme Q10 (n = 1,191)
All with diabetes (n=1195)
All without diabetes (n=7998)
All women
All Women
All~cause mort/HF hosp.
Alleles
Allergic disease by historyb, n (%)
Allergic rhinitis
Allergic rhinitis — no. (%)
Allergic rhinitis duration, mean ± SD, y*
ALLHAT-LLT
Allogliptin
Allopurinol
Allopurinol 200/300 mg daily N = 756
Allopurinol 200/300 mg N = 131
Allopurinol 300 mg (n = 268)+
Allopurinol 300/200 mg daily N = 755
Allopurinolt
Alogliptin
Alogliptin (N = 2701)
Alogliptin (n=1930)
Alogliptin (n=2701)
Alogliptin (n=771)
Alogliptin 12.5 mg + pioglitazone (n=197)
Alogliptin 25 mg + pioglitazone ( n = 199)
Alogliptin, N(%)
Alone
Alpha-blocker
Alpha-blocker/other vasodilator
Alpha-blockers
Alpha-glucosidase inhibitors
Alpha 1 blockers
Alpha blockers
Alpha glucosidase inhibitors
Alpha receptor antagonist
Alpha reductase inhibitors
Alprostadil (n = 414)
Alprostadil n/N
Alprostadil n/N    %
ALT (units/L)
ALT >3x ULN on two consecutive visits
ALT and/or AST > 3 times ULN consecutive#
ALT increased
ALT or AST > 3 x ULN1
ALT or AST > 5 x ULN1
ALT, AST, or both >3x ULN
ALT, U/L
Alteplase
Alteplase (n=418)
Alteplase group (n=81)
Alternative Disability
ALVEDV (per ml)
ALVEF (per 1%)
ALVESV (per ml)
ALVMi (per g/m2)
AM PEF (SD), L/min
AM_%delta
AM_delta
AM△士 s.e.
AMA 士 s.e.
aMann Whitney U test/Wilcoxon Sum Rank test.
AMBITION
Ambulance
Ambulance (%)
Ambulance, n (%)
ambulatory SBP, Difference vs placebo (95% Cl)
ambulatory SBP, N
Amended dabigatran protocol
America
American
American‐Indian/Alaska native
American Hispanic (n = 193)
American indian
American Indian
American Indian or
American Indian or Alaska
American Indian or Alaska native
American Indian or Alaska Native
"American Indian or Alaska native"":"
American indian or alaskan
American Indian or Alaskan native
American Indian or Alaskan Native
American Indian or Native Alaskan
American Indian, Alaskan Native, or Aboriginal Canadian
American Indian/
American Indian/Alaska native
American Indian/Alaska Native
American Indian/Alaskan Native
American Indian/Alaskan native, n (%)
American Indian/Native Alaskan
Americas
Americas (n=1767)
Americas**
Americas, excluding US
Ami 5 mg
Ami 5 mg n=349
Aminosalicylate
Aminosalicylates
Aminosalicylates**
Aminosalicylates, N
Amiodarone
AMIODARONE
Amiodarone (n = 299)
Amiodarone (N =845)
Amiodarone (n, %)
Amiodarone Ote at Baseline
Amiodarone Use at Baseline
Amiodarone use at baseline Yes    1,933
Amiodarone vs. Placebo
Amiodarone vs. Placebo No. Hazard ratio (97.5% Cl)
Amiodarone, n (%)
Aml
AML
AML (n = 101)
AML (n = 119)
AML (n = 150)
AML (n = 73)
AML 10 mg + HCTZ 25 mg
AML 10 mg + HCTZ 25 mg (n = 600)
AML 10 mg/HCTZ 25 mg
AML 10/
AML vs. CHL
AML vs. LIS
Aml/HCTZ (n=46)
Aml/HCTZ (n=63)
Aml/HCTZ (n=87)
Aml/Val 5/80 mg
Aml/Val, 5/80 mg rr=347*
Amlodipine
Amlodipine (N = 103)
Amlodipine (n = 286)
Amlodipine (n = 9048)
Amlodipine 10mg /V=471
Amlodipine 5to10mg (n = 324)
Amlodipine and valsartan
Amlodipine vs Chlorthalidone Normal
Amlodipine vs Chlorthalidone Obese
Amlodipine vs Chlorthalidone Overweight
Amlodipine/ vaisartan (n = 286)
Amlodipine/Chlorthalidone
Amlodipine/Lisinopril 12006
Amlodipine/Lisinopril/Chlorthalidone Comparison
Amlodipine/Valsartan 10/160 MG (n=45i)
Amlodipine/Valsartan 10/160 mg /V=473
Amlodipine/Valsartan 5 to 10/160 mg (n = 322)
Amlodipine/Valsartan 5/160 mg
Amlodipine/Valsartan 5/160 mg (n=443)
Amlodipine/Valsartan 5/160 vs 10/160 mg
Amlodipine/Wlsartan i0/160 MG
AMPD3
Amputation
Amputation — no. (%)
Amputation due to diabetes — no. (%)
Amputations, n (%)
Amputationsa
Anacetrapib (N = 15,225)
Anacetrapib (N=15225)
Anacetrapib 100 mg
Anacetrapib 100 mg (n - 153)
Anacetrapib 100 mg (N = 811)
Anacetrapib 100 mg (n=204)
Anacetrapib 100mg(n=204)
Anacetrapib 25 mg (n - 152)
Anaesthesia/analgesia
Anakinra
Analgesic medication, n (%)
Analysis
"analysis compared with the pretreatment condition (baseline), n; LDL = low-density lipoprotein; CSF = cerebrospinal fluid."
Anatomic complexity characteristics
Anatomic extent of qualifying event, n (%.)x
Anatomical extent of qualifying event — no. (%):t
anatomy
Ancestry (%)f
ANCOVA result
and after PCI, median (IQR), d
and either an ACE inhibitor or angiotension receptor blocker
and infusion
AND INFUSION
and microalbuminuria or macroalbuminuria
and Physical Examination
and VFx status
and/or AZA at baseline
and/or discharge
Anemia
Anemia — no. (%) ||
Anemia (%)
Anemia, %
Anemia, No./total (%)”
Anesthesiad, n (%)
Angina
Angina (past 6 weeks)
Angina class at baseline
Angina class III or IV — no. (%)
Angina class III or IV prior
Angina class III or IV prior myocardial infarction
angina or acute MI
Angina or positive stress test
Angina pectoris
Angina pectoris — no. (%)
Angina pectoris*
Angina pectoris, (%)
Angina pectoris本
Angina pectorisf
Angina status — no. (%)
Angina symptoms^
Angina with documented ischemia
Angina, n (%)
angina.
Angioedema (adjudicated), n (%)
Angioedema present, n (%){
Angioedema present, n (%)6
Angiogenesis
Angiogenin (ng/ml)
Angiographic characteristics, No. (%)
Angiographic complications, site-reported — no./total no. (%)
Angiographic data
Angiographic data and treatment:
Angiographic extent of disease
Angiographic features
Angiographic findings ||
Angiography
Angiography — no. (%)
Angiography and revascularization
Angiography during index hospitalization
Angioplasty
Angiotensin-
Angiotensin-converting-enzyme inhibitor
Angiotensin-converting-enzyme inhibitor or angiotensin-
Angiotensin-converting-enzyme inhibitor or angiotensin- receptor blocker§
Angiotensin-converting enzyme inhibitor
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use (mITT population)
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
Angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
Angiotensin-converting enzyme inhibitors^
Angiotensin-converting enzyme or angiotensin receptor blocker
Angiotensin-eonverting enzyme inhibitors
Angiotensin-eonverting enzyme inhibitors/ angiotensin reeeptor bloekers
Angiotensin-receptor
Angiotensin-receptor blocker
Angiotensin II antagonists
Angiotensin II receptor blocker
Angiotensin II receptor blockers
Angiotensin Il-receptor blocker
Angiotensin ll-receptor antagonist — no. (%)
Angiotensin ll-receptor blocker
Angiotensin receptive blocker
Angiotensin receptor
Angiotensin receptor blocker
Angiotensin Receptor Blocker
Angiotensin receptor blocker and/or ACE
Angiotensin receptor blocker Yes
Angiotensin receptor blockers
Angiotensin Receptor Blockers
Angiotension converting enzyme-inhibitor
Ankle-brachial index £0.9
Ankle-brachial index <0.9
Ankle-brachial index <0.9— no. (%)
Ankle edema
Ankle fracture
Ankle/brachial index
Annanginal drugs (0/l/s»2)^
aNNT or bNNH (95%CI)
Annual asthma exacerbation rates
Annual exacerbation rate
Annualized rate IND/GLY SFC
Anorexigen use
Antagonist
Anterior
Anterior (n, %)
Anterior {%)
Anterior circulation
Anterior infarct location
Anterior MI
Anterior myocardial infarction — no. (%)
Anterior myocardial infarction — no./total no. (%)
Anterior or Non- Anterior Ml
Anthropometric characteristics
Anthropometrics, mean (SD)
Anthropometry: mean (SD)
Anti-anaemics
Anti-arthritic medications
Anti-CCP antibodies*
Anti-CCP antibody-positive, n (%)
Anti-CCP antibody (U/
Anti-CCP antibody positive
Anti-CCP antibody positive, n (%)
Anti-CCP Positive
Anti-CCP positive (>10 U/mL), n (%)
Anti-cholinergics (long-acting)
Anti-cholinergics (short-acting)a
Anti-coagulants
Anti-coagulants - no. (%)
Anti-dsDNA (>30 IU/ml), %
Anti-dsDNA positive
Anti-GAD negative
Anti-GAD negative (n = 7895)
Anti-GAD positive
Anti-GAD positive (n = 267)
Anti-histamines
Anti‐hyperglycaemic agent, n (%)
Anti-hypertensive
Anti-hypertensive therapy
Anti-hypertensive therapy - no. (%)
Anti-hypertensive treatment history, n (%)
Anti-hypertensives
Anti-inflammatory drugs
Anti-ischaemia agents*
Anti-p40
Anti‐platelet agents, n (%)
Anti-platelet therapy
Anti-thrombotics
Anti-TNF
Anti-TNF-experienced patients
Anti-TNF-IR patients
Anti-TNF-naive patients
Anti-TNF-naive patients3
Anti-TNF-naive, n (%)
Anti‐TNF‐naïve, n (%)
Anti-TNF agent(s)
Anti-TNF IR
Anti arrhythmic
Anti platelet therapy
Antialdosterone agents
Antianginal medications
Antiarrhythmic
Antiarrhythmic agent
Antiarrhythmic drug
Antiarrhythmic drugs, n (%)
Antiarrhythmic therapy
Antiarrhythmics
Antibiotics**
Antibodies to infliximab, n (%)**
antibody binding level at baseline
Anticholinergic
Anticholinergic drug
Anticholinergic use, n (%)
Anticholinergics
Anticoagulant
Anticoagulant— no. (%)
Anticoagulant Group (N = 187)
Anticoagulant therapy
Anticoagulants
Anticyclic citrullinated peptide positive^, n (%)
Antidepressant
Antidiabetes drug usage [% (n)]
Antidiabetic
Antidiabetic agent
Antidiabetic agents
Antidiabetic drug
Antidiabetic drug‘i“j‘
Antidiabetic medication
Antidiabetic medication||
Antidiabetic medications
Antihyperglycaemic medication at baseline
AntihyperglycemiC
Antihyperglycemic Medication Usage
Antihyperglycemic medications
Antihyperglycemic oral agent therapy
Antihyperglycemictherapies,%
Antihypertensive
Antihypertensive agent use
Antihypertensive agents
Antihypertensive agents (n per patient)
Antihypertensive agents*
Antihypertensive agents, n (%)
Antihypertensive drug, %
Antihypertensive drugs
Antihypertensive medication
Antihypertensive medication or
Antihypertensive medication use, n (%)
antihypertensive medication)
Antihypertensive medication, open-label, no. (%)
Antihypertensive medication1'
Antihypertensive randomization, No. (%)a
Antihypertensive therapy
Antihypertensive therapy — no. (%)
Antihypertensive therapy, n (%)
Antihypertensive treatment
Antihypertensive treatment, n (%)
Antihypertensive treatments
Antihypertensive use
Antihypertensive, antianginal, and other cardiovascular medications
Antihypertensives
Antihypertensives'*
Antihypertensives, n (%)
Antimalarial
Antimalarials only
Antiplatelet
Antiplatelet-Onl Group (N = 174)
Antiplatelet-Only Group (N = 235)
Antiplatelet— no. (%)
Antiplatelet — no./total no. (%)
Antiplatelet agent
Antiplatelet agent N(%)
Antiplatelet agent or anticoagulant
Antiplatelet agents
Antiplatelet agents (%)
Antiplatelet at randomization
Antiplatelet drug
Antiplatelet drugs
Antiplatelet or anti-inflammatory drugs
Antiplatelet or anticoagulant
Antiplatelet or anticoagulant therapy
Antiplatelet therapy
Antiplatelet therapy Dual
Antiplatelet therapy§
Antiplatelet use
Antiplatelet within 3 mo before randomization
Antiplatelets
Antiplatelets agents
Antiplatelets or anticoagulants
Antiplatelets, any
Antiplateletsa
Antithrombin
Antithrombotic
Antithrombotic agents
Antithrombotic agents, n (%)
Antithrombotic and anticoagulant medications
Antithrombotic drug use at time of event
Antithrombotic medications, n (%)
Antithrombotic therapy
Antithrombotic use
Antithrombotic use before enrollment, No. (%)
Antithrombotic! I
Antithrombotic/coagulant
Any
Any (including corticosteroid)
Any ACUITY bleeding
Any adverse event (AE)
Any adverse event leading to study drug discontinuation, n (%)
Any AE
Any AE leading to discontinuation, n (%)
Any AE, n (%)‡
Any AEs
Any AEs, n (%)
Any albuminuria
Any albuminuria — no. (%)
Any anti-hypertensive agent
Any antianginal drug!
Any anticoagulant
Any antihypertensive agent
Any antihypertensive drug
Any bleeding
Any blood
Any blood-pressure-lowering drug 一 no. (%)
Any blood pressure medications (%)
Any Blood Product Transfusion
Any blood transfusion
Any BP-lowering agents^
Any cardiovascular disease
Any cardiovascular disease history, n (%)
Any cardiovascular diseased
any cause
Any cause
Any clinical AE
Any Clinical or Lesion RF for ST
Any condition
Any COPD medication
Any coronary artery disease
Any coronary revascularization
Any cough
Any CV history/risk factors, n (%)
Any CVD history (%)
Any death
Any disease
Any Dose Reduction
Any drug-related AE, n (%)
Any dynamic ST-segment shift
Any early adverse event
Any electrocardiographic abnormality — no. (%)
Any established coronary artery disease
Any established peripheral arterial disease
Any glucocorticoid*
Any glycoprotein IIb/IIIa inhibitor use
Any GUSTO bleeding
Any HbA1c
Any history of congestive heart failure
Any immunosuppressive agent
Any infarct
Any lipid-lowering agent
Any lipid-lowering agent use
Any LLT other than nutraceuticals, n (%)
Any LLT other than statins, n (%)b
Any medication
Any MI
Any MI (n - 5,340)
Any New Anti-Hyperglycemic Rx
Any of the above
Any oral hypoglycemic drug 一 no. (%)
Any other antihyperglycaemic drugs
Any other lipid‐lowering therapy, n (%)
Any other LLTs (other than statin)
Any overt bleed
Any peripheral arterial disease
Any peripheral revascularization
Any placebo
Any prerandomization failure of an antiarrhythmic drug — no. (%)
Any prior anti-TNF treatment failure
Any pulmonary medication
Any pulmonary medication, n (%)
Any recurrent stroke
Any relevant infarct
Any revascularization
Any risk factor for stent thrombosis
Any SAE
Any secukinumab (N = 49)
Any serious AE, n (%)
Any serious TEAEs
Any severity
Any site
Any statin
Any statin (with/without LLT)
Any statin + other LLT
Any statin versus no statin at randomization
Any stroke
Any Stroke (N=641)
Any sulfonylurea
Any TEAE
Any TEAEs
Any therapy — no. (%)
Any thiazide diuretic
Any thiazolidinedione
Any TIMI bleeding
Any treatment-emergent AE
Any type, according to daily dose**
Any ulcerative colitis medication
Any use
Any vascular diasease
Any vascular disease
Any vascular* efficacy
Any VTE-related death
Any VTE or VTE-related death — no. (%)
Anyantianginal agent
Aortic
Aortic-valve replacement
Aortic stenosis
Aortic stenosis, n (%)
Aortic valve disease (n=21 014)
aP-value from an ANCOVA with corresponding baseline lipid value as the covariate and with a effect for treatment group.
"aP = 0.536; bP   0.001; cP = 0.016. *The study-speciﬁc BP targets were SBP   140 mm Hg and DBP   90 mm Hg (or SBP   130 mm Hg and DBP   80 mm Hg in those with DM). The LDL-C target was   100 mg/dL or   130 mg/dL, depending on risk factor status at baseline in accordance with NCEP ATP III guidelines. Odds ratio and P value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site.  An interaction between treatment effect and DM status was observed for BP goal attainment (P = 0.051) and dual BP/LDL-C goal attainment (P = 0.024) among patients with or without DM calculated based on a mixed-effects linear model (not adjusted for differences in baseline values).
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; NCEP ATP III; National Cholesterol Education Program–Adult Treatment Panel III; OR, odds ratio; SBP, systolic blood pressure"
APASP (per mmHg)
Aphasia
Apixaban
Apixaban (N = 3705)
Apixaban 2.5 mg BID
Apixaban 5 mg BID
Apixaban dose (or matching placebo)
Apixaban vs. Placebo
Apixaban, 2.5 mg
Apixaban, 2.5 mg (N = 840)
Apixaban, 5 mg
Apixaban, 5 mg (N = 813)
Aplxaban 2.5 mg BID
Apo-B
apo A-1, mean (SD), mg/dL
Apo A-I
Apo A-I (mg/dL)*
Apo A-I, mg/dl
Apo A-l (g/L)
Apo A-l (mg/dL) - mean ± SD
apo A1 (g/L)
Apo A1 (mg/dl)
Apo A1, mean (SD)
Apo A1, mg/dL, mean (SD)
Apo B
apo B (g/L)
Apo B (g/L)
Apo B (mg/dl)
Apo B (mg/dL)
Apo B (mg/dL) - mean ± SD
Apo B (mg/dl) **
Apo B*
Apo B, mean (SD)
apo B, mean (SD), mg/dL
Apo B, mg/dl
Apo B, mg/dL, mean (SD)
Apo B/Apo A-L
Apo B/Apo A-l ratio (mean)
Apo B:Apo A-I ratio
Apo Bt
"apo, apolipoprotein; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol;"
"Apo, apolipoprotein; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. *Includes agents acting on the renin-angiotensin system, beta blocking agents, calcium channel blockers, and diuretics. †Median values [standard deviation for medians calculated by (Q3   Q1)/1.075]. §Includes cardiac glycosides, antiarrhythmics class I and III, vasodilators used in cardiac diseases and other cardiac preparations. ‡Expressed as g/l."
ApoA-1, g/l
ApoA-I
ApoA1, mg/dL
ApoAl
ApoAl (mg/dl) *
ApoAl, mg/dL
ApoB
ApoB (mg/dl)
ApoB (week 24)
ApoB, g/l
ApoB, g/l, mean (SD)
ApoB, mg/dL
ApoB: ApoAl
ApoB:ApoA-1 ratio
ApoB:ApoA-I
ApoB:ApoA-I ratio
ApoB:ApoA-l ratio
ApoB:ApoA1
ApoB:ApoA1 ratio
ApoB:ApoAl ratio
ApoB48
ApoBe
APOE e4 carriers, No. (%)
APOE ε4 carrier
Apolipoproiein A1 (tng/1)
Apolipoproiein B (mij/1)
Apolipoprotein
Apolipoprotein A-I*
Apolipoprotein A1 (g/L)
Apolipoprotein A1 (mg/dL)
Apolipoprotein B (g/L)
Apolipoprotein B (mg/dl)
Apolipoprotein B (mg/dL)
Apolipoprotein B 100, mg/dL
Apolipoprotein B Tx difference vs Pbo, LS mean % change from baseline (SE)
Apolipoprotein B, mean (SD), g/L
Apolipoprotein B, mg/dL
Apolipoprotein B^
Apremilast
Apremilast 20 mg BID n=169
Apremilast 30 mg BID n=167
Aqc<75
Aqe ^65
Aqe <65
Aqe i65
AQLQ Score
AQLQ score, mean
AQLQ score, mean (SD)
AQLQ(S) score
AQLQ(S)+12 score, mean (SD)c,f
AQLQ(S)+12 score:§
AQLQ(S)+12 scored
AQLQ(S)+12 scoretS
AQLQ(SI+12 score’
ARA Functional Class
ARA functional class — no. (%)
ARB
ARB (n, %)
ARB + CCB (n = 586)
"ARB = angiotensin II receptor blocker;CCB"
ARB at enrollment
ARB at last follow-up
ARB monotherapy
ARB or ACE inhibitor
ARB or ACE inhibitor, n (%)
ARB, %
ARB, n (%)
ARB/ACE
ARBs
ARBs or ACE inhibitors
ARD (95% Cl) per 1000 patient-years
ARD per 10 000 Patient-Years (95% CI)
Area of fluorescein leakage within the grid, mean (SD), DAb
Area of retinal hemorrhage within the grid, mean (SD), DAb
Area of retinal thickening within the grid, mean (SD), DAb
areas
Argentina
Arial flutter or fibrillation
ARR
ARR (%)
ARR (95% CI)
ARR (95% Cl)
Arrhythmia
Arrhythmia!
Arrhythmias
Arteriai access
Arterial access
Arterial area (mm2)
Arterial blood pressure, mm Hg
Arterial graft
Arterial hypertension
Arterial hypertension — no. (%)
Arterial hypertension*
Arterial hypertension, n (%)
Arterial hypertension, no. (%)
Arterial revascularization
Arteriosclerosis
Arthralgia
Arthritis characteristics
Arthritis mutilans
Arthritis type*
ARVFAC (per 1%)
as
AS
As-needed inhalations/day
AS duration, y, mean (SD)
as major component — no. (%)
ASA
ASA < 150 mg
ASA > 150 mg
ASA or antiplatelet agent
ASA use at baseline
ASA use at baseline, n (%)
ASA, n (%)
ASAS 5/6, %
ASAS 5/6, n (%)
ASAS partial remission, %
ASAS partial remission, n (%)
ASAS20
ASAS20, %
ASAS20, %
ASAS40, %
ASAS40, %
ASAS50
ASAstoppedat randomization,n
ASCOT-LLA
ASCVD
ASCVD as per protocol
ASCVD including TIA
ASCVD no prior Ml
"ascvd"""
ASCVD*. n (%)
ASCVD, n (%)
ASCVD,b No. (%)
ASCVDor >2 CV risk factors
ASDAS-CRP Δ ≥ 1.1
ASDAS-CRP*
ASDAS-CRP < 1.3
ASDAS inactive disease, %
Asia
Asia-Pacific
Asia-pacific and South Africa
Asia-Pacific and South Africa
Asia-Pacific HR (95% Cl)
Asia-Pacific region and South Africa
Asia (excluding Japan)
Asia (n=1,337)
Asia (n=1337)
Asia and Pacific Islands
Asia Pacific
Asia Pacific (n= 758)
Asia Pacific and Africa
Asia Pacific and other
Asia Pacific and Other
Asia Pacific and South Africa
Asia Pacific or other
Asia#
Asia, Pacific and other
Asia/Australia/New Zealand
Asia/Pacific
Asia/Pacific (%)
Asia/Pacific/other
Asia/Pacific/Other
Asian
Asian (3.2%)
Asian (n — 57)
Asian (n = 392)
Asian (N = 392)
Asian (n = 769)
Asian (n=1,360)
Asian (n=1360)
Asian (n=2782)
Asian ITT population by treatment group
Asian ITT population Total (n = 325)
Asian or Oriental
Asian or Pacific Islander
Asian*
Asian, n (%)
Asian, n(%)
Asian/black/white/hispanic/other (%) Clinical parameters
Asian/Oriental
Asian/Pacific Islander, n (%)
Asians (n = 157)
Asians (n = 163)
Aslan
Asp
Aspartate aminotransferase increased
Aspartate aminotransferase, U/L
Aspirin
Aspirin-ERDP    Clopidogrel no. of patients/total no.
Aspirin-ERDP (N = 10,181)
Aspirin — no. (%)
Aspirin (%)
Aspirin (any dose)
Aspirin (ASA) (» = 19 934)
Aspirin (n = 19 934)
Aspirin (N = 19,934)
Aspirin (N =3782)
Aspirin (n, %)
Aspirin (n=175)
Aspirin (N=18 652)
Aspirin (n=21 101)
Aspirin (N=7740) no. of participants with events (%)
Aspirin <24 hours
Aspirin <7 day
Aspirin 一 no. (%)
Aspirin 100 mg
Aspirin 100 mg (N = 1131)
Aspirin 1029
Aspirin 1040
Aspirin 1559
Aspirin 16,241
Aspirin 4 Clopidogrel
Aspirin alone
Aspirin Alone
Aspirin Alone (N = 9126)
Aspirin Alone (N = 9126) 68.2±8.0
Aspirin alone (n/N)
Aspirin alone (n= 8261)
Aspirin alone (n=1376)
Aspirin alone (n=2504)
Aspirin Alone (n=2514)
Aspirin Alone (N=2514) 2.4
Aspirin alone group No of events/total N (%)
Aspirin and other antiplatelet
Aspirin and PPI
Aspirin and thienopyridine therapy
Aspirin at any dose
Aspirin at baseline
Aspirin at enrollment
Aspirin at Enrollment
Aspirin at last follow-up
Aspirin before admission
Aspirin but no PPI
Aspirin dose
Aspirin Dose
Aspirin dose at baseline ,mg
Aspirin dose at Randomization
Aspirin Dose at Randomization
Aspirin dose, mg/d
Aspirin group
Aspirin group (N = 18 652) (181 467 person years)
Aspirin Group (N=7740)
Aspirin i Clopidogrel (N = 5,814)
Aspirin Only
Aspirin Only (N = 1,202)
Aspirin or other antiplatelet agent
Aspirin or other antiplatelet agents
Aspirin or other antiplatelet drug
Aspirin or other antiplatelet or anticoagulant agent
Aspirin or thienopyridines (%)
Aspirin orother antiplatelet drug
Aspirin plus Clopidogrel (N = 1517)
Aspirin plus Placebo (N = 1503)
Aspirin use
Aspirin use (%)
Aspirin use (> 80 mg)
Aspirin use (p=0-19十)
Aspirin use (p=0-19t)
Aspirin use (p=0-26t)
Aspirin use (p=0-92t)
Aspirin use (p=0.89t)
Aspirin use at baseline
Aspirin Use at Baseline
Aspirin use at randomization
Aspirin use at randomization - n (%)
Aspirin use before screening— no. {%)
Aspirin use n (%)
Aspirin, n (%)
Aspirin, No. (%)
Aspirin/antiplatelet
Aspirin/antiplatelet medication
Aspirin/other antiplatelet agents, n (%)
Aspirin+ Clopidogrel (N=2531) 2.6
Aspirin+dipyridamole
Aspirin+dipyridamole (n=1363)
Aspirin+thienopyridine
ASQoL, LS mean change ± SE
ASQoL, LS mean change from baseline ± SE
Assessment of physical function (0-3, HAQ-DI)
Assigned to placebo
Assigned to topiramate
Assigned treatment by sex interaction
Assoc, with connective tissue disease
Assoc, with corrected congenital shunts
Associated with an atrial septal defect
Associated with connective tissue disease
Associated with corrected
Associated with corrected-congenital shunts
Associated with CTD
Associated with drug or toxin exposure
Associated with drug/toxin
Associated with HIV infection
Associated with transient or reversible risk factor
Associatedproximaldeep-veinthrombosisatdiagnosis, No. (%)
AST >3x ULN on two consecutive visits
AST increased
AST, U/L
ASTERIA I/II
Asthma
Asthma-control status at randomization — no. (%)
Asthma-related health-
Asthma control test score at baseline
Asthma duration (SD), years
Asthma exacerbations
Asthma symptoms in the past 2 weeks
aSubset of the ≥65 years subgroup.
ASUI score, mean
ASUI score, mean (SD)
Asymmetric peripheral arthritis
At
At 4 years
At any time
At baseline
At baseline — no. (%)
At C change (%)*
At C data
At clinic diastolic pressure <85 mm Hg
At clinic diastolic pressure >85 mm Hg
At clinic systolic pressure <135 mm Hg
At clinic systolic pressure >135 mm Hg
At end of follow-up
At end of follow-up — no. (%)
At end of follow-up — no./total no. (%)
At entry
at femoral neck, mean (SD)
At goal
At home diastolic pressure < 82 mm Hg
At home diastolic pressure >82 mm Hg
At home systolic pressure <132 mm Hg
At home systolic pressure >132 mm Hg
At Increased Fall Risk (n - 900)
At index ACS event
At index event
At index event: no. (%)
At LDL-C (BQ) goal* at baseline- no. (%)
At least 1 /mo
At least 1 flare
At least 1 severe flare
At least 1/mo
At least two cardiovascular risk factors
At or above median
At or above the median
At qualifying event
At randomization
At screening
At six weeks
At week 12
At week 6
At weeks 6 and 26
Atenoioi (N=2112)
Atenoioi (N=2476)
Atenolol
Atenolol (« = 11 098)
Atenolol (n = 259)
Atenolol (n = 263)
Atenolol (n = 3,622)
Atenolol (n = 4,325)
Atenolol (n = 579)
Atenolol (n = 666)
Atenolol (n = 966)
Atenolol (n=2184)
Atenolol (n=2404)
Atenolol (n=609)
Atenolol (No.=3231)
Atenolol n=3231
Atenolol strategy
Atenolol strategy (n = 2,973)
Atenolol use at 1 month
Atenolol*
Atherectomy
Atherosclerosis
atherosclerosis^, n (%)
Atherosclerotic cardiovascular disease
Atherosclerotic cardiovascular disease*
Atherosclerotic CVD
Atherosclerotic CVD§
Atherosclerotic CVDJ
Atherosclerotic disease (%)
Atherosclerotic disease*
Atherosclerotic vascular disease — no.
Atherosclerotic vascular disease history, n (%)t
Atherosclerotic vascular disease history, No. (%)‡
Atherosclerotic vascular disease history†
Atherosclerotic vascular disease, n (%)§
Atherothrombotic infarction, n (%)
Atherothrombotic stroke, n (%)
atients with Event
ATio - Pla
ATM-Locm
ATM-Locus
ATO 10 mg and SIM 20-40 mg (n = 9221)
ATO 10 mg and SIM 20^10 mg (n = 234)
ATO 80 mg (n = 261)
ATO 80 mg (n = 9173)
Atonic
Atopic
Atopic (based on Phadiatop test)
Atopic at baseline: Yes
Atopy (n = 1,375)
Atopy (specific IgE)c, n (%)
Atopy by Phadiatop test, n (%)
Atorvastatin
Atorvastatin    LS means difference 10 mg    (95% CI)a (n = 1407)
Atorvastatin (n=84, 44)
Atorvastatin {n=81,42)
Atorvastatin 10 mg
Atorvastatin 10 mg (n = 1407)
Atorvastatin 10 mg (n = 21)
Atorvastatin 10 mg (n = 4,951)
Atorvastatin 10 mg (n = 55)
Atorvastatin 10 mg and simvastatin 20-40 mg (zi = 9455)
Atorvastatin 20 mg
Atorvastatin 30 mg
Atorvastatin 40 mg
Atorvastatin 40 mg (n = 263)
Atorvastatin 40 mg + Ezetimibe 10 mg (n = 288)
Atorvastatin 60 mg
Atorvastatin 80 mg
Atorvastatin 80 mg (n = 156)
Atorvastatin 80 mg (n = 291)
Atorvastatin 80 mg (n = 9,278)
Atorvastatin 80 mg (zi = 9434)
Atorvastatin dose
Atorvastatin Factorial Study
Atorvastatin Monotherapy (n = 917*)
Atorvastatin, n (%)
Atorvastatinb
Atrial fibrillation
Atrial Fibrillation
Atrial fibrillation — no. (%)
Atrial fibrillation — no./total no. (%)
Atrial fibrillation (%)
"Atrial fibrillation alone);"
Atrial fibrillation LDL cholesterol level
Atrial fibrillation on baseline EcG, n (%)
Atrial fibrillation onset
Atrial fibrillation or flutter
Atrial fibrillation or flutter— no. (%)
Atrial fibrillation or flutter — no. (%)
Atrial fibrillation or flutter (ECG)§
Atrial fibrillation pattern
Atrial fibrillation type, n (%)
Atrial fibrillation!
Atrial fibrillation, %
Atrial fibrillation, duration — no. (%)
Atrial fibrillation, n (%)
Atrial fibrillation, n (%)
Atrial fibrillation. No. (%)
Atrial fibrillation/atrial flutter, %
Atrial fibrillation/flutter
Atrial fibrillation/flutter, n (%)
Atrial Fibrillation/Flutter, n (%)
Atrial flutter
Atrial flutter/fibrillation
attack (%)
ATTAIN
ATV 10 mg
ATV 20 mg Study Protocol
Atv n(%)
"ATV, atorvastatin; LDL-C, low-density lipoprotein cholesterol. *p-values pertain to treatment-by-stratum interaction test for stratum or treatment-by-subgroup interaction test for subgroups. 'Multiplicity adjustments were not applied to this predefined subgroup analysis of LDL-C goal attainment, ""[expressed as number of patients reaching LDL-C goal at week 6/number of patients above goal at baseline, ^treatment stratum was defined by intake of ATV 10 or 20 mg."
ATV20 mg (n = 214)
aTwo‐Sample T‐test.
Atypical absence
AUGMENT COPD
aUnivariate Logistic regression.
Austrafca and New Zealand
Austral ia/New Zealand
Australasia
Australia
Australia and New Zealand
Australia/New Zealand
Australia/New Zealand/South Africa
Australia/NZ
Austria
Autonomic neuropathy
Available baseline blood specimen n
available data
Average age (year)
Average Daily Dose
Average Daily Dose (% of Target)*
average dose (mg/week)
Average maximum CIMT (mm)
Average maximum common and bifurcation CIMT (mm)
Average of maximum common carotid CIMT (mm)
Average of maximum far wall CIMT (mm)
Average weekly MTX dose (mg/week)
Average weekly MTX dose (mg/week)t
AVM % △  (SE)
AVM % △ (SE)
AVM % △(SE)
AVM (N = 344)
AVP pg/mL
AVR
AZA (N = 170)
Azathioprine
Azathioprine (N = 170)
Azathioprine monotherapy
Azathioprine/6-mercaptopurine
AZL-M
AZL-M + HCTZ (N = 306)
AZL-M 40 mg (n = 132)
AZL-M 40 mg + CLD 25 mg
AZL-M 40 mg 4-CLD 25 mg (n=l85)
AZL-M 80 mg (n = 130)
AZL-M 80 mg + CLD 25 mg
AZL-M 80 mg 4-CLD 25 mg (n=l82)
AZL-M/CLD (N = 303)
AZL-M+CLDb
AZL-Ma
B
b-agonists (long-acting)a
b-agonists (short-acting)a
b-blocker
b-Blocker
b-Blockers
b-Blockers at baseline
b-Blockers, n (%)
B-Natriuretic Peptide. pg/mL
B Digit Symbol Substitution, insulin glargine vs standard care
B Digit Symbol Substitution, omega-3 fatty acids vs placebo
b Includes both ex-smokers and nonsmokers.
B lack
B MACE
B Major Cardiovascular Events
B Nonsevere Hypoglycemia
b Pooled New and Worsened Vertebral Fractures (mFAS)
B Postbronchodilator FEVl (% predicted)
B Reslizumab 3.0 mg/kg n/N
b) those on inhaled corticosteroids and long-acting bronchodilators as previous treatment use.
B, VhD (n=3950)
B. ACR 50
"B. Benralizumab 30 mg Q8W"""
"b.i.d., twice daily; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; MCID, minimum clinically important difference; mMRC, modified Medical Research Council; o.d., once daily; SD, standard deviation; SGRQ-C, St. George’s Respiratory Questionnaire for COPD"
B.Myocardial Infarction
B: U.S. Black and Non-Black Patients
B+A (n=2059)
B+A (n=2887)
B+A (n=791)
B+H (n=2098)
B+H (n=2822)
B+H (n=825)
Back pain
Back Pain
Background AHA therapy at screening, n
Background AHA therapy at screening, n (%)
Background AHA therapy at screening, n (%)§
Background AHA therapy at screening,a
Background AHA therapy at screening,a n (%)
Background csDMARD category
Background LABA use
Background LABA use - yes, n (%)
Background lipid-lowering therapy
Background lipid therapy per ACC/AHA definition, n (%)a
Background therapy
Background treatment, N (%)
Bacterial pneumonia
Bail‐out use of glycoprotein IIb/IIIa inhibitors
Balloon angioplasty
Balloon angioplasty — no. (%)
Balloon angioplasty plus abciximab
BARC 2-5
BARC 3-5
BARC Types 2, 3, or 5
Bare-metal
Bare-metal stent
Bare-metal stent — no. (%)
Bare metal
Bare metal stent
Bare Metal Stent
Bare metal stent, n (%)
Baricitinib 2 mg
Baricitinib 2 mg (N=229)
baricitinib 2 mg (n=479)
Baricitinib 2 mg QD (N=229)
baricitinib 2/4 mg
Baricitinib 4 mg
Baricitinib 4 mg (N=227)
baricitinib 4 mg (n=487)
baricitinib 4 mg (n=997)
Baricitinib 4 mg QD
Baricitinib 4 mg QD (N=227)
Baricitinib, 2 mg Daily (N = 174)
Baricitinib, 4 mg Daily (N = 177)
Basal
Basal alone
Basal insulin
Basal insulin analogue dose*(coefficient
Basal insulin analogue: insulin
Basal insulin dose at run-in (U/day)
Basal insulin doset
Basal only
Basal plus bolus
BASDAI question 2 score (1-10), mean (SD)
BASDAI responses at week 24
BASDAI score (1-10), mean (SD)
BASDAI score, mean (SD)
BASDAI, LS mean change from baseline ± SE
BASDAI, mean change from baseline
BASDAI, total, mean ± SD
BASDAI⁎⁎
BASDAI20, n (%)
BASDAI50, %
BASDAI50, n (%)
BASDAI70, n (%)
Base
Baseiine ACEi/ARB
Baseiine Aspirin
Baseiine CCB
Baseiine Diuretic
Baseiine Statin
Baseline
Baseline-adjusted HR
Baseline --MDRD
Baseline - CKD-Epi
Baseline % BSA involvement
Baseline % predicted FEV1
Baseline (geometric mean, CV)
baseline (mean, SD)
Baseline (mean, SD)
Baseline (mmol/L)
Baseline (n)
Baseline (SD)
Baseline ^STE, mm
Baseline £STD, mm
Baseline 2-h PPG,
Baseline 24-hour mean SBP, mm Hg
Baseline 5-ASA
Baseline 6-Mlnute Walk Distance:
Baseline A1C (%)
Baseline A1C (%) [LSM (SE)]
Baseline ABI, affected limb
Baseline ACQ-7 score
Baseline ADAS-Cog 12
Baseline age
Baseline albumin/creatinine ratio in 3 classes
Baseline albumin: <30
Baseline albuminuria
Baseline AlC <8.0%
Baseline AlC category
Baseline anti-hyperglycemic medications
Baseline Anti-hyperglycemic Medications, n(%)
Baseline anti-hypertensive usea
Baseline antihyperglycemic medications, n (%)
Baseline ASDAS-CRP
Baseline aspirin dose <100 mg
Baseline aspirin use
Baseline aspirin use strata
Baseline Aspirin Use Strata
Baseline BASDAI
Baseline BASFI
Baseline BII, mean (SD)
Baseline BMI
Baseline BMI (kg/m^)
Baseline BMI (kg/m2),
Baseline BMI < 30 kg/m2
Baseline BMI > 30 kg/m2
baseline BMI > 35 kg/m2, n = 2,383
baseline BMI > 35 kg/m2, n = 2,383 change from baseline to 56 weeks
baseline BMI > 35 kg/m2, n = 350 change from baseline to 56 weeks
baseline BMI > 35 kg/m2, n=350
baseline BMI 27 to <35 kg/m2, n = 1,279
baseline BMI 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks
baseline BMI 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks
baseline BMI 27 to <35 kg/m2, n=273
Baseline BNp concentration (pg/mL)
Baseline body mass index
Baseline body weight quartile
Baseline BP, mean (SD)*
Baseline BSA, mean (SD)
Baseline Calcium Yes
Baseline cardiac biomarkers
Baseline cardiac biomarkers elevated
Baseline cardiovascular assessment
Baseline cardiovascular disease
Baseline cardiovascular medication
Baseline cardiovascular medication,c n (%)
Baseline Cardiovascular Medications, n(%)
Baseline CDAI score, mean (s.d.)
Baseline CDAI score, mean (SD)
Baseline CDAI,
Baseline CDAI, mean (SD)
Baseline CDR-sb (N = 249 + 251)
Baseline CHA2DS2-VAScb,c
Baseline CHADS2a,c
Baseline characteristic
Baseline Characteristic
Baseline characteristics
Baseline Characteristics
Baseline characteristics, mean (SD) a
Baseline CKD eGFR <60 mL/min/1.73 m2
Baseline CKD eGFR >60 mL/min/1.73 m2
Baseline composite Mayo Clinic score
Baseline concentration
Baseline concomitant cardiovascular medications
Baseline COPD exacerbation history,* n (%)
Baseline corticosteroid use (mg)
Baseline corticosteroids*
Baseline corticosteroidst (mean dose: 6.52 mg/day), n (%)
Baseline CrCl, ml/min
Baseline creatinine clearance
Baseline creatinine, median (range) mg/dl
Baseline Crohn's disease medications
Baseline CRP
Baseline CRP (mg/dL)
Baseline CRP <2mg/L
Baseline CRP category (mg/L)
Baseline CRP levels <10 mg/L
Baseline CRP levels ≥10 mg/L
Baseline CV medications
Baseline CV medications, n (%)
Baseline CV treatment
Baseline CV treatment, n (%)y
Baseline DAD (N = 249 + 251)
Baseline DAS28, mean (s.e.)
Baseline data
Baseline daytime nasal symptoms score, mean ± SD
Baseline DBP (mm Hg)
Baseline DBP,
Baseline DBP, mean±SD, mm Hg
Baseline demographics
Baseline Demographics
Baseline diabetes
Baseline Diabetes
Baseline diabetes mellitus therapy, n (%)
Baseline diastolic blood
Baseline diastolic blood pressure (mm Hg)
Baseline diastolic blood pressure, mean (SD), mm Hg
Baseline dipeptidyl peptidase 4
Baseline disease and quality-of-life scores
Baseline DLCO. mmol kPa-’-
Baseline DLQI, mean (SD)
Baseline DMARD use, n (%)
Baseline dyslipidemia
Baseline dyspnea index score
Baseline dyspnea index, mean total score
Baseline ECG with LVH, n (%)
Baseline eCrCl
Baseline eCrCl 2 80 mL/min
Baseline eCrCl k 30 to < 60 mL/min
Baseline eCrO < 30 mUmin
Baseline eCrQ 2 60 to < 80 mL/min
Baseline ED severity**:
Baseline eGFR (mL/min per 1«73 m’)
Baseline eGFR < 60 mL/min/1.73 m2
Baseline eGFR <15
Baseline eGFR <60 mL/min/1.73 m2c
Baseline eGFR ≥15 to <30
Baseline eGFR ≥30 to <45
Baseline eGFR ≥45 to <60
Baseline eGFR ≥60 to <90
Baseline eGFR > 60 mL/min/1.73 m2
Baseline eGFR, mL/min/1.73 m2
Baseline eGFR, mL/min/1.73 m2
Baseline eosinophil <300 cells/pL
Baseline eosinophil 2300 cells/pL
Baseline erosion
Baseline estimated GFR
Baseline ezetimibe usec
Baseline factor
Baseline fasting plasma glucose
Baseline fasting TGs, mg/dL
Baseline Fc-LDL-C
Baseline Feature
Baseline fecal caicrctectin
Baseline FEV, (L)
Baseline FEV1
Baseline FEV1#
Baseline FEV1% predicted
Baseline FEV1, L*
Baseline FEV1, median (range), L
Baseline focal seizure frequency/28 days, median (Q1-Q3)
Baseline focal seizure frequency/28 days, median (Q1, Q3)
Baseline FPG,
Baseline FPG, mean (s.e.)
Baseline FPG, mg/dL
Baseline free PCSK9 level
Baseline free PCSK9 level by median
Baseline FVC, L
Baseline geometric mean (10®/L)
Baseline GFR < 60 ml/min/1.73m2, n (%)
Baseline GFR <60 mL/min per 1.73 m2, n (%)
Baseline Glycated
Baseline glycated hemoglobin (%)
Baseline glycemic control
Baseline HAQ mean (s.e.)
Baseline Hb < 120 g 1 1 n=499
Baseline Hb 120g I 1 n=788
Baseline HbA^c
Baseline HbA1c
Baseline HbA1c (%)
Baseline HbA1c < 9.0%
Baseline HbA1c <8.0%
Baseline HbA1c <8.0% (64 mmol/mol)
Baseline HbA1c ≤ median 7.9% (63 mmol/mol)
Baseline HbA1c ≥69 mmol/mol (≥8.5%), n (%)
Baseline HbA1c ≥8.0% to <9.0% (64–75 mmol/mol)
Baseline HbA1c ≥9.0% (75 mmol/mol)
Baseline HbA1c > 9.0%
Baseline HbA1c > median 7.9% (63 mmol/mol)
Baseline HbA1c >8.0%
Baseline HbA1c concentration
Baseline HbA1c in 3 classes
Baseline HbA1c subgroup
Baseline HbA1c, %
Baseline HbA1c, mean (s.e.)
Baseline HbA1c, n (%)
Baseline HbA1c^
Baseline HbAlc
Baseline HbAlc <8%
Baseline HbAlc >69 mmol/mol (>8.5%)
Baseline HbAlc >8% to <9%
Baseline HbAlc >8.5% (69 mmol/mol) 49
Baseline HbAlc >9%
Baseline HbAlc^
Baseline HbAlc’
Baseline HbAlc<8.5% (69 mmol/mol) 131
Baseline HBI, mean (SD)
Baseline HDL-C
Baseline HDL-C in 2 classes
Baseline HDL-C level (n=80» 40) >51.0 mg/dL
Baseline HDL-C level (n=81. 41) >51.0 mg/dL
Baseline HDL-C level (n=89, 46) s51.0 mg/dL
Baseline HDL-C level (n=S5, 45) <51.0 mg/dL
Baseline HDL-C, mg/dL
Baseline HDL‐C, mg/dL
Baseline heart failure severity amongthose with priorheartfailure,%
Baseline heart failure severity NYHA class I
Baseline heart rate
Baseline heart rate (beat/min)
Baseline heart rate (beats/min)
Baseline height ( cm)
Baseline hematocrit, median (IQR)
Baseline hemoglobin Aj^ values
Baseline hemoglobin, median (IQR, g/dL)
Baseline high-density lipoprotein cholesterol (mg/dL)
Baseline high-sensitivity CRP
Baseline history of vascular disease (%)
Baseline hs-CRP tertiles (mg/i]
Baseline hsTnI
Baseline IBDQ total score, mean
Baseline ICS
Baseline ICS >1000 pg per day (fluticasone propionate DPI or equivalent) and LABA
Baseline ICS dose, n (%)
Baseline ICS use, n (%)
Baseline ICS use: no
Baseline ICS use: yes
Baseline if have 2 yr follow-up*
Baseline IFG (FPG 5.6-6.9 mmol/L) - N
Baseline In-Check*’ PIFR (L/min)
Baseline inflammation markers
Baseline insulin
Baseline Insulin
Baseline insulin daily dose/kg
Baseline insulin dose (U=kg) [LSM (SE)]
Baseline Killip class
Baseline laboratory values, median (IQR)d
Baseline LDL-C
Baseline LDL-C > 160 mg/dL
Baseline LDL-C > 2.5 to < 4.2 mmol/lc
Baseline LDL-C 2.0 to < 2.5 mmol/lc
Baseline LDL-C strata, n (°/o)
Baseline LDL-C, mg/dL
Baseline LDL‐C, mg/dL
Baseline LDL-C:
Baseline LDL (mg %)
Baseline LDL cholesterol
Baseline LDL cholesterol (derived)
Baseline LDLC level (n=81, 45) >125.0 mgZdL
Baseline LDLC level (n=84, 40) ^125.0 mg/dL
Baseline LDLC level (n=84. 45) >125.0 mg/dL
Baseline LDLC level (n=86, 42) S125.0 mg/dL
Baseline lipid and apolipoprotein levels
Baseline lipid and lipoprotein values
Baseline lipid parameters, mg/dL, mmol/L or g/L
Baseline lipid profile, mg/dL, mean (sd)
Baseline lipid therapy
Baseline lipid/lipoprotein values
Baseline lipid/lipoprotem values
Baseline lipids
Baseline lipids, mg/dL
"Baseline lipids; mean ± SD (mmol/1)"
"Baseline lipids; mean ± SD (mmol/l)"
Baseline lipoprotein (a) (nmol/L), median (IQR)
Baseline Los Angeles Grade of EO, n (%)
Baseline low-density lipoprotein cholesterol (mg/dl)
Baseline Lp(a) in 2 classes
Baseline Lp(a) in 3 classes
Baseline Lp(a), mg/dL
Baseline LUTS severity*:
Baseline LUTS severity, n (%):
Baseline LVEF
Baseline LVEF, %
BaseLine LVEF, %
Baseline Mayo score
Baseline MDRD eGFR <60 mL/min/1.73 m2
Baseline MDRD eGFR >60 mL/min/1.73 m2
Baseline mean
Baseline mean (mg/dL]
Baseline mean (SD)
Baseline mean (SD), % [mmol/mol]
Baseline mean (SE)
Baseline mean 士 SD
Baseline mean ambulatory SBP, mm Hg (SD)*
Baseline Mean FEV1(SD), ml
Baseline mean mTSS
Baseline mean seated SBP, mm Hg (SD)
Baseline mean serum uric acid, pmol/L (SD)
Baseline mean, mg/dL
Baseline measurements
baseline median
Baseline Median (IQ Range)
Baseline median [mg/L]
Baseline median, mg/dL
Baseline median, mg/L
Baseline medical therapy
Baseline medical therapy, n (%)
Baseline medication
Baseline medications
Baseline medications (%)
Baseline medications, n (%)
Baseline metformin
Baseline Metformin
Baseline Microalbumin: <30
Baseline monthly POS seizure rate
Baseline msDBP (mmHg), mean±SD
Baseline msSBP (mmHg), mean±SD
Baseline msSBP/msDBP, mm Hg
Baseline mTSS subgroup
Baseline MWD, m
Baseline NBP
Baseline NIH Stroke Scale — no. (%)^
Baseline NIHSS
Baseline NIHSS score (%)#
Baseline NIHSS score, median (range)
Baseline non-HDL-Ca
Baseline normoglycaemia (FPG < 5.6 mmol/L) - N
Baseline Normoglycemia
Baseline numberf of ADM classes, n (%)
Baseline OCS use: Yes
baseline of induction
baseline of induction), n (%)
Baseline outcomes
Baseline parameter
Baseline PASI score
Baseline PASI, mean (SD)
Baseline PAV - < Median (n=209, 220)
Baseline PAV - >= Median (n=214, 203)
Baseline PAVa
Baseline PCSI<9a
Baseline PFD, m
Baseline POS frequency per 28 days,
Baseline POS frequency per 28 days, median (min, max)
Baseline post-bronchodilator % predicted FEV, < 30%
Baseline post-bronchodilator % predicted FEV, > 30% and concurrent tiotropium use
Baseline post-bronchodilator % predicted FEV, > 30% and no concurrent tiotropium
Baseline post-bronchodilator % predicted FEV, > 30% and no prior ICS use
Baseline post-bronchodilator % predicted FEV, > 30% and prior ICS use
Baseline post-bronchodilator FEV1 (SD), ml
Baseline PPASI score, mean (SD)
Baseline pre- bronchodilator FEV1,L
Baseline PreDiabetes
Baseline prednisone or oral prednisone equivalent daily dose,
Baseline presence of nasal polyps
Baseline procedure, n (%)
Baseline PSSI score, mean (SD)
Baseline PtGA
Baseline pulmonary medication
Baseline pulmonary medication, n (%)
Baseline pulmonary medication,b n (%)
Baseline pulmonary medications
Baseline renal function (eCLcr)
Baseline Risk Factors
Baseline RST-segment
Baseline RST-segment elevation, mm
Baseline SBP
Baseline SBP (mm Hg)
Baseline SBP (mm)
Baseline SBP {p=O-78)
Baseline SBP,
Baseline SBP, mean±SD, mm Hg
Baseline scales, median (range)
Baseline SeDBP, mean (SD), mm Hg§
Baseline serum calcium level, n (%)
Baseline serum K+, mEq/L
Baseline serum Mg <0.74 mmol/L
Baseline serum Mg >=0.74 mmol/L
Baseline Serum Urate (mg/dL)a
Baseline SeSBP, mean (SD), mm Hg§
Baseline SGRQ score
Baseline SGRQ total score
Baseline SGRQ Total Score
Baseline short-acting anticholinergics
Baseline short-acting anticholinergics, n (%)
Baseline SHS (0-440)
Baseline sildenafil dose mg
Baseline Sitosterol
Baseline Sitosterol/Cholesterol
Baseline Sitosterol/Lathosterol
Baseline sitting DBP,* mm Hg
Baseline sitting SBP,1mm Hg
Baseline SJC, mean (s.e.)
Baseline Skin Pain VAS, mean (SD)
Baseline smoking status
Baseline sPGA, mean (SD)
Baseline spirometry
Baseline statin
Baseline statin intensity
Baseline statin use
Baseline statin usec
Baseline STE in worst lead, mm
Baseline steroids
Baseline SU Dose < 1/2 Maximal
Baseline SU Dose > 1/2 Maximal
Baseline sUA, mean ± SD mg/dl
Baseline subgroup
Baseline Subgroup
Baseline Sulfonylurea    Yes
Baseline symptom days perweek
Baseline systolic blood pressure
Baseline systolic blood pressure (mm Hg)
Baseline systolic blood pressure, mean (SD), mm Hg
Baseline systolic BP
Baseline T-score at femoral neck, n (%)
Baseline TAV - < Median (n=210, 214)
Baseline TAV - >= Median (n=213, 209)
Baseline TAVa
Baseline TBP
Baseline TC, mg/dL
Baseline TG
Baseline TG <1.8 mmol/L
Baseline TG > 1.8 mmol/L
Baseline TG level (n=83, 40) <102.0 mg/dL
Baseline TG level (n=85, 41) s102.0 mg/dL
Baseline TG level (n=85. 46) >102.0 mg/dL
Baseline TG level {n=82, 45) >102.0 mg/dL
Baseline TG, (mg/dL), median (IQR)
Baseline therapy
Baseline TJC, mean (s.e.)
baseline to EoM Placebo (n = 168)
Baseline to year 1
Baseline tobacco use
Baseline Tophusa
Baseline total cholesterol
Baseline Total IPSS
Baseline total IPSS, mean (SD)
Baseline total PCSK9 level
Baseline total PCSK9 level by median
Baseline treatments, n (%)a
Baseline Trig >150 millycerides g/dL
Baseline triglycerides
Baseline Triglycerides <150 mg/dL
Baseline triglycerides >200 mg/dl and
Baseline triglycerides by quintiles
Baseline triglycerides in 2 classes
Baseline triglycerides in 3 classes
Baseline TRL-C by quintiles
Baseline TRL-C in 2 classes
Baseline UACR <300 mg/g
Baseline UACR >300 mg/g
Baseline UAS7
Baseline UPGR >3 gm/gm (339 mg/mmole)
Baseline UPGR, mg/mmole (n = 99, 99, 99)
Baseline use of ADM, n (%)
Baseline use of hormone therapy (%)
Baseline value
Baseline variable
Baseline Variable
Baseline vertebral fracture
Baseline VFx
Baseline Vitamin-D
Baseline weekly ISS
Baseline weight, kg
Baseline WHO Function Class
Baseline,
Baseline, % (n)
Baseline, mean (SD)
baseline, mg/dL (mmol/L)
Baseline, mm Hg
baseline, No. (%)
Baseline.mean _ SD, mg/dL
Baseline.mean _ SD.mg/dL
Baseline.mean _ SD.mg/mg
Baseline/concomitant therapies
Baseline: <3.9 mEq/L EOS: >3.9 or <3.9 mEq/L
Baseline: >3.9 mEq/L EOS: <3.9 mEq/L
Baseline: >3.9 mEq/L EOS: >3.9 mEq/L
Baselineb
Baselinec
BASFI*
BASFI, mean (SD)
BASMI (linear), mean (SD)
Batellna C-reective protein
BB
BDI focal score
BDI Focal Score
BDI focal score1
BDI total score (baseline)
bDMARD-IR
bDMARD-naive
BDP/FF/G (n=764)
BeAM values (mg/dL), mean (SD)
BeAM < 50 mg/dL at week 30, n (%)
Because of AE
Because of drug‐relateda AE
Because of drug‐relateda SAE
Because of SAE
before a change to the enrollment form was implemented in August 2007. BNP
before admission), %
Before amendment
Before Amendment (%)
Before bronchodilation
Before bronchodilation — liters§
Before bronchodilator use
Before index ACS event
Before PCI
Belgium
Belimumab 200 mg SC (n 5556)
Below-knee popliteal
Below-knee popliteal crural
Below median
Bempedoic
Bempedoic Acid (N = 1488)
Benazepril-Amlodipine Group (N = 5744)
Benazepril-Hydrochlorothiazide Group (N = 5762)
Benign prostatic hyperplasia
Benralizumab
Benralizumab 30 mg Q4W (n=116)
Benralizumab 30 mg Q4W (n=124)
Benralizumab 30 mg Q4W (n=241)
Benralizumab 30 mg Q4W (n=275)
Benralizumab 30 mg Q4W (n=399)
Benralizumab 30 mg Q4W (n=425)
Benralizumab 30 mg Q6W
Benralizumab 30 mg Q8W
Benralizumab 30 mg Q8W (n=125)
Benralizumab 30 mg Q8W (n=131)
Benralizumab 30 mg Q8W (n=239)
Benralizumab 30 mg Q8W (n=267)
Benralizumab 30 mg Q8W (n=398)
Benralizumab 30 mg Q8W (n=441)
Benralizumab Q4W (n - 15)
Benralizumab Q4W (n = 241)
Benralizumab Q4W (n = 349)
Benralizumab Q4W (n = 398)
Benralizumab Q4W (n=349)
Benralizumab Q4W (n=398)
Benralizumab Q8W (n - 15)
Benralizumab Q8W (n = 239)
Benralizumab Q8W (n = 352)
Benralizumab Q8W (n = 393)
Benralizumab Q8W (n =352)
Benralizumab Q8W (n=393)
Benzodiazepine or BzRA‡
Beta-adrenergic blocker
Beta-blocker
Beta-Blocker
Beta-blocker— no. (%)
Beta-blocker — no./total no. (%)
Beta-blocker % target dose
Beta-blocker (except sotalol)
Beta-blocker at enrollment
Beta-blocker at last follow-up |
Beta-blocker N(%)
Beta-blocker use
Beta-blocker use at baseline
Beta-blocker use at randomization
Beta-blocker!
Beta-blocker, %
Beta-blockers
Beta-Blockers
Beta-blockers (all), n (%)
Beta-blockers through hospital discharge or day 7 — %
Beta-blockers, (%)
Beta-blockers, n (%)
Beta-carotene
Beta-carotene (n = 18,405)
Beta-carotene (N = 18,405)
Beta blocker
Beta blocker use (%)
Beta Blocker users
Beta blocker, %
Beta blocker, n (%)
Beta blockers
Beta bloekers
Beta receptor antagonist
Beta1 selective
Betablocker
Betablocker Use
Between-treatment comparison of percentage change from baseline in total hip BMD
Beyond popliteal pedal
BI (15.4)
Biack
Biack Hispanic
Biack non-Hispanic
BIAsp 30
BIAsp 30 BID
BID
Bifurcation
Bifurcation lesion
Bifurcation lesion with side branch $2.5 mm stented
Bifurcation lesion with side branch ≥2.5 mm stented
Bifurcation per lesion‡
Bifurcation, n (%)
Biguanide
Biguanide (metformin)
Biguanide use at baseline
Biguanides
Biguanides (metformin)
Biguanides¶
BII (mean ± SD)
BII score
BILAG A, B or C domain score, n (%)
Bilateral disease (%)'j''j'
Biochemical events
Biochemical measures, mean (SD)
Biochemical parameters at randomization, mean
Biolimus A9-eluting stent¶
Biologic
Biologic agents
Biologic naive
Biologic therapeutic failure
Biological
Biologics User
Biomarker high
Biomarker high (periostin > 50ng/mL or blood eosinophils > 300cells per pL), na
Biomarker high (periostin >50 ng/mL or blood eosinophils >300 cells per pL)t
Biomarker levels
Biomarker low
Biomarker low (periostin < 50 ng/mL or blood eosinophils < 300 cells per pL), na
Biomarker status
Biomarkers at baseline
Biometric parameters
Bisphosphonates
Bivalirudin
Bivalirudin (n = 1,245)
Bivalirudin (N = 127)
Bivalirudin (n = 735)
Bivalirudin (N= 127)
Bivalirudin (n=1928)
Bivalirudin (n=735)
Bivalirudin Alone (N = 4612)
Bivalirudin only
Bivalirudin Only
Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors (N = 4604)
Bivalirudin used
Bivalirudin used during PCI
Bivariate frailty model (statin users vs non-users)
Biventricular pacemaker
BL
BL AlC <8.0%
BL BM1<35 kg/m^
BL BMIOO kg/m^
BL BMl <30 kg/m^
BL BMl <35 kg/m^
BL BMl >30 kg/m^
BL BMl >35 ke/m^
BL BMl >35 kg/m^
BL H/Y: Bilateral
BL H/Y: Unilateral
BL mean (cm)
BL mean (mmHg)
BL mean, mg/dl (mmol/1)
BL UPDRS: High
BL UPDRS: Low
Black
Black (n = 102)
Black (N = 102)
Black (n = 166)
Black (n = 174)
Black (n = 181)
Black (n = 183)
Black (n = 95)
Black (n=302)
"Black (n=302); Adjusted Hazard Ratio*"
Black (n=492)
Black and Other
Black Hispanic
Black Hispanic - n (%)
Black non-Hispanic
Black Non-Hispanic
Black non-Hispanic - n (%)
Black or African
Black or African‐American
Black or African-American
Black or African America
Black or African American
Black or African heritage
Black or Asian
Black participants
Black Participants
Black race
Black race — no./total no. (%)f
Black race (n=58 vs 33)
Black race and SS <9 (n=19 vs 15) ■-
Black race and SS >10 (n=39 vs 18)
Black race, n (%)
Black Region or country (%)
Black(n — 22)
Black*
black, n (%)
Black, n (%)
Black, n(%)
Black, No. (%)
Black, non-Hispanic
Black/
BLack/Af rican American
Black/African
Black/African- American
Black/African-American
Black/African-American (10.3%)
Black/African American
Black/African American*
Black/non-black
Bladder
Blaek
Blaek/Afriean-Ameriean
BLAIC <9.0%
BLAIC >8.0%
BLAIC >9.0%
bleeding
Bleeding
Bleeding end points
Bleeding Events During First 90 Days of Treatmen
Bleeding Events During the Entire Study
Bleeding Outcomes
blisibimod (n=245)
blocker
Blood-glucose control
Blood-pressure medications at randomization — no./total no. (%)
Blood bilirubin increased
Blood eosinophil
Blood eosinophil concentration, 109 cells per L
Blood eosinophil count — cells/mm’
Blood eosinophil count (109 cells per L)
Blood eosinophil count >150/mm3 at screening — no. (%)
Blood eosinophil count >300/mm3 in 12 months before screening — no. (%)
Blood Eosinophil Count cells/mm3    no.
Blood eosinophil count, geometric mean (SD loge scale) cells/ll
Blood eosinophil proportion (%)
Blood eosinophils count
Blood eosinophils, cells/mL
Blood eosinophils, mean (range), cells/mL
Blood eosinophils, mean (range), cells/mLb
Blood glucose
Blood glucose-lowering drugs, excluding insulin, n (%)
Blood glucose-lowering treatments, n (%)
Blood glucose lowering treatment
Blood leucocyte concentration (109 cells per L)
Blood leukocyte count (109 cells per L)
Blood oxygenation, mean ± SD
Blood pressure
Blood pressure-lowering treatment
Blood pressure— mm Hg
Blood pressure — mm Hg
Blood pressure — mmHg
Blood pressure (%)
Blood pressure (mm Hg)
Blood pressure (mm Hg) Systolic
Blood pressure (mm Hg)*
Blood pressure (mmHg)
Blood Pressure <140/90 mmHg, n(%)
blood pressure <90 mm Hg
blood pressure >90 mm Hg
Blood pressure at baseline:
Blood pressure at entry (mm Hg)
Blood pressure at target level (%)§
Blood pressure control
Blood pressure control*
Blood pressure eontrolt
Blood Pressure in mm Hg, mean(SD)
Blood pressure lowering medication use
Blood pressure systolic, mm Hg
Blood pressure while seated — mm Hg
Blood pressure, mean (SD) [range], mm Hg
Blood pressure, mean (SD), mm Hg
Blood pressure, mean (SD), mm Hg Systolic
Blood pressure, mean (SD), mm Hgt
Blood pressure, mean ± SD mm Hg
Blood pressure, mm
Blood pressure, mm Hg
Blood pressure, mm Hg, mean (SD)
Blood pressure, mmHg
Blood pressure, mmHg Systolic
Blood pressure, mmHg, mean (SD)
Blood pressure: systolic/diastolic (mm Hg) (mean, SD)
"blood pressure; Pbo y patients with diabe teristics (NCEP ATP I"
Blood transfusion
Blood urea nitrogen (mg/dL)
Blood urea nitrogen, mg/dL
Bloodpressure,mean (SD), m m Hg
BM1 (kg/m2)
BM1, kg/m2 (mean ± s.d.)
BMI
BMI—mean (SD) (kg/m2)
BMI - kg/m2
BMI (.kg/m-)*
"BMI (27.0; 29.9)"
"BMI (30.0; 34.9)"
"BMI (35.0; 39.9)"
BMI (kg/ m 2 )
BMI (kg/(m)2)
BMI (kg/m)
BMI (kg/m^)
BMI (kg/m^), mean (SD)
BMI (kg/m^), mean ± s.d.
BMI (kg/m’)
BMI (Kg/m2 )
BMI (kg/m2)
BMI (kg/m2) (mean ± SD)
BMI (kg/m2) (SD)
BMI (kg/m2) [mean-SD]
BMI (kg/m2) [median (25th to 75th percentile)]
BMI (kg/m2) <25
BMI (kg/m2) <30
BMI (kg/m2) Cardiac parameters
BMI (kg/m2) Cardiovascular history
BMI (kg/m2) Mean (SD)
BMI (kg/m2) mean ± SD
BMI (kg/m2)*
BMI (kg/m2), mean (SD)
BMI (kg/m2), mean (SD)a
BMI (kg/m2), mean±SD
BMI (kg/m2), Mean±SD
BMI (kg/m2), median (range)
BMI (kg/m2): mean ± SD
BMI (kg/m2)a
BMI (kg/rrr)
BMI (kg=m2)
BMI (median, IQR), kg/m2
BMI (SD), kg/m2
BMI [kg/m2]
BMI £30 kg/m* (N=64/61)
BMI <= 30
BMI <25
"BMI <25 kg/m"" (N=144/129)"
BMI <25 kg/m* (N=10/19)
BMI <25 kg/m* (N=144/129)
BMI <25 kg/m^ (N=10/19)
BMI <25 kg/m^ (N=144/129)
BMI <25 kg/m^ (N=32/35)
BMI <25 kg/m2(N=10/19)
BMI <30
BMI <30 kg/m2
"BMI = body mass index; BNP = brain natriuretic peptide; DBP = diastolic blood pressure; GFR = glomerular filtration rate; HR = heart rate; IQR = interquartile range; KCCQ = Kansas City Cardiomyopathy Questionnaire; N = number; NT = N-terminal; NYHA = New York Heart Association; SBP = systolic blood pressure"
BMI > 25, n (%)
BMI > 30
BMI > 30 kg/m2
BMI > 30kg/m2
BMI >= 35
BMI >=25 kg/m2 Population (n = 1632)
BMI >=25Kg/m2
BMI >=40
BMI >25 —no. {%)$
BMI >30
BMI >30 — no. (%)f
BMI >30 kg/m^ (N=203/199)
BMI >30 kg/m^ (N=69/77)
BMI >30 kg/m2
BMI >30 kg/m2 (%)
BMI >30 kg/m2*
BMI >30 kg/m2, n (%)
BMI >30 Obese
BMI >40
"BMI ¼ body mass index; HCTZ ¼ hydrochlorothiazide; MSDBP ¼ mean sitting diastolic blood pressure; MSSBP ¼ mean sitting systolic blood pressure; SD ¼ standard deviation"
BMI 25-<30 kg/m- (N=168/1074)
"BMI 25-<30 kg/m"" (N=106/107)"
"BMI 25-<30 kg/m"" (N=168/1074)"
BMI 25-<30 kg/m* (N =46/35)
BMI 25-<30 kg/m^ (N=106/107)
BMI 25-<30 kg/m^ (N=46/35)
BMI 25-<30 kg/ni- (N=168/1074)
BMI 25–30 Overweight
BMI 27-0-29-9
BMI 30 0-34 9
BMI 35-0-39 9
BMI 35 0-39 9
BMI 640
BMI a40
BMI at baseline (kg/m2 )
BMI categories, n (%)
BMI category
BMI category (%)
BMI category (Kg/m2)
BMI category, no. (%)
BMI distribution, n (%)
BMI group — no. (%)
BMI group (kg/m^)
BMI in kg/m2, mean (SD)
"BMI indicates body mass index; SBP, systolic blood pressure; DBP, lipoprotein(a). LDL-C was calculated with the Friedewald formula. 'Hypertension and diabetes were based on physician diagnosis. !Smoker includes current and past smokers."
BMI kg - m-2
BMI kg·m−2
BMI o30 kg/m2, n (%)
BMI kg·m−2
BMI# kg-m“2
BMI* (kg/m2), median (Q1, Q3)
"BMI, body mass index; HRT, hormone replacement therapy; LVH, left ventricular hypertrophy; NSAIDs, nonsteroidal anti-inflammatory drugs; PVD, peripheral vascular disease;TIA, transient ischemic attack. aHistory of and/or currently taking lipid-lowering or antidiabetic medications. bP< 0.05 for verapamil sustained-release (SR) vs. atenolol. cHistory of or currently have elevated serum creatinine but less than 4 mg/dl. dBlood pressure control defined as <140/90 or <130/80 in patients with diabetes or a history of renal insufficiency."
BMI, kg per m2
BMI, kg/m^
BMi, kg/m^*
BMI, kg/m^, mean (SD)
BMI, kg/m^, mean (SD)’
BMI, kg/m’
BMI, kg/m2
BMI, kg/m2 (mean 6 SD)
BMI, kg/m2 (SD)
BMI, kg/m2 Cholesterol, mg/dL
BMI, kg/m2 UAC, No. (%)
BMI, kg/m2, mean
BMI, kg/m2, mean (SD)
BMI, kg/m2, mean + SD
BMI, kg/m2, mean ± SD
BMI, kg/m2, median (IQR)
BMI, kg/m2, n
BMI, kg/m2, n (%)
"BMI, kg/m2; median (IQR)"
BMI, kg/m21
BMI, mean (SD)
BMI, mean (SD) (kg/m2)
BMI, mean (SD) kg/m2
BMI, mean (SD), kg/m^
BMI, mean (SD), kg/m2
BMI, mean (SD), kg/m2c
BMI, mean (SD), kg/rn2
BMI, mean (SD)b
BMI, mean ± SD
BMI, mean ± SD kg/m2
BMI, mean ± SD, kg/m2
BMI, mean, kg/m2
BMI, mean, kg/m2 (± SD)
BMI, mean±SD, kg/m2
BMI, median (IQR)
BMI, median (IQR), kg/m2
BMI, median (SD), kg/m2
BMI, n (%)
BMI, no. (%)
BMI, X30 kg/m2
BMI: <30.0 kg/m2
BMI: <35 kg/nr
BMI: >30.0 kg/m2
"BMI: body mass index; DBP: diastolic blood pressure; GM: Geometric mean; SBP: systolic blood pressure. The analysis was based on observed data without imputation on missing values. aSubgroup of patients in whom 24 h urine was collected (see Materials and Methods section)."
BMI^
BMI< 30kg/m2
BMI<=30
BMI<25
BMI<25Kg/m2
BMI<30kg/m2
BMI> 30kg/m2
BMI>25(%)
BMI>30
BMI>30kg/m* (N=64/61)
BMI>30kg/m2 (N =203/199)
BMI>30kg/m2 (N=203/199)
BMI>30kg/m2 (N=69/77)
BMIa
BMIJ
BMIT
BMP kg-m“2
BMS
bMultivariate Logistic regression with variables forced in the modela
BNP
BNP — pg/ml
"BNP — pg/ml;i;"
BNP (n=430)
BNP (pg/ml)
BNP (pg/mL)
BNP (pg/ml)H
BNP <80 pg/ml n=2537
BNP > 500 pg/mL or NT pro-BNP > 2000 pg/mL, n (%)
BNP >80 pg/ml n=1874
BNP >80 pg/mL, N = 9751027
BNP >80 pg/mL, N = 325 138
BNP >80 pg/mL, N = 975 1027
"BNP indicates brain natriuretic peptide; and NYHA, New York Heart Association."
BNP O 500 pg/mL or NT pro-BNP O 2000 pg/mL, n (%)
BNP(pg/mL)
BNP, median (IQR), pg/mL
BNP, pg/ml
BNP, pg/mL
BNP, pg/mLt
BNP,* median (IQR), pg/mL
BNP/NT-proBNP
BNP/NTBNP (n=687)
BOCF-iike imputation (Random.) (n=1613)
BOCF-iike imputation (Random.) (n=1616)
BOCF-iike imputation (Random.) (n=2153)
Bodily pain
Body-mass index
Body-mass Index
Body-mass index-!'
Body-mass index - kg/m2, Median (IQR)
Body-mass index — no. (%)$
Body-mass index — no. (%):i:
Body-mass index ( kg / cm2)
Body-mass index (kg/m')
Body-mass index (kg/m-)
Body-mass index (kg/m-)!
Body-mass index (kg/m 2)
Body-mass index (kg/m’)
Body-mass index (kg/m2)
Body-mass index (kg/m2) (mean, SD)
Body-mass index (kg/m2)*
Body-mass index (kg/m2), mean (SD)
Body-mass index (kg/m2)t
Body-mass index (kg/mJ) Previous diagnosis
Body-mass index (kg/mQ
Body-mass index \ kg/m2
Body-mass index > 30, n(%)
Body-Mass Index >30
Body-mass index >30 kg/nrn
Body-mass index categories — no. (%):c
Body-mass index$
Body-mass index)
Body-mass index)'
Body-mass index)-
"Body-mass index)"""
Body-mass index*
Body-mass index, kg/m2
Body-mass index, kq/nrn
Body-mass index, mean (SD)
Body-mass index:!:
Body-mass index:!: Blood pressure — mm Hg
"Body-mass index;!;"
"Body-mass index;!; Waist-to-hip ratio"
Body-mass index^
Body-mass index^:
"Body-mass index^;"
Body-mass index”
Body-mass index§
Body-mass indexf
Body-mass indexj
Body height (cm)
Body mass index
Body Mass Index
Body mass index - kg/m2T
Body mass index - mean (sd)
Body mass index (BMI), kg/m2
"Body mass index (BMI; kg/m2), n (%) < 30 kg/m2"
Body mass index (kg/m )
Body mass index (kg/m^)
Body mass index (kg/m^)^
Body mass index (kg/m’)^
Body mass index (kg/m“)^
Body mass index (kg/m1)
Body mass index (kg/m2 )
Body mass index (kg/m2 ),
body mass index (kg/m2)
Body mass index (kg/m2)
Body Mass Index (kg/m2)
Body mass index (kg/m2) - mean ± SD
Body mass index (kg/m2) Baseline systolic blood
Body mass index (kg/m2)∗
Body mass index (kg/m2)*'
Body mass index (kg/m2),
Body mass index (kg/m2), mean (SD)c
Body mass index (kg/ma)
Body mass index (kg/nr)
Body mass index (kgm _2)
Body Mass Index (median,
Body mass index (mg/m2)
Body Mass Index (range) (kg/m2)
Body mass index [kg/m2], mean ± SD
Body mass index <30 kg/m2
Body mass index >30 — no. (%)f
Body mass index >30 kg/m , n (%)
Body mass index >30 kg/m2*
Body mass index >30 kg/m2, n (%)
Body mass index >30, n (%)
Body mass index >30t
Body mass index Blood pressure — mmHg
Body mass index category, no. (%)l
Body mass index group (≥ 30 kg/m2)—No. (%)
Body mass index group (kg/m2) ≥30 kg/m2—No. (%)
Body mass index mean kg/m2 (SD)
Body mass index subgroups
Body mass index*
Body mass index,
Body mass index, %
Body mass index, kg/m^
Body mass index, kg/m^ (meaniSD)
Body mass index, kg/m^ mean (SD)
Body mass index, kg/m^^
Body mass index, kg/m’
Body mass index, kg/m2
Body Mass Index, kg/m2
BoDy Mass InDex, kg/m2
Body mass index, kg/m2 (mean ± SD)
Body mass index, kg/m2 (SD)
Body mass index, kg/m2 (SD)
Body mass index, kg/m2, mean (SD)
Body mass index, kg/m2, mean (SD)§
Body mass index, kg/m2, mean + SD
Body mass index, kg/m2, mean±SD
Body mass index, kg/m2, median (Q1, Q3)
Body mass index, kg/rn \ mean (SD)
Body mass index, mean (sd)
Body mass index, mean (SD)
Body mass index, mean (SD) (kg m)2)
Body mass index, mean (SD) [range]a
Body mass index, mean (sd) Kg/M2
Body mass index, mean (SD) kg/m2
Body mass index, mean (SD), kg/m2
Body mass index, mean (SD)d
Body mass index, mean (SD)t
Body mass index, mean kg/m^ (SD)
Body mass index, median (IQR)
Body mass index, median (IQR)b
Body mass index, median, (25th—75th percentiles), kg/m2
Body mass index,* kg/m2
Body mass index/ Mean (SD)
Body Mass Index:
"Body mass index; mean + SD (kg/m )"
"Body mass index; mean ± SD (kg/m2)"
Body mass index^
Body mass index+
Body mass index3
Body mass indexa
Body mass indexa <Median
Body mass indexb
Body mass indexc
Body mass indexf
"Body mass indexf; <25"
Body mass indext
Body mass, kg
Body massindex,mean (SD)a
Body weight
Body weight — kg
Body weight (change from baseline)
Body weight (kg)
Body weight (kg)*
Body weight (kg), mean (s.d.)
Body weight (kg), mean (SD)
Body weight (kg), mean±SD
Body weight (kg), n (%)
Body Weight at Randomization
Body Weight at Randonization {IXRS)
Body weight index (kg/m2)
Body weight reduction >5%
Body weight*
Body weight, %
Body weight, kg
Body weight, kg (mean ± SD)
Body weight, kg (SD)
Body weight, kg^
Body weight, mean = SD, kg
Body weight, mean ± SD, kg
Body weighta, kg
Body weiqht
Bodymass index (kg/m2)
Bodyweight (kg)
Bodyweight, kg
Bolus
Bolus administered — no. (%)
Bolus alone
Bolus and corrections
Bolus and infusion
Bolus insulin doseH
Bolus of heparin given
Bone erosion ( judged by physician), n (%)
Bone erosion (judged by physician), n (%)
Bone erosion score, mean (SD)
Bone fracture
Bone fracture due to fall
Bone mineral density (g/cm2), mean (SD)
Bonferroni- adjusted P Value, B vs a
Bonferroni- adjusted P Value, c vs a
Bonferroni- adjusted P Value, D vs a
BOOST INTENSIFY ALL (pan-Asian patient population)
BOOST INTENSIFY PREMIX I (global patient population)
Borg dyspnea score WHO functional class, n (%)
Bosentan
Bosentan (N = 407)
Bosentan Use:
Both
Both (%)
Both ACE inhibitor and ARB
Both adalimumab groups (n = 26)
Both adalimumab groups (n = 31) No baseline CD-related antibiotic use
Both adalimumab groups (n = 39) Baseline immunosuppressant use
Both adalimumab groups (n = 44) Baseline CD-related antibiotic use
Both deep-vein thrombosis and pulmonary embolism
Both impaired glucose tolerance and impaired fasting glucose tolerance — no.
Both IV vasodilator and inotrope
Both PTCA and CABG
Both unfractionated heparin and low-molecular-weight heparin
Bowel function
Bowel stricturing,' n (%)
BP-Lowering Treatment (n=1119)
BP-lowering treatments, n (%)
BP <140/90, n (%)
"BP = blood pressure;eGFR = estimated glomerular filtration rate (men: 194 en: 194 X Cr 1.094 X age 0.287 X 0.739);HDL = high-density lipoprotein."
BP and fasting glucose results
BP Component (mm Hg)
BP control
BP goal attainment
BP goal, no. (%)
BP in pre-treated patients
BP Variable, mm Hg
"BP: blood pressure; CI: confidence interval; ESRD: end-stage renal disease; HR, hazard ratio.
All patients (except patients with other race) were included with missing covariates imputed.
Event: no. of patients with ESRD; rate: event rate per 1000 years of follow-up; pre-specified: a Cox model with treatment group and region as covariates and baseline proteinuria level (o or X2 g/g) as strata; adjusted: a multivariate Cox model with treatment group, time-varying systolic and diastolic BP as covariates.
Pre-specified analysis and adjusted for time-varying BP"
bPearson's chi‐square test.
BPH-LUTS severity
BPH-related health status
Brachial
Brain volume, cm'
Brain volume, cm3
bRandomization was stratified by diabetic status.
Brazil
Breakfastb
Bronchial reversibility %
Bronchitis
BRV >50 mg/day
BRV 100 mg/day ( n = 14)
BRV 100 mg/day (n = 252)
BRV 100 mg/day (n = 253)
BRV 100 mg/day (n = 36)
BRV 100 mg/day (n = 61)
BRV 100 mg/day
BRV 200 mg/day ( n = 6)
BRV 200 mg/day (n =
BRV 200 mg/day (n = 16)
BRV 200 mg/day (n = 249)
BRV 200 mg/day (n = 250)
BRV 200 mg/day (n=41)
BRV 200 mg/day
BRV 50 mg/day (n = 32)
BRV 50 mg/day (n = 4)
BRV 50 mg/day (n = 7)
BRV 50 mg/day
BRV dosage, mg/d
BRV overall
BRV overall (n = 24)
BRV overalla (n = 134)
BRV overalla (n = 59)
BSA (%)
BSA (%), mean (SD)
BSA >3%, n (%)t
BSA affected, %
BSA affected, mean ± SD, %
BSA involved, %1
BSA, %*
Bsl Hb, gl-1
"Bsl, baseline; Cl, confidence interval; ESRD, end-stage renal disease; Hb, hemoglobin; HR, hazard ratio; K (rate), # of events per 1000 patient-years of follow-up; Yr, year. Multivariate Cox model with hemoglobin category and baseline urinary albumimcreatinine ratio, serum albumin, serum creatinine, and hemoglobin as covariates."
"bsl, baseline; Cl, confidence interval; ESRD, end-stage renal disease; Hb, hemoglobin; K (rate), # of events per 1000 patient-years of follow-up; RRR, relative risk reduction; Yr, year. ^Treatment effect of losartan versus placebo. interaction test between treatment group and hemoglobin group (<120 or > 120g I-1). cMultivariate Cox model with baseline log urinary albumimcreatinine ratio, serum albumin, serum creatinine, and hemoglobin as covariates. dMultivariate Cox model with baseline log urinary albumimcreatinine ratio, serum albumin, serum creatinine, and hemoglobin and change in hemoglobin at year 1 as covariates."
BUD 320 ptg n = 123
BUD/FM 320/9 Atg n = ^27
Budesonide
Budesonide- Formoterol (N = 5846)
Budesonide- Formoterol 160 ^g + 4.5 ^g (N = 4201)
Budesonide- Formoterol 80    + 4.5 ^g (N = 1645)
Budesonide — no. (%)
Budesonide (N = 5847)
Budesonide (symptom days a week)
Budesonide {symptom days a week)
Budesonide 160 ^g (N = 4201)
Budesonide 80 ^g (N = 1646)
Budesonide MMX 6 mg, (n=128)
Budesonide MMX 9 mg, (n=128)
Budesonide, n (%)
Budesonide/formoterol FDC
Bumetanide
BUN (mg/dl)
BUN, mg/dL
BUN, mmol/l
BUN, mmol/L
Bundle branch block
BW at 24 weeks, kg+
BW, kg
BW, mean (SD), kg
By baseline diabetic status
By Cause of Death
By genotyping
By GFR stratum for all participants, mL/min per 1.73 m’!
By GFR stratum for diabetic participants, mt/min per 1.73 m’§
By GFR stratum tor all participants, mL/min per 1.73 m^!
By GFR stratum tor diabetic participants, mL/min per 1.73 m’§
By Treatment Arm
By WHO/Simon Broome criteria
Bypass graft
Bypass graft§
Bypass surgery
C
C-peptide
C-Peptide Tx difference vs Pbo, median change from baseline (SE)1
C-Peptide, median (Q1, Q3), nmol/L
C-Peptide, median (Ql, Q3), nmol/L
C-reactive protein
C-reactive protein — mg/liter**
C-reactive protein — mg/literj
"C-reactive protein (high-sensitivity assay); MITT = modified intent-to-treat; Pbo cholesterol; Cl = confidence intervals; HDL-C = high-density lipoprotein cholest = National Cholesterol Education Program Adult Treatment Panel y patients with diabetes (FC >_ 126 mg/dL [> 7.0 mmol/L]). To qualify as having acteristics described in Methods (NCEP ATP III definition); + Baseline values are rr d hs-CRR for which medians are presented; **p<0.001; §p=0.002; *p=0.027. nteractions were not statistically significant (p>0.05)."
C-reactive protein (mg/dl)
C-reactive protein (mg/dl_)
C-reactive protein (mg/L)
C-reactive protein concentration (mg/L)
C-reactive protein, median (IQR), mg/L
C-reactive protein, median (Q1, Q3)
C-reactive protein, mg/L
C-Reactive Protein, mg/L
C-reactive protein, U/L
C-reactive protein,* mg/L
C-reactive proteinc
c Clinical Fractures (FAS)
C group ( n = 585)
C peptide, nmol/L*'
c, right-sided VhD (n=165)
C. DAS28-CRP <3.2
C100 ml decrease in trough FEV1
C4-unit SGRQ total score increase
c7E3 Fab BOLUS
c7E3 Fab Bolus (N = 695)
c7E3 Fab Bolus and Infusion (N = 708)
Ca-channel blockers, n (%)
CABG
CABG — no. (%)
CABG — no. {%)
CABG (%)
CABG >1 month ago
CABG during index hospitalization
CABG history
CABG only
CABG or angioplasty
CABG or PCI
CABG or PTCA (%)
CABG or PTCA/PCI
CABG or valve
CABG performed during index hospitalization
CABG surgery
CABG surgery by No. of vessels 1
CABG(%)
CABG, n (%)
CABG:
CABGorPTCA
CAD
CAD and ABI <0-90§
CAD and/or CRVD (%)
CAD Death
CAD history and risk factors, n (%)
CAD*
Caffeine
Caffeine consumption (yes) (n)
Caffeine consumption*
Caffeine user
Caffeine user, n (%)
Caffeine users, n (%)
Calcification, n (%)
Calcitonin
Calcium-channel antagonists
Calcium-channel blocker
Calcium-channel blocker (ratelowering)
Calcium-channel blocker*
Calcium-channel blockerf
Calcium-channel blockers
Calcium-channel blockers (%)
Calcium-channel blockersubgroup
Calcium-channel inhibitor
Calcium (mmol/L)
Calcium aniagonisi
Calcium antagonist
Calcium antagonist— no. (%)
Calcium Antagonist Strategy (CAS) (events/n)
Calcium Antagonist Strategy (n = 11 267)
Calcium antagonists
Calcium antagonists, n (%)
Calcium channel
Calcium channel antagonists, n (%)
Calcium channel blocker
Calcium channel blocker (%)
Calcium channel blockers
Calcium Channel Blockers
Calcium channel blockers, n (%)
calcium channelantagonist
Calcium Level
Calcium supplements
Calcium, mmol 1 1
Calculated annual decline, mean ± SE
Calculated LDL-C in 4 classes
Calculated LDL cholesterol (week 12)
Caleitonin, ng/L, females Mean±SD
Caleitonin, ng/L, males Mean±SD
Caleium ehannel bloekers (CCB)
CALIMA Japan (N = 83)
CALIMA Japandhigh-dosage ICS/LABA and baseline blood eosinophils >300 cells/mL (n = 46)y
CALIMA overall (N = 1306)
CALIMA overalldhigh-dosage ICS/LABA and baseline blood eosinophils >300 cells/mL (n = 728)
CANA
Cana 100 mg
CANA 100 mg
CANA 100 mg ( n 5 665)
CANA 100 mg (n- 157)
CANA 100 mg (n-195)
CANA 100 mg (n-368)
CANA 100 mg (n = 1441)
CANA 100 mg (n = 1445)
CANA 100 mg (n = 1557)
CANA 100 mg (n = 159)
CANA 100 mg (n = 159)*
CANA 100 mg (n = 217)
CANA 100 mg (n = 315)
CANA 100 mg (n = 338)
CANA 100 mg (n = 339)
CANA 100 mg (n = 368)
CANA 100 mg (n = 408)
CANA 100 mg (n = 425)
CANA 100 mg (n = 493)
CANA 100 mg (n = 494)
CANA 100 mg (n = 518)
CANA 100 mg (n = 59)
CANA 100 mg (n = 616)
CANA 100 mg (n = 674)
CANA 100 mg (n = 774)
CANA 100 mg (n = 833)
CANA 100 mg (n = 867)
CANA 100 mg (n 5 168)
CANA 100 mg (n= 197)
CANA 100 mg (n=222)
CANA 100 mg (n=611)
CANA 100 mg (n=833)
CANA 100mg (n=833)
Cana 300 mg
CANA 300 mg
CANA 300 mg (n-156)
CANA 300 mg (n-197)
CANA 300 mg (n-367)
CANA 300 mg (n = 1074)
CANA 300 mg (n = 1441)
CANA 300 mg (n = 149)
CANA 300 mg (n = 191)
CANA 300 mg (n = 1932)
CANA 300 mg (n = 260)
CANA 300 mg (n = 328)
CANA 300 mg (n = 340)
CANA 300 mg (n = 377)
CANA 300 mg (n = 404)
CANA 300 mg (n = 430)
CANA 300 mg (n = 494)
CANA 300 mg (n = 506)
CANA 300 mg (n = 56)
CANA 300 mg (n = 598)
CANA 300 mg (n = 643)
CANA 300 mg (n = 645)
CANA 300 mg (n = 685)
CANA 300 mg (n = 744)
CANA 300 mg (n = 778)
CANA 300 mg (n = 834)
CANA 300 mg (n 5 141)
CANA 300 mg (n 5 693)
CANA 300 mg (n=226)
CANA 300 mg (n=608)
CANA 300 mg (n=834)
CANA 300mg (n=1461)
CANA 300mg (n=834)
CANA100 (n =237)
CANA100/MET (n = 237)
CANA300/MET (n =237)
Canada
Canada or United States
Canagiiflozin
Canagliflozin
Canagliflozin (N = 5795)
Canagliflozin (n=1110)
Canagliflozin (n=4684)
Canagliflozin (n=4992)
Canagliflozin (n=803)
Canagliflozin 100 mg vs Sitagliptin 100 mg
Canagliflozin 300 mg vs Sitagliptin 100 mg
Canagliflozin Dose
Canakinumab
Canakinumab 150 mg
Canakinumab 300 mg
Canakinumab 50 mg
Canakinumab Dose
Canakinumab Dose (per mo)
Canakinumab Dose (per month)
Canakinumab, 3-month on-treatment IL-6 below the median value (<1.65 ng/L) (n = 1617)
Canakinumab, 3 month on-treatment Il-6 above the median value (≥1.65 ng/L) (n = 1619)
Canakinumab, hsCRP <2-0 mg/L at 3 months (n=3484)
Canakinumab, hsCRP >2-0 mg/L at 3 months (n=2868)
Canakinumab, IL-6 lowest tertile
Canakinumab, IL-6 middle tertile
Canakinumab, IL-6 top tertilec
Cancer
Cancer — no. (%)
Cancer (N=1480)
Cancer Medications
Cancer n (%)
Cancer surgery
Cancer*
Cancer**
Cancer, fatal and nonfatal
Cancer§
Cancert
Candesartan
Candesartan 14/63
Candesartan 37/62
Candesartan group (n = 203)
Candesartan Group (N = 391)
Cangrelor
Cangrelor    Clopidogrel no. of events/total no. (%)
Cangrelor (N = 3946)
Cangrelor (N = 4433)
Cangrelor (N = 487)
Cangrelor (N = 5472)
Cangrelor (n = 6639)
Cangrelor (N=1558)
Cangrelor (N=1558) n/N (%)
Cangrelor (N=1583) n/N (%)
Cangrelor (N=3914)
Cangrelor (N=3914) n/N (%)
Cangrelor (N=3946) n/N (%)
Cangrelor (N=5404)
Cangrelor (N=68)
Cangrelor Dyspnoea vs No dyspnoea*
Cangrelor n/N (%)
Cangrelor, %
Canrenone (n Z 146)
Canrenone (n Z 73)
CANVAS
CANVAS-R
"CANVAS (N = 4327): Placebo (n = 1441); CANA 100 mg (n = 1445); CANA 300 mg (n = 1441)"
Carbamazepine
Cardiac
Cardiac-biomarker status — no./total no. (%)$
Cardiac-biomarker status 一no./total no. (%)$
Cardiac and echocardiography parameters
Cardiac arrhythmia
Cardiac arrhythmia, n (%)
Cardiac biomarker elevation
Cardiac biomarker status!
Cardiac biomarker, n (%)
Cardiac catheterisation or PCI for index event
Cardiac death
Cardiac disease
Cardiac diseasec
Cardiac disorder
Cardiac disorder, n (%)§
Cardiac disorders (SOC)
Cardiac enzyates raised
Cardiac failure
Cardiac failure—
Cardiac failure*
Cardiac failure, n (%)
Cardiac failure§
Cardiac failurec
Cardiac glycosides
Cardiac history
Cardiac history, %
Cardiac index, L • mn ' • m 2
Cardiac mediations
Cardiac medications at discharge, %
Cardiac medications during index hospital stay and/or discharge
Cardiac medications during index hospitalization
Cardiac medications during index hospitalization — no. (%)
Cardiac medications during index hospitalization, %
Cardiac medications during indexhospitalization and/or discharge
Cardiac pacemaker — no. (%)
Cardiac parameters
Cardiac Procedure:
Cardiac resynchronization therapy
Cardiac resynchronization therapy N(%)
Cardiac rhythm
Cardiac rhythm disorder at baseline NO
Cardiac rhythm disorder at baseline YES
Cardiac rhythm disorders
Cardiac risk
Cardiac stretch
Cardiac therapy
Cardiac therapy, n (%)d
Cardiac therapy§
Cardiac troponin T level >0.03 pg/L
Cardiac troponin T level, median (IQR), pg/L
Cardiac valve surgery: No (n=707)
Cardiac valvular disease
Cardio-renal risk
Cardioembolic
Cardioembolic infarction, n (%)
Cardioembolism
Cardiogenic shock during first 24 hr after randomization
Cardiometabolic syndrome, ^n (%)
Cardiomyopathy
Cardiothoracic ratio >0.55
Cardiovascu lar subg roup
Cardiovascuiar mortaiity
Cardiovascular
Cardiovascular and oral hypoglycemic drugs - no.(%)
Cardiovascular and respiratory
Cardiovascular death
Cardiovascular Death
Cardiovascular death (n=104)
Cardiovascular death and hospital admission for heart failure
Cardiovascular Death or Heart Failure Hospitalization
Cardiovascular death or hospitalization for heart failure
Cardiovascular death or hospitalized HF
Cardiovascular death or nonfatal myocardial infarction
Cardiovascular death!
Cardiovascular death*
Cardiovascular death, MI, or stroke
Cardiovascular death, myocardial infarction, or stroke
Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke
Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
Cardiovascular death/ Hospitalization for heart failure
Cardiovascular death/myocardial infarction/stroke
Cardiovascular death®
Cardiovascular disease
Cardiovascular Disease
Cardiovascular disease (n=1083)
Cardiovascular disease (n=1101)
Cardiovascular disease (n=1480)
Cardiovascular disease history
Cardiovascular disease history, n (%)*
Cardiovascular disease history‡
Cardiovascular disease n (%)
Cardiovascular disease risk category
Cardiovascular disease*
Cardiovascular disorder
Cardiovascular disorder, n (%)
Cardiovascular events
Cardiovascular history
Cardiovascular history — no. (%)
Cardiovascular history — no./total no. (%)
Cardiovascular history 一no. (%)
Cardiovascular hospitalisation§
Cardiovascular hospitalization
Cardiovascular inclusion criteriat
Cardiovascular Medication Usage
Cardiovascular medications
Cardiovascular medications, %
Cardiovascular metabolic syndrome risk lactors
Cardiovascular mortality
Cardiovascular Mortality
Cardiovascular mortality (per 100 person-years)
Cardiovascular mortality or MI
Cardiovascular mortality, MI, or revascularization
Cardiovascular risk
Cardiovascular risk factor—no. {%)
Cardiovascular risk factors
Cardiovascular risk factors — no. {%)
Cardiovascular risk factors — no./total no. (%)
Cardiovascular Risk Factors Alone (n=2565)
Cardiovascular risk factors and history
Cardiovascular risk factors and history — no. (%)
Cardiovascular risk factors and history (%)
Cardiovascular risk factors and medical history
Cardiovascular risk factors, n (%)
Cardiovascular risk factors, no. (%)
Cardiovascular risk, n (%)
Cardiovascular therapies — no. {%)
Cardiovasculardeath
Cardiovasculardeath/myocardial infarction/stroke
Cardioversion in previous 2 wk
CARDS
CARE
care use
Caribbean
Carisbamate 1,200 mg (N = 182)
Carisbamate 800 mg (N = 180)
Carotid
Carotid artery— no. (%)
Carotid artery disease
Carotid artery diseaset
Carotid artery intervention*
Carotid artery stenosis, n (%)
Carotid bulb sites
Carotid endarterectomy
Carotid IMT
Carotid infarct
Carotid revascularization
Carotid Stenosis
Carrier (N=194)
Carvedilol
Carvedilol, % (n)
Cases
Casual plasma glucose (mg/dL)
CAT >=  15 (n = 2,544)
CAT >=  20 (n = 1,617)
CAT >= 10
CAT >= 10 (n = 3,227)
CAT >=15
CAT >=20
CAT score
CAT Score
CAT score category
CAT score, mean (SD)
CAT scoreff
CAT total score
CAT total score1
Cat. 1 n/N (%)
Cat. 2 n/N (%)
CAT<10
CAT>0
Cataract
Cataract removal
Catecholamines or corticosteroids without hospitalization
Categorical variables,
Categorical variables. No. (%)*’
Categories of Urinary ACR, ^g/mg
Category
Category— no./total no. (%)
Category 1
Category 2
Category 3
Category 4 and 5
Catheter access site
Catheter site—femoral
Catheterization laboratory in
Catheterization laboratory in center
Catheterization performed for qualifying event
CATscorecategory,n (%)
Caucasian
Caucasian (%)
Caucasian 1
Caucasian ethnicity
Caucasian EZE/SIMVA
Caucasian EZE/SIMVA („ = 1082}
Caucasian EZE/SIMVA (n = 1082)
Caucasian N = 1,863
Caucasian race
Caucasian race (%)
Caucasian SIMVA
Caucasian SIMVA („ = 1055}
Caucasian SIMVA (n = 1055)
Caucasian, %
Caucasian, n (%)
Caucasian, n (%)*
Caucasiana (%)
Caucasians
Caucasians (n = 651)
Caucasians (n = 668)
Causaslan
Cause of death unknown
Cause of DVT or PE — no. (%)
Cause of heart failure
Cause of heart failure — no. (%)
Causes of DVT or PE — no. (%)^|
Causes of DVT or PE, n (%)
CBZ-exposed
CBZ-naive
CC
CCB
CCBs, (%)
CCLEAR <50
CCLEAR 50-79
CCLEAR 80+
CCLEAR<50
CCQ score§§
CCQ total score
CCS class§
CCSC at 1 month before enrollment
CCV history/condition
CCV history/condition at baseline
CD [GEMINI 2]*’
CD [GEMINI 3]*’
CD complications
CD duration, y
CDAI
CDAI (0-76)
CDAI <10t
CDAI <2.8*
CDAI >330, n [%]
CDAI score
CDAI score <250
CDAI score, mean (s.d.)
CDAI score, mean ± SDa
CDAI score, median (min, max)
CDAI score§
CDAI, mean (SD)
CDAI, mean [SD]
CDAI§
cDMARD
cDMARD experience, n (%)
Celecoxib
Celecoxib (N = 318)
center
Center-Level IHR Percent Time in Therapeutic Range for Warfarin Subjects
Center Level TTR
Center location
Central America and South America
Central and Eastern Europe
Central and South America
Central and South America and Mexico
Central eosinophil count
Central eosinophil count (cells per pL)
Central eosinophil count (cells per pL)t
Central Europe
Central nervous system
Central or South America
Central/Eastern
Central/Eastern Europe and Russia HR (95% Cl)
Central/Eastern Europe/Russia
Central/South
Central/South America
Central/South America and Mexico
Centrally acting sympathomimetics
centre
Centrilobular emphysema
Cerebral
Cerebral embolism
Cerebral hemorrhage
Cerebral infarction
Cerebral ischemia
Cerebral thrombosis
Cerebral vascular disease
Cerebrovascuiar disease
Cerebrovascular
Cerebrovascular accident
Cerebrovascular accident/TIA
Cerebrovascular disease
Cerebrovascular disease n (%)
Cerebrovascular disease, %
Cerebrovascular disease, n (%)
Cerebrovascular disorders, n (%)
Cerebrovascular or peripheral arterial disease
Cerebrovascular or peripheral arterial disease, n (%)
Cerebrovascular or peripheral arterial disease, n (%)
Certolizumab Group
Certolizumab Group (N = 215)
Certolizumab Group (N = 331)
Certolizumab pegol (n = 223)
CFB at Week 168
CFB at Week 216
CFB at Week 96
cFisher's exact test.
Cg/LD
cGFR, ml/min/1.73m2
cGFRby CKD-EPI, mL/min/1.73 m2, median (IQR)
CGI-S, n (%)z:
CGM use
CHA0S2 Score
CHA2DS2-VASc
CHA2DS2-VASc #4
CHA2DS2-VASc $2
CHA2DS2-VASc <4
CHA2DS2-VASc >2
CHA2DS2-VASc >4
CHA2DS2-VASC >5
CHA2DS2-VASC 0-1
CHA2DS2-VASC 0 1
CHA2DS2-VASc score
CHA2DS2-VASc score (median, IQR)
CHA2DS2-VASc score,
CHA2DS2-VASc score, mean±SD
CHA2DS2-VASc score, n (%)
CHA2DS2-VASc, mean±SD
CHA2DS2VASC score
CHA2DS2VASC Score
CHA2DS2VASc score (%)
CHA3DS2-VASC 2-4
CHAD52>3
CHADS-2 score
CHADS score, n (%)
chads2
CHADS2
CHADS2 risk factors, n (%)
CHADS2 score
CHADS2 Score
CHADS2 score >3
CHADS2 Score 2
CHADS2 score 4-6, n (%)
CHADS2 Score per Outcome Stroke or systemic embolism
CHADS2 score*
CHADS2 score, Mean (±SD)
CHADS2 score, mean±SD
CHADS2 score, n (%)
CHADS2 scoreb
CHADS2 scoret
CHADS2 score, n (%)
CHADS2, mean±SD
chads2^
CHADS2<3
CHADS2components, n (%)
CHADS2scoref
CHADSa <3
CHADSj <3
CHADSj >3
CHAjDSa-VASc 2-4
CHAjDSj-VASc >5
CHAjDSj-VASc 2-4
CHAjDSrVASc 0-1
Change
Change at week 104
Change From
Change from baseline
Change from baseline (%)
Change from baseline at week 12
Change from baseline at week 164
Change from baseline at week 26
Change from baseline at Week 26
Change from baseline at week 28
Change from baseline in
Change from Baseline in % Predicted FEV1
Change from baseline in ACQ-5
Change from baseline in ACQ-5 score
Change from baseline in AQLQ{S) score
Change from baseline in DAS28-ESR, mean6 SD
change from baseline in FEVj (mb)
Change from baseline in HbA1c (%)
Change from baseline in mean 24-h DBP, mmHg
Change from baseline in mean 24-h SBP, mmHg
Change from baseline in morning PEF during weeks 28-32, mean l/min (SE)
Change from baseline in post-BD
Change from baseline in pre-BD
Change from baseline in rescue medication use (puffs per day)
Change from baseline in SGRQ
Change from baseline Stage 3 CKD
Change from baseline Stage 4 CKD
Change from baseline to EOS, mg/dL
Change from baseline to EOS, uU/mL
Change from baseline to final APBM
Change from baseline to week 12 in DLQI scorez
Change from baseline to week 12 in UAS7
Change from baseline to week 12 in weekly ISS
Change from baseline to week 12 in weekly no. of hives score
Change from baseline to week 12 in weekly size of largest hive score
Change from baseline to week 24
Change from baseline*
Change from baseline, adjusted mean (95% CI)
Change from baseline, adjusted mean (95% CI), %
Change from baseline, median (IQR)
Change from baseline, mg/dL, mean(sd)
Change from baseline, mmHg
Change from pre- to
Change in BP, mm Hg
Change in DAS28-ESR (mean)i Physical function outcomes week 52
Change in DAS28 > 1.2
Change in erosion score (mean)
Change in femoral neck BMD from FIT baseline to FLEX baseline
Change in FPG 0 to month 4 (mg/dl)
Change in HAQ-DI (mean)t
Change in HbA1c 0 to month 4 (%)
Change In HbAlc after 18 weeks ETD (95% Cl)
Change In HbAlc after 26 weeks ETD (95% Cl)
Change in HDL‐C
Change in LDL‐C
Change in Lp(a)
Change in mTSS (mean)
Change in NT-proBNP at 12 months (log-transformed)
Change in NT-proBNP at 4
Change in NT-proBNP at 8
Change in PAV, Mean (95% Cl), %
Change in PsA‐modified SHS, baseline to week 24‡
Change in PsA‐modified SHS, baseline to week 52
Change in retinal pathology
Change in SBP
Change in SBP (12 months)
Change in SBP (4 months)
Change in SBP (8 months)
Change in SeDBP, LS mean (SE)
Change in SeSBP, LS mean (SE)
Change in TC
Change in TG
Change to Week 12
Change to Week 48*
Change to Week 48*’’
Change to Week 12
change, mg/dL (mmol/L)
Change3
Changes (A) in metabolic syndrome parameters HDL cholesterol
Changes at baseline
Changes from baseline in msSBP and msDBP are shown as least-squares mean SEM. *P 0.05 vs  65 y.
Changes in serum creatinine, pmol/L
Changes in SHS
Characteristic
CHARACTERISTIC
Characteristic (A)
Characteristic Age
Characteristic Age — yr
Characteristic Age Mean ±SD — yr
Characteristic and Treatment
Characteristic at Baseline
Characteristic*
Characteristic, No. (%)
Characteristic/Outcome
Characteristic^
Characteristic_level
Characteristic_name
Characteristic†
Characteristica
Characteristics
Characteristics No. of participants
Characteristics of pulmonary embolism at inclusion
Characteristics*
Characteristicsa
Charlson
Charlson comobility score, n (%)
Charlson comorbidity index
Charlson Comorbidity Index
Charlson comorbidity index, mean (SD)
Charlson index (%)
CHARM
CHD
CHD (nonfatal MI + fatal CHD)
CHD (primary outcome)
CHD + Cl All
CHD at baseline
CHD death
CHD Death
CHD deaths
CHD disease death
CHD EZE/SIMVA
CHD EZE/SIMVA („ = 240)
CHD EZE/SIMVA (n = 240]
CHD history, n (%)
CHD Men
CHD plus cerebral infarction
CHD Risk- no. (%)
CHD risk equivalents, n (%)
CHD risk factors#
CHD SIMVA
CHD SIMVA („ = 210)
CHD SIMVA 0 = 210]
CHD status
CHD status §
CHD*, n (%)
"CHD, coronary heart disease; EZE/SIMVA, ezetimibe/simvastatin combination tablet; FPG, fasting plasma glucose; PVD, peripheral vascular disease;"
CHD, n (%)
CHD, total
CHD+ cerebrovascular disease Men    71 /1248 (12.9)
CHD+ cerebrovascular disease Men 71 / 1248 (12.9)
CHD+cerebral infarction
CHDa
Chest discomfort
Chest x-ray
CHF
CHF (%)
CHF on Losartan (%)
CHF on Placebo (%)
CHF score (U)
Chi-square p value
China
China/Japan
China/tJapan
Chinese
Chinese Subgroup
CHL
Chlor
Chloroquine
Chlorthalidone
Chlorthalidone (N = 171)
Chlorthalidone 10174
Chlorthalidone Group
Chlorthalidone vs Amlodipine
Chlorthalidone vs Doxazosin
Chlorthalidone vs Lisinopril
Cholecystectomy (N=267)
Cholecystitis chronic
Cholesterol
Cholesterol- mean (sd, N)
Cholesterol — mg/dl
Cholesterol — mmol/liter
cholesterol (%)
Cholesterol (mg/dl)
Cholesterol (mg/dL)
Cholesterol (mmol/L)
cholesterol (ng/ml)
Cholesterol (nmol/L)
Cholesterol absorption inhibitor (ezetimibe)
Cholesterol, (. 5.5 mmol/L), n (%)
Cholesterol, mg/dL
Cholesterol, mg/dL Total
Cholesterol, mg/dl, mean (SD)§
Cholesterol, mmol/L
Cholinesterase inhibitor use at baseline, No. (%)
Chondroitin
Chondroitin Sulfate
Chondroitin Sulfate (N = 318)
Chronic bronchitis
Chronic bronchitis (%)
Chronic bronchitis (ITT) (n=1075)
Chronic bronchitis (ITT) (n=1088)
Chronic bronchitis (ITT) (n=792)
Chronic bronchitis (ITT) (n=800)
Chronic bronchitis (ITT) (n=817)
Chronic bronchitis (ITT) (n=824)
Chronic bronchitis (n=855)
Chronic bronchitis!
Chronic bronchitist
Chronic cardiovascular disease, no. (%)
Chronic COX2 inhibitors
Chronic CVD
Chronic heart failure
Chronic inflammatory disease
Chronic kidney disease
Chronic kidney disease (%)
Chronic kidney disease stage: eGFR (ml/min per 1.73 m2)
Chronic kidney disease, n (%)
Chronic kidney disease, no. (%)t
Chronic kidney disease†
Chronic kidney diseased
Chronic non-steroidal antiinflammatory drugs
Chronic obstructive lung disease
Chronic obstructive pulmonary
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease—No. (%)
Chronic obstructive pulmonary disease, n (%)
Chronic pulmonary disease
Chronic renal disease
Chronic renal disease—No. (%)
Chronic renal failure
Chronic renal failure, n (%)
Chronic renal insufficiency
Chronic renal insufficiency, %
Chronic respiratory failure
Chronic sinusitis + nasal polypsd, n (%)
Chronic stable angina
Chronic treatment with aspirin
Chylomicron cholesterol
Chylomicron triglycerides
CI-AKI risk score
"CI = confidence interval; NA = not applicable or not analyzed."
"CI, confidence interval; ESRD, end-stage renal disease; n/N, number of patients who had an event/total number of patients. aAdjusted with terms including treatment (losartan or placebo), geographic region, genotype, and the treatment  genotype interaction. bP value for treatment  genotype interaction (i.e., comparison of the losartan treatment effect between the 3 genotype groups)."
Ciass i
Ciass ll-IV
Cigarette-smoking status — no. (%)
Cigarette-smoking status (%)
Cigarette smoker
Cigarette smoker*
Cigarette smoker, No. (%)
Cigarette smoking
Cigarette Smoking in the past year
Cigarette smoking status
Cigarette smoking, mean pack-years (SD)
Cigarette smoking, n (%)
Cigarette users
Cigarettesmoking,%
Cilostazol
Circumflex
CK-MB, ng/ml
CK > 10 x ULN1
CK > 5 x ULN1
CK>10xULN
CK>5xULN
CKD
CKD (eGFR < 60b)
CKD (eGFR<60), n (%)
CKD N
CKD prognosis by KDIGO''
CKD Rate (#events)
CKD Stage 1
CKD Stage 1 (%)
CKD Stage 2
CKD Stage 2 (%)
CKD Stage 3
CKD Stage 3 (%)
CKD stages
CKD*
CKD, n (%)t
CKDC, n (%)
Cl-3]
Cl-7]
Cl-8]
Cl-9]
Cl 95%
Class >11
Class >II
Class 1
Class 1 antiarrhythmic agents
Class 1 or no symptoms
Class 111
Class I
Class I or III AAD use in 12 months before enrollment
Class I or no symptoms
Class IA
Class IB
Class IC
Class II
Class II (b-blockers)
Class III
Class III/III - V
Class IV
Class IV glomerulonephritis
Class IV only
Class IV/IV - V
Class l/ll heart failure
Class ll-IV
Class V only
Classification of AF, No. (%)
Classification of epilepsy type, n (%)
Classification of index venous thromboembolism — no. (%)
Claudication
Claudication (Fontaine class > 1)
Claudication (Fontaine class >1)
Claudication only
Clavicle fracture
CLD 25 mg
CLD 25 mg (n=l84)
Clean, n (%)a
Clinic research experience, n (%)
Clinical
Clinical AE, n (%}
Clinical and laboratory measurements
Clinical and patient-reported characteristics at baseline and randomization
Clinical and patient reported outcomes, % (observed n) unless otherwise indicated
Clinical atherosclerotic disease*
Clinical characteristics
Clinical characteristics (%)
Clinical characteristics, n (%)
Clinical COPD phenotype^
Clinical criteria3
Clinical Dementia Rating sum of boxes, mean (SD)f
Clinical details
Clinical disease activity index
Clinical Disease Activity Index score (0-76)
Clinical efficacy at week 100
Clinical Endpoint
Clinical features of HF
Clinical fracture
Clinical history
Clinical history— no. (%)
Clinical history — no. (%)
Clinical history, n (%)
Clinical history, no. (%)
Clinical indication at the index procedure, n (%)
Clinical or Lesion RF for ST
clinical outcome
Clinical presentation
Clinical presentation of VTE at initial diagnosis — no. (%)
Clinical remissione
Clinical responsed
Clinical variables, median (IQR)
Clinically relevant non
Clonic
Clopidogrel
Clopidogrel %
Clopidogrel (N = 10,151)
Clopidogrel (N = 2549)
Clopidogrel (N = 3935)
Clopidogrel (n = 425)
Clopidogrel (N = 4444)
Clopidogrel (N = 509)
Clopidogrel (N = 5470)
Clopidogrel (N = 570)
Clopidogrel (n = 6604)
Clopidogrel (n = 864)
Clopidogrel (N=1493)
Clopidogrel (N=1493) n/N (%)
Clopidogrel (N=1509) n/N (%)
Clopidogrel (N=17)
Clopidogrel (N=1752)
Clopidogrel (n=22 961)
Clopidogrel (N=3977)
Clopidogrel (N=3977) n/N (%)
Clopidogrel (N=4018) n/N (%)
Clopidogrel (N=5453)
Clopidogrel /total no. of patients%%
Clopidogrel dose
Clopidogrel dose on/ before PCI
Clopidogrel Dyspnoea vs No dyspnoea*
Clopidogrel given before procedure
Clopidogrel loading dose 300 mg
Clopidogrel loading dose 600 mg
Clopidogrel n/N (%)
Clopidogrel n/N {%)
Clopidogrel no. of patients%)
Clopidogrel or ticlopidine
Clopidogrel plus Aspirin
Clopidogrel plus Aspirin %/yr
Clopidogrel plus Aspirin (N = 3772)
Clopidogrel Plus Aspirin (n=174)
Clopidogrel Pretreatment Duration
Clopidogrel, %
Clopidogrel, 300-mg loading dose
Clopidogrel, 300 mg loading dose!
Clopidogrel, 300 mg loading doset
Clopidogrel, 300 mg*
Clopidogrel, 600-mg loading dose
Clopidogrel, 600 mg loading dose!
Clopidogrel, 600 mg loading doset
Clopidogrel, 600 mg*
Clopidogrel, ticlopidine, or prasugrel
Clopidogrel/ticlopidine
Clopidogrel+Aspirin (n=2531)
Clopiodogrel
Closure
"cLow-potency stratum: simvastatin 20mg, pravastatin 40 mg, fluvastatin 80 mg,atorvastatin 10 mg; high-potency stratum: simvastatin 40 mg, atorvastatin"
Cluster 1: diuretic (N=454)
Cluster 2: reversible, no diuretic (N=756)
Cluster 3: not reversible, no diuretic (N=333)
Cluster seizures
CM
cMann Whitney U test/Wilcoxon Sum Rank test.
CMH RR (95% CI)
CNS systemic embolism
Co-morbidities
Co-morbidities, n (%)
Co-morbidities,a n (%)
CochraneManteleHaenszel (repeated 97.5% CI)c
Coefficient
Coenzyme Q10
Coenzyme Q10 p,g/ml#
Coenzyme Q10, ^g/ml#
Coexisting conditions
Coexisting conditions — no. (%)
Cognitive
Cognitive subscale on Alzheimer's Disease Assessment Scale, mean (SD)e
Cohort
Cohort 1 (N = 225)f
Cohort 1 (uACR <22.5 mg/g)
Cohort 2 (N = 521)
Cohort 2 (uACR >22.5 mg/g)
Coiticosieroids at baseline
Colchicine (n = 179)
Colectomy (partial or total)
Colesevelam (n = 77)
Colesevelam Hydrochloride Group (n=159)
College degree or higher
College graduate or more
Colombia
Colon
Colon' SES-CD score, mean (SD)
Colon only
Colon only,' n (%)
Colon only, n (%)
Colon or rectum
Colonic area involved
Colonoscopy
Colorectal cancer
Combination
Combination-Facilitated PCI (%)
Combination-Facilitated PCI (N = 828)
Combination (n = 107)
Combination Therapy (N = 169)
Combination therapy**
combination therapy, n=4121
Combination treatment IFX + AZA
Combinationf
Combinations of aspirin and PPI use (p=0.63t)
Combined
Combined (dutasteride/ta msu losi n)
Combined (N = 746)
Combined cardiac failure, cardiomyopathy or other cardiac disorder, n (%) LUTS severity, n (%)
Combined cardiac failure, cardiomyopathy or other cardiac disorders
Combined CHD
Combined CVD
Combined End Point
Combined end points
Combined End Poir
Combined estimated GFR and albuminuria status
Combined fatal/nonfatal outcomes
Combined golimumab groups
Combined Infliximab
Combined insulin/oral hypoglycaemic agent use
Combined ischaemic heart disease and/or cerebrovascular disorder*
Combined macro+micro
Combined major macrovascular events, neohroDathv. and all-cause mortalitv    ■
Combined major macrovascular events.
Combined n=1287
Combined statin and other lipid-lowering agent use
Combined therapy (/V= 1610), 0/0
Combined therapy vsdutasteride
Combined therapy vsta msu Iosin
Combined Trials
Combo-Facilitated PCI
Combo vs. Primary
Commercially available fondaparinux
Common carotid artery sites
Common study baseline
Community hospital
Community hospital (%)
Community hospital, n (%)
Comorbid conditionsb
Comorbid Diseasesa Diabetesb
Comorbid illnesses
Comorbidites, n (%)
Comorbidities
Comorbidities (%)
Comorbidities and concomitant medications
Comorbidities other than diabetes
Comorbidities, %
Comorbidities, n (%)a
Comorbidities, no. (%)
Comorbidities/concomitant medications
Comorbidity, no. (%)
Companion: 5-6 hours
Companion: Wake-Up Stroke
Comparator
comparison
Comparison
Comparison with baseline
Comparison with baseline (mean
Comparison with placebo
Comparison with placebo (mean
Comparison: Cat. 2 vs. Cat. 1
Complete healinga
Complete Mayo Clinic Score, median (min, max}
Completed Previous Febuxostat Study
Completed Prior Febuxostat Studya
Completed trial
Complex Anatomy (n - 3,730)
Complex lesions^
Complex partial (IB)
component. For all instruments, higher scores indicate more severe disease. ARA denotes American Rheumatism Association (now called
Components
Components of Primary Composite End Point—Secondary End Points
Components of the first CID
Composite
Composite endpoint
Composite endpoint (A1C <7.0%, BP
Composite endpoint of doubling of serum creatinine, ESRD,
Composite events
Composite Index of Insulin Sensitivity (ISI)
Composite microvascular end point*
Composite ocular end point^
Composite of 40% reduction in eGFR, end-stage kidney disease, or death from renal causes
Composite of Death/MI/Stro ke/Urgent Revasc/Definit e Acute Stent Thrombosis
Composite of Death/MI/Urg ent Revasc
Composite of doubling of serum creatinine, end-stage kidney disease, or death from renal causes
Composite physiologic index§
Composite vascular endpoint
Compression stockings
Computed tomographic angiography
concentrations at baseline
Concern
Concomitant
Concomitant AEDs, n (%)
Concomitant AEDsa
Concomitant AEDsb, n (%)
Concomitant AEDsb, n (%)
Concomitant aminosalicylates, N [%] Concomitant corticosteroids, N [%] Mayo score, mean [SD]
Concomitant antibiotic use, n [%]
Concomitant anticoagulant, antithrombotic or NSAID, n (%)
Concomitant antihyperglycaemic drugs, n (%)
Concomitant Antiplatelet
Concomitant Aspirin Use
Concomitant asthma medications, n (%)
Concomitant atorvastatin dose, mg
Concomitant cardiovascular therapies — no. (%)
Concomitant cardiovascular therapy
Concomitant cardiovascular therapy — no. (%)
Concomitant cardiovascular therapy (taken >30 days)
Concomitant conventional DMARD use
Concomitant corticosteroid use, n (%)
Concomitant csDMARDs other than methotrexate, n (%)
Concomitant drug therapies, n (%)
Concomitant drug therapy at discharge
Concomitant drug treatment
Concomitant drugs
Concomitant drugs, %
Concomitant DVT — no. (%) Baseline NT-proBNP — no. (%)
Concomitant DVT, n (%)
Concomitant immunosuppressive and/or prior anti-TNF use
Concomitant lipid-lowering therapy (any)
Concomitant lipid-lowering therapy, n (%)
Concomitant lipid-modifying therapy — no. {%)
Concomitant medication
Concomitant medication — no. (%)
Concomitant medication — no. {%) | ACE inhibitor
Concomitant medication (%)
Concomitant medication (>10%)
Concomitant medication after randomisation
Concomitant medication use
Concomitant medication, n (%)
Concomitant medication, n (%)d
Concomitant medication, n [%]
Concomitant medication, no. (%)
Concomitant medication||
Concomitant medications
Concomitant medications — no. (%)
Concomitant medications (%)
Concomitant medications (yes), n (%}
Concomitant medications after randomization
Concomitant medications at baseline
Concomitant medications for ulcerative colitis — no. (%)
Concomitant medications in >10% of subjects, No. (%)
Concomitant medications, n (%)
Concomitant medications, no. (%)
Concomitant medications,* n (%)
Concomitant methotrexate use, n (%)
Concomitant methotrexate, n (%)
Concomitant MTX—
Concomitant MTX use, n (%)
Concomitant OADs, n (%)
Concomitant oral anti-DM drugs, No. (%)a
Concomitant oral corticosteroids, n (%)**
Concomitant oral glucose-lowering agents, zz (%)
Concomitant PD medications at baseline, n (%)c,d
Concomitant therapies at hospital discharge
Concomitant therapies n (%)
Concomitant therapy
Concomitant therapy, n [%]
Concomitant therapy, no. (%)
Concomitant treatment
Concomitant treatment 一 no. (%)
Concomitant treatments at randomization
Concomitant use of bosentan, n (%)
Concomitant use of conventional synthetic DMARD up to 3 mo — no. {%) Methotrexate
Concomitant use of corticosteroids
Concomitant use of MTX to Week 96
Concomitant Use of NSAIDs to Week 96
Concordant stress test abnormalities
Concurrent illness
Concurrent medications
Concurrent prednisolone
Concurrent treatment at study entry — no. (%)**
Concurrent treatment of Crohn's disease at study entry — no. of patients (%)ff
Condition 3622 (32.1)
Congenital heart disease
Congestion*
Congestive Heart
Congestive heart failure
Congestive Heart Failure
Congestive heart failure— no. (%)
Congestive heart failure—No. (%)
Congestive heart failure — %
Congestive heart failure — no. (%)
Congestive heart failure — no. (%)|
Congestive heart failure — no. (%)||
Congestive heart failure (<6 wk)
Congestive heart failure (CHF) (in past 6 weeks)
Congestive heart failure (definite)
Congestive heart failure at randomisation
Congestive heart failure, n (%)
Congestive heart failure§
Congestive heart failure†
Congestive HF
Conieosieroids and/or 6-MP
Connective-tissue disease
Connective tissue disease
Conservative
Conservative strategy (n = 3,116)
Consistency of effect
Constipation
Constitutional
Continuation
Continuation (n=635)
Continue Thienopyridine N=2715
Continue Thienopyridine N=3147
Continued Thienopyridine %
Continued thienopyridine (n 5 5862)
Continued Thienopyridine (n=1737)
Continued Thienopyridine (N=5862)
Continued Thienopyridine N (%)
Continued Thienopyridine N=5020 Subjects
Continued Treatment Study
Continued use of GPA
Continued Use of GPA
Continuous
Continuous LVEF 3 treatment interaction
Continuous variables, mean (SD)
Continuous variables, mean (SD)^
Contrast angiography
Contrast nephropathy risk score
Contrast used (ml)*
Contrast volume
Contrast volume (ml)
Contrast volume >140 (ml)
Contrast volume >140 ml
Contrast volume, ml
Control
Control (n - 252)
Control (n = 150)
Control (n = 252)
Control (N = 265)
Control (N = 495)
Control (n = 569)
Control (n=1331)
Control (n=1355)
Control (n=271)
Control (n=9319)
Control (nZ2222)
Control (nZ784)
Control = Warfarin
Control 12 Months (n - 131)
Control Baseline (n - 150)
Control group
Control group (n = 203)
Control group (n=244)
Control group (n=442)
Control group (N=7988)
Control n = 1336
Control n = 558
Control n = 785
Control n =785
Controlld
Controlled
Controlled: ACQ-6 <1.5
Controlled11—no. (%)
Controllertreatment before entry*
Controls (n=1649)
Controls (n=9319)
Contusion
Conventional agents*
Conventional synthetic DMARD use at baseline
Conventional treatment
Conversion to sinus rhythm in <5 days
converting enzyme inhibitor
Convulsion
COPD
COPD-placebo (522 pt) N. (%)
COPD-placebo (N = 522)
COPD-rosuvastatin (538 pt) N. (%)
COPD-rosuvastatin (N = 538)
COPD —no. (%) Medication use
COPD (%)
COPD (N = 1060)
COPD assessment test (CAT) score
COPD disease severity
COPD duration, mean (SD), yr*
COPD exacerbation history in the previous year, n (%)
COPD exacerbation history, n (%)
COPD Exacerbation History, n (%)
COPD exacerbation: no
COPD exacerbation: yes
COPD exacerbations during the previous year
COPD history yrs
COPD medication at study entry
COPD medication taken for at least 2 months before st
COPD medication taken for at least 2 months before study entry
COPD or asthma
COPD or asthma, (%)
COPD severity
COPD severity (GOLD 20087)
COPD severity stage (GOLD)
COPD severity, %
COPD severity, n (%)
COPD severity, n (%)*
COPD severity, n (%)a
COPD severity: mild/moderate
COPD severity: severe/very severe
COPD severitya, n (%)
COPD severityy
COPD type
COPD worsening
COPD, n (%)
Coping
Cor Revasc
Core Cardiovascular Endpoint
Core laboratory percent stenosis
Core study to first infusion
Corneii product, mm-ms
Cornell index, pV
Cornell voltage-duration product (mmxmsec)*
Cornell voltage-duration product, mm × ms
Cornell voltage-duration product, mm x ms
Cornell voltage duration (mV×ms)
Cornell voltage x duration product, mm x ms
Coronaiy artery disease
Coronar y-artery bypass grafting
Coronar y artery disease
Coronarv arterv disease
Coronary
coronary-artery bypass grafting
Coronary-artery bypass grafting
Coronary-artery bypass grafting§
Coronary angiography
Coronary Angiography
Coronary angiography — no. (%)
Coronary angiography and intervention
Coronary angiography during the index hospital stay
Coronary angiography during the index hospitalization
Coronary angioplasty or stenting
Coronary artery
Coronary artery bypass
Coronary artery bypass graft
Coronary artery bypass graft—No. (%)
Coronary artery bypass graft, n (%)
Coronary artery bypass grafting
Coronary artery bypass grafting N (%)
Coronary artery bypass surgery
Coronary artery disease
Coronary Artery Disease
Coronary artery disease — %
Coronary artery disease — no. (%)
Coronary artery disease — no. (%):!:
Coronary artery disease — no. (%):c
Coronary artery disease — no./total no. (%)
Coronary artery disease (%)
Coronary artery disease (n=21 102)
Coronary Artery Disease History
Coronary artery disease*
Coronary artery disease, %
Coronary artery disease, n (%)
Coronary artery disease, n (%)
Coronary artery disease^
Coronary artery disease§
coronary artery Osteochondrosis
Coronary artery stenosis >50%
Coronary artery treated, no. (%)
Coronary bypass graft
Coronary bypass surgery
Coronary bypass, n (%)
Coronary disease
Coronary end point
Coronary Endpoint
Coronary events5
Coronary heart disease
Coronary heart disease — no. (%)
Coronary heart disease (%)
Coronary heart disease death
Coronary heart disease risk equivalents, n (%)c
coronary heart disease, n (%) Cardiovascular risk (per protocol), n (%) Very high
Coronary heart disease, n (%) t
Coronary heart disease, n (%)b
Coronary procedure (% of group)
Coronary revascularisation
Coronary revascularisation§
Coronary revascularization
Coronary revascularization 230 days after randomization
Coronary revascularization procedure
Coronary risk factors — no. (%)
"coronary syndrome. CI = confidence interval; HR = hazard ratio."
Cortical only
Corticosteroid
Corticosteroid-free remissioni
Corticosteroid - azathioprine/6-mercaptopurine
Corticosteroid (with or without immunosuppressants)
Corticosteroid (without IMM)
Corticosteroid (without IMM), N
Corticosteroid + IMM
Corticosteroid and immunosuppressant
Corticosteroid dose (prednisone
Corticosteroid or azathioprine/6-mercaptopurine
Corticosteroid or immunosuppressant
Corticosteroid use
Corticosteroid Use
Corticosteroid use at baseline
Corticosteroid use at baseline-No
Corticosteroid use at baseline-Yes
Corticosteroid use at randomization
Corticosteroid use at randomization, n (%)
Corticosteroid use, %
Corticosteroid use, n (%)
Corticosteroid use,11 n (%)
Corticosteroids
Corticosteroids'1
Corticosteroids (excluding budesonide)
Corticosteroids and antimalarials only
Corticosteroids and immunosuppressants
Corticosteroids and immunosuppressants only
Corticosteroids only
Corticosteroids. immunosuppressants. and antimalarials
Corticosteroidsa
CortteosteroM relrsclory status
Cough
Cough (investigator reported)
Cough (leading to study drug discontinuation)
Cough, n (%)
Coumadin
Country
Country, n (%)
Country: Argentina (n=342)
Covariate
Covariates
COX-2 selective inhibitor use
COX-2 selective NSAID
COX-2 selective NSAID use
Cox bsl onlyc
Cox bsl+Yr 1 Hbd
Cox HR (95% CI)
CPK > 10 times ULN
CR + CRPnorr
CR + MH
CR + MH + CRPnorr
CR imputation (Random.) (n=1613)
CR imputation (Random.) (n=1616)
CR imputation (Random.) (n=2153)
CrCb- (ml/min), mean (s.e.)
CrCI>50
CrCI>60-<90
CrCI>90
CrCl (ml/min)
CrCl (mL/min)
CrCl (mL/min) at randomization
CrCL (SD) mL/min
CrCl < 60
CrCl < 60 mL/min
CrCl <50 ml/min
CrCl <50 mL/min
CrCl <50ml/min
CrCl > 30-< 50mL/min
CrCl >50 ml/min
CrCl >50ml/min
CrCl 30-50
CrCl at baseline <60 ml/min
CrCl at baseline, mL/min
CrCl at randomization - mL/min
CrCl at randomization, ml/min
CrCl of 30-50 mL min ', n (%)
CrCl, mean, mL/min (± SD)
CrCl, median (IQR), mL/min
CrCl, mL/min
CrCL, mL/min Mean (SD)
Creat Clearance <30 ml/min
Creat Clearance >30 ml/min
Creatine clearance category
Creatine clearance category 0 to <30 mL/min    0/0
Creatine clearance, ml/min
Creatinine
creatinine — mg/dl
Creatinine — mg/dl
Creatinine — mg/dl Urinary albumin-to-creatinine ratio§
Creatinine (^mol/L) (median, IQR)
Creatinine (µmol/l)
Creatinine (mg/dL)
Creatinine (mg/dL), mean (SD)
Creatinine (p,mol/L)
Creatinine ≥3.0 mg/dL
Creatinine >1.5x baseline and above ULN
Creatinine >2 x baseline
Creatinine 1.7 mg/dl Medications
Creatinine ciearance
Creatinine clearance
Creatinine Clearance
Creatinine clearance — ml/min
Creatinine clearance — no. (%)
Creatinine clearance (ml/min)
Creatinine clearance (mL/min)
Creatinine clearance (mL/min), mean±SD
Creatinine clearance <30 mL/min
Creatinine clearance <50 ml/min
Creatinine clearance <50 ml/min — no. (%) Weight <60 kg — no. (%)
Creatinine clearance <60 ml/min
Creatinine clearance <60 mL/min
Creatinine clearance <60 mL/min (%)
Creatinine clearance <60 mL/min, No./total (%)
Creatinine clearance >30 to <50 ml/ min — no. (%)f
Creatinine clearance at admission (mL/min)
Creatinine Clearance at Randomization
Creatinine Clearance at Randomization (IXRS)
Creatinine clearance by C-G (mL/min)
Creatinine Clearance category [ml/min]
Creatinine clearance category, mL/min, No. (%)b
Creatinine clearance, mL/min
Creatinine clearance, ml/min-1*
Creatinine clearance, n (%)
Creatinine clearance, no. (%)
Creatinine clearance，::60 ml/min, %
Creatinine clearance,an (%)
Creatinine clearanceb, mL/min
Creatinine level
Creatinine ratio
creatinine ratio 30-300
Creatinine, mean (SD), mg/dL
Creatinine, mg/dL
Creatinine, mg/dL (SD)
Creatinine, mg/dL, mean
Creatinine, mg/dl_
Creatinine, mmol八
Creatinine, pmol/l
Creatinine, pmol/L
Criteria for subcortical VaD (by MRI), %
Criterion
Criterion reached first, n (%)
Critical site
CRj
Crohn's disease
Crohn's disease-related medication at baseline, n (%)
Crohn's Disease Activity Index score]
Crohn's disease duration
Crohn’s disease related surgery
Cromoglicate
Cross-clamp
Cross-damp time: <l:llhrs:min (n=724)
cRosuvastatin + fenofibric acid vs. rosuvastatin monotherapy.
CRP
CRP—mg/L
CRP — mg/liter^
CRP $10 mg/l, N
CRP (mg/dl)
CRP (mg/dL)
CRP (mg/dl) <1.7
CRP (mg/dL)**
"CRP (mg/dl; per unit)"
CRP (mg/L)
CRP (mg/L) (CV)
CRP (mg/L) [b], median (min - max)
CRP (mg/L), mean (SD)
CRP (mg/L), median (min, max)
CRP (mg/L), median ± SD
CRP (mg/L), n
CRP (mg/L): <10
CRP (ng/ml)
CRP (normal <1.0 mg/dL)
CRP (normal range: 0-0.5), mg/dL, mean (SD)
CRP [mg/L], median
CRP <10 mg/l, N
CRP >0.8 mg/dL, n (%)
CRP >10 mg/1, n [%]
CRP concentration >1.0 mg/dl (10 mg/l), n (%)
CRP concentration >10 mg/L, n (%)\
CRP level, mean ± SD mg/dl
CRP mean (mg/dl ± SD)
CRp median (SE), rng/L
CRP, mean [SD] mg/1
CRP, mean mg/l (SD)
CRP, median (range) mg/literl
CRP, median, mg/dL
CRP, mg/dl
CRP, mg/dL
CRP, mg/dl, mean (SD)
CRP, mg/dl, median
CRP, mg/L
CRP, mg/L*
CRP, mg/l: median (range)
CRP, nmol/L, median (range)
CRP ≤ ULN
CRP > ULN
CRPnonr?
CRT
CRT-D
CRT-P
CRT-P+D, n (%)
Crude
Crude analysis, n (%)
Crude model HR (95% CI)
Crude Rate
CRUSADE bleeding score
CRUSADE bleeding score, mean (SD)^
CRUSADE score
Cryptogenic
Cryptogenic localization-related
CS
CS and IM
CS and IMM
CS and IS
CS only
CS use: No
csDMARD otherthan methotrexate
csDMARD use at baseline^
csDMARDs + MTX (n = 245)
CSE]+
CSF
CSF 24S-hydroxy-
CSF A (340 (PM)
CSF A (342 (PM)
CSF cholesterol
CSF lathosterol (|JLg/cll)
CSII
CT
CT findings
CT or MR scan of the brain*
CT ratio (%)
CT ratio > 0.55
"CT, calcitonin; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HbAlc, glycated hemoglobin; H2, histamine 2; IQR, interquartile range; n, number of patients; SD, standard deviation."
CT+TT
CTD population subgroup
cTn-I, ng/ml
cTn-l, ng/ml
CU index test, n (%)3
Cuban
Culprit vessel
Cumulative Events
Cumulative incidence 2 years
Cumulative incidence 3years
Cumulative incidence lyear
Cumulative NSAID score, mean ± SD
CURE Trial
Current
Current (%)
Current (,15 cigs/day)
Current (15+ cigs/day)
Current (n = 2,630)
Current alcohol drinking, n (%)
Current alcohol use — no./total no. (%)
Current alcohol use, n (%)
Current alcohol, n (%)
Current alendronate use
Current angina
Current angina (%)
Current atrial fibrillation or flutter on ECG
Current bone disease
Current cigarette smoker
Current cigarette smoker or within past year
Current cigarette smoker, n (%)
Current cigarette smoking
Current cigarette smoking, No. (%)
Current cigarette use
Current cigarette use, n (%)
Current cigarette, n (%)
Current corticosteroid use, n
Current CVD/diabetes, n (%)
Current dactylitis, n
Current drinker
Current enthesitis, n (%)’
Current inhaled corticosteroid use
Current LABA use
Current LAMA use
Current LRA use
Current medication — no. (%)
Current medication use
Current medication, n (%)
Current n Z 1278
Current Non-Smoker
Current nonsmoker
Current nonsmokers
Current or former smoker
Current or previous atrial fibrillation
Current or prior smoking, %
Current oral corticosteroid use
Current other (predefined) medical conditions
Current smoker
Current Smoker
Current smoker— no. (%)
Current smoker— no. {%)
Current smoker—no. (%)
Current smoker — no. (%)
Current smoker — no. (%) Blood pressure — mm Hg
Current smoker — no. of patients (%)
Current smoker — no./total no. (%)
Current smoker    »
Current smoker (%)
Current smoker (>10 cigarettes/day) — no. (%)
Current smoker (n=3,804)
Current smoker (n=3,804) Former smoker (n=4,428)
Current Smoker (n=3804)
Current Smoker (n=95, 110)
Current smoker 一 no. (%)
Current smoker 一no. (%)
Current smoker at baseline, n (%)
Current smoker at screening, n (%)
Current smoker at screeninga, n (%)
Current smoker Yes
Current smoker,
Current smoker, %
Current smoker, n (% of patients)
Current smoker, n (%)
Current smoker, n (%) Post-bronchodilator screening
Current smoker, n (%}
Current smoker, n [%]
Current smoker, n/N (%)
Current smoker, no (%)
Current smoker, no. (%)
Current smoker, No. (%)
Current smoker:ex-smoker (%)
Current smokers
Current smokers (%)
Current smokers (ITT) (n=1005)
Current smokers (ITT) (n=1018)
Current smokers (ITT) (n=758)
Current smokers (ITT) (n=768)
Current smokers (ITT) (n=779)
Current smokers (ITT) (n=784)
Current smokers (n=683)
Current smokers*
Current smokers, n (%)
Current smokers, n (%) Medicai history, n (%)
Current smokers, n (%)
Current smoking
Current smoking — no. (%)
Current smoking — no./total no. (%)
Current smoking (%)
Current smoking*
Current smoking, %
Current smoking, n (%)
Current tobacco abuse, n (%)
Current tobacco smoker
Current tobacco smoker (%) Qualifying event (%)
Current tobacco use
Current Tobacco Use
Current use of an ACE inhibitor
Current use of hormone therapy
Current weekly alcohol use (%)
Current xanthine derivative use
Current, n (%)
Current/past
Current/past smoker
Currentd
Currently
Currently on AHA therapy
Currently smoker
Currently smokes
Currentother(notpredefined) medical conditions
Cutoffs
CV
CV death
CV Death
CV death    n
CV death + HF hospitalization
CV death or first HHF
CV death or HF hosp.
CV death or HF hospitalization    n
CV death or HHF
CV death or Ml
CV death, MI, ischemic stroke
CV death, MI, ischemic stroke, hospitalization for HF, coronary revascularization, UA
CV death, MI, or ischemic stroke
CV death, MI, or stroke
CV death, MI, stroke
CV death, MI, stroke, or urgent coronary revascularization
CV death, MI, stroke, recurrent ischemia
CV death, Ml or ischemic stroke
CV death, Ml, ischemic stroke
CV Death, Ml, Ischemic Stroke
CV Death, Ml, Ischemic Stroke, Hosp. for HF, Cor. Revasc., UA
CV DEATH, Ml, ISCHEMIC STROKE, HOSPITALIZATION FOR UNSTABLE ANGINA, REVASCULARIZATION OR HEART FAILURE
CV death, Ml, or stroke
CV Death, Myocardial infarction, Stroke
CV death, Non-fatal MI or Non-fatal Stroke
CV Death/MI/Stroke
CV Death/MI/Stroke/UCR
CV disease
CV disease history, No. (%)§
CV Endpoints n (%)
CV entry criteria
CV Entry Criteria
CV event, years
CV historya
CV medication
CV medication, % of patients
CV mortality
CV Mortality
CV risk factor
CV risk factor - no. (%)
CV risk factors
CV risk factors and history
CV risk factors, % of patients
CVD
CVD death
CVD deaths
CVD events
CVD mortality
CVD or MI
CVD risk factors (age > 60)^“^
CVD risk factors (age >60 )
CVD subjects
CVD Without MI or Stroke (n=3083)
CVD without MIAtroke
CVD without Ml/stroke
CVD without Ml^troke
CVD, MI, or stroke
CVD, MI, stroke, or recurrent ischemia- urgent revascularization, or hospitalization for unstable angina
CVD, MI, stroke, or recurrent ischemia-urgent revascularization
CVD, total
CVD/MI/stroke
CVD/MI/stroke/revascularization/urgent vascular hospitalization
CVD/MI/stroke/urgent coronary revascularization
CVD/MI/stroke/urgent vascular hospitalization
CVD/stroke/SEE
CVDEATH, Ml, OR ISCHEMIC STROKE
CWT, Mean (SE), mm
Cyclo
Cyclosporin
Cyclosporine (N = 474)
CYP26A1
CYP3A4 inhibitors
Cystitis
Cystoscopic procedure
Czech Republic
Czech RepuMc
CZP 200 mg
CZP 200 mg (n = 201)
CZP 200 mg (n = 326)
CZP 200 mg (n = lll)
CZP 200 mg (n 5 326)
CZP 200 mg (n 5111)
CZP 200 mg (n5201)
CZP 200 mg every 2 weeks (n = 138)
CZP 200 mg Q2W
CZP 400 mg
CZP 400 mg (n = 109)
CZP 400 mg (n = 221)
CZP 400 mg (n = 305)
CZP 400 mg (n 5 221)
CZP 400 mg (n 5305)
CZP 400 mg (n5109)
CZP 400 mg every 4 weeks (n = 135)
CZP 400 mg Q4W
CZP 400 mg, % (n/N)
CZP baseline
CZP combined arms (n = 219)
CZP combined arms (n = 54)
CZP+MTX
CZP+MTX n=159
CZP+MTX n=655
CZP+MTX to MTX
CZP+MTX^MTX
d
D
D-Dimer (ng/ml)
D-dimer level, mean (SD), ng/mLd
D-dimer levelsatinclusion
D-value
D (95% CI)
D 110 mg vs. warfarin
D 150 mg vs. warfarin
d Includes cardiac glycosides, antiarrhythmics classes I and III, vasodilators used in cardiac disease and other cardiac preparations.
d Non-Vertebral Fragility Fractures (FAS)
d population
D, Mitral stenosis VhD (n=193)
D/MI/IDFVST
D/MI/IDR/ST
D110 % (n/N)
D110 vs Warfarin
D110 vs Warfarin RR (95% CI, P Value)
D150 % (n/N)
D150 vs Warfarin
D150 vs Warfarin RR (95% CI, P Value)
Dabetes
Dabigatran
Dabigatran (N = 1273)
Dabigatran (N = 1430)
Dabigatran (N = 681)
Dabigatran 110 mg
dabigatran 110 mg (n=6015)
Dabigatran 110 mg 150 mg % per yr
Dabigatran 110 mg bid
Dabigatran 110 mg BID
Dabigatran 110 mg BID (N=1487)
Dabigatran 110 mg BID Events/n (%/y)
Dabigatran 110 mg BID vs Warfarin
dabigatran 110 mg versus warfarin
Dabigatran 110 mg b.i.d.
Dabigatran 150 mg
dabigatran 150 mg (n=6076)
Dabigatran 150 mg BID
Dabigatran 150 mg BID (N = 1546)
Dabigatran 150 mg BID Events/n (%/y)
Dabigatran 150 mg BID vs Warfarin
dabigatran 150 mg versu swarfarin
Dabigatran 150 vs Dabigatran 110 mg BID
Dabigatran 150 mg b.i.d.
Dabigatran 150mg bid
Dabigatran 220 mg (n= 2,156)
Dabigatran group
Dabigatran, 110 mg
Dabigatran, 110 mg BID
Dabigatran, 110 mg Twice Daily
Dabigatran, 110 mg, vs. Warfarin
Dabigatran, 150 mg
Dabigatran, 150 mg BID
Dabigatran, 150 mg Twice Daily
Dabigatran, 150 mg,
Dabigatran, 150 mg, vs. Warfarin
Dabigatran110 vs. WARFARIN P(INTER)
Dabigatran150 vs. WARFARIN P(INTER)
Dactylitis
Dactylitis count
Dactylitis count (0-20), mean (SD)
Dactylitis in >1 digit
Dactylitis score
Dactylitis score (1-60)
Dactylitis score (1-60), mean (SD)
Dactylitis score (1–60 scale)
Dactylitis score at baseline, median (IQR) Week 100
Dactylitis Severity Score) Score >0 — no. {%)
Dactylitis, %#
Dactylitis, n (%)
Daily
Daily “off” time, mean ± SD, h/dayf
Daily bowel movements
Daily dose > 1600 mg n = 1339
Daily dose 400 mg n = 2380
Daily dose 401-1599 mg n = 4334
Daily dose of inhaled glucocorticoid — no. (%)§
Daily dose of study medication prescribed
Daily dose of vitamin D (IU/day)
Daily Exercise (%)
Daily iGlar dose at week 30 (U)
Daily insulin dose, mean (SD), IU
Daily total dose of insulin — lU/kg
Dalteparin (n=746)
DAPA+MET n =179
DAPA+MET n=179
Dapaglifloiin, n*
Dapaglifloz.in, n
Dapagliflozin
Dapagliflozin (n=225)
Dapagliflozin (n=57)
Dapagliflozin (n=60)
Dapagliflozin (N=8582)
Dapagliflozin (n=92)
Dapagliflozin 10 mg
Dapagliflozin 10 mg (N = 108)
Dapagliflozin 10 mg + insulin (n = 270)
Dapagliflozin 10 mg + Insulin (n=270)
Dapagliflozin 10 mg group (n = 263)
Dapagliflozin 10 mg group (n = 455)
Dapagliflozin 10 mg group (n =455)
Dapagliflozin 10 mg group (n=192)
Dapagliflozin 10 mg/day (N = 108)
Dapagliflozin 5 mg
Dapagliflozin 5 mg + insulin (n = 271)
Dapagliflozin 5 mg + Insulin (n=271)
Dapagliflozin 5mg
Dapagliflozin Placebo no. of events/no. of patients
Dapagliflozin, n*
Dapagliflozint
DAS-28 (CRP) <2.6, n (%)
DAS-28 (CRP), mean (SD)
DAS28
DAS28-4 (ESR) <2.6*
DAS28-4 (ESR) <3.2t
DAS28-4(ESR)
DAS28-4(ESR)1
DAS28‐CRP
DAS28-CRP
DAS28-CRP, LS mean change from baseline (SE)¥
DAS28-CRP, LS mean change from baseline (SE)§
DAS28-CRP§
DAS28-ESR
DAS28-ESR LDA
DAS28-ESR remission
DAS28-ESR remission, %
DAS28-ESR, mean (SD)
DAS28-ESR, mean ± SD DAS28-ESR remission, %
DAS28-hsCRP
DAS28-hsCRP, mean (SD)
DAS28 (C-reactive protein)
DAS28 (CRP)
DAS28 (CRP), mean (SD)
DAS28 (ESR)
DAS28 score
DAS28(CRP)
DAS28(ESR)
DAS28(ESR), mean (SD)
DAS28, mean (SD)
DAS28, mean ± SD
DAS28, range 0-10, mean (SD)
"Data are expressed as n/total (%) unless otherwise speciﬁed. Systeme International unit conversion: to convert creatinine clearance to ml/s, multiply by 0.0167. *Estimated with Cockroft-Gault equation; †at discharge.
ACE   angiotensin-converting enzyme; CABG   coronary artery bypass graft; CCSC   Canadian Cardiovascular Society classiﬁcation; MI   myocardial infarction; PCI   percutaneous coronary intervention."
"Data are expressed as n/total (%) unless otherwise specified. Systeme International unit conversion: to convert creatinine clearance to ml/s, multiply by 0.0167. *Estimated with Cockroft-Gault equation;"
"Data are mean (SD) or n (%).  ACE=angiotensin-converting enzyme, ARB=angiotensin-receptor blocker. 
CHF=congestive heart failure. *Any use in 24 h before surgery except for aspirin which only required any use in the 7 days before surgery."
"Data are mean (SD) or number (%). BMI=body-mass index. SBP=systolic blood pressure. DBP=diastolic blood pressure. LVEF=left ventricular ejection fraction. 
HF=heart failure. AMI=acute myocardial infarction. CABG=coronary artery bypass graft. PCI=percutaneous coronary intervention. ICD=implantable cardioverter deﬁ brillator. COPD=chronic obstructive pulmonary disease. ACE=angiotensin-converting enzyme. ARBs=angiotensin receptor blockers. *Available for 4523 patients (2257 rosuvastatin, 2266 placebo)."
Data are mean (SD) or number (%). PUFA=polyunsaturated fatty acids, BMI= body-mass index. SBP=systolic blood pressure. DBP=diastolic blood pressure. NYHA=NewYork Heart Association. LVEF=left ventricular ejection fraction. HF=heartfailure. AMI=acute myocardial infarction. CABG=coronary artery bypass graft. PCI=percutaneous coronary intervention. ICD=implantable cardioverter defibrillator. COPD=chronic obstructive pulmonary disease. ACE=angiotensin-converting enzyme. ARBs=angiotensin receptor blockers. *Available for 6899 patients (3455 n-3 PUFA, 3444 placebo).
Data are mean ± standard deviation for continuous variables and number (%) for categoric variables. P
Data are number of patients (%) or hazard ratio (95% Cl), p values are forthe test of heterogeneity. CAD=coronary artery disease. BMI= body-mass index, which is weight in kg divided by the square of height in metres. LDL=low-density lipoprotein. HDL=high-density lipoprotein.There is a deficit of clinical data in some patients with the events.
Data are number of patients (%) or mean (SD), unless otherwise indicated. CABG=coronary-artery bypass grafting. PTCA=percutaneous transluminal coronary angioplasty, LDL=low-density lipoprotein. HDL=high-density lipoprotein. IQR=i nterquarti le range, HMG CoA RI=3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. BMI=body-mass index, which is weight in kg divided by the square of height in metres, *Median (IQR).
"Data are presented as mean   SD. * n   193 for LDL cholesterol.
†
n   390 for LDL cholesterol.
‡
Signiﬁcantly different from baseline values by repeated measures (analysis of variance), p  0.0001.
§
Signiﬁcantly different from baseline values by repeated measures (analysis of variance), p   0.0002.
¶
Signiﬁcantly different from baseline values by repeated measures (analysis of variance), p   0.0004."
Data are reported as n (%). Event rates in parentheses are Kaplan-Meier estimates (%) at 1 year. *Cardiovascular (CV) death, myocardial infarction (MI), or recurrent ischemia. †CV death, MI, or severe recurrent ischemia
"Data are reported as percentage or mean ± standard deviation, unless otherwise indicated. NG, normoglycemia; IGM, impaired glucose metabolism; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose. a Median (interquartile range). * P < 0.05 vs. NG. † P < 0.01 vs. NG."
"Data are reported as percentage or mean ± standard deviation, unless otherwise indicated. NG, normoglycemia; IGM, impaired glucose metabolism; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose. a Median (interquartile range). ‡ P < 0.05 vs. non-EPA. § P < 0.01 vs. non-EPA"
Data missing
Data missing or no drug given
"Data presented as mean ± SD, unless otherwise specified; aCOPD severity is based on the GOLD 2015 criteria [27]; GOLD 2011 [28]; bOn a scale of 0–100, with higher scores indicating worse health status; the MCID is a change of 4 units; On a scale of 0–4, with higher scores indicating more severe dyspnea; On a scale of 0–40, with higher scores indicating worse health status"
"Data represent number of patients (%) or mean (standard deviation), unless otherwise indicated. a Self-reported information. bc Physician-diagnosed diabetes or fasting plasma glucose ≥126 mg/dL or hemoglobin A1C ≥6.5%. d Physician-diagnosed hypertension or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.
Median (interquartile range). LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride."
data,'' n
Dates of recruitment
Day 1 oral glucocorticoid use — no. {%)
Days between ACS and Rand
Days from ACS to randomization
Days of study-drug administration (%)** 1 day
Days with asthma symptoms/week
Days with heartburna (days)
Days without albuterol use,* %
Daytime mean DBP (ABPM) at week 12, mmHg
Daytime mean SBP (ABPM) at week 12, mmHg
Daytime nasal symptoms score change from baseline, mean ± SE
Daytime symptoms more than twice per week
DB baseline (Week 0)
DBP
DBP (mean over 24 h), mmHg
DBP (mm Hg)
DBP (mm Hg), median (IQR)
DBP (mmgHG), mean (SD)
DBP (mmHg)
DBP (mmHg), mean (SD)
DBP (office measurement), mmHg
DBP (SD)
DBP (SD), mm Hg
DBP <80 mmHg
DBP <90 mmHg
DBP ≥90 mmHg
DBP >90 or SBP >140 mm Hg Laboratory determinations
DBP 90.0 (8.9) Baseline lipid profile, mg/dL, mean (SD)
DBP at Visit 2
DBP during the follow-up period (mmHg)
DBP mm Hg
DBP(mm Hg)
DBP(mmHg)
DBP, mean (SD)
DBP, mean (sd) mm Hg
DBP, mean (SD), mm Hg
DBP, mean (SD), mm Hg Glycaemic parameters
DBP, mean (SD), mmHg
DBP, mean ± SD (mmHg)
DBP, mm Hg
DBP, mm Hg (mean 24 h), mean (SD)
DBP, mm Hg (office measurement), mean (SD)
DBP, mm Hg, mean ± SDC
DBP, mm Hg
DBP, mm Hg (SD)
DBP, mmHg
DBP. mean (sd) mm Hg
DCCT A1c
DD
DD (n = 399)
DE
DE (n=1676)
DE (n=209)
DE (n=262)
DE (n=433)
DE (n=668)
DE (n=735)
DE 110 mg BID (n - 5,424)
DE 150 mg BID (n - 5,472)
DE110 n=2322
DE110 n=3693
DE150 n=2304
DE150 n=3772
Dead (n=313)
Death
Death (all-cause)
Death (all cause)
Death due to renal failure or sustained ESRD
Death due to renal failure®
Death from
Death from any cause
Death from cardiovascular causes
Death or 6MWD decrease >50 m
Death or absolute FVC decrease >10%
Death or disabling stroke
Death or ICH
Death or myocardial infarction
Death or stent thrombosis
Death*
Death, large MI
Death, MI, IDR, or ST
Death, MI, IDR, ST or GUSTO severe bleeding
Death, MI, IDR, ST or GUSTO Severe Bleeding
Death, MI, IDR, ST, or any TIMI bleeding
Death, MI, IDR, ST, or any TIMI Bleeding
Death, MI, IDR, ST, or GUSTO Mod/Sev Bleeding
Death, MI, IDR, ST, or GUSTO moderate/severe bleeding
Death, MI, IDR, ST, or GUSTO Moderate/Severe Bleeding
Death, n (%)
Death, Q wave MI or ischemia-driven revasc
Death, with PE not
Death/MI/IDR/ST
Death/MI/IDR/ST/ GUSTO-defined moderate or severe bleeding
Death/Q- Ml/stent thrombosis
Death/Q-MI/IDR
Death/Q-wave MI/IDR
Death/ST
Death/UDMI/IDR
Deaths
Deaths, n (%)
Deathsb
Decline# mL·yr−1
Decreased appetite
Deep-vein thrombosis
Deep-vein thrombosis (%)
Deep-vein thrombosis only
Deep-vein thrombosis or pulmonary embolism — no. (%)
Deep vein thrombosis only
Definite
Definite Acute Stent Thrombosis
Definite stent thrombosis
Definite/probable stent thrombosis
Degree of stenosis, % of diameter
Delayed
Delayed-Eptifibatide Group (N =4684)
Delayed-Start Group (N = 295)
Delayed-Start Group (N = 300)
Delayed Eptifibatide
Delayed reaction
Delighted
Demographic
Demographic 66.0 (9.7)
Demographic and clinical
Demographic and clinical characteristics
Demographic and medical variables
Demographic characteristic
Demographic Characteristic
Demographic characteristics
Demographic Characteristics
Demographic characteristics, mean (SD), unless otherwise stated
Demographic characteristics, mean ± SD unless otherwise indicated
Demographic data
Demographic factors
Demographic feature
Demographic features
Demographic variable
Demographic/disease characteristics at baseline
Demographics
Demographics Age (years)
Demographics Age, years, mean (SD)
Demographics and clinical characteristics
Demography
Denosumab
Denosumab (n = 166)
Denosumab (N=3902) n (%)
Denosumab (N=435)
denotes angiotensin-converting enzyme.
Dense calcium
Dense calcium, mm’
"density lipoprotein; CSF ="
Dental procedure
Depression
Depression^
Depression®
Dermal
Dermatitis atopic
DES
DES (% previous stenting)
DES implantation for restenosis, n (%)
DES type
DES type at index procedure
descent
Detected during tumor evaluation
detemir/insulin glargine, %
Deterioration in renal function (investigator reported)
deviation, mm
"deviation; TG, triglyceride."
Device = Watchman Filter
Device Group
Device Group (n = 463)
Devices
Devices for heart failure at screening visit
Dexlansoprazole MR
Dexlansoprazole MR (n = 4270)
Dexlansoprazole MR 30 mg, N =152
Dexlansoprazole MR 60 mg QD
Dexlansoprazole MR 90 mg QD
dFisher's exact test.
DHA (n = 238)
DHA intake on food frequency questionnaire, mean (SD), mg/d
Diabetes
Diabetes-related medication use, n (%)
Diabetes — no. (%)
Diabetes (%)
Diabetes (n - 6,806)
Diabetes (n [%])*
Diabetes (N = 214)
Diabetes (n=1106)
Diabetes (P = .17)
Diabetes (P = .46)
Diabetes (P = .O2)
Diabetes (P = .OO4)
Diabetes (P=.004)
Diabetes Absent 13202 (72.6)
Diabetes and currently on an oral hypoglycaemic agent orinsulin
Diabetes at baseline
Diabetes at randomization
Diabetes BL
Diabetes classificationa
Diabetes Duration
Diabetes duration (known), % of patients
Diabetes duration (y)
Diabetes duration (years)
Diabetes duration (years)*
Diabetes duration at baseline
Diabetes duration Mean±SD
Diabetes duration subgroups
Diabetes duration, median (IQR), years
Diabetes duration, n (%)
Diabetes duration, y
Diabetes duration, ycars“
Diabetes duration, years
Diabetes duration, years (mean ± SD)
Diabetes duration, years^
Diabetes durationa <Median
Diabetes Etiology
Diabetes history, mean (SD), years
Diabetes medication
Diabetes melitus
Diabetes mellitus
Diabetes meLLitus
Diabetes Mellitus
Diabetes mellitus — no. (%)
Diabetes mellitus — no./total no. (%)
Diabetes mellitus (%)
Diabetes mellitus (type 1 or 2)
Diabetes mellitus (type 2), n (%)
Diabetes mellitus [n (% )]
Diabetes mellitus 一 no. (%)
Diabetes mellitus classification
Diabetes mellitus duration (SD), y
Diabetes mellitus duration, y
Diabetes mellitus duration, y (SD)
Diabetes mellitus n = 1,163
Diabetes mellitus status
Diabetes mellitus Yes (n, %) Hypertension
Diabetes mellitus!
Diabetes mellitus, %
Diabetes mellitus, (%)
Diabetes mellitus, n (%)
Diabetes mellitus, n (%) yes
Diabetes mellitus, n/N (%)
Diabetes Mellitus, n=2907
Diabetes mellitus, no. (%)
Diabetes mellitus, No./total No. (%)
Diabetes mellitus,§ n (%)
Diabetes Mellitus:
Diabetes mellitust
Diabetes n (%)
Diabetes N(%)
Diabetes Present 4933 (27.4)
Diabetes status
Diabetes Status
Diabetes status, n (%)
Diabetes status, No. (%)
Diabetes t
Diabetes Therapy
Diabetes therapy at baseline (alone or in combination)
Diabetes therapy, n (%)
Diabetes treatment
Diabetes type II, n (%)
Diabetes with no use of diabetes drugs
Diabetes with target organ disease*
Diabetes with use of oral diabetes drugs
Diabetes*
Diabetes, %
Diabetes, n (%)
Diabetes, no. (%)
Diabetes, No. (%)c
Diabetes,* n (%)
Diabetes^
Diabetes||
Diabetes|| Yes
Diabetes11
Diabetes3
Diabetes5 (%)
Diabetesc
Diabetesduration,mean(SD),y
Diabetese
Diabetesf
DiabetesH Yes
Diabetesz
Diabetic
Diabetic (no)
Diabetic (yes)
Diabetic eye disease
Diabetic history (years)x
Diabetic kidney disease
Diabetic No
Diabetic participants
Diabetic participants!
Diabetic patients
Diabetic status
Diabetic status, n (%)
Diabetic subjects, N=312
Diabetic therapy use, n (%)* No therapy
Diabetic treatments!
Diabetic Yes
diabetic, n (%)
Diabetic, n (%)
Diabetic0
Diabeticb
Diabetics
Diabetics - No (n=155, 80)
Diabetics - Yes (n=10, 5)
Diabetics - Yes (n=12, 5)
Diabetics (n= 4221)
Diabetics • No (n=161, 83)
Diagnosed Diabetes (n = 627)
Diagnosed, y
Diagnoses/risk factors, n (%)
Diagnoses/risk factors, n (%]
diagnosis — yr
diagnosis (y), mean (SD)
diagnosis (years)
Diagnosis at presentation
Diagnosis at presentation — no. (%)
Diagnosis at study entry — no. (%)
Diagnosis of allergic rhinitis
Diagnosis of diabetes, n (%)
Diagnosis of HeFH, n (%)
Diagnosis of heterozygous familial hypercholester
Diagnostic angiography
Diagnostic catheterization
Diameter stenosis, mean (SD), %
Diarrhea
Diarrhoea
Diary variables, mean (SD)
Diastoiic biood pressure, mm Hg
Diastolic
Diastolic—mean (SD) (mm Hg)
Diastolic — mm Hg
Diastolic (mean, SD)
Diastolic (mmHg)
Diastolic blood pressure
Diastolic blood pressure - mmHg
Diastolic blood pressure — mm Hg
Diastolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg) Medications
Diastolic blood pressure (mm Hg), mean (SD)
Diastolic blood pressure (mm Hg):
Diastolic blood pressure (mmHg)
Diastolic blood pressure >85 mm Hg,
Diastolic blood pressure mmHg, mean(sd)
Diastolic blood pressure subgroups
Diastolic blood pressure,
Diastolic blood pressure, (mm Hg)
Diastolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg (SD)
Diastolic blood pressure, mm Hg, mean (SD)
Diastolic blood pressure, mm Hg, mean±SD
Diastolic blood pressure, mm Hg, median (range)
Diastolic blood pressure, mm Hg^
Diastolic blood pressure, mm Hq
Diastolic blood pressure, mm Hg
Diastolic blood pressure, mmHg
Diastolic blood pressure, mmHg, mean (SD)
"diastolic blood pressure; and Lp(a),"
Diastolic blood pressurea,mmHg
Diastolic BP
Diastolic BP (mm Hg)
diastolic BP (mmHg)
Diastolic BP (mmHg)
Diastolic BP (mmHg)*
Diastolic BP, mm Hg
Diastolic BP, mm Hg, mean (SD)
Diastolic BP, mm Hg, mean (SD)
Diastolic BP, mmHg
Diastolic BP, mmHg (SD)
Diastolic BP, mmHg, mean ± SD
Diastolic fmmHff')
Diastolic pressure, mm Hg
Diastolic(mm Hg)
Diastolic, mean (SD), mm Hg
Diastolic, total
Diastolic, treated at baseline
Diclofenac
Diclofenac (n = 17,289)
Diclofenac (n=10378)
Diclofenac (n=11 616)
Diclofenac (n=17 289)
Diclofenac (n=5673)
Diclofenac (n=6911)
Diclofenac 150 mg (n = 2054) n (%)
Diclofenac 150 mg (N 5 2054), ...n..(.%..)............
Diclofenac 150 mg (N 5 2162), .n...(.%..)...........
Diclofenac 150 mg (N 5 2855), ...n..(.%..)...........
Diclofenac 150 mg (N 5 3518), ..n...(.%..).................
Diclofenac 150 mg (N 5 6700), ..n..(.%..)...........
Diclofenac 150 mg, N = 3518,n(%)
Diclofenac group (n=17 289)
Did not enrol into Osler
Did not meet atopy and IgE30-700kU/Lcriteriaa (n = 1,471)
Diet
Diet-controlled (%)
Diet-i-Pravastatin (n=2638)
Diet    Diet + pravastatin
Diet    Diet + pravastatin Event / Patients (1OOO/pt-y)
Diet (n 二2718)
Diet (n=2718)
Diet + pravastatin group
Diet 49 / 1248 (8.9)
Diet 49/1248 (8.9)
Diet alone
Diet and exercise
Diet controlled or no
Diet group
Diet group (n=3966)
Diet only
Diet plus pravastatin group (n=3866)
Diet(n 二1664)
diet+ pravastatin
Diet+pravastatin
Diet+Pravastatin (n=1613)
Diet+Pravastatin (n=2638)
Diet+pravastatin 31 / 1228 (5.7)
Dietary calcium intake, mean (SD), mg/d
Dietary EPA-DHA intake (mg/day)*
diff_measure
diff_measure (DM added this as table had multiple headings)
Difference
Difference (%)
Difference (95% CI)*
"Difference (95% CI; p value)"
Difference (95% Cl)
Difference (a) vs Placebo (95% Cl)
Difference (Glargine -Standard Care) LSM ± SE (mm/year)
Difference (N-3 FA - Placebo) LSM ± SE (mm/year)
Difference (SE)
Difference (Tiotropium - Placebo) ml (95% CI)
Difference 2 Years-Baseline
Difference 4 Years-Baseline*
Difference FF/VI versus UC, %
Difference from  placebo
Difference from baselinea
Difference from placebo
Difference from placebo (95% CI)
Difference from placebo (95% Cl)
Difference from placebo* (95% CI)
Difference from placebo¥
Difference from placeboa
Difference in Change
Difference in LS mean vs placebo (95% CI), %
Difference in LS mean vs placebo (95% CI), mmol/mol
Difference in LS mean8 (95% Cl)
Difference in LS means (95 % CI)4
Difference in LS means (95% Ci)
Difference in LS Means (95% CI)
Difference in LS means (95% CI) versus placebo
Difference in LS means (95% CI)a
Difference in means
Difference in means (95% Cl)
Difference in SBP between treatment
Difference MEPO-PBO (95% CI)
Difference vs FF 100 pg (95 % CI)
Difference vs PBO
Difference vs PBO (95% CI)
Difference vs placebo
Difference vs placebo'
Difference vs placebo (95 % CI)
Difference vs placebo**
Difference vs placebo, % [95% Cl], P
Difference vs. PBOf Mean (s.e.)t
Difference vs. placebo
Difference VS. placebo, % (95% Cl)
Difference vs. placebo, kg (95% Cl)
Difference, % median
Difference13
Differences between indacaterol + tiotropium versus tiotropium + placebo
Differencevs. PBOf
Diffusion capacity of the lung for carbon monoxide, % predicted!
Digit Symbol Substitution
Digital clubbing, n (%)
Digitalis
Digitalis glycoside
Digitalis, n (%)
Digoxin
Digoxin at enrollment
Digoxin at last follow-up
Digoxin N(%)
Digoxin n=6327 (30%)
Digoxin or digitalis glycoside
Digoxin or digitalis preparation
Digoxin or digitalis preparations
Digoxin SCD, No. (%/y)
Digoxin, %
Digoxin, % (n)
Digoxin, (%)
Digoxin, n (%)
Digoxin/digitalis glycoside
Dihydropyridine
Dihydropyridine calcium-channel blocker
Dihydropyridine CCBs
Dilatative
Dilatative, n (%)
Dilated cardiomyopathy
Diltiazem or verapamil
DIP involvement,! n (%)
DIP joint arthritis
Dipeptidyl peptidase-4 inhibitor
Dipeptidyl peptidase 4 inhibitor
Dipeptidyl peptidase 4 inhibitors
Dipyridamole
Dipyridamole alone
Direct stenting per lesion‡
Direct thrombin inhibitors
Direction of HR
Disabling or fatal
Disabling or fatal stroke
Disabling stroke
Discharge medication, n (%)
discontinu- ation
Discontinuation of ICS/LABA prior to baseline, n (%)
Discontinuation of LAMA prior to baseline, n (%)
Discontinuations
Discontinuations due to AE
Discontinuations TEAEs
Discontinued
Disease
Disease-progression composite outcome!
Disease activity
Disease activity (n (%))
Disease activity outcomes (ITT population) week 52
Disease and quality-of-life scores
Disease and quality-of-life scores, mean (SD)
Disease characteristics
Disease characteristics Duration of psoriatic arthritis — yr
Disease characteristics*
Disease characteristics,
Disease characteristics, n (%), unless otherwise stated
Disease duration
Disease duration (y), median (m/n, max)
Disease duration (years)
Disease duration (years), mean ± s.d.
Disease duration (yr)
Disease duration [year], mean ± SDa
Disease duration > 5 years ( N = 536)
Disease duration >7 years, 77 [%] Disease activity‘s
Disease duration 2 to b5 years (N=148)
Disease duration b 2 years ( N = 93)
Disease duration, mean [SD] years
Disease duration, mean yr (SD)
Disease duration, median (range) years
Disease duration, y
Disease duration, y, mean ± SD
Disease duration, year (median)
Disease duration, years
Disease duration, years: median (range)
Disease duration, yrs, mean (SD)
Disease duration: <baseline mean
Disease extent, n (%)
Disease Hare. no. (%)i
Disease history
Disease localization'’, n (%)
Disease localization, n (%)
Disease location (%)*
Disease location, %
Disease location/type: terminal ileum
Disease Severity
Disease site — no. (%)^
Disease site — no. of patients (%)|
Disease site, n [%]
disorders (SOC)
Disposition Index
Dissatisfied with/stopped $ 1 prior systemic therapy because of side effects
Dissatisfied with/stopped $ 2 prior systemic therapies because of side effects
Disseminated  tuberculosis
Distal
Distal anastomosis (%)
Distal forearm
Distal Lower
Distal one-third of radius
Distance to LDL-C goal
Distribution— no. {%)
Distribution — no. (%)
Distribution — no. {%)
Distribution of metformin dose at randomization, n (%)
Diurciic
Diuretic
Diuretic— no. (%) Surgery
Diuretic — no./total no. (%)
Diuretic (any)
Diuretic agent
Diuretic agents
Diuretic agents (excluding antialdosterone)
Diuretic drugs
Diuretic drugs (excluding antialdosterone)
Diuretic drugs, n (%)
Diuretic N(%)
Diuretic subgroup
Diuretic therapy
Diuretic Thiazide
Diuretic use
Diuretic use at baseline
Diureticff
Diuretics
Diuretics (%)
Diuretics group (n=544)
Diuretics**
Diuretics, %
Diuretics, n (%)
Diuretics^
Diureties
Dizziness
DLQI
DLQI (0-30), mean (SD)
DLQI (patients with £3% BSA psoriasis)
DLQI improvement from baseline to week 24
DLQI score
DLQI, 0-30*
DLQI§
DM
DM- (Aliskiren vs. Placebo)
DM (n = 2,153)
DM (n=3623)
DM absent
DM Duration
DM duration, years
DM medication, n (%)c
DM or CKD*
DM or diabetic complications
DM present
DM, n (%)
DM+ (Aliskiren vs. Placebo)
DMAb (N = 151)
DMAb (N = 191)
DMAb (N = 342)
DMAb (N = 628)
DMARD− (n = 74)
DMARD-biologic IR
DMARD-IR
DMARD-IR/anti-TNF-IR
DMARD at baseline
DMARD or Corticosteroid
DMARD User
DMARD||
DMARD+ (n = 199)
Documented asymptomatic cardiac ischemiac
Documented coronary artery disease
Documented hypoglycaemiac
Documented MI
Documented symptomatic CHDb
Door-to-balloon time — hr
Dopa and dopa derivativese
Dopamine agonist use, No. (%)
Dose (IU)
Dose (mg/day)
Dose (mg/week)
Dose (n)
Dose Adjusted
Dose adjustment n (%)
Dose adjustment reason < 60 kg
dose equivalent, mg (SD))
Dose of aspirin
Dose of atorvastatin
Dose of rosuvastatin
Dose ratio at week 18 (95% Cl)
Dose ratio at week 26 (95% Cl)
Dose reduced at randomization*
Dose reduction at randomization
"Dose reduction at randomization — no. (%);i;"
Dose reduction at randomization, %
Dose reduction, n (%)
Dose, mg
Dose/weight (IU/kg)
Dosing
Double-dummy phase**
Double-vessel disease, n (%)
Doubling of baseline serum creatinine or ESRD RR (CI)“
Doubling of creatinine
Doubling of creatinine level,
Doubling of creatinine†
Doubling of serum creatinine
Doubling statin dose
Doxazosin
Doxazosin Group
DPP-4
DPP-4 inhibitor
DPP-4 inhibitor therapy
DPP‐4 inhibitors
DPP-4 inhibitors
Draining cutaneous fistula at baseline, n (%)
Draining fistulae, n (%)
Drinker (%)
Drinker (%)a
Drinker (1-14 drinks/week)
Drinker (1 to 14 drinks/week)
Drinker, n (%)
Drinking
Drinking, n (%)
Drinking, n (%) Lipid values, mmol/L
Dronedarone
Dronedarone (n = 2168)
Dronedarone (N = 2301) 71.6±8.9
Dronedarone (N = 411)
Dronedarone (N = 417)
Dronedarone (N = 828)
Dronedarone (n = 95)
dRosuvastatin + fenofibric acid vs. fenofibric acid monotherapy.
Drug- related AE*
Drug-eluting
Drug-eluting stent
Drug-Eluting Stent
Drug-eluting stent — no. (%)
Drug-eluting stent implanted
Drug-eluting stent implanted (at least one)
Drug-eluting stent, n (%)
Drug-related SAEs
Drug-related TEAEs
Drug-related TEAEs*
Drug-related TEAEs3
Drug‐relateda
Drug-relateda
drug and insulint
Drug Discontinuation Not Due To Death
Drug eluting
Drug eluting stent
Drug Naive
Drug therapy
Drug therapy at admission — no. (%) Aspirin
Drug therapy at admission 一no. (%) Aspirin
Drug therapy, n (%)
Drug therapy, No. (%)
Drugs and toxins
Drugs used in diabetes
Drugs used in diabetes, n (%)
Dual antiplatelet
Dual antiplatelet therapy
Dual BP/LDL-C goal attainment
DUAL I extension
DUAL II
DUAL IV
Dual therapy
Due to AE
Due to drug-relateda AE
Due to drug-relateda SAE
due to ECG changes
Due to SAE
due worsening angina
Dulaglutide 0.75 mg
Dulaglutide 0.75 mg (n = 270)
Dulaglutide 0.75 mgf
Dulaglutide 0·75 mg (n=190)
Dulaglutide 1.5 mg
Dulaglutide 1.5 mg (n = 269)
Dulaglutide 1.5 mg*
Dulaglutide 1·5 mg (n=192)
Dupiiumab, 200 mg (N = 631)
Dupiiumab, 300 mg (N = 633)
Dupilumab 631
Dupilumab 633
Duplex ultrasonography
Durable clinical remissionh
Durable clinical responseg
Duration
Duration — yr
Duration <1 year, n (%)
Duration >1 to <5 years, n (%)
Duration >5 years, n (%)
Duration alendronate use, years (meaniSD)
Duration antiplatelet use as % of study duration (SD)
Duration diabetes (years)
Duration DM in DM (years)
Duration from clopidogrel/placebo to PCI, min (median, IQR)
Duration from hospital admission to PCI, h (median, IQR)
Duration of
Duration of alendronate use, mean (SD), y
Duration of AS, n (%)
Duration of AS, years
Duration of assigned regimen before surgery
Duration of assigned regimen before surgery POST-RANDOMISATION CHARACTERISTIC*
Duration of assigned regimen before surgery POST-RANDOMISATION CHARACTERISTIC**
Duration of asthma — yr
Duration of asthma (years)
Duration of asthma >5 years
Duration of asthma,
Duration of asthma, y
Duration of asthma, years
Duration of CHF (months)
Duration of chronic kidney disease* (years)
Duration of clopidogrel pretreatment — hr Median
Duration of clopidogrel pretreatment 一hr Median
Duration of COPD — days^
Duration of COPD — yr
Duration of COPD (years)
Duration of COPD (years), mean (SD)
Duration of COPD (yr)
Duration of COPD (yr)f
Duration of COPD,
Duration of COPD, y
Duration of COPD, years
Duration of COPD, yr
Duration of coronary artery disease — yr
Duration of Crohn's disease (yrs)
Duration of Crohn’s disease (yrs)
Duration of current flare, median (range) months (n = 99, 99, 96)
Duration of dementia symptoms, months
Duration of diabetes
Duration of Diabetes
Duration of diabetes — yr
Duration of diabetes — yr^
Duration of Diabetes    <5 yrs
Duration of diabetes (months)
Duration of diabetes (y)
Duration of diabetes (years)
Duration of diabetes (years), mean (SD)
Duration of diabetes (years), mean, (SD)
Duration of diabetes (years)t
Duration of Diabetes < 10 years
Duration of Diabetes > 10 years
Duration of diabetes by tertiles
Duration of diabetes in years, median (IQR)
Duration of diabetes mellitus
Duration of diabetes mellitus, median (IQR), y
Duration of diabetes mellitus, y
Duration of diabetes mellitus, y, mean (SD)§
Duration of diabetes Microvascular disease — no. (%)
Duration of diabetes, mean (SD), y
Duration of diabetes, Median (IQR)
Duration of diabetes, y
Duration of diabetes, y, mean (SD)
Duration of diabetes, years
Duration of Diabetes, years
Duration of diabetes, years, mean (SD)
Duration of diabetes, years, median (IQR)
Duration of diabetes, yrs
Duration of disease — mo
Duration of disease — yr
Duration of disease — yr:t
Duration of disease — yr^ Mean
Duration of disease (y), median (min, max}
Duration of disease (years)
Duration of disease (yr)
Duration of disease before baseline
Duration of disease since
Duration of disease, median
Duration of disease, n (%)
Duration of disease, y
Duration of DM-years
Duration of epilepsy, mean (SD), years
duration of epilepsy, years
Duration of epilepsy, years, mean (SD)
Duration of full-dose warfarin therapy before enrollment (mo)
Duration of heart failure (years)
Duration of HF, y
"Duration of hypercholesterolaemia; mean ± SD (year)"
Duration of hypercholesterolemia (yr)
"Duration of hypercholesterolemia; mean ± SD (years)"
Duration of hypertension (months)
Duration of hypertension (years)
Duration of hypertension, n (%)
Duration of hypertension, y
Duration of infusion — hr
Duration of infusion after PCI — hr
Duration of infusion before CABG — hr
Duration of infusion before PCI — hr
Duration of infusion during medical management— hr
Duration of initial anticoagulation, mean (SD), mo
Duration of last qualifying episode of atrial fibrillation >7 days
Duration of macular edema, mo
Duration of metformin therapy (months)
Duration of morning
Duration of oral antidiabetic treatment, y, mean (SD)
Duration of osteoarthritis symptoms — yr
Duration of PAOD (years), mean ± SD
Duration of PCI — min
Duration of PCI (min), median
Duration of PCI (min), median N (IQR)
Duration of PCI, min
Duration of PD, y
Duration of pre-randomization anticoagulant therapy
Duration of previous use of VKA, months
Duration of prior alendronate use, months
Duration of prior statin therapy^
Duration of procedure
Duration of psoriasis (years), mean (SD)
Duration of psoriasis, years
Duration of qualifying atrial fibrillation »2 days — no. (%)
Duration of RA
Duration of RA (time from symptom onset), years
Duration of RA (Years)
Duration of RA, mean (min-max) (yrs)
Duration of RA, mean ± SD years
Duration of RAt, years
Duration of rheumatoid arthritis — yr
Duration of rheumatoid arthritis (years)
Duration of rheumatoid arthritis, year
Duration of study-drug administration — hr
Duration of study-drug infusion
Duration of sulphonylurea use (months), mean ± s.d.
Duration of symptoms > 10 min
Duration of symptoms, h
Duration of T1D (years)
Duration of T2D (years)
Duration of T2D, y
Duration of T2DM
Duration of T2DM (%)
Duration of T2DM (years)
Duration of T2DM <10 years
Duration of T2DM >10 years
Duration of T2DM, y
Duration of T2DM, years
Duration of total exposure to study treatment, weeks
Duration of treatment in the healing study, n
Duration of type 2 diabetes
Duration of type 2 diabetes (years)
Duration of type 2 diabetes categories, n (%)
Duration of type 2 diabetes mellitus (years)
Duration of type 2 diabetes mellitus, years
Duration of type 2 diabetes, years
Duration of ulcerative colitis
Duration ofdiabetes — yr
Duration since diagnosis (years)
Duration, mean (SD), years
during overall study period
Dutasteride
Dutasteride (n = 106)
Dutasteride (n = 184)
Dutasteride (n=117)
Dutasteride (n=67)
Dutasteride (W= 1623), 0/0
DVT
DVT only
DVT Only
Dx at presentation, n (%)
Dynamic measure of β-cell function (ϕs) (change from baseline) – assessed for MMTT subset only
"dysfunction; EF = erectile function; IIEF = I"
Dysglycaemia or MetS
Dysglycemic categories, n (%)
Dyslipidaemia
Dyslipidaemia—No. (%)
Dyslipidaemia and hypertension, n (%)
Dyslipidaemia and hypertensiont
Dyslipidaemia including Hypercholesterol—No. (%)
Dyslipidaemia, n (%)
Dyslipidaemia本
DyslipidaemiaJ
Dyslipidaemiat
Dyslipidemia
Dyslipidemia — no. (%)
Dyslipidemia — no. (%)|
Dyslipidemia — no. {%)
Dyslipidemia, n (%)
Dyslipidemia, n(%)
Dyslipidemia3
Dyspepsia
Dyspnea
Dyspnea – mMRC grade, n (%)
Dyspnea at rest (NYHA IV), (%)
Dyspnea t
Dyspnea, % (frequent/continuous)
Dyspnea, frequent/continuous
Dyspnoea - mMRC grade, n (%)
Dyspnoea (N=18)
Dyspnoea (N=68)
E
E-RS total scoreb
E ( Characteristic n
E Europe
e Major Non-Vertebral Fragility Fractures (FAS)
E. Europe
E/A ratio
E/E' (septal)
E10 + A10
E10 + A10 -
E10 + A20
E15 (n = 248)
E15/S100 (n = 244)
E15/S100 vs E15
E15/S100 vs S100
E5 (n = 250)
E5/S100 (n = 243)
E5/S100 vs E5
E5/S100 vs S100
EACIT-E total score) |
Early
Early-Eptifibatide Group (N = 4722)
Early-Start Group (N = 288)
Early-Start Group (N = 293)
Early (n=107)
Early (n=201)
Early (n=207)
Early clopidogrel intended
Early Crohn's disease*
Early death
Early Eptifibatide
Early ichaem ic stroke
Early invasive strategy (n = 3,116)
Early Invasive*
"Early Invasive1"""
Early load
Early Load
Early routine
Early use intended
Early, n (%)
EASE-2
EASE-3
East Asia
East Asian
East Europe
Eastern and central Europe
Eastern Europe
Eastern Europe (%)
Eastern Europe (n = 1,154)
Eastern Europe and Africa
Eastern Europe, Africa
Eastern European
ebriA
eCFR (mL/min per 1-73 m’)
eCFR, mL/min per 1.73 m2
ECG
ECG-LVH (Cornell)
ECG-LVH (Sokolow-Lyon)
ECG abnormality (resting), %
ECG abnormality at entry
ECG and imaging data
ECG at time of qualifying symptoms
ECG atrial fibrillation, n (%)
ECG changes (%)t
ECG findings
ECG findings at baseline — no. (%)
ECG left ventricular
eCrCl <30 ml/min
eCrCl <60 ml/min
eCrCl, ml/min
eCrCL, ml/min
Eczema
ED >1 yr, no. (%)
ED characteristics
ED duration
ED duration >1 yr, n (%)
ED duration, visit 2**
ED etiology, no. (%)
ED history, n (% Yes)
ED severity **, n (%):
ED severity, no. (%)a
ED severity, visit 2**
ED therapy
ED visit related to exacerbation, n (%)
EDA, %
Edema peripheral
Edema, %z
Edema, (%)
Edema, n (%)
Edema, peripheral
EDGE
EDGE II
Edo
Edoxaban
EdOXaban
Edoxaban (N = 1650)
Edoxaban (N = 2468)
Edoxaban (N = 4118)
Edoxaban (n=14023)
edoxaban at randomization, n (%)
Edoxaban dose adjusted at randomisation, n (%)*
Edoxaban higher dose vs warfarin
Edoxaban lower dose vs warfarin
Edoxaban N = 3555
Edoxaban N = 3555 n/N (%)
Edoxaban N = 563
Edoxaban N = 563 n/N (%)
"Edoxaban n/N; rate (%)"
Edoxaban vs. Warfarin
Edoxaban Warfarin
EDSS score
EDSS stratification, No. (%)
EDSS stratification. No. (%)
Educ >12Y
Educ 9-12Y
Educ sSY
Education
Education — no. (%)
Education (%)
education (years)
Education (years)
Education <8 y
Education <8 years
Education >12 y
Education >12 years
Education >12 yr (%)
Education 8-12 years
Education 9 to 12 y
Education in years, mean
Education in years, mean (SD)
Education level
Education*
Education, mean (sd) years
Education, mean (SD), y
Education, mean (SD), ya
Education, y
Education, y, mean (SD)
Education, years, mean (SD)
Education, yrs, mean (sd)
Eduglinozin 15 mg vs placebo/glimepiride
EF (%), mean (SD)
EF < 50% (N 5 520)
EF <30%
EF <40% (n = 3,116)
EF <40% n=385
EF <45%
EF <50% (N 5 520)
EF > 50% HFpEF (n = 1953, 26%)
EF >40% (n = 3,116)
EF >40% n=3894
EF >60% (N 5 1333)
EF 40-49%
EF 40-49% HFmrEF (n = 1322, 17%)
EF 50-54.99% (N 5 712)
EF 55-59.99% (N 5 879)
EF b 50%
EF domain
EF, %
EF<40%
EF<40% HFrEF (n = 4323, 57%)
EF>50%
Effect estimate
Effect of Covariates on Slopes
Effect of ranolazine compared with placebo on angina and recurrent ischemia
Effect size!
Effect size^
Efficacy
Efficacy and safety: net adverse clinical events*
Efficacy end points
Efficacy Endpoint
Efficacy endpoints*
Efficacy measures
Efficacy parameter
Efficacy variable
Efficacy, n (%)a
eGFR
eGFR-
eGFR— mean (sd, N)
eGFR — ml/min/1.73 m**
eGFR — mL/min/1.73 m^
eGFR — ml/min/1.73 m2
eGFR (CKD-EPI, cystatin C), mL/min/1.73 m2
eGFR (MDRD), ml min−1 1.73 m−2
eGFR (MDRD), mL/min/1.73 m**
eGFR (MDRD), mL/min/1.73 m2
eGFR (MDRD), n (%)
eGFR (median, IQR), mL/min/1,73m2
eGFR (mL/min per 1-73 kg/m^)
eGFR (mL/min per 1-73 m')
eGFR (mL/min per 1-73 m^)
eGFR (mL/min per 1-73 m’)
eGFR (mL/min per 1-73 m2)t
eGFR (mL/min per 1-73 m3)
eGFR (ml/min per 1.73 m2),
eGFR (mL/min per 1^73 m')
eGFR (mL/min per 1+73 m”
eGFR (mL/min per 1·73 m2)
eGFR (mL/min)
eGFR (mL/min/1-73 mz)
eGFR (mL/min/1.73 m2 [MDRDequation])
eGFR (ml/min/1.73 m2)
eGFR (mL/min/1.73 m2)
eGFR (ml/min/1.73 m2), mean (SD)
eGFR (mL/min/1.73 m2), mean (SD)
eGFR (mL/min/1.73 m2)§
eGFR (ml/min/1.73m2)
eGFR (mL/min/1.73m2)
eGFR (mL/min/1.78 m2)
eGFR (mUmin/1.73 m2)
eGFR ,30 mL/min/1.73 m2 (n =206)
eGFR ,30 mL/min/1.73 m2 (n =336)
eGFR ,60 mL/min/1.73 m2, n (%)
eGFR .50 mL/min/1.73 m2 (n = 10,621)
eGFR .50 mL/min/1.73 m2 (n = 13,916)
eGFR £60 mL/min/1.73m2
eGFR < 30 mL/min/1.73 m2
eGFR < 60 ml/min/1.73m2
eGFR <30
eGFR <30 mL/min/1.73
eGFR <30 ml/min/1.73 m2
eGFR <45 mL/min/1.73 m2
eGFR <45 mL/min/1.73 m2 (N = 554)
eGFR <45.0 (vs eGFR >75)
eGFR <50 mL/min, n (%)
eGFR <50 mL/min/1.73 m2§
eGFR <60
eGFR <60 (mL/min/1.73 m2)
eGFR <60 mL/ min/1.73m2
eGFR <60 mL/min
eGFR <60 mL/min per 1^73 m'
eGFR <60 mL/min per 1·73 m2
eGFR <60 mL/min/1-73 m2
eGFR <60 mL/min/1.73
eGFR <60 mL/min/1.73 m^
eGFR <60 ml/min/1.73 m2
eGFR <60 mL/min/1.73 m2
eGFR <60 ml/min/1.73 m2 (MDRD)
eGFR <60 ml/min/1.73 m2*
eGFR <60 mL/min/1.73 mz
eGFR <60 mL/min/1.73m2
eGFR <60, ml/min/m2
eGFR <60, n (%)
eGFR <78
eGFR ≥60 mL/min per 1·73 m2
eGFR ≥60 mL/min/1.73 m2
eGFR ≥90 mL/min/1.73 m2 (N = 2476)
eGFR > 60, n (%)
eGFR >=90ml/min/1.73m2 N=3,325 (22.9%)
eGFR >50 mL/min
eGFR >50 mL/min/1.73 m2
eGFR >60 (mL/min/1.73 m2)
eGFR >60 mL/min per 1^73 m'
eGFR >60 mL/min/1-73 m2
eGFR >60 mL/min/1.73 m^
eGFR >60 ml/min/1.73 m2
eGFR >60 mL/min/1.73 mz
eGFR >75
eGFR >80 mL/min, n(%)
eGFR >90 ml/min/1.73m2
eGFR 290 mL/min/1.73
eGFR 30-44 ml/min/1.73m2
eGFR 30-44 ml/min/1.73m2 N=783 (5.4%)
eGFR 30-50
eGFR 30-50 mL/min/1.73 m2 (n = 2,240)
eGFR 30-50 mL/min/1.73 m2 (n =1,533)
eGFR 30-59 ml/min/1.73 m2
eGFR 30–50 mL/min/1.73 m2
eGFR 30 to <45 mL/min/1.73
eGFR 45-59 ml/min/1.73m2
eGFR 45-59 ml/min/1.73m2 N=2,538 (17.5%)
eGFR 45 to <60 mL/min/1.73 m*
eGFR 45 to <60 mL/min/1.73 m2 (N = 1485)
eGFR 45.0-59.9 (vs eGFR >75)
eGFR 50 to <80 mL/min, n (%)
eGFR 560 mL/min/1.73 m^
eGFR 60-89 ml/min/1.73m2
eGFR 60-89 ml/min/1.73m2 N=7,879 (54.2%)
eGFR 60 to <75 mL/min/1.73 m’
eGFR 60 to <90 mL/min/1.73 m2 (N = 5625)
eGFR 60.0-74.9 (vs eGFR >75)
eGFR 75 to <90 mL/min/1.73 m^
eGFR and albuminuria
eGFR at baseline , 60 mL/min (%)b
eGFR by creatinine (mL/min per 1·73 m2)
eGFR by creatinine (mL/min per 1·73 m2, geometric mean [SE])
eGFR by cystatin C (mL/min per 1·73m2, geometric mean [SE])
eGFR by cystatin C (mL/min per 1·73m2, mean [SE])
eGFR category
eGFR category (mL/min/1.73 m2), n (%)
eGFR category, n (%)
eGFR CrCl <60 ml/min/1.73 m2
eGFR CrCl mL·min−1·1.73 m−2
eGFR from the MDRD equation (SD), mL·min−1·1.73 m−2
eGFR in 3 classes
eGFR in ml/min/1.73 m^ , median (IQR)
eGFR s60 mL/min/1.73 m^
eGFR S60 mL/min/1.73 m^
eGFR S6O mL/min/1.73 m^
eGFR using CG/MDRD formulae, % of patients
eGFR via MDRD (mL/min/1.73m2)
eGFR <60 ml/min/1.73 m2
eGFR ≥60 ml/min/1.73 m2
eGFR(CKD-EPI,cystatinC),mL/min/1.73 m2,n(%)
eGFR(mL/min/1.73 m2)
eGFR, mean (SD), mL/min/1.73 m2
eGFR, mean = SD, mL/min/1.73 m2
eGFR, mean±SD
eGFR, median (SD), mL/min
eGFR, mL • mn ' • 1.73 m 2
eGFR, ml min 1 1.73 m 2
eGFR, mL/ min/1.73 m2
eGFR, mL/kg per 1.73 m2
eGFR, ml/min
eGFR, mL/min
eGFR, mL/min per 1.73 m2
eGFR, ml/min per 1.73 m2, mean (SD)
eGFR, mL/min per 1·73 m2
eGFR, mL/min/1.73 m^
eGFR, ml/min/1.73 m2
eGFR, mL/min/1.73 m2
eGFR, mL/min/1.73 m2 (MDRD)
eGFR, mL/min/1.73 m2 (MDRD), mean (SD)
eGFR, mL/min/1.73 m2 (SD)
eGFR, mL/min/1.73 m2, mean (SD)
eGFR, mL/min/1.73 m2, mean ± SD
eGFR, mL/min/1.73 m2
eGFR, ml/min/1.73m2
eGFR, mL/min/1.73m2,‡
eGFR, mL/min/BSA
eGFR, ml/min/m2
eGFR, mL/minute/1.73 m2
eGFR, n (%) Normal (eGFR >90 mL/min/em^)
eGFR,* mL/min/1.73 m2
eGFR_P_interaction
eGFR+, mL/min/1.73 m2 (mean ± SD)
eGFR>50
eGFR‡ (mL/min per 1·73 m2)
eGFRMDRD <60 mL - min-1-1.73 m-2, n (%)
eGFRMDRD, mL - min-1-1.73 m-2
eGFRMDRD, ml/min/1.73 m2 BSA
eGFRMDRD，mL - min-1- 1.73 m_2
Either OCS use, nasal polyps, pre-BD FVC <65% of predicted or age at diagnosis sl8 years
Ejection fraction
Ejection Fraction
Ejection fraction — mean ±SD
Ejection fraction (%)
Ejection fraction (mean)
Ejection fraction based on local reading
Ejection fraction group
Ejection fraction*
Ejection fraction, %
Ejection Fraction, %
Ejection fraction, % NYHA class, n (%)
Ejection fraction, mean (SD), %
Ejection fraction, percent (SD)
Ejection fraction: <50% (n=288)
EL, n (%)
Elderly
Elderly (>65 years)
Elderly patients (n — 2778)
Elective peripheral revascularization
Elective procedure
Elective surgery
electrocardiogram
Electrocardiograph results, No. (%)
Electrocardiographic findings — no. (%)
Electrocardiographic findings at randomization
Electrocardiography
Electrophysiological study— no. (%) Weight — IbJ
Elevated at wk 0 — no. (%)!
Elevated at wk 12 — no. (%)1
Elevated baseline CRP
Elevated biomarkers and ST-segment changes
Elevated blood pressure
Elevated BNP
Elevated BNP (80 pg/ml), %
Elevated BNP, >80 pg/ml (n = 1,876)
Elevated BUN (>14.3 mEq/L)
Elevated cardiac markers
Elevated cardiac markers — no. (%):t
Elevated cholesterol
Elevated creatine kinase-MB (>24 U/L)
Elevated creatine kinase MB (>24 U/L)
Elevated creatinine (>177 pmol/L)
Elevated CRP (>ULNt), n (%)
Elevated CRP, n (%)
Elevated fasting glucose
Elevated high-sensitivity CRP—no. {%)**
Elevated hsCRP
Elevated hsCRP >5 mg/L, n (%)
Elevated Natriuretic Peptide Level (n=92)
Elevated natriuretic peptides in previous 60 days — no. (%)$
Elevated natriuretic peptides in previous 60 days — no. (%):!:
Elevated non-HDL cholesterol
Elevated serum creatinine (>2.5 mg/dl_)
Elevated Serum Creatinine, >2.5 mg/dl
Elevated Serum Potassium, >6.0 mmol/l
Elevated Symptomatic Serum Creatinine, Hypotension    >2.5 mg/dl
Elevated TG
Elevated Troponin
Elevated troponin — %
Elevated troponin (>0.03 pg/L)
Elevated troponin (>0.04 mg/l), %
Elevated troponin T (>0.03 /xg/L)
elevated vs normalb
elevated vs. normalb
elevated vs. normalc
Elevation of cardiac biomarker levels — no./total no. (%)
Elevation of cardiac biomarker levels or ST-seg- ment deviation >1 mm — no./total no. (%)
Elevation of troponin levels — no./total no. (%)
Eligibility risk factors
Eligibility risk factors—n (%):
Eligibility risk factors!
Eligibility risk factors, %t ASCVO
Eligibility risk factors, No. (%)t
Eligibility risk factors/
Eligibility risk factors:
Eligibility risk factors’)
Eligibility risk factorsa
Eligibility strata
Eligibility stratum
ElMs, n (%)
embolism
Emergent/urgent surgery
Emotional function
Emotional status
EMPA
EmpagIiflozin 10 mg
EmpagIiflozin 25 mg
Empaglifiozin 10 mg (W = 243)
Empaglifiozin 10 mg (W = 244)
Empaglifiozin 2.5 mg (W = 237)
Empaglifiozin 25 mg (W = 241)
Empaglifiozin 25 mg (W = 242)
Empagliflozin
Empagliflozin (N = 1212) 67.1±7.6
Empagliflozin (N = 3473) 61.7±8.5
Empagliflozin (n = 1175)
Empagliflozin (n = 3512)
Empagliflozin (n=1338)
Empagliflozin (N=1498)
Empagliflozin (n=2789)
Empagliflozin (N=3149)
Empagliflozin (n=509)
Empagliflozin 10 mg
Empagliflozin 10 mg (N = 2345)
Empagliflozin 10 mg (n=122)
Empagliflozin 10 mg (n=135)
Empagliflozin 10 mg (N=1740)
Empagliflozin 10 mg (n=19)
Empagliflozin 10 mg (n=276)
Empagliflozin 10 mg (N=605)
Empagliflozin 10 mg/day (n = 700)
Empagliflozin 25 mg
Empagliflozin 25 mg (N = 2342)
Empagliflozin 25 mg (n=116)
Empagliflozin 25 mg (n=139)
Empagliflozin 25 mg (N=1733)
Empagliflozin 25 mg (n=21)
Empagliflozin 25 mg (n=276)
Empagliflozin 25 mg (N=607)
Empagliflozin 25 mg/day (n = 703)
Empagliflozin n with event/n
Empagliflozin Pooled (n=1446)
Empagliflozin Pooled (n=1639)
Empagliflozin Pooled (n=1869)
Empagliflozin Pooled (n=3048)
Empagliflozin Pooled (n=564)
Empagliflozin Pooled (n=805)
Empagllflozin
Empagllflozln
Emphysema
Emphysema (%)
Emphysema (ITT) (n=433)
Emphysema (ITT) (n=438)
Emphysema (ITT) (n=444)
Emphysema (ITT) (n=446)
Emphysema (ITT) (n=577)
Emphysema (ITT) (n=582)
Emphysema (n=462)
empty
ENACT-1 Trial
ENACT-2 Trial Rerandomization to Natalizumab (N=168)
Enalapril
Enalapril    LCZ696 (n = 747)    (n = 752)
Enalapril (n = 1684)
Enalapril (n = 1812)
Enalapril (n = 2400)
Enalapril (n = 490)
Enalapril (n = 491)
Enalapril (n = 642)
Enalapril (n = 652)
Enalapril (n = 665)
Enalapril (n=1877)
Enalapril (n=2335)
Enalapril + aliskiren (n = 1675)
Enalapril + aliskiren (n = 665)
Enalapril + aliskiren DM = 665 Non-DM = 1675
Enalapril DM = 652 Non-DM = 1684
End-point (SD)
End-stage renal disease
End of Follow-up
End of trial
End point
End Point
End points
End Points
Ended >90 days before trial entry
Endoscopic disease severity
Endoscopy subscore
Endoscopy subscore, n (%)
Endothelin-receptor antagonists
Endothelin-receptor antagonists plus phosphodiesterase type 5 inhibitors
Endothelin 1 (pg/ml)
Endovascular
Endovascular— no. (%)
Endpoint
Endpoint rate
Endpoint Week 161
Endpoint*
Endpoint/baseline
Endpoint/baselinec
Endpointc
Endpoints
Enox
Enoxaparin
Enoxaparin (N = 10,021)
Enoxaparin (N = 10,256)
Enoxaparin (n = 4993)
Enoxaparin (n = 906)
Enoxaparin (n= 2026)
Enoxaparin 40 mg (n = 2,157)
Enoxaparin Only
Enoxaparin/VKA
Enoxaparin/VKA n/N    (%) 51/1718    (3.0)
Enrolled from RE-COVER II study — no. (%)
Enrolled from RE-COVER study — no. (%)
Enrolled in Russia or Georgia
Enrolled in the Americas
Enrolled into Osler
Enrollment by region, no. (%)
Enrollment in LMWH
Enrollment in LMWH substudy
Enrollment strata: prior hospitalization
Enrollment to randomization
Enrolment through HF
Enrope + Sonth Afriea
Entacapone
Enthesitis
Enthesitis count
Enthesitis score (MASES, 1-15), mean (SD)
Enthesitis score at baseline, median (IQR) Week 100
Enthesitis score*
Enthesitis, %§
Enthesitis, n (%)
Entire cohort
Entire cohort Gender
Entire evaluable cohort
Entocort EC (n=126)
Entry category
Entry criteria
Entry criteria (%)
Entry hip fracture location, n (%)
Environmental stimuli
EO
EO severity by LA classification at baseline (baseline of the healing study), n (%)
EOS count (cells/pL)
EOS serum K+, mEq/L
Eosinoohil count
Eosinophil counf cells pL '
Eosinophil count
Eosinophil count (cells per pL)
Eosinophil count (cells/pL), median (range)c
Eosinophil high
Eosinophil low
Eosinophils
Eosinophils (cells/ll) inclusion criteria, n (%)
Eosinophils £2% (ITT) (n=936)
Eosinophils £2% (n=1254)
Eosinophils <0 2x10*9/L (n=748)
Eosinophils <0.2x10''9 (ITT) (n=966)
Eosinophils <0.2x10''9 (ITT) (n=978)
Eosinophils <0.2x10''9 (n=978)
Eosinophils <0.2x10''9 (n=986)
Eosinophils <0.2x10*9 (ITT) (n=1294)
Eosinophils <0.2x10*9 (n=1310)
Eosinophils <2% (ITT) (n=654)
Eosinophils <2% (ITT) (n=670)
Eosinophils <2% (ITT) (n=886)
Eosinophils <2% (n=512)
Eosinophils <2% (n=661)
Eosinophils <2% (n=677)
Eosinophils <2% (n=896)
Eosinophils >0 2x10*9/1 (n=782)
Eosinophils >0.2x10''9 (ITT) (n=625)
Eosinophils >0.2x10'^ (ITT) (n=829)
Eosinophils >0.2x10*9 (n=629)
Eosinophils >0.2x10*9 (n=841)
Eosinophils >0.2x10^^ (ITT) (n=626)
Eosinophils >2% (ITT) (n=934)
Eosinophils >2% (n=1018)
Eosinophils >2% (n=938)
Eosinophils 20.2x10''9 (n=634)
Eosinophils 22% (ITT) (n=1236)
Eosinophils 22% (n-950)
EPA    HR events (%)
EPA (mol%)
EPA (n = 2303)
EPA (n = 7023)
EPA Group n=485
EPA Group n=8841
EPA Group No. of Events (%)
EPA treatment (n=9326)
EPA(mol%)
EPA(n = 2303)
EPA(n = 7023)
EPA(n=9326)
EPA, mol%
EPA/AA ratio
Epilepsy drug
Epilepsy with grand mal seizures on awakening
Epistaxis
Eplerenone (n = 506)
EQ-5D-3 L, no pain or discomfortc
EQ-5D-3 L, no pain or discomfortf
EQ-5D (visual analog score)
EQ-5D Mobility
EQ-5Dprofile-mobility, n (%)
EQ5Da health index status score
ER visit
ERA
ERA and PDE-5i
ERA and PDE5 inhibitors
ERA monotherapy
ERD*, n (%)
Erectile dysfunction
"Erectile Function; IPSS"
Erlugliflozin 15 mg vs placebo/glimepiride
Erosion
Erosion score
Erosion score (0-168)
Erosion score (0-280)
Erosion score (0–320 scale)
Erosion score, mean ± SD
Erosion score, mean 6 SD
Erosion score, median (min, max)
Erosion, mean ± SD
ErtugliflDzin 5 mg vs placebo/glinepiride
Ertugliflozin
Ertugliflozin 15 mg
Ertugliflozin 15 mg (n = 153)
Ertugliflozin 15 mg (n 5 155)
Ertugliflozin 15 mg vs placebo/giimepiride
Ertugliflozin 15 mg vs placebo/glimepiride
Ertugliflozin 15 mg vs placebo/glirneplride
Ertugliflozin 15 mg
Ertugliflozin 15 mg (n = 169)
Ertugliflozin 5 mg
Ertugliflozin 5 mg (n = 156)
Ertugliflozin 5 mg (n 5 158)
Ertugliflozin 5 mg (n = 170)
Ertugliflozin 5 mg vs placebo/glimepiride
Ertugliflozin 5 mg vs placebo/glinepiride
Ertugliflozin 5mg
Ertuglrflozin 15 mg vs placebo/glimepiride
Erysipelas
Erythrocyte sedimentation rate — mm/hr||
Erythrocyte sedimentation rate (mm/h)
Erythrocyte sedimentation rate, mm/hour
ESAM (ng/ml)
Esophageal hiatal hernia*
ESR
ESR — mm/hr
ESR (mm/h)
ESR (mm/h), mean (SD)
ESR (mm/h), median (min - max)
ESR (mm/h), median (min, max)
ESR (mm/hour)
"ESR (mm/hour; per unit)"
ESR, 0-100 mm/hour
ESR, mean ± SD mg/dl
ESR, median (range) mm/hour
ESR, mm/hour
ESRD
ESRD'
ESRD on Losartan (%)
ESRD on Placebo (%)
ESRD only RR (CI)“
ESRD or 25% decline in GFR
ESRD or 50% dedine in GFR
ESRD or death
ESRD SAXA 2.5 mg (n = 15)
ESRD*
Established
Established (n=172)
Established (n=190)
Established (n=79)
Established ASCVD
Established ASCVD or >2 CV risk factors
Established atherosclerotic
Established atherosclerotic cardiovascular disease
Established atherosclerotic cardiovascular disease — no. {%)
Established atherosclerotic CV disease§
Established atherosclerotic disease
Established atherosclerotic disease — no. {%)
Established atherosclerotic disease, n(%)
Established cardiovascular disease
Established CVD (age >50)
Established CVD/chronic kidney disease (age > 50)^*’
Established maerovaseular disease and albuminuria
Established renal disease (eGFR 15 - <45 mL/min/1.73 m^ with any UACR mg/g or eGFR >45-75 mL/inin/L73 m2 with an UACR >200 mg/g) without previous maerovaseular and albuminuria disease
Established renal disease*
estimate
Estimate (95% CI)
Estimate (95% Cl)
"Estimated creatinine clearance — ml/min;i;"
Estimated creatinine clearance — ml/min§
Estimated creatinine clearance (mL/min)
Estimated creatinine clearance <60 ml/min*
Estimated creatinine clearance <60 mL/mint
Estimated creatinine clearance <60 rmb'mint
"Estimated creatinine clearance""!"""
Estimated creatinine clearancet
Estimated CV risk at baseline
Estimated difference
Estimated Difference %
estimated difference (95% CI)
Estimated GFR
Estimated GFR — ml/min/1.73 m^ |
Estimated GFR — ml/min/1.73 m2
Estimated GFR — no. (%)^|
Estimated GFR — no. (%)51
Estimated GFR (mL/min per 1.73 m2), mean (SD)
Estimated GFR (ml/min/1.73 m2)
Estimated GFR (mL/min/1.73 m2) Lipid baseline lipid profile
Estimated GFR (ml/min/1.73 m2), mean (sd)
Estimated GFR (ml/min/1.73 m2)^|
Estimated GFR (ml/min/1.73m2)
Estimated GFR <60 ml/min/1.73 m^ — no. (%)
Estimated GFR <60 ml/min/1.73 m2
Estimated GFR <60 mL/min/1.73 m2, no. (%)
Estimated GFR >60 ml/min/1.73 m2
Estimated GFR at Baseline, mL • min 1
Estimated GFR renal function stage
Estimated GFR, <60 ml min-1 1.73 m-2, n (%)a
Estimated GFR, mean (SD), mLVmin per 1.73 m^*
Estimated GFR, ml min-1 1.73 m-2 (SD)a
Estimated GFR, mL/min
Estimated GFR, ml/min/1.73 m2
Estimated GFR, mL/min/1.73 m2 of body-surface area
Estimated GFR^
Estimated glomerular filtration
Estimated Glomerular Filtration
Estimated glomerular filtration rate
Estimated glomerular filtration rate - mL/min, Median (IQR) '
Estimated glomerular filtration rate - mL/min/1.73m2TT
Estimated glomerular filtration rate - no. (%)::
Estimated glomerular filtration rate — ml/min/1.73 m^
Estimated glomerular filtration rate — ml/min/1.73 m2
Estimated glomerular filtration rate — ml/min/1.73 m2 of body-surface area§
Estimated glomerular filtration rate — no. (%)
Estimated glomerular filtration rate (MDRD), mL/min/1.73m2
Estimated glomerular filtration rate (MDRD), mL·min1·1.73m2
Estimated glomerular filtration rate (MDRD), mL·min1·1.73m2*
Estimated glomerular filtration rate (ml/min/1.73m2)
Estimated glomerular filtration rate <60
Estimated glomerular filtration rate <60 mL/min per 1.73 m2
Estimated glomerular filtration rate <60 ml/min/ 1.73 m2— no./total no. (%)§
Estimated glomerular filtration rate <60 ml/min/ 1.73 m2 — no./total no. (%)§
Estimated glomerular filtration rate <60 ml/min/1.73 m2:i:§
Estimated glomerular filtration rate, mL/min per 1.73 m2
Estimated glomerular filtration rate, mL/min/1.73 m2
Estimated glomerular filtration rate, mL/min/1.73 m2, mean (SD)§
Estimated glomerular filtration rate, n(%)
Estimated glomerular filtration rate^
Estimated glomerular filtration rate||
Estimated glomerular filtration rate§
Estimated mean
Estimated mean    95% Cl
Estimated means and difference
Estimated means and treatment differences (%)
Estimated number of pack-years
Estimated odds ratio
Estimated proportions (%) and odds ratios
Estimated response rate and odds ratio
Estimated treatment difference (%)
Estimated* creatinine clearance <60 mLVmin, %
Estonia
Estradiol (E2) (pmol/L)
Estradiol (pmol/L)
Estradiol quartiles
Estrogen
Estrogen-containing hormones
Estrogen ('%?)
Estrogen supplementation
Estrogen supplementation-
Estrogen therapy
Estrogens
Etanercept
Etanercept (n = 266)
Etanercept (n=358)
Etanercept (n=382)
ETD (%) [95% CI]
ETD (95% CI)
"ETD: −0.01 [−0.31; 0.29]95% CI, p  = 0.9521"
"ETD: −0.10 [−3.38; 3.18]95% CI, p  = 0.9521"
"ETD: −1.86 [−2.75; −0.97]95% CI, p  < 0.0001"
"ETD: −33.58 [−49.63; −17.53]95% CI, p  < 0.0001"
Ethacrynic acid
Ethnic background
Ethnic group
Ethnic group — no. (%)'
Ethnic group (%)
Ethnic minority group — no. (%)
Ethnic origin
Ethnic Origin
Ethnic origin White
Ethnic origin*
Ethnic origin, n (%)
Ethnicity
Ethnicity -- Hispanic or Latino
Ethnicity - no. (%)
Ethnicity (%)
Ethnicity t
Ethnicity,
Ethnicity, %
Ethnicity, Hispanic/Latino, n (%)
Ethnicity, n (%)
Ethnicity, n (%)*
Ethnicity, n (%):
Ethnicity, n (%)b
Ethnicity, no. (%)
Ethnicity, No. (%)
Ethnicity, not Hispanic/Latino, n (%)
Ethnicity1'
Ethnicitya Hispanic or Latino
Ethnieity
Etiology
Etiology (%)
Etiology, n (%)
Etiology, n (%)
ETN 25 mg + MTX n = 184
ETN 25 mg + MTX n = 201
ETN 25 mg + MTX n = 202
ETN 50 mg + MTX n = 184
ETN 50 mg + MTX n = 201
ETN 50 mg + MTX n = 202
ETN 50 mg + MTX N = 709
ETN 50 mg + MTX N = 834
ETN, no
ETN, yes
ETN+MTX (n = 478)
Etoricoxib
Etoricoxib (n = 17,412)
Etoricoxib (n=10 461)
Etoricoxib (n=11 667)
Etoricoxib (n=17 412)
Etoricoxib (n=5745)
Etoricoxib (n=6951)
Etoricoxib 60 mg (N 5 6769), ..n...(.%..)............
Etoricoxib 60 mg N = 818 n (%)
Etoricoxib 90 mg (N 5 2032), ...n...(.%..)...........
Etoricoxib 90 mg (N 5 2171), ..n...(.%..).............
Etoricoxib 90 mg (N 5 2841), ...n..(.%..)............
Etoricoxib 90 mg (N 5 3593), ...n..(.%..)...........
Etoricoxib 90 mg N = 468 n (%)
Etoricoxib 90 mg, N = 3593,n(%)
Etoricoxib dose
Etoricoxib group (n=17 412)
"ETR: 0.78 [0.65; 0.95]95% CI, p  = 0.0121"
EU
EULAR good response
EUROPA (n=122l8)
Europe
Europe (EU)
Europe (including South Africa)
Europe (non-EU)
Europe (plus South Africa)
Europe (Zone 1)
Europe (Zone 2)
Europe 1
Europe 1 (n=2,643)
Europe 1 (n=2643)
Europe 1¶
Europe 2
Europe 2 (n=2,314)
Europe 2 (n=2314)
Europe 2+
Europe and Australia
Europe and Canada
Europe and Russia
Europe I
Europe II
Europe n Z 1831
Europe, Israel, or Australia
Europe/lsrael
Europe1
European
European or Arab
European Quality of Life-5 Dimensions-5 Level (EQ-5D)
European subcategories
European Trial
European Union
EuroSCORE additive, median (25th, 75th %) §
EuroSCORE logistic, median (25th, 75th %) £
Evaluable for ACR20 at week 16, n
Evening
Evening mealb
Evenls per 1,000 palienl-years
Event
event (p=0.3O+)
Event / Patients (1000/pt-y)
Event during on-
Event during overall
Event Incidence/N
Event Number
Event rate
Event rate ( per 100
Event Rate (%) of Primary Endpoints
Event rate (%/vr)
event rate (%/year)
Event rate (%/year)
Event rate (per 100 person-years)
Event rate (per 100 person years)
Event rates per 100 patient-years (95% CI)
Event rates, %
event(%)
Event, n (%)
Event/patients in group (incidence/1000 person-year)
Event/Total
event{ n (%)
Events
Events (%)
Events / N
Events consistent with genital infection
Events consistent with UTI
Events consistent with volume depletion
Events requiring assistance
Events Treatment (45002)
Events Treatment (45054)
Events(%)
Events, n (%)
Events, n (%/y)
Events, No.
Events/Control Group
Events/patient-year (n)
Events/Statin Group
Ever
Ever-smoker
Ever been on a VKA
Ever Been on a VKA
Ever smoked (current/former)
Everolimus
Everolimus-eluting
Every day
Evidence or thombus, n (%)
Evolocumab
Evolocumab (420 mg)
Evolocumab (n = 164)
Evolocumab (n = 35)
Evolocumab (n = 484)
Evolocumab + SOC (N = 3200)
Evolocumab 140 mg every 2weeks(n=110)
Evolocumab 420 mg monthly (n=110)
EvoMab
EvoMab (N = 182)
EvoMab (N = 194)
EvoMab (N = 274)
EvoMab (N = 325)
EvoMab (N = 77)
EvoMab + SOC
Ex-/current smoker
Ex-drinker
ex-smoker
Ex-smoker
Ex-smoker/ smoker, %
Ex-smoker/current
Ex-smoker/smoker, %
Ex-smokers
Ex-smokers    128
Ex-smokers (ITT) (n=1118)
Ex-smokers (ITT) (n=1133)
Ex-smokers (ITT) (n=825)
Ex-smokers (ITT) (n=831)
Ex-smokers (ITT) (n=833)
Ex-smokers (ITT) (n=844)
Ex-smokers (n=849)
Ex-smokers: QVAI49-SFC
Exacerbation historyh, n (%)
exacerbation in previous year
Exacerbation rate in the previous year (range)
Exacerbation rate per year
Exacerbation within 12 mo, %
Exacerbation within previous 12 mo, No. (%)
Exacerbations
Exacerbations in past 12 mo — no. (%)
Exacerbations in previous 12 mo (n), mean (SD)
Exacerbations in previous year
Exacerbations in previous year requiring hospitalization and/or ED visit, n (%)
Exacerbations in previous year requiring hospitalization, n (%)
Exacerbations in the past 12 months n
Exacerbations in the prev. year: 2
Exacerbations in the previous year
Exacerbations in the year before study
Exacerbations requiring hospitalisation ( past year) (%)
Exacerbations requiring oral steroids/antibiotics ( past year) (%)
EXACT-PRO total score, mean (SD)
EXACT (B)
Exenatide
Exenatide ± OAD
Exenatide ER
Exenatide LAR
Exenatide N=7356
Exenatide no. of events/total no. (%)
Exercise
Exercise (%)
Exercise > once weekly
Exercise > once weekly?
Exercise at least weekly (A)
Exercise category (%)
Exercise status
Exercise times per week, (minimum
Exercise, n (%)
Exetimibe/simvastatin
Exlertl ot disease
Expanded CV endpoint
Expanded MACE
Experience (n, %)
Experienced
Experimental intervention group (N=7980)
Experimental treatment group
Exploratory Cardiovascular and Death Outcomes
Exploratory Kidney and Microvascular Outcomes
Exposed
Exposed (n = 349)
Exposed (n = 424)
Exposed (n = 428)
Exposed (n = 578)
Exposure to study drug — days
Exsmoker
Extended- Duration Enoxaparin (n = 2159)
Extended- Duration Enoxaparin (n = 2975)
Extended- Duration Enoxaparin (n = 816)
Extended-Duration Enoxaparin, n/N(%)
Extended-Release Niacin plus Statin (N = 1718)
Extended Cardiovascular Endpoint
Extensive
Extensive colitis
Extensive colitis or pancolitis
Extensive colitis, N
Extensive colitisy
Extensive disease other
Extensive, n (%)
Extensive/pancolitis
Extenswe
Extent of disease
Extent of disease — no./total no. (%)§^|
Extent of disease, %
Extent of disease, n (%)
Extent of index DVT' (n, % of DVT patients')
Extent of index event
Extent of index PE'(n,%of PE patients)
Extracranial
Extracranial carotid stenosis, n (%)
Extreme tortuosity
EZ/Simva
EZ/Simva <%>
EZ/Simva 10/20 mg
EZ/simva 20 mg
EZ/simva 40 mg
EZ/simva 80 mg
EZ/Simva N=336 n (%)
EZ/Simva N=8727 n (%)
EZE
EZE + statin
EZE + statin n=552
EZE + statin n=691
EZE + statin n=768
"EZE = ezetimibe 10 mg; pooled SINVA = simvastatin pooled across doses; pooled EZE/SINVA = ezetimibe/simvastatin tablet pooled across doses; BNI = body mass index; LDL-C = low-density lipoprotein cholesterol; T G = triglycerides; T C = total cholesterol; HDL-C = high-density lipoprotein cholesterol; apo — apolipoprotein; C RP — C-neactive protein; RLP-C= remnant-like particle-cholesterol."
EZE 10 mg
EZE 10 mg (n = 187)
EZE/ SIMVA  - 7yr KM rale (%)
EZE/ SIMVA („ = 1236}
EZE/Simva
EZE/SIMVA
EZE/SIMVA (n = 1236)
EZE/SIMVA 10/20 mg (n = 221)
EZE/SIMVA 10/20 mg N = 100
EZE/SIMVA 10/20 mg N = 213
EZE/SIMVA Gender
EZE/SIMVA, 10/20 mg + FENO, 160 mg dn = 123) '
EZE/SIMVA, 10/20 mg + FENO, 160 mg dn = 58)
EZE/SIMVA, 10/20 mg dn = 7c8)
EZE/SIMVA, 10/20 mg dr = 106)
Ezetimibe
Ezetimibe + Simvastatin (n = 1,007*)
Ezetimibe + Simvastatin (n = 915*)
Ezetimibe 10 mg (n — 220)
Ezetimibe 10 mg (n = 220)
Ezetimibe 10 mg (n = 246*)
Ezetimibe 10 mg + Statin (n = 2,315)
Ezetimibe use
Ezetimibe, n (%)
Ezetimibe/ Simvastatin
Ezetimibe/Simvastatin
Ezetimibe/simvastatin 10/40 mg (n = 261)
Ezetimibe/simvastatin group
F
F-Plasma glucose, mmol/L
F emale
F40 vs placebo
F80 vs placebo
FA 135 mg
FA 135 mg («= 123)
Facial psoriasis, n (%)
Facilitated PCi (n = 656)
FACIT-F
FACIT-F score
FACIT-Fatigue. mean 6SD (range 0-52)
Factor
Factor absent
Factor at baseline
Factor present
Factor V Leiden (%)
Factor V Leiden or prothrombin mutation
Factor Xa inhibitor
Factor*
Factors    Dabigatran
Factors    Dabigatran Event Incidence/N
factors that confer a
Failure
Fair control (7-9.5)
Fair or poor
Fair/poor
Fall in last 12 mo
Fall in last 12 months (%)
Familial
Familv historv of CAD
Family history of CAD
Family history of CAD (diagnosed at <55 yr of age) — no. (%) Cigarette smoker — no. (%)
Family history of cancera
Family history of cancerf
Family History of CHD (n=133, 149)
Family history of coronary artery disease
Family history of coronary disease
Family history of diabetes — no. (%)
Family history of diabetes (-)
Family history of diabetes (%)*
Family history of diabetes (+)
Family history of diabetes mellitus — no. (%)
Family history of diabetes mellitus — no. {%)
Family history of myocardial infarction prior to age 60, %
Family history of premature
Family history of premature CHD
Family history of premature CHD**
Family history of premature CHDJ
Family history of premature coronary heart disease
Family history of premature heart disease
Family history of venous thromboembolism (%)
Family history of VTE
Family history ol diabetes?
Family history ot CHD, n (%)
Family history, n (%)
Family history^
Famotidine 20 mg (n = 177)
Famotidine 40 mg (n = 174)
FAS
FAS, range 0-10, mean (SD)
Fascng Plasma Glucose a Medan
Faster aspart
Faster aspart (mealtime)
Faster aspart + basal
Fastest third
Fasting
Fasting blood glucose
Fasting blood glucose — mmol/liter
Fasting blood glucose (mg/dL)
Fasting blood glucose >100 mg/dl
Fasting blood glucose >110 mg/dL (>6.11 mmol/L)
Fasting blood glucose, mean (SD), mg/dLt
Fasting C-peptide (ng/mL)
Fasting C-peptide (nmol/L)c
Fasting C-peptide, ng/mL
Fasting cholesterol — mg/dl
Fasting free fatty acids (^mol/liter)
Fasting glucose
Fasting glucose — mg/dl
Fasting glucose (mg/dL)
Fasting glucose (mg/dl),
Fasting glucose (mmol/L)
Fasting glucose > 126 mg/dL, n(%)
Fasting glucose >100 mg/dl*
Fasting glucose level, mg/dL
Fasting Glucose mg/dL Diabetes classification
Fasting glucose*
Fasting glucose, mean (SD), mg/dL
Fasting glucose, mg/dL
Fasting glucose, mg/dL '
Fasting glucose, mg/dl, mean (SD)§
Fasting glucose, mmol/L, mean±SD
Fasting indices
Fasting insulin
Fasting insulin — /tIU/ml§
Fasting insulin — pmol/liter
Fasting insulin (gIU/mL)
Fasting insulin (mIU/mL)
Fasting insulin (pmol/l)
Fasting insulin (pmol/L)
Fasting insulin, iiIU/mL, mean ± SD
Fasting Insulin, pmol/L (mean ± SD)
Fasting insulin,* median (IQR), gU/mL
Fasting lipid levels, mmol/l
Fasting lipids (mmol/1)
Fasting plasma glucose
Fasting plasma glucose— mmol/liter
Fasting plasma glucose — mg/dl
Fasting plasma glucose (change from baseline)
Fasting plasma glucose (mg/dl)
Fasting plasma glucose (mg/dL)
Fasting plasma glucose (mg/dL)1
Fasting plasma glucose (mmol/L)
Fasting plasma glucose (mmol/L)11
Fasting Plasma Glucose < Median
Fasting Plasma Glucose 2 Medan
Fasting plasma glucose categories, n (%)
Fasting plasma glucose in mmol/L (median (Q1, Q3) [n])
Fasting plasma glucose*
Fasting plasma glucose, mg/dl
Fasting plasma glucose, mg/dL
Fasting plasma glucose, mg/dL, mean (SD)
Fasting plasma glucose, mg/dL, mean (SD)b
Fasting plasma insulin — mU/liter
Fasting proinsulin (pmol/L)
Fasting serum glucose — mg/dl**
Fasting serum glucose (mg/dl)
Fasting serum glucose (mg/dL)
Fasting serum glucose (mg/dl), Median (IQR)
Fasting serum glucose level, mean (SD), mg/dL
Fasting serum glucose, mean (sd) mg/dl
Fasting serum glucose, median (SD), mg/dL
Fasting serum glucose, mg/dL
Fasting serum glucose, mmol/l, median (Q1, Q3)
Fasting TGs, median (Q1:Q3)
Fasting TGs§
Fasting triglyceride level, mean (SD), mg/dL
Fasting triglycerides
Fasting triglycerides — mg/dl
Fasting triglycerides >150 mg/dl*
Fasting triglycerides, mean (sd) mg/dl
Fasting triglycerides, mean (SD), mg/dL
Fasting triglycerides, mg/dL
Fastng Plasma Glucose < Median
Fatal
Fatal & nonfatal CCVD
Fatal & nonfatal hospitalized heart failure
Fatal & nonfatal hospitalized stroke
Fatal AEs
Fatal and nonfatal Ml
Fatal and nonfatal stroke
Fatal bleed
Fatal bleeding
Fatal Bleeding
Fatal CHD + Nonfatal Ml
Fatal CHD and nonfatal MIa
Fatal myocardial infarction
Fatal or non-fatal myocardial infarction
Fatal or non-fatal stroke
Fatal or nonfatal myocardial infarction
Fatal or nonfatal stroke
Fatal or nonlatal myocardial Inlarctlon
Fatal or nonlatal stroke
Fatal stroke
Fatal Stroke
Fatal/nonfatal MI, n (%)
Fatal/nonfatal Ml
Fatal/nonfatal stroke
Fatal/nonfatal stroke, n (%)
Fatigue
Fatigue (range 0-10)
Fatty acid composition
Fatty Acid Group (N = 7740)
Fatty acid profile
Favors    Favors Amlodipine    Chlorthalidone
Favors    Favors Lisinopril    Chlorthalidone
Favors Amlodipine Favors Chlorthalidone
Favors comparator
Favors dabigatran
Favors FF/VI    Favors Placebo
Favors FFA/I    Favors Placebo
Favors Lisinopril    Favors Chlorthalidone
Favors Lisinopril Favors Chlorthalidone
FBG (mg/dL)
FBG (mmol/L)
FBG baseline
FBG, mmol/l
FBG, mmol/L
FBS <100 mg/dl
FBS >=100 mg/dl
Fc-LDL-C, FriedewaLd-caLculated
Fc-LDL-C, mg/dL
FC > 110 mg/dL (>_ 6.1 mmol/L) or history of diabetes
fCal, mg/g, mean ± SD
FDC 400/12 pg
FDC 400/12 pg vs aclidinium 400 pg
FDC 400/12 pg vs formoterol 12 pg
FDC 400/12 pg vs placebo
FDC 400/12 μg (n = 720)
Feature
Febuxostat
Febuxostat 120 mg
Febuxostat 120 mg (n = 269)
Febuxostat 240 mg
Febuxostat 240 mg (n = 134)
Febuxostat 40 mg
Febuxostat 40 mg daily N = 757
Febuxostat 40 mg N = 115
Febuxostat 80 mg
Febuxostat 80 mg (n = 267)
Febuxostat 80 mg daily N = 756 % (n/N)
Febuxostat 80 mg daily N = 756 n (%)
Febuxostat 80 mg N = 128
Fecal calprotectin — pg/g**
Feet
Fema le
Femaie
Female
FemaLe
FEMALE
Female-N (%)
Female - n (%)
Female — no. (%)
Female (%)
Female (n — 238)
Female (n = 2,227)
Female (N = 392)
Female (n = 896)
Female (N = 896)
Female (n = 1,481)
Female (n=115, 117)
Female (n=1535)
Female (N=1547)
Female (n=2,049)
Female (n=2049)
Female (N=308)
Female (n=422)
Female (n=68, 45)
Female (n=71,46)
Female (n=lll8)
Female 1
Female ACR definition, ^g/mg
Female EZE/ SIMVA (n = 645)
Female EZE/SIMVA
Female EZE/SIMVA („ = 645}
Female gender
Female gender (%)
Female gender n (%)
Female N(%)
female participants who are ≥3 years postmenopausal
Female patients, n (%)
Female patients^
Female Race White
Female Race/ethnicity
Female sex
Female sex— no. (%)
Female sex— no. {%)
Female sex—number (%)
Female sex — %
Female sex — no. (%)
Female sex — no. (%) Race — no. (%)f
Female sex — no. {%)
Female sex (%)
Female sex, %
Female sex, n (% of patients)
Female sex, n (%)
Female sex, n (%) Race, n (%)
Female sex, no. (%)
Female sex, No. (%)
Female sex, No./total (%)
Female SIMVA
Female SIMVA („ = 645}
Female SIMVA (n = 645)
Female subgroup
Female subjects (n = 226)
Female, %
Female, n (%)
Female, n (%) Race, n (%)
Female, no (%)
Female, no. (%)
Female, No. (%)
Female/male (%)
Female: ≥3 years postmenopausal
Female: perimenopausal or <3 years postmenopausal
Female: Premenopausal
Female5
Femaleb
Females
Females (ITT) (n=379)
Females (ITT) (n=385)
Females (ITT) (n=388)
Females (ITT) (n=484)
Females (ITT) (n=493)
Females (n=432)
FEMALES ONLY
Females, %
Females, <0.85
Females, <30
Females, >0.85
Females, >30
Females, n (%)
Femalesex
Femoral
Femoral access
Femoral access — no./total no. (%)
Femoral neck
Femoral Neck
Femoral neck (n= 1,765) BMD (g/cm2) (SD)
Femoral neck BMD (g/cm2)
Femoral neck BMD T-score
Femoral neck F-score at FLEX baseline
Femoral neck T-score
Femoral neck T-score (mean = SD)
Femoral neckc
Femoralneck T-scorebybaselineVFxstatus
Femur fracture
FENO
Feno — ppb
FENO + EZE
FENO 160 mg (n = 189)
FENO 160 mg/EZE 10 mg (n = 185)
FENO Placebo (LSM)
FENO, 160 dn = 109)
FENO, 160 mg dn = 75)
Fenofibrate (N = 2765)
Fenofibric
Fenofibric acid
Fenofibric Acid
Fenofibric acid-1-low-dose statin
Fenofibric acid-i- moderate-dose statin
Fenofibric acid-i-low-dose statin
Fenofibric acid + low-dose statin
Fenofibric acid + moderate-dose statin
Fenofibric Acid 72=254
Fenofibric Acid n = 254
FEV AUC I    12h
FEV,
FEV, % predicted
FEV, <50% predicted
FEV, >50% predicted
FEV, at baseline
FEV_(L):
FEV1
FEV1 — % of predicted value
FEV1 — liters
FEV1 % pred
FEV1 % pred. (post-albuterol), %
FEV1 % predicted
FEV1 % predicted (post salbutamol)
FEV1 % predicted at baseline
FEV1 % predicted normal
FEV1 % predicted, post-albuterol, %
FEV1 % reversibility
FEV1 (% predicted normal)
FEV1 (% predicted)
FEV1 (l)
FEV1 (L)
FEV1 (L) pre-bronchodilator
FEV1 (L), mean (SD)
FEV1 (liters)
FEV1 (post-albuterol), L
FEV1 (pre-albuterol), L
FEV1 at week 32, mean ml (SE) Difference MEPO-PBO (95% CI)
FEV1 AUC5mine8h
FEV1 percent predicted (SD)
FEV1 post-bronchodilator
FEV1 post-bronchodilator, % predicted normal
FEV1 pre-bronchodilator
FEV1 pre-bronchodilator (% predicted normal), mean (SD)c,d
FEV1 pre-bronchodilator (L), mean (SD)c
FEV1 prebronchodilator [% PN], mean ± SD
FEV1 prebronchodilator [L], mean ± SD
FEV1 reversibility, %*
FEV1 reversibility, %b
FEV1 reversibility, pre-/post-albuterol, %
FEV1 reversibilityz (pre/post ipratropium), %
FEV1 reversibilityz (pre/post salbutamol), %
FEV1 % of predicted normal post-bronchodilator
FEV1 at baseline (randomization)∗
FEV1 at screening∗
FEV1% predicted
FEV1% predicted (SD)
FEV1% predicted <50%
FEV1% predicted ≥50%
FEV1% predicted, mean (SD)
FEV1% reversibility (SD)
FEV1(% of predicted value)
FEV1,
FEV1, % predicted
FEV1, % predicted, mean (SD)
FEV1, % predicteda
FEV1, L
FEV1, L Prebronchodilator FEV1, % predicted
FEV1, L*
FEV1, L, mean (SD)
FEV1, La
FEV1, litres (post-salbutamol), mean (SD)
FEV1, litres (post ipratropium), mean (SD)
FEV1, litres (pre ipratropium), mean (SD)
FEV1, litres (pre salbutamol), mean (SD)
FEV1, mean (SD) Pre-BD FEV1/FVC,
FEV1, mean, % predicted
FEV1, mean, L
FEV1, post-albuterol, L
FEV1, pre-albuterol, L
FEV1,La
FEV1/FVC %
FEV1/FVC (post-albuterol)
FEV1/FVC (post salbutamol)
FEV1/FVC at baseline (randomization) (%)∗
FEV1/FVC prebronchodilator, mean ± SD
FEV1/FVC prebronchodilatort
FEV1/FVC ratio*
FEV1/FVC ratio, %
FEV1/FVC ratio, % (SD)
FEV1/FVC, %*
FEV1/FVC, %, mean (SD)1
FEV1/FVC, %a
FEV1/FVC, mean (SD)
FEV1/FVC, post-albuterol, %
FEV1:FVC ratio
"FEV1:FVC ratio;"
FEV5 at baseline
FEVi AUC0-3L
FEVi percent predicted (%)
FEVi reversibility — %
FEVi, % predicted*
FEVi, % predicted, mean (SD)1
FEVi, L
FEVi, L*
FEVi, L, mean (SD)1
FEVi/FVC (%)
FEVi1 L
FEVj % predicted!,t
FEVt:FVC ratio — %|
ff-Blocker
FF -46% (-211%, 32%)
FF –1% (95% CI –15–12%)
FF    3% (-23%, 23%)
FF 100 |ig (N=1010)
FF 100 µg
FF 100 gg (N = 1,010)
FF 100 pgOD
FF 11% (-34%, 41%)
FF 12 pg(N=715)
FF 24% (95% CI –3–44%)
FF 4% (95% CI –22–24%)
FF 5% (95% CI –7–15%)
FF 7% (-60%, 45%)
FF MDI
FF/VI
FF/VI –2% (95% CI –29–20%)
FF/VI (n = 1325)
FF/VI (n = 1512)
FF/VI (n = 2114)
FF/VI (n = 484)
FF/VI (n = 750)
FF/VI (n = 997)
FF/VI 0.05
FF/VI 0.25
FF/VI 1% (-126%, 57%)
FF/VI 100 mg/25 mg (n = 806)
FF/VI 100/25 |ig (N=1009)
FF/VI 100/25 µg
FF/VI 100/25 gg (N = 1,009)
FF/VI 100/25 pg OD
FF/VI 12% (-32%, 42%)
FF/VI 20% (95% CI 10–29%)
FF/VI 200 mg/25 mg (n = 811)
FF/VI 23% (2%, 39%)
FF/VI 23% (95% CI 12–34%)
FF/VI 35% (95% CI 11–52%)
FF/VI 5% (-61%, 44%)
FF/VI 50 mg/25 mg (n = 820)
FFA (mmol/l)
FFA/I
FG > 13
FGF-23 High/ <1 Elevated Biomarkers
FGF-23 High/ >2 Elevated Biomarkers
FGF-23 High/ eGFR <60
FGF-23 High/ eGFR >60
FGF-23 Low/ <1 Elevated Biomarkers
FGF-23 Low/ >2 Elevated Biomarkers
FGF-23 Low/ eGFR <60
FGF-23 Low/ eGFR >60
FH 1
FH II
Fibrate
Fibrate or other lipid-lowering agent
Fibrates
fibrillation/flutter)
Fibrin-specific
Fibrin-specilic
Fibrinogen
Fibrinogen (pmol/L)c
Fibrinogen, g/L
Fibrinolysis    Primary PCI (N=944) (N =948) no. of patients/total no. (%)
Fibrinolysis (N = 944)
Fibrinolysist
Fibrinolytic
Fibrinolytic agent — no. (%):t
Fibrinolytic agent before randomisation
Fibrinolytic agents before or after entry
Fibrinolytic for qualifying event
Fibrinolytic therapy — no. (%)
Fibrinolytics
Fibrofatty
Fibrofatty, mm^
Fibrous
Fibrous, mm’
Fibula fracture
"Figure 4 Least squares (LS) mean differences between roﬂumilast and placebo in (A) pre- and (B) postbronchodilator FEV1 in the ITT population and subpopulations. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting b2-agonist."
Filtration Rate 30-60
Final
Final (mg/dL)
Final A1C (%)
Final analysis (all patients)
final mean
Final mean, mg/dL
Final median, mg/L
Final TIMI Flow
Final TIMI flow grade <3
Final TIMI flow grade post-PPCI
First-generation stentt
"First-recorded event; no. (and %) of patients"
First (N=2701)
First co-primary
First Co-Primary Outcome
First CV hospitalization
First diagnosed
First disease-progression outcome to occur§
First Dose Admin. 0-12h/12-24h post onset of symptoms
First episode of atrial fibrillation (vs. recurrent episode) — no. (%)f
First HHF
First hospitalization for CHF or CV death
First loading dose
First MACE
First medical contact — no. (%)§
First medical contact in ambulance
First primary (change in UPDRS score/wk, wk 12-36)
First primary composite outcome
First serum creatinine
First year*
Fish oil
Fish Oil (n = 153)
Fistula at baseline, n (%)
Fistula,' n (%)
Fixed triple (n=1077)
fl( 0.0)
fl( 1B)
Flecainide
FLEX Ain'’
FLEX Aln^
FLEX baseline BMD T-score at femoral neck (meaniSD)
FLEX baseline BMD T-score at lumbar spine (meaniSD)
FLEX baseline BMD T score
FLEX baseline BMD, g/cm^ (meaniSD)
FLEX baseline BMD, mean (SD), g/cm2
FLEX FN F-score < -2.5
FLEX Pbo®
Fluindione, No. (%)
Fluticasone- Salmeterol (N = 5834)
Fluticasone Alone (N = 5845)
Fluticasone furoate and vilanterol (n=2114)
Fluticasone furoate, n=4135
Fluticasone propionate/salmeterol FDC
Fluvastatin (N = 250)
Fluvastatin (N=250)
Fluvastatin 80 mg
FN T-score < —2.5
FN T-score <= -2.5 (%)
Focal
Follow-up
Follow-up in-trial at 4 yr
Fondaparinux
Fondaparinux — no. (%)
Fondaparinux (N = 10,057)
Fondaparinux (n = 636)
Foot fracture
for baseline hemoglobin    120 g 1 ’
for baseline hemoglobin < 120 g 1 '
for combined hemoglobin groups
For patients not using personal CGM
For patients using personal CGM
For treatment of index event
Forearm
Forearm fracture
FORM/BUD
Formal education, years
Former
Former (n = 3,482)
Former n Z 1813
Former or current smokers (%)
Former or never
Former or never Diabetes
Former smoker
Former Smoker
Former smoker — no. (%)
Former smoker — no. {%)
Former smoker (n=4,428)
Former Smoker (n=4428)
Former smoker, n (%)
Former smokers
Former smoking
Former, n (%)
Former/current smoker (n=21 098)
Former/current smoker, n (%)
Former/non-drinker
Formoterol 12 gg (n=227)
Formoterol 12 gg (n=233)
Formoterol 12 gg bid
Formoterol 12 pg
Formoterol 12 pg vs placebo
Formoterol 12 μg (n = 715)
Formoterol Tiotropium n=108 Non-tiotropium n=336
Formoterol Tiotropium n=111 Non-tiotropium n=344
FP
FP (n [1552)
FP (n = 1248)
FP (n = 1,356)
FP (n[1552)
FP 500 mg
FP versus no ICS
FP versus other ICS
FP/SAL 250/50 pg (N = 314)
FP/SAL 250/50 pg (N= 314)
fPCI vs. pPCI In men
fPCI vs. pPCI in women
FPG
FPG (mg/dl)
FPG (mg/dL)
FPG (mmol/1)
FPG (mmol/l)
FPG (mmol/L)
FPG (mmol/L), mean (SD)
FPG (mmol/l), mean (SD)、
FPG (mmol/l), mean ± s.d.
FPG (range) (mmol/L)
FPG change (mg/dL)*
FPG data'
FPG Month 0 (mg/dl)
FPG Tx difference vs Pbo, median change from baseline (SE)1
FPG(mg/dl)x
FPG, (mg/dL)
FPG, (mmol/L)
FPG, mean (SD), mg/dL
FPG, mean (SD), mg/dL [mmol/L]
FPG, mean (SD), mg/dLf
FPG, mean (SD), mg/dLt
FPG, mean (SD), mmol/L
FPG, median (Q1, Q3), mmol/L
FPG, median (Ql, Q3), mmol/L
FPG, mg/dL
FPG, mg/dL (mmol/L)
FPG, mg/dL, mean ± SD
FPG, mmol/l
FPG, mmol/L
FPG, mmol/L (mean ± SD)
FPG, mmol/L (mg/dL)
FPG, mmol/L, mean (SD)
FPG, mmol/La
FPG, mmol/Lt
FPI, gU/mL (pmol/L)
FPI, M-U/mL (pmol/L)
FPI, mean (SD), pU/mLt
FPI, mean (SD), pU/rnFf
fraction (%)
Fracture
Fracture during follow-up
Fracture history
Fracture history (predefined), n (%)
Fracture history, n (%)
Fracture status Prevalent vertebral fractured
fractures
Fractures (site not specified)
Fragile
Frail
Frailty status
Framingham 10-year CV risk score
Framingham risk score
Framingham risk score (%)
Framingham risk score*
Framingham risk score, arbitrary units
Free fatty acids — mmol/liter
Free fatty acids (mmol/L)
Freedom from GTC seizures, n (%)
Freqency of Events
Frequency of Events
Frequent exacerbator
Frequent or Continuous
from baseline (95% CI)
FSG (mg/dL)
FSG, mg/dL (mean ± SD)
fSN score, mean ± SD
Full analysis set
Full Analysis Set
Full analysis set, n
Full cohort
Full population
Function subscale
Functional Assessment of Chronic Illness
Functional outcome (mRS 3-6)
Furosemide
Furosemide equivalent, mg/kg
FVC
FVC — liters
FVC % predicted!,t
FVC (% predicted)
FVC (l)
FVC (L)
FVC (L) Proportion taking pulmonary medications (%)b
FVC (L)*
"FVC (L);"
FVC (liters)
FVC <90% predicted
FVC >90% predicted
FVC change
FVC post-bronchodilator
FVC pre-bronchodilator
FVC(L)
FVC∗
FVC, % predicted
FVC, % predicted, mean (SD)
FVC, L
FVC, L, mean (SD)
FVC, mL
G
G-Blockers
G+C
GA
Ga/A
GAD positive — no. (%)^
Gained BMD
GAIT
Galectin-3 (ng/ml)
Gall bladder adverse event (N=603)
Gallbladder-related AEs
Gamma glutamyltransferase, U/L
Gastroduodenal
Gastroduodenum
Gastroenteritis
Gastroesophageal reflux disease
Gastrointestinal (GI) disorders
Gastrointestinal area involved — no./ total no. (%)
Gastrointestinal area involved, n/total n (%)
Gastrointestinal bleeding
Gastrointestinal disorders
gastrointestinal event
Gastrointestinal major bleed
Gaviscon DA (n = 536)
GDF-15 (ng/ml)
GDS score*
Gemfibrozil
Gemfibrozil (N=12641
Gendar
Gender
Gender - male, n (%)
Gender - n (%)
Gender (%) male/female
Gender (female:male, %)
Gender (M/F), (%)
Gender (male), n (%)
Gender (male/female) (number)
Gender [n (%)]
Gender Female
Gender Male
Gender n (%)
Gender, %
Gender, % of patients
Gender, female, n (%)
Gender, male
Gender, male (%)
Gender, male, n (%)
Gender, male/female
Gender, n (%)
Gender, n (%) male
Gender, n (%]
Gender, N [%] male
Gender, No. (%)
Gender, women N, %)
Gender, N (% men)
Gender, n (%)
Gender:
Gender: male, n (%)
Gene
Gene/Chr/SNP
General
General allergic events
General alone
General anaesthesia
General and lumbar epidural
General andthoracic epidural
General health
General health (self-reported)
General health VAS, 0-100 mm
General health, self-reported
Generalized
Genetic Subgroup
Genital mycotic infections Male3
Genotype
Genotype-by- treatment interaction P values*
Genotype-specific treatment effect hazard ratio (95%CI)
Genotyping
Gentype
Geo graphic region: Asia
Geographic distribution - no. (%)
Geographic location
Geographic region
Geographic Region
Geographic region-Europe
Geographic region-North America
Geographic region-Other
Geographic region—number (%)
Geographic region — no. (%)
Geographic region, %
Geographic region, n (%)
Geographic region?
Geographic region^
Geographic site, %
Geographical location, n (%)
Geographical region
Geographical region (%)
Geographical region, n (%)
Geometric anti-dsDNA antibody binding level
Geometric C3 concentration, mg/dl
Geometric C4 concentration, mg/dl
Geometric mean
Geometric mean blood eosinophil count (SD on a loge scale) — cells/mm3
Geometric mean blood eosinophil count on loge scale — cells/^lJJ
Geometric mean CRP concentration (mg/L)
Geometric mean IgE on loge scale — U/ml
Geometric mean of baseline
Geometric mean ofCRP— mg/liter (range)
Geometric mean UACR
Germany
Gertder
GetGoal-L-Asia
GetGoal-S
GFF MDI
GFR (CKD-EPI)
GFR (MDRD) (mL/min/1-73 m3)
GFR (ml/min per 1.73 nr)
GFR <30mL/min/1.73 m2
GFR <60
GFR >60
GFR 2 90
GFR 60 - 89
GFR as assessed by MDRD
GG
GGT increased
GI Bleed
GI major bleeding
Giargine
Giimepiride ± OAD
GISSI Prevention 1/1994-5/1996
GLACIAL11
Glargine
Glargine 222
Glargine allocation
Glargine N (N/lOOpy)
glatiramer acetate, No. (%)
Gliclazide (modified release) 一 no. (%)^
glimepiride
Glinide
Glinide 一 no. (%)
Glipizide
Glipizide (n=339)
Global assessment of disease status score
Global ischemia
Global ischemia (%)**
Global trial population
Glomerular
Glomerular Filtration Rate (ml/min/1.73ma,
glomerular filtration rate,3 ml/min/1.73 m2
Glomerular filtration rate§
GLP-1 analogue
GLP-1 receptor agonist
GLP-1 receptor agonist (other than study drug)
GLP-1 receptor agonists
glu298asp G. T
Glucagon-like peptide-1 agonist
Glucagon-like peptide-1 receptor agonist
Glucocorticoid
Glucocorticoid]
Glucocorticoids
Glucocorticoids and immunosuppressants
Glucocorticoids at baseline
Glucocorticoids combined with immunosuppressive agents
Glucocorticoids only
Glucocorticoids plus immunosuppressive agents
Glucocorticoids*
Glucosamine
Glucosamine (N = 317)
Glucosamine + Chondroitin Sulfate
Glucosamine + Chondroitin Sulfate (N = 317)
Glucose-lowering drug
Glucose-lowering medication
Glucose-lowering medications
Glucose-lowering therapies
Glucose-lowering therapies — no. {%)
Glucose-lowering therapy
Glucose-lowering therapy - no. (%)
Glucose-lowering therapy, n (%)
Glucose — mg/dl
Glucose — mmol/liter
Glucose (mg/dL)
Glucose in urine, ≥1+
Glucose metabolism
Glucose test
Glucose, mg/dL, mean
Glucose, mmol/L
Glucose, non-fasting or random (nmol/L)
Glulisine + OAD
Glulisine monotherapy
GLY
GLY (15.6 pg b.i.d.) N=216
GLY 15.6 gg b.i.d n/N (%)
GLY 15.6 mg b.i.d. n = 251
GLY 25 μg BID
GLY 50 μg BID
Glyburide
Glyburide (n = 1441)
Glyburide (N = 1441)
Glyburide dose duringthe study (mg)
Glycaemic control (HbA1c), n (%)
Glycaemic control group
Glycaemic parameters
Glycated haemoglobin (%)
Glycated haemoglobin, %
Glycated hemoglobin
Glycated Hemoglobin
Glycated hemoglobin - %’
Glycated hemoglobin — %
Glycated hemoglobin — %-
Glycated hemoglobin (%)
Glycated hemoglobin <Median
Glycated hemoglobin level
Glycated hemoglobin, %
Glycated hemoglobin, %, mean (SD)
Glycated hemoglobin, mean (SD), %
Glycated hemoglobin, Median (IQR)
Glycated hemoglobin, n(%)
Glycated hemoglobin, nonstandardized level — %
Glycated hemoglobin, standardized level — %
Glycated hemoglobin||
Glycatedhemoglobin category,%
Glycemia, mg/dl
Glycemic characteristics
Glycemic drugs
Glycemic indexes
Glycemic status
Glycemic status f
Glycemic variability, mmol/Lc
Glyceryl trinitrate infusion
Glycohemoglobin, %
Glycohemoglobin, %, mean (SD)
Glycoprotein IIb/IIIa inhibitor
Glycoprotein IIb/IIIa inhibitor use before angiography
Glycoprotein IIb/IIIa inhibitors
Glycoprotein IIb/IIIa inhibitort
Glycoprotein IIb/IIIareceptorinhibitor
Glycoprotein Ilb/IIIa inhibitor before PCI]
Glycoprotein llb/Illa inhibitor
Glycoprotein llb/llia Inhibitor
Glycoprotein llb/llla inhibitors
Glycoprotein llb/llla receptor inhibitor
Glycopyrrolate/    Glycopyrrolate/ eFlow CS 25 meg eFlow CS 50 meg (n=431)    (n=432)
Glycopyrrolate/ eFlow CS 50 meg (n=620)
Glycopyrronium 50 mg (n = 1059)
Glycosylated hemoglobin, %
Glyeated haemoglobin
GM
"GM, geometric mean; GMR, geometric mean ratio over baseline; UACR, urinary albumimcreatinine ratio. % Reduction: 100 x (1 —ratio of GMR for losartan versus GMR for placebo). aMean of change, with change calculated as difference between time indicated and baseline as measured for each participant, difference of changes between treatment groups. cP-values compare differences from no change."
GMI (men)
GMI (women)
GMR
Goal
GOLD 1
GOLD 2
GOLD 2 (« = 1140)
GOLD 2 (« = 1148)
GOLD 2014 groups
GOLD 2014 Groups, n (%)
GOLD 3
GOLD 3-4
GOLD 3-4 (« = 1597)
GOLD 3-4 (n = 973)
GOLD 4
GOLD A
GOLD B
GOLD C
GOLD classification
GOLD D
GOLD Grade 2
GOLD Grade 2 and ICS non-users at screening
GOLD Grade 2 and ICS users at screening
GOLD Grade 3
GOLD Grade 3 and ICS non-users at screening
GOLD Grade 3 and ICS users at screening
GOLD Grades 1-4 (percent-predicted FEV(), n
Gold group
GOLD Group A
GOLD Group B
GOLD Group C
GOLD Group D
GOLD group D — no. (%)||
GOLD group, n (%)
GOLD Groups a-D using mMrCb
GOLD II
GOLD III-IV
GOLD stage
GOLD Stage
GOLD stage — no. (%)**
GOLD stage #
GOLD stage (%):c
GOLD stage (%)f
GOLD stage [N (%)]
GOLD stage II
GOLD stage III
GOLD stage IV
GOLD stage, n (%)
GOLD stage, nf* (%)
GOLD, n (%)
GOLDEN-3 and -4
GOLDEN-5
Golimumab
Golimumab 100 mg (n = 146)
Golimumab 2 mg/kg+MTX
Golimumab 200/100 mg
Golimumab 400/200 mg
Golimumab 50 mg (n = 146)
Golimumab 50 mg (n = 146)†
Golimumab 50 mg/100 mgt
Golimumab combined (n = 292)
Goncomitant treatment with AGE inhibitors/angiotensin
Good
Good control (<7)
Good/moderate response
Gout history, mean ± SD years
GP IIb/IIIa inhibitor before PCI—No. (%)
GP IIb/IIIa inhibitor used
GP IIb/IIIa inhibitors
GP llb/llla inhibitors
GP MDI
GPI used during PCI
GPIfeellla inhibitor use before angography
GPIfo'llIa inhibitor use before angography
GpIIb-IIIa inhibitors
GPIIb/IIIa receptor inhibitor
Grade > 2
Grade > 3
Grade > 4
Grade 0
Grade 1
Grade 2
grade 2 (moderate COPD), n (%)
Grade 3
Grade 3 (severe COPD), n (%)
Grade 4
Grade of hypertension
Graft
Graft occlusionsa
Graft, n (%)
"graft; PCI, percutaneous coronary intervention; TIA, transient"
Granulating, n (%)a
Greater than or equal to 140 mm Hg
Greater than or equal to 50%
Greater than or equal to 60 ml/min/1.73m2
Grip strength (kg)
Grip Strength < Meidan
Grip Strength >= Median
Group
Group — no. (%)
Group A
Group A (n = 103)
Group B
Group B (low risk, more symptoms), n (%)
Group B (n = 100)
Group C
Group C (n = 103)
Group D
Group D (high risk, more symptoms), n (%)
Group Dif. (4)
Group Dif. (9)
Group difference
Grouped region
Groups
GRS
GT
GT+TT
GUSTO-bleeding severe/moderate
GUSTO-defined bleeding
GUSTO moderate
GUSTO Moderate
GUSTO moderate bleeding/ICH
GUSTO moderate or severe
GUSTO moderate or severe bleeding
GUSTO moderate/severe
GUSTO Moderate/Severe
GUSTO moderate/severe bleed
GUSTO moderate/severe bleeding
GUSTO severe
GUSTO Severe
GUSTO severe bleed
GUSTO severe or
GUSTO Severe/Moderate
H
H DL cholesterol <35 mg/dl
H pylori serology*
H. pylori status, n (%)
H2-receptor antagonist
H2 blocker (n, %) Long-term VKA therapy
H2 receptor antagonist
HAb1c (mean±SEM), %
Habitual fish intake: <2 servings/wk (n=381)
Haematological
Haemodynamics and LV function
Haemoglobin (g/dL)
Haemoglobin (g/dL), mean + SD, available for 3666 patients
Haemoglobin (g/L)
Haemoglobin (mg/dL)
Haemoglobin (mmol/L)
Haemoglobin, mg/dl
Haemorrhagic
Haemorrhagic stroke
Haemorrhagic stroke—No. (%)
Hale
Hand
Hand fracture
Hands
Haplotype
HAQ
HAQ-DI
HAQ-DI (0-3)
HAQ-DI (0-3), mean (SD)
HAQ-DI (range 0-3)
HAQ-DI improvement >0.22
HAQ-DI improvement >0.5
HAQ-DI improvement from baseline to week 24
HAQ-DI MCIDe
HAQ-DI score
HAQ-DI score (0-3)
HAQ-DI score (0-3), mean (SD)
HAQ-DI scored
HAQ-DI scoreff
HAQ-DI total score, mean (SD)
HAQ-DI*
HAQ-DI**
HAQ-DI, mean (SD)
HAQ-DI, mean [SD]
HAQ-DI, number (%)
HAQ-DI, range 0-3, mean (SD)
HAQ Alternative Disability score
HAQ DI
HAQ DI (range 0-3)
HAQ DI score (0-3)
HAQ DI score (range 0-3), mean ± SD
HAQ Pain Scale, mean
HAQ Pain score
HAQ score
HAQ score (0–3 scale)
Hard MACE
Harzar ratio(95% CI)
Harzard ratio(95% CI)
HAS-BLED >3
HAS-BLED 1-2
HAS-BLED score
HAS-BLED Score
HAS-BLED score >3
HAS-BLED score’
HAS-BLED>3
HAS-BLED1-2
HAS-BLEDO
Hawaiian Pacific Islander
Hawaiian/Pacific Islander
Hazard
Hazard    Inleraction
Hazard    Interaction
Hazard ratio
Hazard Ratio
Hazard Ratio (95% C
Hazard ratio (95% CI)
Hazard Ratio (95% CI)
Hazard Ratio (95% CI)-j-
Hazard Ratio (95% CI) for Adjudicated Type 2 Diabetes
Hazard ratio (95% CI) vs. Placebo
Hazard Ratio (95% CI)*
Hazard ratio (95% CI)3 with vs. without psoriasis
Hazard ratio (95% Cl)
Hazard Ratio (95% Cl)
Hazard Ratio (95% Cl) 0.87 (0.80, 0.94)
Hazard Ratio (95% Cl) 0.93 (0.75, 1.14)
Hazard ratio (95% Cl) Nateglinide vs. Placebo
Hazard ratio (95% Cl) Valsartan vs. Placebo
"Hazard Ratio (95% Cl)"""
Hazard Ratio (95% Cl)*
Hazard Ratio (95% Cl]
Hazard Ratio (95% Confi dence Interval)
Hazard Ratio (95% Confidence Interval)
Hazard ratio (95% Confidence interval)*
Hazard ratio (95%CI)
Hazard Ratio (95%CI)
Hazard Ratio [95% Cl]
Hazard ratio [95%CI]
Hazard ratio 4)
Hazard Ratio and 95% Confidence Interval
Hazard Ratio for Cardiovascular Death,
Hazard Ratio for Cardiovascular Death, Stroke, or Myocardial Infarction (95% CI)
Hazard Ratio for Event (95% CI)
Hazard ratio GLP-1 analogue vs placebo [95% Cl]
Hazard ratio or difference1* (95% Cl) P-value
Hazard ratio or difference3 (95% Cl) P-value
Hazard ratio vs. Placebo
Hazard Ratio with
Hazard Ratio with Dabigatran, 110 mg (95% Cl)
Hazard Ratio with Dabigatran, 150 mg (95% Cl)
Hazard Ratio with High (95% Cl)
Hazard Ratio with Low (95% Cl)
Hazard ratio* (95% CI)
Hazard ratio* (and 95% CI)
Hazard ratio, UMEC/VI vs. TIO (95% CI)
Hazard Ratio2
Hazard Ratiof
Hazard ratiof (95%CI)
Hazard.Ratio.(95% CI)..........
Hb decrease ≥2 g/dL
Hb, g/dl
HbA , % 1c
HbA <median
HbA,,(%)
HbA,c (%)
HbA]c (mmol/mol)
HbA„(%)
HbA1c
HbA1c — % Cholesterol — mmol/L
HbA1c $5.7% (39 mmol/mol)
HbA1c % (range)
HbA1c (% patients <7.0%)
HbA1c (%)
HBA1c (%)
HbA1c (%) All countries
HbA1c (%)*
HbA1c (%), mean (SD)
HbA1c (change from baseline)
HBA1c (mmol/mol [SE])
HbA1c (mmol/mol)
HbA1c (n)
HbA1c (SD), %
HbA1c (SD), mmol/mol
"HbA1c \N;"
HbA1c < 6.5%
HbA1c < 7.0%, BP < 130/80 mm Hg, LDL-C < 100 mg /dL
HbA1C < 8% level
HbA1c < 8.0%, BP < 140/90 mm Hg, LDL-C < 100 mg /dL
HbA1c <= 8%
HbA1c <= 8% (n 5 94)
HbA1c <= 8% (n 5 97)
HbA1c <7% (n - 4119)
HbA1c <8%
HbA1c ≤6.5%
HbA1c ≤6.5% without GI adverse reactions
HbA1c > 6.5%
HbA1C > 8% level
HbA1c > 9%
HbA1c > 9% (n 5 69)
HbA1c >8·5%
HbA1c >9%
HbA1c >9% (n 5 81)
HbA1c 12 weeks
HbA1c 24 weeks
HbA1c 6.5 to <7.0% (48-53 mmol/mol)
HbA1c 7-<=8%
HbA1c 7%-<8% (n - 5416)
HbA1c 8-<=9%
HbA1c 8%-<9% (n - 3139)
HbA1c at 24 weeks*
HbA1c at baseline
HbA1c at baseline, %
HbA1c at Baseline:
HbA1c categories, n (%)
HbA1c category
HbA1c category, n (%)
HbA1c distribution
HbA1c distribution at baseline
HbA1c distribution at baseline, n (%)
HbA1c in % (median (Q1, Q3) [n])
HbA1c in patients with baseline HbA1c <8% (<64 mmol/L), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo-subtracted change (SE)
HbA1c in patients with baseline HbA1c >8% to <9% (>64 to <75 mmol/mol), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo subtracted change (SE)
HbA1c in patients with baseline HbA1c >9% (>75 mmol/mol), % [mmol/mol], LA, n Baseline (SD) Adjusted mean change (95% CI) Placebo-subtracted change (SE)
HbA1c levels
HbA1c Month 0 (%)
HbA1c strata
HbA1c subgroups
HbA1c Tx difference vs Pbo, median change from baseline (SE)1
HbA1c (%)
HbA1c (mmol/mol)
HbA1c at randomization
HbA1c baseline (%)
HbA1c(%)
HBA1c(%) (median (IQR)
HbA1c, %
HbA1c, % (mean ± SD) [range]
HbA1c, % (mean 6 SD)
HbA1c, % (SD)
HbA1c, % [mmol/mol]
HbA1c, %*
HbA1c, %, mean (SD)
HbA1c, %, mean (SD)b
HbA1c, %, mean±SD
HbA1c, %, median (Q1, Q3)
HbA1c, %, n (%)b
HbA1c, %§
HbA1c, %d
HbA1c, (%)
HbA1c, (mmol/mol)
HbA1c, <6.0
HbA1c, >6.4
HbA1c, 6.0–6.4
HbA1c, Baseline mean HbA1c, % (SD)
HbA1c, Difference vs placebo (95% Cl)
HbA1c, mean (SD)
HbA1c, mean (SD), %
HbA1c, mean (SD), % [mmol/mol]
HbA1c, mean = SD, %
HbA1c, median (Q1–Q3)
HbA1c, median (Q1, Q3), %
HbA1c, median (SD), %
HbA1c, mmol/mol
HbA1c, mmol/mol (mean)
HbA1c, mmol/mol, mean (SD)
HbA1c, mmol/mol, median (Q1, Q3)
HbA1c, mmol/mold
HbA1c, mmol/mole
HbA1c, N
hba1c,%
HbA1c,%
HbA1c<7%
HbA1C<8%
HbA1C>=8%
HbA1c>=9%
HbA1ca, % (mmol/mol)
HbA1ca, %, mean ± SD
HbAi,
HbAic —%
HbAic (%)
HbAic (%), mean ± s.d.
HbAic group (%)
HbAie (%)
HbAie (%) Mean±SD
HbAie, %
"HbAj(- (%; mmol/mol)"
HbAjc (mmol/mol) Mean±SD
HbAK <median
HbAK>median
HbAlc
HbAlc (%)
HbAlc (%), mean (SD)^
HbAlc (mmol/mol)
HbAlc £58 mmol/mol (£7.5%) (N=38/36)
HbAlc £58 mmol/mol (<7.5%) (N=188/201)
HbAlc £64 mmol/mol (£8.0%) (N=163/148)
HbAlc £64 mmol/mol (£8.0%) (N=51/54)
HbAlc £64 mmol/mol (>8.0%) (N=110/95)
HbAlc < 53 mmol/mol (<7.0%) at Week 20
HbAlc < 6% (42 mmol/mol)
HbAlc < Medan
HbAlc < Median
HbAlc <58 mmol/mol (£7.5%) (N=108/120)
HbAlc <58 mmol/mol (<7.5%) (N=108/120)
HbAlc <58 mmol/mol (<7.5%) (N=188/201)
HbAlc <58 mmol/mol (<7.5%) (N=38/36)
HbAlc <7% (<53 mmol/mol), n (%)
HbAlc <8%
HbAlc <median
HbAlc >=9% (n - 3525)
HbAlc >58-<64 mmol/mol (>7.5-<8.0%) (N=31/25)
HbAlc >58-<64 mmol/mol (>7.5-<8.0%) (N=70/73)
HbAlc >58-<64 mmol/mol (>7.5-<8.0%) (N=83/84)
HbAlc >64 mmol/mol (>8.0%) (N=110/95)
HbAlc >64 mmol/mol (>8.0%) (N=163/148)
HbAlc >64 mmol/mol (>8.0%) (N=51/54)
HbAlc >8%
HbAlc a64 mmol/mol (>8.0%) (N=110/95)
HbAlc in %, median (IQR)
HbAlc Tx difference vs Pbo, median change from baseline (SE)1
HbAlc, %
HbAlc, %, mean (SD)
HbAlC, mean (s.d.)
HbAlc, median (Ql, Q3), %
HbAlc, mmol/mol
HbAlc<median
HbAlc>median
HbAlca Median
"HbAu, %"""
hC
HCQ+MTX (n = 81)
HCRU (A)
HCTZ
HCTZ - hydrochlorothiazide. *Data were missing for some patients.
HCTZ = hydrochlorothiazide. * Based on a '/_2 test, t Data were missing for some patients.
HCTZ = hydrochlorothiazide. * Based on Wilcoxon 2-sample rank-sum tests for age and body mass index, t tests for systolic and diastolic blood and '/2 tests for categorical variables. t Data were missing for some patients.
HCTZ*
HCTZ* (n=109)
HCTZ* (n=59)
HD (n=7008)
HD Edoxaban vs Warfarin
HDER*
HDL
HDL-C
HDL-C (median, IQR), mg/dL
HDL-C (mg/dl)
HDL-C (mg/dL)
HDL-C (mg/dL) - mean ± SD
HDL-C (mg/dL)*
HDL-C (mmol/L)
HDL-C (mmol/L, mean)
HDL-c < 35 mg/dL
HDL-C < 35 mg/dL
HDL-C <35 mg/dL
HDL-C <35 mg/dL, No. (%)
HDL-C <35 mg/dl_
HDL-C >40 mg/dL (1.0 mmol/L)
HDL-c at Baseline.
HDL-C level, < 35 mg/dLd
HDL-C level, mean (SD), mg/dL
HDL-C level, mg/dL
"HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; SEstandard error; TG triglycerides."
HDL-C, mean (SD)
HDL-C, mean (SD), mg/dL
HDL-C, mg/dL
HDL-C, mg/dL, mean (SD)
HDL-C, mg/dL, mean + SD
HDL-C, mg/dL, mean ± SD
HDL-C, mmol/L
HDL-C, mmol/L (mg/dL)
HDL-C, mmol/l, mean (SD)
HDL-C, mmol/L, mean (SD)
HDL-C,35 mg/dL, n (%)
HDL-C<35mg/dl. n (%)
HDL-Cd
HDL-cholesterol
HDL-cholesterol (mg/dL)
HDL-cholesterol (mmol/L)
HDL-cholesterol, mean (sd) mg/dl
HDL-cholesterol, mg/dL, mean (SD)
HDL-cholesterol, mmol/L
HDL-cholesterol, mmol/le
HDL-Cy
HDL—female
HDL—male
HDL (mg/dl)
HDL (mmol/L)
HDL <35 mg/dL
HDL <40/50 mg/dL (1.03/1.29 mmol/L) for men/women
HDL choleslerol
HDL cholesterol
HDL cholesterol — mg/dl
HDL cholesterol — mg/dl Triglycerides — mg/dl
HDL cholesterol (mg/dl)
HDL cholesterol (mg/dL)
HDL cholesterol (mg/dL), mean + SD, available for 3552 patients
HDL cholesterol (mmol/l)
HDL cholesterol (mmol/L)
HDL cholesterol (mmol/L) (median, IQR)
HDL cholesterol (mmol/L), mean (SD)
HDL cholesterol (mmol/L):
HDL cholesterol (SD), mg/dL
HDL cholesterol (week 24)a
HDL cholesterol <1-17 mmol/L
HDL cholesterol <35 mg/dl*
HDL cholesterol <40 (men) or <50 mg/dl (women)
HDL cholesterol >1-17 mmol/L
HDL cholesterol level
HDL cholesterol Mean
HDL cholesterol*
HDL cholesterol, (mmol/L)
HDL cholesterol, mean (SD), mg/dL
HDL cholesterol, mg/dl
HDL cholesterol, mg/dL
HDL Cholesterol, mg/dL
HDL cholesterol, mmol/冲
HDL cholesterol, mmol/L
HDL cholesterol, mmol/L*
HDL cholesterol, mmol/L, men, mean±SD
HDL cholesterol, mmol/L, women, mean±SD
HDL cholesterol, mmol/lt
HDL cholesterol^:
HDL cholesterol§
HDL*
HDL, mean (SD), mg/dL
hdl2
hdl2-c
hdl3
hdl3-c
HDLcholesterol
HDM n = 130
HDM n = 138
HDM n = 139
HDM n = 484
HDM n = 77
Headache
Health-care use rate (peryear)
Health-related quality of life
Health Assessment Questionnaire-Disability Index
Health Assessment Questionnaire (0-3 range)
Health Assessment Questionnaire score
Health habits
Health Practices
Health State Index Score, UK algorithm
Healthy weight
Heart-rate group at baseline
Heart disease risk factors
Heart failure
Heart Failure
Heart failure — no. (%)
Heart failure — no./total no. (%)
Heart failure (Class I—III)
Heart failure (class l-lll)
Heart failure (HF), (%)
Heart failure (NYHA II‐III), n (%)
Heart failure (treated /hospitalized/fatal)
Heart failure (treated/hospitalized/fatal)
Heart failure 1 mo before admission
Heart failure 1 month before admission
Heart failure 1 yr before admission
Heart failure at entry, No. (%)
Heart failure cause
Heart failure criteria met
Heart failure history
Heart failure hospitalisation or CV death
Heart failure hospitalizations
Heart failure NYHA II - III
Heart failure or LVEF <40% associated with index ACS event
Heart failure*
Heart failure, hospitalized or fatal
Heart failure, LVEF <40%, or both
Heart failure, n (%)
Heart failure, No./total No. (%)
"heart failure; CI, confidence interval."
Heart failure‡
Heart failurea
Heart rate
Heart Rate
Heart rate — beats/min
Heart rate — bpm
Heart rate (b.p.m.)
Heart rate (b.p.m.), mean ± SD
Heart rate (beats per min)
Heart rate (beats per minute)
Heart rate (beats/min)
Heart Rate (beats/min)
Heart rate (bpm)
Heart rate (bpm)*
Heart rate (bpm0)*,**
Heart Rate (Median 73.0}
Heart rate (min−1)
Heart rate (SD)
Heart rate (SD), bpm
Heart rate (SD), bpm Blood pressure, mm Hg
Heart rate < 69 bpm
Heart rate 一beats/min
Heart rate > 69 bpm
Heart rate at baseline (bpm
Heart rate at baseline, bpm
Heart rate at rest — beats/min
Heart rate at rest in the supine position (beats/min)
Heart rate, /min
Heart rate, b.p.m. mean ± SD
Heart rate, beats per min
Heart rate, beats per minute
Heart rate, beats/min
Heart rate, beats/min, mean ± SD
Heart rate, bpm
Heart rate, bpm, mean (SD)
Heart rate, mean (SD)
Heart rate, mean (SD) [range], beats/min
Heart rate, mean (SD), beats/min
Heart rate, mean (SD), bpm (n=21 074)
Heart rate, mean ± SD (b.p.m.)
Heart rate, min_1 (mean)
Heart rates (beats/minutes)
Heartburn severity during the run-in periodT
Heat failure
Heavy calcification
Heavy Calcification
Height', cm
Height — cm
Height ( cm)
Height (cm)
Height (cm) (mean ± SD)
Height (cm), mean (s.e.)
Height (cm), mean (SD)a
height in meters.
Height loss
Height loss (cm)
Height, cm
Height, cm (mean ± s.d.)
Height, cm*
Height, cm, mean (SD)
Height, mean (SD), cm
Helicobacter pylori-negative, n (%)
Helicobacter pylori infection (+) (n)
Hematocrit, %
Hematologic
Hemispheric stroke n = 526
Hemispheric TIA n = 603
Hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy
Hemoglobin
Hemoglobin-A1c (%)'•■**
Hemoglobin — g/dl
Hemoglobin    level, %
Hemoglobin (< 13 men,，::12 women)
Hemoglobin (g 1 !)
Hemoglobin (g r1)
Hemoglobin (g/dL)
Hemoglobin (g/l)
Hemoglobin (g/L)
Hemoglobin (gl ')
Hemoglobin (gm/dl)
Hemoglobin 一g/dl
Hemoglobin A,,, (%)
Hemoglobin A^c, %
Hemoglobin A1C
Hemoglobin A1c (%)
Hemoglobin A1c, %
Hemoglobin A1C, mean (SD), %
Hemoglobin A1c, mean (SD), %b
Hemoglobin Aj^ (%)
Hemoglobin Ale*
Hemoglobin Ale, %, median (IQR)
Hemoglobin category
Hemoglobin concentration — g/liter
Hemoglobin, g 1 1
Hemoglobin, g/dl
Hemoglobin, g/dL
Hemoglobin, g/dlf
Hemoglobin, g/l
Hemoglobin, g/L
Hemoglobin, mg/dl
Hemorrhagic
Hemorrhagic stroke
Hemorrhagic Stroke
Hemorrhagic stroke (N=102)
Heparin
Heparin + tirofiban (n=1459)
Heparin ± tirofiban (n=1459)
Heparin Alone (n = 729)
Heparin at randomization
Heparin Dose Regimen
Heparin only
Heparin Only
Heparin Plus a GPI (n=1870)
Heparin Plus GPI (n = 1,285)
Heparin Plus Tirofiban (n = 730)
Heparin use
Heparin, ‘ondaparinux or brvalirudin use between rxJex event
Heparin, fondaparinux or brvalirudin use between -oex event
Heparins and fondaparinux
Hepatic disorders
Heritable
Heterogeneity or Trend P Vaiue
Heterogeneity or Trend P Value
Heterogeneity p value
Heterogeneity test
Heterogeneity Test
Heterogeneity/ trend test
Heterozygous familial hypercholesterolemia
Heterozygous familial hypercholesterolemia†
HF
HF 'Without known reduced EF
HF cause
HF duration, y, n (%)
HF Hosp.
HF hospitalisation
HF hospitalization
HF hospitalization    n
HF hospitalization or cardiovascular death
HF hospitalizations, median (IQR)
HF or LVEF <40% associated with index event
HF signs and symptoms
HF symptoms and signs
HF without known reduced EF
HF without known reduced EF (n=1316)
HF, LVD, or both
HF, total
HFpEF (EF N 45), (%)
HFrEF
HFrEF (n=671)
Hgb, g/dl
Hgb, g/dl <13 men, <12 women
HHF (N =159)
HI)Ah(%)
Hiatal hernia (yes) (n)
High
High-density lipoprotein
High-density lipoprotein cholesterol — mg/dl
High-density lipoprotein cholesterol mean (mg/dl ± SD)
high-density lipoprotein cholesterol metabolic syndrome, patients were to
High-density lipoprotein cholesterol Tx difference vs Pbo, LS mean % change from baseline (SE)
High-density lipoprotein cholesterol, mean (SD), mmol/L
High-density lipoprotein cholesterol, median, (25th—75th percentiles), mg/dL
High-density Lipoprotein cholesterol, mg/dL
High-density lipoprotein cholesterol, mg/L
High-density lipoprotein]
High-dosage ICS plus LABA with baseline blood eosinophils <300 cells per pL (n=363)
High-dosage ICS plus LABA with baseline blood eosinophils <300 cells per pL (n=395)
High-dosage ICS plus LABA with baseline blood eosinophils >300 cells per pL (n=809)
High-dosage ICS plus LABA with baseline blood eosinophils a300 cells per pL (n=728)
High-dose ARB (n = 578)
High-dose aspirin
High-dose edoxaban
High-Dose Edoxaban (N = 7035)
High-dose edoxaban vs warfarin
High-dose statin
High-Dose Statin Pretreatment (n=1692)
High-dose statin use at screening*
High-dose statin use, n (%)e
High-intensity statin
High-intensity statin use
High-intensity statin vs medium- or low-intensity statin at randomization
High-intensity statin*
High‐intensity statins‡
High-probability ventilation/perfusion lung scanning
High-risk
High-risk clinical features
High-risk CVD, n (%)
High-school graduate
High-school graduate or GED
High-sensitivity C-reactive protein — mg/liter |
High-sensitivity C-reactive protein (mg/L)
High-sensitivity C-reactive protein stratification
High-sensitivity C-reactive protein, mg/L
High-sensitivity C-reactive protein, mg/Ltt
High-sensitivity CRP — mg/liter||
High-sensitivityC-reactive protein, mg/L
High (> ULN and ≤ 3xULN) (n = 299)
High (>10%)
High (>2 risk factor)
High (>22)
High (>25 kg/m^) Baseline BMI
High (>26)
"High (>3) (n = 4,393; 25%)"
High (>3), %
High (>34.99 U/ml)
High (>8%) Baseline HbAlc
High (>ULN)
High (210%)
High (5-7)
High (i25 kg/m2) baseline BMI
High (i8 %) baseline HbA1c
High (N=159)
High blood pressure
High cardiovascular risk, n (%)^
High CRP and ESR
High CRP or ESR
High CV risk
High density lipoprotein (mg/dL)
High density lipoprotein cholesterol - mg/dL**
High density lipoprotein cholesterol, mg/dL^
High disease activity: >5.1, n (%)
High Dose
High Dose Statin (n=255, 253)
High Eosinophil Subgroup (>260/ml) (n = 414)
High FENO Subgroup (>19.5 ppb) (n = 201 )
High fracture risk stratum
High HDL-C (for men ≥40 mg/dL / for women ≥50 mg/dL)
High intensity
High Microalbuminuria to Macroalbuminuria (n=148)
High NAFLD Fibrosis Score (NFS > 0.67)
High NFS NFS >0.67 (N = 2106)
High Normal (n=520)
High on-treatment platelet reactivity*
High Periostin Subgroup (>50 ng/ml) (n = 255)
High potencyc
High risk
High risk (-ICS)
High risk (?ICS)
High risk (>14)
High risk (7-14)
High risk (N 5 4284)
High risk (receiving treatment for):
High Risk (RI≥3)
High risk and fewer symptoms (Group C)
High risk and more symptoms (Group D)
High risk for diabetes*
High risk of diabetes
"High risk of diabetes"""
High risk with atherosclerotic vascular disease*
High risk without atherosclerotic vascular disease+
High risk*, %
High sensitivity C-reactive protein (mg/L)
High Subgroup
High titre (>3 times of ULN), n (%)
High TRS: 5-7 (n = 1,308)
High TT>10.41 (N = 647)
high vs. normalb
high vs. normalc
High*
High, %
Higher-dose
Higher-Dose Edoxaban (n=7035), n (%/y)
Higher-Dose Edoxaban vs Warfarin
Higher-target group (n=1519)
Higher dose
Higher dose edoxaban regimen
Higher Risk (n=4911)
Highest
Highest Killip Classiciation pre-PCI
"Highest Tertile (Range, 2.1-3.6 mg/dl; Mean ± SD, 2.4 ± 0.3 mg/dl)"
Highest TG tertile
Highjj
Highly sensitive
Highly Sensitive Responder (N=140)
highly sensitive responders (n=131)
Hip
Hip + 1 vertebral fractures
Hip + nonvertebral + vertebral
Hip + other nonvertebral fractures
Hip circumference — cm
Hip fracture
Hip Fracture
Hip Fracture +>1
Hip fracture only
Hip Fracture Only
Hip, Femur
Hip, wrist, or spine*
Hispanic
Hispanic — no. (%)
Hispanic (n = 232)
Hispanic (N = 232)
Hispanic (n=9l6)
Hispanic American
Hispanic black
Hispanic ethnic group—no. (%)f
Hispanic ethnic group—no. {%)’i'
Hispanic ethnic group — no. (%):t
Hispanic ethnic group — no./total no. (%)‘j‘
Hispanic ethnic group, n (%)
Hispanic ethnicity
Hispanic Ethnicity
Hispanic ethnicity, n (%)
Hispanic or Latino
Hispanic or Latino (n — 248)
Hispanic or Latino (n=588)
Hispanic or Latino ethnic group!
Hispanic or Latino ethnic group*
Hispanic or Latino ethnic groupb
Hispanic or Latino ethnic groupf
Hispanic or non-Hispanic ethnic group — no. (%)f
Hispanic, n (%)
Hispanic, n(%)
Hispanic/Latin American
Hispanic/Latino
Hispanic/Latino (n=588)
Hispanic/Latino ethnicity
Hispanic/Latino ethnicity, n (%)
Hispanic/non-Hispanic
Hispanie/Latino
Histamine-2-receptor antagonist
Histor y of congestive heart failure — no. (%)
Histor y of heart failure
Histor y of myocardial infarction
Histor y of stable angina
Histor y of unstable angina
History
History (pack-years)
History cHD
History Congestive heart failure
History coronary
History coronary revascularization
History MI or stroke
History myocardial infarction
History of (%)
History of >1 previous VTE (excluding index event)
History of a transient ischaemic attack
History of AF
History of alcohol use
History of amputation
History of amputation — no. (%)
History of amputation, n (%)
History of amputation, No. (%)
History of asthma-related intubation — no. (%)
History of atherosclerotic vascular disease — no. (%)§
History of atrial arrhythmia, n (%)
History of atrial fibrillation
History of Atrial Fibrillation
History of atrial fibrillation and/or flutter
History of atrial fibrillation or fl utter
History of atrial fibrillation or flutter
History of atrial fibrillation or flutter Treatment at randomisation
History of atrial fibrillation, n (%)
History of atrial fibrillation, type 一no. (%)
History of atrial fibrillation/flutter
History of atrial fibrillation/flutter, (%)
History of bone disease (predefined), n (%)
History of bowel resection (ref)
History of bowel resections, n (%)
History of CABG
History of CABG surgery
History of CABG surgery, n (%)
History of CABG, n (%)
History of CAD
History of CAD/MI
History of cancer
History of Cancer
History of cardiac arrhythmia
History of cardiovascular disease
History of cardiovascular disease — no. (%)
History of cardiovascular disease — no. (%)^|
History of cardiovascular disease — no. {%)
History of cardiovascular events
History of carotid artery disease
History of Carotid Disease - n (%)
History of cerebrovascular disease
History of Cerebrovascular disease
History of cerebrovascular disease — no. {%)
History of CHD
History of CHD at baseline
History of CHD at baseline d,g
History of CHD at baseline, No. (%)
History of CHD at baseline§
History of CHD, n (%)
History of CHF
History of CHF - n (%)
History of CHF before index event
History of CHF, n (%)
History of CHF, NYHA class II or III — no. (%)
History of chronic HF
History of claudication
History of clinical fracture (>45 years old)
History of clinical fracture (>45 years)
History of congestive heart failure
History of COPD
History of coronary
History of Coronary Arteiy disease
History of coronary artery disease
History of Coronary Artery Disease - n (%)
History of coronary artery disease — no. {%)
History of coronary heart disease at
History of coronary heart disease, No. (%)
History of coronary revascularization
History of coronary revascularization d
History of coronary revascularization, No. (%)
History of Crohn's disease surgery, n (%)
History of currently treated hypertension, n (%)
History of CV disease
History of CVD
History of CVD and of CV risk factors - no. (%)
History of CVD, n (%)
History of diabetes
History of Diabetes
History of Diabetes - n (%)
History of diabetes (%)
History of diabetes (A)
History of diabetes (n=1979)
History of diabetes {p=0*64)
History of diabetes mellitus
History of Diabetes Mellitus
History of diabetes mellitus (n = 95)
History of diabetes mellitus, n (%)
History of diabetes mellitus, no. (%)
History of diabetes NYHA class
History of diabetes requiring drugs
History of diabetes:
History of diagnosed hypertension n (%)
History of diagnosed hypertension prior to randomization, n (%)
History of disease refractory to treatment with TNF antagonist — no. (%)
History of dyslipidaemia
History of Dyslipidemia
History of dyspepsia
History of ElMs, n (%)
History of extra-intestinal manifestations of IBD
History of falls
History of falls in year before randomization
History of fistulising disease, n [%]
History of fistulizing disease, n (%)
History of fistullzing disease, n (%)
History of gestational diabetes mellitus — no. (% of women)
History of GI bleeding or ulcer — no./total no. (%)
History of H pylori eradication*
History of heart failure
History of heart failure — no. (%)
History of heart failure — no. {%)
History of heart failure at baseline
History of heart failure, n (%)
History of heart failure, No. (%)
History of HF
History of HF hospitalization
History of HF or LVEF b40% with index event, no. (%)
History of high cholesterol (A)3
History of HTN, %
History of hypercholesterolemia
History of hypercholesterolemia, n (%)
History of hyperlipidemia (%)
History of hypertension
History of Hypertension - n (%)
History of hypertension — no. (%)
History of hypertension (%)
History of hypertension (A)c
History of hypertension (n = 344)
History of hypertension (n=4314)
History of hypertension for 6 mo or more
History of hypertension*
History of hypertension, n (%)
History of hypertension, No. (%)
History of hypertension. No. (%)
History of hypertension^, %
History of impaired renal function
History of impaired renal function, no. (%)
History of intermittent claudication and ABI <0-90 or substantial peripheral arterial stenosis >50%
History of ischemic heart disease — no. (%)
History of ischemic stroke
History of LVH on Echocardiogram
History of LVH on Electrocardiogram
History of macroalbuminuriat, n (%)
History of macrovascular disease
History of macrovascular disease (%)
History of macrovascular disease at baseline, n (%)
History of major bleeding
History of major cardiovascular disease, n (%)
History of major macrovascular disease — no. (%)
History of major macrovascular disease, n (%)
History of major microvascular disease — no. (%)
History of major microvascular disease, n (%)
History of MI
History of MI (n= 145, 142)
History of MI or stroke
History of MI or stroke d
History of MI or stroke History of coronary
History of MI or Stroke, n (%)
History of MI or stroke, No. (%)
History of MI, n (%)
History of MI, N (%)
History of microalbuminuria — no. (%)
History of microvascular disease
History of microvascular disease — no. (%)
History of microvascular disease (%)
History of microvascular eye disease本,n (%)
History of Ml
History of Ml at baseline
History of Ml before index event
History of Ml or ischemic stroke
History of Ml or stroke
History of more than 1 prior MI (%)
History of myocardial infarction
History of myocardial infarction (%)
History of myocardial infarction, n (%)
History of nicotine use
History of non-hemor-rhagic stroke
History of omalizumab treatment
History of omalizumab treatment:
History of or current cardiac disorders, %
History of osteoporotic fracture, n (%)a
History of other medical Conditions, n (%)
History of oxygen use - yes, n (%)
History of PAD
History of parental myocardial
History of paroxysmal AF
History of paroxysmal atrial fibrillation, n (%)
History of PCI
History of PCI — no./total no. (%):t
History of PCI or CABG before index event
History of PCI with stenting
History of PCI, n (%)
History of PCI/PTCA
History of percutaneous coronary intervention
History of Peripheral Arterial disease
History of peripheral arterial disease (%)
History of peripheral artery disease
History of peripheral artery disease — no. {%)
History of peripheral vascular disease
History of postmenopausal fracture*
History of PVD
History of PVD, n (%)
History of PVD, no. (%)
History of recurrent venous thromboembolism
History of second prior MI
History of second prior MI, n (%)
History of smoking
History of stroke
History of Stroke
History of stroke (%)
History of stroke at baseline
History of stroke or TIA
History of Stroke or TIA - n (%)
History of stroke or TIA — no. (%)
History of stroke or transient ischemic attack
History of stroke*
History of stroke**
History of stroke, n (%)
History of stroke, N (%)
History of stroke/ SEE/TIA, n (%)
History of stroke/SEE/TIA
History of stroke†
History of stroke1
History of strokea
History of symptomatic
History of systemic hypertension
History of thyroid disease, n (%)
History of TIA or stroke
History of TIA, n (%)
History of TIA/stroke
History of TNF antagonist treatment failure — no. (%)**
History of upper
History of upper gastrointestinal event
History of upper GI events (perforations, ulcers  and bleeding) n (%)
History of upper Gl events (perforations, ulcers, bleeding), n (%)
History of venous
History of VTE
History of VTE**
History ol CHD at baselines
History ol coronary revascularization*
History ol MI or stroke
History ot CHD, n (%)
History PCI
History/presence of tophi
HIT-6 score
HIV
Hl 土 15.5
HLA-B27
HLA-B27 positive at baseline, n (%)
HLA-B27 positive, n (%)
HLA‐B27 positive, n (%)
HLA-B27, n (%)⁎⁎
HMG-CoA reductase inhibitors
HMGCoA Rl
Ho
Ho Active Cancer
Hoehn & Yahr stage
Hoehn & Yahr stage (“off”), n (%)
Hoehn & Yahr stage (“on”), n (%)
Hoehn and Yahr stage
Hoehn and Yahr stage (baseline), mean (SD)
Hoehn and Yahr stage (range, 1-5)
HOMA
HOMA-b
HOMA-IR
HOMA-IR (%)b
HOMA-IR (mU/L^mmol/L)
HOMA-IR index
HOMA-IR index — median (IQR)
HOMA-IR score
HOMA-IR, mean (SD)
HOMA-IR, mean (SD) (mU/L$mmol/L)b
HOMA-IR, median (Q1, Q3)
HOMA-p
HOMA >median
HOMA.%B, median (Ql, Q3), %
HOMA.IR, median (Ql, Q3), %/100
HOMA_%B Tx difference vs Pbo, median change from baseline (SE)1
HOMA_%B, median (Q1, Q3), %
HOMA_IR Tx difference vs Pbo, median change from baseline (SE)1
HOMA_IR, median (Q1, Q3), %/100
HOMA>median
HOMAJR Tx difference vs Pbo, median change from baseline (SE)1 Lipid parameters
Hong Kong
HOPE (n=9297)
HOPE patients with coronary-artery disease (n=7477)
Hordic
Hormonal status
Hormonal therapy — no. (%)
hormone-refractory prostate carcinoma
Hormone replacement
Hormone replacement therapy
Hormone replacement therapy use
Hormone replacement!!
Hormone therapy
hormone therapy use
Hormones
Hosji fcrHypoglycemia
Hosp. for HF
Hosp. worsening HF
Hospitaiization for angina
Hospitaiization for heart faiiure
Hospital admission for heart failure
Hospital factor #1
Hospital factor #2
Hospital stay (days)
Hospital stay, days
Hospitalisation
Hospitalisation for CHF within 3 years of randomisation
Hospitalisation for heart failure
Hospitalisation related to exacerbation, n (%)
Hospitalization
Hospitalization for
Hospitalization for ACS
Hospitalization for acute limb ischemia
Hospitalization for heart                                 failure N(%)
Hospitalization for heart failure
Hospitalization for heart failure or CV
Hospitalization for heart failure or CV death
Hospitalization for heart failure within 6 mo
Hospitalization for heart failure within previous 6 mo — no. (%)
Hospitalization for HF
Hospitalization for HF previous year,(%)
Hospitalization for unstable angina
Hospitalization for unstable AP
Hospitalization for/due to
Hospitalization in previous year with management of heart failure
Hospitalization in previous year with management of heart failure as major component — no. (%)
Hospitalization in the past 12 months prior to baseline
hospitalization stratum, n (%)
Hospitalization to enrollment
Hospitalization, n (%)
Hospitalizations
Hospitalizations, n
Hospitalized
Hospitalized angina
Hospitalized Exacerbation Rates
Hospitalized for an exacerbation
Hospitalized for asthma, n (%)*
Hospitalized for heart failure during that time period
Hospitalized heart failure
Hospitalized HF
Hospitalized HF!
Hospitalized pneumonia events, n
Hospitalized without airway compromise
Hospitalized!
Hospitalized/fatal heart failure
Hot climate subset
Hours from clopidogrel loading, mean (SD)
HPS
HR
HR (95% C!)
hr (95% cI)
HR (95% Ci)
HR (95% CI)
HR (95% CI)*
HR (95% CI), multivariate Cox proportional-hazard regression
HR (95% CI), univariate Cox proportional-hazard regression
HR (95% Cl)
HR (95% Cl) = 0 64 (0.43. 0,95)
HR (95% Cl) = 0.9B (047, 2.04)
HR (95% Cl) = 1.10 (0.71, 1 70)
HR (95% Cl) = 1.10(0 87,1.39)
HR (95% CL) pValue
HR (95% Cl)*
HR (95%CI)
HR (95%CI)    P value for interaction*
HR (9s%a)
HR (9S%CI)
HR (adjusteda)
HR (b.p.m.)
HR (bpm)
HR (ENL vs LCZ) (95% Cl)
HR [95%CI)
HR 0-54 (95% Cl 034-0-86)
HR 0-57 (95% Cl 0-41-0-79)
HR 0-60 (95% Cl 0-39-0-93)
HR 0.46
HR 0.54
HR 0.55
HR 0.75
HR 0.78
HR 0.88 (95% Cl 0.68, 1.14) p=0.33*
HR 0.92 (95% Cl 0.70, 1.22) p=0.56*
HR 0.95 (95% Cl 0.76, 1.19) p=0.67*
HR 0.96 (95% Cl 0.73, 1.26) p=0.77*
HR 1.03
HR 1.05
HR 1.08
HR 1.13
HR 1.20
HR 1.24
HR 1.28
HR 1.30
HR 1.31
HR 1.33
HR 1.38
HR 1.48
HR 95% Cl
HR 95%CI
HR and 95% CI*
HR is <1 if pravastatin is better than diet alone
HR vs control (95% Cl)*
HR vs placebo (95% CI)
HR vs. Warfarin (95% CI)
HR with edoxaban (95% CI)
HR(95% CI)
HR(95% CI)P Value
HR(95%CI)
HR(95%CI)“
HR* or RR†
"HR* or RR† (95% CI);"
HR, (95% Ci)
HR, (95% Cl)
HR, 95% Cl
HR, bpm
HR, bpm (SD)
"HR: 0.33
(95% Cl: 0.14-0.79)
P=0.0088"
"HR: 0.52
(95% Cl: 0.18-1.52)
P=0.2243"
"HR: 0.63
(95% Cl: 0.34-1.18)
P=0.1427"
"HR: 1.27
(95% Cl: 0.71-2.27) P=0.4256"
HR‡
HR2 and 95% Cl
HRadj (95%CI)
HRadjusted (95% CI)b
HRG
HRQL mean (SD)
HRQoL
HRT
HRT use
Hs- CRP (mg/L)
hs-CRP
Hs-CRP
hs-CRP    mg/L
hs-CRP (median, IQR), mg/L
hs-CRP (mg/L)
hs-CRP (mg/L, median)
hs-CRP _=2.0 mg/L
hs-CRP <2.0 g/L
hs-CRP <2.0 mg/L
hs-CRP <2.0 nlg L
hs-CRP >2.0 mg/L
hs-CRP J2.0 mg/L
hs-CRP j2.0mg/L
hs-CRP, mg/l
hs-CRP, mg/L
HS Graduate/GED
hsCRP
hsCRP — mg/liter
hsCRP (mg/l)
hsCRP (mg/L)
hsCRP (mg/L), median (first, third quartiles)
hsCRP (mg/l), median (min–max)
hsCRP (mg/L), median (minimum‒maximum)
HsCRP (mg/L)c
hsCRP (nmol/l)
hsCRP (nmol/L)
hsCRP (post-baseline/baseline ratio), LS mean ± SE
hsCRP < 2.0 mg/L
hsCRP < 2.0 mgA.    259(13.9X281(15.6)
hsCRP > 2.0 mg/L
hsCRP > 2.0 mgA.
hsCRP >2 to <4 mg/L
hsCRP >2.0 mg/L
hsCRP >4 mg/L
hsCRP §
hsCRP at Baseline
hsCRP level
hsCRP range, mg/L
hsCRP, Exp LS mean change ± SE‡
hsCRP, mean (SD)
hsCRP, median (IQR), mg/L
hsCRP, median (min, max), mg/L
hsCRP, mg/dL
hsCRP, mg/l
hsCRP, mg/L
hsCRP, mg/L, median (min–max)
HTN
HTN hx
Hub
Humerus fracture
Hungary
Hvookalemia
Hvpercholesterolemia
Hvpertension
Hx CABG
Hx MI or stroke
Hx of diabetes, n (%)
Hx Stroke/TIA
Hydochlorothiazide (n=557)
Hydralazine
Hydrochlorothiazide
Hydroxychloroquine
Hydroxychloroquine treatment§
Hyper- tension
Hypercholesterolaemia
Hypercholesterolaemia (%)
Hypercholesterolemia
Hypercholesterolemia — no. (%)
Hypercholesterolemia — no. (%)*
Hypercholesterolemia (%)
Hypercholesterolemia (>240 mg/dL)
Hypercholesterolemia 一no. (%)
Hypercholesterolemia*
Hypercholesterolemia, n (%)
Hypercholesterolemia, no. (%)
Hypercholesterolemiat
Hyperkalaemia
Hyperkalaemia (investigator reported)
Hyperkalaemia (serum potassium > 5.5 mmol/L)
Hyperkalemia (>5.5 mEq/L)
Hyperkalemia*’
Hyperkalemia, n (%)
Hyperkalemia‡ (potassium ≥5.5 mmol/L)
Hyperkalemiab
Hyperlension
Hyperlipidaemia
Hyperlipidaemia (%)
Hyperlipidaemia therapy use, n (%)* No lipid-lowering agent therapy
Hyperlipidaemia, n (%) yes
Hyperlipidemia
Hyperlipidemia — no. (%)
Hyperlipidemia — no./total no. (%)
Hyperlipidemia (%)
Hyperlipidemia (%)§
Hyperlipidemia ||
Hyperlipidemia || Yes
Hyperlipidemia, %
Hyperlipidemia, n (%)
Hyperlipidemia, n/N (%)
Hyperlipidemia^
Hyperlipidemia§
Hyperlipidemia§ Yes
Hyperlipidmemia
Hypersensitivity, n (%)
Hypertension
Hypertension— no. (%)
Hypertension—No. (%)
Hypertension — no. (%)
Hypertension — no. (%) Hypercholesterolemia — no. (%)
Hypertension — no. (%)|
Hypertension — no./total no. (%)
Hypertension (%)
Hypertension (%):t
Hypertension (>140/90 mm Hg or taking
Hypertension (BP > 130/85 mmHg or using antihypertensive medication)
Hypertension (n 二3277)
Hypertension *
Hypertension 一 no. (%)
Hypertension Absent
Hypertension and left ventricular hypertrophy
Hypertension at baseline
Hypertension history
Hypertension History
Hypertension N(%)
Hypertension requiring medical treatment
Hypertension requiring treatment
Hypertension Serum lipid values
Hypertension severity at baseline, n (%)
Hypertension!
Hypertension*
Hypertension, %
Hypertension, (%)
Hypertension, n (%)
Hypertension, N (%)
Hypertension, n (%) yes
Hypertension, n(%)
Hypertension, n/N (%)
Hypertension, No./total No. (%) Medications in use at baseline, No./total No. (%)
Hypertension, receiving treatment, n (%)
Hypertension, treated
Hypertension, n (%)
Hypertension,* n (%)
Hypertension/ Yes
Hypertension: No (n=368)
Hypertension^
Hypertension本
Hypertension§
Hypertension§ Yes
Hypertension0 (%)
Hypertensiont
Hypertensive
Hypertensive, n (%)
Hypertrophic cardiomyopathy
Hypertrophy per ECG (n=20 950)
hypertrophy, n (%)
Hypoglycaemiad,%
Hypoglycaemic agents
Hypoglycaemic therapy
Hypoglycemia
Hypoglycemia^
Hypoglycemiat
Hypoglycemic agent
Hypokalaemia
Hypokalemia
Hypokalemia‡ (potassium <3.5 mmol/L)
Hyponatremia
Hyponatremic (<135 mEq/L) at Baseline
Hypotension
Hypotension, n (%)
Hypovolaemia
Hzard ratio
I
I- 5 mg/d (n = 329)
i-^W«-i-1
i-H
I & II: FEV1>50% predicted
i (0.i)
i 51.3 vs 33.3
I Amiodarone
I IDL cholesterol (mg/dl)
"i Intensive; 80 mg of Atorvastatin (n = 253)"
I Lisinopril (n = 9054)
"i Moderate; 40 mg of Pravastatin (n = 249)"
I No. of Events
I or II
I Placebo
I Placebo (n = 282)
I Rosuvastatin (n = 702)
I U -UJ
I Vitamin E
I Vitamin E (n = 19937)
I With MetS (n=15750)
I With MetS (n=7327)
I Without MetS (n=5491)
I Without MetS (n=8723)
i.09 (0.92-i.29)
i.2i (0.99-i.47)
I/II
i03 (i0.0)
i08 (i0.5)
i09 (i0.6)
i25 (i2.i)
i28 (i2.3)
i28 (i2.4)
i2i8±489
i34 (i2.9)
i35 (i3.i)
i370±52i
i393±5ii
i3i (i2.7)
i40 (i3.6)
i64±i48
i65 years of age
i68±i43
i74±i50
i77±i38
i7i±i46
i8i
IB ( 11.9)
IBDQ domain scores, mean [SD]
IBDQ score, mean (SD)
IBDQ score|
IBDQ total score
IBDQ total score, mean [SD]
IBS (5.4)
Ibuprofen
ICA stenosis 70%-99%f
ICD
ICD or CRT-D
ICD Therapy (N =
ICD Therapy vs. Placebo No. Hazard ratio (97.5% Cl)
ICD vs. Placebo
ICD, %
ICD, n (%)
ICD/CRT-D, n (%)
ICH
Icosapent Ethyl (events/n(%))
ICS
ICS (tiotropium n = 126, placebo n = 113)
ICS ? LABA (free or FDC)
ICS + LABA
ICS alone
ICS dose of stable maintenance treatment (μg)∗,†
ICS no LABA
ICS non-users
ICS non-users at screening
ICS non-users: QVAI49-SFC
ICs nonusers, n (%)
ICS only
ICS plus LABA
ICS subset
ICS usage
ICS use
ICS use at baseline
ICS use at baseline, n (%)
ICS Use at Baseline, n (%)
ICS use at baseline: no
ICS use at baseline: yes
ICS use at enrollment, mean, mg/d
ICs use at screening
ICS use at screening, n (%)
ICS use at screeningg, n (%)
ICS use No
ICS use Yes
ICS use yes/no, %
ICS use, %
ICS use, yes/no %
ICS use, yes/no, %
ICS users
ICS users at baseline, %
ICS users at baseline, n (%)
ICS users at screening
ICs users, n (%)
ICS users, n (%)
ICS users: QVAI49-SFC
ICS##
ICS, mg/day
ICS, n (%)
ICS, no LABA, n (%)
ICS/LABA
ICS/LABA subset
ICS/LABA therapy, n (%)
ICS/LABD
ICS/LAMA
ICS: no
ICS: yes
"ICS; no LABA (tiotropium n = 76, placebo n = 65)"
ICSa plus LABA, n (%)
ICsf
ICSusers atbaseline,n (%)
ID
ID (n = 674)
ID Genotype
IDeg
IDegAsp–BIAsp 30
IDegAsp BID
IDegLira
Idiopathic
Idiopathic/familial
Idiopathica
IDM
IDR
IDuration of symptoms > 10 min
IeE at baseline: <30IU/L
IFG
IFG and IGT
IFG Pbo (N = 99) vs EvoMab (N = 194)
IFG/IGT
IFG/prediabetes^
IFX (N = 169)
IFX + AZA (N = 169)
IFX treatment
IG (n = 223)
IGA 0/1
IGA mod 2011 score, n (%)
IgE (kU/L), median (range)c
"IgE high (>150 kU/L; n = 1,204)"
"IgEhigh(>i50kU/L;n=i,204)"
"IgElow(<150kU/L; n=1,053)"
"IgElow(<i50kU/L;n=i,053)"
IgElow(n=1,053)
IgG (>16.2 g/l), %
IGL (N = 107)
IGL (N = 40)
IGL (N = 93)
iGlar
IGlar
iGlar (insulin glargine l00 U)
iGlar (n = 258)
iGlar dose at randomization (U/day)
iGlarLixi
iGlarLixi (fixed-ratio combination)
iGlarLixi (n = 259)
IGM
IGM(n = 4565)
IGT or IFG
IGT/IFG
IHD
II
II-IV
II - IV (%)
II    1 Amlodipine-    Lisinopril- Chlorthalidone    Chlorthalidone
II (497)
II (n = 370)
ii = 50
II Chiorthaiidone Amiodipine
II Lisinopril
II Lisinopril i
II or III
II.    0 (0.7) 285
II.    0 (0.9)160
II.    1 (1.1) 116
II.    2 (0.8) 223
II.    7 (0.9)177
II/III
ii=45
ii=46
ii=47
ii=49
ii=50
ii=51
ii=53
ii0 (i0.8)
ii7 (ii.4)
ii80±493
ii9 (ii.5)
ii9 (ii.6)
IIEF-EF domain score, visit 2**
IIEF-EF domain score, visit 3y
III
III-IV
III & IV
III (496)
III / IV
III and IV
III and IV Ejection fraction
III or IV
III: FEV1>30% - <50% predicted
IIIV
iJB^
IL-6
IL-6 (pg/ml)
IL-6 (pg/mL)
IL-6 range, ng/L
IL-6, ng/l
IL-6, ng/L
Ilb/IIIa inhibitors
Ileocolon
Ileocolonic (both ileum and colon)
Ileum
Ileum and colon
Ileum and colon,' n (%)
Ileum and colon, n (%)
Ileum only
Ileum only, n (%)
Ileum or colon
Ileum SES-CD score, mean (SD)
ill-
IM-UNITI
IM and CS use: No
IM on]y
IM or CS use: No
IM use: No
image only
Imaged artery
Imaging data, mean (SD)
IMM
IMM (without corticosteroid)
IMM + corticosteroid, N
IMM only
ImmobAzaton
Immobilization
Immobilization — no. (%)
Immobilization at randomization, n (%)
Immunologic
Immunomodulators
Immunomodulatory drugs
Immunosuppressant (with or without corticosteroid)
Immunosuppressant use, %
Immunosuppressant^
Immunosuppressant^^
Immunosuppressants
Immunosuppressants and antimalarials only
Immunosuppressants only
Immunosuppressants onlyff
Immunosuppressive agents at baseline
Immunosuppressive agents only
Immunosuppressive use, n (%)
IMMy (without corticosteroid), N
Impacts
Impaired cognitive
Impaired cognitive function (SPMSQ >2). N-350 N (%) participants with the event of interest
impaired Fasting Giucose Levei (n = 323)
Impaired fasting glucose
Impaired fasting glucose (>100 mg/dL) (%)
Impaired Fasting Glucose Level (n = 323)
Impaired fasting glucose§
Impaired fasting glucosex
Impaired glucose tolerance or impaired fasting glucose
Impaired glucose tolerance or impaired fasting glucose — no. (%)
Impaired renal function§
Impaired renal function†
Implantable cardioverter-defibrillator
Implantable cardioverter-defibrillator N(%)
Implanted cardioverter-defibrillator
Implanted cardioverter defibrillator
Implanted pacemaker
Improved
Improvement from baseline ≥ 3
"Improving anemia Bsl Hb < 120g I-1; Yr 1 > 120g I-1"
Imputed
IMT (1)
IMT (mm)
in
In-clinic UAS5
In-clinic UASk
In-h
In-hospital medication
In-Hospital Ticagrelor (N = 953)
In-hospital ticagrelor (n=952)
In-stent restenosis
In-stent restenosis of DES
In-trial 6-year rates per 100 (se) Total events/number at risk
In-trial and post-trial 10-year rates per 100 (se) Total events/number at risk
In-trial nonfatal or fatal stroke N=1,525
In ambulance
In emergency department before ambulance transfer
in extension study
In hospital ticagrelor
in IBDQ total score at Week 52, mean [SE]
in IBDQ total score at Week 8, mean [SE]
in patients with a history of chronic angina who have presented with an acute
in previous year, mean (SD)
In remission at maintenance study baseline
in the spironolactone group and 197 patients in the placebo group.
in Therapeutic Range for Warfarin Subjects
in thirds
Inadequate response
Inadequate response'^
Inadequate response'’'
Inadequate response (>3 months MMF/GGs)
Inadequate response or intolerance to >1 anti-TNFdrug
Inadequate response/intolerance to prior therapy, %
inappropriate
Incidence [n/N (rate per 1000 person-years)]
Incidence of each outcome
Incidence rate
Incidence rate (n)
Incidence rate (n)a
incidence rate (per 100 person-yr)
Incidence Rate Difference, Linagliptin -Placebo (95% Cl)
Incidence rate No. (/1000person-years)
Incidence rate of CV events, n (%)
Incidence rate per 100 person-years
Incidence rate per 100 person years
Incidence Rate*
Incidence*
Incidence, %
Incidence, °/o (950/0 Cl)
Incidence, 100 person-year
incidence^
Incidencea
Incident DM or change in
Incident or worsening nephropathy
Included in analysis
Included in this study (n = 188)
Inclusion criteria
Inclusion criteria — no. (%)
Inclusion findings (%)
Inconsistent FAO (n [ 118)
Incontinence episodes/24h
Increase Creatinine, <0.3 mg/dL
Increase Creatinine, >0.3 mg/dL
Increase in serum creatinine
Increased-risk for thrombotic cardiovascular
Increased Risk for Falls
Increased risk for thrombotic cardiovascular event^, n (%)
Increased waist circumference
IND + GLY (N=226)
IND + PBO (N=221)
IND 75 gg q.d. n/N (%)
IND 75 mg q.d. n = 256
IND/GLY
IND/GLY (n=768)
IND/GLY 110/50 mg Once Daily (n = 1,043)
IND/GLY 110/50 mg Once Daily (n = 629)
IND/GLY n = 811
IND/GLY110/50 pg o.d. n = 298
IND/GLYb n = 811
Indacaterol- Glycopyrronium Group
Indacaterol- Glycopyrronium Group (N = 1680)
Indacaterol + tiotropium (n[570)
Indacaterol + tiotropium (n[572)
Indacaterol 150 gg qd
Indacaterol 150 mg
Indacaterol 150 mg[n Z 41]
Indacaterol 150 mg[n Z 73]
Indacaterol 150 ug (n = 187)
Indacaterol 150 ug versus placebo
Indacaterol 300 gg qd
Indacaterol 300 mg
Indacaterol 300 mg[n Z 48]
Indacaterol 300 mg[n Z 68]
Indacaterol 300 ug (n = 188)
Indacaterol 300 ug versus indacaterol 150 ug
Indacaterol 300 ug versus placebo
Indacaterol 600 gg qd
Indacaterol 75 pg
Indacaterol Group (n = 159)
Indacaterol Group (n = 163)
Indacaterol N = 159
Indacaterol N = 163
Indacaterol/glycopyrronium 110/50 μg o.d.
Indeterminate NFS -1.455 < NFS <0.67 !N = 7273)
Indeterminate!!
Index ACS — no. (%)
Index ACS (%)
index AcS event
Index ACS event
Index acute coronary syndrome — no. {%)
Index diagnosis
Index Diagnosis
Index event
Index event — no. (%)
Index event asymptomatic or unconfirmed
Index event information
Index event not confirmed
Index event subtype
Index event to randomization, median (IQR), h
Index event, %
Index event, n (%)
Index event, n/N (%)
Index events
Index events: DVT n (%)
Index events: PE ± DVT n (%)
Index inclusion acute coronary syndrome
Index MI (n - 3,576)
Index PCI performed
Index PE: event during
Index percutaneous coronary intervention
Index stroke >10 days before randomization — no. (%)
India
Indian
Indian (American) or Alaska Native
Indian (American) or Alaskan Native
Indian (Indian subcontinent)
Indian subpopulation
Indication
Indication for index PCI
Indication for Index PCI
Indication for index procedure
Indication for PCI
Indication for stent
Individual Endpoints
Individual intended study duration — no. (%)
Individuals with diabetes, n = 623
Individuals with diabetes, n = 632
Individuals with normoglycaemia
Individuals with pre-diabetes, n (%)
Individuals with prediabetes
Individuals with T2DM (SCALE Diabetes)
Individuals with type 2 diabetes, n (%)
Individuals without diabetes, n = 3,662
Indomethacin
Inducing
Induction-trial group assignment — no. (%)
Induction study treatment
INDZGLY
Ineffective therapy
Infarct-related vessel (%)
Infarct characteristics
Infarct ion w ithin previous 7 day s
Infarct localisation
Infarct localization
Infarct localization, n (%)
Infarct location
Infarct location — no./total no. (%)
Infarct location (Interactsn$: p=0.29)
Infarct location anterior
Infarct on brain imaging^
Infarct on brain imaging丰
Infarct related artery location
Infarct size
Infarct territory (%)
infarction (yr) History of congestive heart failure (%)
Infarction >30 days previously
Infarction 8-30 days
infarction before age 60 (A)
Infarction, date not reported
Infected, n (%)a
Infections
Infections and infestations
Inferior
Inferior (%)
Inferior (n, %)
Inferior MI*, %
Inferior or posterior
Inferior/posterior
Inflammation
Inflammatory
Inflammatory bowel disease
Inflammatory disease
Infliiimab i
INFLIX, no
INFLIX, yes
Infliximab
Infliximab-experienced (n = 103)
Infliximab-naive (n = 322)
Infliximab (combined 3 mg/kg and 5 mg/kg), n (%)
Infliximab (N = 169)
Infliximab 3 mg/kg
Infliximab 5 mg/kg
Infliximab combination therapy
Infliximab monotherapy
inflotmas io mgluj versus piecew
Influenza
Infrequent exacerbator
Infusion administered — no./total no. (%)
Inguinal hernia repair
Inhaled anticholinergic§
Inhaled corticosteroid
Inhaled corticosteroid - yes, n (%)
Inhaled corticosteroids
Inhaled glucocorticoid use at screening
Inhaled j82-agonist§
Inhaled^
Inhaled§
Inhaledb
inhibitor
inhibitors — no. {%) SE-36 physical functioning score^^
inHixanab 5 mgikg versus piacoM
Initial aspirin — no. (%)
Initial diagnosis — no. (%)
Initial heparin — no. (%)§
Initial Heparin Treatment Duration
Initial Heparin Treatment Duration On or After Randomization
Initial symptomatic PE
Initial TIMI Flow
Initial TIMI flow grade 3
Initial treatment randomization
Initial Type of Heparin Treatment Received
Initiated use during double-blind treatment period
initiation of dialysis, renal transplantation, or creatinine .6.0 mg/dL (530 mmol/L)
Initiation of Insulin
Injectable anti‐hyperglycaemic, n (%)
Injection-site reaction, n (%)
Inotropic agent
Inspiratory capacity (L)
insufficient
Insuiin giargine ± OAD
Insulin
Insulin-dependent
Insulin-dependent diabetes
Insulin-dependent diabetes mellitus
Insulin-na'ive
Insulin-naive, n (%)
Insulin-requiring
Insulin-requiring diabetes
Insulin-treated
Insulin-treated diabetes
Insulin-treated diabetes, %
Insulin-treated DM
Insulin — /tU/ml
Insulin — IU
Insulin (%)
Insulin (mU/mL)
Insulin (pmol/l)
Insulin (pmol/l)t Vital signs
Insulin + metformin
Insulin + OAD
Insulin + oral antidiabetic medication(s)
Insulin 一 no. (%)
Insulin administration
Insulin alone
Insulin and oral hypoglycemic drugs
Insulin aspart
Insulin aspart (mealtime)
Insulin at baseline
Insulin based
Insulin dependentc
Insulin detemir
Insulin dose — lU/day
Insulin dose (IU/day), median
Insulin dose (lU/day)
Insulin dose (U)
Insulin dose, U
Insulin Glargin Arm
Insulin glargine
Insulin Glargine
Insulin glargine (n=194)
Insulin Glargine (n=533)
Insulin glargine (n=58ll)
"Insulin Glargine + Insulin Lispro (AWARD-4; N = 296)"
Insulin Glargine Allocation
Insulin glargine dose at screening visit, IU
Insulin Glargine N (%)    /100py
Insulin Glargine N(X)
Insulin Glargine Slope LSM ± SE (mm/year)
Insulin glargine vs standard care Least-squares mean (95% Cl)
Insulin glargine ± OAD
Insulin glargine ± OAD + >BD prandial
Insulin glargine ± OAD + BD prandial
Insulin glargine ± OAD + OD prandial
Insulin lispro mix 25
Insulin only
Insulin plus >1 oral agent
Insulin plus 1 oral agent
Insulin plus oral
Insulin secretagogue
Insulin sensitivity — %§
Insulin therapy
Insulin therapy, n (%)
Insulin therapy, n (%)本
Insulin treated
Insulin treatment
Insulin treatment, n (%)
Insulin Tx difference vs Pbo, median change from baseline (SE)1
Insulin type, n (%)
Insulin use
Insulin use at baseline
Insulin use, n (%)
Insulin Yes
Insulin, IU/mL, median (Q1, Q3)
Insulin, median (Q1, Q3), pmol/L
Insulin, median (Ql, Q3), pmol/L
Insulin, n (%)
Insulin, pmol/L
Insulin:glucose ratio
Insulin+metformin
Insulin+metformin+sulphonylureas
Insulin+sulphonylureas
Insulina
Insulina, n (%)
Insulinogenic Index (Dinsulino_3o min/Dglucoseo-3o min)
Insulins
Insulins and analogs
Int. P*
Integrated analysis set (N = 679)
Intended clopidogrel dose 600 mg
Intended durat-sm of antccagubficn
Intended duration of anticoagulation
Intense
Intense physical activity
Intensification of antianginal therapy
Intensified (n 二 150)
Intensified 12 Months (n - 137)
Intensified Baseline (n - 150)
Intensity of rest pain (mmVAS), mean ± SD
Intensity of statin therapy
Intensity of statin therapy at baseline — no. {%)
Intensity11
Intensive (n=2149)
Intensive (n=3348)
Intensive blood glucose control
Intensive BP Lowering, <120 mm Hg (n=2154)
Intensive Control
Intensive Control (N=5571) No.of patients (percent)
Intensive glycemia lowering
Intensive Therapy (N = 5128)
Intent-to-treat population
Intent-to-treat population, n (%)
Intent-to-treatb
Intent of conservative strategy, %
Intent of early invasive strategy, %
Intent to use direct thrombin
Intent to use glycoprotein IIb/IIIa inhibitor
Intention-to-Treat
Intention-to-Treat with ST-segment-Elevation Myocardial Infarction
Intention-to-Treat without ST-segment-Elevation Myocardial Infarction
Intention to treat
Inter P-value
Inter.
Inter. P- Value
Interact!
interaction
Interaction
Interaction-P
Interaction between treatment and baseline BMI category
Interaction j7-valuet
Interaction p
Interaction P
Interaction P-vaiue
Interaction p-value
Interaction P-value
Interaction P-Value
Interaction p-value*
Interaction p-value3
Interaction p-value4
Interaction p-valuef
Interaction p = 0.0489
Interaction p = 0.1026
Interaction p = 0.3025
Interaction p = 0.4147
Interaction p = 0.6113
Interaction p = 0.6955
Interaction P =0.689
interaction P vaiue
Interaction p value
Interaction p Value
Interaction P value
Interaction P Value
Interaction P value 0.06
Interaction P value 0.09
Interaction P value 0.57
Interaction P value 0.67
Interaction p Value!
Interaction P Value!
Interaction p Value∗
Interaction P Value*
Interaction p Value中
Interaction p Value§
Interaction P Value§
"Interaction P values are as follows: Amlodipine vs. chlorthalidone: age, P=0.421; gender, P=0.385; race, P=0.737; history of CHD, P=0.120; history of diabetes, P=0.093. Lisinopril vs. chlorthalidone: age, P=0.408; gender, P=0.239; race, P=0.603; history of CHD, P=0.704; history of diabetes, P=0.040. Peripheral arterial disease refers to in-trial hospitalization or lower extremity revascularization procedure."
Interaction Pf
Interaction: treatment by psoriasis p value6
Interaction: treatment by psoriasis p valueb
Interaction13
Interactior p-value
intercourse satisfac-
Interim analysis
Interim analysis (all patients)
Interleukin-6 (ng/L)
Interleukin 6 (pg/ml)
Intermediate
Intermediate-acting
Intermediate  Risk (RI=2)
"Intermediate (2) (n = 5,292; 30%)"
Intermediate (2), %
Intermediate (3-4)
Intermediate Risk (RI=2)
Intermediate/long-acting + fast-acting
Intermittent claudication
Internal carotid artery sites
Interquartile range
Interquartile range — ml/min
Interquartile range — yr
Interquartile range Height — cm
Interruption
Interruption (n=624)
Intertrochanteric
Interval after index event
Interval between clinical evaluation and initiation of treatment —no. (%)
Interval between clinical evaluation and initiation oftreatment — no. (%)
Interval clopidogrel to PCI
Interval from clopidogrel loading, h
Interval from onset of symptoms
Interval from randomization to angiography
Interval from symptom onset to qualifying ECG obtained in the ER — hr
Interval of >10 yr since diagnosis of type 2 diabetes — no. (%)
Interval pain onset to admission
Interval study drug to PCI
Intervention
Intervention group (n=463)
Intervention in complex lesions
intervention.
Interventional or surgical procedures
Intestinal area involved — no. (%)
Intestinal area involved, n (%)$
Intolerance
Intolerance'
Intolerance®
Intra-abdominal abscess (past),
Intracerebral
Intracranial
Intracranial bleed
Intracranial bleeding
Intracranial disease of major artery disease t
Intracranial disease of major artery寸
Intracranial hemorrhage
Intracranial Hemorrhage
Intracranial hemorrhage, n (%)
Intracranial hemorrhage†
Intraperitoneal
Intrathoracic or intraperitoneal surgery
Intravenous (N = 191)
Intravenous anticoagulant during hospitalisation*
Intravenous anticoagulant during hospitalization
Intravenous anticoagulant prior to pre-PCI angiography
Intravenous dobutamine
Intravenous heparin
Intravenous inotropes or vasopressors (%)
Intravenous loop diuretics!
Intravenous nitrates
Intravenous study drug administered — no. (%)
Intravenous vasoactive drugs, %y
Intravenous vasodilators (%)
Invasive
inversion
Investigations
Investigator-defined drug-related AEs
Investigator-determined myocardial infarction
Investigator-reported AEs
Investigator-reported hypoglycaemia*
Involved gastrointestinal
Involved Gl areas
Involved intestinal area, n (%)
IOP-lowering medication
IOP, mm Hg
IPAH, HPAH, HIV, drug or toxin induced
IPAH/HPAH
ipeated-measures State Examinatioi
IPF
IPF-related
IPSS
IPSS-S
IPSS-V
IPSS (LS mean ± SE)
IPSS (mean ± SD)
IPSS (unit)
IPSS categories
IPSS HRQL
IPSS QoL
IPSS QoL (LS
IPSS storage subscore
IPSS total score
IPSS voiding subscore
IPSS, “/o
IPST
IPST (n = 89)
IQR
Irbesartan
Irbesartan (N = 2067)
IROFIBAN
IRR=0.75(0.58–0.96)0.024
IRR=0.83(0.42–1.62)0.58
Irregular or ulcerated ICA p)laque:[:
Irregular or ulcerated ICA plaquef
Irritative subscore
IS domain LUTS severity (%)
IS only
Ischaemic
Ischaemic (n=4418)
Ischaemic (n=44l8)
Ischaemic aetiology
Ischaemic cardiomyopathy
Ischaemic cause
Ischaemic dilated cardiomyopathy
Ischaemic etiology N(%)
Ischaemic heart disease
Ischaemic heart disease or cerebrovascular disorder, n (%)
Ischaemic heart disease, n (%)
Ischaemic or unknown stroke
Ischaemic skin lesions
Ischaemic stroke
Ischaemic stroke, n (%)
Ischaemic, n (%)
Ischemia
Ischemia-driven revascularization
Ischemia driven revascularization
Ischemia Driven Revascularization
Ischemia on cECG (%)
Ischemia on cECG (n = 1,271)
Ischemic
Ischemic aetiology
Ischemic aetiology, n (%)
Ischemic cardiomyopathy
Ischemic cause
Ischemic cerebrovascular disease, n (%)
Ischemic coronary artery disease
Ischemic etiology
Ischemic etiology (%)
Ischemic etiology, %
Ischemic heart disease
Ischemic heart disease (%)
Ischemic Heart Disease Indicator    No (n=650l)
Ischemic heart disease*
Ischemic heart disease, %
Ischemic heart disease, (%)
Ischemic heart disease, n (%)
Ischemic heart disease, No. (%)
Ischemic heart failure etiology
Ischemic HF etiology
Ischemic HF, % (n)
Ischemic Outcomes
Ischemic stroke
Ischemic Stroke
Ischemic stroke (%)
Ischemic stroke (incl. uncertain)
Ischemic stroke (vs. TIA)
Ischemic Stroke or SEE
Ischemic stroke subtype
Ischemic Stroke with Hemnrrhnaic Cnnversinn
Ischemic Stroke without Hemorrhagic Conversior
Ischemic TVR
Isehemie heart disease
ISH
ISH status, n (%)
Islander
isoiated systoiic hypertension*
Isolated deep-vein thrombosis
Isolated IGT
Isolated impaired glucose tolerance — no.
Isolated pulmonary embolism
Isolated systolic hypertension
Isolated systolic hypertension, n ('%>
Isolated systolic hypertension, n (%)“
Isolated systolic hypertension^
Isolated systolic hypertension⁎
Isolated upper gastrointestinal Disease behavior, n (%)
Israel
it 0.68
Italy
Italy (n=728)
ITCA 650 40 mg/day (n = 153)
ITCA 650 60 mg/day(n = 153)
Itch NRS
Itch NRS 0 (V = 50)
Itch NRS 1-3 (AT = 369)
Itch NRS 4-6 (V = 660)
Itch NRS 7-8 (.\' = 930)
Itch NRS 9-10 (A' = 550)
Item
ith vs. without)
itherCHDt
ITT
ITT cohort, Overall Study Period
ITT patients, n (%)
ITT population
ITT Population
ITT population, n
IU
IUSS score, mean (SD)
iV
IV
IV-75 mg
IV -150 mg
IV (496)
IV inotropic drug
IV nitrates
IV vasodilator
IV: FEV1 <30% predicted
Ivabradine
Ivabradine (N = 9550)
Ivabradine (N =9550)
Ivabradine group
Ivabradine group (n=3241)
IVC (n=20)
IVC (n=32)
IVC (n=61)
IVC (n=72)
IWQOL-Lite physical score (arbitrary units)
IWQOL-Lite total score (arbitrary units)#
Ixekizumab every 2 weeks (n=351)
Ixekizumab every 2 weeks (n=385)
Ixekizumab every 4 weeks (n=347)
Ixekizumab every 4 weeks (n=386)
IXEQ2W, n=40
IXEQ2W, n=53
IXEQ2W, n=63
IXEQ4W, n=39
IXEQ4W, n=57
IXEQ4W, n=68
ization — no. (%)
j3-Blocker, % (n)
j3 -Blocker
j3 coefficient
Japan
Japan and South Korea
Japan N = 148
Japanese
Japanese subgroup (N = 83)
Japanese subpopulation
JBS-2 primary prevention only3
JBS-2 secondary prevention only3
Jejunum
Joint damage outcomes (mITT population)
Joint space narrowing score
Joint space narrowing score, mean (SD)
Joint swelling
Joint swelling, effusion, or both on clinical examination
Joint swelling, effusion, or both on clinical examination — no. (%)
jS2-Agonists
JSN score
JSN score (0-168)
JSN score (0-280)
JSN score (0–208 scale)
JSN score, mean 6 SD
JSN, mean ± SD
JSN, median (min, max)
Jugular venous distension, n (%)
Jugular venous distention >10 cm
Juvenile myoclonic epilepsy
JVD $10 cm H2O, %
JVP $10 cm H2O
JVP (〉10 cm)
JVP >10cm
JVP, (%)
K-M %
K-M % n
K (mmol/L)
K (rate)
K, mmol/l
Kaplan-Meier Rates, %
Kaplan-Meier Rates, % I    I
Karnofsky score < 80
Karnofsky score 竺 80
KCCQ (12 months)
KCCQ score
KDL cholesterol (mmol/)
Kellgren and Lawrence radiographic reading grade 2 — no. (%)
Key secondary end point: ST
Key secondary end points
"Key: FC = fasting glucose; BP = *This category did not include ar have 3 of the indicated charac"
"Key: TC = triglyceride; hs-CRP = LDL-C = low-density lipoprotein FC = fasting glucose; NCEP ATP * This category did not include ar to have >_ 3 of the indicated char least-square means, except TC an Note: All treatment by subgroup"
kg
kg/m2
kg/m2)
kheeatne index DVT
Kidney disease (USRDS)
Killip at baseline
Killip ciass
Killip class
Killip class — no. (%) I
Killip class — no./total no. (%) I
Killip class (Interaction: p=0.62)
Killip class >11, No. (%)
Killip class >I, %
Killip class >II (%)
Killip class 1
Killip class 2/4
Killip class at admission — no./total no. (%)
Killip class I—No. (%)
Killip class I — no. (%)
Killip class II-IV, n (%)
Killip class II, III, or IV — %
Killip class IV at randomization
Killip class*
Killip class, n (%)
Killip class, n (%) I
KIM 1 (pg/ml)
KL 2 (%)
KL 3 (%)
KM Event (%) at 7 y
KM event rate (%)
KM Rate (%)
KM rates {%) E/S
KM rates {%) P/S
Knee
Knees (N)
Known CHD
Known duration
Known duration of diabetes, yr
Known duration of T2DM, y
Known duration of type 2 diabetes (years)
Known duration of type 2 diabetes,
Known prothrombotic genotype
Known t 'rc-iitoji cccndilon
Known thrombophilia
Known thrombophilia — no. (%)
Known thrombophilic condition — no. (%)
Known tiromtcch*c ccndifeon
Korea
Korea, Republic of
Korean
L
l ( < l)
l (< l)
L Compared wi
L Compared wit
L eft anterior descending
L eft anterior descending coronary artery
L vs. C
l.i (0.4)
l.l±0.3
L/C
l/ll
L’-value’
L20-40 vs placebo
L40-80 vs L2-5-5
LA diameter
LA grade A, n (%)f
LA grade B, n (%)f
LAA
LAA Closure
LAA Closure (n - 732)
LAA Closure (n = 732)
LAA length
LAA Length
LAA ostium
LAA Ostium
laBa
LABA
LABA'
LABA-inhaled glucocorticoid use at screening
LABA (inhaled),d n (%)
LABA (only monotherapy)
"LABA (tiotropium n = 56; placebo n = 55)"
LABA + ICS
LABA + ICS (free or fixed-dose combination)
LABA + ICS n = 269
LABA alone
LABA non-users
LABA or LAMA
LABA or LAMA’
LABA or LAMA’ versus IND/GLY LSM difference (95% Cl)
LABA or LAMAb n = 268
LABA plus ICS (tiotropium n = 50, placebo n = 48)
LABA plus ICS, n (%)
LABA use at enrolment
LABA use at screening
LABA use at screening, n (%)
LABA use, % patients
LABA users
LABA, n (%)
LABA, no ICS, n (%)
LABA/ICS use at screening, n (%)
LABA/ICS#
LABA/LAMA
LABA/LAMA/ICS
LABA+ICS
LABA+ICS versus INDZGLY LSM difference (95% Cl)
LABA + ICS
LABD alone
Laboratory AE, n (%}
Laboratory data
Laboratory data, mean (SD)
Laboratory determinations
Laboratory evaluations
Laboratory examination
Laboratory findings
Laboratory investigations
Laboratory measurements
Laboratory measures
Laboratory parameters, median (IQR)
Laboratory testing
Laboratory tests
Laboratory values
Laboratory values at admission (median and IQR)
Laboratory values at randomization (median and IQR)
Laboratory values in patients with history of diabetes
Laboratory variables
Laboratory variables at baseline
Labs at randomization
Labs at the index ACS event
LACI
LACI (n=510)
Lack of effectiveness
Lack of efficacy
Lack of efficacy with >1 anti-interleukin 6
Lack of efficacy with >1 bDMARD
Lacosamide
Lacunar
Lacunar infarction, n (%)
LAD
LAD artery
LAMA
LAMA (only monotherapy)
LAMA (tiotropium),b n (%)
LAMA use at screening
LAMA use at screening, n (%)
LAMA use, n (%)
LAMA+
laMad
Lamotrigine
Lansoprazole (n = 1363)
Lansoprazole 30 mg QD
Laparoscopic cholecystectomy
Large-artery atherosclerosis
Large MI
Large shunt
Large vessel
Large vessel atherosclerosis
Large/very large
Laser or vitrectomy
last infusion in the HORIZON-PFT
Last study visit
Late load
Late Load
Lateral
Lathosterol (jimol/L)
Lathosterol/Total C (|imol/mmol)
Latin
Latin America
Latin America (n=694)
Latin America HR (95% Cl)
Latin America or South Africa
Latin American
Latin American subgroup
Latin Ameriea
Latin and North America
Latino
Latvia
LAV (ml)
LAVOLTA 1
LAVOLTA II
lb
LC, n = 372
"LCE — L-dopa/carbidopa/entacapone; LC — L-dopa/carbidopa; PD — Parkinson disease; UPDRS — Rating Scale; ADL — activities of daily living; PDQ-39 — Parkinson Disease Questionnaire."
LCE, n = 373
LCL
LCZ696
LCZ696 (n = 496)
LCZ696 (n = 497)
LCZ696 (n = 649)
LCZ696 (n = 683)
LCZ696 treatment, n (%)
LD
LD Edoxaban vs Warfarin
LDA, %
LDI-B > 0 (N=155)
LDI, mean (SD)a
LDI, mean [SD]b
LDI1
LDL
LDL-C
LDL-C (BQ) (mg/dL) - mean ± SD
LDL-C (calculated)*
LDL-C (calculated), mean (SD)
LDL-C (calculated), mg/dL, mean (SD)
LDL-C (measured)*
LDL-C (measured), mean (SD)
LDL-C (median, IQR), mg/dL
LDL-C (mg/dL)
LDL-C (mg/dl) **
LDL-C (mg/dl) <100
LDL-C (mmol/L)
LDL-C (mmol/L, mean)
LDL-C < 1.8 mmol/l
LDL-C < 2.0 mmol/l
LDL-C < 2.5 mmol/l
LDL-C <100 mg/dL
LDL-C <100 mg/dL (2.6 mmol/L)
LDL-C <50 mg/dL
LDL-C <70 mg/dL
LDL-C >70 mg/dL
LDL-C 50-70 mg/dL
LDL-c at Baseline:
LDL-C goal attainment
"LDL-C in mmol/L (baseline: mean (SD) [n]; wk 48 and change: mean (SE) [n])"
"LDL-C in mmol/L (mean ± SD for baseline [n]; mean ± SE for week 12 [n])"
LDL-C level, mean (SD), mg/dL
LDL-C level, mg/dL
LDL-C * (mmol/L)
LDL-C* (mmol/L)
LDL-C, mean (SD)
LDL-C, mean (SD), mg/dL
LDL-C, mg/dl
LDL-C, mg/dL
LDL-C, mg/dL*
LDL-C, mg/dL, mean + SD
LDL-C, mg/dL, mean ± SD
LDL-C, mmol/L
LDL-C, mmol/L (mg/dL)
LDL-C, mmol/L (SD)
LDL-C, mmol/l, mean (SD)
LDL-C, mmol/L, mean (SD)
LDL-C/HDL-C
LDL-C/HDL-C ratio
LDL-C/HDL-C ratio, mean (SD)
LDL-C/HDL-Cx
LDL-C:HDL-C
LDL-C:HDL-C ratio
LDL-C<130mg/dL,No. (%)
LDL-C>median
LDL-cholesterol
LDL-cholesterol (
LDL-cholesterol (mg/dL)
LDL-cholesterol (mmol/)
LDL-cholesterol (mmol/L)
LDL-cholesterol, mean (sd) mg/dl
LDL-cholesterol, mg/dL, mean (SD)
LDL-cholesterol, mmol/L
LDL-cholesterol, mmol/lf
LDL-CiHDL-C, mean (SD)
LDL-Csmedian
LDL-Cz
LDL-to-HDL cholesterol ratio, mean (SD)
LDL (mmol/L)
LDL cholesicrol (minol/l)
LDL choleslerol
LDL cholesterohHDL cholesterol ratio
LDL cholesterol
LDL cholesterol-lowering therapy
LDL cholesterol — mg/dl
LDL cholesterol — mg/dl||
LDL cholesterol (mg/dl)
LDL cholesterol (mg/dL)
LDL cholesterol (mg/dL), mean + SD, available for 3306 patients
LDL cholesterol (mmol/l)
LDL cholesterol (mmol/L)
LDL cholesterol (mmol/L) (median, IQR)
LDL cholesterol (mmol/L), mean (SD)
LDL cholesterol (mmol/L):
LDL cholesterol (SD), mg/dL
LDL cholesterol <2-07 mmol/L
LDL cholesterol >2-07 mmol/L
LDL cholesterol at baseline (mmol/L)* LDL cholesterol at screening
LDL cholesterol level
LDL cholesterol Mean
LDL cholesterol mean (mg/dl ± SD)
LDL cholesterol, mean (SD), mg/dL
LDL cholesterol, mg/dl
LDL cholesterol, mg/dL
LDL Cholesterol, mg/dL
LDL cholesterol, mmol/L
LDL cholesterol, mmol/L*
LDL cholesterol, mmol/L, mean (SD)§
LDL cholesterol, mmol/L, mean±SD
LDL cholesterol, mmol/l丰
LDL cholesterol, mmol/lt
LDL cholesterol^:
LDL cholesterolt
LDL particle numbers (week 24)
LDL particle size (week 24)
LDL*
LDL,-C
LDL/HDL cholesterol ratio, mean (SD)§
LDL:HDL ratio
ldl2-c
ldl3-c
LDLC
LDLC:HDLC
LDU-C
LEADER
Leading to death
Leading to discontinuation
Leading to study drug discontinuation
Leading to study withdrawal
Lean (<25 kg/m2)
Least-squares mean difference (95% CI)*
Least-Squares Mean Difference (95% Cl)
Least square mean (SE)
Least squares mean between-treatment difference (95% CI)
Lebrikizumab (n = 104)
Lebrikizumab 125 mg
Lebrikizumab 125 mg (n=357)
Lebrikizumab 125 mg (n=359)
Lebrikizumab 37-5 mg
Lebrikizumab 37-5 mg (n=356)
Lebrikizumab 37-5 mg (n=360)
Leeds Dactylitis Index-Basic, mean (SD)’'^
Leeds Enthesitis Index, mean (SD)’’*’
Leeds Enthesitis Index^ Score >0 — no. {%)
LEF+MTX (n = 69)
Leflunomide
Leflunomide (mean dose: 19.20 mg/day)
Left
Left-sided colitis
Left-sided colitisz
Left-sided disease only
Left anterior descending
Left anterior descending artery
Left anterior descending artery, n (%)
Left anterior descending coronary artery
Left anterior descending, n (%)
Left atrial anteroposterior diameter — mm
Left atrial diameter
Left atrial diameter, mm (SD)
Left atrial diameter: <42 mm (n=480)
Left atrial dimension, cm
Left bundle-branch block
Left circumflex
Left circumflex artery
Left circumflex artery, n (%)
Left circumflex coronary artery
Left circumflex, n (%)
Left main
Left main artery
Left main coronary artery
Left main coronary artery bifurcation
Left main coronary artery, n (%)
Left main disease
Left main disease, n (%)
Left main treated
Left shoulder
Left side of colon
Left side, n (%)
Left sided colitis
Left ventricular dysfunction
Left ventricular EF, mean (SD), %
Left ventricular ejection
Left ventricular ejection fraction
Left ventricular ejection fraction — %
Left ventricular ejection fraction — %§
Left ventricular ejection fraction — no./total no. (%)
Left ventricular ejection fraction (%)
Left ventricular ejection fraction <30%
Left ventricular ejection fraction within previous 12 mo — no./total no. (%)1
Left ventricular ejection fraction within previous 6 mo |
Left ventricular ejection fraction, %
Left ventricular ejection fraction, % AF history
Left ventricular ejection fraction, %*
Left ventricular ejection fraction, mean (SD), %
Left ventricular ejection fraction, median (IQR), %
Left ventricular hypertrophy
Left Ventricular Hypertrophy
Left ventricular hypertrophy — no. (%)
Left ventricular hypertrophy (%)
Left ventricular hypertrophy on echo
Left ventricular hypertrophy**
Left ventricular hypertrophy, n (%)
Left ventricular systolic dysfunction, n (%)
Left ventricular systolic or diastolic dysfunction
legend
Legs only
LEI >0 (N = 403)
LEI, mean (SD)
LEI, mean [SD]c
LEI1
Lelt ventricular hypertrophy*
Length of stay (randomization to discharge, h)
Length of stent < median
Length of stent > median
Lesion Characteristics
Lesion length $30 mm
Lesion length ≥30 mm
Lesion length > 30 mm
Lesion length, mean (SD), mm
Lesion location
Lesion(s)
Lesions
Lesions B2/C
Lesions treated per patient
Less severe
Less severe OA symptoms at baseline
Less severe0
Less than 1 year
Less than 10 y ears
Less than 140 mm Hg
Less than 30
Less than 30 kg/m2
Less than 50%
Less than 60 ml/min/1.73m2
Less than 65 y ears
Less than 7.5%
Less than high school
Less than median
Less than the median
Leukocytes, 103/nl
Leukopenia
Leukotriene-receptor antagonist
Leukotriene modifier
Leukotriene receptor antagonists
LEV-exposed
LEV-naive
LEV (n = 103)
LEV (n = 104)
LEV (n = 117)
LEV (n = 126)
LEV (n = 14)
LEV (n = 22)
LEV status
LEV status, n (%)
Level — no. (%)
Level 1
Level 1 immobility§||
Level 2
Level 2 immobility^
Level of renal impairment
Level of renal impairment'
Level of thyroperoxidase antibody at baseline
Levetiracetam
Levodopa dose, mean ± SD, mg/day
Levosimendan (n = 299)
Levosimendan (n = 51)
lGM(n = 4565)
li 652(2.3)
lieum only, n (%)
life-threatening
Life-threatening bleed
Life-threatening bleeding, disabling stroke, and death
Lifestyle
Lifestyle behaviors
Lifestyle behaviours
Lifestyle modifications
Likelihood test
Limb
limb (SD)
Limb amputation
Limited
Limited    I-
Limited to left side of colon
Linagliptin
Linagliptin (n = 182)
Linagliptin (n = 3319)
Linagliptin (n = 3494)
Linagliptin (n = 3494)'
Linagliptin (n Z 1624)
Linagliptin, patients with events/total patients
Linagliptin/metformin
Linear regression
Lioid trial participants
LIPC
LIPID
Lipid-lowering
Lipid-lowering agent
Lipid-lowering agent§
Lipid-lowering agents
Lipid-lowering agents (%)
Lipid-lowering drug
Lipid-lowering drug**
Lipid-lowering drugs
Lipid-lowering drugs, n (%)
Lipid-lowering medication
Lipid-lowering medication (%)
Lipid-lowering medications
Lipid-lowering medications^
Lipid‐lowering therapies, n (%)
Lipid-lowering therapy
Lipid-lowering therapy - no. (%)
Lipid-lowering therapy — no. (%)
Lipid-lowerinq druq
Lipid-modulating drug
Lipid and lipoprotein values (mg/dL)
Lipid concentrations
Lipid concentrations Total cholesterol (mmol/L)
Lipid Difference (mg/dL)
Lipid levels — mg/dl
Lipid levels — mg/dlj Total cholesterol
Lipid lowering
Lipid lowering agent N(%)
Lipid lowering agents
Lipid lowering drugs
Lipid lowering medication use
Lipid lowering therapy
Lipid measure*
Lipid measures at baseline — mg/dl
Lipid medication, n (%)
Lipid modifiers
Lipid parameters
Lipid parameters, mg/dL, mean (SD)
Lipid profile
Lipid treatment
Lipid trial participants
Lipid trial participants - n (%)
Lipid trial participants#
Lipid trial participants, No. (%)
Lipid trial participantsk
Lipid trial participantss
Lipid values
Lipid values, mean (SD)
Lipid values, mmol/L
Lipids
Lipids — mg/dl
Lipids medications
Lipids, mean (SD), mg/dLf
Lipids, mean (SD), mg/dLt
Lipoprotein (a) (mmol/L)
Lipoprotein (a) (nmol/L)
Lipoprotein (a) Tx difference vs Pbo, LS mean % change from baseline (SE)
Lipoprotein (a), median (QI, Q3), nmol/L
Lipoprotein (a), median (Ql, Q3), nmol/L
Lipoprotein(a) (mg/dL)
Lipoprotein(a) (nmol/L)
LIPS
Lira
Liraglutide
Liraglutide (« = 4668)
Liraglutide (1.8 mg) ± OAD
Liraglutide (N = 2487)
Liraglutide (n=1265)
Liraglutide (n=1538)
Liraglutide (n=1865)
Liraglutide (N=4,668)
Liraglutide (N=4668)
Liraglutide 1.8 mg (n= 94)
Liraglutide 1.8 mg (n=131)
Liraglutide 1.8 mg/day (n=225)
Liraglutide 3-0 mg (n=1505)
Liraglutide 3-0 mg Mean (n)
liraglutide 3.0 mg
Liraglutide 3.0 mg LS means (N)
Liraglutide 3.0 mg Mean (n)
Liraglutide 3.0 mg n = 115
Liraglutide 3.0 mg n = 2845
Liraglutide 3.0 mg n = 348
Liraglutide 3.0 mg n = 76
liraglutide 3.0 mg,
liraglutide 3.0 mg, n = 1,581
liraglutide 3.0 mg, n = 185
liraglutide 3.0 mg, n = 227
liraglutide 3.0 mg, n = 856
Liraglutide N(%)
Lis
LIS
Lisinopril
Lisinopril (N = 102)
Lisinopril CVD Total
Lisinopril vs Amlodipineb
Lisinopril vs Chlorthalidone
Lisinopril vs Chlorthalidone Normal
Lisinopril vs Chlorthalidone Obese
Lisinopril vs Chlorthalidone Overweight
Lisinopril/Chlorthalidone
LISRs
LITHE
Lived alone
Liver disorder
Lixi
Lixisenatide
Lixisenatide (N = 3034)
Lixisenatide (n=225O)
Lixisenatide (n=552)
ll (4)
LL, n (%)
ll5 (34)
lll-IV
lll/IV
LLPASI 75
Llraglutide 3-0 mg Mean (n)
LLT other than statin at randomization
llv wlalil 1 Statin
LM Bifurcation Not Treated
LM Bifurcation Treated
LM25 258
LM25 bid (N = 114)
LM25 bid (N = 51)
LM25 bid (N = 71)
LMWH
LMWH within 7 days before randomization — no./total no. (%)
LO(LO-LO)
Loading dose of clopidogrel or ticlopidine
Locafon of index DVT
Local eosinophil count
Local eosinophil count (cells per pL)t
Local eosinophil count [cells/µL], median (range)
Local eosinophil count [cells/mL], median (range)
Locally advanced
Location
Location of Crohn's disease, %
Location of disease, n (%)
Location of infarction
Location of infarction — no. (%)§
Location of Ml
Location of treatment center
Location, n (%)
LOCF)
Log-Rank
Log-Rank P Value
Log Rank P-value
Logistic regression
Lone atrial fibrillation — no. (%)§
Long-acting
Long-acting b2-agonists
Long-acting bronchodilator use at screening
Long-acting nitrate
Long-acting nitrate agents
Long-acting nitrates
Long-acting or short-acting nitrates
Long-acting, intermediate/long-acting + fast-acting
Long-acting^
Long-standing persistent
Long-term antiplatelet therapy
Long-term aspirin
Long-term treatment with aspirin — no./total no. (%)
Long-term vitamin K antagonist
Long-term VKA therapy
Long-Term Warfarin (n - 382)
Long-Term Warfarin (n = 382)
Long (>10 years) Duration of Diabetes
Long (>40mm) stenting Yes (N=1193)
Long (i10 years) duration of diabetes
Long acting nitratef
Long term (n = 331)+
Long term VKA Therapy
Long term*
Loop
Loop at enrollment
Loop at last follow-up
Loop diuretic
Loop diuretic use
Loop diuretics
Loop diureties
Loop or thiazide diuretic
Loop or thiazide diuretic#
Loop or thiazide diuretic:!:
Loop or thiazide diuretic^
lor II
Losartan
Losartan (n = 1,004)
Losartan (n = 264)
Losartan (n = 270)
Losartan (n = 3,601)
Losartan (n = 4,355)
Losartan (n = 605)
Losartan (n = 660)
Losartan (n=2098)
Losartan (N=2118)
Losartan (N=2487)
Losartan (n=2507)
Losartan (n=586)
Losartan n=26
Losartan n=387
Losartan n=648
Losartan plus Lisinopril (N=724)
Losartan plus Placebo (N = 724)
Losartan, n/N (%)
Losartan+ Lisinopril
Losartan+ Placebo
Losmapimod
Losmapimod (n = 1731)
Loss of response
Loss of response:!::!:
Loss of response‘s
Loss of response®
Lost BMD
Lovastatin 80 mg
Low
low-ceiling diuretic
Low-density lipoprotein
Low-density Lipoprotein choles-
Low-density lipoprotein cholesterol — mg/dlf
Low-density lipoprotein cholesterol Tx difference vs Pbo, LS mean % change from baseline (SE)
Low-density lipoprotein cholesterol, %
Low-density lipoprotein cholesterol, mean (SD), mmol/L
Low-density lipoprotein cholesterol, median, (25th—75th percentiles), mg/dL
Low-density lipoprotein cholesterol, mg/dL
Low-density Lipoprotein cholesterol, mg/dL
Low-density lipoprotein^
Low-dose aspirin use
Low-dose aspirin use at baseline
Low-dose aspirin use at baseline Yes
Low-dose aspirin use strata* n (%)
Low-dose aspirin use. strata*, n (%)
Low-dose Corticosteroid User
Low-dose edoxaban
Low-Dose Edoxaban (N = 7034)
Low-dose edoxaban vs warfarin
Low-dose rivaroxaban + aspirin (n/N)
Low-dose rivaroxaban + aspirin group
Low-dose rivaroxaban plus aspirin (n=2492)
Low-dose rivaroxaban plus aspirin (n=8313)
Low-dose statin
Low-Medium Microalbuminuria (n=642)
Low-molecular-weight
Low-molecular-weight heparin
Low-molecular-weight heparin — no. (%)
Low-molecular-weight heparin only
Low-molecular-weight only
Low-molecular weight heparin or intravenous unfractionated heparin
Low-trauma fracture since age 45, n (%)
Low (<25 kg/m^) Baseline BMI
Low (<25 kg/m2) baseline BMI
Low (<5%)
Low (<8 %) baseline HbA1c
Low (<8%) Baseline HbAlc
Low (>2.8 and <10)
Low (>3.3 and <11)
"Low (0-1) (n = 8,032; 45%)"
Low (0-1), %
Low (0-2)
Low (N=133)
Low (no risk factor)
Low {<5%)
Low body weight (<60 kg)
Low C3 (<0.9 g/L)
Low C3 (<90 mg/dl), %
Low C3/C4 and anti-dsDNA
Low C4 (<0.18 g/L)
Low C4 (<16 mg/dl), %
low complement/anti-dsdNA positive (n=876)
Low density lipoprotein cholesterol - mg/dLTT
Low density lipoprotein cholesterol, mg/dL**
Low Dose
Low Dose Combination Therapy
Low Eosinophil Subgroup (,260/ml) (n = 383)
Low FENO Subgroup (,19.5 ppb) (n = 193)
Low HDL-C
Low HDL-C (for men <40 mg/dL / for women <50 mg/dL)
Low HDL cholesterol
Low HDL cholesterol* |
Low molecular weight (LMW) heparin before randomisation
Low molecular weight heparin
Low NAFLD Fibrosis Score (NFS < -1.455)
Low NFS NFS <-1.455 (N = 5440)
Low Normal (n=508)
Low or moderate
Low Periostin Subgroup (,50 ng/ml) (n = 279)
Low potencyc
Low renin (PRA <0.65 ng/mL/h) (n=178)
Low risk
Low risk (-ICS)
Low risk (?ICS)
Low risk (0-10)
Low risk (0-3)
Low risk (N 5 2610)
Low Risk (RI=0-1)
Low risk and fewer symptoms (Group A)
Low risk and more symptoms (Group B)
Low Subgroup
Low to Medium Microalbuminuria (n=642)
Low TRS: 0-2 (n = 1,704)
Low TT<10.41 (N = 311)
Low, %
Low’
Lower-dose
Lower-limb angioplasty or bypass surgery
Lower-limb arterial — no. (%)
Lower-target group (n=1501)
Lower dose
Lower dose edoxaban regimen
Lower limb fracture
Lower limb fractures
Lower limbs
Lower risk
Lower Risk (n=4282)
Lower tertile: b 0.23
Lower than normal range — %^
Lowest
Lowest activated clotting
Lowest Normal (n=640)
"Lowest Tertile (Range, 0.9-1.6 mg/dl; Mean ± SD, 1.4 ± 0.1 mg/dl)"
Lowest TG tertile
LowZmedium intensity
Lp(a) (μmol/L)
Lp(a) (pmol/L)
Lp(a) (week 24)
Lp(a), mean (SD)
Lp(a), median (Q1:Q3)
Lp(a), mg/dL, median (Q1:Q3)
Lp(a), nmol/l, mean (SD)
Lp(a)§
Lpa, mg/dL
LRG
LS-mean between-group difference (95% CI)
LS-mean change from baseline (95% CI)
LS-mean difference between treatment groups (95% CI)
LS-mean difference® (95% Cl)
LS mean
LS Mean
LS mean       (SE)
LS mean % change from baseline _ SE
LS mean (95% CI)
LS Mean (95% CI)
LS mean (95% CI), %
LS mean (95% CI), mmol/mol
LS mean (95% CI)a
LS mean (s.e.) primary endpoint: % change from baseline to week 24
LS mean (SE)
LS Mean (SE)
LS mean [95% CI] treatment difference vs placebo
LS mean ± SE
LS mean change
LS mean change (SE)
LS mean change ± SEa
LS mean change from baseline
LS mean change from baseline (SE)
LS mean change from baseline (SE), %
LS mean change from baseline, mL (SE)a
LS mean change from baseline1
LS mean change from baseline2
LS mean change from baseline3
LS mean difference (95% CI)
LS mean difference (95% Cl)
LS Mean Difference (SE)
LS mean difference (SE) vs placebo
LS mean difference ± SEb
LS mean difference vs placebo (95% CI)
LS mean difference vs placebo (95%CI)
LS mean treatment difference (95% CI)
LS means difference (95% CI)3
LS means difference (95% CI)a
LS T-score < —2.5
ls/ul 655    631
LSM (95% CI)
LSM (95% Cl)
LSM difference
LSM difference (95% Cl)
LSMs difference (95% CI)3
LTA (max response to 20 pM ADP) defined HPR (% patients)
LTBR (ng/ml)
LTG-exposed
LTG-naive
LTG subgroup, n = 220
LTT other than statin
lU/kg
lue for interaction
Lumbar
Lumbar epidural
Lumbar spine
Lumbar spine BMD T-
Lumbar spine BMD T-score
Lunchb
Lung
Lung function, mean
Lung infection
Lung neoplasm malignant
"LUTS = lower urinary tract symptoms; IS ="
LUTS severity
LUTS/BPH characteristics
LV diastolic dysfunction, n (%)
LV ejection fraction
LV ejection fraction (%)
LV ejection fraction >40% and <50%,
LV ejection fraction, % (n=7869)
LV ejection fraction, mean (SD) [range], %
LV ejection fractionb
LV Function
LV function >0.40 and <0.50, n (%) Medications, n (% of patients)
LV Heart Structure
LV hypertrophy per ECG
LV hypertrophy, n (%)
LV mass
LV mass index (g/m2-7)
LV mass index (mg/m2)
LV systolic dysfunction, n (%)
LVDd (mm)
LVEDV (ml)
LVEF
"LVEF — no. (%);i;"
LVEF (%)
LVEF (%), mean ± SD
LVEF (mean ± SD)
LVEF (U)
LVEF < 30%
LVEF <0.40
LVEF <33%
LVEF <40%
LVEF <40%, N = 917 947)“
LVEF ≤40%, N = 302 278a
LVEF ≤40%, N = 917 947)a
LVEF >33%
LVEF >40%
LVEF within 6 mo, %
LVEF within 6 months, %
LVEF, %
LVEF, %, median (IQR)
LVEF,%, median (IQR)
LVEF^0.40 and NYHA class II, III at baseline
LVEF<30%
LVEF>30%
LVESV (ml)
LVH
LVH - N = 2652
LVH -N =2666
LVH -N =2701
LVH (from echocardiogram)
LVH (from electrocardiogram)
LVH +N = 771
LVH +N =791
LVH by ECG
LVH by ECG (Minnesota code)
LVH by ECG or Echo. n (%)
LVH by ECG or echocardiography, No (%)
LVH by ECG or echocardiographyd
LVH by ECG/Echo
LVH by ECGt Blood pressure, mm HG
LvH by echo or EcG
LVH by echocardiogram
LVH by echocardiography
LVH by electrocardiogram
LVH by electrocardiogram, n (%)
LVH by Minnesota code
LVH by Minnesota code, No. (%)
LVH on ECG
LVMI (61
lyear mean change from baseline
Lymphadenopathy
Lymphocytes, 103/+il
M
M being
M/F
M1 subgroup
M2 subgroup
M3 subgroup
M6S
mab
MACCE
MACCE (%)
MACCE (%) Abciximab Placebo
MACCE (death, MI, stroke)
MACCE (Death, MI, Stroke)
MACE
MACE category, N (%) [IR]
MACE+
Macro-albuminuria
Macroalbuminuria
Macroalbuminuria — no. (%) Drug therapy — no. (%)
Macroalbuminuria — no./total no. (%)
Macroalbuminuria (UACR >300)
Macroalbuminuria at baseline (11% of patients treated)
Macroalbuminuria, n (%)
Macroalbuminuriaf
Macrovascular disease, n (%)
Mae
MAF
Mafcaiancy at randorrtzaton
Magnetic resonance angiography
Main concomitant treatments, No. (%)
Main effect Baseline hormone
Main Etiology of Heart Failure
Maintenance dose
Maintenance OCS use, n (%)
Maintenance use — no. (%)
Major
Major adverse cardiovascular events
Major amputationsb
Major and CRNM bleeds
Major bleed
Major Bleed
Major bleeding
Major Bleeding
Major Bleeding (MB)
Major bleeding (statin use vs non-use)
Major bleeding 0 to 1
Major bleeding events*
Major cardiovascular
Major cardiovascular event
Major Cardiovascular Event*
Major cardiovascular events
Major cerebrovascular
Major clinical response
Major coronary
Major coronary disease event (Fatal/Non-fatal MI)
Major coronary event
Major CV Event
Major CVD/
Major diabetic eye disease, n (%)
Major gastro-intestinal bleeding
Major Gl Bleeding
Major Hypoglycemia
Major macrovascular events
Major or clinically relevant non-major bleed
major or clinically relevant non-major bleeding
Major secondary end pointf
Major ST depression or
Major ST depression or T-wave
Major ST depression or T-wave inversion
Major surgery
Major/CRNM bleed
Malaysia
Male
MALE
Male - no. (%)
Male (%)
Male (n - 257)
Male (n = 1171)
Male (N = 1171)
Male (n = 4,128)
Male (N = 802)
Male (N =1802)
Male (n = 4,631)
Male (n=102, 42)
Male (N=190)
Male (n=308, 306)
Male (N=3498)
Male (n=4970)
Male (n=6,183)
Male (n=6183)
Male (n=97, 40)
Male ACR definition, ^.g/mg
Male EZE/SIMVA
Male EZE/SIMVA („ = 591}
Male EZE/SIMVA (n = 591)
Male gender
male gender (%)
Male gender (%)
Male gender, n (%)
Male gender, n (%)
Male NYHA class
Male patients*
Male patients, n (%)
Male sex
Male sex— no. (%)
Male sex— no. (%) Race — no. (%)):
Male sex— no. {%)
Male sex — %
Male sex — no. (%)
Male sex — no. (%) Medical history — no./total no. (%)
Male sex — no. (%) Risk factors
Male sex — no. (%) Weight — no. (%)
Male sex — no. (%)f
Male sex — no. {%)
Male sex — no. of patients (%)
Male sex — no./total no. (%)
Male sex (%)
Male sex (%) Race or ethnic group (%)f
Male sex \ no. (%)
Male sex 一no. (%)
Male sex, %
Male sex, (%)
Male sex, n (%)
Male sex, N (%)
Male sex, n [%]
Male sex, no. (%)
Male sex, No. (%)
Male sex, No./total No. (%)
Male sex^
Male SIMVA
Male SIMVA („ = 589}
Male SIMVA (n = 589)
Male subjects (n = 3,875)
Male vs. female
Male(%)
Male(n-4970)
Male(n=1902)
Male*, n (%)
Male, %
Male, % (n)
Male, n
Male, n (%)
Male, N (%)
Male, n(%)
Male, n/N (%)
Male, no (%)
Male, n (%)
Male/female
Male/female, %
Males
Males (%)
Males (ITT) (n=1212)
Males (ITT) (n=1219)
Males (ITT) (n=1227)
Males (ITT) (n=1639)
Males (ITT) (n=1658)
Males (n=1100)
Males [n (% )]
Males, %
Males, <1.00
Males, <30
Males, >1.00
Males, >30
Males, n (%)
Malignancy at randomization
Malignancy death
Managed medically — no./total no. (%)
Management distribution
Management distribution Medical treatment
Management of event — no. (%)
MAP (mmHg)
MAR (ITT) (n=1532)
MAR imputation (Random.) (n=1613)
MAR Imputation (Random.) (n=1613)
MAR imputation (Random.) (n=1616)
MAR Imputation (Random.) (n=1616)
MAR imputation (Random.) (n=2153)
MAR Imputation (Random.) (n=2153)
Married
MASES (0-13), mean (SD)
"mass index;"
Mate
MATE!
Maternal history, n (%)
Maximal diameter stenosis
Maximum
Maximum CIMT < Median
Maximum CIMT a Med an
Mayo $10, N
Mayo <10, N
Mayo Clinic score, mean ± SD
Mayo Clinic score§
Mayo Clinic scoreb
Mayo score (0-12)
Mayo score, mean (SD)
MBEs/CRBEsb, n/N (%)
MBEs/CRBEsc,
MBEsb, n/N (%)
MBEsc, n/N (%)
MCA
MCS score
MCS score (0–100 scale)
MDG (mmol/L)
MDI
MDRD-eGFR (ml/min per 1.73 m2)
MDRD eGFR geometric mean (CV%),a,b ml/
MDRD eGFR, mL/min/1.73 m2
Mean
Mean — %
Mean — g/dl
Mean — kg
Mean — mg/dl
Mean — mg/dl Level — no. (%)
Mean — ml/min
Mean — ml/min/1.73 m^
Mean — ml/min/1.73 m2
Mean — ml/min/1.73 m2 Level — no. (%)
Mean — ml/min/1.73 m2 of body-surface area
Mean — ml/min/1.73m2
Mean — mm Hg
Mean — mm Hg Level — no. (%)
Mean — yr
Mean — yr Age group — no. (%)
Mean % change in FN BMD
Mean % predicted DLco* (SD)
Mean % predicted FVC (SD)
Mean % predicted value prebronchodilation
Mean (= SD) days since
Mean (±s.d.)
Mean (±SD) baseline score
Mean (±SD) change from
Mean (25th to75thquartile) BNP (pg/ml)
Mean (95% CI) change from 0.5 to 1.0 mg, %
Mean (95% CI) change from 0.5 to 1.0 mg, %‐points
Mean (95% CI) difference vs SAXA+DAPA+MET
Mean (median) MTX dose, mg/week
mean (s.d.)
Mean (s.d.)
Mean (s.d.) age, years
Mean (s.d.) ApoB, mg/dL
Mean (s.d.) ApoC-ll 1, mg/dL
Mean (s.d.) baseline FPG, mmol/l
Mean (s.d.) baseline HbA1C, %
Mean (s.d.) BMI, kg/m2
Mean (s.d.) calculated LDL cholesterol
Mean (s.d.) diastolic blood pressure, mm Hg
Mean (s.d.) duration of T2DM, years
Mean (s.d.) eGFR, mL/min/1.73 m2
Mean (s.d.) FPG
Mean (s.d.) free PCSK9, ng/mL
Mean (s.d.) HbAlc, %
Mean (s.d.) HbAlc, mmol/mol
Mean (s.d.) HDL cholesterol
Mean (s.d.) LDL particle number, nmol/L
Mean (s.d.) LDL particle size, nm
Mean (s.d.) measured LDL cholesterol
Mean (s.d.) metformin dose†, mg/day
Mean (s.d.) non-HDL cholesterol
Mean (s.d.) systolic blood pressure, mm Hg
Mean (s.d.) total PCSK9, ng/mL
Mean (s.d.) weight, kg
Mean (s.e.)
Mean (s.e.)t
mean (SD on loge scale) U/ml
mean (SD)
Mean (SD)
Mean (SD) % of predicted normal EEVi
Mean (SD) % of predicted normal FEV1
Mean (SD) % of predicted normal FEVi
mean (SD) % reversibility FEV1 at
Mean (SD) (years)
Mean (SD) [range]
Mean (SD) [range] duration of epilepsy, years
Mean (SD) 56.6 (9.2)
Mean (SD) age (years)
Mean (SD) age in years
Mean (SD) age,
Mean (SD) age, y
Mean (SD) age, y Race, n (%)*
Mean (SD) age, years
Mean (SD) age, yr
Mean (SD) anthropometry
Mean (SD) AQLQ
Mean (SD) Baseline
Mean (SD) baseline scores
Mean (SD) BMD in g/cm2
Mean (SD) BMI
Mean (SD) BMI (kg/m2)
Mean (SD) BMI, kg/m2
Mean (SD) body mass index, kg/m2
Mean (SD) calcium intake in mg daily
Mean (SD) CDAI*
Mean (SD) change from pre- to post-bronchodilator FEV1, L
Mean (SD) change from pre- to post-bronchodilator FEVi, mL
Mean (SD) change from pre- to post-bronchodilator FEVi, niL
Mean (SD) CRP, mg/L*
Mean (SD) DAS28-4(ESR)*
Mean (SD) disease duration, years
Mean (SD) duration of COPD, years
Mean (SD) duration of smoking, pack-years
Mean (SD) duration of smoking, pack years
Mean (SD) duration of T2DM, y
Mean (SD) E-ETDRS visual acuity letter score (Snellen equivalent)
Mean (SD) EEVi, mL
Mean (SD) eGFR, mL/min/1.73 m2
Mean (SD) ESR, mm/h*
Mean (SD) extent of exposure, days
Mean (SD) FENO, ppb
Mean (SD) FEV 1 , L
Mean (SD) FEV 1 /FVC, %
Mean (SD) FEV1 (L) post-bronchodilator
Mean (SD) FEV1 (L) pre-bronchodilator
Mean (SD) FEV1 postbronchodilator, L
Mean (SD) FEV1, L
Mean (SD) FEV1/FVC, %
Mean (SD) FEVi, mL
Mean (SD) FEVi/EVC, %
Mean (SD) FEVi/FVC, %
Mean (SD) HbA1c level, %
Mean (SD) HbA1c, %
Mean (SD) improvement from baseline to week 12 in BASDAI
Mean (SD) improvement from baseline to week 24 in BASDAI
Mean (SD) improvement from baseline to week 24 in BASDAI questions*
Mean (SD) MTX dose, mg/week
Mean (SD) nonstudy eye E-ETDRS visual acuity letter score
Mean (SD) number of albuterol per day, puff
Mean (SD) number of exacerbations*
Mean (SD) pain VAS*
Mean (SD) periostin, ng/ml
Mean (SD) PGA VAS*
Mean (SD) post-bronchodilator
Mean (SD) post-bronchodilator FEV1 percentage predicted
Mean (SD) post-bronchodilator FEV1 reversibility, %
Mean (SD) post-bronchodilator FEV1/FVC, %
Mean (SD) postbronchodilator FeV1 % predicted
Mean (SD) postbronchodilator FeV1 reversibility, %
Mean (SD) postbronchodilator FeV1/FVC, %
Mean (SD) pre-bronchodilator
Mean (SD) PtGA VAS*
Mean (SD) SDAI*
Mean (SD) swollen joint count*
Mean (SD) tender joint count*
Mean (SD) total asthma symptom scores
Mean (SD) values are presented for all variables, except medical history, race or ethnic group, and sex (n, %) and urinary albumin/creatinine ratio (median (range)). aBody mass index is the weight in kilograms divided by the square of the height in meters. bTo convert values to micromoles per liter, multiply by 88.4. Estimated using the modified equation from the Modification of Diet in Renal Disease study. dTo convert values to millimoles per liter, multiply by 0.02586. eTo convert values to millimoles per liter, multiply by 0.01129. ^To convert values to millimoles per liter, multiply by 0.6206.
Mean (SD) weight, kg
mean (SD) years Daily OCS use, n (%)
Mean (SD)% predicted normal FEV1
mean (SD), kg/m2
mean (SD), mg/kg2
mean (SD), mmHg
mean (SD), ng/mL£
Mean (SD), y
mean (SD)d
Mean (SE)
Mean (SE) 6-Year Rates per 100 Population
Mean (SE) AUC^p L
Mean (SE) AUC0-3, L
Mean (SE) trough L
Mean (SE) trough, L
Mean = SD
Mean ± s.d.
Mean ± s.d. age, years
Mean ± s.d. duration of diabetes, years
Mean ± s.d. FPG
Mean ± s.d. HbA1c
Mean ± s.d. weight, kg
mean ± SD
Mean ± sd
Mean ± SD
Mean ± SD age (y) Mean BMI category (%)
mean ± SD mg (n = 98, 99, 99)
mean ± SD unless otherwise indicated
Mean ± SE
mean ± SE) BII (LS mean ± SE)
Mean ± SD
Mean ±SD
Mean ±SD (yr)
Mean 10-year CVD risk*
Mean 24-h DBP+
Mean 24-h SBP*
Mean 6 SD
Mean 6MWD*, m (SD)
Mean A ± SD (mmHg)
Mean A ± SD, mg/dl (mmol/1)
Mean A ± SDt
Mean A ± SEM (%)
"Mean ACQ-6 score at randomization;!;"
Mean ACQ-7 scores
Mean ACRn
Mean age — yr
Mean age — yr (range)
Mean age (range) — yr
Mean age (SD)
Mean age (SD), y
Mean age (SD), years
Mean age (SD), yr
Mean age (y)
Mean age (y) (SD)
Mean age (years)
Mean age (years) (s.d.)
Mean age (years) Race
Mean age (years, SD)
Mean age (yr)
Mean age (yrs)
Mean age 士 s.d., year
Mean age ± s.d., year
Mean age ± s.d., years
Mean age, y
Mean age, y (range)
Mean age, y (SD)
Mean age, y, mean = SD
Mean age, y, median (range)
Mean age, y: (range)
Mean age, years
Mean age, years (range)
Mean age, years (SD)
Mean age, years± SD
Mean age, yrs
Mean age±SD (years)
Mean AlC, %
Mean annualized exacerbation rate
Mean AQLQ total score t
Mean arterial pressure, baseline
Mean arterial pressure, difference
Mean arterial pressure, last
Mean ASUI scored
Mean baseline (n)
mean baseline bmi
mean baseline BMI
Mean baseline EI score
Mean baseline IBDQ score (SD)§ CRP concentration, mg/L
Mean Baseline LDL-C (mmol/L)
Mean baseline nasal congestion score
Mean baseline UCDAI score
Mean BDI focal score (SD)
Mean blood eosinophil count (cells per pL)
Mean blood pressure at screening visit (mm Hg)
Mean blood pressure, mm Hg
Mean blood pressure, mmHg (s.d.j
Mean BM1 ± s.d., kg/m2
Mean BMD (= SD), g/cm2
Mean BMI
Mean BMI (kg/m2) (SD)
Mean BMI (SD)
Mean BMI (SD),
Mean BMI (SD), kg/m2
Mean BMI ± s.d., kg/m^
Mean BMI ± s.d., kg/m2
Mean BMI, kg/m2
Mean BMI, kg/m2 (s.d.)
Mean BMI, kg/m2 (SD)
Mean BMI, kg/m2 ± SD
Mean BMI±SD (kg/m2)
Mean BMII 士 s.d., kg/m2
Mean body-mass index (= SD), kg/m2
Mean body-mass index (kg/mQ
Mean body-mass index, kg/m2
Mean body-mass index, kg/m2 (SD)*
Mean body-mass index, kg/m2 (SD)*
Mean body-mass indexj
Mean body mass index (kg/m2)
Mean body mass index (kg/m2)*
Mean body mass index (SD), kg/m2
Mean body mass index, kg/m2
Mean body weight (SD), kg
Mean body weight, kg (range)
mean BP (mmHg)
Mean CDAI score
Mean CDAI score (SD)
Mean change at week 30
Mean change from baseline in ACQ overall score (SD)*
Mean change from baseline in FEV1 % predicted, % (SD)*
Mean change from baseline in the number of
Mean change from baseline, %
Mean change from baseline, %‐points
Mean change in ACQ score
Mean change in DBP from baseline, mg/dL, mean(SD)
Mean change in FEV1
Mean change in radiographic end points
Mean change in radiographic end points SHS, mean ± SD
Mean change in SBP from baseline, mmHg, mean(SD)
Mean change in SGRQ
Mean change in total UPDRS scores adjusted according to baseline UPDRS
Mean change,
Mean change, % (SE)
Mean change,% (SE)
Mean change‘s in fasting blood glucose [mg/dL (mmol/L)]
Mean COPD duration, y (SD)
Mean CRP level, mg/L (SD)
"Mean daily dose (range) — mg;i;"
Mean diastolic blood pressure (SD), mm Hg
Mean diastolic blood pressure, mm Hg
Mean diastolic BP, mmHg, mean = SD
Mean difference (95% Cl)
Mean difference = SEb
Mean disease duration, y (SD)
Mean disease duration, years
Mean DlcO ± SD
Mean dose'’
Mean dose (SD) (mg/day)
Mean dose (SD) (mg/week)
Mean doseb
Mean duration of disease, years
Mean duration of PD, yr
Mean duration of surgery ± SD, min
Mean duration offollow-up (years)*
Mean eosinophil count, per ml
Mean fecal calprotectin level, mg/g stool (SD)
Mean femoral neck T score
Mean FEV1, L (SD)
Mean FPG, mmol/L
Mean FVC ± SD
Mean Glycated Hemoglobin Reduction during Characteristic Follow-up (95% CI) percent
Mean HbA1c ± s.d., %
Mean HbA1c, %
Mean HbA1c, mmol/mol†
Mean HbAic =•= s.d., %
Mean hsCRP, mg/L (SD)
"Mean ICS (fluticasone propionate DPI or equivalent; pg per day)"
Mean ICS use at enrolment (pg)*
Mean iGlar dose ± SD (U/day)
Mean IIEF EF score Mean IIEF domain score by BMI (<25/<25 to <30/<30 kg/m2)
Mean IPSS QoL (SD)
Mean IPSS, storage Sub-Score (SD)
Mean IPSS, voiding SubScore (SD)
Mean Lipid Difference (mg/dL) HDL-C
Mean lipid values, mg/dL
Mean Lixi dose ± SD (lg/day)
Mean lumbar spine T score
Mean LVEF
Mean Mayo score (SD)
Mean mMRC grade, units (SD)
Mean MMSE score
Mean No. agents (SD) Other medications
Mean number of antihypertensive medication at last visit ‡
Mean number of antihypertensive medications at 1 year *
Mean number of CAEs in past 12 months (number per patient)] |
Mean number of clinically significant asthma exacerbations†
Mean number of combined visits/hospitalizations†
Mean number of exacerbations (per patient-year [95% CI])
Mean number of exacerbations in previous 12 months (SD)
Mean number of exacerbations in previous y (SD)
Mean number of puffs per day
Mean of JSW (mm)
Mean of maximum CIMT, mean (SD), mm
Mean of mean CIMT, mean (SD), mm
Mean or n
Mean percentage change from baseline to final visit
Mean PGA score ±SD
Mean platelet volume, fL
Mean postbronchodilatora FEV1, % predicted (SD)
Mean prebronchodilation (L)
Mean prebronchodilator FEV1 (SD), % predicted
Mean preoperative ABPI of the index
Mean proportion (%)
Mean pulmonary artery pressure, mm Hg
Mean pulse pressure, mmHg (s.d.)“
Mean Qmax score by BMI (<25/ <25 to <30/ <30 kg/m2)
Mean reversibility (%)
Mean score
Mean score (min, max range)
Mean score on DAS28-3(CRP)^
Mean score on HAQ-DI§
Mean SD 24-h ASBP, mm Hg
Mean SD FPG, mg/dL
Mean SD HDL-C, mg/dL
Mean SD LDL-C, mg/dL
Mean SD MSSBP, mm Hg
Mean SELENA-SLEDAI score ±SD
Mean serum cholesterol, mg/dL
Mean serum creatinine, mg/dL
Mean serum glucose, mg/dL, mean = SD
Mean serum potassium, mg/dL
Mean SGRQ total score
Mean SGRQ total score (SD)
Mean sitting DBP (mmHg)
mean sitting diastolic blood pressure
Mean sitting SBP (mmHg)
mean sitting systolic blood pressure
Mean SLICC damage index score ±SD
Mean stent diameter per lesion, mm (SD)†
Mean stents per lesion (SD)‡
Mean systolic blood pressure (SD), mm Hg
Mean systolic blood pressure, mm Hg
Mean systolic blood pressure, mm Hg (SD)
Mean systolic BP, mmHg, mean = SD
Mean systolic pressure gradient
Mean Systolic Pressure Gradient
Mean time since AS diagnosis, years, mean ± SD
Mean time since asthma
Mean time since diagnosis (years)
Mean time since diagnosis, y
Mean time to first oral dose postsurgeryh, hr
Mean time to first subcutaneous injectiong,h in relation to surgery, hr
Mean total IPSS (SD)
Mean total IPSS Mean IPSS by BMI (<25/<25 to <30/<30 kg/m2)
Mean total serum IgE (SD), IU/ml
Mean total serum PSA
Mean total stent length per lesion, mm (SD)‡
Mean treatment exposure, wk
Mean UCSD-SOBQ score* (SD)
Mean wall thickness (cm)
Mean weight (SD), kg
Mean weight, kg (SD)
Mean weight, kg, mean = SD
Mean yearly decline
Mean years since menopause
Mean ± SD
Mean(SE)
Mean, mg/dL
Mean, mL (SD)
Mean, SD
mean_delta
Mean土SD (N)
Mean± SD
Mean±s.d. BMI,kg/m2
Mean±SD
Mean±SD (N)
Mean±SD 24-h ADBP, mm Hg
Mean±SD BMI, kg/m2
Mean±SD eGFR, mL/min/1.73 m2
Mean±SD fasting insulin, uU/mL
Mean±SD MSDBP, mm Hg
Mean±SD triglycerides, mg/dL
Mean±SD waist circumference, cm
Mean±SD, n
Mean±SD, n (%)
Measure
MEASURE
Measured at clinic visit with automated device§
Measured at clinic visit with usual device
Measured at home with automated device
Measurements
Measures
Measures (%)
Measures (mmol/l)
Measures of lung function
MEDAL
MedDRA SMQ
Medial-Distal-Diag
Median
Median — ml/min
Median — ml/min/1.73 m2
Median — vr
Median — yr
Median (25th, 75th percentile)
Median (95% CI) time to weekly ISS MID response up to week 12 (wk)f
Median (days)
Median (interquartile range)
Median (interquartile range) —yr
Median (IQ range)
Median (IQR)
Median (IQR) — yr
Median (IQR) admission data
Median (IQR) age, years
Median (IQR) Change from baseline to week 100 in PsA-modified total SHS score
Median (IQR) cholesterol,
Median (IQR) Mean6SDchange from baseline to week 100 by weight group and MTX use: Weight
median (IQR), h
median (min, max)
Median (min, max)
Median (minimum–maximum) focal seizure frequency/28 days at baseline
Median (Q1–Q3)
Median (Q1 :Q3)
Median (Q1, Q3)
Median (Q1,Q3)
Median (Q1:Q3) duration of diabetes, years
Median (Q1:Q3) duration of insulin use, years
Median (Q1:Q3) Lp(a), mg/dL
Median (Q1:Q3) TG-rich lipoprotein cholesterol
Median (Q1:Q3) TGs
Median (Q1:Q3) total daily insulin dose5
Median (range)
Median (range) duration of asthma (y)
Median (range) duration of asthma (years)
Median (range) duration of hospital stayi, d
Median (range) total IgE level (IUml~’)4
Median (range) treatment duration, d
median (SD), mg/mmol
Median age — yr
Median age — yr§
Median age (25%, 75%), y
"Median age (IQR; years)"
Median Age [interquartile range] — yr
Median age, y (range)
Median age, years (IQR)
Median albumin-to-creatinine ratio (interquartile range)
median albumin/creatinine ratio (g/mg)
Median blood eosinophil count (cells per pL)t
Median blood eosinophil count, cells per pLa
Median BNP (IQR) – pg/ml
Median body mass index, kg/m2 (range)
Median body mass index, kg/m2(IQR)
Median body weight — kg
Median body weight (kg)
Median C-reactive protein — mg/dl^
Median C-reactive protein — mg/liter
Median cardiac troponin T (IQR) — pg/ml
Median cardiac troponin T (IQR) 一pg/ml
Median change, %
Median CrCl — ml/min
Median Crohn's disease duration, y (range)
Median daily dose - IU™
Median delay (h)§
Median disease duration — yr
Median dose (range)'’
Median dose (range)b
Median duration of CHF — mo
Median duration of diabetes (yr)
Median duration of study-drug administration
Median duration of study-drug administration (IQR) — days
Median duration of symptoms (range), yr
Median duration oftype 2 diabetes (IQR) — yr
Median eGFR (interquartile range)
Median fasting insulin (IQR) —pU per milliliter
Median fecal calprotectin — mg/kg GI areas involved — no. (%)
Median FeNO (ppb)f
Median FeNO, ppba
Median infusions — no. (range)
median m/kg2 (IQR)
Median N-terminal proBNP (IQR) — pg/ml
Median NT-proBNP (IQR) – pg/ml
Median of JSW
"Median PASI score {range)'i""i'"
median seconds
Median serum periostin (ng/mL)t
Median serum periostin, ng/mLa
Median time delay (interquartile range) — min
Median time from index acute coronary syndrome to randomization (IQR) — mo
Median time in therapeutic range for warfarin recipients, %
Median time since diagnosis* (range), yr
Median time to event (weeks)
Median time to first exacerbation (months [95% CI])
Median total cholesterol, mmol/L
Median triglyceride (mg/dl)
Median weight, kg (IQR)
Median, IQR
median, IQR)
Median, mg/dL
Median, mL
Median, range
Median, y (range)
Median§
Medians (IQR)
Medical and lifestyle history
Medical conditions, No. (%)
Medical historv
Medical history
Medical History
Medical history— no. (%)
Medical history — %
Medical history — no. (%)
Medical history — no./total no. ( %)
Medical history — no./total no. (%)
Medical history (%)
Medical history and risk factors
Medical history and risk factors (%)
Medical history and risk factors, No./total (%)*
Medical history at randomization — no. (%)
Medical history before index acute coronary syndrome — no. {%)
Medical history Duration of heart failure (years) Primary cause of heart failure
Medical history of CV disease or heart failure, n (%)
Medical history of diabetic retinopathy§
Medical history of hypertension
Medical history, n (% of patients)
Medical history, n (%)
Medical History, n (%)
Medical history, no. (%)
Medical history, No. (%)
Medical history, n (%)
Medical history. No. (%)
Medical History: Cancer
Medical management only
Medical management only—no. {%)
Medical therapies
Medical therapy
Medical Therapy
Medical Therapy (n = 472)
Medical Therapy (n=204)
Medical Therapy (n=214)
Medical Therapy (n=54)
Medical Therapy Alone
Medical therapy before admission
Medical therapy before randomization — no./total no. (%)
Medical therapy during index hospitalization — %
Medical therapy only
Medical Therapy Only (N = 472)
Medical treatment
Medical treatment, n (%)
Medically important infectionsa
Medication
Medication — no. (%)
Medication 6418 (57.0)
Medication adherence
Medication Adherence
Medication after enrolment
Medication at enrollment — no. (%)
Medication at entry (%)
Medication at randomization
Medication at randomization, %
Medication at randomization, n (%)
Medication at time of randomization
Medication at time of randomization — no. (%)
Medication continued into double-blind treatment period
Medication in use at the baseline
Medication prior to admission, (%)
Medication taken alone or in combination
Medication use
Medication use— no. (%)^|
Medication use — no. (%)
Medication use — no. {%)
Medication use (%)
Medication use (%) Aspirin
Medication use at baseline - n (%)
Medication use at baseline — no. (%)
Medication use at baseline, n (%)
Medication use at entry (%)
Medication use before enrollment, No. (%)
Medication use, n (%)
Medication use, No./total No. (%)
Medication useb
Medication within 7 days before enrolment
medication, n (%)
Medication, n (%)
Medications
Medications — no. (%)
Medications — no. {%)**
Medications (%)
Medications Antihypertensive drugs
Medications at baseline, n (%)
Medications at baselinet
Medications at coronary angiography
Medications at discharge
Medications at discharge or day 7, if earlier (%)
Medications at enrollment, n (%):
Medications at enrolment
Medications at randomization
Medications at study entry — no./total no. (%)
Medications at the time of randomization — no. (%)
Medications at time of randomization — no. (%)
Medications at timing of randomization, n (%)
Medications before admission
Medications during hospitalization or at discharge
Medications for Crohn's disease taken at baseline — no. (%)
Medications in the hospital after randomization — no. (%)
Medications in use at baseline — no. (%)
Medications in use at baseline — no./total no. (%)
Medications in use at baseline, n (%)
Medications on admission, %
Medications taken at time of randomization Statins
Medications through day 7
Medications*
medications, n
Medications, n (% of patients)
Medications, n (%)
Medications, no. (%)
Medications. no. (%)
Medium
Medium- or low-intensity statin
Medium Normal (n=519)
Meglitinide
Meglitinides (glinides)
Meloxicam
Memantine use at baseline, No. (%)
Men
Men (%)
Men (n [%])
Men (n 二4269)
Men (n = 362)
Men (n, %)
Men (n=13 728)
Men (n=1493)
Men (N=2112)
Men (N=2118)
Men (n=363 vs 176)
Men (n=4269), n/N (%)
Men (N=723)
Men (N=7891)
Men (N=8723)
Men With ED (N = 716) 62.6 ± 7.9
Men Without ED (N = 340) 60.9 ± 7.7
Men, %
Men, <100 cm
Men, >100 cm
Men, n (%)
Men, n (%)*
Men, No. (%)
Men, Total (n 二2476)
Men, Total (n=2476)
Men, n (%)
Men/women
Men: <40 mg/dL (<1.04 mmol/L)
Men: QVAI49-SFC
Men:women (%)
Menopausal status and hormone therapy use
Menopausal status and hormone therapy use Premenopausal
Menopausal status and use of HRT(%)y
Menopausal status and use of HT
Menopause and HRT
Menopause and HT
MENSA
MenT
Mental
Mental activities UPDRS subscore (baseline), mean (SD)
Mental component
Mental component score (MCS)
Mental health
Mental Status
Mental status (baseline SPMSQ scores), n (%)
MEPO (N = 23)
MEPO (N = 331)
MEPO (N = 46)
MEPO (N = 54)
Mepolizumab
Mepolizumab 100 mg (n=274)
Mepolizumab Group
Mepolizumab, 100 mg (N = 223)
Mepolizumab, 100 mg (N = 233)
Mepolizumab, 100 mg (N = 417)
Mepolizumab, 300 mg (N = 225)
mer’s Disease Assessment
Mercaptopurine
Merformin
Mesalamine use, n (%)a
Mesothelin (ng/ml)
Mestizos
MET %△ (SE)
MET (N = 334)
MET (n =237)
"Met atopy and IgE 30-700 kU/L criteria"" (n= 824)"
Met criterion at BL (n [%])
Met criterion at BLt (n [%])
Met criterion at final (n [%])
Met criterion at finalt
MET%△(SE)
MET/SU/TZD
MET/TZD
Metabolic syndrome
Metabolic Syndrome
Metabolic syndrome — no. (%)!
Metabolic syndrome — no. (%)^
Metabolic syndrome — no. (%)5
Metabolic syndrome (%)
Metabolic syndrome (%)b
Metabolic syndrome (>3 of 5 characteristics)
Metabolic syndrome (n = 203)
Metabolic Syndrome (n = 2636)
Metabolic syndrome characteristics, n (%)
Metabolic syndrome Visit 2 low-density lipoprotein cholesterol strata
Metabolic syndrome w/o T2DM
Metabolic syndrome*
Metabolic syndrome* n=813
Metabolic syndrome,
Metabolic syndrome, n (%)
Metabolic syndrome, n/N (%)*
Metabolic syndrome,! n (%)
Metabolic syndrome1*
Metabolic syndrome11 Baseline lipids, mg/dL
Metabolic syndromeb
Metabolism and nutrition
Metabolizer phenotype (%)§
Metastatic
Metastatic disease
Metformin
Metformin-dose
Metformin — no. (%)
Metformin (HDM)
Metformin (n = 1454)
Metformin (N = 1454)
Metformin (n =268)
Metformin (n 5 328)
Metformin ? pioglitazone
Metformin ? SU
Metformin + SU
Metformin +SU+TZD
Metformin 一 no. (%)
Metformin ± other oral anti-DM drugs
Metformin • pioglitazone
Metformin alone
Metformin dose
Metformin dose, mg
Metformin monotherapy
Metformin Monotherapy
Metformin only
Metformin open-label*
Metformin Use
Metformin use, n (%)
Metformin, n (%)
Metformin: no/yes, %
Metformin+sulphonylureas
Metforminmonotherapy
Method of assessing ejection fraction
Method of identification ofstenosis (%)
Method of insulin administration
Method used to diagnose the incident pulmonary embolism, No. (%)
Methotrexate
Methotrexate alone^
Methotrexate dose at baseline
Methotrexate dose on day 1 — mg per wl<55
Methotrexate dose||, mg
Methotrexate plus other csDMARDfl
Methotrexate treatment!
Methotrexate use
Methotrexate use at baseline
Methotrexate use at randomisation
Methotrexate use at randomization
Methotrexate use at randomization, n (%)
Methotrexate User
Methylxanthines
Metoprolol (n=22 929)
METREO Modified Intention-to-Treat Population§
METREX Modified Intention-to-Treat Population with an Eosinophilic Phenotypey
METREX Overall Modified Intention-to-Treat Population?:
MetS
MetS Pbo (N = 107) vs EvoMab (N = 182)
MetS w/o T2DM
MetS, n (%)
MetSyn
MetSyn with LDL >156.9 mg/dL
Mexican
Mexico
Mexico, Central/South America
MFNS (n = 104)
MFNS (n = 164)
MFNS (n = 494)
MFNS (n = 65)
mg daily)
mg/day
mg/dl
mg/dL
mg/dL FPG (mmol/L)
mg/dL, mean ± SD
mg/g
mg/mmol
MH + CRPnorr
MHi
MHIS score
MI
MI—No. (%)
MI (fatal/nonfatal)
MI <3 months*
MI >3 months*
MI or CAD
MI type unknown (%)
MI*
MI, n (%)
Miami K antagonist received
Micral test result
Micro- or macroalbuminuria, n (%)§
Micro- or macroalbuminuria, No. (%)
Micro-/macro-albuminuria, CKD and/or retinopathy
Micro-albuminuria
Micro/macroaibuminuria
Micro/macroalbuminuria
Micro/Macroalbuminuria
Microalbuminuria
Microalbuminuria — no. (%)
Microalbuminuria — no./total no. (%)
Microalbuminuria (UACR 30–300)
Microalbuminuria at baseline (29% of patients treated)
Microalbuminuria or macroalbuminuria
Microalbuminuria or macroalbuminuria§
Microalbuminuria or proteinuria
Microalbuminuria, mg/g Cr
Microalbuminuria, n (%)
Microvascular complications, n (%)’
Microvascular complicationsb
Microvascular disease history
Microvascular disease history, n (%)
Microvascular disease history, No. (%)
Microvascular disease*
Microvascular disease, n (%)
Microvascular eye diseased
Microvascular outcome
Micturitions/24h
MIDAS score
middle
Middle East, Africa, or Asia-Pacific
"Middle Tertile (Range, 1.6-2.0 mg/dl; Mean ± SD, 1.8 ± 0.1 mg/dl)"
Middle tertile: > 0.23 to b 0.37
Middle TG tertile
Middle third
Migraine — no. (%)$
Migraine duration (h)
Migraine occurrence (days/month)
Migraine severity score
Migraine with aura
Migraine With Aura
Migraine without aura
Migraine Without Aura
Mild
Mild-to-moderate (IPSS < 20)
Mild (<8)
Mild (>50 to <80)
Mild (3-6)
Mild (60–89 mL·min−1·1.73 m−2), n (%)
Mild (FEV, >50% predicted)
Mild (GOLD 1)
Mild (IIEF-EF 17-25)
Mild (IPSS <8)
Mild (N=187)
Mild (N1 = 83)1
Mild decrease (60-<90 mL/min per 1.73 m2)
Mild Decrease In GFR (60-89 mL/mln per 1.73 m^)
"Mild dysfunction (crcl >50-95 ml/min; n=8208 [58.3%])"
Mild ED
Mild ED    Severe ED
Mild impairment
Mild impairment      (eGFR 60-89)
Mild impairment (£60 to
Mild impairment (60 to <90)
Mild impairment (60 to590mL/min)
Mild impairment (eGFR 60-89 mL/min/m^)
Mild impairment (eGFR 60-89)
Mild impairment (eGFR 60–89), N (%)
Mild impairment, <60 to <90
Mild or moderate COPD
"Mild or no dysfunction (crcl >50 ml/ min; n=11 331; [81.5%])"
Mild Reduction in eGFR
Mild TEAEs
Mild thrombocytopenia (<100x 109/L)
Mild to moderate
Mild to moderate renal impairment*
Mild/moderate (IPSS < 20)
Mildly impaired
Mildly Impaired
MildlyDecreased Baseline GFR (60-89 mL/min/1.73m2)
min-’
Min-Max
Min-Max Age
Min–Max
min per 1.73 m2
Min, Max
Mineralcorticoid receptor antagonist
Mineralocorticoid receptor antagonist
Mineralocorticoid receptor antagonist N(%)
Mineralocorticoid receptor antagonists
Mini-Mental State Examination
Mini-Mental State Examination, mean (SD)d
Minimum
Minimum-maximum
Minimum—maxim um
Minimum—maximum
Minimum stent diameter
Minimum, maximum
Minimum/maximum
Minimum:maximum
Minor
Minor Bleed
Minor bleeding
Minor ischaemic stroke
Minor surgery
Minor/Major
Minority
Minutes from pre-PCI angiography to post-PCI angiography, median (IQR)
Minutes from prehospital ECG to PCI, median (IQR)
Minutes from symptom onset to prehospital ECG, median (IQR)
Missing
Missing—number/N (%)
Missing data
Missing data — no./total no. (%)
Missing data Initial diagnosis — no.
Missing ED duration (y)
Missing Hb at Yr 1
Missing*
Missing, n (%)a
Mitral insufficiency
Mitral insufficiency, n (%)
Mitral regurgitation, (%)
Mitral regurgitation, n (%)
Mitral valve disease (n=20 983)
mITT Population
mITT Population (n = 1856)
Mixed
Mixed (ITT) (n=329)
Mixed (ITT) (n=331)
Mixed (ITT) (n=355)
Mixed (ITT) (n=363)
Mixed (ITT) (n=454)
Mixed (ITT) (n=464)
Mixed (n=215)
Mixed chronic bronchitis and emphysema
Mixed Hispanic
mL
Ml
Ml    C
Ml with ST-segment elevation
Ml without ST-segment elevation!
mL)
mm Hg
MMF (n = 62)
MMF (n=22)
MMF (n=26)
MMF (n=75)
mmol/l
mmol/L
mmol/L [n]
mmol/L)
mmol/mol
MMP-3 (ng/mL)
MMP-3 (ng/mL)*
MMP-9, median (IQR), gg/L
mMRC at baseline
mMRC dyspnea scale score:t:t
mMRC dyspnea scale, n (%)
mMRC Dyspnea Scale, n (%)
mMRC grade
mMRC grade, n (%)
MMRM estimates, LS mean (SE), [95% CI]
MMSE (points)
MMSE <23
"MMSE = Mini-Mental State Examination; ADAS—cog = Alzhei-"
MMSE >28
MMSE 12-20
MMSE 12-26
MMSE 21-26
MMSE 24-27
MMSE score
MMSE score*
MN-naïve population
MN population
MN population, n
mNAPSI
mNAPSI, mean (SD)
mNAPSI, mean [SD]d
Mod/Sev Exacerbation Rate
Mod/Sev Exacerbation Rates
Model , n
Model 1
Model 1+
Model 2
Model 2t
Model 3§
Moderate
Moderate- dose statin
Moderate-dose statin
Moderate-intensity statin
Moderate-intensity statin use
Moderate-to-
Moderate-to-severe COPD exacerbation
Moderate    Severe (n = 408)    (n = 168)
Moderate    Severe (n = 452)    (n = 160)
Moderate    Severe (n = 453)    (n = 160)
Moderate    Severe (n = 463)    (n = 136)
Moderate (> 10 and <22)
Moderate (>11 and <26)
Moderate (>30 to <50)
Moderate (>5%. <10%)
Moderate (1 risk factor)
Moderate (25%. <10%)
Moderate (30–59 mL·min−1·1.73 m−2), n (%)
Moderate (30% <FEV, <50% predicted)
Moderate (7-16)
Moderate (8-19)
Moderate (8 < IPSS <20)
Moderate (GOLD 2)
Moderate (IIEF-EF 11-16)
Moderate (IIEF-EF 11-16), n (%)
Moderate (IPSS <20) (n=393)
Moderate (N=311)
Moderate (N1 = 187)
Moderate (N1 = 36)
Moderate (S5%. <10%)
Moderate chronic kidney disease
Moderate CKD
Moderate CKD at randomization
Moderate COPD
Moderate COPDb [N Z 207]
Moderate CORD*: QVA149-SFC
Moderate decrease (30-<60 mLYmin per 1.73 m2)
Moderate disease
Moderate disease activity: >3.2 to <5.1, n (%)
"Moderate dysfunction (crcl 30-50 ml/min; n=2740 [19.5%])"
Moderate impairment
Moderate impairment (30 to <60)
Moderate impairment (30 to560mL/min)
Moderate impairment (eGFR 30-59 mL/min/m^)
Moderate impairment (eGFR 30-59)
Moderate impairment (eGFR 30–59), N (%)
Moderate impairment, <30 to <60
Moderate n Z 250
Moderate or less airflow limitation
Moderate or severe COPD exacerbations
Moderate or Severe Decrease in GFR (<60 mL/min/1.73 m2)
Moderate or Severe Decrease In GFR {<60 mL/mln per 1.73 m^)
Moderate or severe exacerbations in the previous year (range)
Moderate or severe impairment
Moderate or severe renal disease, n (%)
Moderate or severe renal disease,b n (%)
Moderate renal impairment
Moderate renal impairment, n (%)*
Moderate risk
Moderate risk (>10-14)
Moderate risk (4-6)
Moderate severity
Moderate TEAEs
Moderate thrombocytopenia (<50X109/L)
Moderate TRS: 3-4 (n = 3,343)
Moderate, GOLD 2
Moderate, n (%)a
Moderate/low
Moderate/severe exacerbation
"Moderate/severe exacerbations, ITT population; n (%)"
"Moderate/severe exacerbations, patient subgroups; n (%)"
Moderate/Severe Reduction in eGFR
Moderate’
Moderately high risk
Moderately high risk without atherosclerotic vascular disease*
Moderately impaired
Moderately Impaired
Moderatex
Moderatey
Moderatez
Modi fied LA Grade*
Modified ACC-AHA lesion class B2 or C
Modified ACC or AHA lesion class B2 or C
Modified ACC/AHA lesion class B2 or CJ
Modified ACC/AHA Lesion Class B2/C
Modified Hachinski ischemia scale, mean (SD)c
Modified HAS-BLED
Modified HAS-BLED $3
Modified HAS-BLED <3
Modified HAS-BLED >3
Modified HAS-BLED score, mean±SD
Modified Rankin scale — no. (%)|
Modified Rankin scale at screening, 0-2
Modified Rankin Scale score
Modified Rankin score
Modified Rankin Score
Modified SE-ADL scale
Modified total Sharp score
Modified total Sharp score**
ModMy al randcnxzaton
Monitoring group (n=435)
Monitoring Treatment
Monoamine oxidase B inhibitors
Monocytes, 103/nl
Monotherapy
Monotherapy10
Monteiukast
Monteiukast (n = 929)
Monteiukast vs placebo
Montelukast (n = 101)
Month 1
Month 12
Month 12    Subgroup X Treatment Interaction p-value
Month 18
Month 24
Month 24    Subgroup X Treatment Interaction p-value
Month 25
Month 3
Month 6
Month12
Month18
Monthly
months (log-transformed)
Months from MI—median (IQR)
Months from qualifying stroke* (%)
Months since first RA symptom, mean (SD)f
Months since RA was first diagnosed, mean (SD)
More severe
More severe^
More than 2 lesions per vessel
More than 2 vessels stented
Morning
Morning peak expiratory flow — liters/min
Morning stiffness duration, min
Morning stiffness severity, 0-10 scale
Morphine use for index event/PCI
Morphometric vertebral
mortality
Mortality
Mortality outcomes
Most common AEs in any group
Most common AEs‡
Most common concomitant AEDs,d n(%)
Most frequent AEsa
Most frequent GI disorders
Most frequent infections
Most frequent non-infectious TEAEsb
Most frequent serious TEAEs
Mostly dissatisfied
Mostly satisfied
Motor
Motor subscale (range, 0-108)
Motor UPDRS subscore (baseline), mean (SD)
Motor weakness
Mouth ulceration
MPO (ng/ml)
MRA
MRA (spironolactone or eplerenone)
MRA at baseline
MRA at Baseline
MRA Regimen (n - 802)
MRA Use
MRA, (%)
MRAs
MRF
MRF subjects
MRI Substudy (n=1014)
MS <6, n [%]
MS 6-8, n [%]
MS 9-12, n [%]
Ms&ng
MS, mean [SD]
mSASSS, mean (SD)
msDBP
MSDBP
MSDBP (mm Hg)
MSDBP ± SD, mmHg
msDBP, mm Hg
MSDBP, mm Hga
MSDBP, mmHg (SD)
MSFC timed 25-foot walk test, median seconds
MSFC timed 25-foot walk test.
msSBP
MSSBP
MSSBP (mm Hg)
MSSBP <180 mmHg
MSSBP <180mmHg
MSSBP >180 mmHg
MSSBP >180mmHg
MSSBP ± SD, mmHg
msSBP, mm Hg
MSSBP, mm Hga
MSSBP, mmHg (SD)
MSSBP/MSDBP
mTSS
mTSS (0-448)
mTSS at
mTSS at baseline Observed case
mTSS CfB
mTSS CFB mean±SD
mTSS units
mTSS, mean (SD)
mTSS, median (min, max)
MTX
MTX-IR
MTX (mean dose: 14.75 mg/wk)
MTX (n)
MTX (n=116)
MTX £10 mg/week
MTX + non-MTX
MTX + other csDMARDs
MTX + other csOMARDs
MTX + otheTcsDMARDs
MTX <15 mg/week
MTX ≤10 mg/week
MTX ≥15 mg/week
MTX >10–15 mg/week
MTX >10 and £15 mg/week
MTX >10 and SI 5 mg/week
MTX >15 mg/week
MTX at baseline
MTX at baseline, n (%)
MTX average weekly dose, mg/week, mean (SD)
MTX dose > 15 mg/week, %
MTX Exposure (mg/week)
MTX IR
MTX n = 167
MTX n = 197
MTX n = 200
MTX naive or free
MTX only
MTX plus infliximab
MTX plus placebo
MTX SIO mg/week
MTX use at baseline
MTX use at randomization, n (%)
Mucocutaneous
Mucolytic agent
Mucolytics
Mucosal healingc n/n (%)
Mucosal healingf
Multi-racial
Multi-Racial
Multi-vessel coronary artery disease
Multi vessel (or left main)
Multiple
Multiple (>2) CHD risk factors that confer a 10-year risk of CHD >20%
Multiple (2+) CHD risk
Multiple diagnoses
Multiple Risk Factors
Multiple TNFi and other bDMARDs§
Multiple TNFi*
Multiracial
Multiracial or other
Multiracial, n(%)
Multivariable
Multivariable Adjusted HR (95% CI)
Multivariable adjusted model HR (95% CI)
Multivariable OR (95% CI), p Value*
Multivariate logistic modelb
Multivessel (two vessel, three vessel, or left main)
Multivessel CAD (%)
Multivessel CAD, n (%)
Multivessel coronary-artery bypass grafting
Multivessel coronary artery disease
Multivessel coronary artery disease — no./total no. (%)
Multivessel disease
Multivessel Disease
Multivessel disease — no. (%)
Multivessel disease 一no. (%)
Multivessel disease, n (%)
Multivessel disease, no. (%)
Multivessel intervention, n (%)
Multivessel PCI
Multivessel stenting
Multivitamin use
Multivitamin use (current)
Multivitamin use Yes
Multivitamins
Muscle spasms
Musculoskeletal
MVD (n - 12,558)
Myalgia
Mycophenolate (any derivative)
Mycophenolate mofetil
Myocardiai infarction
Myocardial infarction
Myocardial Infarction
Myocardial infarction — no. (%)
Myocardial infarction (%)
Myocardial Infarction at Presentation (N=3576)
Myocardial infarction before index ACS — no. (%)
Myocardial infarction N(%)
Myocardial infarction or angina
Myocardial infarction within the previous 5 yr
Myocardial infarction without ST-segment elevation — no. (%)
Myocardial infarction, (%)
Myocardial infarction, n (%)
Myocardial infarction/CABG/PCI
Myocardial infarction/CABG/PCI <2 years
Myocardial infarction:
Myocardial infarction§
Myocardial ischaemia
Myoclonic
Myopathy
Myopathyt
N
n-3-PUFA (N=758)
n-3 allocation
n-3 fatty acids
N-3 Fatty Acids - Placebo LSM (95% Cl)
n-3 Fatty Acids (n=539)
N-3 Fatty Acids Slope LSM ± SE (mm/year)
N-3 Fatty Acit
n-3 PUFA
n-3 PUFA (n=3494)
n-3 PUFA Events/patients (%)
N-terminal pro-BNP — pg/ml§
N-terminal pro-brain natriuretic peptide, pg/mL
N    Event (rate)
n (% of patients)
n (%) Blood pressure - mean (sd) mm Hg
N (%) Liraglutide 1 placebo
n (%) Patients with risk faetors for CV disease aged >60
n (%) responders
N (%) unless otherwise specified
n (3yr KM Event Rate, %)
n (indacaterol 150 ug/ indacaterol 300 ug/placebo)
N (IQR)
n (lesions)
n (stented lesions)
n = 218t
n = 244t
N America
N analysed
N events (%)
N events/ N subjects
N events/N at risk
n nt
N o
n observed
N participants
n t%)
n.a.
n/a
N/A
n/N
n/N (%)
n/N 138/1711
n/N 139/1716
n/N (%)
n/N(%/yr)
n/PYR
N/R
N+V (n = 177)
N=6413 Lesions
N=6594 Lesions
N1/N2
N50 yrs
Na
"NA"
Na (mmol/L)
NACE (primary endpoint)
Nadroparin
Nadroparin (n = 244)
Nail involvement, %
naire can range from 0 to 3 for the Alternative Disability portion and from 0 to 100 for the Pain portion. Scores for the Medical Outcomes
Naive
Naive (n = 339)
Naive (n = 639)
Naive (n = 696)
Naive (n = 743)
Naive (no treatment for current flare)
Naive to antihyperglycemic agent therapy
Naive: no
Naive: yes
NAP
Naproxen
NAPSI score (0-8) of target fingernail
NAPSIt
Nasal polyposis or chronic rhinosinusitis — no. {%)
Nasal polyps
Nasal polyps at baseline: Yes
Nasal polyps, n (%)
Nasopharyngitis
Natalizumab (N = 724)f
Nateglinide (N=4645)
Nateglinide and repaglinide
Nateglinide n/N
Nationality
Native American
Native American or Alaska Native
Native American or Alaskan Native
Native American/Alaskan
Native coronary
Native Coronary
Native coronary-artery lesions
Native Hawaiian or
Native Hawaiian or other Pacific
Native Hawaiian or Other Pacific
Native Hawaiian or other Pacific islander
Native Hawaiian or other Pacific Islander
Native Hawaiian or Other Pacific Islander
Native Hawaiian/ Pacific Islander
Native Hawaiian/Other
Native Hawaiian/Pacific Islander
Native Latin
Nausea
Nausea and/or vomiting adverse events
NBP
nc
NC
NC group ( n = 534)
NCEP ATP-III metabolic syndrome features, n (%)
NCEP ATP III risk factors
NCEP risk category at study entry, n (%)
NCT00000476
NCT00000542
NCT00000556
NCT00000620
NCT00038961
NCT00043784
NCT00059306
NCT00063687
NCT00071331
NCT00077792
NCT00089791
NCT00090103
NCT00092625
NCT00093158
NCT00093899
NCT00099268
NCT00105027
NCT00120289
NCT00134160
NCT00139386
NCT00141960
NCT00143221
NCT00144911
NCT00168792
NCT00170950
NCT00174785
NCT00174915
NCT00174993
NCT00185159
NCT00216619
NCT00222573
NCT00225589
NCT00250445
NCT00255164
NCT00259376
NCT00303459
NCT00321737
NCT00338260
NCT00350168
NCT00359905
NCT00365170
NCT00368979
NCT00377637
NCT00397657
NCT00398931
NCT00403910
NCT00430677
NCT00432796
NCT00433966
NCT00440050
NCT00441350
NCT00454662
NCT00454896
NCT00464269
NCT00475852
NCT00527943
NCT00570739
NCT00596752
NCT00621140
NCT00627016
NCT00679380
NCT00734630
NCT00740623
NCT00783237
NCT00790907
NCT00818883
NCT00862251
NCT00885352
NCT00919711
NCT00986050
NCT00993109
NCT01059136
NCT01392573
NCT01444430
NCT01472185
NCT01474369
NCT01475721
NCT01508936
NCT01523301
NCT01720446
NCT01869491
NCT02738632
NCT03021343
ND
ND not due to swelling or ICH
NE
Nebivolol (N = 258)
Necessitating hospitalization in previous year — no. (%)
Necrosis, n (%)a
Necrotic core
Necrotic core, mm^
Need for 30 ng Edoxaban Dose at
Need for urgent coronary-artery bypass grafting
Negative
Negative (<0.5), n (%)
Negative cTnl (n = 1,550)
Negative for Helicobacter pylori — no./total no. (%)
Neither
Neither ACE-I nor ARB Use
Neither ACE inhibitor nor ARB
Neither corticosteroid nor immunosuppressant
Neither CS nor IMM
Neither deep-vein thrombosis nor pulmonary embolism^
Neither deep-vein thrombosis nor pulmonary embolism§
Neither glucocorticoids nor immunosuppressive agents
Neither ICS nor LABA
Neither n = 1,044
Neither Pbo + statin    EZE + statin
Neither PE nor DVT
Neither T2DM nor MetS
Neither UH or LMW heparin
Neither unfractionated heparin nor low-molecular-weight heparin
neohroDathv. and all-cause mortalitv
Neoplasia
Neoplasia, n (%)
Nephropathy
NERD
Nesiritide (N = 3496)
Nesiritide, %z
Net clinical benefit*
Net clinical benefit: CV death, MI, stroke, GUSTO moderate/severe bleeding
Net clinical benefit: on-treatment VTE or major bleeding
Net Composite
Net EP 1
Net EP 2
Net EP 3
Network
Neuraxial alonee
Neuraxial anaesthesia
Neurocognitive disorders
Neurologicai events
Neuropathy
Neuropathy — no. (%)
Neuropilin (ng/ml)
Neutropenia
Neutrophils, 103/nl
Never
Never been on a VKA
Never Been on a VKA
Never drink
Never NSAID
never or past
Never smoked
Never smoked — no. (%)
Never smoked, n (%)
Never smoker
Never smoking
Never took alendronate
Never used LEV
Never/rarely
New-onset atrial fibrillation
New-onset diabetes
New-onset diabetes§
"New anemia Bsl Hb > 120g I-1; Yr 1 < 120g I-1"
New Anti-Anginal Therapy
New DES (N=1727)
New diabetes
New diabetes — no. (%)
New DM
New HF medication
New OM
New or suspected thrombus
New or worsenina neohroDathv
New or worsentna neohroDathv
New stroke*
New use of GPA
New Use of GPA
New York Heart Association class
New York Heart Association Class
New York Heart Association congestive heart failure class
New Zealand
Newly diagnosed asthma (n)
NFS <-1.455 (low)
NFS > 0.67 (high)
NFS >0.67 (high)
NG
NG (n = 14,080)
NGAL (ng/ml)
Niacin
Niacin (n=87)
niacin, n (%)
Niacin+Statin
Niacini
NICE classification of COPD severity of obstruction, n (%)[2]
NICE primary prevention onlyb
NICE secondary prevention onlyb
Nicotine pack-years
night-time awakenings in past 2 weeks (SD)*
Night-time awakenings in past 2 weeks prior to baseline
Night-time awakenings/week
Nighttime mean DBP (ABPM) at week 12, mmHg
Nighttime mean SBP (ABPM) at week 12, mmHg
NIH Stroke Scale
NIHSS at baseline
NIHSS at randomization
NIHSS at randomization, 0-4
NIHSS score
Nilvadipine
Nintedanib (n = 61)
Nintedanib (n=166)
Nintedanib (n=472)
Nitrate
Nitrate — no. (%)
Nitrate (oral or intravenous)
Nitrate (oral or topical)
Nitrates
Nitrates (%)
Nitrates (oral or topical)
Nitrates, (%)
Nitrates, n (%)
Nitratesf
NKF Stage
NNT
No
NO
No-CKD intensive (N= 3244)
No-CKD standard (N= 3262)
No-diuretics group (n=586)
No    9,123
No (%)
no (74.8)
No (n = 309)
No (n = 412)
No (N=1982)
No (N=3441)
No (N=3627)
No (N=3852)
No (N=4206)
No (N=4731)
No (reference)
No ACE-I/ARB
No ACE inhibitor/ARB
No ACS
No active cancer
No Active Cancer Center-Level INR Percent Time
No adk/e cancer
No alcohol consumption, on average,
No aminosalicylates, N
NO AMIODARONE
"No anemia Bsl Hb > 120g I-1; Yr 1 > 120g I-1"
No antidiabetic drug
No antihypertensive medication
No Antihypertensive Medication
No antiplatelet therapy
No apparent heart disease
NO ASA
No ASA use at baseline
No ASCVD
No ASCVD + additional CV risk factors, n (%)
No aspirin
No aspirin at baseline
No aspirin or PPI
No atopy (n = 883)
No atrial fibrillation
NO BASELINE CHARACTERISTICS
No baseline corticosteroids
No baseline immunosuppressant use
No beta-blocker
No Beta-blocker use
No Betablocker Use
No Body Weight at Randomization (IXRS)
No CAD/MI
No cardiac disease
No cardiovascular disease (n=514)
No cardiovascular disease (n=529)
No cardiovascular disease (n=671)
No Cardiovascular disorder1'
No cases
No change
No CHD
No CHD at baseline
No CHD EZE/SIMVA
No CHD EZE/SIMVA (n = 995)
No CHD EZE/SIMVA 0 = 995}
No CHD SIMVA
No CHD SIMVA („ = 1023)
No CHD SIMVA (n = 1023]
No CKD
No CKD (%)
No CKD N
No CKD Rate (#events)
No Clinical or Lesion RFs for ST
No colchicine (n = 181)
No Concomitant Antiplatelet
No concomitant cortcosteroid use
No Concomitant immunosuppressive and/or prior anti-TNF use
No corticosteroid
No corticosteroid + no IMM, N
No corticosteroid, no IMM
No corticosteroids or immunosuppressants
No CS and IMM
No CS and IS
No culprit vessel identified
No current smoking
No Current Tobacco Use
No CV event (N =4,644)
No CVD
No depression
No Depression
No DES
No diabetes
No Diabetes
No Diabetes (n - 14,355)
No diabetes (N = 1,416)
No Diabetes (P = .07)
No Diabetes (P = .09)
No Diabetes (P = .67)
No Diabetes (P = .88)
No Diabetes (P = .O7)
No Diabetes (P = .O9)
No diabetes mellitus
No Diabetes Mellitus
No Digoxin n=14 778 (70%)
No Digoxin SCD, No. (%/y)
No diuretic therapy
No DM
No DM (n = 4,202)
No DM (n=13273)
No draining fistulas*
No dysglycaemia or MetS
No dysglycaemia or MetS Pbo (N = 119) vs EvoMab (N = 274)
No Dyspnoea (N=5461)
No Dyspnoea (N=5509)
No EF data||
No EPA Group n=457
No EPA Group n=8862
No EPA Group No. of Events (%)
No estimate
No estrogen
No extensive colitis, N
No Family History of CHD (n=290, 274)
No fracture history
No GI Bleed
No glucocorticoids at baseline
No glucocorticoids or immunosuppressants
No glucose lowering drugs
No heart failure
No Heart failure
No hemoconcentration Hemoconcentration
No high-intensity statin
No history of AF
No history of bowel resections
No History of Cancer
No history of CHF
No history of diabetes (n=4526)
No history of extra-intestinal manifestations of IBD (ref)
No history of heart failure at baseline
No history of HF
No history of hypertension (n=2191)
No History of MI (n=278, 281)
No history of migraine
No History of Migraine
No history of paroxysmal AF
No history of TIA/stroke
No history of TNF antagonist treatment — no. (%)
No hospitalization in the past 12 months prior to baseline (ref)
No HTN
No hx of HF (n=15173)
No hypertension
No Hypertension (n=4555)
No ICS
No Ilb/IIIa inhibitors
No immoMtedion
No immunosuppressive agents at baseline
No in-trial stroke N=31,832
No incident DM or change in FG > 13
No Increased Risk for Falls
No inducer at core study entry
No infarct visible
No IPST
No IPST (n = 10,850)
No Ischemia (n = 5,084)
No known frtrontxtfufoc cond Aon
No LABA, no ICS, n (%)
"No LABA; no ICS (tiotropium n = 59, placebo n = 63)"
No longer met study criteria
No metabolic syndrome
No Metformin
No Metformin Use
No methotrexate, hydroxychloroquine, or sulfasalazine treatment
No MI
No MI (n - 6,308)
No moderate CKD
No MRA at baseline
No MRA at Baseline
No MTX at baseline
No MTX use at baseline
No Multivessel Disease
No MVD (n - 8,600)
No Myocardial Infarction at Presentation (N=8072)
No Nadroparin (n = 259)
No nasal polyps
No new A or and no more than 1 new BILAG B domain score, %
No new erosions among patients with ≥1 uninvolved joint at baseline¶
No new JSN among patients with ≥1 uninvolved joint at baseline¶
No nonsevere hypoglycemia
No OAM
No OCS
No OCS use, no nasal polyps, pre-BD FVC s65% of predicted and age at diagnosis <18 years
No of Events / Total N (%)
No of events women men*
No of events womenmen*
No of events/total N (%)
No OP, no VFx
No OP, VFx
No or unknown
No oral antidiabetic medication
No p-blocker intake at randomisation (n=685)
No P-blocker intake at randomisation (n=685)
No p Value for Ischemia Ischemia HR (95% CI) Interaction
No pa
No PAD (n - 20,017)
No PAD baseline
No PAH-specific therapy
No PAH therapy
No PCI
No PCI or CABG — no. (%)
No Peripheral Revascularization (n = 4,911)
No Persistent WRF (n = 1,658)
No PO
No polyvascular disease (n=16 204)
No polyvascular disease* (n=16 204)
NO PPI
No Pretreatment
No previous CD related surgery3
No previous COPD medication
No Previous CV Event
No Previous Diagnosis of Diabetes Mellitus
No previous DMARD therapy
"No Previous Ischemic Stroke/ TIA (n=15 132; 71.7%)"
No previous myocardial infarction
No previous myocardial infarction 117/2659
No previous myocardial infarction 87/2659
No previous stroke or TIA (n=4819)
No previous stroke or TIA (n=4827)
No previous stroke or TIA (n=4843)
No previous stroke orTIA
No previous stroke/TIA
No previous treatment with infliximab
No Prior ADMc
No prior angina (n = 3,475)
No prior aspirin
No Prior CABG
No Prior Cancer
No Prior CV Event
No Prior CVD
No Prior DM
No Prior Heart Failure
No Prior Heart Failure (n = 14,387)
No prior HF (n = 5,286)
No prior HF hospitalization
No Prior HF Hospitalization (n = 3,125)
No Prior HF Hospitalization (n = 3,125)
No Prior HF n=5277
No prior HTN (n = 4,653)
No prior LGI event
No prior LLT
No prior MI
No Prior MI
No prior MI (n = 13,576)
No prior MI (n = 4,142)
No Prior MI n=4136
No prior Ml
No Prior Ml
No prior Ml or stroke
No prior MS therapies
No prior OMA use
No prior OMA use (N = 591)
No Prior PCI
No prior revascularization (n = 4,661)
No Prior Statin (n=44, 51)
No prior statin use
No Prior STEMI
No prior stroke
No Prior Stroke
No prior stroke (N = 6489)
No Prior stroke/TIA
No Prior Stroke/TIA
No prior TNF inhibitor exposure
No prior UGI event
No Readmission (n=1442)
No regular aspirin use
No regular consumption
No regular PPI use
No renal dysfunction
No Renal Dysfunction
No reperfusion
No resistant HTN n = 1,361
No revascularisation
No revascularization for index ACS event
No revascularization for index ACS event, no. (%)
No Second MI
No severe hypoglycemia
No smoking
No Smoking
No ST Depression or Elevation
No statin
No Statin
No statin (+/-LLT)
No statin during admission
No statin group
No Statin Use
No statin vs statin alone vs any statin plus other LLT
No steroid use at baseline (ref)
No steroids (n=74 vs 39)
No Stroke (N=17503)
no stroke n=13 889
No Stroke/TIA
No STSD >1 mm on admission (n = 4,109)
No Ststm
No symptoms
No Thienopyridine
No treatment or antihistamines only
No Type 2 Diabetes (n=336, 335)
No use
No use of 5-ASA compounds
No use ofdiabetes drugs — no. (%)
No VHD
No VHD Event Rate/Year (n)
No VKA at randomization
No VKA at Randomization
No worsening in PGA, %
No(n = 16,011)
No*
no.
No.
no. (%)
No. (%)
No. (%)'
No. (%) 182 (73)
No. (%) of Individuals*
No. (%) of participants
No. (%) of Participants
No. (%) of patients with ≥3% BSA affected
No. (%) of Patients With Atrial Tachyarrhythmia
No. (%) of patients with fingernail involvement
No. (%) of Patients With Stroke
No. (%) With Event [Incidence Rate per 100 patient-y]
No. (%)*
No. *
No. copies Gly16-Glu27-523C
No. evenls
No. fingernails
No. in the 12 mo before screening
No. Japanese
No. men
No. Needed to Treat (95% Cl)*
No. of
No. of ' signs or symptoms of CHFf
No. of 500-mg acetaminophen tablets/day
No. of 500-mg tablets of acetaminophen
No. of agents
No. of background glucose-lowering therapies, No. (%)
No. of cardiovascular events (cardiovascular events/1000 person-years)
No. of coronary vessels with >50% diameter stenosis
No. of days to HOMA-IR testing — median (IQR)
No. of days to randomization — median (IQR)
No. of Deaths
No. of diseased vessels (% of group)
No. of Drugs
no. of events
No. of events
No. of Events
No. of events (rate)
No. of events / total
no. of events/no. of patients
No. of Events/Patients
No. of events/patients %/yr
No. of Events/Sample Size
No. of Events/Sample Size I    I
no. of events/total no. (%)
no. of events/total no. 1%)
no. of events/totol no. (%)
No. of exacerbations in past year
No. of hospitalised patients
No. of infusions
No. of moderate or severe exacerbations in previous
No. of Non-TNFI
No. of pack-yr
no. of panents.total no. 1%)
no. of participants
No. of participants
No. of Participants (%)
no. of participants with events (%)
no. of patients
No. of patients
No. of Patients
No. OF Patients
No. of patients (%)
No. of Patients (Indacaterol/Placebo)
No. of patients IND/GLY SFC
No. of patients with AS
No. of patients with events (%)
No. of patients with PsA
No. of patients with RA
No. of patients/no. of events
no. of patients/no. of events (%) 742/2067 (36)    763/2061 (37)
no. of patients/total no. (%)
No. of predictors of cardiovascular risk
No. of previous anti-TNF drugs — no. (%)
No. of previous biologic DMARDs — no. (%)
No. of previous CIU/CSU medications
No. of previous CIU/CSU medications, mean (median)
No. of previous csDMARDs, n (%)
No. of previous TNE inhibitors
No. of previous venous thromboembolic events
No. of prior AEDs, n (%)
No. of prior AEDs, n (%) 0-1
No. of prior AEDs,c n(%)
No. of prior AEDsd
No. of Prior bDMARDs
No. of Prior TNFi
No. of risk factors (%)||
No. of risk factors for venous thromboembolism, no. (%)
No. of stents
No. of strokes (%)
No. of strokes/no. of patients in category (and %)
No. of subjects
No. of target vessels
No. of TNFi Among Non-TNFi Naive
No. of treated lesions
No. of treated vessels
No. of vessels
No. of vessels treated
No. of vessels with >50% stenosis
No. patients (%)
No. patients with
No. previous alpha-blocker use
No. previous DMARD, mean (SD)
No. pts
No. randomized
no. with event/total no. {%)
No. With Visit
No. women
No.*
No./100 Person-Yr
NO./100 Person-Yr
no./total
no./total no. (%)
no./total no. (%)t
no./total	no. (%)
No.a
no.of participants per 1000 patient-yr
No/unknown
No?
Nob Systolic blood pressure (mm Hg)
NoCAD/MI
Nocturia episodes/24h
Nocturnal back pain, 0–100 mm VAS, mean ± SD
Nocturnal symptoms in past week
Noirecerving
Noliecervrig
Nominal change
Nominal P vs placebo
Non- HDL-C
Non- White
Non-/Ex-drinker
Non-/Ex-tobacco User
non-anterior
Non-anterior
Non-Anterior
Non-Asian
Non-Asian (n=15 331)
Non-biological systemic
Non-black
Non-Black
Non-Black (n = 371)
Non-Black (n = 397)
Non-Black (n = 408)
Non-Black (n = 422)
Non-black participants
Non-Black race (n=496 vs 246)
Non-Black race and SS <9 (n=183 vs 96)
Non-Black race and SS >10 (n=313 vs 150)
Non-C
Non-CABG related bleeding at 48 h
Non-Calcium Antagonist Strategy (n = 11 309)
Non-Calcium Antagonist Strategy (NCAS) (events/n)
Non-CANA (n = 1178)
Non-CANA (n = 2109)
Non-CANA (n = 309)
Non-CANA (n = 621)
Non-cardiovascular Mortality
Non-carrier (N=135)
Non-caucasian
Non-Caucasian
Non-Caucasian EZE/SIMVA
Non-Caucasian EZE/SIMVA („ = 154}
Non-Caucasian EZE/SIMVA (n = 154)
Non-Caucasian SIMVA
Non-Caucasian SIMVA („ = 179}
Non-Caucasian SIMVA (n = 179)
Non-colorectal cancer
Non-compliance
Non-cortical
Non-CV mortality
Non-CVD deaths
Non-CVD mortality
Non-detectable/unknown
Non-detectable/unknown, n (%)
Non-diabetes
Non-diabetic
Non-Diabetic
Non-diabetic (n=1914)
Non-diabetic patients
Non-diabetic subjects, N=1957
Non-diabetics
Non-diabetics (n = 13892)
Non-dihydropyridine CCBs
Non-DM
Non-drug-eluting stent
Non-early Crohn's disease
Non-East Asian§
Non-East Asianf
Non‐elderly
Non-elderly (<65 years)
Non-end-stage renal dysfunction
Non-Endstage Renal Dysfunction*
Non-EPA (n = 2262)
Non-EPA (n = 7057)
non-EPA Number of <
Non-EPA(n = 2262)
Non-EPA(n = 7057)
Non-European Trial
Non-extensive
Non-fatal MI
Non-fatal Ml
Non-fatal myocardial infarction
Non-fatal stroke
Non-fibrin-specific
Non-frail
Non‐haemorrhagic stroke—No. (%)
Non-HDL
non-HDL-C
Non-HDL-C
Non-HDL-C (mg/dL)
Non-HDL-C (mg/dL)- mean ± SD
Non-HDL-C (mg/dl) **
Non-HDL-C (mmol/L)
Non-HDL-C (mmol/L, mean)
Non-HDL-C in 4 classes
Non-HDL-C*
Non-HDL-C, mean (SD)
Non-HDL-C, mean (SD), rng/dL
Non-HDL-C, mg/dl
Non-HDL-C, mg/DL
Non-HDL-C, mg/dL, mean (SD)
Non-HDL-C, mmol/L
Non-HDL-C, mmol/l, mean (SD)
Non-HDL-C/HDL-C
Non-HDL (mg/dl) <130
Non-HDL choleslerol
Non-HDL cholesterol
Non‐HDL cholesterol
Non-HDL cholesterol (mg/dl)
Non-HDL cholesterol (mg/dL)
Non-HDL cholesterol (week 24)
Non-HDL cholesterol J
Non-HDL cholesterol(mmol/l)
Non-HDL cholesterol/ApoB (ratio)
Non-HDLC
Non-High Density Lipoprotein (mg/dL) - Baseline - < Median (n=204, 212)
Non-High Density Lipoprotein (mg/dL) - Baseline - >= Median (n=214, 199)
Non-HisHnic
Non-Hispanic
Non-Hispanic and Latino
Non-Hispanic black
Non-Hispanic black or African-American
Non-Hispanic or Latino
Non-Hispanic white
Non-Hispanic, non-Latino
Non-Hispanic/Latino
Non-Hispanicwhite
Non-ICS+
Non-inhaled steroid use, n (%)
Non-insulin treated DM
Non-ischaemic
Non-ischaemic (n=2087)
Non-ischaemic (n=2O87)
Non-ischaemic aetiology
Non-ischaemic cardiomyopathy
Non-ischaemic cause
Non-ischaemic dilated cardiomyopathy
Non-Ischemic
Non-LAD artery
Non-MetS
Non-MetSyn
Non-MTX
Non-MTX csDMARDs
Non-PCI intravenous unfractionated heparin
Non-Q-wave myocardial infarction
Non-reversible (%)
Non-rheumatic valvular heart disease
Non-rollover
Non-severe hypoglycaemia
Non-smoker
Non-smoker (n=328, 313)
Non-smokers (at baseline)
Non-smokers receiving lipid-lowering drugs, p blockers,
Non-smokers receiving lipid-lowering drugs, p blockers, and either an ACE inhibitor or angiotension receptor blocker
Non-smokers receiving lipid lowering drugs, (5 blockers, and either an ACE inhibitor or angiotension receptor blocker
Non-spondylitis
Non-ST-elevation MI
Non-ST-Elevation MI
Non-ST-elevation Ml
Non-ST-Elevation Ml
Non-ST-elevation myocardial infarction
Non-ST-segment elevation
Non-ST-segment elevation ACS
Non-ST-Segment Elevation ACS
Non-ST-segment elevation MI
Non-ST-segment elevation myocardial infarction
Non-ST—elevation MI
non-statin (n=1054)
non-statin (n=704)
Non-STEMI
Non-stenotic vessels, n (%)
Non-steroidal anti-inflammatory drugs
Non-study PPI use
Non-sulfonylurea secretagogues
non-tiotropium
Non-tiotropium
Non-TNF inhibitors
Non-transient risk factors for recurrent VTE, n (%)
Non-trial antiplatelet
Non-trial p blocker
Non-trial treatment during hospital stay
Non-U.S.
Non-United States
Non-US
Non-US (N=6845)
Non-user 1
Non-white
Non-White
Non-White race
Non-White Raceb
non–small-cell lung cancer
Non—ST-segment—elevation myocardial infarction
Non CNS embolism
Non CV Mortality
Non diuretics
Non High Dose Statin (n=168, 170)
Non Stent Thrombosis-Related MI
Non USA
Non white
Nonanterior
Nonaspirin antiplatelet
Nonaspirin antiplatelet agent
Nonbiologic disease-modifying drug other than methotrexate::
Nonblack
Nonblack (n=1465)
"Nonblack (n=1465); Adjusted Hazard Ratio*"
Nonblack Participants
Nonblack race — no. (%)-j-
Nonblack race — no. (%)f
Noncardiac death
Noncardiovascular
Noncardiovascular death
Noncaucasian
Noncomplex Anatomy (n - 7,824)
Noncompliant
Noncurrent smoker
Nondiabetes
Nondiabetic
Nondiabetic participants!
Nondisabling, nonfatal stroke
None
None (cDMARD-naive or past use at baseline)
None (n = 4216)
None 一 no. (%)
None at baseline
None of the above
None or diet
None or Seldom
NoneH
Nonfatai Myocardiai infarction
Nonfatal
Nonfatal ischemic stroke
Nonfatal MI (N = 316)
Nonfatal MI+fatal CHDt
Nonfatal Ml
Nonfatal Myocardiail Infarction
Nonfatal myocardial infarction
Nonfatal myocardial infarction®
Nonfatal stroke
Nonfatal stroke (N=57)
Nonfatal stroke®
Nonglycemic cardiovascular risk factors
Nonglycemic cardiovascular risk factors Systolic blood pressure — mmHg
Noninducing
Noninsulin therapy
Nonischemic
Nonischemic cardiomyopathy
Nonischemic cardiomyopathy — no. (%)
Nonmetabolic Syndrome (n = 5196)
Nonobese (<30 kg/nr)
nonreversible
Nonsevere hypoglycemia
Nonsmoker
Nonsmoker, n (%)
Nonsustained ventricular tachycardia — no. (%)-j-
Nontatal Ml
Nontraumatic leg or foot amputation
Nontrial PPI
Nonuser
Nonvertebral
Nonwhite
Nonwhite race
Nonwhite race — no. (%) Ejection fraction
Nonwhite race!
NOPPI
Nordic
Nordic countries
Normai Fasting Giucose Levei (n = 1425)
Normal
Normal-high renin (PRA >0.65 ng/mL/h) (n=144)
Normal (£90 ml/minute)
Normal (<34.99 U/ml)
Normal (≤ ULN) n = 371
Normal (≥90 mL·min−1·1.73 m−2), n (%)
Normal (>80)
Normal (>90 mL/min)
Normal (>90 mLVmin per 1.73 m2)
Normal (>90)
Normal (BMI <25)
Normal (eGFR ≥90), N (%)
Normal (eGFR >90)
Normal >0-90
normal ACR (<30 mg/mg) at baseline to albuminuria (ACR >30 mg/g)
Normal albuminuria (UACR <30)
Normal baseline CRP
Normal BNP, ^80 pg/ml (n = 2,542)
Normal cognitive
Normal cognitive function (SPMSQ <2). N-1.616 N (%) participants with the event of interest
Normal coronary angiography
Normal CRP and
normal eGFR (60 < eGFR < 130 ml/min per 1.73 m2) at baseline to high eGFR (>130 ml/min per 1.73 m2)
Normal Fasting Glucose Level (n = 1425)
"normal Function (crcl >95 ml/ min; n=3123 [22.2%])"
Normal function or mild impairment
Normal HbA1c, n=2158
Normal hsCRP
Normal left ventricular ejection fraction — no. (%)J
normal or high eGFR (>60 ml/min per 1.73 m2) at baseline to low eGFR (<60 ml/min per 1.73 m2)
Normal or Increased Baseline GFR (>90 mL/min/1.73 m2)
Normal or Increased eGFR
Normal or Increased GFR (>90 mL/mln per 1.73 m^)
Normal or mild (IIEF-EF 17-30), n (%)
Normal renal function
Normal responder
Normal Responder (N=2982)
normal responders (n=2459)
Normal study termination
Normal Troponin
Normal weight (BMI <25)
Normal, <90
Normal/mild CKD
Normalfunction or mild impairment
Normalized
Normalized volume measures
Normalized WOMAC score
Normoalbuminuria
Normoalbuminuria — no. (%)
Normoalbuminuria — no./total no. (%)
Normoalbuminuria (UACR <30 mg/g)
Normoalbuminuria at baseline (59% of patients treated)
Normoalbuminuria or microalbuminuria
Normoalbuminuria, No. (%)
Normoalbuminuria§
Normoglycaemic individuals, n (%)
Normoglycemia
Normoglycemia^
Normoglycemic
Normoglycemic^
Normoglycemic{
Normoglycemic3
Normonatremic (>135 mEq/L) at Baseline
Normotensive (n=314)
North
North America
North America (%)
North America (n=162)
North America (n=1960)
North America (plus America and New Zealand)
North America (plus Australia and New Zealand)
North America HR (95% Cl)
North America n Z 786
North America plus Australia and New Zealand
North America*
North America/Oceania
North American
North Ameriea
NorthAmerica
NOS3 2690 C.T, n (%)
NOS3 2922 A.G, n (%)
NOS3 glu298asp G.T, n (%)
Not-Japan
Not-Japan N = 3,066
Not anterior
Not assessable
Not at goal
Not available
Not collected^
Not estimable
Not Hispanic
Not Hispanic or Latino
Not Hispanic or Latino (n — 247)
Not Hispanic or Latino (n=7644)
Not Hispanic/Latino
Not Hispanic/Latino (n=7,644)
Not Hispanie/Latino
Not hospitalized for heart failure in the year prior to study enrollment
Not localized
Not on an AHA
Not on metformin
not perfused
Not present at screening, but within previous year
Not provided
Not Rando. in NA*
Not receiving
Not reported
Not reported in eCRF
Not reported/unknown
Not Severe
Not tested
Not treated
Notable abnormalities
NotatIncreased Fall Risk (n - 20,205)
Notes:
NotHFrEF
NP Tercile 1 (BNP <166 pg/ml, NT-proBNP <682 pg/ml) (n - 230)
NP Tercile 3 (BNP >322 pg/ml, NT-proBNP >1,431 pg/ml) (n - 227)
NPH
NPI-12 score*
NPTercile2(BNP166-322 pg/ml, NT-proBNP 684-1,431 pg/ml) (n - 230)
Ns
NS
Ns cardiac cisease
NSAID
NSAID use — no./total no. (%)
NSAID at Least Once
NSCLC
NSTE-ACS
NSTE-MI
NSTE ACS
NSTEACS
NSTEMI
NSTEMI (%)
NSTEMI (n = 3,240)
NT-pro-BNP
NT-pro-BNP— pmol/liter-j-
NT-pro-BNP — pmol/literf
NT-pro BNP
NT-proBNP — pg/ml
NT-proBNP —pg/ml**
NT-proBNP ( pg/mL)
NT-proBNP (pg/ml)
NT-proBNP (pg/mL) (Q1-Q3)
NT-proBNP (pg/ml)H
NT-proBNP pg/mLa (IQR)
NT-proBNP pg/mLa(IQR)
NT-proBNP values were reported in 868 of 981 patients enrolled in this stratum
NT-proBNP, median (IQR), pg/mL
NT-proBNP, median pg/ml
NT-proBNP, pg/ml
NT-proBNP, pg/mL
NT-proBNP, pg/mLt
NT-proBNP, pmol/H
NT-proBNP, pmol/L
NT-proBNP, pmol/L^
NT-proBNP，pmol/H
NT-proBNP11 pmol-L-1
Nt estimated
NT proBNP > 500 ng/mL n (%)§
NTBNP (n=257)
nteraction p value
nternational Index of
NTpro-CNP (ng/ml)
NTproBNP (pg/mL)
numab
Number
Number (%)
Number (%) of patients
Number (%) of patients with event
Number (%) reporting migraine on 12-month questionnaire
Number and % of participants with events, and incidence rate per 100 person-year
Number insulin glargine
Number of (%) females
Number of (%) patients >65 years
Number of “off” periods
Number of agents
Number of antidiabetes drugs at screening, n (%)
Number of antihypertensive agent reported
Number of antihypertensive medications at study entry
Number of antihypertensive medications used, n (%) No antihypertensive therapy
Number of antihypertensive medications, n (%)
Number of arterial beds involved
Number of clinically significant asthma exacerbations in last year prior to baseline
Number of co-AEDs, n (%)
Number of concomitant AEDs, n (%)
Number of concomitant AEDsc
Number of concomitant csDMARDs, n (%)
Number of COPD exacerbations in the previous year, n (%)
Number of COPD exacerbations in the previous year, n (%)
Number of COPD exacerbations within 12 months, mean (SD)
Number of diseased vessels, mean (SD)
Number of draining fistulae per patient, n
Number of e
Number of ER visits in last year prior to baseline
number of events
Number of events (annualised rate [%])
Number of events, event per 1000 person-years
Number of events/patients
Number of exacerbation in the previous 12 months, n (%)
Number of exacerbations
Number of exacerbations 12 months before randomisation
Number of exacerbations in last 12 months,
Number of exacerbations in previous 12 months
Number of exacerbations in previous 12 months
Number of exacerbations in previous year, mean (SD)
Number of exacerbations in the 12 months before screening
Number of exacerbations in the last 12 months,
Number of exacerbations in the last 12 months, mean ± SD
Number of exacerbations in the past 12 months
Number of females n (%)
Number of hospitalizations in last year prior to baseline
Number of implanted stents, n, mean (SD)
Number of individuals
Number of lesions, n (%)a
Number of medications, n (%)
Number of pack-years
Number of Pack Years
Number of participants
Number of participants with an event
Number of patients
Number of Patients
Number of patients (%) or mean 士 SD
Number of patients (%) or mean ±SD
Number of patients >65 years (%)
Number of patients randomized
Number of patients with
Number of patients with available data
Number of patients with dose available
Number of patients with events
Number of patients with exacerbations in the previous 12 months, n (%)
Number of patients with fractures
Number of people (n)
Number of prevalent vertebral fractures
Number of previous anti-TNF treatments for PsA, n (%)
Number of previous anti-TNF treatments for psoriatic arthritis
Number of previous DMARDS
Number of previous reported AEDs
Number of previous TNFa inhibitors
Number of prior AEDs
Number of prior AEDs, n (%)
Number of prior AEDs, n (%)
Number of prior csDMARDS, n (%)
Number of stent=1
Number of stent=l or 2 or 3
Number of stents
Number of stents (per patient)
Number of stents implanted
Number of subjects
Number of Subjects in Analysis
Number of swollen joints (0-66)
Number of swollen joints (0-66), mean (SD)
Number of swollen joints (66 assessed)
Number of target vessels,
Number of tender joints (0-68)
Number of tender joints (0-68), mean (SD)
Number of tender joints (68 assessed)
Number of treated lesions
Number of treated lesions (per patient)
Number of treated patients
Number of treated vessels
Number of treated vessels (per patient)
Number of vessels disease
Number of vessels treated, index PCI
Number of visits, mean ± SD
Number of visits, median
Number ol (%) patients >65 years
Number omega-3 Number placeb fatty acid
Number randomized
Number resulting in ED visit
Number resulting in emergency department visit
Number resulting in hospital admission
Number standard care
Number stent >2
Number stent >3
Number(s) of features present
Numbera
Numbers of events (%):
Nutraceuticals, n (%)
NVF at FLEX baseline -2 < FLEX FN T- score
Nx*
NYHA
NYHA cHF class
NYHA class
NYHA Class
NYHA class — no. (%)
NYHA class —no. (%)
NYHA class —no. (%)$
NYHA class (when patient was last in stable condition
NYHA class (when patient was last in stable condition before admission), %
NYHA class >II
NYHA class 2-4: No { n=llll)
NYHA class 3 or higher
NYHA class I
NYHA class II
NYHA class II (n=3169)
NYHA class II (n=3l69)
NYHA class III
NYHA class III or IV (n=3334)
NYHA class III or IV, n (%)
NYHA class III, % (n)
NYHA class III/IV
NYHA class IV
NYHA class not reported
NYHA class within past month — no./total no. (%)
NYHA class, (%)
NYHA class, n (%)
NYHA Class, n (%)    I
NYHA class, n (%) I
NYHA class, n (%) II
NYHA classes III-IV
NYHA functional class
NYHA functional class (%)
NYHA functional class 1
NYHA functional class at randomization
NYHA functional class at screening
NYHA functional class I
NYHA functional class III
NYHA functional class III (%)
NYHA functional class, n (%)
NYHA functional classification — no. (%)
NYHA functional classification — no. (%) I
NYHA II
NYHA II, n (%)
NYHA III or IV
NYHA III or IV§ (n=11 988)
NYHA III, n (%)
NYHA IV, %
NYHA IV, n (%)
NYHA ll/lll patients with LVEF <0.40 at baseline
NYHA lll-IV
NYHA_class
NYHAII
NYHAIIIorIV
o
O-OI65 (-0-0097 to 0-0427)
O-OO37 (-0-0144 to 0-0217)
O Total randomized
O12O(OO31-O-21O)
o80 kg, n (%)
OA
OAB-q score, mean (SD)
OAB therapy
OAC experienced,bn (%)
OAD
OAD at screening, n (%)
OAD history, years
OAD only
OAD plus insulin
OAD use, n (%)
OADs, n (%)
OAM
OAM use [n (%)]
OASCVD
OAT
OAT (n = 23)
Obese
Obese (>30 kg/m^2)
Obese (>30 kg/m2)
Obese (>30 kg/m2)b
Obese (BMI £30)
Obese (BMI >30kg/m2)
Obese patients,! n (%)
Obesity
Obesity (%)§
Obesity (BMI £30 kg/m2)
Obesity (BMI >25 kg/m2), %
Obesity (body mass index >30 kg/m2)
Obesity t
Obesity*
Obesity* (BM1 > 30 kg/m2)
Obesity, %*
Obesityj
Observation
Observed
Observed case
Obstructive subscore
ocn
OCS
OCS at baseline
OCS dose*, mean (SD)
OCS maintained/increased
OCS reduced/stopped
OCS use
OCS, n (%)
OCT center point thickness, pm
OCTAVE Induction 1
OCTAVE Induction 1 and 2
OCTAVE Induction 2
OCTAVE Sustain
OCTI
OCTI & MATE1
Odds‐ratio (95% CI)
Odds ratio
Odds Ratio
Odds ratio (95% CI)
Odds Ratio (95% CI)
Odds ratio (95% Cl)
Odds Ratio (95% Cl)
Odds ratio (95%CI)
Odds ratio adj (95% Cl)
Odds Ratio and 95% Cl
Odds ratio versus placebo (95% CI)
Odds ratios (95% CI)
of Patients
of patients meeting criterion/total no. of patients
of T2DM (years)
of variation), IU
Off-pump
Off OMT
Off OMT (N=4280)
Off pump
oHS graduate
Oil
ol/L)
olaemia, n (%)
Old stroke*
Older DES (N=3318)
Older patients (aged > 75 years)
Older subjects (aged >55 years'
Older than 75 years
Olmesartan (N = 2232)
Olmesartan (n = 578)
Olmesartan along with CCB (N - 1057)
Olmesartan along with CCB (N - 1399)
Olmesartan along with diuretic (N- 1379)
Olmesartan along with diuretic (N - 1041)
Olmesartan medoxomil 40 mg (n = 282)
Olmesartan medoxomil 40mg/HCTZ12.5mg (n = 556)
Olodaterol
Olodaterol 1 0 |ig Tiotropium n=114 Non-tiotropium n=333
Olodaterol 1 0 |ig Tiotropium n=115 Non-tiotropium n=341
Olodaterol 10 gg (n=225)
Olodaterol 10 gg (n=234)
Olodaterol 10 Jig
Olodaterol 5 |ig Tiotropium n=117 Non-tiotropium n=332
Olodaterol 5 |ig Tiotropium n=117 Non-tiotropium n=335
Olodaterol 5 gg (n=227)
Olodaterol 5 gg (n=232)
Olodaterol 5 Jig
Olodaterol 5 m g
Olodaterol 5 Mg
Olodaterol 5 mg(n = 1038)
Olodaterol 5pg
Olodaterol Sgg
OM 40 mg + AML 10 mg + HCTZ 25 mg
OM 40 mg + AML 10 mg + HCTZ 25 mg (n = 627)
OM 40 mg/ AML 10 mg
OM 40 mg/ AML 10 mg (n = 628)
OM 40 mg/ HCTZ 25 mg
OM 40 mg/ HCTZ 25 mg (n = 637)
OM 40 mg/AML 10 mg
OM 40 mg/AML 10 mg/HCTZ 25 mg
OM 40 mg/HCTZ 25 mg
OM 40/
OM 40/ AML 10/
OM 40/AML 10/HCTZ 12.5 mg
OM 40/AML 10/HCTZ 25 mg
OM 40/AML 5/HCTZ 12.5 mg
OM 40/AML 5/HCTZ 12.5 mg*
OM 40/AML 5/HCTZ 25 mg
OM 40mg/AML 10 mg
OMA/OAT
OMA/OAT (n = 59)
Omalizumab
Omalizumab (LSM)
Omalizumab 150 mg (n [ 162)
Omalizumab 300 mg (n [ 160)
Omalizumab 300 mg (n [ 252)
Omega-3 FA
Omega-3 FA (n = 7740)
Omega-3 FA intake 1st third
Omega-3 FA intake 2nd third
Omega-3 FA intake 3,d third
Omega-3 fatty acid
Omega-3 fatty acid (n=5855)
Omega-3 fatty acid vs placebo Least-squares mean (95% Cl)
Omega-3 fatty acids
Omega 3 Allocation
Omeprazole
OMERACT-OARSI response
On-pump
On-pump time: <l:36hrs:min (n=721)
On-Treatment
On 1
On 2
On antihypertensive medication at baseline, n (%)‡
On antihypertensive treatment, n (%)
On aspirin at baseline
On BP medication, n (%)
On drug treatment (%)
On maximum tolerated medications (%) Median (25th to 75th quartile) SUA (mg/dl)
On metformin IR or metformin XR 1000 mg/d
On non‐metformin AHA
On OAC at time of randomisation, n (%)
On OMT
On OMT (N=7363)
On or After E^andomization
On pump
On statins at baseline
On Step-1 Drug, %
On steroid at baseline
On sulfonylurea
One-third radius
One-vessel disease
One antihypertensive medication
One at baseline
One lesion
One of the above
One or more blood pressure medications, n (%)
One or more COPD exacerbations (n/N [%])
One or more exacerbations
One or more medications
One or more requiring hospitalization in 12 mo before screening — no. (%)1
One TNFi and
One TNFi*
One vessel
Ongoing atopic or allergic condition — no. {%)
Only cerebrovascular disease
Only coronary artery disease
Only DVT
Only peripheral artery disease
onset 1 [5]
onset 2 [6]
onset 3 [7]
OnsetofAF,No.(%)
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) can range from 0 to 500 for the pain subscale, 0 to 200 for the stiffness
OP concomitant medications (%)
OP, no VFx
OP, VFx
OPAQb physical function score
Open
Open-label clopidogrel after completion of study drug
Open-Label Phase (Baseline=Week 0)
Open-label population
Open — no. (%)
Open triple (n=537)
Operative Procedure
OPG, (ng/mL)
Ophthalmologic events
OPTION
OR
OR (95 % CI)
OR (95% CI)
OR (95% CI)a
OR (95% Cl)
OR (95% Cl) = 0 88 (0.60, 1 29)
OR (95% Cl) = 0.80 (0 51.1.26)
OR (95% Cl) = 0.90 (0.71. 1.14)
OR (95% Cl) = 1 37(0.72. 2 61)
OR (ITT) (n=1532)
OR (unadjusted)
OR [95% Cl]
OR [95%CI]
OR 95% CI
or death
or ESRD
OR for CANA vs PBO (95% CI)||
OR for CANA vs PBO (95% CI)§
OR morbidity and mortality
or no microalbuminuria or macroalbuminuria
OR per Unit for Continuous Variables
OR primary outcome
or raloxifene
or severe
or taking antihypertensive medication
or ulcerations,® n (%)
OR, 1.2 (95% Cl, 0.7-1.9)
OR, 1.8 (95% Cl, 1.1- 3.0)
OR, 2.2 (95% Cl, 1.5-3.5)
OR, 3.8 (95% Cl, 2.7-5.5)
OR, 4.2 (95% Cl, 2.7—6,4)
OR, 4.2 (95% Cl, 2.9-6.3)
"OR: 1.35 (1.06, 1.74); p=0.017"
OR、 (95% CI)
OR=0.51(0.40–0.64)<0.001
OR=0.87(0.68–1.11)0.26
OR=1.30(0.95–1.77)0.10
OR=3.46(2.62–4.56)<0.001
ORadj (95% CI)
ORadj (95% Cl)
Oral
Oral (%)
Oral agent
Oral agent and/or insulin therapy
Oral agents
Oral agents use
Oral aminosalicylates
Oral anti-DM drug status, No. (%)
Oral anticoagulant
Oral anticoagulant — no./total no. (%)
Oral anticoagulant agent
Oral anticoagulant drugs
Oral anticoagulant drugs, n (%)
Oral anticoagulant N(%)
Oral anticoagulant, n (%)
Oral anticoagulants
Oral antidiabetes combination therapy without insulina, n (%)
Oral antidiabetes monotherapya, n (%)
Oral antidiabetic drugs
oral antidiabetic drugs/insulin (%/%)
Oral antihyperglycaemic, n (%)
Oral blood glucose-lowering
Oral blood glucose-lowering drug 23 (27.1)
Oral contraceptive pills — no./total no. (%)
Oral contraceptives
Oral corticosteroid
Oral corticosteroid dose (mg/day)
Oral corticosteroid use at baseline
Oral corticosteroid use at enrolmentt
Oral corticosteroid use, n (%)
Oral corticosteroids
Oral diabetic agent
Oral fi-blockers
Oral glucocorticoid dose, mg (prednisone equivalent)
Oral glucocorticoid use
Oral glucocorticoid use at baseline — no. (%):t
Oral hypoglycaemics only
Oral hypoglycemic
Oral hypoglycemic agent
Oral hypoglycemic agents
Oral hypoglycemic agentsj
Oral hypoglycemic drug
Oral hypoglycemic drugs only
Oral hypoglycemics
Oral hypoglycemics Hormone replacement
Oral medications
Oral or other systemic corticosteroid
Oral β-adrenergics, n (%)
Oral study drug administered — no./total no. (%)
Oral Treprostinil (n=151)
Oral Treprostinil (n=233)
Oralb
ORC (95% Cl)
Oretal
Organ system involvement, no. (%)
Organic
Oriental
Origin [n (%)]
Original dabigatran protocol
Oropharyngeal pain
ORs (95% Cis):
Orthopaedic
Orthopnea
Orthopnea, (%)
Orthopnea, frequent/continuous
Orthostatic hypotension
orthostatic test*
OS domain
Osmotic diuresis-related AEs
Osteitis
Osteoarthritis
Osteopontin (ng/ml)
Osteoporosis
Osteoporosis drug
Osteoprotegerin decreased
Other
Other'
Other'i'
Other— no. (%)
Other (%) Diabetes (Interaction: p=0.94)
Other (2.1%)t
Other (n — 66)
Other (n = 49)
Other (n = 904)
Other (n, %)
Other (n=13, 4)
Other (n=13, 4]
Other (n=83)
Other , n(%)
Other {n=83)
Other anti-hypertensive
Other anti-hypertensives
Other anti-platelet agents
Other antiarrhythmics^
Other anticoagulant
Other antihyperglycemic agents, not listed
Other antihypertensive
Other antihypertensive agents
Other antihypertensive drug
Other antihypertensive medications
Other antiplatelet
Other antiplatelet agent 一 no. (%)
Other antiplatelet agents
Other antiplatelet agents, n (%)
Other antithrombotic medication for index event — no. (%)
Other AScvD
Other ASCVD
Other ASCVD, No. (%)
other Asian
Other Asian
Other atherosclerotic
Other atherosclerotic CVD
Other atherosclerotic CVD ST depression on
Other Atherosclerotic CVD**
Other atherosclerotic CVDd,e
Other atherosclerotic event
other bDMARD§
Other bDMARDs (no TNFi taken)t, n (%)
Other biologic agent
Other blood-pressure drug
Other blood glucose-lowering agents
Other blood pressure-lowering drugs
Other BP drug
Other BPH-LUTS therapy
Other cardiac surgery, n (%)
Other cardiovascular risk factors
Other cause
Other cause, n (%)
Other CHD
Other climate subset
Other clinical characteristics
Other combination
Other countries
Other defined
Other determined etiology
Other diagnostic procedure*
Other diuretic
Other DMARD use
Other DMARDs
Other drug therapy, n (%)
Other drugs
Other drugs — no. (%)
Other end points
Other forms of
Other forms of atherosclerosis^
Other forms of atherosclerosis’
Other GLP-1 receptor agonist
Other glucose-lowering drugs
Other glucose status
Other hypoglycemic agent, n (%)
Other ICS
Other ICS versus no ICS
Other individual and exploratory end points
Other ischaemic heart disease (non-infarction)
Other lipid-lowering medication
Other lipid-modifying drug 一 no. (%)
Other lipid-modifying drug use at study entry, n (%)
Other lipid lowering drugs
Other lipid parameters
Other LLT at randomization
Other LLT use
Other major risk factors
Other medical history — no. (%)
Other medical history — no./total no. (%)
Other medical history, no. (%)
Other Medication Usage
Other medications
Other medications at enrollment
Other n (%)
Other NSAIDs
Other NSAIDS
Other or missing data
Other oral hypoglycemic drug(s)
Other osteoporosis medication
Other outcomes
Other Pacific Islander
Other plain vitamin preparations
Other prespecified end points
Other race
Other race, n (%)
Other risk factors
Other selected AEs
Other SGLT-2 inhibitor
Other statin
Other stent
Other steroids
Other sulfonylurea 一 no. (%)
Other supraventricular tachycardia
Other TEAEs
Other treatment assignment
Other UC-related Gi surgical procedure
Other vascular disease
Other vascular disease — no. (%)
Other vascular disease (CVD or PAD), %
Other vascularS
Other vasodilator
Other vasodilators§
Other!
Other(n=83)
Other*
Other* (n=153)
other*’
Other, n (%)
Other, No. (%)
Other/missing
Other/Missing
Other/mixed (n=74)
Other/multiple
Other/multiracial
Other::
Other^
Other® Region — no. (%)
Other†
Other1
Othera
Otherb
Otherc
Otherd
Otherf
OtherJ^:
Others
Others, classes I and IIIc
Others, n (%)
Othersc
Othert
Otherx
Othery Ethnicity, n (%)
Othery Ethnicity, n (%)*
Otherz
Outcome
Outcome - Variant
Outcome (N, %}
Outcome according to no. of risk factors for VTE
Outcome according to primary cancer site — no./total no. (%)
Outcome According to Renal Function Level (in mL/min)
Outcome according to stage of cancer — no./total no. (%)
Outcome and Metabolizer Phenotype
Outcome measure
Outcome severity
Outcome type
Outcome_subgroup
Outcomes
Outcomes by Treatment (spironolactone vs placebo)
Outcomes during ACCORD
Ovary
over past 5 years, n (%)
Overaii
Overaii (N=4230)
Overaii (N=4963)
Overal event rate
Overall
OVERALL
Overall (12,174)
Overall (ITT) (n=1532)
Overall (ITT) (n=1591)
Overall (ITT) (n=1604)
Overall (ITT) (n=1612)
Overall (ITT) (n=1615)
Overall (ITT) (n=2123)
Overall (ITT) (n=2151)
Overall (N = 1,630)
Overall (N = 1306)
Overall (n = 17,717)
Overall (N = 214)
Overall (n = 359)
Overall (N = 493)
Overall (n = 838)
Overall (n=1091)
OVERALL (n=1516)
OVERALL (N=4060)
Overall (n=442)
Overall (n=554 vs 279)
Overall (n=874)
Overall (n=U685)
Overall (per protocol) (n=1503)
Overall (per protocol) (n=1517)
Overall (per protocol) (n=1998)
Overall (PP) (n=1479)
Overall (W = 4844), 0/0
Overall 26352
Overall A phase population
Overall analysis
Overall cohort (post hoc analysis excluding metformin users)
Overall cohort (primary analysis)
Overall CTD
Overall DLQI score
Overall DLQI score7
Overall early-morning COPD symptom severity scorec
Overall Effect
Overall efficacy
Overall event rate
Overall FREEDOM population (N = 7808)
Overall HR (95% Cl)
Overall mortality
Overall N (N/lOOpy)
Overall N=3,214
Overall night-time COPD symptom severity scorec
Overall PAD
Overall PEA population
Overall population
Overall Population
Overall population (n - 207)
Overall population (n - 209)
"Overall Population (N = 10 194): Non-CANA (n = 3640); CANA 100 mg (n = 3092); CANA 300 mg (n = 3462)"
Overall Population (N=1902)
overall study period
Overall study population
Overall treatment effect
Overall VERO population
Overall, male:female
Overall, N = 305
"Overall; QVAI49-SFC"
Overall®    0.1436
Overall®    0.1909
Overall®    0.8990
Overallb
Overally
Overweight
Overweight (25 to <30 kg/m2)
Overweight (BMI £25 to <30)
Overweight (BMI=25-29.9)
Oxcarbazepine
Oxidative stress
Oxypurinol (n = 203)
P
P'Value
p- interactio n
p- interaction
P- value
P- value (Int)
p-blocker
p-Blocker
P-Blocker
p-blocker (%)
p-blocker intake at randomisation (n=5820)
P-blocker intake at randomisation (n=582O)
P-Blocker Use
p-Blocker Yes
p-blockers
p-Blockers
P-Blockers
p-blockers (%)
P-Blockers, n (%)
p-Blocking agents, selective
p-for interaetion
P-gp inhibitor
P-gp use
p-heterogeneity
P-heterogeneity
p-int
P-int
P-int.
P-inte Faction
P-Inter
p-interaction
P-interaction
P-sitosterol/Lathosterol
P-sitosterol/Total C (|imol/mmol)
p-val. (10)
p-val. (5)
p-value
p-Value
p‐Value
P-value
P‐value
P-Value
P‐Value
"p-value """
P-value (■nt)
p-value (ANCOVA treatment difference)a
p-value (ANOVA)
P-value (Int)
P-Value (Int)
P-value (interaction)≠
P-value (Overall)
P-Value (Trend)
P-value (vs placebo)
P-value D 110 mg vs. warfarin
P-value D 150 mg vs. warfarin
P-value for
P-value for East Asian versus non-East Asian*
p-value for interaction
p-value for Interaction
P-value for interaction
P-value for Interaction
p-value for interaction 0.64
P-value for interaction*
p-value for interaction13 :
P-value for trend across categories
P-value for trend*
p-value for variance
P-value interaction
P-Value Interaction
p-Value low vs. high NFS^
P-value n/n (%)
P-value vs. placebo
P-value(lnteraction)
p-Value*''
P‐value*
P-value*
P-value}
p-Value‘’
p-value¶
P-value13
P-valuea
P-valueb
p-Valuec
P-valuec
P—value for Interaction
P -value
P (95% Cl)
P (inter- action)
P (Losartan versus Placebo)
P (Women vs Men)
p .b *int
p .b “int
P [Int]
p 1 Interaction
p 1 interaction Women vs Men
P between age groups
P blocker
P Blocker
P blocker before admission
P blocker*
P blockers
P blockers (%)
P blockersubgroup
P for i
P for inter -act
p for Interaction
P for interaction
P for Interaction
P for interaction between RHTN and no RHTN and treatmenta
P for interaction*
p for trend
p for trend-
P for trend
P for Trend
P inleraclion
P Int.f
P Inter
p Interaction
P interaction
P Interaction
P Interaction (Rx Arm *Sex)
P interaction Women vs Men
P interaction=0.002
p J 3 * trend
P lace of randomization (Interaction: p=0.10)
P Trend
p Vaiue
P Vaiue
P Vaiue (interaction)
p Value
P value
P Value
P VALUE
P value (aged >65 vs. <65 years)
P Value (Cangrelor Versus Clopidogrel in Men)
P Value (Cangrelor Versus Clopidogrel in Women)
P Value (int)
P Value (Int)
P Value (Inter)
P Value (Interaction)
P Value (Men Versus Women)
p value (nominal)
P value (On vs off OMT)
p Value (vs. previous time point)
P value *
P Value 0.81
p Value Between Groups
P value by GT
P Value by GT
P value c
p value f
P Value fo Interactio
P Value for
P Value for  interaction
P value for adjusted HR
P value for DM vs. no DM
P Value for Heterogeneity
P Value for Heterogeneity （Rosiglitazone versus Glyburide）
P Value for Heterogeneity（Rosiglitazone versus Metformin）
P value for interaction
P value for Interaction
P Value for interaction
P Value for Interaction
P Value for Interaction - dosage with Dabigatran, 110 mg
p value for interaction (age continuous)
p value for interaction (age groups)*
P value for interaction by region
P Value for Interaction, dosage with Dabigatran, 150 mg
P Value for Interaction^
p Value for interaction®
p Value for interaction® Vertebral fracture at FLEX baseline:
P Value for Interactiont
P Value for MRA vs No MRA
p Value for Trend
p Value for Trend Across Tertiles
p Value for Trend*
P Value Heart Failure vs No Heart Failure
P value interaction
P value within category
p value*
p Value*
P value*
P Value*
P Value*, Placebo Group P Value*, Hyponatremia Normonatremic Group, Tolvaptan vs Hyponatremic vs Placebo
p value*3
p Value∥
P value§ (<65 vs. >=65 years)
P value§ (<75 vs. >=75 years)
P value§®(w
P value2
p value3
P Value8
P valuea
p valueb
P valueb
P valuec
P Valued
P Valuej'
P valuer
P values
P Valuey
P vs placebo
p value
P Value
P Value for Interaction
P Values for Interaction
P Values of Interaction
P vs. placebo
P(INTER)
P)atients with >1 exacerbations resulting in emergency department visit
P, All vs All
P, Interaction!
P, Net Difference
P, Regional Difference
P, Regional Difference*
P, Subgroup*
P, Treatment-by-Region Interaction
p. interaction
p.O)
P/Interaction
P: Interaction
P<0.05) between the study groups in any of the baseline characteristics. ACE
P20 vs no treatment 4271
P2Y12 antagonist
P2Y12 antagonists
P2Y12 inhibitor
p30 min twice/week
P3Z3 (N = 1223)
P40 vs placebo
P40 vs usual care
Pace, no. (36)
Pacemaker
Pacemaker — no. (%)
Pacemaker or ICD
Pacemaker, (%)
Pacemaker, n (%)
PACI
PACI (n=850)
Pacific
Pacific Islander
pack-years (IQR)
Pack-years smoked
Pack-years, mean (SD)
pack years
Paclitaxel
Paclitaxel-eluting
Paclitaxel-eluting stent use, n (%)
PAD
PAD (n - 1,143)
PAD at baseline
PAD details, n (%)
PAD lower extremities
PAD symptoms (%)
PAH-CTD
PAH-MCTD/CTD-other
PAH-SLE
PAH-SSc
PAH classification
PAH classification — no. (%)
PAH etiology
PAH Etiology:
PAH origin/cause
PAH therapy at baseline
Pain
Pain (0-100 mm VAS)
Pain (100 mm VAS)
Pain (VAS)
Pain subscale
Pain VAS (range 0-100), mean ± SD
Pain VAS, 0-100 mm
Pain VAS, mean change from baselinea
Pain VAS, mean change from baselined
Pain VAS, range 0-100 mm, mean (SD)
Pain, 0-100 mm VAS
Pain, mm
Pairwise comparison
Pancolitis
Pancreas
Pancreatic cancer
Panel A
Panel B
PaO2 at rest, mm Hg
PAOD
Paracetamol
Parameter
Parameter (mg/dl)
Parameter at baseline
Parameter mean±s.d.
Parameter statistics
Parameter, % (95% CI)
Parameter, N (%)
Parameter/variable
Parameters
Parameters at baseline
Parental history of MI before age 60 y
Parental history of MIi
Parental history of Ml before age 60 y Yes
Parental history of myocardial infarction before 60 yr of age (%)
Parental history of myocardial infarction before age 60 y
Parental history of myocardial infarction before age 60 y Yes
Parenteral anticoagulalion before randomization
Parenteral anticoagulation
Paresthesia
Paroxysmal
Paroxysmal (n, %)
Paroxysmal AF
Paroxysmal atrial fibrillation — no. (%)
Paroxysmal nocturnal dyspnea
Paroxysmal!
Paroxysmal, n (%)
Partial evolving to secondarily generalized (IC)
Partial Mayo Clinic scored
Partial Mayo score
Partial Mayo score$||
Partial Mayo score, mean (SD)
Participant-reported hypertension — no. {%)
Participants
Participants at baseline, n
Participants n
Participants randomized,
Participants taking insulin
Participants with a history of CABG
Participants with an event per 1000 patient-years
Participants With Heart Failure
Participants With HF at Baseline
Participants with metabolic syndrome
Participants without a history of CABG
Participants Without Heart Failure
Participants Without HF at Baseline
Participants without metabolic syndrome
Participants, n
Participants, No. (%)
Participated in a previous febuxostat studyb, n (%)
Participation in phase A
Participation in Phase A
partner, n (% Yes)
PASI
PASI #3 at week 100,
PASI [c], median (min - max)
PASI <10*
PASI 100
PASI 75
PASI 90
PASI response by baseline MTX use, no./total no. (%)* PASI75
PASI response by baseline weight, no./total no. (%)* PASI75
PASI score
PASI score (0-72)
PASI score (0-72), mean (SD)
PASI score (0-72)d
PASI score (0-72)t, mean (SD)
PASI score (0–72 scale)
PASI score >10*
PASI score!**
PASI score, 0-72*
PASI score, mean (SD)
PASI score, mean ± SD
PASI score1
PASI*
PASI, mean (SD)
PASI, median (range)**
PASI^I
PASI100a
PASI75 response}
PASI75, no./total no. (%)4
PASI75a
PASI90
PASI90 response}
PASI90, no./total no. (%)4
PASI90a
PASIa
Passive smoker
Past
Past cardiovascular history, no. (%)
Past only
Past or current
Past or current angina pectoris
Past or never
Past or nonsmoker (n = 370)
Past smoker
Past smoker, n (%)
Past smoking
Past treatment for PAOD
Patella fracture
Patent foramen ovale
Paternal history, n (%)
Pathologic Q waves — no. (%)
Pathologic Q waves, n (%)
Pathological Q waves
Patient
Patient's assessment of pain
Patient's Assessment of Pain (0-100 VAS)
Patient's Assessment of Pain!
Patient's GA, 0-100 mm VAS
Patient's global assessment
Patient's global assessment (VAS)
Patient's global assessment of
Patient's Global Assessment of Disease
Patient's global assessment of disease activity (0-100 mm VAS), mean (SD)
Patient's global assessment of disease activity, mean (SD)
Patient's global assessment of disease status score
Patient's global assessment of response to therapy score
Patient's Global Assessment!
Patient's history of:
Patient's preference not to take
Patient's preference not to take VKA, only reason
Patient's preference not to take VKA, only reason**
Patient-reported hypertension — no. {%)
Patient-reported outcome measures
Patient-reported outcomes
patient-years) HR (unadjusted)
Patient assessment of arthritis pain, mm
Patient assessment of disease activity, mm
Patient assessment of pain (0-10 cm, VAS)
Patient assessment of pain (0-100 mm), mean (SD)
Patient Characteristic
Patient characteristics
Patient Characteristics
Patient characteristics at randomization
Patient classification
Patient demographics Age — yr
Patient global assessment (0-100 mm VAS)
Patient global assessment of disease
Patient global assessment of disease activity (0-10 cm, VAS)
Patient Global Assessment of disease activity (VAS 0-100 mm)
Patient global assessment of disease activity, mean (SD)
Patient Global Assessment of pain (VAS 0-100 mm)
Patient history of disease
Patient history of disease n (%)
Patient population
Patient presentation
Patient status after wake-up, % of days patient woke:
Patient years
Patients
Patients' characteristics
Patients' characteristics Age (years), mean + SD
Patients (ft)
Patients (full analysis sety), n
Patients (n)
Patients (treated set*), n
Patients <65 y
Patients <65 y*
Patients <8%
Patients >65 y
Patients >65 y*
Patients >8%
Patients aged >65 y, no, (SS)
Patients analyzed, n
Patients assessed
Patients entering PT period n=108
Patients entering PT period n=71
Patients having exacerbation
Patients in analysis, n
"patients in the placebo group; NT-proBNP values were reported for 203 patients"
Patients included in analysis
Patients meeting the criteria to receive 30 mg of
Patients n
Patients not receiving corticosteroids at baseline
Patients not receiving immunosuppressive agents at baseline
Patients not receiving MTX, N =
Patients not receiving statin
Patients not treated with statins (n=473)
Patients not treated with statins (n=485)
Patients on antihypertensive medications, n (%)||
Patients on atorvastatin, rosuvastatin, or simvastatin at
Patients per 1000 patient-years
Patients randomised, N
Patients randomized
Patients randomized, n
Patients randomized, no.
Patients randomly assigned
Patients receiving 30 mg of edoxaban at randomization — no. (%)f
Patients receiving any UC medication, n (%)
Patients receiving corticosteroids at baseline
Patients Receiving ENL, No. (%)
Patients receiving immunosuppressive agents at baseline
Patients receiving Immunotherapy, no. (%)
Patients Receiving LCZ, No. (%)
Patients receiving MTX
Patients receiving MTX, N =
Patients receiving statin
Patients taking MTX, n (%)
Patients taking MTX, no. (%)
Patients taking oral corticosteroids at baseline, n (%)
Patients total no.
Patients treated
Patients treated and operated, n (%)
Patients treated for >24 weeks (%)
Patients Treated with Atenoloi (n = 3484)
Patients treated with insulin
Patients Treated with Losartan (n = 3402)
Patients treated with statins (n=113)
Patients treated with statins (n=117)
Patients using concurrent tiotropium
Patients who did not use insulin pump
Patients who had ulcerations at
Patients who received 1 drug
Patients who received 2 or 3 drugs
Patients who received indeterminate results on test for antibodies to infliximabt
Patients who received negative results on test for antibodies to infliximabt
Patients who received positive results on test for antibodies to infliximabt
Patients who used insulin pump
Patients with $1 dactylitis digit at week 100 Enthesitis
Patients with $3% BSA at baseline, no.
Patients with >1 exacerbation in previous 12 months
Patients with >1 exacerbation requiring admission to hospital in the 12 months before screening
Patients with >1 exacerbation requiring ER visit or admission to hospital in the 12 months before screening
Patients with >1 exacerbations resulting in ED visit
Patients with >1 exacerbations resulting in emergency department visit
Patients with >1 exacerbations resulting in hospital admission
Patients with >12% ■ 200 mL increase in FEV1 post-bronchodilator (%)
Patients with >3 co-AEDs
Patients with >3% BSA
Patients with >3% BSA psoriasis skin involvement, n (%)
Patients with 1 co-AED
Patients with 2 co-AEDs
Patients with 3 co-AEDs
Patients With a Prior MI or Stroke at Baseline
Patients with an event per 1000 patient-years
Patients with any clinical
Patients with any clinical event
Patients with ASCVD but no prior Ml HR (95% Cl)
Patients with at least one concomitant disease*
Patients with at least one concomitant disease||
Patients with baseline CRP concentration £10 mg/L
Patients with baseline CRP concentration <10 mg/L
Patients with BP $130/80 mmHg (ABPM) at baseline, nt
Patients with BW decrease of $5% in patients with baseline BMI of $27 kg/m2+
Patients with cardiac disorders, n (%)§
Patients with cardiac disorders, n (%)c
Patients with change from baseline in PsA-modified total SHS score #0
Patients with change from baseline in total PsA‐modified SHS ≤0
Patients with chronic
Patients with Clinically Evident Vascular Disease
Patients with complicated events
Patients with complicated events (p=0-74十)
Patients with dactylitis
Patients with dactylitis at baseline, no.
Patients with dactylitis at week 24, n (%)
Patients with dactylitis, no. (%)
Patients with dactylitisa
Patients with Deep-Vein Thrombosis Only
Patients with diabetes
Patients With Diabetes Mellitus
Patients With Diabetes Mellitus (n=3391)
Patients with diabetesb
Patients with diabetic nephropathy
Patients with digits with dactylitis, n (%)
Patients with DM (n = 4171)
Patients with DM (n = 4221)
Patients with DM vs. patients without DM
Patients with draining fistulae at baseline[n = 57]
Patients with early CD (n = 63)
Patients with eGFR <60 mL/min/1.73m2 at baseline
Patients with eGFR >60 mL/min/1.73m2 at baseline
Patients with eGFR >90 ml/min/1.73m2, n
Patients with eGFR 2>30 to <60 ml/min/1.73m2, n
Patients with eGFR 2>60 to <90 ml/min/1.73m2, n
Patients with eligible SES-CD score
Patients with End Point
Patients with endpoin t, n (%)
Patients with enthesitis
Patients with enthesitis (LEI >0)
Patients with enthesitis at baseline, no.
Patients with enthesitis at week 100 Radiographic progression§ Change from baseline to week 52 in PsA-modified total SHS score
Patients with enthesitis at week 24, n (%)
Patients with enthesitis, n (%)
Patients with enthesitis, no. (%)
Patients with EOT data, n
Patients with established CV disease aged >50 years.
Patients with evaluable endoscopy
Patients with event (n, %)
Patients with event/ patients analysed
Patients with event/ patients analyzed
Patients with event/analyzed
Patients with fingernail involvement
Patients with fistulas at baseline
Patients with glycated hemoglobin <7.0% and no severe hypoglycemia or diabetic ketoacidosis
Patients with glycated hemoglobin >7.0% and >1 episode of severe hypoglycemia*
Patients with glycated hemoglobin >7.0% and >1 episode ofdiabetic ketoacidosis*
Patients with hospitalized pneumonia events, n (%)
Patients with improvement $0.3
Patients with level >500 pg/ml
Patients with low (<16 mg/dl) C4
Patients with low (<90 mg/dl) C3
Patients with macroalbuminuria at baseline
Patients with measurement
Patients with microalbuminuria at baseline
Patients with microvascular complications, n (%)
Patients with mild pain (WOMAC pain score, 125-300)
Patients with moderate-to-severe pain (WOMAC pain score, 301-400)
Patients with nail psoriasis (mNAPSI >0)
Patients with negative anti-dsDNA
Patients with no prior CVD (primary
Patients with normoalbuminuria at baseline
Patients with only MRF HR (95% Cl)
Patients with perianal fistulae, n [%]
Patients with pneumonia event, n (%)#
Patients with pneumonia events, n (%)#
Patients with pneumonia resulting in death, n (%)
Patients with possible new DM at randomization (FPG>126-400)
Patients with possible new DM at randomization (HbA1c >6.5-10%)
Patients with prevalent kidney disease at baseline
Patients with previous intolerance of infliximab
Patients with previous loss of response to and intolerance of infliximab*
Patients with previous loss of response to infliximab
Patients with prior COPD-related
Patients with prior DMARD use, n (%)a
Patients with prior Ml HR (95% Cl)
Patients with psoriasis (BSA ≥ 3%)
Patients with psoriasis (n = 52)
Patients with psoriasis >3% of body surface area
Patients with Pulmonary Embolism
Patients with RA, AS, or PsA (n = 280)
Patients with radiographic erosion, n/N (%)
Patients with remission
Patients with serum 25(OH)D ≥ 9.2 and < 20 ng/mL, n/N (%)
Patients with specific disease characteris-
Patients with specific disease characteristics
Patients with specific disease characteristics, n (%)
Patients with supplemental vitamin D dose of 2000 IU/day starting at screeningc, n (%)
Patients with syndesmophytes at baseline
Patients with uncomplicated events
Patients with uncomplicated events (p=O-63十)
Patients with weekly ISS MID response, n (%)v
Patients without
Patients Without a Prior MI or Stroke at Baseline
Patients without chronic
Patients without Clinically Evident Vascular Disease
Patients without diabetes
Patients Without Diabetes Mellitus (n=8257)
Patients without diabetesb
Patients without DM (n = 13,739)
Patients without DM (n = 13892)
Patients without draining fistulae at baseline[n = 404]
Patients without prevalent kidney disease at baseline
Patients without psoriasis (n = 2786)
Patients without RA, AS, or PsA (n = 18,609)
Patients without syndesmophytes at baseline
Patients, n
patients, n (%)
Patients, n (%)
Patients, n/N (%)a
Patients, no.
Patients, No.
Patients, No./Total No. (%)
Patients, n (%)
Patients/events n
Patientswith BP $130/80 mmHg (ABPM) at baseline, nt
Patientswith BP ,130/80 mmHg (ABPM) at baseline, n§
PAV, Mean (95% CI)
pb
PBO
PBO-adjusted LS mean change
PBO-Adjusted LS mean change (SE)
PBO-SC every other week (n = 219)
PBO (n- 183)
PBO (n-156)
PBO (n -192)
Pbo (N = 107)
Pbo (N = 107) vs
Pbo (N = 119)
PBO (n = 119)
Pbo (N = 119) vs
PBO (n = 137)
PBO (n = 164)
PBO (N = 170)
PBO (n = 178)
PBO (n = 18)
Pbo (N = 183)
PBO (N = 21)
PBO (N = 22)
PBO (n = 23)
PBO (n = 237)
PBO (n = 259)
PBO (n = 261)
PBO (n = 266)
PBO (n = 312)
PBO (n = 334)
PBO (n = 380)
PBO (n = 40)
PBO (n = 409)
PBO (n = 42)
Pbo (N = 43)
Pbo (N = 43) vs
PBO (N = 44)
PBO (n = 468)
PBO (n = 509)
PBO (n = 606)
PBO (n = 646)
PBO (n = 85)
Pbo (N = 99)
Pbo (N = 99) vs
PBO (n 5 115)
PBO (n 5 531)
PBO (n = 109)
PBO (n = 12)
PBO (n = 97)
PBO (n=163)
PBO (n=483)
PBO (n5 164)
PBO (n5119)
PBO (n542)
Pbo + statin
Pbo + statin    1
Pbo + statin n=261
Pbo + statin n=353
Pbo + statin n=395
PBO CZP 200 mg Q2W Week 16 (N=30)
PBO CZP 200 mg Q2W Week 24 (N=30)
PBO CZP 400 mg Q4W Week 16 (N=29)
PBO CZP 400 mg Q4W Week 24 (N=31)
Pbo n (%)
PBO N=216
PBO to CZP Week 16 Dose Combined
PBO to CZP Week 24 Dose Combined
PBO, n=37
PBO, n=59
PBO, n=69
Pbo, No. (%)^
Pbo, No. (o/o)^’
PBO/SIMVA - 7yr KM rale (%)
PBO+MTX
PBO+MTX n=157
PBO+MTX n=213
PBO+MTX to MTX
PBO+MTX^MTX
PCI
PCI—No. (%)
PCI — no. (%)
PCI — no. {%)
PCI (%)
PCI >1 month ago
PCI alone (n=838)
PCI data
PCI delay due to low risk
PCI duration
PCI duration in min (median, IQR)
PCI during index hospitalization
PCI for Index Event
PCI for index MI (%)
PCI history
PCI indication
PCI or CABG surgery for index event
PCI orCABG
PCI performed
PCI Postindex event
PCI revascuLarization
PCI, n (%)
PCI/thrombolysis at randomization
pci:
"PCI=percutaneous coronary intervention. CABG=coronary-artery bypass graft. For HOPE >201 mg/L; for EUROPA >250 mg/L or on a lipid-lowering treatment; for PEACE, data are mean (SD). Data are mean (SD) unless otherwise indicated."
PCIperformed for qualifying event
PCR after ACS
PCS score
PCS score (0–100 scale)
PcTindopnl- indapamide (n=5569)
PDE-5i
PDE-5i monotherapy
PDE5 inhibitor monotherapy
PDE5 inhibitors
PDQ-39
PDQOL scale
PE
PE (with or without DVT)
PE ± DVT
PE and DVT
PE associated with DVT at diagnosis
PE only
PE With/Without DVT
PEACE (n=8290)
Peak creatine kinase-MB, U/L
Peak FEV1(0-3h) response
Peak procedural ACT — sec
Peak systolic pressure gradient
Peak Systolic Pressure Gradient
Pedal edema, slight/moderate/marked
PEF at baseline, l_/min
PEF!
PEF, post-bronchodilator, % predicted normal
PEFAM (L/min)∗
PEFPM (L/min)∗
Pelvic fractures
pen-label empagliflozin 25 mg (baseline HbA1c >10%)
Penetrating
Penetrating disease, %
Penetrating No. of resections, n (%)
Pentraxin-3 (ng/ml)
People with diabetes N = 1554
People without diabetes N = 3680
Pepsinogen I/II ratio
Per body weight, U/kg
Percent  Change
Percent activity impairment due to asthma
Percent Atheroma Volume at Baseline
Percent Change from Baseline at Week 24
Percent change from baseline to week 12 in AUC (mean, SEM)
Percent impairment while working due to asthma
Percent improvement, baseline to week 100, median (IQR)
Percent of Patients
Percent of predicted FEV1
Percent of predicted normal value
Percent of predicted value before bronchodilation^
Percent of the time that INR was in the therapeutic range
Percent overall work impairment due to asthma
Percent Stenosis [Core Lab]
Percent Stenosis [Investigator]
Percent work time missed due to asthma
percentage
Percentage difference (95% Cl)
Percentage of BSA involved
Percentage of females
Percentage of FEVj reversibility
Percentage of P
Percentage of patients receiving dose adjustment
Percentage of patients using ICS or ICS/LABA on entry
Percentage of Patients with Event
Percentage of predicted pre-bronchodilator FEV^
Percentage of time in therapeutic INR range, mean (SD)
Percentage patients reaching target
percentage points
"Percentage unless otherwise noted. CABG indicates coronary artery bypass graft; LVH, left ventricular hypertrophy; NSAIDs, nonsteroidal antiinflammatory drugs; PVD, peripheral vascular disease; TIA, transient ischemic attack. ‘History of hypercholesterolemia or reporting use of lipid-lowering medications at baseline. tHistory of or currently have elevated serum creatinine level <4 mg/dL. tBased on participant history or review of chart."
Percentage with disease duration <2 years
Percentages
Percentages of patients with event
Percutaneous coronary intervention
Percutaneous coronary intervention done*
Percutaneous coronary intervention N(%)
Percutaneous coronary intervention or coronary-artery bypass grafting for index acute coronary syndrome — no. {%)
Percutaneous coronary intervention or coronary artery bypass graft surgery, n (%)
Percutaneous coronary intervention, n (%)
Percutaneous coronary intervention§
Percutaneous coronary revascularization
Percutaneous intervention
Percutaneous transluminal coronary angioplasty
Perfusion defectsatinclusion
Peri- or postmenopausal
Peri-op ACE-inhibitors/ARBs: No (n=655)
Peri-op amiodarone: No (n=1295)
Peri-op beta-blockers: No (n=456)
Peri-op statins: No (n=550)
Peri-operative CABG Participants:
Perianal GI tract
Perianal or anus
Perianal, n (%)
Perindopril
Perindopril-indapamide
Period I
Period II
Periostin
Periostin (ng/ml)
Periostin high
Periostin low
Peripherai arteriai disease
Peripheral
Peripheral-artery disease
Peripheral-artery disease — no. (%)
Peripheral-artery disease (%)
Peripheral-artery stenosis
Peripheral angioplasty
Peripheral arterial disease
Peripheral arterial disease — no. (%)
Peripheral arterial disease — no. (%)§
Peripheral arterial disease (n=21 096)
Peripheral arterial disease, n (%)
Peripheral arterial disease§
Peripheral arterial revascularization
Peripheral arterial stenosis
Peripheral artery
Peripheral artery disease
Peripheral artery disease--
Peripheral artery disease — no. (%)
Peripheral artery disease 一 no. (%)
Peripheral artery disease details
Peripheral artery disease*
Peripheral artery diseaseb
Peripheral artery diseasef
Peripheral artery occlusive disease
Peripheral artery occlusive disease (stage 0/1/2/3/4)
Peripheral artery revascularization without amputation
Peripheral edema
Peripheral embolism
Peripheral limb vascular efficacy
Peripheral neuropathy
Peripheral revascularisation
Peripheral revascularization
Peripheral Revascularization (n = 934)
Peripheral sensory neuropathy
Peripheral vascular disease
Peripheral vascular disease, n (%)
Peripheral vasodilators
Periprocedural anticoagulant
Periprocedural medications
Periprocedural medications — no./total no.
Periprocedural medications — no./total no. (%)
Periprocedural medications, n (%)
Periprocedural medications, n (%) Clopidogrel, 300 mg*
Permanent
Permanent (n, %)
Permanent AF
Permanent users
Permanent users, n
Permanent, n (%)
Permanently stopped study drug because of adverse events
Persisent
Persistent
Persistent (n, %)
Persistent AF
Persistent AF, n (%)
"Persistent anemia Bsl Hb < 120g I-1; Yr 1 < 120g I 1"
Persistent FAOD (n [ 113)
Persistent FAOL (n [ 155)
Persistent or paroxysmal
Persistent or permanent immobilization
Persistent WRF (n = 283)
Persistent*
Persistent, n (%)
Persistent/permanent
Person-years
Pervious cerebrovascular event
PFO + ASA
PFO Closure
PFO Closure Group (N = 238)
PFO with large shunt and atrial septal aneurysm
PFO with large shunt without atrial septal aneurysm
PFO with mild-to-moderate shunt and atrial septal aneurysm
Pfor
Pfor interaction
Pfor Interaction
pfor trend
PGA score (range)
PGA score, mean (SD)
PGA subscore
PGA, 0-10
PGI-S, n (%)y:
Phakic
Pharmaco-Invasive (n=944)
Pharmaco-invasive n=944
Pharmacological therapy for HF
Pharmacotherapy
Pharyngitis
Phenobarbital
PhGADA (mm)
Phi (N-161)
PhI (n=171)
Philippines
phosphatase, mean (SD), ng/'mLf
Phosphate (mmol/L)
Phosphodiesterase type 5 inhibitors
Phospholipid omega-3 levels: <4% (n=200)
Phosphorus, mmol 1 1
Phototherapy
Phototherapy Previous systemic treatment, n (%)
Physical activity (hours walking/wk)
Physical activity, kcal/wk
Physical activity, kcal/wk <1000
Physical activity, kcal/wk*
Physical Activity§
Physical and cognitive examination:!:
Physical characteristics
Physical component
Physical component score (PCS)
Physical exam oedema
Physical examination
Physical examinations
Physical function
Physical function (0-100, Short Form-36 subscale)
Physician
Physician's assessment of disease activity (VAS), mm
Physician's GA, 0-100 mmVAS
Physician's global assessment
Physician's global assessment (VAS)
Physician's global assessment of dis-
Physician's global assessment of disease activity (0-100 mm VAS), mean (SD)
Physician's global assessment of disease status score
Physician's Global Assessment!
Physician's global assessment. mean 6 SD
Physician's judgment that VKA
Physician's judgment that VKA inappropriate
Physician's judgment that VKA inappropriate]
Physician global assessment (0-100 mm VAS)
Physician global assessment of disease
Physician global assessment of disease activity (0-10 cm, VAS)
Physician Global Assessment of disease activity (VAS 0-100 mm)
Physician global assessment of disease activity, mean (SD)
Physiological measures
PI
Piacebo
Piacebo (N=7740) no. of participants with events (%)
PIFR L/min
PIGR (ng/ml)
Pin/
Pint
Pinteraction
pinteraction for treatment and history of heart failure
Pinteraction=0.003
PIO 15
PIO 30
PIO 45
Pioglitazone
Pioglitazone (n = 1939)
Pioglitazone (N = 303)
Pioglitazone (N =1,939)
Pioglitazone (n=1939)
Pioglitazone (n=2605)
Pioglitazone dose, mean (SD), mg
Pioglitazone Events / N (%)
Pioglitazone Group (n = 644)
Pioglitazone only
Pioglitazone Pts / N (%)
Piroxicam
Pitavastatin 4 mg
Pla
PLA
PLA « = 82
PLA n = 107
PLA n = 38
Plac
Place of randomization
Place!
Placebo
PLACEBO
"Placebo-adjusted mean difference in % HbA1c (95% CI; [ p value])"
Placebo-Control Study
Placebo‐controlled period
Placebo       no.of events/total no. (%)
Placebo    |
Placebo    119
Placebo    1o1
"Placebo "" (n = 157)"
Placebo %
Placebo ( N = 466)
Placebo (%)
Placebo (« = 4672)
Placebo (» = 4672)
Placebo (0=244)
Placebo (593, 50.5%)
Placebo (DM- vs. DM+)
Placebo (DM-vs. DM+)
Placebo (events/n(%))
Placebo (LSM)
Placebo (n-207)
Placebo (n - 16)
Placebo (N - 209)
Placebo (n -10.090)
Placebo (n — 230)
Placebo (n : 418)
Placebo (n [ 159)
Placebo (n [ 83)
Placebo (n = 1,118)
Placebo (n = 1,161)
Placebo (n = 1,776)
Placebo (N = 10,186)
Placebo (n = 100)
Placebo (n = 1010)
Placebo (n = 105)
Placebo (N = 1069)
Placebo (n = 107)
Placebo (n = 108)
Placebo (N = 108)
Placebo (n = 110)
Placebo (N = 112)
Placebo (n = 113)
Placebo (n = 113)†
Placebo (n = 114)
Placebo (n = 116)
Placebo (N = 122)
Placebo (n = 1231)
Placebo (N = 1244)
Placebo (n = 1256)
Placebo (n = 128)
Placebo (N = 13,224)
Placebo (N = 131)i-
Placebo (n = 132)
Placebo (N = 133)
Placebo (n = 134)
Placebo (n = 136)
Placebo (N = 137)
Placebo (n = 1379)
Placebo (n = 140)
Placebo (n = 142)
Placebo (N = 143)
Placebo (n = 1441)
Placebo (n = 147)
Placebo (N = 149)
Placebo (N = 15,224)
Placebo (n = 153)
Placebo (n = 154)
Placebo (N = 1604)
Placebo (n = 163)
Placebo (n = 164)
Placebo (N = 1649)
Placebo (n = 166)
Placebo (n = 167)
Placebo (n = 168)
Placebo (n = 170)
Placebo (N = 1723)
Placebo (N = 1726) 61.9±8.6
Placebo (n = 173)
Placebo (n = 174)
Placebo (n = 1758)
Placebo (N = 176)
Placebo (n = 177)
Placebo (n = 178)
Placebo (n = 18,330)
Placebo (N = 18,330)
Placebo (n = 180)
Placebo (n = 181)
Placebo (N = 181)
Placebo (n = 1817)
Placebo (n = 1835)
Placebo (N = 185)
Placebo (n = 186)
Placebo (n = 187)
Placebo (n = 19 939)
Placebo (n = 19 942)
Placebo (n = 19)
Placebo (N = 19,942)
Placebo (n = 190)
Placebo (N = 191)
Placebo (n = 1937)
Placebo (n = 196)
Placebo (N = 197)
Placebo (N = 198)
Placebo (n = 19939)
Placebo (n = 20)
Placebo (N = 201)
Placebo (n = 202)
Placebo (N = 202)
Placebo (n = 203)
Placebo (n = 2061)
Placebo (N = 208)
Placebo (n = 21)
Placebo (n = 215)
Placebo (n = 2167)
Placebo (n = 2176)
Placebo (N = 2215)
Placebo (N = 226)
Placebo (N = 229)
Placebo (n = 230)
Placebo (N = 2327) 71.7±9.0
Placebo (N = 233)
Placebo (N = 2333)
Placebo (n = 234)
Placebo (n = 24)
Placebo (n = 248)
Placebo (n = 25)
Placebo (N = 2510)
Placebo (n = 2526)
Placebo (n = 257*)
Placebo (n = 26)
Placebo (N = 2679)
Placebo (N = 2753)
Placebo (n = 28)
Placebo (n = 29)
Placebo (n = 2988)
Placebo (N = 299)
Placebo (n = 3,941)
Placebo (N = 3006)
Placebo (n = 302)
Placebo (N = 3034)
Placebo (n = 31)
Placebo (N = 313)
Placebo (N = 324)
Placebo (n = 3281)
Placebo (n = 331)
Placebo (n = 345)
Placebo (n = 3485)
Placebo (n = 3485)'
Placebo (N = 3511)
Placebo (N = 3687)
Placebo (N = 3906) n (%)
Placebo (n = 399)
Placebo (n = 4,271)
Placebo (N = 409)
Placebo (N = 419)
Placebo (n = 424)
Placebo (n = 426)
Placebo (N = 4347)
Placebo (n = 437)
Placebo (N = 4502)
Placebo (N = 4675)
Placebo (n = 47)
Placebo (n = 483)
Placebo (n = 484)
Placebo (n = 497)
Placebo (n = 4i3)
Placebo (n = 503)
Placebo (N = 525
Placebo (n = 528)
Placebo (n = 537)
Placebo (N = 582)
Placebo (N = 586)
Placebo (N = 594)
Placebo (n = 596)
Placebo (n = 6,930)
Placebo (n = 60)
Placebo (N = 60)
Placebo (N = 607) 67.1±8.2
Placebo (n = 63)
Placebo (n = 64)
Placebo (N = 640)
Placebo (n = 649)
Placebo (n = 65)
Placebo (N = 662)
Placebo (n = 677)
Placebo (n = 69)
Placebo (N = 696)
Placebo (n = 7)
Placebo (n = 7,051)
Placebo (n = 7,268)
Placebo (N = 7067)
Placebo (n = 72)
Placebo (n = 73)
Placebo (n = 74)
Placebo (n = 741)
Placebo (N = 742)
Placebo (N = 746)
Placebo (n = 76)
Placebo (n = 7740)
Placebo (n = 78)
Placebo (n = 80)
Placebo (n = 812)
Placebo (N = 812)
Placebo (n = 82)
Placebo (N = 829)
Placebo (N = 8578)
Placebo (n = 86)
Placebo (n = 896)
Placebo (n = 933)
Placebo (N = 9462)
Placebo (N = 9552)
Placebo (n = 97)
Placebo (n = 98)
Placebo (N =1,937)
Placebo (n =154)
Placebo (n =163)
Placebo (n =167)
Placebo (N =353)
Placebo (N =720)
Placebo (n 5 1,785)
Placebo (n 5 154)
Placebo (n 5 232)
Placebo (n 5 418)
Placebo (n 5 5786)
Placebo (n 5 692)
Placebo (n 5 78)
Placebo (n 5280)
Placebo (n Z 1033)
Placebo (n Z 146)
Placebo (n Z 1965)
Placebo (n Z 261)
Placebo (n Z 435)
Placebo (n Z 600)
Placebo (n Z 77)
Placebo (n Z 932)
Placebo (n = 1,261)
Placebo (n = 105)
Placebo (n = 155)
Placebo (N = 23)
Placebo (n = 234)
Placebo (n = 301)
Placebo (n = 49)
Placebo (n = 506)
Placebo (n = 103)
Placebo (n = 104)
Placebo (n = 125)
Placebo (n = 128)
Placebo (n = 129)
Placebo (n = 2,717)
Placebo (n = 21)
Placebo (n = 25)
Placebo (n = 26)
Placebo (n = 51)
Placebo (n = 626)
Placebo (N[130)
Placebo (n[1544)
Placebo (N = 117)
Placebo (n = 1597)
Placebo (n = 167)
Placebo (n = 1770)
Placebo (n = 20)
Placebo (n = 236)
Placebo (n = 270)
Placebo (n = 273)a
Placebo (n = 331)a
Placebo (N = 34)
Placebo (n = 40)
Placebo (n = 52)
Placebo (n = 525)
Placebo (n = 563)
Placebo (n = 578)
Placebo (n = 578)b
Placebo (N = 83)
Placebo (n= 1,174)
Placebo (n= 225)
Placebo (n= 350)
Placebo (n= 352)
Placebo (N=10 090)
Placebo (n=1005)
Placebo (n=102)
Placebo (n=1070)
Placebo (n=108)
Placebo (N=1080)
Placebo (n=112)
Placebo (n=116)
Placebo (n=118)
Placebo (n=122)
Placebo (n=124)
Placebo (N=1267)
Placebo (n=129)
Placebo (n=130)
Placebo (n=1300)
Placebo (n=134)
Placebo (n=137)
Placebo (n=1382)
Placebo (n=139)
Placebo (n=140)
Placebo (n=1428)
Placebo (N=146)
PLACEBO (N=151)
Placebo (n=1518)
Placebo (N=15224)
Placebo (n=1545)
Placebo (N=1569)
Placebo (n=1645)
Placebo (n=1654)
Placebo (n=168)
Placebo (n=1694)
Placebo (N=1726)
Placebo (N=1739)
Placebo (n=179)
Placebo (N=18 618)
Placebo (N=181)
Placebo (n=1827)
placebo (n=1917)
Placebo (n=1917)
Placebo (n=193)
Placebo (n=1937)
Placebo (n=197)
Placebo (n=20)
Placebo (n=206)
Placebo (N=2061)
Placebo (n=2078)
Placebo (n=211*)
Placebo (N=2118)
Placebo (n=2191)
Placebo (n=22 891)
Placebo (n=22 923)
Placebo (n=22)
Placebo (n=224)
Placebo (n=225)
Placebo (N=228)
Placebo (N=2289)
Placebo (n=232)
Placebo (n=235)
Placebo (n=236)
Placebo (N=2448)
Placebo (N=247)
Placebo (n=2477)
Placebo (n=248)
Placebo (n=249)
Placebo (n=258)
Placebo (n=26)
Placebo (n=260)
Placebo (n=2633)
Placebo (n=267)
Placebo (n=2679)
Placebo (n=269)
Placebo (n=271)
Placebo (n=275)
Placebo (n=277)
Placebo (n=294)
Placebo (n=315)
Placebo (n=3182)
Placebo (n=3417)
Placebo (n=348l)
Placebo (n=352)
Placebo (n=354)
Placebo (n=362)
Placebo (N=3667)
Placebo (n=3689)
Placebo (n=381)
Placebo (n=399)
Placebo (N=4,672)
Placebo (n=403)
Placebo (n=407)
Placebo (n=4127)
Placebo (n=413)
Placebo (n=42)
Placebo (n=425)
Placebo (n=428)
Placebo (n=4287)
Placebo (n=430)
Placebo (n=440)
Placebo (N=4661)
Placebo (N=4672)
Placebo (n=4732)
Placebo (n=476)
Placebo (n=488)
Placebo (N=52)
Placebo (n=552)
Placebo (n=5571)
Placebo (N=5786)
Placebo (n=583O)
Placebo (n=585)
Placebo (n=59)
Placebo (n=596)
Placebo (N=607)
Placebo (n=635)
Placebo (n=646)
Placebo (N=6471 )
Placebo (n=658)
Placebo (n=667)
Placebo (n=675)
Placebo (n=6l)
Placebo (N=703)
Placebo (n=749)
Placebo (N=752)
Placebo (N=758)
Placebo (n=76)
Placebo (n=760)
placebo (n=762)
Placebo (n=762)
Placebo (n=77)
Placebo (n=770)
Placebo (n=779)
Placebo (n=80)
Placebo (n=815)
Placebo (n=82)
Placebo (N=8212)
Placebo (N=847)
Placebo (n=929)
Placebo (n=95)
Placebo (N=96)
Placebo (n=961)
Placebo (n=98)
Placebo (n=l69)
Placebo (symptom days a week)
Placebo (W = 238)
Placebo (W = 239)
Placebo [N = 112|
Placebo [N = 122]
Placebo [N = 198|
Placebo [n Z 51]
Placebo [n Z 66]
Placebo + 20 mg/d of Simvastatin
Placebo + 20 mg/d of Simvastatin (n = 2232)
Placebo + glimepiride
Placebo + insulin (n = 272)
Placebo + Insulin (n=272)
"Placebo + insulin glargine (AWARD-9; N = 150)"
Placebo + MTX
Placebo + MTX (n=249)
Placebo + pioglitazone (n=97)
Placebo + Statin (n = 1,584)
Placebo 0.07
Placebo 0.35
Placebo 1030
Placebo 1116
Placebo 127
Placebo 128
Placebo 129
Placebo 137
Placebo 151
Placebo 152
Placebo 1556
Placebo 16,186
Placebo 18/66
Placebo 3 Year KM (%)
Placebo 3 yr KM%
Placebo 317
Placebo 321
Placebo 50/66
Placebo allocation
Placebo Allocation
Placebo analysed (%)
Placebo arm
Placebo Croup, n/n (%)
Placebo Diabetes n=18
Placebo dn = 16)
Placebo dr = 42)
Placebo Estimated mean
Placebo Event Rate (n=1814), %
Placebo Event Rate (n=6625), %
Placebo Events / N (%)
Placebo Events/patients (
Placebo Events/patients (%)
Placebo every 2 weeks (n=54)
Placebo group
Placebo Group
Placebo group  (n =459)
Placebo Group (n = 159)
Placebo Group (n = 160)
Placebo Group (n = 166)
Placebo group (N = 18 618) (180 652 person years)
Placebo Group (N = 210)f
Placebo group (n = 263)
Placebo Group (N = 328)’j'
Placebo Group (N = 381)
Placebo Group (N = 383)
Placebo group (n = 459)
Placebo Group (N = 7740)
Placebo Group (n = 810)
Placebo Group (n=157)
Placebo group (n=196)
Placebo Group (N=253)
Placebo group (n=3264)
Placebo Group (n=381)
Placebo Group (N=7740)
Placebo group (n=8881)
Placebo KM%
Placebo LS means (N)
Placebo MDI
Placebo mean
Placebo Mean (n)
Placebo Mean change (SD)
Placebo monthly (n=55)
Placebo Mortality Rate, Events per 1000 Person-y
placebo N
Placebo N (%)
Placebo n (Rate)*
Placebo n (rate)1
Placebo n = 115
Placebo N = 117
Placebo N = 118 n (%)
Placebo N = 123
Placebo n = 126
Placebo N = 144
Placebo n = 149
Placebo n = 154
Placebo N = 159
Placebo N = 160
Placebo n = 1651
Placebo n = 172
Placebo N = 180
Placebo N = 189
Placebo n = 202
Placebo n = 229
Placebo n = 278
Placebo n = 35
Placebo n = 355
Placebo n = 53
Placebo n = 73
Placebo n = 76
Placebo n =107
Placebo N =156
Placebo N(%)
Placebo n/N
Placebo n/N (%)
Placebo N[130
Placebo n=169
Placebo N=1771
Placebo N=191
Placebo N=193
Placebo N=2232
Placebo N=2625
Placebo N=3161
Placebo n=3184
Placebo n=401
Placebo N=4015
Placebo N=4941 Subjects
Placebo n=51
Placebo N=6207
Placebo N=638
Placebo n=639
Placebo N=651
Placebo N=7339
Placebo N=7396
Placebo No Diabetes n=46
Placebo No. (3-y KM%)
Placebo no. of events/no.
Placebo No./ total (%)
Placebo No./Total No.
Placebo patients with events
Placebo patients with events/total
Placebo patients/events n
Placebo plus Aspirin
Placebo plus Statin (N = 1696)
Placebo Pts / N (%)
Placebo r%
Placebo secukinumab 150 mg
Placebo secukinumab 75 mg
Placebo secukinumab pooled
Placebo Slope LSM ± SE (mm/year)
Placebo Tiotropium n =114 Non-tiotropium n =323
Placebo Tiotropium n =115 Non-tiotropium n =335
Placebo to ustekinumab 45 mgt
Placebo Tolvaptan (30 mg) (n 5 232) (n 5 243)
Placebo(n = 2573)
Placebo(n=1895)
Placebo(n=1895), n (%)
Placebo(N=842)
Placebo(n=881)
Placebo* (add on to basal insulin)
placebo,
Placebo, % (n/N)
Placebo, % >    (n/N)
Placebo, 1.14 ml (N = 317)
Placebo, 2.00 ml (N = 321)
Placebo, events/patients (%)
Placebo, n
Placebo, n (%)
Placebo, n (rate)
placebo, n = 123
placebo, n = 423
placebo, n = 802
placebo, n = 88
Placebo, N = i334
Placebo, n = l47
Placebo, N =153
Placebo, N(%)
Placebo, n*
Placebo, n/N (%)
Placebo, N = 1334
Placebo, N = 442
Placebo, n=147
Placebo, n=4111
Placebo/
Placebo/ Simvastatin
Placebo/open-label abatacept
Placebo/Rosu vastatin
Placebo/Simva
Placebo/Simvastatin
Placebo+MTX
Placebo+Statin
Placebo→Golimumab 50 mg/100 mga,b
Placebo§
Placeboa
PlacebofiGolimumab 50 mg/100 mgt
Plaeebo
Planned conservative therapy subgroup
Planned Thienopyridine at baseline
Planned Thienopyridine at enrollment
Planned treatment duration, n (%)
Planned treatment strategy
Planned valve surgery, n (%)
Plaque (N, %)
Plaque score (1-8)
Plasma cholesterol — mg/dl
Plasma creatine, mg/dL
Plasma DHA, mean (SD) weight, %
Plasma glucose — mmol per liter
Plasma glucose 2 hr after glucose load — mmol/liter
Plasma lipids (mg/dl)5 Total cholesterol Mean
Plasma lipoproteins, mmol/L
Plasma triglyceride — mg/dl
Platelet aggregation inhibitors excluding heparin
Platelet aggregation inhibitors, n (%)
Platelet count, X 103 mm3
Platelet, 109/L
Platelets xlOOO/mm^
Pleased
PLP-C, mean (SD), mg/dL
"Plus–minus values are means ±SD. CABG denotes coronary-artery by-pass graft, PTCA percutaneous transluminal coronary angioplasty, and ACE angiotensin-converting enzyme. Hypertension and diabetes were de-fined by clinical history. A more complete list of base-line characteristics is given in Rubins et al.
18
†Nitrates includes all preparations except as-needed nitroglycerin. ‡Any antianginal drug includes any nitrate (as defined above), calcium-channel blocker, or beta-blocker. §The body-mass index is the weight in kilograms divided by the square of the height in meters. ¶To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129."
Plus metformin
PM PEF (SD), L/min
PM, n (%)
PND
Pneumonia
Pneumonia events, n
Pneumonia in past year
PnorCABG
PnorPCI
POBA, n (%)
POCI
POCI (n=236)
Poland
Pollen exposure
Pollent < 10
Pollent s 10
Polyarticular arthritis, no rheumatoid nodules
Polyvascular disease (n=1930)
Polyvascular disease and no type 2 diabetes (n=1193)
Polyvascular disease and type 2 diabetes (n=737)
Polyvascular disease* (n=1930)
Polyvascular disease* and type 2 diabetes status
Polyvascular disease* status
Pool of FH I and II studies
Pool of LONG TERM (HeFH patients only) and HIGH FH
Pooled
Pooled analysis
Pooled analysis of SUSTAIN 1—5 trials
Pooled analysis sample
Pooled empagliflozin (N = 4687)
Pooled EZE/SIMVA
Pooled ITT
"Pooled Non-CANVAS Studies (N = 5867): Non-CANA (n = 2199); CANA 100 mg (n = 1647); CANA 300 mg (n = 2021)"
Pooled PAH-MCTD and PAH
Pooled placebo
Pooled secukinumab
Pooled SIMVA
Pooled Simvastatin Factorial Studies
Pooled trials* n = 5325
Poor
Poor compliance/noncompliance
Poor outcome at 6 months
Population
Populations:
Positive
Positive atopic status
Positive cTnl (n = 2843)
Positive CU index test
Positive CU index test,z n (%)
Positive family history of type 2 diabetes (%)
Positive for anti-cyclic citrullinated peptide antibody — no. (%)f
Positive for HLA-B27, n (%)
Positive for rheumatoid factor — no. (%):t
Positive for rheumatoid factor, anti-cyclic citrullinated peptide antibodies, or both — %ff
Positive HLA-B27 status, n (%)
Positive orthostatic test}
Positive troponin I or T, No. (%)
Positive troponin or CK-MB
Positive vs. negative
Positive vs. Negative
Poslmenopausal, HT
Poslmenopausal, no HT
Post-acute ischemic stroke
Post-albuterol% predicted FEV1 Mean (SD)e
Post-bronchodilation FEV1
Post-bronchodilation FVC
Post-bronchodilator
Post-bronchodilator FEV i Reversibility, %b
Post-bronchodilator FEV, % predicted
Post-bronchodilator FEV, (L)
Post-bronchodilator FEV, reversibility
Post-bronchodilator FEV,, % predicted
Post-bronchodilator FEV,/FVC
Post-bronchodilator FEV1 — % of predicted value
Post-bronchodilator FEV1 — liters
Post-bronchodilator FEV1 (% predicted normal)a
Post-bronchodilator FEV1 (% predicted*)
Post-bronchodilator FEV1 (L)
Post-bronchodilator FEV1 (l)*
Post-bronchodilator FEV1 (L)a
Post-bronchodilator FEV1 at screening
post-bronchodilator FEV1 mL
Post-bronchodilator FEV1 reversibility, %
Post-bronchodilator FEV1 reversibility, %a
Post-bronchodilator FEV1% predictedb
Post-bronchodilator FEV1, % predicted
Post-bronchodilator FEV1, % predicted of normal value
Post-bronchodilator FEV1, % predicted, mean (SD)
Post-bronchodilator FEV1, % predicted, mean (SD)c
Post-bronchodilator FEV1, L
Post-bronchodilator FEV1, L *
Post-bronchodilator FEV1, L, mean (SD)
Post-bronchodilator FEV1, L, mean (SD)c
Post-bronchodilator FEV1, mean (SD), L
Post-bronchodilator FEV1, reversibility percentage of baseline value
Post-bronchodilator FEV1,% predicted
Post-bronchodilator FEV1/FVC (%)a
Post-bronchodilator FEV1/FVC ratio, mean (SD)
Post-bronchodilator FEV1/FVC, %
"Post-bronchodilator FEV1; % Predicted"
Post-bronchodilator FEVi, n (%)
Post-bronchodilator FEVi1    % predicted
Post-bronchodilator FEVX (L)
Post-bronchodilator FVC (L)a
Post-bronchodilator percent of predicted FEV1, % (SD)
Post-bronchodilator ratio of FEV1 to FVC — %
post-bronchodilator Reversibility FEV1 (%) Mean (SD)
Post-bronchodilator screening
Post-bronchodilator screening FEV1 mL
Post-CABG
Post-dose
Post-fibrinolysis angioplasty (n = 104)
Post-menopausal (A)
Post-menopausal with hormone replacement
Post-menopausal without hormone replacement
Post-MI
Post-procedure
Post-salbutamol FeV1 (l)b, mean (sD)
Post-salbutamol FeV1/FVCb, mean (sD)
Post erior-anterior spine
Post FEV1
Post FEV1 % pred
Post FVC
Post FVC % pred
Post Hoc Analysis
Post SVC
Postamendment
Postbaseline binding antibodies
Postbaseline new-onset diabetes - n (%)
Postbronchodilator
Postbronchodilator 1.10 (0.38)
Postbronchodilator 36.2 (10.2)
Postbronchodilator FEV1 reversibility, %
Postbronchodilator FEV1, % predicted
Postbronchodilator FEV1, L
Postbronchodilator FEV1,L
Postbronchodilator FEV1/FVC, %
Postbronchodilator FEVj (% predicted)
Postbronchodilator lung function at screening
Postdose FEV/FVC at screening
Posterior circulation
Postmenopausal
Postmenopausal (%)
Postmenopausal and current HRT
Postmenopausal and current HT
Postmenopausal and no HRT
Postmenopausal and no HT
Postmenopausal hormone use
Postmenopausal,
Postmenopausal, current hormone
Postmenopausal, current hormone therapy use
Postmenopausal, current HRT
Postmenopausal, never or past hormone therapy use
Postmenopausal, no HRT
Postoperative glucocorticoid use
Postoperative glucocorticoid use POST-RANDOMISATION CHARACTERISTIC**
Postoperative NSAID or glucocorticoid use
Postoperative NSAID or glucocorticoid USE POST-RANDOMISATION CHARACTERISTIC**
Postoperative use of p-blocker
Postprandial indices
Potassium
Potassium-sparing at enrollment
Potassium-sparing at last follow-up
Potassium-sparing diuretic
Potassium — mg/dl
Potassium — mmol/liter
potassium (mEq/L)
Potassium (mEqL), mean + SD, available for 3662 patients
Potassium (mg/dl)
Potassium (mmol/L)
Potassium at admission, mmol/l-1
Potassium supplement
Potassium, mean (SD), mEq/L
Potassium, mEq/dL, mean
Potassium, mEq/l
Potassium, mmol/L
Potent phosphorylated glycoprotein inhibitor use
Potential injection site reactions
Potential predictor
PPBC score, mean (SD)
PPCI
PPCI (n=173)
PPCI IN-1671
PPG post-meal test, mmol/L
PPG, mg/dL
PPG, mmol/L
PPI
PPI but no aspirin
PPI or H2 receptor antagonist, n (%)
PPI use
PPI use (p=0-28t)
PPI use (p=0-36t)
PPI use (p=0-97t)
PPI use (p=0.27t)
PPI use at baseline
PPI use within 6 months of randomization
PR/Virgin Islands, n (%)
PRA, median (min, max), ng/mL/h
Pramlintide
Prasugrel
Pravastatin
PRAVASTATIN
Pravastatin (N = 4512>
Pravastatin (n=2081)
Pravastatin 40 mg
Pravastatin 80 mg
Pravastatin n = 793
Pravastatin n =793
Pravastatin Sodium
Pravastatin vs Usual Care
Pre'rtous eptscde(s} d DVT/PE
Pre-BD FVC <65% of predicted
Pre-BD FVC s65% of predicted
Pre-bronchodilation FEV1
Pre-bronchodilation FVC
Pre-bronchodilator
Pre-bronchodilator FEF25.75 (mL/s) Baseline blood eosinophil count
Pre-bronchodilator FEV i (L)
Pre-bronchodilator FEV, % predicted
Pre-bronchodilator FEV, (L)
Pre-bronchodilator FEV^ (L)
Pre-bronchodilator FEV1
Pre-bronchodilator FEV1 (% predicted normal)
Pre-bronchodilator FEV1 (L)
Pre-bronchodilator FEV1, L*
Pre-bronchodilator FEV1/FVC (%)
Pre-bronchodilator FEV1/FVC ratio*
Pre-bronchodilator FEVi change
"Pre-bronchodilator FEVi/FVC"" %"
Pre-bronchodilator FEVj
Pre-bronchodilator FEVr % pred
Pre-bronchodilator FEVr L
Pre-bronchodilator FVC (L)
Pre-bronchodilator FVC’ % pred
Pre-bronchodilator mean (SD) FEV1,.L
Pre-bronchodilator screening
Pre-bronchodilator screening FEV1 mL
Pre-dose
Pre-enrollment antihyperglycemic therapy
Pre-h
Pre-hospital ticagrelor (n=906)
Pre-menopausal with hormone replacement
Pre-menopausal without hormone replacement
Pre-operative cardiac medications*
Pre-procedure
Pre-randomization PCI
Pre-specified HR (95% Cl)
Pre-specified Trial Endpoints
Pre-treatedforhypertension [n (%)]
Pre-treatment[n (%)]c
Pre–Diabetes Mellitus
Pre–Diabetes Mellitus, n=2103
Pre FEV1
Pre FEV1 % pred
Pre FVC
Pre FVC % pred
Pre hospital ticagrelor
Pre SVC
Preamendment
Prebronchodilator
Prebronchodilator FEV1
Prebronchodilator FEV1 (%
Prebronchodilator FEV1 (% predicted normal)t
Prebronchodilator FEV1 (L)
Prebronchodilator FEV1 (L)t
Prebronchodilator FEV1, % predicted
Prebronchodilator FEV1, L
Prebronchodilator FEV1, mean (SD), L
Prebronchodilator FEV1,L
Prebronchodilator FEV1/FVC
Prebronchodilator FEVi — liters
Prebronchodilator FEVi (% predicted)
Prebronchodilator FEVj (% predicted)
Prediabetes — no. (%)1
Prediabetes, %
Prediabetes, n (%)
Prediabetese
Prediabeticb
Predicted normal (%)
predicted normal)t
Predictive factor
Prednisone
Prednisone-equivalent dose — mg
Prednisone-equivalent dose, mg,
Prednisone or equivalent dose (mg/day)
Prednisone use, %
Predominant cardiac diagnosis — no. (%)
Predominant type of heparin
Predose FEV-, at randomization
Predose FEV/FVC
Predose FEV^ at screening
Predose FEV1 (L)*
Predose FVC (L)
Predose FVC (L)*
Preferred term, %
Pregnancy
Prehospital Ticagrelor (N = 909)
Premature CAD among family members
Premature discontinuation
Premature treatment discontinuation
Premenopausal
Premenopausal, %
Premixed insulin only (%)
Premixed insulin with OADs (%)
Preoperative blood pressure (mm Hg) Patients fulfilling eligibility criteria
Preoperative heart rate (beats per minute)
Preoperative p-blocker use Yes
Preoperative serum creatinine >175 pmol/L
Preoperative use p-Blocker
Prerandomization PCI
Prerandomization statin therapy
Presence of angioedema at baseline
Presence of dactylitis
Presence of dactylitis, n (%)
Presence of enthesitis
Presence of enthesitis, n (%)
Presence of erosions, n (%)
Presence of honeycombing,1 n (%)
Presence of MetS
Presence of MetS (%)a
Presence of tophi
Presence of tophi, n (%)
Present
Present (£100 mg/dL)
Present (£110 mg/dL)
Present (>100 mg/dL)
Present at screening
Present smoker
Present smokerc
Presentation of index event
Presentation to tertiary care hospital — %
Presentation*
Presenting condition, n (%)
Presenting diagnosis
Presenting Diagnosis
Presenting history or diagnosis — no. (%)
Presenting signs and symptoms
Prespecified Analysis
Prespecified medical conditions, n (%)f
Prespecified subgroup analyses
Prespecified subgroups
pressure (mm Hg)
pressure,
Prestudy treatment (%)a
Prestudy treatment status
Pretreatment HDL-C
Pretreatment triglycerides
Pretreatment/ concomitant treatment
Prevalence of each metabolic syndrome criterion
Prevalent CVD
Prevalent kidney disease (eGFR< 60 mL/min/USm^ or maeroalbuminuria UACR >300 mg/g)
Prevalent vertebral fracture
Prevalent vertebral fracture status
Prevalent vertebral fracture, n (%)
prevention), n (%) Patients on LLT (other than statin), n (%)
Previous
Previous 5-ARI use (%)
Previous 5ARI use
Previous a-blocker
Previous a-blocker use
Previous acute hypersensitivity reaction to infliximab — no. of patients (%)
Previous AF
Previous AMI
Previous AMI, n (%)
Previous analgesic products n (%)
Previous angina pectoris
Previous angina, n (%)
Previous angioplasty, n (%)
Previous anti-inflammatory/antirheumatic products n (%)
Previous anti-TNF therapy, N [%]
Previous antiarrhythmic treatment — no. (%)
Previous antihypertensive treatment
Previous antihypertensive treatment — no.(%)
Previous antiparkinson medication, No. (%)
Previous aorta-femoral or lower extremity bypass surgery, PTA of iliac, or infrainguinal artery
Previous balloon angioplasty
Previous balloon angioplasty, n (%)
Previous bDMARD received
Previous bowel resection performed — no. of patients (%)
Previous bypass surgery, n (%)
Previous CABG
Previous CABG (% total)
Previous CABG (before index ACS)*
Previous CABG surgery
Previous CABG, n (%)
Previous CAD
Previous CAD, n (%)
Previous cancer
Previous cancer — no. (%)
Previous cancer, n (%)
Previous cancerc
Previous cardiovascular disease!
Previous cardiovascular event — no. (%)
Previous cardiovascular event (%)
Previous cardiovascular event at randomization
Previous cardiovascular events
Previous CD related surgery (ref)a
Previous cerebrovascular event
Previous CHF
Previous CHF — no. (%)
Previous CHF, n (%)
Previous chronic kidney disease
Previous chronic use of antiplatelet drugs
Previous clinical stroke or TIA
Previous clinical stroke or transient ischemic attack (%)
Previous congestive heart failure
Previous congestive heart failure — no. (%)
Previous congestive heart failure (%)
Previous COPD treatment, n (%)*
Previous coronary-artery bypass grafting
Previous coronary angioplasty, n (%)
Previous coronary artery bypass graft
Previous coronary artery bypass grafting
Previous coronary artery bypass surgery, no. (%)
Previous coronary artery disease, n (%)
Previous coronary heart disease
Previous coronary intervention
Previous coronary procedure (% of group)
Previous coronary revascularisation
Previous coronary revascularization
Previous coronary revascularization — no. (%)
Previous CV event
Previous CV Event
Previous CV events
Previous CVD^
Previous deep-vein thrombosis or pulmonary embolism
Previous diabetes
Previous Diabetes Mellitus
Previous diagnosis
Previous digoxin use
Previous digoxin use (%)
Previous disease — no. (%)f
Previous disease and drug use
Previous disease:
Previous DM
Previous DM, n(%)
Previous DMARDs use, n (%)
Previous DMARDs, mean ± SD
Previous episode of heart failure
Previous events, No. (%)
Previous exposure to a vitamin K antagonist — no. (%) Current or Former Never
Previous exposure to biologic systemic psoriasis therapyb (yes), n (%)
Previous exposure to non-biologic systemic psoriasis therapyb (yes), n (%)
Previous exposure to systemic psoriasis therapyb (yes), n (%)
Previous heart failure
Previous heart failure — no. (%)
Previous HF
Previous HF hospitalization, n (%)
Previous history of cardiovascular events
Previous hospital admission for heart failure
Previous hospitalization for heart failure
Previous hospitalization for unstable angina
Previous HTN, n (%)
Previous hypersensitivity reaction — no. (%)
Previous hypertension
Previous ICS alone
Previous ICS only
Previous ICS/LABD
Previous infarction
Previous infarction (% of group)
Previous infliximab therapy — no. of patients (%)**
Previous infliximab therapy||
Previous intervention (%)
Previous intolerance of infliximab, n (%)*
Previous ischemic heart disease — no. (%)
Previous ischemic stroke orTIA
Previous ischemic stroke, n (%)
"Previous Ischemic Stroke/ TIA (n=5973; 28.3%)"
Previous LABD alone
Previous LABD only
Previous LEV only
Previous limb or foot amputation
Previous loss of response to and intolerance of infliximab, n (%)*
Previous loss of response to infliximab, n (%)*
Previous major bleeding
Previous medication for respiratory disease — no. (%)
Previous medications, n (%)
Previous metformin use, %
Previous MI
Previous MI — no. (%)
Previous MI (%)
Previous MI, %
Previous MI, n (%)
Previous Ml
Previous Ml (before index ACS)
Previous Ml (Interaction: p=0.09)
Previous Ml or abnormal angiogram
Previous myocardial infarction
Previous myocardial infarction — no. (%)
Previous myocardial infarction (%)
Previous myocardial infarction, n (%)
Previous myocardial infarction, no. (%)
Previous myocardiaUnfarction
Previous number of CIU/CSU medications
Previous OAD (%)
Previous or current CS use: No
Previous or current IM use: No
Previous or current use of IM and CS: No
Previous or current use of IM or CS: No
Previous oral antidiabetic medication use, n (%)
Previous oral glucose-lowering agents, % of patients
Previous PCI
Previous PCI (% total)
Previous PCI (before index ACS)
Previous PCI or CABG
Previous PCI, n (%)
Previous PCI/CABG, n (%)
Previous PDE5-I therapy, no. (%)
Previous PDE5 inhibitors
Previous percutaneous coronary intervention
Previous percutaneous coronary intervention, %
Previous Pneumonia
Previous receipt of therapy against TNF-a — no. (%)
Previous renal disease, n(%)
Previous respiratory disease other than COPD — no. (%)
Previous revascularization
Previous segmental resection — no. (%)
Previous segments resection(s)*
Previous smoker
Previous smokers
Previous statin use
Previous stenting (% previous PCI)
Previous stroke
Previous stroke— no. (%) Concomitant treatment—no. (%)
Previous stroke — no. (%)
Previous stroke 一 no. (%)
Previous stroke or TIA
Previous stroke or TIA (%)
Previous stroke or TIA (n=1195)
Previous stroke or TIA (n=1233)
Previous stroke or TIA, n (%)
Previous stroke or Tl A
Previous stroke or Tl A    1-39
Previous stroke or transient ischemic attack — no./total
Previous stroke or transient ischemic attack, No./total No. (%)
Previous stroke orTIA
Previous stroke orTIA    2-19
Previous stroke ortransient ischaemic attack (%)
Previous stroke Yes (n, %) Previous myocardial infarction
Previous stroke*
Previous stroke, n (%)
Previous stroke/TIA
Previous systemic treatment, n (%)
Previous therapies, n (%)
Previous therapy
Previous TIA
Previous TIA or stroke
Previous TNF-antagonist use, n (%)
Previous TNF antagonist exposure, n (%)
Previous transient ischaemic attack/ischaemic stroke Previous warfarin use
Previous transient ischemic attack
Previous treatment
Previous treatment failure — no. (%)§**
Previous treatment in the healing study, n (%)
Previous treatment with a LABA and / or LAMA, n (%)c
Previous treatment with infliximab
Previous treatment with TNF antagonist — no. (%)§
Previous treatment?
Previous use of amiodarone
Previous use of antiarrhythmic drugs
Previous use of antiplatelet drugs
Previous use of biologic systemic therapy, n (%)
Previous use of niacin or Niaspan§
Previous use of nonbiologic systemic therapy, n (%)
Previous use of other biologic agents in addition to TNE
Previous use of systemic steroids for CIU/CSU
Previous use of systemic steroids, n (%)
Previous use of vitamin K antagonist for >60 days — no. (%)
Previous vascular disease
Previous venous thromboembolism — no. (%)
Previous venous thromboembolism —no. (%)
Previous VKA Use
Previous VKA use (stratified randomization)
Previous VTE
Previous VTE — no. (%)
Previous VTE n (%)
Previous VTE, n (%)
Previous warfarin use, No. (%)
Previousdistaldeep-veinthrombosisorsuperficial-vein thrombosis
Previously
Previously failed anti-TNF treatment, no. (%)
Previously on ACEI+ARB
Previously taken any other DMARDs, n (%)
Previously taken DMARDs other than methotrexate, %
Previously taken methotrexate, %
Previously taken TNFi, %
Previously untreated isolated systolic hypertension
Primary
Primary-prevention cohort
Primary +GUSTO severe bleeding
Primary analysis
"Primary and secondary prevention subgroups; adjusted for age, gender, hypertension, diabetes mellitus, and smoking. HR indicates hazard ratio; 95% Cl, 95% confidence interval; TIA, transient ischemic attack."
Primary angioplasty (n = 108)
Primary cardiovascular endpoint
Primary cause of CHF
Primary cause of heart failure
Primary composite end point
Primary composite end point‡
Primary composite end points
Primary composite endpoint‡
Primary composite outcome
Primary composite^
Primary CV endpoint
Primary efficacy outcome
Primary end-point
Primary end point
Primary End point
Primary End Point
Primary end point |
Primary End Point Kaplan-Meier Rate, %
"Primary end point"""
Primary end point*
Primary End Point, No. of Events/Total No. (%)
Primary end point: Death/MI/IDR/ST
Primary end points
Primary endpoint
Primary Endpoint
Primary endpoint death/MI/IDR/ST
Primary endpoint:
Primary endpoint^
Primary endpoint’
Primary endpoint4
Primary enrollment diagnoses, n (%)
Primary EP (CVD/MI/RI)
Primary hemorrhagic stroke
Primary indication
Primary ischemic stroke
Primary MACE endpoint
Primary nonresponse
Primary outcome
Primary Outcome
Primary Outcome (3-Point MACE)
Primary outcome plus revascularization or nonfatal HF
Primary outcome!
Primary outcome! (n=743)
Primary outcome: 20% decrease in WOMAC pain score
Primary outcomes
Primary PCI
Primary PCi (n = 686)
Primary PCI (n = 806)
Primary PCI (N = 806)
Primary PCI (N = 948)
Primary PCI (n=948)
Primary PCI n=948
Primary PCI no.
Primary PCIt
Primary prevention subgroup
Primary Prevention Subgroup
Primary Renal Endpoint
Primary Renal Endpoint or Death
Primary safety end point: Severe/life-threatening
Primary safety outcome -
Primary study joint, n (%)
Primary target vessel (%)
Primary trial end point
Primary*
Primary/key efficacy endpoint
Primary+GUSTO moderate or severe bleeding
Prior
Prior a-blocker use
Prior ACBi or ARB use
Prior ADMb
Prior AEDs, ≥1, n (%)
Prior AF ablation, n (%)
Prior amputation
Prior analgesic products, n (%)
Prior angina
Prior Angina
Prior angina (n = 2,768)
Prior angina pectoris
Prior angina pectoris — no./total no. (%)
Prior angina, n/N (%)
Prior angiography showing stenosis ≥50%, N = 247 235a
Prior angiography showing stenosis ≥50%, N = 521 09a
Prior angiography showing stenosis >50%, N = 52109°
Prior angioplasty
Prior anti-TNF exposure
Prior anti-TNF failure
Prior anti-TNF therapy
Prior anti-TNF therapy — no. (%)
Prior anti-TNF treatment
Prior antihypertensive medication, n (%)
Prior antiinflammatory/antirheumatic products, n (%)
Prior aortocoronary bypass surgery
Prior aortocoronary bypass surgery — no. (%)
Prior aortocoronary bypass surgery 一no. (%)
Prior arrhythmias, n (%)
Prior ASA use
Prior aspirin
Prior aspirin use
Prior BB plus ACBi plus ARB use
Prior biologic exposure
Prior biologic therapeutic failures, n (%)
Prior biologic therapy (including anti-TNFs)
Prior biologic use
Prior bisphosphonate usage
Prior BP use
Prior brachytherapy
Prior bypass graft surgery
Prior CABG
Prior CABG (before index ACS)
Prior CABG surgery
Prior CABG, %
Prior CAD
Prior cancer
Prior Cancer
Prior cardiac resynchronization therapy, n (%)
Prior cardiac surgery, n (%)
Prior cardiovascular disease
Prior cardiovascular event
Prior cardiovascular event— no. (%)-j-
"Prior cardiovascular event""'"""
Prior cardiovascular history
Prior carotid intervention
Prior cerebrovascular disease
Prior CHF
Prior CHF, %
Prior clinical fracture (since age 45)
Prior congestive heart failure
Prior Congestive heart failure
Prior congestive heart failure Yes
Prior conventional synthetic DMARDs, n (%)
Prior COPD medication
Prior COPD medicationa, n (%)
Prior coronary artery bypass graft
Prior coronary artery bypass graft surgery
Prior coronary artery bypass grafting
Prior coronary artery bypass surgery
Prior coronary artery disease Yes
Prior coronary intervention or coronary artery bypass grafting
Prior coronary revascularization
Prior coronary revascularization — no. {%)
Prior coronary revascularization (PCI or CABG)
Prior coronary revascularization, n (%)
Prior coronary revascularization, n(%)
Prior coronary revascularization, n/N (%)
Prior coronary revascularization, no. (%)
Prior corticosteroid failure only
Prior corticosteroid treatment
Prior CV event
Prior CV Event
Prior CV event at randomization!
Prior CV history
Prior CV history, n (%)
Prior CVD
Prior diabetes
Prior Diagnosis- no. (%)
Prior disease
Prior disease-modifying drugs resulting in inadequate response — mean no./patient
Prior DM
Prior ED therapy
Prior electrical cardioversion for AF (n=21 104)
Prior failure of anti-TNF therapy — no. (%)
Prior gestational diabetes
Prior heart failure
Prior Heart Failure
Prior heart failure — no. {%)
Prior Heart Failure (n = 2,105)
Prior Heart Failure Yes
Prior heart failure, %
Prior heart failure, n (%)
Prior heart failure, n/N (%)
Prior HF (n = 1,069)
Prior HF hospitalization
Prior HF Hospitalization (n=147)
Prior HF n=1068
Prior history Ml or stroke
Prior history of bleeding on OAC
Prior history of cardiovascular disease, n (%)
Prior history of MI or ischaemic stroke
Prior history of Ml or ischemic stroke
Prior hospitalization for HF, %
Prior hospitalizations, n (%)
Prior HTN (n = 1,659)
Prior hypertension
Prior Hypertension Yes
Prior hypertensiona Yes
prior immunnosupressive failure but no anti-TNF failure
Prior immunosuppressant failure
"Prior immunosuppressant failure"""
Prior immunosuppressant failurec
Prior immunosuppressive exposure, n (%)
Prior implantable cardiodefibrillator, n (%)
Prior infarction
Prior insulin use (years)
Prior ischemic stroke
Prior Ischemic Stroke
Prior known stenosis >50%
Prior LEV
Prior LEV treatment
Prior LEV treatment, n (%)
Prior LEV use
Prior LGI event
Prior lipid-lowering agent use
Prior lipid-modifying therapy
Prior LLT
Prior lower GI clinical event
Prior medication use, n (%)
Prior medications
Prior mesalazine use*
Prior MI
Prior MI (n - 2,456)
Prior MI (n = 2,151)
Prior MI (n= 3,584)
Prior MI diagnosis:
Prior MI n=2147
Prior MI within 5 y, no. (%)
Prior MI, %
Prior MI, n/N (%)
Prior migraine
Prior Migraine*
Prior Ml
Prior Ml (before index ACS)
Prior Ml or abnormal angiogram
Prior Ml or stroke at baseline
Prior Ml/stroke
Prior MS treatment with IFN-beta or
Prior MS treatment with IFN-beta or glatiramer acetate. No. (%)
Prior myocardial infarction
Prior myocardial Infarction
Prior Myocardial Infarction
Prior myocardial infarction — no. (%)
Prior myocardial infarction — no. {%)
Prior myocardial infarction — no./total no. (%)
Prior myocardial infarction (%)
Prior myocardial infarction 一no. (%)
Prior myocardial infarction Yes
Prior myocardial infarction, %
Prior myocardial infarction, n (%)
Prior myocardial infarction, n(%)
Prior myocardial infarction, No./total No. (%)
Prior myocardial intarction
Prior non-CNS SE
Prior non-haemorrhagic stroke
Prior nonvertebral fracture
Prior nonvertebral fracture at age >55 years
Prior NSAID use
Prior NSAID, n (%)a
Prior OABG surgery
Prior OAC
Prior OAD:
Prior OM
Prior OMA use
Prior OMA use (N = 120)
Prior or new diabetes
Prior pacemaker, n (%)
Prior PAD
Prior PCI
Prior PCI or CABG
Prior PCI or CABG surgery
Prior PCI, %
Prior percutaneous coronary intervention
Prior percutaneous coronary intervention — no. (%)
Prior percutaneous coronary intervention — no./total no. (%)
Prior percutaneous coronary intervention, n (%)
Prior Peripheral arterial disease
Prior peripheralarterialdisease
Prior PTCA or CABG
Prior PTCA or PCI
Prior PTCA/PCI
Prior revascularization
Prior revascularization (%)
Prior revascularization (n = 1,690)
Prior smoker
Prior Statin (n=379, 372)
Prior statin use
Prior statin use (n = 144)
Prior STEMI
Prior stent
Prior Stent
Prior stroke
Prior Stroke
Prior stroke — no. (%)
Prior stroke (%)
Prior stroke (before index event)
Prior stroke (N = 902)
Prior stroke or TIA
Prior Stroke or TIA
Prior stroke or TIA, %
Prior stroke or transient ischemic attack
Prior Stroke or TZA
Prior stroke/MI, N (%)
Prior stroke/TIA
Prior Stroke/TIA
Prior sulfasalazine use*
Prior surgery for CD, n (%)
Prior surgery for CD, n [%]
Prior surgery: No
Prior therapy with omalizumab: Yes
Prior therapy with TNF antagonist, n (%)
Prior therapy, %
Prior Thienopyridine (-)
Prior Thienopyridine (+)
Prior TIA
Prior TNF antagonist failure-No
Prior TNF antagonist failure-Yes
Prior TNF antagonist failure, n [%]
Prior TNF antagonist failure, n(%)b
Prior TNF antagonist treatment-No
Prior TNF antagonist treatment-Yes
Prior TNF antagonist, n [%]‘*
Prior TNF inhibitor exposure
Prior TNF inhibitor exposure, no. (%)
Prior TNFI Treatment
Prior TNFi, n (%)
Prior to index event
Prior tobacco use, n (%)
Prior transient ischaemic
Prior transient ischemic attack
Prior treatment
Prior treatment — %
Prior treatment — no. (%)
Prior treatment History1
Prior UGI event
Prior upper GI clinical event
Prior urate lowering therapies, n (%)
Prior use of $ 2 systemic therapies
Prior use of biologic agents
Prior use of biologics, n (%)
Prior use of conventional DMARDs only (biologic-nai've), n (%)
Prior use of osteoporosis medications
Prior use of osteoporosis medications, n (%)
Prior use of synthetic DMARDs
Prior use of synthetic DMARDs, n (%)
Prior use of systemic
Prior VKA experience
Prior VKA use for >60 d, %
Prior years taking warfarin
Priorbone disease
Priorheartfailure,%
Priorother(not predefined) medical conditions
Priorother(predefined) medical conditions
Priorvascular disease,%
Pro-active intervention
Pro/Pro homozygotes
Proactive Intervention (n = 436a)
proADM (ng/ml)
"Probability""of event %"
Probable
Probable stent thrombosis
Probenecid
Procalcitonin (ng/ml)
Procedure
Procedure**
Procedures after discharge — no. (%)
Procedures for index event
Procedures in the hospital — no. (%)
Proctosigmoiditis
Profound thrombocytopenia (<20x109/L)
Progestins
Progression of albuminuria
Progression to Diabetes
Propafenone
Propionic acid derivatives
proportion
Proportion (%) of individuals • Control    Alirocumab
Proportion (%) of individuals A Alirocumab • Placebo
Proportion (95% CI) adjusted for baseline HbA1c , %
Proportion of angioedema-free days from week 4 to week 12x
Proportion of Patients in Corticosteroid-free Clinical Remission at Week 26
Proportion of patients who achieved ACR20 n/N (%)
Proportion of patients with trough FEVi >100 mL above baseline, n (%)
"Proportion of predicted normal FEV1 value;,§"
Proportion of responders n/N (%)
Proportion taking pulmonary medications (%)b
Proportions, n (%)
Proprotein Convertase Subtil/Kexin Typ9 (ng/mL) -Baseline - < Median (n=215, 203)
Proprotein Convertase Subtil/Kexin Typ9 (ng/mL) -Baseline - >= Median (n=201, 209)
PROSPER
Prostate biopsy
Prostate cancer
Prostate volume (cm3)
Prostate volume (mL)
Prosthetic
Protein in urine, ≥1+
Proteinuria (>2 g/24 h), %
Proteinuria3 (g/day)
Prothrombin mutation (%)
Proton-pump inhibitor
Proton-pump inhibitors
Proton pump inhibitor
Proton pump inhibitor (n, %)
Proton pump inhibitor use
Proton pump inhibitors
Provoked
Proximal
Proximal-MainLeft
Proximal gastrointestinal tract
Proximal GI tract
Proximal Gl tract, n (%)
Proximal to the splenic flexure
PsA
PSA
PsA-modified MASES score (1-15)
PsA‐modified MASES score (1–15 scale)
PsA-modified SHS of hands & feet1(0-528)
PsA‐modified SHS of hands and feet
PsA-modified SHS(0-528)
PsA-modified total SHS
PSA (ng/mL)
PsA duration (years)
PsA duration (years), mean (SD)
PsA duration, years
PSA level, ng/mL
PsA pain (VAS)
PsA reported, n (%)
PsA subtypes, n (%)
PSA, ng/ml, mean (SD)
PSAP-B (ng/ml)
PsAQOL
Psoriasis
psoriasis (n =
Psoriasis > 3% of BSA
Psoriasis affecting >3% of body-surface
Psoriasis body surface area >3%
Psoriasis BSA >3%, n (%)
Psoriasis characteristics
Psoriasis covering >3% BSA, n (%)§
Psoriasis duration (years), mean (SD)
Psoriasis duration, mean ± SD, years
Psoriasis duration, years
Psoriasis duration, yrs*
Psoriatic arthritis
Psoriatic arthritis pain]
Psoriatic arthritis, %
Psychoactivesd
Psychogenic
Psycholeptics
Pt
PT baseline (Week 52)
Pt. Years= 245
Pt. Years= 556
Pt. Years= 810
Pt. Years=1484
Pt. Years=1563
Pt. Years=2283
Pt. Years=3099
Pt. Years=3818
Pt. Years=3898
Pt. Years=4572
Pt. Years=4825
Pt. Years=5136
PTCA
PTCA only
PTCA or PCI
PTCA/CABG
PtGA (0-10 cm VAS)
PtGA of disease activity (0‒100 mm), mean (SD)†
PtGA, 0-10
PtGA⁎⁎⁎
PtGADA (mm)
ptrend Across Doses
Pts
PTX3 (ng/mL)
Puerperium
Puerto Rican
Pulmonary congestion (CXR)
Pulmonary disease
Pulmonary disease — no. (%)
Pulmonary embolism
Pulmonary embolism ± deep vein thrombosis
Pulmonary embolism only
Pulmonary embolisma, n/N (%)
Pulmonary embolismb, n/N (%)
Pulmonary function tests (post-bronchodilator), mean (SD)
Pulmonary function tests, % of predicted
Pulmonary medication during baseline!'
Pulmonary medications (%)
Pulmonary rales
Pulmonary rales, n (%)
Pulmonary vascular resistance, dyne • s • cm 5
Pulse — beats/min
Pulse (beats/min) Cholesterol (mmol/l)
Pulse in beats/minute, mean(SD)
Pulse pressure
Pulse Pressure (Median 50.0]
Pulse pressure (mm Hg)
Pulse pressure (mmHg)
Pulse rate (bpm)
Pulse rate (mean 24 h), bpm*
Pulse rate, bpm (mean 24 h), mean (SD)*
Pulse, beats/min
Pump
Pure motor hemiparesis
Pure sensory stroke
PUVA
PV, mL
pValue
Pvalue
PValue
PValue for Heterogeneity
Pvalue∗
pValuefor Any MI Versus No MI
pvaluefor interaction 0-28
pvaluefor interaction 0-39
pValuefor Trend
PValuefor Trend
PVD
PVR volume, ml, mean (SD)
PVR, mL
PY*
PY=1630.8)
PY=1948)
PY=2187.2)
PY=2612.8)
PY=2766.7)
PY=2957.6)
Pyrexia
Q-wave MI
Q (Q 1\
Q wave in the infarct territory at baseline*, %
Q wave MI
Q waves in the infarct territory at baseline*, %
Q1-Q3
Q1 (n = 82)
Q1: <55.05 kg (n=139vs70)
Q2 (n = 106)
Q2: 55.05 to <65.15 kg (n=141 vs 66)
Q2W (n 5 490)
Q3 (n = 92)
Q3: 65.15 to <78.25 kg (n=135 vs 73)
Q4 (n = 96)
Q4: >78.25 kg (n=139vs70)
Q4W (n = 28)
Q4W (n = 425)
Q4W (n = 438)
Q8W (n = 30)
Q8W (n = 428)
Q8W (n = 441)
QD
QIDS-SR16
Qmax (ml/S)
Qmax (mL/s)
Qmax category, n (%):
Qmax, mL/s
Qmax, ml/s, mean (SD)
Qmaxi rn L/s
QMI
QoL
QoL due to urinary symptoms,
QRS $120 ms (95% CL) (n - 613)
QRS <120 ms (95% CL) (n - 2,813)
QRS <120 msec
QRS >120 ms*
QRS >120 ms, % (n)
QRS >120 ms, n (%), available for 3653 patients
QRS >120 msec 6-Min walk test
QRS duration > 120 ms, n (%)
QRS duration, ms
QRS interval >120 msec — no. (%)
QRS width, ms
QTc >450 n=1190
QTC<450 n=5117
Qualifying ACS event — no. (%)
Qualifying Atherosclerosis
Qualifying CV event, n (%)
Qualifying diagnosis
Qualifying event
Qualifying event — no. (%)
Qualifying events
Qualifying HbA1c (%)
Qualifying high-risk features — %
Qualifying index event as PE
Qualifying MI $2 yrs prior
Qualifying MI <2 yrs prior
Qualifying MI type
Qualifying MI: STEMI
Qualifying myocardial infarction
Qualifying Myocardial Infarction
Qualifying NSTEMI, n (%)
Qualifying peripheral arterial disease
Qualifying risk factor
Qualifying risk factor — no. (%)
Qualifying risk factor, n (%)
Qualifying risk factors — no. (%)
Qualifying stroke
Qualifying symptomatic event, n (%)a
Qualifying type of atherosclerosis — no. (%)
Qualifying type of atherosclerosis, n (%)
Quality of life
Quartiles of FGF-23 (RU/ml)
Question 1 (fatigue/tiredness)
Question 2 (neck/back/hip pain)
Question 3 ( pain/swelling in joints other than neck/back/hips)
Question 4 (discomfort from any areas tender to touch/pressure)
Question 5 (morning stiffness since arising)
Question 6 (length of morning stiffness since arising)
QUICKI
Quintile (n)
Quintile 1 (1.11%-3.58%) (n=497)
Quintile 2 (3.59%-5.26%) (n=497)
Quintile 3 (5.26%-7.30%) (n=496)
Quintile 4 (7.30%-11.14%) (n=496)
Quintile 5 (11.15%-63.48%) (n=497)
Quintile, range, mg/dL
QVA149 110/50 |ig od n=372
QVA149110/50 pg once daily (n=258)
Qveral
R
r-tPA
R 10 mg
R 10 mg («=52)
R 10 mg + FA
R 10 mg + FA («=52)
R 20 mg
R 20 mg (n=53)
R 20 mg + FA
R 20 mg + FA («=52)
R 5 mg
R 5 mg (n=68)
R 5 mg + FA
R 5 mg + FA («=73)
R ight coronar y artery
R ight coronary
R wave in aVL (mm)
R|R''' (95% CI)
R10 (n = 98)
R10 + EZIO (n = 122)
R20 (n = 121)
R5 + EZIO (n = 99)
RA
rA-beAM
RA duration (months)*
RA duration (years), mean (s.e.)
Ra ndosii zat ion
RA symptom duration—year
RA symptom duration <3 months—number (%)
RAAS inhibitor
RAAS inhibitor use
RAAS inhibitors
Race
RACE
Race- no. (%)
Race-Non- White
Race-nonwhite
Race - n (%)
Race - no. (%)
Race - Non-White (n=26, 24)
Race - White (n=397, 399)
Race — no. (%)
Race — no. (%)'(
Race — no. (%):c
Race — no. (%):t
Race — no. (%)|
Race — no. (%)卞
Race — no. (%)f
Race — no. {%)'i'
Race — no. {%)-i-
Race — no./total no. (%)f
Race (% White)
Race (%)
Race (%) White
Race (%)$
Race (%))'
Race (%)*
Race (non-white) (%)
Race (p=O-85)
Race (white, n [%])
Race / ethnicity, n (%)
Race and SS at baseline
Race n (%)
Race N(%)
Race nonwhitet
Race or ethnic background — no. (%)f
Race or ethnic group
Race or ethnic group — no. (%):t
Race or ethnic group — no. (%)f
Race or ethnic group — no. {%)■'( White
Race or ethnic group — no./total no. (%)f
Race or ethnic group — no.f
Race or ethnic group (%)
Race or ethnic group (%)f
Race or ethnic group, n (%)*
Race or ethnic group, no. (%)
Race or ethnic origin
Race or ethnicity
Race or ethnicity, n (%)
Race White
Race*
Race, %
Race, % Caucasian
Race, % nonwhite
Race, % of patients
Race, % white
Race, Asian, n (%)
Race, Black or African-American, n (%)
Race, n (%)
Race, N (%)
Race, n (%) White
Race, n (%)*
Race, n (%):
Race, n (%)’
Race, n (%)+
Race, n (%)a
Race, n (%)b
Race, n (%)t
Race, n (%)y
Race, n (%]
Race, n(%)
Race, no. (%)
Race, No. (%)
Race, no. (%) white
Race, no. (%)*
Race, no. (%)b
Race, No. (%)c
Race, No./total (%)
Race, Non-White
Race, While
Race, white (%)
Race, white, n (% of patients)
Race, white, n (%)
Race, White, n (%)
Race, white, n (%)
Race, zz (%)
Race, n (%)
Race,*’ n (%)
Race,n (%)
Race,n(%)
Race/ethnicity
Race/Ethnicity
Race/ethnicity Chinese
Race/ethnicity n (%)
Race/ethnicity White
Race/ethnicity, %
Race/ethnicity, % White non-Hispanic
Race/ethnicity, no. (%)
Race/ethnicity, No. (%)
Race/ethnicity, no. (%)*
Race/ethnicity, zz (%)
Race:
Race: Non-White
Race: White
Race_White, %
Race§
Race3
Racea
Racea White
Racec, n (%)
Racey,z
Racial category
Racial category*
Racial group, n (%)
Radial
Radial access
Radial access — no./total no. (%)
Radial access site
RADIATE
Radiographic characteristics at baseline and randomization
Radiographic progression based on change from baseline > SDC
Radionuclide ventriculography
Radius fracture
Raee
RAGE (ng/ml)
Rales
Rales, (%)
Rales, n (%)
Ramus
Rando. in NA**
Randomisation scheme
Randomisation visit (baseline)
Randomised patients (n)
Randomised patients with >3% BSA psoriasis skin involvement at baseline
Randomised patients with BASDAI assessment at baseline and week 12, N
Randomised patients with BASDAI assessment at baseline and week 24, N
Randomised patients with dactylitis at baseline
Randomised patients with enthesitis at baselinet
Randomised patients with spondylitis at baseline, N
Randomised to canakinumab 150 mg
Randomised to canakinumab 300 mg
Randomised to canakinumab 50 mg
Randomised treatment
Randomization
Randomization-to-
Randomization-to- angiography
Randomization-to- angiography distribution time
Randomization group
Randomization Groups 1 and 2
Randomization Groups 1 and 3
Randomization Stratum
Randomization to
Randomization to angiography
Randomization to arrival in catheterization laboratory
Randomization to arterial sheath insertion
Randomization to end of study
Randomization to first balloon inflation, min
Randomization to placebo or telmisartan
randomization)
randomization, n (%)
Randomize
Randomized
Randomized <4 hr after presentation — %
Randomized group by subgroup interaction
Randomized group by subgroup Interaction
Randomized patients
Randomized to active yitamin E
Randomized to aspirin use
Randomized to canakinumab 150 mg
Randomized to canakinumab 300 mg
Randomized to canakinumab 50 mg
Randomized to receive aspirin Yes
Randomized to receive beta carotene
Randomized to receive vitamin E
Randomized to receiveaspirin
Randomized treatment
Randomized treatment, % (n)
Randomized treatments, n (%)
Randomized, Double-Blind Reversal Phase (Baseline=Week 26)
Randomly assigned to ACE
Randomly assigned to calcium channel blocker
Randomly assigned to diuretic
Range
Range (min, max)
Range (Min, Max)
Range ED etiology (n)
Range IGA modified 2011 score, n (%)
Range of SBP
Range Race, n (%)
Range, (min, max)
Range: min, max
Range: min,max
Rank based on treatment = placebo
Rankin grade
Rankin scale ≥3
Ranolazine
Ranolazine (n = 1,789)
Ranolazine (n = 3279)
Ranolazine (n = 462)    Placebo (n = 465)
Ranolazine (n 5 232)
Ranolazine (n=1401)
Ranolazine (n=2441)
Ranolazine (n=707)
Ranolazine n=3161
Ranolazine vs. Placebo KM Failure Rate
Ranolazine, N = i3i7
Ranolazine, N = 1317
Ranolazine, N = 472
Ranotazine vs. Placebo KM Failure Rate
Ranozaline
Rarely
Rarely/Never
Rarertd antocagibtcn before andorrtzafon
RAS-aldosterone inhibitor^
RAS % target dose
RAS agents
RAS antagonist, %
Rasagiline, 1 mg/day
Rasagiline, 2 mg/day
Rash
Rate
RATE-CONTROL GROUP (N=2027)
Rate (% per year)
rate (mL/min/1.73m2)
Rate difference (events/year)
Rate difference (lebrikizumab-placebo)
Rate estimate (95% CI)
Rate in All Participants, %/y
Rate of non-progression (defined as CFB in mTSS £0), n/N (%)*
Rate of non-progression (defined as CFB in mTSS £0.5), n/N (%)*
Rate of oral or systemic corticosteroid
Rate of SAREs
Rate per 100-patient-years (control vs alirocumab)*
Rate per 100-patient-years (control vs alirocumab)i
Rate per 100 Patient-Years
Rate per 1000 patient-years
Rate ratio
Rate ratio (95% CI)
Rate Ratio (95% Ci)
Rate ratio (95% Cl)
Rate Ratio (95% Cl)
Rate ratio (95%CI)
Rate ratio (lebrikizumab vs placebo, 95% Cl)
Rate ratio {95% Cl)
Rate ratio MEPO/PBO (95% CI)
Rate ratio vs placebo (95% CI)
Rate reduction (%)
Rate(%/year)
Rate*
Rate* (n)
Rate, %/y
Rate/100 PYO
Rate/1000 patient- years
Rate/1000 patient-years
Rate†
Rate‡
rates
Rates per 100 patient-years
Ratet
Ratet    n (%)
Ratet (95% Cl)
Ratio
Ratio (95% CI)*
Ratio FP/SAL:SAL (95% CI)
Ratio MEPO/PBO (95% CI)
Ratio of FEV1 to FVC
Ratio of FEV1to FVC (%)
Ratio of HRs (95% CI), p for sex interaction
Ratio of HRs (95% Cl), p for sex interaction
Ratio of LDL to HDL
Ratio of LDL to HDL cholesterol
Ratio of urinary albumin (mg) to creatinine (g)
Ratio of urinary albumin (mg) to creatinine (g) Median
Ratio of women to men — %
Ratio to baseline in eosinophil count at week 32, geometric mean (SE on loge scale) cells/ll
Ratio to baseline in total IgE at week 32, geometric mean (SE on loge scale) U/ml
RCA
RCA, n (%)
RE-COVER 1 Dabigatran
RE-COVER 1 Warfarin
RE-COVER II
RE-COVER/RE-COVER II
RE-MEDY
Readmission (n=421)
Reason for discontinuation of previous TNFa inhibitor
Reason for enrollment in ACTIVE A
Reason for enrollment in ACTIVE A — no. (%)
Rec. Ischemia
Rec. Ischemia due to ECG changes
Rec. Ischemia due worsening angina
Rec. Ischemia leading to hasp
Rec. Ischemia leading to hosp
Rec. Ischemia requiring revasc
Received >2 prior anti-TNF therapies, n
Received 1 prior anti-TNF therapy, n
Received 1 prior biologic therapy, n
Received 2 prior biologic therapies, n
Received 3 prior biologic therapies, n
Received an oral AHA within 8 weeks prior to screening
Received antihypertensive within last 3 days, n (%)
Received drug-eluting stent
Received first loading dose
Receiving antihypertensive
Receiving antihypertensive treatment -
Receiving antihypertensive treatment, n (%) Blood pressure, mm Hg, mean (sd)
Receiving concomitant corticosteroids
Receiving concomitant NSAIDs and/or COX-2 inhibitors
Receiving insulin therapy
Recent cardiovascular eventf
Recent cardioversion (within 5 days before randomization) —
Recent cardioversion (within 5 days before randomization) — no. (%)
Recent surgery or trauma
Recent treatment (<3 months MMF/GGs)
Recent use of allopurinol (within 30 days of
receptor blocker
receptor blockers
receptor blockers, n (%)
receptor blockers, n (%) Baseline lipid and apolipoprotein levels
Recervini}
Recervng
Rectal bleeding subscore
Rectal bleeding subscore{
Rectum
Rectum and sigmoid colon only
Recurrent heart failure
Recurrent HF
Recurrent HF hospitalization
Recurrent infections (>1 per year)
Recurrent ischemia
Recurrent Ischemia
Recurrent ischemia- urgent revascularization
Recurrent VTE (statin use vs non-use)
Red blood cell counting, 1012/L
Redon
Reduced EF
Reduced HDL cholesterol
Reduction in Odds %
Reduction in risk % (95% CI)
Reduction of HbA1c from baseline≥0.5%
Reduction of HbA1c from baseline≥0.7%
Reduction of HbA1c from baseline≥1.0%
"REDUCTION
IN RISK
(95% CI) %"
Ref.
REF§
Reference
Referent
Refractory to corticosteroids, n (%)
Refractory to such therapy — no. (%)
Regadenoson
Regadenoson (n = 334)
Region
Region-North America
Region - n (%)
Region - no. (%)
Region — no. (%)
Region — no. {%)
Region    North America
Region (%)
Region (pooled)
Region (US)
Region 一no. (%)
Region Latin American
Region N(%)
Region of enrollment
Region of enrollment— no. (%)
Region of enrollment — no. (%)
Region of enrollment, n (%)+
Region of enrollment, No. (%)
Region of residence (p=0 09)
Region of the world
Region of world — no. (%)
Region ofenrollment — %
Region ofthe world
Region United States
Region*
Region,
Region, %
Region, Asia/Paafic
Region, Europe
Region, Europe Union
Region, Latin America
Region, n (%)
Region, N (%)
Region, n (%)a
Region, no. (%)
Region, No. (%)
Region, No. (%)c
Region, No./total (%)
Region, North America
Region, n (%)
Region:
Regional anaesthesia
Regions, n (%)
Regiont
Regular alcohol consumption per week, no. (%)
Regular aspirin use
Regular PPI use
Reinfarction
Related to study druga
Relative decrease >10%
Relative decrease >5%
Relative risk (95% CI)
Relative Risk (95% CI)
Relative Risk (95% CI) ofPrimary End Point
Relative risk (95% Cl)
Relative Risk (95% Cl)
Relative Risk (95% Cl) Comparing ICD Therapy and Placebo Using a Linear Interaction Term in the Model (SHFMXICD)*
Relative Risk (95% confidence interval)
Relative Risk (95% Confidence Interval)
Relative Risk (95%CI)
Relative Risk {95%CI)
Relative Risk Comparing ICD Therapy and Placebo
Relative risk reduction (95% Cl)
Relative Risk Reduction (95% Cl) percent
Relative Risk vs. Placebo (95% Cl)
Relative risk* (95% Cl)
Relative risk®' (95% Cl)
Relative risk® (95% Cl)
Relative wall thickness
Remaining patients
Remission
Remission at maintenance-trial entry — no. (%)
Remission by: baseline duration of steroid
Remission by: baseline steroid doses
remission component of variable
Remission in overall population
Remission, n (%)
Remodeling
Renal
Renal biopsy class
Renal composite*
Renal disease
Renal disease)
Renal dysfunction
Renal Dysfunction
Renal events
Renal failure
Renal fmclicn: creatntoe clearance
Renal function
Renal function (eGFR) according to MDRD, n (%)
Renal function (eGFR, ml/min/1.73 m2)
Renal function (eGFR, mL/min/1.73 m2, according to MDRD), n (%)
Renal function (ml/min)
Renal function <60 eGFR, mL/min/1.73 m2
renal Function at randomization
Renal function subgroups
Renal function*
Renal Function, Moderate
Renal Function, Normal- Mild
Renal Function, Severe
Renal Function,bn (%)
Renal function: creatinine clearance
Renal function:!: n (%)
Renal Functiona
Renal Functionb
Renal Functionc, n (%)
Renal impairment
Renal impairment (CrCl <50 mL/min)
Renal impairment*
Renal impairment, n (%)
Renal impairmentf
Renal impairmentt
Renal Insufficiency
Renal insufficiency— no. (%)
Renal Insufficiency or Failure
Renal insufficiency*
Renal insufficiency/ failure
Renal insufficiency/failure
Renal insufficiency11
Renal parameters
Renal subgroup
Renin-angiotensin-aldosterone system blocker
Renin-angiotensin inhibitors
Renin-angiotensin system inhibitor use
Renin–angiotensin system inhibitor
Renin inhibitor
Renin inhibitor (e.g. aliskerin)
Renin inhibitors
Rentrop score
Repaired CHD
Repaired congenital shunts
Repaired S-P Shunts
Reported diabetes mellitus
Reported high cholesterol'!
Reported hypertension*
Reported in eCRF
Reqion
Required corticosteroid and/or antibiotic (without hospitalization)
Required hospitalization
requiring assistance
Rerandomization to Placebo (N = 171)f
Rescue medication use, inh/d{
Rescue medication use, mean inhalations/previous 3 d
Rescue use: mean No. of inhalations/d
Resection performed — no. {%)
Resection performed, %
Residence in Asia, n (%)
Residual deep-vein thrombosis, No. (%)
Residual perfusion defect >10% on lung scan, No. (%)
Resistant HTN n = 403
Resistant HTN: placebo n = 212
Resistant HTN: spiro n = 191
Reslizumab
Reslizumab (n=232)
Reslizumab (n=245)
Reslizumab 0.3 mg/kg (n = 104)
Reslizumab 3.0 mg/kg (n = 398)
Reslizumab 3.0 mg/kg (n = 106)
Resllzumab
Respiratory-related^
Respiratory medication (%)
Respiratory medication taken at baseline, n (%)
Respiratory rate (breaths/min)
Respiratory rate, breaths/min
Responder analyses (achieving AlC <7.0%)
Responders of three-item end point at 24 weeks*
Rest-of-world (n=645)
Rest-of-World (n=645)
Rest angina but not past 48 h
Rest angina past 48 h
Rest of the world
Rest of the World
Rest of world
Rest of World
Rest of world n Z 474
Rest ofthe world
Rest ofworld
Rest pain
Restenotic vessel
Restriction in normal activities in the past 2 weeks
Result
Ret/Abx- Facil. PCI
Reteplase
Reteplase/Abciximab-Facilitated PCI (n = 828)
Retinopathy
Retinopathy — %
Retinopathy — no. (%)
Retinopathy (stage 0/1/2/3)
Revascularisation but no antiplatelets, lipid-lowering agents, or p blockers
Revascularisation, n (%)
Revascularisation+antiplatelets+ lipid-lowering agents+p blockers
Revascularization
Revascularization during index hospitalization, %
Revascularization history
Revascularization in 9 days
Reversibility
Reversibility — %
Reversibility %
Reversibility (% predicted FEV1)*
Reversibility (%)
Reversibility (%), median (range)c
Reversibility (%)t
Reversibility (anticholinergic), %, mean (SD)$
Reversibility (b2-agonist), %, mean (SD)1
Reversibility [%], median (range)
Reversibility <12% (ITT) (n=1123)
Reversibility <12% (ITT) (n=1132)
Reversibility <12% (ITT) (n=1141)
Reversibility <12% (ITT) (n=1505)
Reversibility <12% (n=1025)
Reversibility >12% (ITT) (n=468)
Reversibility >12% (ITT) (n=472)
Reversibility >12% (ITT) (n=474)
Reversibility >12% (ITT) (n=477)
Reversibility >12% (ITT) (n=618)
Reversibility >12% (ITT) (n=627)
Reversibility >12% (n=507)
Reversibility of FEV1 (%)
Reversibility S12% (ITT) (n=1135)
Reversibility S12% (ITT) (n=1524)
Reversibility stratum*
Reversibility to
Reversibility to salbutamol, %
reversibility to salbutamolc,d, mean (sD)
Reversibility*
Reversibility, %
Reversibility: <5%
Reversibility: >12%
Reversibility: >5 - <12%
Reversibility’' %
reversible
Reversible (%)
Reversible to albuterolc,d, n (%)
Reversible to bronchodilator,b %
REVIVE I
REVIVE II
RF-positive, > 14 IU/ml, %
RF (IU/mL)
RF (mg/dl)
"RF (mg/dl; per unit)"
RF and ACPA negative, n (%)
RF and ACPA negative8
RF and ACPA positive, n (%)
RF negative and ACPA positive, n (%)
RF or ACPA positive
RF positive
RF positive—number (%)
RF positive (>14 IU/mL), n (%)
RF positive and ACPA negative, n (%)
RF positive, %
RF positive, n (%)
RF positive, no. (%)
RF, % positive
Rhabdomyolysis
Rhabdomyolysis (N=31)
Rhabdomyolysis or myopathy
Rhabdomyolysis, myopathy, or elevated creatine phosphokinase >5x upper limit of normal (N=111)
Rhabdomyolysis, myopathy, or myalgia with CK elevation >5x ULN
Rheumatic heart disease
Rheumatoid arthritis
Rheumatoid factor-positive
Rheumatoid factor and ACPA positive
Rheumatoid factor or ACPA positive, or both
Rheumatoid factor positive
Rheumatoid factor Positive
Rheumatoid factor positive§, n (%)
Rheumatoid factor!
Rhinitis
RHYTHM-CONTROL GROUP (N=2033)
Rib
Right
Right coronary
Right coronary artery
Right coronary artery, n (%)
Right ventricular dysfunction — no./total no. (%)§
Right ventricular dysfunction, n/n (%)J
Right ventriculardysfunction atinclusion
Risedronate (N = 680)
Risedronate (N=435)
Risedronate n/N (%)
Risk
Risk  Ratio [95% Cl]
Risk At
Risk Categories
Risk Category (Points)
Risk Difference
Risk Factor
Risk factor (predefined) for falling at screening, n (%)
Risk factor for venous thromboembolism, no. (%)
Risk factor profile index event
Risk factors
Risk Factors
Risk factors — no. (%)
Risk factors (% of group)
Risk factors (%)
Risk factors and diabetes status (%)
Risk factors and immobility level, n (%)
Risk factors and medical history
Risk factors BMI (kg/m2), mean + SD
Risk factors for atherosclerosis
Risk factors for PAD
Risk factors for recurrent VTE — no. (%)f
Risk factors for stroke
Risk factors for stroke, No. (%)
Risk factors specified as inclusion criteria — no. (%)f
Risk factors, %
Risk factors, No. (%)
Risk group
Risk level at admission
Risk Marker and Model
Risk Model Endpoint
Risk of bleeding
Risk of moderate/severe exacerbations
"Risk Reduction (%; 95% CI)"
Risk Reduction (95% Cl)
Risk Reduction, %
Risk Score Category (Points)
Risk stratum
Risk*
Rituximab
Rituximab (2x1000 mg) + MTX
Rituximab (2x1000 mg) + MTX (n=250)
Rituximab (2x500 mg) + MTX
Rituximab (2x500 mg) + MTX (n=249)
Rituximab, n = 292
Rituximab, n=292
Riva roxa ban n/N    {%) 3671731    (2.1)
Rivaroxaban
Rivaroxaban (N = 1731)
Rivaroxaban (N = 602)
Rivaroxaban (n = 1002)
Rivaroxaban (n = 417)
Rivaroxaban (n = 585)
Rivaroxaban 2.5 mg BID + Aspirin 100 mg OD
Rivaroxaban 20 mg
Rivaroxaban Alone (N = 9117)
Rivaroxaban Alone (N = 9117) 68.2±7.9
Rivaroxaban alone (n=2474)
Rivaroxaban alone (n=8250)
Rivaroxaban plus
Rivaroxaban plus Aspirin (95% Cl)
Rivaroxaban plus Aspirin (N = 9152)
Rivaroxaban plus Aspirin (N = 9152) 68.3±7.9
Rivaroxaban+
Rivaroxaban+ Aspirin
Rivastigmine
Rivastigmine (n = 365)
Rofecoxib
Roflumilast (n = 1,178)
Role emotional
Role physical
Rolofylline
Rolofylline (n = 1,356)
Rolofylline (N=104)
Rolofylline (N=266)
Rolofylline (N=741)
Rolofylline 30 mg (N=185)
Rolofylline Dose
Rolofylline N
Rolofylline Rx
Romania
Rope score
RoPE score**
Rosigiitazone ± OAD
Rosiglitazone
Rosiglitazone (n = 1456)
Rosiglitazone (N = 1456)
Rosiglitazone (n=333)
Rosiglitazone 8 mg daik
rosiglitazone 8 mg daily
Rosiglitazone versus Glyburide
Rosiglitazone versus Metformin
Rosuva 10 mg
ROSUVA 10 mg N = 221
ROSUVA 10 mg N = 82
Rosuva 20 mg
Rosuva 40 mg
"ROSUVA, rosuvastatin; SD, standard deviation; T2DM, type 2 diabetes mellitus."
Rosuvastain + Fenofibric Acid 72=253
Rosuvastain + Fenofibric Acid n = 253
Rosuvastatin
Rosuvastatin (n = 1855)
Rosuvastatin (n=1711)
Rosuvastatin (N=2285)
Rosuvastatin (n=77, 34)
Rosuvastatin (n=777)
Rosuvastatin (n=81. 35)
Rosuvastatin +
Rosuvastatin + Fenofibric Acid
Rosuvastatin 10 mg
Rosuvastatin 15 mg
Rosuvastatin 20 mg
Rosuvastatin 30 mg
Rosuvastatin 40 mg
Rosuvastatin 5-10 mg (n = 262)
Rosuvastatin 5 mg
Rosuvastatin Events/patients (%)
Rosuvastatin n (Rate)
Rosuvastatin n (Rate)*
Rosuvastatin n (rate)1
Rosuvastatin n=251
Rosuvastatin of patients (rate)
Rosuvastatin n = 251
Rosuvastatin, events/patients (%)
Rosuvastatin, n (%)
Rosuvastatin, n (rate)
Rotablator use, n (%)
Rotigotine (n = 170)
Rotigotine (n = 184)
Rotigotine n = 174
ROW
ROW* N= 618
ROW* N= 624
RoW§
RR
RR (95% CI)
RR (95% CI)*
RR (95% CI)c
RR (95% Cl)
RR (95% Cl)    P Value
RR (95% Cl) [/’Value]
RR (95%CI)
RR (Cl)
RR 0-60 (0.36, 0,55)’
RR 0.47 (0.23,0.95)*
RR 0.56 <0.34, 0.93)*
RR 0.66 (0.17, 2.49)
RR 0.68 (0.43, 1.07)
RR 0.68 (0.46, 0.99)*
RR 0.69 (0.50.0.95)
RR 0.70 (0.20, 2.49}
RR 0.72(0.54, 0.96)*
RR 0.73 (0.53, 1.00)
RR 0.76 (0.56, 1.03)
RR 0.77 (0.52,1.13)
RR 0.77(0.47. 1.27)
RR 0.78 (0.65, 0.94)**
RR 0.81 (0.44,1.49)
RR 0.82 (0.53, 1.28)
RR 0.82(0.65. 1.05)
RR 0.83 (0.63, 1.10)
RR 0.86 (0.65,1.14)
RR 0.87 (0.65, 1.17)
RR 0.87 (0.66,1.15)
RR 0.87 (0.72,1.05)
RR 0.88 (0.46,1.66)
RR 0.88 (0.57. 1.36)
RR 0.89 (0.61,1.30)
RR 0.90 (0.21, 3.85)
RR 0.93(0.74, 1.18)
RR 0.94 (0.71,1.25)
RR 0.94(0.75, 1.19)
RR 0.96 (0.80, 1.16)
RR 0.97 (0.28, 3.40)
RR 0.97 (0.71,1.32)
RR 0.97 (0.72, 1.29)
RR 1.02
RR 1.05 (0.63, 1.75)
RR 1.07
RR 1.08 (0.82, 1.42)
RR 1.09
RR 1.10(0.66, 1.81)
RR 1.14(0.72. 1.82)
RR 1.17
RR 1.25
RR 1.34
RR 1.35
RR 1.35 (0.41,4.49)
RR 1.37
RR 1.46
RR 1.47
RR 1.48
RR 1.58
RR 1.62 (0.46, 5.73)
RR 1.79 (0.07,46.02)
RR 3.14(0.30, 32.79
RR 3.50(0.16, 77.92)
RR reduction, 0/0 (950/0 Cl)
RR(957aCI) [P Value]
RR*
RR^ (95% CI)
RR0.55 (0-35. 0.91)*
RR0.87 (0.56. 1.37)
RR0.88 (0-56, 1.37)
RR1.22 (0.80. 1.84)
RRO.83 (0.51.1.36)
RRO31 (0.48, 1.39)
RRR
RRR (95% Cl)
RS-Breathlessnessb
RS-Chest Symptomsd
RS-Cough & Sputumc
RS-Totala
rs11212617
rs12208357
rs1532085
rs2068888
rs2289669
rs2923084
rs622342
rs622342 & rs2289669
rs622342 (AA) & rs2289669
rs622342 (AC) & rs2289669
rs622342 (CC) & rs2289669
RSG 4 mg/day
RSG 8 mg/day
ruled out Non-fatal PE with or
Russia
Russia and Georgia
Russia/Georgia
Russia/Georgia (n=1678)
RV and Pulmonary Vascular
Rvalue
Rvalue for Interaction
RVFAC (%)
rvW
S
S-ASA compounds at baseline
S (S41
S 130 mmHg
S 5 yrs
s Arm
S fS 71
S fS 91
s Median
S Median
S wave in V3 (mm)
S.E.
S/SE, MB or death
S100 (n = 247)
s113 mg/mmol
S20-40 vs placebo
s226 mg/mmol
s23 kg/m^
s28 kg/m2
s3 exacerbations
S3 gallop, n (%)
S40 vs placebo
s56.5 mg/mmol
s65 years (n=2474)
s75 years
S80 ml/min
S84(18.S)
s9-0-s10.5%
S9 months
SA
SA ACS
SABA
SABA (inhaled),c n (%)
SABA puffs per day at baseline
SABA reversibility
SABA use in past 3 days
SABA use, occasions/weekt
SABA§
saBae
Sack
Sacral and/or lumbar
Sacubitril/valsartan
Sacubitril/Valsartan (n = 1916)
Sacubitril/Valsartan (n = 2271)
Sacubitril/valsartan (n=1907)
Sacubitril/valsartan (n=2280)
SAEs
Safety population
Safety population, n (%)
Safety variable
Safety, %
Safety, n (%)b
Safety: non-CABG-related bleeding
SAL (n = 1232)
SAL (n = 1,334)
SAL 50 mg
SAL 50 pg (N = 325)
SAL 50 pg (N= 325)
salbutamol, %
Salmeterol
Salmeterol- Fluticasone Group
Salmeterol-Fluticasone Group (N = 1682)
Salmeterol (n [1542)
Salmeterol (N = 3669)
Salmeterol (n[1542)
Salmeterol 50 gg bid
Salmeterol/fluticasone 50/500 pg twice daily
Salmeterol/fluticasone 50/500 μg b.i.d.
SAMA
SAMA,b n (%)
SAMA1
saMac
sample size
Sample size (n)
Sample Size, n
Sample size, n (%) by treatment
sample sizea
Sample statistics
Saphenous vein graft
Saudi Arabia
SAXA 10 mg (n 5 335)
SAXA 10 mg 1 metformin (n 5 323)
SAXA 2.5 mg
SAXA 2.5 mg (n = 18)
SAXA 2.5 mg (n = 44)
SAXA 2.5 mg (n = 85)
SAXA 5 mg 1 metformin (n 5 320)
SAXA+DAPA+MET n =179
SAXA+DAPA+MET n=179
SAXA+MET n =176
SAXA+MET n=176
Saxagiiptin
Saxagliptin
Saxagliptin (%)
Saxagliptin (n = 1,169)
Saxagliptin (n = 3,990)
Saxagliptin (n = 4,290)
Saxagliptin (n = 7,111)
Saxagliptin (N = 8280)
Saxagliptin 2.5 mg
Saxagliptin 2.5 mg (n = 1,122)
Saxagliptin 2.5 mg (n = 172)
Saxagliptin 2.5 mg (n Z 264)
Saxagliptin 2.5 mg (n Z 492)
Saxagliptin 5 mg
Saxagliptin 5 mg (n = 6,986)
Saxagliptin 5mg
Saxagliptin 5mg(n Z 247)
Saxagliptin 5mg(n Z 509)
SBP
SBP (mean over 24 h), mmHg
SBP (mm Hg)
SBP (mm Hg), median (IQR)
SBP (mmgHG), mean (SD)
SBP (mmHg)
SBP (mmHg) <120
SBP (mmHg)*
SBP (mmHg), mean (SD)
SBP (mmHg), mean ± SD
SBP (office measurement), mmHg
SBP (SD)
SBP (SD), mm Hg
SBP <129mm Hg
SBP <130 mmHg
SBP <140 mm Hg and DBP <90 mm Hg    81/2907
SBP <140 mmHg
SBP <140 mmHg and DBP <90 mmHg
SBP <160 mmHg
SBP ≥140 mmHg
SBP > 138mmHg n= 466
SBP >140 mm Hg and/or DBP >90 mm Hg 83/1780
SBP >140 mmHg
SBP >140 mmHg and/or DBP >90 mmHg
SBP >140 mmHg or DBP >90 mmHg
SBP >160 mmHg
SBP at Baseline
SBP at Visit 2
SBP during the follow-up period (mmHg)
"SBP indicates systolic blood pressure; DBP, diastolic blood pressure; AA, arachidonic acid; EPA, eicosapentaenoic acid. Values for age, BMI, total cholesterol, LDL cholesterol, HDL cholesterol, SBP, DBP, AA, EPA, and EPA/AA ratio represent the mean values represent the median (interquartile range). P values are for the differences between the no EPA and EPA groups."
SBP(mm Hg)
SBP, baseline
SBP, difference
SBP, last
SBP, mean (sd) mm Hg
SBP, mean (SD), mm Hg
SBP, mean (SD), mmHg
SBP, mean = SD, mmHg
SBP, mean ±SD (mmHg)
SBP, mm Hg
SBP, mm Hg (mean 24 h), mean (SD)
SBP, mm Hg (office measurement), mean (SD)
SBP, mm Hg, mean + SDC
SBP, mm Hg, mean ± SDC
SBP, mm Hg
SBP, mm Hg
SBP, mm Hg (SD)
SBP, mmHg
"SBP, systolic blood pressure; SD, standard deviation; DBP, diastolic blood pressure; b.p.m., beats per minute; MI, myocardial infarction; TIA, transient ischaemic attack."
SBP,Difference vs placebo (95% Cl)
SBP. mean (sd) mm Hg
SBP/DBP $130/$85 mmHg
SBP/DBP (mmHg)
SBP/DBP Mean
SBP< 118mmHg n = 403
SBP<129mm Hg
SBP<129mmHg
SBP<median (n=13O6)
SBP> median (n=400)
SBP>130mm Hg
SBP>130mmHg
SBP>130mnn Hg
SC belimumab 200 mg (n = 248)
"Scale—Cognitive Portion; LDL — low-"
Scalp psoriasis, n (%)
Scarring on renal biopsy
SCD (%)
scDBP, mean (SD), mmHgf
Schwab & England score
Sco.’ita'ROjS DVT.'PE
score
score (>5) at 8 monthsb Unadjusted OR
Score 一no. (%)
Score > 15%, % of patients
Score >2.5
Score >2.75
Score 1-3
Score 3.0
Score 4-9
score at week 32, mean (SE) Difference MEPO-PBO (95% CI)
Score distribution:
Score distribution: <5
Score improvement, baseline to week 100, median (IQR)
Score of #9, no. (%)
Score of $10, no. (%)
Score of >5.1 — %
Score on Asthma Control Questionnaire**
Score on Modified Mini-Mental State Examination — median (IQR)
Score on Modified Rankin Scale — median (IQR)
Score on modified Rankin Scale — no. (%)§
Score on modified Rankin scale ('%/'
Score on NIH Stroke Scale — median (IQR)
Score on St. George's Respiratory Questionnaire^^
Score on the Minnesota Living with Heart Failure scaled
Score, %
Score, No. (%)
Scores for global and pain assessments§
Scr, gmol/L
Screening
Screening % predicted FEV1
Screening % reversibility FEV1
Screening (Visit 1)
Screening absolute reversibility FEV1,mL
Screening and baseline lung function characteristics
Screening BMI (kg/m2)
Screening FEV1 % predicted
Screening HbA1c (%)
Screening prebronchodilator FEV1,L
Screening visit
screening, L
screening, mean (SD) Morning PEF, mean
scSBP, mean (SD), mmHge
SD
"SD = standard deviation; BMI = body mass index; ED = erectile"
SD of SBP
SD or %
SD, standard
SDAI
SDAI (0-86)
SDAI <11 t
SDAI <3.3*
SDAI, mean (SD)
SDC (0.5-0.9 ng/ml)
SDC (1.2-2.0 ng/ml)
SDC (ng/ml)
SE
Seated DBP, mean (SD), mmHg
Seated SBP at 24 weeks, mmHg+
Seated SBP at 8 weeks, mmHg+**
Seated SBP, mean (SD), mmHg
seated SBP, N
Second-generation stent
Second (N=2344)
Second co-primary
Second Co-Primary Outcome
Second loading dose
Second MI
Second primary (estimated change in total UPDRS score from baseline to wk 72)
Second primary composite outcome
Second prior MI
Second serum creatinine
Second year!
Secondary' outcomes
Secondary-prevention cohort
Secondary #1
Secondary #2
Secondary #3
Secondary (change in total UPDRS score from baseline to final visit in phase 1)
Secondary cardiovascular endpoint
Secondary DVT.'FE
Secondary end points
Secondary end points 1
Secondary end points II
Secondary end points III
Secondary endpoints:
Secondary III*
Secondary IP
Secondary Kidney Composite Outcome
Secondary MACE endpoint
Secondary nonresponse
Secondary outcome
Secondary Outcome
Secondary outcomes
Secondary P
Secondary PCI
Secondary Prevention Subgroup
Secondary*
Section 6a
Section 6b
Section 6c
Section 7a
Section 7b
Section 7c
Secukinumab
Secukinumab 150 mg
Secukinumab 150 mg (N = 138)
Secukinumab 150 mg (n = 29)
Secukinumab 150 mg (n 5 692)
Secukinumab 150 mg (n=100)
Secukinumab 150 mg
Secukinumab 150 mg (N = 116)
Secukinumab 150 mg (N = 31)
Secukinumab 150 mg (N = 85)
Secukinumab 150 mg no load (N = 117)
Secukinumab 150 mg no load (N = 32)
Secukinumab 150 mg no load (N = 85)
Secukinumab 300 mg
Secukinumab 300 mg (N = 139)
Secukinumab 300 mg (n = 29)
Secukinumab 300 mg (n 5 691)
Secukinumab 300 mg (n=100)
Secukinumab 300 mg
Secukinumab 75 mg
Secukinumab 75 mg (n=99)
Secukinumab intravenous 150 mg (n=86)
Secukinumab intravenous 75 mg (n=82)
Secukinumab pooled† (N = 46)
Secukinumab, 150 mg (N = 202)
Secukinumab, 75 mg (N = 202)
SeDBP
SeDBP (mmHg) [mean _SD]d
SeDBP (mmHg) [mean_ SD]a
Sedentary
Seizure frequency during 8‐week baseline, median (range)
Seizure history, n (%)
Seizure types reported during baseline,b n(%)
Seizure types reported during baselinee
Select lipids and lipoproteins
Selected baseline medications
Selected clinical characteristics
Selected clinical characteristics — no./total no. (%)
Selected clinical characteristics, n (%)
Selected key secondary efficacy endpoints
Selected medications — no. (%)
Selective vascular history
SELENA-SLEDAI (range U-1U5)t
SELENA-SLEDAI >10, %
SELENA-SLEDAI activity, n (%)
SELENA-SLEDAI mean score (SD)
SELENA-SLEDAI total score
Selexipag
Selexipag (N = 122)
Selexipag (N = 179)
Selexipag (N = 55)
Selexipag (N = 574)
Selexipag patients/events n
Selexipag vs placebo Hazard ratio (95% Cl)
Self-rated health status
Self-reported descent, n (%)
Semaglutide
Semaglutide (N = 1648)
Semaglutide 0.5 mg
Semaglutide 1.0 mg
Semaglutide exposure, nmol/L
Semuloparin (N = 1608)
Sensitive
Sensitive Responder (N=1711)
sensitive responders (n=1366)
Sensitivity analyses
Sensorimotor stroke
Septal anomaly — no. (%)
Serious
Serious adverse events
Serious AE
Serious AEs
Serious decline in kidney function*
Serious decline in kidney function1
Serious GI disorder
Serious infections
Serious TEAEs
SERMs
Seronegative (RF -ve and ACPA -ve) subgroup
Seropositive (RF +ve and/or ACPA +ve) subgroup
Seropositivity
Seropositivity status, n
Sertraline
Serum
Serum 25-hydroxyvitamin D, ng/mL
Serum 25(OH)D concentrations, ng/mL, mean (SD)
Serum albumin-adjusted calcium (mg/dL)
Serum albumin concentration, g/l
Serum albumin, g 1 1
Serum albumin, g/dl
Serum albumin, g/l
Serum biochemistry Potassium, mmol/L
Serum bone-specific alkaline
Serum C-terminal telopeptide of
Serum calcium, mmol/l
Serum cholesterol — mmol/liter
Serum cholesterol (mg/L)*
Serum cholesterol, mean (sd) mg/dl
Serum cholesterol, mean (SD), mg/dL
Serum cholesterol, median (IQR), mg/dL
Serum cholesterol, mg/dL
Serum cholesterol, mg/dld
Serum creatinine
Serum creatinine - mean (sd, N)
Serum creatinine — mg/dl
Serum creatinine — mg/dl||
Serum creatinine — mg/dl§
Serum creatinine — pmol/liter
Serum creatinine (gmol/)
Serum creatinine (mg/dl)
Serum creatinine (mg/dL)
Serum creatinine (mmol/L)
Serum creatinine (pmol/L), mean (SD)
Serum creatinine >130 /xmol/l, n (%)||
Serum creatinine >130 Mmol/L, n (%)
Serum creatinine >130 pmol/l. n (%) |
serum creatinine concentration and randomization to losartan
Serum creatinine level
Serum creatinine level, mean (SD), mg/dL
Serum creatinine, /xmol/l||
Serum creatinine, ^mol/l
Serum creatinine, ≥2.5 mg/dL
Serum creatinine, ≥3.0 mg/dL
Serum creatinine, μmol/l
Serum creatinine, gmol/'L, mean (SD)
Serum creatinine, gmol/l |
Serum creatinine, Limo 1 1
Serum creatinine, mean (sd) mg/dl
Serum creatinine, mean (SD), mg/dL
Serum creatinine, mean (SD), pmol/L
Serum creatinine, mg/dl
Serum creatinine, mg/dL
Serum creatinine, mg/dL, mean (SD)
serum creatinine, mg/dlb
Serum creatinine, umol/Lf
Serum creatinine,弘mol儿||
Serum Creatinine. mg/dL
Serum CTX-1, ng/mL, median (IQR)
Serum CTX (ng/ml)
Serum CTX I (ng/mL)
Serum FG, mg/dL
Serum gastrinT, pg/mL
Serum glucose (mmol/L)
Serum glucose(mg/dl)
Serum haemoglobin A1c concentration (%), mean (SD)
Serum HDL cholesterol (mmol/L), mean (SD)
Serum K+ Level and Drug Treatment
Serum LDL cholesterol
Serum Mg <0.74 mmol/L (hypomagnesemia)
Serum Mg >0.74 mmol/L (normal Mg/hvpermagnesemia)
Serum N-propeptide of type 1 collagen,
Serum P1NP (^g/liter)
Serum pepsinogen I/IIT
Serum phosphate, mmol/l
Serum potassium — mmol/liter
Serum potassium (mmol/L)
Serum potassium 一mmol/liter
Serum potassium level, mean (SD), mEq/L
Serum potassium, >5.5 mmol/L
Serum potassium, >6.0 mmol/L
Serum potassium, mean (sd) mmol/l
Serum potassium, mEq/L
Serum potassium: <4.18mmol/L (n=729)
Serum sodium — mEq/liter
Serum sodium — mmol/liter
Serum sodium, mEq/l
Serum sodium, mEq/L
Serum Sodium. mEq/L
Serum total cholesterol (mmol/L), mean (SD)
Serum total cholesterol, mmol/l (SD)
Serum total IgE, IU/mL
Serum TRAP-5b (U/liter)
Serum triglycerides — mmol/liter
Serum triglycerides — pmol/liter
Serum triglycerides, mg/dle
Serum urate (mg/dL)
Serum Urate (mg/dL)
Serum urate (mg/dl), n (%)
Serum Urea Nitrogen, mg/dL
Serum uric acid (mg/dL)
serum uric acid, difference vs placebo (95% Cl)
serum uric acid, N
Serum values
Serum values^
Serum vitamin D (nmol/L)
SES-CD, mean (SD)
SeSBP
SeSBP (mmHg) [mean - SD]d
SeSBP (mmHg) [mean _SD]a
Severe
Severe (<30 mL·min−1·1.73 m−2), n (%)
Severe (>16)
Severe (>20)
Severe (FEV, <30% predicted)
Severe (GOLD 3)
Severe (IIEF-EF <10)
Severe (IIEF-EF 1-10), n (%)
Severe (IPSS > 20)
Severe (IPSS > 20) Age group
Severe (IPSS >20)
Severe (IPSS >20) (n = 185)
Severe (ITT) (n=1257)
Severe (ITT) (n=1265)
Severe (ITT) (n=1270)
Severe (ITT) (n=1274)
Severe (ITT) (n=1676)
Severe (ITT) (n=1694)
Severe (N1 = 115)
Severe (N1 = 56)
Severe AEs
Severe COPD
Severe COPDc [N Z 140]
Severe CORD*: QVAI49-SFC
Severe disease
Severe ED
Severe episodes in previous year — no./patient
Severe exacerbations
"Severe exacerbations, ITT population; n (%)"
Severe Hyperkalemia'S
Severe Hyperkalemia‘s
Severe Hyperkalemiac
Severe hypoglycemia
Severe impairment    (eGFR <30)
Severe impairment (<30)
Severe impairment (eGFR <30 mL/min/m^)
Severe impairment (eGFR <30)
Severe impairment (eGFR <30), N (%)
Severe n Z 1932
Severe OA symptoms at baselined
Severe OAB subgroup
Severe or moderate
Severe or very severe
Severe or very severe COPD
Severe or very severe Smoking status
Severe or worse airflow limitation
Severe recurrent ischemia
Severe renal impairment
Severe TEAEs
Severe to end-stage impairment (530 mL/min)
Severe, GOLD 3
Severe, n (%)b
Severe/life threatening
Severe/life ttireatening
Severe/lite threatening
Severe/Moderate
Severe/very severea
Severely impaired
SEVERITY
Severity n (%)
Severity of airflow limitation
Severity of airflow limitation (GOLD 2011-2014), n (%)
Severity of airflow limitation (GOLD 2013), n (%)
Severity of airflow obstruction
Severity of COPD
Severity of COPD — no. (%)f
Severity of COPD*, n (%)
Severity of COPD, (GOLD 20087), %
Severity of COPD, airflow limitation, n (%)
Severity of COPD, combined assessment, n (%)
Severity of COPD, n (%) (GOLD 2008): Moderate
Severity of COPD, n (%)*
Severity of COPDa, Airflow Limitation, n (%)
Severity of COPDa, Combined Assessment of COPD, n (%)
Severity of heartburnb
Severity of hypertensionb
Severity of the disease (GOLD 2008), n (%)
Severity ofCOPD (GOLD2015),n (%)
Severity ofhypertension [n (%)]b
Severitya
Sex
Sex— no. (%)
Sex—No. (%)
Sex — no. (%)
Sex — no./total no. (%)
Sex (%)
Sex (female)
Sex (Female)
Sex (Interaction: p=0.59)
Sex (male)
Sex (male)- no. (%)
Sex (male) Ethnic origin
Sex (male), %
Sex (male), n (%)
Sex (male, %)
Sex (male/female)
Sex (male/female) (n)
Sex (men/women)
Sex (no.)
Sex (p=050)
Sex (women, men)
Sex (women, n [%])
Sex M/F
Sex, %
Sex, % female
Sex, % male
Sex, female
Sex, Female
Sex, female, %
Sex, female, n (%)
Sex, female, n (%)
Sex, male
Sex, Male
Sex, male, n (%)
Sex, male, no. (%)
Sex, male/female, %
Sex, men (%)
Sex, men/women, %
Sex, n (%)
Sex, n (%) Male
Sex, n (%)*
Sex, n (%)b
Sex, No, (%)
Sex, no. (%)
Sex, No. (%)
Sex, no. (%) male
Sex:
Sex: female
Sex: male
Sex: Male
Sex: Male (n=1094)
Sexa Male
Sexually active
Sexually active with female
Sexually active1 (%)
Sexy
SF-12 MCS score
SF-12 PCS score
SF-36 (health transition score)
SF-36 bodily pain, mean change from baselineb
SF-36 bodily pain, mean change from baselinee
SF‐36 health survey
SF-36 MCS
SF-36 PCS
SF‐36 PCS, LS mean change ± SE
SF-36 PCS, LS mean change from baseline ± SE
SF-36 physical component summaryJJ
SF-36 score
SF-36 summary scores
SF-36v2 domain scores, mean [SD]
SF-36v2 MCS, mean [SD]
SF-36v2 PCS, mean [SD]
SF36-PCS
SFC
SFC (n [1546)
SFC (n = 1240)
SFC (n = 1,392)
SFC (n[546)
SFC 50 mg/500 mg
SFC 50/500 |ig bid n=369
SFC 50/500 mg Twice Daily (n = 1,005)
SFC 50/500 mg Twice Daily (n = 672)
SFC 50/500 pg twice daily (n=264)
SFC50/500 pg b.i.d. n = 297
SGLT-2 inhibitors^
SGRQ-C total scoreb
SGRQ Responder (%)
SGRQ score, mean (SD)
SGRQ Scores, mean (SD)
SGRQ total score
SGRQ Total Score
SGRQ total score (units)
SGRQ total score (units):!:
SGRQ total score (week
SGRQ total score* (units)
SGRQ total score**
SGRQ total score1
Shared epitope,a % positive
SHFM Annual Mortality
Short-acting
Short-acting anticholinergics
Short-acting b2-agonists
Short (<10 years) duration of diabetes
Short (<10 years) Duration of Diabetes
Short Form 36 (SF-36)
Short term (n = 321)+
Short term^
"SHS (0-440; per 10 score)"
SHS, mean ± SD
SHS, mean 6 SD
Si.gni.fi.canr ECG changes, positive biomarkers, and age <60 vrs
Significant worsening in KCCQ clinical
Significant worsening in KCCQ clinical score (≥5) at 8 mo†
Significant worsening in KCCQ clinical score (>5) at 8 months3
Sildenafil (n = 189)
Silodosin 8 mg (n = 381)
Simple partial (IA)
Simplified disease activity index
Simplified Disease Activity Index
Simplified Disease Activity Index score
Simplified Disease Activity Index score (0-86)
Simva
SIMVA
Simva (%)
SIMVA („ = 1234}
SIMVA (n = 1234)
Simva N=346 n (%)
Simva N=8728 n (%)
Simvastatin
Simvastatin (40/80 mg/d)
Simvastatin (40/80 mg/d) (n = 2265)
Simvastatin (n = 24)
Simvastatin (n=6. 9)
Simvastatin (n=7, 9)
Simvastatin 20 mg (n = 189)*
Simvastatin 20 mg Plus Fenofibrate 160 mg (n = 388/
Simvastatin 40 mg
Simvastatin 40 mg (n = 4,380)
Simvastatin 40 mg (n = 69)
Simvastatin 60 mg
Simvastatin 80 mg
Simvastatin Monotherapy (n = 1,031*)
Simvastatin, n (%)
Since diagnosis
Since onset
Single
Single-vessel disease
Single-vessel disease, n (%)
Single vessel coronary artery disease*
Single vessel coronary artery disease†
Single vessel coronary artery disease1
Single vessel coronary artery diseasea
Single vessel PCI
Sinus rhythm
Sinus rhythm at baseline
Sinus tracts/perforation,'^ n (%)
Sinusitis
SIRIUS
Sirolimus
Sirolimus-eluting
Sirolimus-eluting stent use, n (%)
Sirukumab 100 mg q2w
Sirukumab 50 mg q4w
SITA 100
SITA 100 mg (n = 378)
SITA 100 mg (n = 649)
SITA 100 mg (n = 744)
SITA 100+ PIO 15
SITA 100+ PIO 30
SITA 100+ PIO 45
SITA/PIO 100/15
SITA/PIO 100/30
SITA/PIO 100/45
Sitagliptin
Sitagliptin    218
Sitagliptin    265
Sitagliptin    62    11.0 士 2.6 2-h Postprandial Plasma Glucose (PPG) (mmol/L)
Sitagliptin    62    8.5 士 0.9 Fasting Plasma Glucose (FPG) (mmol/L)
Sitagliptin (n = 352)
Sitagliptin (n=111)
Sitagliptin (n=132)
Sitagliptin (n=243)
Sitagliptin (n=249)
Sitagliptin ± OAD
Sitagliptin 100 mg N = 122
Sitagliptin 100 mg N = 128
Sitagliptin 100 mg N = 191
Sitagliptin 100 mg N=157
Sitagliptin 100mg N = 185
Sitagliptin 288
Sitagliptin 291
Sitagliptin 292
Sitagliptin 296
Sitagliptin 314
Sitagliptin 315
Sitagliptin 317
Sitagliptin N=7332
Sitagliptin No./Total No.
Site
Site of disease — no. (%)
Sites
Sitting blood pressure — mmHg
Sitting diastolic blood pressure (mm Hg)
Sitting pulse, bpma
Sitting systolic blood pressure (mm Hg)
Six-minute walk distance, m
six-study placebo-controlled set
Size (cm2) (mean ± standard deviation)
Size of left atrium normal — no. (%)£
SJC
SJC (/28 joints)
SJC (0-76), mean (SD)
SJC (28 joints)
SJC (28 joints), mean (SD)
SJC (76 joints)
SJC, 0-28
SJC, mean (SD)
sk .89
Skull, and facial bone fractures
sl35 mm Hg
SLE markers, n (%)
Sleep
Sleeping problems in the past 2 weeks (%)
slO days
Slowest third
Small-artery occlusion
Small-artery occlusion (lacune)
Small vessel
Small/medium
sMedian prednisone dose, n (%)
SMI:
SMMSE
SMMSE < 20
Smoker
Smoker (%)
Smoker (%)a
Smoker (current/former)
Smoker at baseline
Smoker or ex-smoker, n (%)
smoker, %
Smoker, n (%)
Smoker,! n (%)
Smokers
Smokers (at baseline)
Smokers, %
Smokers, n (%)
Smokers, no. (%)
Smokers, No. (%)
Smokers: QVA149-5FC
Smoking
Smoking'!'
Smoking—current
Smoking (%)
smoking (%) Laboratory parameters
Smoking (A)
Smoking (current)
Smoking (during the previous month)
Smoking (ever)
Smoking classification, n (%)
Smoking consumption pack-years
Smoking habit, n (%)
Smoking history
Smoking history — no. (%)
Smoking history (ever)
Smoking history (pack-years)
Smoking history (pack-years)∗
Smoking history (pack-yr)
Smoking history,
Smoking history, n (%)
Smoking History, n (%)
Smoking history, pack-years
Smoking history, pack-years, mean (SD)
Smoking history, r (%)
Smoking history, n (%)
Smoking history: current smoker
Smoking history: ex-smoker
Smoking in past yr
Smoking in the past year
Smoking index — pack-yr§
Smoking pack-years
smoking pack-yearsa
Smoking pack-yearsb, n (%)
Smoking pack year (years)^
Smoking pack year (years)fl
Smoking Past
Smoking status
Smoking Status
Smoking status—no. {%)
Smoking status — no. (%)
Smoking status — no. {%)
Smoking status (%)
Smoking status (ongoing) (n)
Smoking status (previous) (n)
Smoking status at screening
Smoking status at screening, n (%)
Smoking status Current
Smoking status Current smoker (n = 132)
Smoking status*
Smoking status, n (%)
Smoking status, n (%) Former
Smoking status, n (%)*
Smoking status, n [%]®
Smoking status, no. (%)
Smoking status. No. (%)
Smoking*
Smoking* (> 10 pack-years)
Smoking, %
Smoking, % current
Smoking, mean
Smoking, N (%)
Smoking: current smoker
Smoking: ex-smoker
Smokingb
Smokinq status
SNP
SO
SO 0%
SOC
SOCAlone (N = 1602)
Social function
Social functioning
Social interaction
Sodium
Sodium-glucose cotransporter 2 inhibitor
Sodium, mEq/l
SOE or SUE
Sokoiow-Lyon voitage, mV
Sokolow-Lyon (mm)*
Sokolow-Lyon voltage, mm
Sokolow-Lyon, mm
Sokolow–Lyon voltage (mV)
Solifenacin (n = 357)
Solifenacin (n = 84)
Some
Some college
Some college/tech
Some physical activity
Some walking
Some Walking
Somnolence
Sonti Amenca
Sotagliflozin
Sotagliflozin (N=699)
Sotagliflozin 200 mg (n=261)
Sotagliflozin 400 mg (n=263)
Sotalol
Sou ti Africa
Source
South Africa
South Africa/South America
South America
South America (%)
South America (n=776)
South American
South Asia
South Asian
South or Central America
South or Central American
South! Central America
South, n (%)
Southern Europe
Southern hemisphere
Spacer use during the study
Spain
Spain (n=366)
Special interest categories
Specific risk of bleeding^
Specific syndromes
sPGA >4
Spinal
Spinal fractures
Spine
Spine*
Spiralcomputedtomographyangiography
Spirometric values at baseline
Spirometry
Spirometry after bronchodilation§
Spirono (n=121)
Spirono (n=50)
Spirono (n=71)
Spironolactone
Spironolactone (N = 1722)
Spironolactone(N=836)
Spironolactone(n=886)
spironolactone, n (%)
Spironolactone, n (%)
Spoke
Spondylitis
Spondylitis with peripheral arthritis
SPRINT ACR <3-4
SPRINT ACR >3-4
Squamous cell carcinoma
Sr ii B 5- CJl 3
SRI‐4 response rate, %
SRI response, %
β-blocker
β‐Blocker
β-Blocker
β-Blockers
SS >10(n=352vs 168)
SS at baseline
β blocker
β blockers
SS years
SS<9(n=202vs111)
ssed as LS means
ssi-4
sso-9
SSOmgdayP.Eq.
SSS score
SSZ+MTX (n = 95)
ST
ST-
ST-2 (ng/ml)
ST-depression and T-wave inversion
ST-depression only
ST-elevation MI
ST-elevation myocardial infarction
ST-segment-elevation myocardial infarction — no. (%)
ST-segment—elevation myocardial infarction
ST-segment depression
ST-segment depression <0.1 mV, %
ST-segment depression >0.1 mV
ST-segment depression >0.1 mV on admission, %
ST-Segment Depression >1 mm
ST-segment depression >1 mm — no. (%)
ST-segment depression or T-wave inversion on ECG
ST-segment deviation >1 mm — no./total no. (%)
ST-segment deviation TIMI risk score, %
ST-segment elevation
ST-segment elevation MI
ST-Segment Elevation MI
ST-segment elevation myocardial infarction
ST‐STR ≥70% post PCI
ST‐STR ≥70% pre‐ CI
ST-T wave
ST-T wave abnormality d
ST-T wave changes
ST-T Wave, n (%)
ST-T wave, No. (%)
ST-T waveft
ST-T wavett
ST (ARC definite only)
ST change >1 mm
ST depression (without ST elevation)
ST depression >1 mm
ST Depression or Elevation
ST elevation
St George's Respiratory Questionnaire total score!
ST segment depression
ST segment elevation
ST/T wave
ST+
Stable angina
Stable Angina
Stable angina — no. (%)
Stable Angina (n - 6,358)
Stable Angina (n = 6,358)
Stable angina, n (%)
Stable coronary artery disease
Stage >3 chronic kidney disease (%)
Stage 1
Stage 1 CKD eGFR > 90 mL/ (N=842)
Stage 1: >90 ml/min/1.73 m2
Stage 2
Stage 2 CKD eGFR 60 to 89 mL/min (N=4069)
Stage 2: >=60
Stage 2: 60 -89 ml/min/1.73 m2
Stage 3
Stage 3 CKD eGFR 30 to 59 mL/min (N = 2817)
Stage 3: 30-59 ml/min/1.73 m2
Stage 3a
Stage 3A CKD cohort (post hoc analysis excluding metformin users)
Stage 3A CKD cohort (secondary analysis)
Stage 3A: >=45 and <60
Stage 3a: 45 -59 ml/min/1.73 m2
Stage 3A: eGFR >=45 and <60 ml/min per 1.73 m2
Stage 3b
Stage 3B: >=30 and <45
Stage 3b: 30-44 ml/min/1.73 m2
Stage 3B: eGFR >=30 and <45 ml/min per 1.73 m2
Stage 4
Stage 4 CKD eGFR 15 to 29 mL/min (N = 73)
Stage 4: <30
Stage 4: 15 -29 ml/min/1.73 m2
Stage 5: <15 ml/min/1.73 m2
Stage I (GFR >90 ml/min per 1.73 m2) and stage V (GFR <15 ml/min per 1.73 m2) were not considered because they included only 0 and 1 patient, respectively. CHF, congestive
Stage II
Stage III
Stage IV
Stage of PDa
Stalin
Standard
Standard (3)
Standard (8)
Standard (N = 247)
Standard (n=2162)
Standard (n=3367)
Standard allocation
Standard BP Lowering, <140 mm Hg (n=2177)
Standard care
Standard Care
Standard Care (n=558)
Standard care (n=5874)
Standard Care Allocation
Standard Care N (%)
Standard Care N (%)    /100py
Standard Care N(%)    /100py
Standard Care Slope LSM ± SE (mm/year)
Standard Control
Standard Control (N=5569)  No.of patients (percent)
Standard therapy
Standard Therapy (N = 5123)
Standard Therapyy (N = 1718)
Standard Treatment (n - 801)
Standardized Mean Difference
Standardized total hip BMD (g/cm2)
Standing after 1 minute Change from baseline
Standing after 3 minutes Change from baseline
State
Statin
Statin — no./total no. (%)
Statin (%)
Statin (n - 252)
Statin (n = 252)
statin (n=137)
statin (n=84)
Statin (open)
Statin + Ezetimibe
Statin + ezetimibe (n=125. 65)
Statin + ezetimibe {n=120, 62)
Statin + ezetimibe, n (%)
Statin + fibrate or
Statin + Fibrate or Niacin
Statin alone
Statin and/or ezetimibe
Statin and/or other lipid-lowering agent therapy
Statin at enrollment
Statin at last follow-up
Statin during admission
Statin group
Statin intensity per ACC/AHAC
Statin intensity1*8
Statin intolerance8, n (%)
Statin intolerant*
Statin medication
Statin monotherapy
Statin non-users (N=348)
Statin only
Statin only (n=32, 19)
Statin only (n=35,19)
Statin only, n (%)
Statin or ezetimibe
Statin or Ezetimibe
Statin potency Medium (N=582)
Statin potency stratum, n (%)
Statin therapy
Statin treatment
Statin usage
Statin use
Statin Use
Statin use — no. {%)
Statin use (%)
Statin use at baseline
Statin Use at Baseline:
Statin use at study entry, n (%)
Statin use, n (%)
Statin users
Statin users (N=276)
Statin with ezetimibe
Statin with fibrate
Statin with niacin
Statin with other LLT
Statin without other LLT
Statin(s)
Statin, % (n)
Statin, n (%)
Statin+ER Niacin (n=1034)
Statin+ER Niacin (n=1718)
Statin+Placebo (n=1020)
Statin+Placebo (n=1696)
Stating
Statini
Statins
Statins 一 no. (%)
Statins used during follow-up
Statins, n (%)
Statins, No. (%)
Statins/ezetimibe
Statistic**
Statisticd
Statistics
status (SPMSQ <21
status (SPMSQ >21
STD N (N/lOOpy)
STEMI
STEMI (%)
Stenosis >50%
Stent
Stent (n = 459)
Stent (n=199)
Stent (n=209)
Stent (n=51)
Stent diameter $3 mm
Stent diameter < 3 mm
Stent group (n=81)
Stent implanted
Stent length per lesion, mm
Stent plus abciximab
Stent plus Medical Therapy
Stent plus placebo
Stent thrombosis
Stent Thrombosis
Stent Thrombosis-Related MI
Stent Thrombosis ARC Definite/Probable
Stent thrombosis or MI
Stent thrombosis*
Stent type
Stented lesions
Stented vessel
Stented vessels
Stenting plus Medical Therapy (N=459)
Stents per lesion, n
Steroid-free CR-100
Steroid-free remission
Steroid-sparing remission*
Steroid use at baseline
Steroid use at baseline (mg/day)
Steroid use at baseline, n (%)
Steroid use, %
Steroids (inhaled)a
Steroids (n=480 vs 240)
Steroids (other)
Steroids, n (%)
Steroids§§
stiffness (min)
Stiffness subscale
Still taking alendronate at study entry, n (%)
Stomach
Stool frequency subscore
Storage subscore
Strain (%)
Strata modelb HR, 95% CI, P value
Strategy
Stratification factor: Menopausal status, n (%)
Stratification factors
Stratification variables
Stratified analyses
Stratified by
Stratified Hazard Ratio (95% CI)
Stratified Log-Rank P Value
Stratified Log-Rank P Value
Stratum
Stratum 1: inadequate response or intolerance to 1-2 bDMARDs of same MoA
Stratum 2: inadequate response or intolerance to >3 bDMARDs of same MoA or >2 of multiple MoA
Stratum I
Stratum II
Stratum*
Stratum, n (%)
Streptokinase
Stricturing
Stroke
Stroke — no. (%)
Stroke — no./total no. (%)
Stroke (fatal/nonfatal)
Stroke (vs TIA)
Stroke and TIA, n (%)
Stroke Any
Stroke at entry
Stroke at entry (vs transient ischemic attack)
Stroke deaths
Stroke N(%)
stroke n=213
Stroke Non-fatal
Stroke of any etiology
Stroke of atherosclerotic origin
Stroke of undetermined cause
Stroke or
Stroke or cerebrovascular disease
Stroke or PVD, (%)
Stroke or SE (S/SE)
Stroke or SEE
Stroke or systemic
Stroke or systemic embolism
Stroke or TIA
Stroke or TIA — no. (%)
Stroke or transient ischemic attack
Stroke orTIA
Stroke orTIAb
Stroke risk score
Stroke subtype
Stroke subtype, n (%)
Stroke thought due to atherothrombotic disease
Stroke, fatal and nonfatal
Stroke, n (%)
Stroke, SEE, or CV death
Stroke, SEE, or death
Stroke, total
Stroke/Embolism
Stroke/M 1
Stroke/M l/HF hospitalization
Stroke/Non-
Stroke/SE
Stroke/SEE
Stroke/TIA
Stroke/transient ischemic attack
StrokeZSEE
Structural
Structural heart disease
Structural heart disease — no. (%)f
Structural heart disease§
STSD >1 mm on admission (n = 2,246)
Study
Study 1
Study 1222.11
Study 1222.12
Study 1222.13
Study 1222.14
Study 2
Study 36-item Short-Form General Health Survey (SF-36) can range from 4 to 71 for the physical component and from 2 to 74 for the mental
Study drug
Study drug loading days (actual): 0 (n=34)
study druga
Study end concentration
Study eye characteristics
Study medication — no. (%)
study medication, pre-dose
study period Fatal PE
Study population
Study Population
Study treatment
Study treatment — no./total no. (%)
SU
SU monotherapy
SU Monotherapy
SU, n (%)
SU/MET
SU/TZD
SUA <9.5
Subacute (1-30 days)
Subarachnoid hemorrhage
Subcortical WML load diameter, mm, mean (SD)
Subcortical WML load diameter, mm,, mean (SD)
Subcutaneous (N = 194)
Subcutaneous injections
Subcutaneous unfractionated heparin
Subdural/epidural
subgoup_name
Subgroup
Subgroup    1
Subgroup analyses
Subgroup analysis: Change from baseline in HbA1c at Week 26 per baseline HbA1c category
Subgroup based on:
Subgroup by treatment interaction p-value
subgroup level
Subgroup level
subgroup levels
Subgroup name/level
Subgroup No.
Subgroup Overall
Subgroup p-value3
Subgroup p Value!
Subgroup P Value本
Subgroup p Valuef
Subgroup Sex
Subgroup statistics
Subgroup Treatment
Subgroup w.r.t. RE-COVER
subgroup_level
Subgroups
SUBGROUPt
Subject Characteristics
Subject completion status, n (%)
Subject disposition, N (%)
Subject Group
Subjects
Subjects $65 years of age, n (%)
Subjects (N)
Subjects ,65 years of age, n (%)
Subjects n
Subjects randomized
Subjects stratified by baseline PRA
Subjects who did not receive LABD prior to the study
Subjects who did receive LABD prior to the study
Subjects with imputed value for end‐of‐treatment body weight
Subjects with prevalent vertebral fracture, n (%) Prevalent vertebral fracture
Subpopulation
Subpopulation analyses according to baseline HbA1c
Subpopulation analyses according to BMI
"subscale, and 0 to 1700 for the function subscale; normalized scores can range from 0 to 300. Scores for the Health Assessment Question-"
Subset of patients not on metformin
Subset of patients on metformin
Subsets
Subtrochanteric
Sudden cardiac death§
Sudden Death
sufficient
SUIT index, nmol/mmol
SUIT quartile 1 (b 24.5 nmol/mmol) (n = 110)
SUIT quartile 2 (>24.5-<34.7 nmol/mmol) (n = 109)
SUIT quartile 3 (>34.7-<49.6 nmol/mmol) (n = 109)
SUIT quartile 4 (>49.6 nmol/mmol) (n =109)
Sulfasalazine
Sulfasalazine (mean dose: 1.69 g/day)
Sulfasalazine treatment
Sulfasalazine use at randomization
Sulfasalazine use at randomization, n (%)
Sulfonylurea
Sulfonylurea — no. (%)
Sulfonylurea based
Sulfonylurea derivatives
Sulfonylurea use at baseline
Sulfonylureaa
Sulfonylureas
Sulfonylureasb
Sulphonamides, urea derivatives
Sulphonylurea
Sulphonylureas
Sulphonylureas only
SUN-101 (25)
Supine after 5 minutes Change from baseline
Supplemental oxygen
Supplementary oxygen
Supplementary Table 3. Change from baseline in urine albumin-to-creatinine ratio by HbA1c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria.
Supraventricular tachyarrhythmias (incl. atrial
Surgery
Surgical repair of VSD or PDA >1-year duration
Surgical technique
Surgical technique POST-RANDOMISATION CHARACTERISTIC**
Suspected myocardial infarction
SUSTAIN
SUSTAIN 1
SUSTAIN 1: Semaglutide vs. placebo
SUSTAIN 2
SUSTAIN 2: Semaglutide vs. sitagliptin 100 mg
SUSTAIN 3
SUSTAIN 3: Semaglutide vs. exenatide ER 2.0 mg
SUSTAIN 4
SUSTAIN 4: Semaglutide vs. IGlar
SUSTAIN 5
SUSTAIN 5: Semaglutide add‐on to insulin vs. placebo
Sustained decrease of >40% in eGFR®
Sustained ESRD, death due to kidney failure, or sustained decrease of >40% in eGFR from baseline
Sustained ESRD, death due to kidney failure, or sustained decrease of >50% in eGFR from baseline
Sustained mucosal healingc
Sustained mucosal healingc n/n (%)
Swollen
Swollen-joint count (of 66 joints assessed) — no.
Swollen-joint count (of 76 joints)
Swollen-joint count, of 66 joints examined
Swollen joint count
Swollen joint count (0-44)
Swollen joint count (0-66 joints)
Swollen joint count (0-66 possible joints)
Swollen joint count (0-66)
Swollen joint count (0–66 joints), mean (SD)
"Swollen joint count (0—44; per swollen joint)"
Swollen joint count (28 joints)
Swollen joint count (28), mean (SD)
Swollen joint count (66 joints), mean (SD)
Swollen joint count (66 joints), mean (SD)’
Swollen joint count (66), mean (SD)
Swollen joint count (76 joints)
Swollen joint count (n/68)
Swollen joint count (range 0-66 joints)
Swollen joint count of 66 joints
Swollen joint count, of 28
Swollen joint count, of 66
Swollen joints (66-joint count), mean ± SD
Swollen joints >1, n (%)
Symbol digit score
Symmetric T-wave inversions
Symmetric T wave inversions
Symptom-free days in the past 2 weeks (%)
Symptom bother
Symptom duration
Symptom duration, months
Symptom Onset
Symptom onset-to-
Symptom onset-to-randomization
Symptom onset to arrival in catheterization laboratory
Symptom onset to enrollment
Symptom onset to first medical contact: ambulance or emergency department
Symptom onset to hospital admission
Symptom onset to hospital arrival, hours
Symptom onset to hospital arrival, median (IQR), h
Symptom onset to hospitalization
Symptom onset to PCI, h
Symptom onset to randomization
Symptom onset to start of reperfusion treatment: tenecteplase or arterial sheath insertion!
Symptom score (SD)
Symptomatic
Symptomatic deep-vein thrombosis
Symptomatic heart fail
Symptomatic hypoglycaemia
Symptomatic hypotension
Symptomatic Hypotension
Symptomatic hypotension (SBP <90 mmHg)
Symptomatic hypotension with SBP <90 mm Hg
Symptomatic ICH
Symptomatic infarct swelling
Symptomatic localization-related
Symptomatic PAD
Symptomatic PAD of lower extremities*
Symptomatic PADt
Symptomatic PE
Symptomatic remissionb n/n (%)
Symptomaticb
Symptoms
symptoms mean (SD)
Symptoms of atrial fibrillation in the 3 months before randomiza-
Symptoms of atrial fibrillation in the 3 months before randomization — no. (%)
Symptoms onset to first balloon inflation, min
Syncope
Syncope — no. (%)
Syndecan-1 (ng/ml)
Syndesmophyte present, n (%)
Syndrome, n (%)
Synovitis
Sys: NS Dia: <0.001
Syst. BP (mmHg)
Systemic arterial hypertension, n (%)
Systemic corticosteroid use
Systemic corticosteroids — no. (%)
Systemic corticosteroids, n (%)
Systemic corticosteroids, n (%)a
systemic embolism
Systemic glucocorticoid use at randomisation
Systemic glucocorticoid use at randomization, n (%)
Systemic hypertension
Systemic SLE medications, n (%)
Systemic symptoms
Systoiic biood pressure, mm Hg
Systolic
Systolic—mean (SD) (mm Hg)
Systolic — mm Hg
Systolic (mean, SD)
Systolic (mm Hg)
Systolic (mmHg)
Systolic blood pressure
Systolic blood pressure - mmHg
Systolic blood pressure — mm Hg
Systolic blood pressure — mmHg
Systolic blood pressure (change from baseline)
Systolic Blood Pressure (median 125.0)
Systolic blood pressure (mm Hg)
Systolic blood pressure (mm Hg), mean (SD)
Systolic blood pressure (mmHg)
Systolic blood pressure (mmHg), mean±SD
Systolic blood pressure [mmHg] (Interaction: p=0.56)
Systolic blood pressure <140 mm Hg and diastolic
Systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg
Systolic blood pressure >130 mm Hg — no. (%)
systolic blood pressure >130 mm Hg,
Systolic blood pressure >130 mm Hg, n (%)
Systolic blood pressure >140 mm Hg or diastolic
Systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg
Systolic Blood Pressure mmHg, mean (sd)
Systolic blood pressure subgroups
Systolic blood pressure,
Systolic blood pressure, (mm Hg)
Systolic blood pressure, mean (SD), mm Hg
Systolic blood pressure, mean (SD), mm Hga
Systolic blood pressure, mm Hg
Systolic blood pressure, mm Hg (SD)
Systolic blood pressure, mm Hg <140
Systolic blood pressure, mm Hg, mean (SD)
Systolic blood pressure, mm Hg, mean±SD
Systolic blood pressure, mm Hg, median (range)
Systolic blood pressure, mm Hg^
Systolic blood pressure, mm Hq
Systolic blood pressure, mm Hg
Systolic blood pressure, mmHg
Systolic blood pressure, mmHg*
Systolic blood pressure, mmHg, mean (SD)
Systolic blood pressure^
Systolic blood pressurea, mm Hg
Systolic BP
Systolic BP (mm Hg)
systolic BP (mmHg)
Systolic BP (mmHg)
Systolic BP (mmHg)*
Systolic BP at Baseline:
Systolic BP, mm Hg
Systolic BP, mm Hg (mean) NYHA class
Systolic BP, mm Hg, mean (SD)
Systolic BP, mm Hg, mean (SD)
Systolic BP, mmHg
Systolic BP, mmHg (SD)
Systolic BP, mmHg, mean (SD)
Systolic BP, mmHg, mean ± SD
Systolic pressure — mm Hg
Systolic pressure at ankle level (mmHg), mean ± SD
Systolic pressure, mm Hg
Systolic pulmonary arterial pressure, mean (SD), mm Hg
Systolic, mean (SD), mm Hg h
Systolic, total
Systolic, treated at baseline
t
T-JJ (0-73)
T-Score at Femoral neck
T-score categories Lumbar spineb
T-wave inversion
T-wave inversion only
t (n=2,042)
T 0.2 mg
T 0.4 mg
T wave inversion
T1 (0.44-4.09 ng/mL)
T1D
T1DM
T2 (4.11 -6.66 ng/mL)
T2 lesion volume, mm'
T2 lesion volume, mm3
T2D
T2D duration, years
T2DM
T2DM duration (years)
T2DM duration, y
T3 (6.67- 139.83 ng/mL)
tA
TA (n = 155)
Table 1 Baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela
Table 1. Characteristics of Patients Treated With Losartan and Atenolol*
Table 1. Characteristics of the Patients at Baseline.*
Table 1. Selected Baseline Characteristics of the Study Patients.*
table_group
Tachyarrhythmias, n (%)
TACI
TACI (n=129)
Tadalafil
Tadalafil 10 mg n = 120
Tadalafil 2.5 mg
Tadalafil 2.5 mg (n = 394)
Tadalafil 2.5 mg n = 113
Tadalafil 20 mg n = 116
Tadalafil 5 mg
Tadalafil 5 mg (N = 492)
Tadalafil 5 mg (N = 752)
Tadalafil 5 mg (n = 923)
Tadalafil 5 mg Mean change (SD)
Tadalafil 5 mg n = 117
TAH (n = 155)
Taiwan
Taking antihypertensive medication at baseline, No. (%)e
Taking antihypertensive treatment at
Taking calcium supplements at baseline, n (%)
Taking statins, n (%)a
tAmong those enrolling via BNP stratum. The study-qualifying BNP or
Tamsulosin
Tamsulosin (n = 112)
Tamsulosin (W= 1611), 0/0
Tamsulosin 0.2 mg (n = 165)
Tamsulosin 0.2 mg vs. placebo
Tamsulosin 0.4 mg (n = 162)
Tamsulosin 0.4 mg (n = 384)
Tamsulosin 0.4 mg vs. placebo
Tamsulosin 0.4mg vs. 0.2mg
Tanezumab (all doses combined)
Tanezumab (all doses combined) + NSAIDa
Tanezumab 10 mg
Tanezumab 10 mg + NSAID
Tanezumab 2.5 mg
Tanezumab 2.5 mg + NSAID
Tanezumab 5 mg
Tanezumab 5 mg + NSAID
Target-vessel revascularization
Target nail NAPSI score (1–8 scale)
Target vessel
TASS’
TBP
TC
TC (mg/dL)
TC (mmol/L)
TC level, mean (SD) mg/dL
TC, mean (SD)
TC, mean (SD), rrig/dL
TC, mg/dL, mean + SD
TC, mg/dL, mean ± SD
TC, mmol/L (mg/dL)
TC/HDL-C
TC/HDL-C ratio
TC:HDLC
TCHDL-C, mean (SD)
tComparison of proportion of patients with NYHA class lll/IV heart failure.
TCZ-SC 162 mg every other week (n = 437)
TCZ 8 mg/kg n=51
TCZ+MTX (n)
TDI E' (septal) (cm/sec)
TDI total score (week 12
TEAEs
TEAEs (>3% in any treatment group)
TEAEs (>5% in any treatment group)*
TEAEs in a5% of individuals
TEAEs leading to discontinuation of study drug
TEAEs Of special interest
TEAEs reported by ≥5% patients in the overall BRV group, n (%)
TEAEs, cases per 100-patient years (CI)
Telmisartan
Telmisartan (N = 10,146)
Telmisartan (n=390)
Telmisartan Group (n=390)
Temporal data and management strategy
Temporary discontinuation of study drug
Temporary Factors
Temporary risk factor
Tender
Tender- or painful-joint count (of 68 joints assessed) — no.
Tender-joint count (of 78 joints)
Tender-joint count, of 68 joints examined
Tender and swollen joints — mean no.::
Tender joint count
Tender joint count (0-44)
"Tender joint count (0-44; per tender joint)"
Tender joint count (0-68 joints)
Tender joint count (0-68 possible joints)
Tender joint count (0-68)
Tender joint count (0–68 joints), mean (SD)
Tender joint count (28 joints)
Tender joint count (28), mean (SD)
Tender joint count (68 joints), mean (SD)
Tender joint count (68 joints), mean (SD)’
Tender joint count (68), mean (SD)
Tender joint count (78 joints)
Tender Joint count (n/66)
Tender joint count (range 0-68 joints)
Tender joint count of 68 joints
Tender joint count, of 28
Tender joint count, of 68
Tender joints (68-joint count), mean ± SD
Tenecteplase
Tenecteplase and PCI (n=829)
Teriparatide (N = 680)
Teriparatide n/N (%)
Terlile 1
Terminal ileum
"terol; HDL-C, high-density Lipoprotein cholesterol;"
Terrible
Tertiary
Tertiary amines
Tertiary end points
Tertiary endpoints:
Tertile 1
Tertile 1 (<3.98 ng/mL) n-482
Tertile 1 (n = 400)
Tertile 1 Index PCI performed
Tertile 1: 4.78 (0.016)
Tertile 2
Tertile 2 (3.99-5.43 pg/mL) n=483
Tertile 2 (n = 387)
Tertile 2: 5.66 (0.19)
Tertile 3
Tertile 3 (>5.43 pg/mL) n-482
Tertile 3 (n = 404)
Tertile 3: 6.58 (0.44)
Tertile of Total Cholesterol at Baseline, Mean (SD), mmol/L
Test for interaction
Test for Interaction (p Value)
test for interaction between treatment and race
Test for trend
Testing order
Testosterone (nmol/L)
Testosterone (TT) (nmol/L)
Testosterone level (nmol/L)
tests for categoric
TexCAPS
TG
TG (mg/dL)
TG (mg/dl), median ± SD
TG (mmol/L)
TG (mmol/L)c
TG (mmol/L, median)
TG > 150. HDL <40 (mg/dL) (/? = 957)
TG >150 mg/dl, n (°/o)
TG >3.1
TG mg/dL, median (SD)
TG*
TG, median (interquartile range)
TG, median (min, max)
TG, median (SDy rng/cJL
TG, mg/dL, mean ± SD
TG, mmol/L (mg/dL) [median]
TG, mmol/L [mg/dL]
TG, triglycerides. *Median values (standard deviation for medians).
TG’
TG+
TG< 150, HDL>40 (n = 6614)
TG<=3.1
TG§
TGs (mg/dl)
TGt
TH (100%)
th C
the American College of Rheumatology).
The metabolic syndrome^
the Netherlands, Australia, New Zealand, and South Africa
The plot shows hazard ratios and 95% confidence intervals for the primary outcome, with patients stratified according to eight sub-groups prespecified in the statistical analysis plan. No heterogeneity was observed for these subgroups.
the square of the height in meters. Patient's and physician's global assessment scores can range from 0 to 100. Scores for the Western
The test for heterogeneity (interaction) indicates whether the treatment effect varied significantly among the sub-groups. The Hochberg method was applied to each of the two comparisons of the treatment groups. BMI denotes body-mass index (the weight in kilograms divided by the square of the height in meters).
Theophylline compound
Theophylline use at screening
Theophyllines
Therapies
therapy
Therapy-Fatigue (FACIT-F, 0-52)
therapy (ASA 3,261/Placebo 3264)
therapy (ASA 4626/Placebo 4703)
therapy (ASA 530/Placebo 481)
therapy (ASA 6,091/Placebo 5957)
Therapy at discharge
therapy use
Thiazide
Thiazide at enrollment
Thiazide at last follow-up
Thiazide diuretic
Thiazide diuretic*
Thiazide diuretics
Thiazide users
Thiazides
Thiazolidinedione
Thiazolidinedione (includes Pioglitazone)
Thiazolidinedione 一 no. (%)
Thiazolidinedione based
Thiazolidinedione No
Thiazolidinedione use at baseline
Thiazolidinedione Yes
Thiazolidinedioneb
Thiazolidinediones
Thiazolidinediones*
Thiazolidinedionesc
Thienopyridine
Thienopyridine (N=2162)
Thienopyridine (N=3696)
Thienopyridine alone
Thienopyridine at baseline
Thienopyridine at discharge
Thienopyridine at Enrollment
Thienopyridine at randomization
Thienopyridine at Randomization
Thienopyridine drug at start of open-label period
Thienopyridine N=1805
Thienopyridine N=4057
Thienopyridine Type
Thienopyridine+dipyridamole
Third heart sound
Third heart sound, n (%)
Third primary (change in UPDRS score/wk, wk 48-72)
Third yeart
This study
Thoracic cage fractures
Threatened abrupt vessel closure
Three-point MACE
Three-vessel disease
Three arm
Three of seven risk factors
Three or more agents
Three or more drugs
Three or more lesions
Thromboaspiration
Thromboaspiration — no. (%)
Thrombocytopenia
thromboembolism
Thrombolysis
Thrombolytic agents
Thrombolytic treatment before randomization
Thrombophilia
Thrombophilia, No. (%)e
Thrombus-containing lesion
Thrombus aspiration
Thrombus aspiration done per lesion†
Thyroid disease
Thyroid hormone
TIA
TIA, n (%)
Tibia fracture
Ticagrelor 60 mg
Ticagrelor 60 mg 3 Year KM (%)
Ticagrelor 60 mg 3 yr KM%
Ticagrelor 60 mg Diabetes n=20
Ticagrelor 60 mg KM %
Ticagrelor 60 mg No Diabetes n=38
Ticagrelor 60 mg vs. Placebo HR (95% CI)
Ticagrelor 90 mg
Ticagrelor 90 mg 3 Year KM (%)
Ticagrelor 90 mg 3 yr KM%
Ticagrelor 90 mg Diabetes n=12
Ticagrelor 90 mg No diabetes n=46
Ticagrelor 90 mg vs. Placebo HR (95% CI)
Ticagrelor in‐Hosp (N = 116)
Ticagrelor pre‐Hosp (N = 98)
Ticagrelor, 60 mg (N = 7045)
Ticagrelor, 90 mg (N = 7050)
Ticlopidin
Ticlopidine
Ticlopidine (n = 870)
Ticlopidine after completion of study drug
tics — no. (%)
Tier 1 AEs
Tier 1AEs
TIM 1 nsk score
Time-to-first-infusion from hip surgery (days), n (%)
Time-to-first infusion
time (sec)*
Time between cessation of full-dose warfarin therapy and enrollment (mo)
Time between index ACS and randomization — days
Time between index ACS and randomization (days)
Time from ACS to randomization
Time from ACS to randomization (median, IQR)
Time from acute coronary syndrome to randomization (days)
Time from end of FIT, years (meaniSD)
Time from event to randomization — days
Time from fibrinolytic therapy to study-drug administration — no./total no. (%)
Time from first eval
Time from hospital admission to enrollment,
Time from hospital admission to PCI, h, median (Q1, Q3)
Time from hospitalization to randomization — hr
Time from index AcS event to randomisation (days)
Time from last dose of P2Y12 inhibitor, days
"Time from LD to PCI, min; median (Q1–Q3)"
Time from longest event to randomisation
Time from most recent qualifying
Time from onset of pain to randomization — hr
Time from onset of pain to randomization, median (25th—75th percentiles), n
Time from onset of pain to randomization, median (IQR), h
Time from onset of qualifying stroke to randomization
Time from onset of symptoms to presentation — hr
Time from onset of symptoms to randomization — days
Time from onset of symptoms to start of fibrinolytic therapy — hr
Time from onset to medication, h, mean±SD
Time from onset to randomization, h, mean±SD
Time from PAH diagnosis months
Time from Parkinson’s disease diagnosis in months, mean (SD)
Time from presentation to randomization — hr
Time from psoriatic arthritis diagnosis [a], years
Time from qualifying ECG to balloon inflation
Time from qualifying event to randomization
Time from qualifying MI, %
Time from qualifying MI, yrs
Time from qualifying myocardial infarction
Time from Qualifying Myocardial Infarction
Time from qualifying stroke to randomization
Time from RA diagnosis, years, median
Time from randomization to CABG — hr
Time from randomization to coronary angiography— hr
Time from randomization to PCI — hr
Time from randomization to PCI (non-ST-elevation MI), h
Time from randomization to PCI (ST-elevation MI), min
Time from randomization to study-drug administration — hr
Time from randomization to study-drug initiation — hr
Time from study drug administration to coronary revascularization, median (IQR), h
Time from sx onset to baseline ECG, min
Time from symptom onset of RA, years, median
Time from symptom onset to balloon inflation
Time from symptom onset to enrollment,
Time from symptom onset to randomization
Time from symptom onset to start of fibrinolytic therapy — hr
Time from symptoms to randomization, h
Time from symptoms to treatment
Time from, median (IQR), h
Time in therapeutic range
Time in therapeutic range before inclusion
Time in therapeutic range, median (IQR), %
Time in Trial
Time Intervals
Time intervals, h
Time of qualifying ECG to balloon inflation (hrs)
Time of randomization
Time of Randomization
Time of randomization (Interaction: p=0.04)
Time of symptom onset to balloon inflation (hrs)
Time of symptom onset to randomization (hrs)
Time point
Time sample drawn (h)
Time since AS diagnosis (years), mean (SD)
Time since AS diagnosis (years), mean ± SD
Time since AS diagnosis, mean (SD) years
Time since asthma
Time since asthma diagnosis (years)
Time since asthma diagnosis [years], median (range)
Time since asthma diagnosis years
Time since BPH diagnosis (years)
Time since CABG
Time since cessation of full-dose warfarin therapy
Time since COPD diagnosis (yrs)
Time since diagnosis — mo
Time since diagnosis of CIU/CSU (years)2
Time since diagnosis of CIU/CSUf (y)
Time since diagnosis of COPD, years
Time since diagnosis of diabetes
Time since diagnosis of diabetes — no. (%)
Time since diagnosis of diabetes (years) (median, IQR)
Time since diagnosis of diabetes, mean (SD)
Time since diagnosis of diabetes, n (%)
Time since diagnosis of diabetesa, n (%)
Time since diagnosis of heart failure
Time since diagnosis of LN, years
Time since diagnosis of osteoarthritis — yr
Time since diagnosis of PAH — yrf
Time since diagnosis of PAH years#
Time since diagnosis of PsA (years), mean (SD)
Time since diagnosis of SLE, years
Time since diagnosis of T2DM
Time since diagnosis of T2DM, y, n (%)
Time since diagnosis of type 2 diabetes
Time since diagnosis of type 2 diabetes - no. (%)
Time since diagnosis of type 2 diabetes mellitus
Time since diagnosis, years
Time since end of FIT, mean (SD), y
Time since epilepsy diagnosis (years)
Time since first AF diagnosis, yrs
Time since first COPD diagnosis (years)
Time since first LUTS (years)
Time since first psoriasis diagnosis (y), mean (SD)
Time since IPF diagnosisa, mean years (SD)
Time since last dose of
Time since most recent myocardial
Time since onset (h)
Time since PAH diagnosisc (years)
Time since PD diagnosis, mean ± SD,
Time since primary diagnosis,
Time since prior alendronate use, n (%)
Time since PsA diagnosis (years), mean (SD)
Time since PsA onset, mean years (SD)
Time since psoriasis diagnosis, years1
Time since qualifying event
Time since randomization
Time since rheumatoid arthritis diagnosis, years
Time since start insulin (years)
Time since start of FIT, mean (SD), y
Time since start of FIT, years (meaniSD)
Time to admission, min
Time to all-cause death up to end of the study
Time to angiography — hr
Time to balloon/needle, min*
Time to death due to PAH or hospitalization due to PAH up to the end of the treatment periodd
Time to end-of-study IVUS, median (IQR), days
Time to first CV hospitalization or death from any cause
Time to first exacerbation
Time to first inhaled corticosteroid (%)
Time to first morbidity/mortality event up to the end of the treatment periodd
Time to first oral or systemic corticosteroid (%)
Time to first SARE*(%)
Time to randomisation [hours] (Interaction: p=0.71)
Time to randomization
Time to randomization (h)
Time to randomization from symptom onset
Time to rx
Time to treatment
Time to treatment (min)t
Time to treatment initiation (min)
"Time to treatment initiation (min;"
Time to treatment, h
Time, mean (SD), min Procedure
TIMI-bleeding major/minor
TIMI-defined bleeding
TIMI ≥2
TIMI ≥3
TIMI ≥3 and spoke
TIMI ≥3 and spoke and time ≤2 h
TIMI ≥3 and spoke and time ≤3 h
TIMI ≥3 and spoke and time ≤4 h
TIMI ≥3 and spoke and time ≤5 h
TIMI ≥4
TIMI ≥5
TIMI clinically significant
TIMI flow grade 3 of MI culprit vessel post‐PCI
TIMI flow grade 3 of MI culprit vessel pre‐PCI
TIMI flow‡
TIMI major
TIMI Major
TIMI major bleeding
TIMI major or
TIMI major or minor bleeding
TIMI major/minor
TIMI Major/Minor
TIMI major/minor bleeding
TIMI minor
TIMI Minor
TIMI minor bleeding
TIMI non-CABG major
TIMI risk score
TIMI risk score — %
TIMI risk score — no. (%):t
TIMI risk score — no./total no. (%):c
TIMI risk score — no./total no. (%)f
Timi risk score (Interaction: p=0.49)
TIMI risk score >5, %
TIMI Risk Score >5, %
TIMI risk score >5, n (%)
TIMI Risk Score 0-2
TIMI Risk Score 3-7
TIMI risk score category—No. (%)
TIMI risk score!
TIMI risk score*
TIMI Risk Score*
TIMI risk score, %
TIMI risk score, n/N (%)
TIMI risk scoret
Timing of clopidogrel loading dose
TIO
TIO (N 5 258)
TIO (N 5 869)
TIO 18 |ig (n=508)
TIO i8 mcg (N=508)
tion — no. (%)
"tion; OS = overall satisfaction; Qmax = maximal urinary flow rate."
Tiotropium
Tiotropium (N = 2986)
Tiotropium (N = 3707)
Tiotropium (n=1076)
Tiotropium (n=1304)
Tiotropium (n=1384)
Tiotropium (n=250)
Tiotropium (nZ2251)
Tiotropium (nZ735)
Tiotropium + olodaterol 2.5/ 5 pg
Tiotropium + olodaterol 2.5/ 5 Pg
Tiotropium + olodaterol 5/5
Tiotropium + olodaterol 5/5 pg
Tiotropium + placeb (n[570)
Tiotropium + placebo (n[561)
Tiotropium 18 gg qd
Tiotropium 18 meg (n=466)
Tiotropium 18mg(n=267
Tiotropium 2.5 μg (n = 154)
Tiotropium 2.5 Mg
Tiotropium 2.5 pg
Tiotropium 2.5 μg (n = 121)
Tiotropium 2.5 μg (n = 129)
Tiotropium 2.5 μg (n = 22)
Tiotropium 2.5 μg (n = 30)
Tiotropium 2.5 μg (n = 71)
Tiotropium 2.5 μg (n = 80)
Tiotropium 5 m g
Tiotropium 5 Mg
Tiotropium 5 mg Respimat® (n = 1952)
Tiotropium 5 mg Respimat® (n Z 1058)
Tiotropium 5 mg Respimat® (n Z 894)
Tiotropium 5 mg(n = 1033)
Tiotropium 5 Pg
Tiotropium 5 μg (n = 120)
Tiotropium 5 μg (n = 127)
Tiotropium 5 μg (n = 155)
Tiotropium 5 μg (n = 25)
Tiotropium 5 μg (n = 32)
Tiotropium 5 μg (n = 58)
Tiotropium 5 μg (n = 94)
Tiotropium 5Mg
Tiotropium Group (N = 388)
Tiotropium Salmeterol no. of patients/total no.
Tiotropium vs. salmeterol
Tiotropium/ olodaterol 2.5/5 Mg
Tiotropium/ olodaterol 5/5 Mg
Tiotropium/olodaterol 5/5 mg
Tiotropium/olodaterol 5/5 mg(n = 1029)
Tiotropium+olodaterol 2.5/5 Mg
Tiotropium+olodaterol 2.5/5 pg
Tiotropium+olodaterol 5/5 Mg
Tiotropium+olodaterol 5/5 pg
Tiotropiumc
TIROFIBAN (N=2398)
Titre (U/mL) t
Titre (U/mL)t
TJ (15-50)
TJ (16%)
TJC
TJC (/28 joints)
TJC (0-78), mean (SD)
TJC (28 joints)
TJC (28 joints), mean (SD)
TJC (78 joints)
TJC, 0-28
TJC, mean (SD)
tk
TlMi risk score
TNF-alpha (pg/mL)
TNF-failure patientsa
TNF-failurea
TNF-IR
TNF-naïve
TNF-naive patientsa
TNF-naivea
TNF-R1a (ng/ml)
TNF antagonist
TNF antagonist-exposed
TNF antagonist-failure population (n - 157)
TNF antagonist-failure population (n - 158)
TNF antagonist-naive'’
TNF antagonist-naive subgroup (n - 50)
TNF antagonist-naive subgroup (n - 51)
TNF antagonist-naive®
TNF inhibitor
TNF inhibitors
TNFi-exposed†
TNFi-IR
TNFi-naive
TNFi-naïve
TNFi-naïve, n (%)
TNFi (no other bDMARD taken)t, n (%)
TNFi and other bDMARDst, n (%)
TNFi exposed
TNFi naive
Tnglycendes < Median
Tngtycendes a Median
Tngtycerides < Median
Tngtycerides a Median
TnI ultrapositive ≥0.04 µg/L, n = 970 1023
TnI ultrapositive, ≥0.04 µg/L, N = 322 312
Tnl ultrapositive >0.04 pg/L, 0 = 9701023
TNT and IDEAL (pooled)
TOAST classification
TOAST classification of qualifying stroke
TOAST classification of qualifying stroke (%)
TOAST classification of qualifying stroke, no. (%)
Tobacco abuse
Tobacco use
Tobacco use — no. (%)
Tobacco use (%)
Tobacco use, n (%)
Tobacco Use, n (%)
Tobacco use, yes, n (%)
Tobacco User
Tocilizumab
Tocilizumab (n = 225)
Tofacitinib
Tofacitinib 10 mg BID
Tofacitinib 10 mg BID (n = 905)
Tofacitinib 10 mg BID (n = 905)
Tofacitinib 10 mg BID (n=21)
Tofacitinib 10 mg BID (n=95)
Tofacitinib 10 mg BID [N = 197|
Tofacitinib 10 mg BID [N = 429|
Tofacitinib 10 mg BID [N = 476|
Tofacitinib 10 mg twice daily N=1066
Tofacitinib 10 mg twice daily N=1090
Tofacitinib 10 mg twice daily N=251
Tofacitinib 10 mg twice daily N=253
Tofacitinib 10 mg two times a day
Tofacitinib 15 mg BID
Tofacitinib 5 mg BID
Tofacitinib 5 mg BID (n=22)
Tofacitinib 5 mg BID [N = 198|
Tofacitinib 5 mg twice daily N=1043
Tofacitinib 5 mg twice daily N=1071
Tofacitinib 5 mg twice daily N=258
Tofacitinib 5 mg twice daily N=259
Tofacitinib 5 mg two times a day
Tofacitinib, 10 mg (N = 132)
Tofacitinib, 10 mg (N = 197)
Tofacitinib, 10 mg (N = 245)
Tofacitinib, 10 mg (N = 429)
Tofacitinib, 10 mg (N = 476)
Tofacitinib, 10 mg twice daily
Tofacitinib, 15 mg twice daily
Tofacitinib, 5 mg (N = 131)
Tofacitinib, 5 mg (N = 198)
Tofacitinib, 5 mg (N = 243)
Toial cholcsierol (mg/dl)
Tolal choleslerol
Tolal choleslerol-lo-HDL choleslerol ralio
Tolvaptan
Tolvaptan (n = 2072)
Tonic
Tonic–clonic
Took prior antihyperglycemic agent (any)
Tophi present, n (%)
Tophi Present, n (%)
Topical
Topical non-prescription
Topical prescription
Topical therapy
Topiramate
toricoxib 90 mg n= 2032) (%)
Torsemide
Totai mortaiity
Total
Total-C
Total-C:HDL-C
Total-hip BMD T-score
Total (N [ 386)
Total (n = 1,301)
Total (N = 10,142)--
Total (n = 1065)
Total (N = 1156)
Total (N = 1176)
Total (n = 146)
Total (N = 2,019)
Total (n = 2313)
Total (N = 252)
Total (N = 327)
Total (N = 3297)
Total (N = 376)
Total (N = 39 876)
Total (N = 39876)
Total (N = 4327)
Total (N = 4447)
Total (n = 462)
Total (n = 494)
Total (N = 5059)
Total (n = 528)
Total (N = 547)
Total (n = 561)
Total (N = 639)
Total (N = 70)
Total (N = 755)
Total (N = 895)
Total (n = 955)
Total (N =1,186)
Total (N =39,876)
Total (N 5 1889)
Total (N 5 424)
Total (n 5 467)
Total (n = 376)
Total (N = 464)
Total (n)
Total (n = 1161)
Total (n = 42)
Total (n = 459)
Total (N = 506)
Total (n = 566)
Total (n = 94)
Total (n= 2,048)
Total (N=1,017)
Total (n=1461)
Total (N=1863)
Total (N=1962)
Total (N=2019)
Total (n=2039)
Total (N=21 105)
Total (n=344)
Total (N=351)
Total (N=4158)
Total (n=4331)
Total (n=5356)
Total (N=782)
Total (n=8101)
Total (n=8681)
Total (n=878)
Total (V= 18,889)
Total >atients
Total 22180
Total AIM‐HIGH Study
Total antihypertensive use
Total asthma symptom score
Total Asthma Symptom Score
Total asthma symptom score, mean ± SD‡
Total asthma symptom score, mean ± SDz
Total asthma symptom score:
Total back pain score (0–100 mm scale), mean ± SD
Total back pain, 0–100 mm VAS, mean ± SD
Total back pain, mean (SD)
Total BASDAI score, mean (SD)
Total BASDAI score, mean ± SD
Total BASDAI, mean (SD)
Total baseline insulin dose
Total bilirubin > 2 x ULN1
Total bilirubin, mg/dl
Total bleeding
Total bleeds
Total body
Total body (without head)
Total by treatment
Total C
Total C (mg/dl) *
Total C (mmol/L, mean)
Total C/HDL-C ratio **
Total CARMELINA Population
Total Cataract
Total Cataract Extraction
Total chol, mg/DL
Total cHol, mg/DL
Total cholesterohHDL cholesterol ratio
Total cholesterol
Total Cholesterol
Total cholesterol-to-HDL cholesterol ratio
Total cholesterol - mg/dL**
Total cholesterol — mg/dl
Total cholesterol (median, IQR), mg/dL
total cholesterol (mg/dl)
Total cholesterol (mg/dl)
Total cholesterol (mg/dL)
Total Cholesterol (mg/dl)
Total cholesterol (mg/dL), mean + SD, available for 3658 patients
Total cholesterol (mmo 1/1)
Total cholesterol (mmol/l)
Total cholesterol (mmol/L)
Total cholesterol (mmol/L), mean (SD)
Total cholesterol (mmol/L):
Total cholesterol (SD), mg/dL
Total cholesterol (week 24)
Total cholesterol <4-87 mmol/Lt
Total cholesterol <4 97 mmol/Lt
Total cholesterol >200 mg/dl
Total cholesterol >4'97 mmol/Lt
Total cholesterol >4-87 mmol/Lt
Total cholesterol level, mg/dL
Total cholesterol*
Total cholesterol, %
Total cholesterol, mean (SD)
Total cholesterol, mean (SD), mg/dL
Total cholesterol, mg/dl
Total cholesterol, mg/dL
"Total cholesterol, mg/dL""^"
Total cholesterol, mg/dL, mean (SD)
Total cholesterol, mg/dL^
Total cholesterol, mmol/L
Total cholesterol, mmol/L (SD)
Total cholesterol, mmol/l, mean (SD)
Total cholesterol, mmol/L, mean (SD)
Total cholesterol, mmol/l本
Total cholesterol, mmol/le
Total cholesterol, mmol/lt
Total cholesterol/HDL-C
Total cholesterol:HDL-C ratio
Total cholesterol^
Total cholesterol3 <194 mg/dL
Total cholesterol3 >194 mg/dL
Total cigarette pack-years, mean (SD)
Total cohort
Total Cohort
Total comparators (n = 1920)
Total comparators, patients with events/total patients
Total daily dose of ICS, mean, μgc
Total daily insulin dose (lU/kg)
Total daily insulin dose (U/day)
Total daily insulin dose, U
Total daily insulin dose, units/kgt
Total death
Total deaths
Total Deaths, n
Total diuretic dose (IV + oral) on day 1, mg
Total Events, n
Total feet score
Total gadolinium-enhancing lesion count, No. (%)
Total gadolinium-enhancing lesion count. No. (%)
Total glucose mg/dL
Total Glucose mg/dL
Total group
Total Group (n=551)
Total hands score
Total HAQ, 0-3
Total hip
Total hip (n = 1,687) BMD (g/cm2) (SD)
Total hip BMD (g/cm2)
Total hip BMD T-score
Total hip BMI) T-score
Total hip or knee replacement
Total hipc
Total HO population (n = 4951)
Total ICS dose at entry, /xg/d
Total IgE — lU/ml
Total IgE levelx (IU/mL), median (range)
Total IgE, geometric
Total included in combined analysis
Total intravenous loop diuretic (mg) Median
Total intravenous loop diuretics, mg
Total Invasive Cancer
Total IPSS
Total LDL-C*
Total length of implanted stents, mm, mean (SD)
Total macular volume, mean (SD), mm3
Total Mayo score
Total Mayo score$||
Total mortality
Total Mortality
Total mortality All
Total n
Total N = 827
Total N = 958
Total N =534
Total n = 867
Total N= 1404 n (%)
Total n1
Total no.
Total No.
total no. 26449
Total No. of Events (% of Participants)/ Total No. of Participants
Total No. of Events/ Total No. of Participants
Total No. of Events/Participants
Total No. of patients
Total No. of Patients
Total Number of Events/Participants
Total number of patients
Total occlusion, n (%)
Total pack-years Mean (SD)
Total pack-yrs
Total patients
Total Patients
Total patients n=157
Total patients n=159
Total patients, n
Total periventricular WML score, mean (SD)
total phase 3 pooled (n=1684)
Total population
Total Population
Total population (n = 6112)
Total population n
Total PsA‐modified SHS
Total randomised (N)
Total randomized
Total randomized, n
Total resolution of dactylitisb
Total resolution of enthesitisc
Total resolution of nail psoriasisd
Total sample =1174 (%)
Total score
Total score (0–528 scale)
Total score <12
Total score >12
"Total score on the SGRQ-C;i;"
Total score§
Total scores (total score range: 32-224)
Total SGRQ mean total score (SD)
Total SGRQ score
Total stent length
Total stent length- mm
Total stent length (mm), Mean±SD
Total stent length, mm
Total study ITT population (n = 4844)
Total study population
Total study population (n = 27,939)
Total Study Population (N=894)
Total subjects
Total time of fondaparinux treatment before
Total UPDRS score (baseline), mean (SD)
Total UPDRS score (range, 0-176)卞
Total UPDRS score (range, 0—176)y
Total vdH-S score
Total vdH-S score (0-448) (n)
Total!
Total! By baseline diabetic status
Total(N=2313)
Total*
Total, adjusted weight of 0.1 for gastrointestinal bleeding
Total, adjusted weight of 0.25 for gastrointestinal bleeding
Total, adjusted weight of 0.5 for gastrointestinal bleeding
Total, N = 439
Total, N = 745
total, n=16 485
Total, N=439
TotaLHDL cholesterol ratio
TOWARD
TP vs No TP
TPASI 75
TPM-exposed
TPM-naive
TPM subgroup, n = 122
TR jet velocity (m/sec)
Traditional Chinese medicine for respiratory disease — no. (%)
Traditional NSAID
Traditional NSAID use
Trait
Trandolapril
Trandolapril (n=4153)
Transaminases increased
Transfemoral
transfusion
Transfusion
Transfusion ≥2 units RBCs or whole blood
Transfusions
Transient
Transient ischaemic attack
Transient Ischaemic attack—No. (%)
Transient ischemic attack
Transient ischemic attack (%) Type of lacunar syndrome (%)
Transient monocular blindness
Transient ST elevation
Transradial
Treated
Treated at baseline
Treated at baseline, mean (SD), mm Hg
Treated at baseline, mm Hg: SBP, mean (SD)
Treated for hypertension, %
Treated hypertension:
Treated lesions‡
"Treated patients with baseline and   1 post-baseline efﬁcacy measurement; bP value for treatment group comparison (proactive intervention vs usual care) was calculated based on a 2-sample t test for continuous variables and chi-square test for categorical variables; cBP values were measured at baseline (week 0), whereas information on all of the other variables listed was collected during screening.
Abbreviations: BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CRUCIAL, Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-Term-Risk; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride."
Treated vessel
Treated vessel - Native coronary
Treated vessel!
Treated vessel(s)
Treated with Atenolol (n = 1104)
Treated with Atenolol (n = 3484)
Treated with CABG — no./total no. (%)
Treated with insulin
Treated with LABA, %
Treated with Losartan (n = 1203)
Treated with Losartan (n = 3402)
Treated with PCI — no./total no. (%)
Treatment
Treatment-by-subgroup interaction
Treatment-by-subgroup interaction, P =  0.06
Treatment-by-subgroup interaction, P = 0.67
Treatment (DE vs warfarin) by thrombophilia interaction
Treatment after admission
Treatment after randomization, in the single-dummy phase — days]
Treatment and parameter
Treatment arm
Treatment Arm
Treatment arm (zoledronate) (%)
Treatment at baseline
Treatment at randomisation
Treatment at randomization
Treatment at randomization — no. (%)
Treatment before admission (%)
Treatment before catheterization
Treatment before randomization — days
Treatment before randomization, %
Treatment by eGFR stage
Treatment by subgroup interaction
Treatment Characteristics
Treatment comparison
Treatment comparison (mg/day)t
Treatment Diff. vs TIO (95% CI)
Treatment difference
Treatment Difference
Treatment Difference % (95% Cl)
Treatment difference (95% CI)
Treatment difference (95% Cl)
Treatment Difference (95% Cl)
Treatment Difference, mL
Treatment duration before randomization — days
Treatment duration Mean (SD)
Treatment duration, days
Treatment during or after catheterization
Treatment effect (HR)
Treatment for latent tuberculosis^
Treatment glargine
Treatment group
Treatment Group
Treatment group, on-treatment IL-6 threshold
Treatment groups [n/Nb(%)]
Treatment groups, n (%)
treatment period Index DVT: event
Treatment randomization
Treatment Stratum^:
Treatment throughout study
Treatment with anti-platelet drugs
Treatment with antiplatelet drugs
Treatment with any blood-pressure-
Treatment with any BP lowering drugs
Treatment with candesartan
Treatment with drugeluting stent
Treatment with open-label perindopril
Treatment with statins
Treatment with sulphonylurea + biguanide, n (%)
Treatment with sulphonylurea + biguanide, n {%)
Treatment with sulphonylurea, n (%)
treatment, n (%)
Treatment × lipid interaction
Treatmentofpulmonary embolismpriorto randomization
Treatments at randomisation
Trend/het. test
Triacylglycerol, mmol/l, mean (SD)
Triacylglycerol, mmol/le
Trial
Trial 1
Trial 2
Trial 3
Trial completers
Trigl yeerides* (m mol/l)
Triglyceride
Triglyceride  a
Triglyceride (median: mg/dL)a [25-75 percentile]
"Triglyceride (median; mg/dL)-1 [25-75 percentile|"
Triglyceride (mg/dL)
Triglyceride (mg/dl) 3
Triglyceride (mg/dL)d
Triglyceride (mm
Triglyceride (mmol/L)
Triglyceride (mmol/L)* Blood pressure
Triglyceride (mmol/L)t
Triglyceride level
Triglyceride, mg/dL, mean (SD)
Triglyceride, mmol/L
Triglycerides
Triglycerides - mg/dL**
Triglycerides — mg/dl
Triglycerides — mg/dl^
Triglycerides — mg/dl||
Triglycerides — mmol/L
Triglycerides — mmol/liter
Triglycerides $150 mg/dL (1.69 mmol/L)
Triglycerides (median, IQR), mg/dL
triglycerides (mg/dl)
Triglycerides (mg/dL)
Triglycerides (mg/dL)**
Triglycerides (mg/dL), mean + SD, available for 3643 patients
Triglycerides (mmol/l)
Triglycerides (mmol/L)
Triglycerides (mmol/L) (median, IQR)
Triglycerides (mmol/L), mean (SD)
Triglycerides (mmol/L):
Triglycerides (SD), mg/dL
Triglycerides (week 24)a
Triglycerides <1-69 mmol/L
Triglycerides >1-69 mmol/L
Triglycerides >150 mg/dl
Triglycerides >150 mg/dL (>1.70 mmol/L)
Triglycerides 1st third
Triglycerides 2nd third
Triglycerides 3,d third
Triglycerides at Baseline
Triglycerides level, mg/dL
Triglycerides Mean
Triglycerides mean (mg/dl ± SD)
Triglycerides Tx difference vs Pbo, LS mean % change from baseline (SE)
Triglycerides*
Triglycerides* (mg/dl)
Triglycerides**
Triglycerides, median (IQR), mg/dL
Triglycerides, median (Q1:Q3)
Triglycerides, median (QI, Q3), mmol/L
Triglycerides, median (Ql, Q3), mmol/L
Triglycerides, median (range)
Triglycerides, mg/dl
Triglycerides, mg/dL
TriglyceriDes, mg/DL
Triglycerides, mg/dL, median (Q1:Q3)
Triglycerides, mg/dL^
Triglycerides, mg/L
Triglycerides, mmol/L
Triglycerides, mmol/L, mean (SD)
Triglycerides, mmol/L, mean±SD
Triglycerides, mmol/l§
Triglycerides, mmol/L®
Triglycerides, mmol/Lf
Triglycerides, mmolT1 (GM*)
Triglycerides,* mmol/L
Triple-vessel disease, n (%)
Triple therapy use at screening, n (%)
Trochanter
Troponin
Troponin (-)
Troponin (+)
Troponin 1 at baseline
Troponin 1 at baseline*
Troponin I (pg/ml)
Troponin Level
Troponin Negative (N=888)
Troponin Positive (N=1291)
Troponin T
Troponin T (pg/ml)
Trough FEV, response (L)i
Trough FEV| response (L)
Trough FEV1
Trough FEV1 response
Trough FEVi L
Trough FVC response (L)
Trough FVC response (L)!
Trough seated DBP (mmHg)a
Trough seated HR (bpm)a
Trough seated SBP (mmHg)a
Troy (ng/ml)
TT
TTf-fV
TTR (warfarin arm only)
TVR
Two-dimensional echocardiography
Two-sided P-value for hetero- geneity
Two-vessel disease
Two agents
Two arm
Two lesions
Two of the above
Two or more
Two or more antihypertensive medications
Two or more at baseline
Type
type 1 collagen, mean (SD), ng/mL£
Type 1, n (%)
Type 2 diabetes
Type 2 diabetes — no. (%)
Type 2 diabetes — no. (%)§
Type 2 diabetes — no. {%)§
Type 2 Diabetes (n=87, 88)
Type 2 diabetes 一no. (%)
Type 2 diabetes duration, mean (SD), years
Type 2 diabetes duration, years
Type 2 diabetes history, n (%)
Type 2 diabetes meiiitus
Type 2 diabetes mellitus
Type 2 diabetes mellitus'1'
Type 2 diabetes mellitus, n (%)
Type 2 diabetes mellitus’
Type 2 diabetes mellitusa
Type 2 diabetes Pbo (N = 43) vs EvoMab (N = 77)
Type 2 diabetes*
Type 2 diabetes, n (%)
Type 2 diabetes, n (%)d
Type 2 diabetes, No. (%)
Type 2 diabetes. n (%)
Type 2, n (%)
Type B2/C lesions, n (%)
Type IA
Type IB
Type IC
Type II diabetes
Type of AF
Type of AF, n (%)
Type of antihypertensive medication use among patients using antihypertensive medications, n (%)
Type of atrial fibrillation
Type of atrial fibrillation - n (%)
Type of atrial fibrillation — no./total no. (%)
Type of atrial fibrillation (%)
Type of atrial fibrillation (n=21 099)
Type of atrial fibrillation, n (%)
Type of atrial fibrillation, No./total No. (%)
Type of basal insulin, n (%)
Type of concomitant statin
Type of Concomitant Statin
Type of concomitant statin by daily dose
Type of concomitant statin by daily dose- no. (%)
Type of DES
Type of DES at index procedure
Type of drug-eluting stent, n (%)
Type of End Point
Type of event
Type of event — no. (%)
Type of event:
Type of hospital care
Type of Hospitalization
Type of index event — no. (%)
Type of insulin
Type of insulin therapy— no. (%)5
Type of intervention
Type of Lipid-Lowering Regimen
Type of MI (%)
Type of Ml, No. (%)
Type of myocardial infarction — no. (%)
Type of reference treatment strategy
Type of stent at index procedure
Type of surgery
Type of surgery CABG
Type of surgery CABG only
Type of TNF antagonist failure, n (%)'’
Type of TNF antagonist failure, n (“/o)”
Type of TNF failure, n (%)b
Type of treatment, n (%)
Type of vessel involved
Type/No. of valves repaired/replaced Mitral
Types of antihypertensive medications at 1 year †
Types of antihypertensive medications at last visit §
Types of fibrinolytic agent
TZD
U.S. Black Patients
U.S. Non-Black Patients
U.S. site
U.S. sites
u»c»(mg/g)
UA
UA (N =204)
UAC =
UAC >300 mg/g
UAC 30-300 mg/g
UACR
UACR — mg/g, median (IQR)
UACR (mg/g)
UACR (mg/g, median [IQR])
UACR (mgg-1)
uACR Not Available
uACR <3 mg/mmol∗
uACR ≥3 mg/mmol∗
"UACR*, mg/g (q1; q3)"
UACR, median (IQR), mg/g
UACR, mg/g, median (25th−75th percentile)
UACR, mg/g, median (IQR)
UACR, mg/mmol (interquartile range)b
UACR, mgg 1 (GM)
UACR, n (%)†
UACR, pg/mg
UACRa, mg/g, gMean = gCV
UACRa, mg/g, n (%)
UAE (p,g/min)
UAS7{
UAS76
UC
UC (n = 1325)
UC (n = 1514)
UC (n = 2119)
UC (n = 492)
UC (n = 755)
UC (n = 989)
UC [GEMINI 1]‘
UC disease duration (y)
UC disease durslion
UC duration, y, mean (range)
UC history
UCL
UCR
udy entry
UFH
UFH Only
UGT induction status: as randomizeda, n (%)
UGT induction status: per AEDa, n (%)
UIstekinumab
UKPDS 10-year risk score <20%
UKPDS 10-year risk score >20%
Ukraine
Ularitide (N = 1088)
Ularitide n/N (%)
Ulcer
Ulcer, n (%)a
Ulcerative colitis
Ulcers/gangrene
ULPASI 75
Ultra
Ultrasound carotid arteries
UMEC 62.5 |ig (n=509)
UMEC 62.5 mcg (N=509)
UMEC/VI 62.5/25
UMEC/VI 62.5/25 (N 5 275)
UMEC/VI 62.5/25 (N 5 878)
umied
Unacceptable adverse events
Unacceptable side effects
Unadjusted
Unadjusted 8-y Risk per 100 Population = SE (Adjusted Rate)
Unadjusted Hazard Ratio (95% Ci)
Unadjusted Hazard Ratio (95% Cl)
Unadjusted HR
Unadjusted HR (95% CI) for 1 SD increment
Unadjusted HR (95% CI) for 1 standard deviation increment
Unadjusted HR (95% CI)a
Unadjusted HR.
Unadjusted IRR
Unadjusted model HR, 95% CI, P value
Unadjusted OR (95% CI) P Value
Unadjusted P-value for Interaction
Unadjusted p Value
Unadjusteda Beta (SE)
Unbound PCSK9 (nmol/L)
Uncerlain
Uncertain
Unclassified
Uncodable
Uncontrolled
Uncontrolled on basal insulin
Uncontrolled on OAD(s)
Uncontrolled: ACQ-6 >1.5
UNCOVER-2
UNCOVER-3
Undergoing major vascular surgery
Underlying disease
Undetermined
Undetermined etiology
Undetermined etiology, n (%)
Undetermined, other, or cardioembolism
Undeterminedc
Undiagnosed Diabetes (n = 142)
Undiagnosed Diabetes Mellitus
Undiagnosed Diabetes Mellitus, n=1106
Unfractionated
Unfractionated heparin
Unfractionated heparin — no. (%)
Unfractionated Heparin (N = 10,223)
Unfractionated heparin (n = 1961)
Unfractionated Heparin (n = 4985)
Unfractionated heparin (n = 872)
Unfractionated heparin before randomisation
Unfractionated heparin only
Unfractionated Heparin or Enoxaparin plus Glycoprotein IIb/IIIa Inhibitors (N = 4603)
Unfractionated heparin within 3 hr before randomization — no./total no. (%)
Unfractionated only
Unhappy
Unified Parkinson Disease
United States
United States (n = 1,388)
United States and Canada
United States or Canada
United States, Canada
United States, Canada,
UNITI-1
UNITI-1 and UNITI-2    IM-UNITI
UNITI-2
Units per week, mean (SD)
Univariable
Univariable OR (95% CI), p Value*
Univariate logistic modela
Unknown
Unknown — no. {%)
Unknown (%)
Unknown (none of the above)
Unknown or missing
Unknown type
Unknown/missing
Unprotected left main stented
Unprovoked
Unprovoked VTE n (%)
Unrelated to effectiveness
Unspecified
Unstable
Unstable angina
Unstable Angina
Unstable angina — no. (%)
Unstable angina (biomarker negative)
Unstable angina (n = 2,874)
Unstable angina >1 mo ago
unstable angina Age
Unstable angina requiring hospitalization
Unstable angina*
Unstable angina, n (%)
Unstable angina§
Unstable anginad
Unstable anginat
Unstable but no rest angina
Unstableangina
Unsuccessful procedure
Untreated
Untreated at baseline
Untreated at baseline, mean (SD), mm Hg
Untreated at baseline, mm Hg: SBP, mean (SD)
UPA 15mg QD
UPA 30 mg QD
Upadacitinib 15 mg (n=l64)
Upadacitinib 30 mg (n=l65)
UPCR, n (%)
UPDRS III (motor)
UPDRS score
UPDRS total (II + III)
UPDRS, Part II (ADL)
UPDRS, Part III (motor)
UPLIFT® population
Upper abdominal pain
Upper gastrointestinal
Upper gastrointestinal tract
Upper Limb
Upper limb fracture
Upper limb fractures
Upper limbs
Upper respiratory tract infection
Upper respiratory tract infection 84 (5.7)
Upper respiratory tract inflammation
Upper tertile: > 0.37
UPS score, mean (SD)
ure
Urgency episodes/24h
Urgent Cor Revasc
Urgent coronary revascularization
Urgent peripheral revascularization
Urgent revascularisation due to unstable angina
Urgent revascularizati on
Urgent revascularization because of unstable angina
Urgent surgery
Urgent vascular hospitalization
Uric acid (mg/dL)
uric acid (mg/dl) creatinine clearance (ml/min per 1.73 m2)
Uric acid fertile 3 (>6.51 mg/dl)
Uric acid tertile 1 (<5.2 mg/dl)
Uric acid tertile 2 (5.2 to <6.51 mg/dl)
Uric acid tertile 3 (>6.51 mg/dl)
Urinary ACR
Urinary ACR (mg/mmol)
Urinary albumimcreatinine ratio
Urinary albumin-to-creatinine ratio — no. (%)§
Urinary albumin-to-creatinine ratio^
Urinary albumin-to-creatinine ratio§
urinary albumin/creatinine ratio, median mg/g (range)
Urinary albumin:creatinine ratio (mg/g)
Urinary albumin:creatinine ratio (pg/mg), median (IQR)
Urinary albumin:creatinine ratio*
Urinary albumin:creatinine ratio^
Urinary albumin:creatinine ratioa (mg/g)
Urinary protein-to-creatinine ratio||
Urinary protein:creatinine ratioa (mg/mg)
Urinary tract infection
Urine ACR (mg/g)
Urine ACR (mg/mmol)
Urine ACR < Median
Urine ACR >= Median
Urine ACR geometric mean (CV %),a,b mg/g
Urine albumin-to-creatinine ratio
Urine albumin-to-creatinine ratio - no. (%)§§
Urine albumin-to-ereatinine ratio
Urine albumin/creatinine (mg/mmol)
Urine albumin/creatinine ratio (mg/g)
Urine albumin/creatinine ratio, mg/mmol
Urine P/Cr
Urine Qmax, ml/s
URTI
Urticaria
US
US (N=4097)
US N= 96
US Resident
US site
US site of enrollment
US W= 92
USA
USA (n=1,293)
USA (n=446)
USA and Canada
USA(n=1293)
USA/Canada
Use
use (%)
Use 5-ASA compounds
Use at baseline
Use at baseline, n
Use of ACE inhibitor
Use of ACE inhibitor, ARB, or both — no. (%)
Use of ACE inhibitors/ARBs, n (%)
Use of anti-hypertensive agents, n (%) *
Use of antiarrhythmic agent
Use of antiplatelet agents — no./total no. (%)
Use of antiplatelet agents, n (%)
Use of antiplatelet agents^
Use of aspirin at time of qualifying event (%)
Use of beta-blocker
Use of beta-blockers
Use of blood pressure lowering medication*
Use of cardiac medication*
Use of CGM (Yes)
Use of CGM interaction test p-value^ =
Use of clopidogrel
Use of compression stockings, No. (%)
Use of concomitant lipid-lowering therapy- no. (%)
Use of concomitant lipid-lowering treatment
Use of concomitant lipid-modifying therapy
Use of Concomitant Lipid-Modifying Therapy
Use of diuretics, n (%)
Use of H2 bloekers, n (%)
Use of high-dose inhaled glucocorticoid — no. {%)
Use of hormone replacement therapy (A)
Use of ICS
Use of ICS at baseline, %
Use of inhaled glucocorticoids at baseline
Use of inhaled glucocorticoids at screening — no. (%)
Use of loop diuretics
Use of loop diuretics, n (%)
Use of Low-dose Aspirin (< 325
Use of low-dose aspirin (< 325 mg daily)
Use of low-dose aspirin (<325 mg daily)
Use of medication at baseline — no. (%)
Use of medication for PAH
Use of medication from randomization through 24 hr — no./total no. (%)
Use of medications for PAH — no. (%)
Use of methotrexate at randomization —
Use of oral glucocorticoids
Use of other medications — no. (%)
Use of parenteral antithrombotic
Use of parenteral antithrombotic agents — no. (%)
Use of PCI or thrombolysis within one day of Randomization
Use of proton inhibitors, n (%)
Use of rescue albuterol, puffs/day*
Use of rescue medication
Use of statin at any follow-up visit (%)
Use of statins
Use of supplemental oxygen, n (%)
Use of systemic glucocorticoid at random-
Use of ticagrelor
Use of verapamil or quinidine
Use oforal glucose-lowering agent— no. (%)
used
Useofmedical therapyathospitaldischarge
User
Using alendronate at baseline (%)
Using HRT or raloxifene at baseline (%)
Usteki
Ustekinu
Ustekinumab
Ustekinumab'’ (n = 46)
Ustekinumab 45 mg (n=205)
Ustekinumab 90 mg (n=204)
Ustekinumab Combined
Ustekinumab® (n = 155)
Usual care
Usual Care
Usual Care (n = 276a)
Usual Care (n = 38la)
Usual care (n=2119)
UTI
UTIs
UVB
Uveitis
V alsartan/HCTZ, n (%)
V(n=190)
V/HCTZ
V/HCTZ (n=103)
V/HCTZ (n=67)
V160 (n = 1
VaDAS score*
Val/HCTZ (n=46)
Val/HCTZ (n=63)
Val/HCTZ (n=80)
Valdecoxib
Valproate
Valsartan
Valsartan (N = 722)
Valsartan (n = 836)
Valsartan (N =4631)
Valsartan (n=565)
Valsartan n/N
Valsartan, n (%)
Valsartan, n/N (%)
Valsartan/HCTZ
Valsartan/HCTZ (n = 832)
Valsartan/HCTZ, n/N (%)
Value
Value for nteraction
Value*
"Values are expressed as percentages unless otherwise indicated. BMI, Body mass index; CABG, coronary artery bypass ischemic attack; NSAIDS, nonsteroidal anti-inflammatory drugs, SBP, systolic BP; DBP, diastolic BP. *History of or currently taking antidiabetic or lipid-lowering medications."
"Values are mean±SD, median [quartile range], or %. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction; and NT-proBNP, N-terminal pro-B-type natriuretic peptide."
"Values are presented as mean SD unless stated otherwise. Data shown are for the randomized population. *Body mass index values were missing from 5 patients in the aliskiren group and 2 patients in the hydrochlorothiazide group. †Obesity was defined as body mass index  30 kg/m2. ‡Metabolic syndrome was defined according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) criteria10 as any 3 of the following: waist circumference  102 cm for men or  88 cm for women; triglycerides  150 mg/dL; high-density lipoprotein cholesterol  40 mg/dL for men or  50 mg/dL for women; msSBP  130 mm Hg or msDBP  85 mm Hg; fasting glucose  110 mg/dL. §By medical history.  Aliskiren, n 566; hydrochlorothiazide, n 558."
"Values expressed as mean   SD or number (percent). * Two patients were missing values for body mass index.
†
Other forms of atherosclerosis are peripheral arterial disease, abdom-inal aortic aneurysm, symptomatic carotid artery disease, transient isch-emic attack, and stroke.
‡
Family history of premature CHD deﬁned as CHD in male ﬁrst-degree relative aged  55 years or female ﬁrst-degree relative  45 years.
§
Blood pressure  130/85 mm Hg, on antihypertensive medication, or diagnosis of hypertension based on medical history. n   number of randomly assigned patients; NCEP ATP   National Cholesterol Education Program Adult Treatment Panel."
values were calculated using t tests for continuous variables and chi-square
values were reported for 229 patients in the spironolactone group and 239
Valve repair/replacement only
Valve repair/replacement with or without CABG
Valve replacement/ repair with or without CABG
Valve surgery, n (%)
Valvular disease
Valvular disease (%)
Valvular disease, mitral
Valvular heart disease
Valvular heart disease — no. (%)
Valvular heart disease, n (%)
van der Heijde mTSS, mean (SD)
Varespladib
Varespladib (n = 2572)
Variable
VARIABLE
Variable'!'
Variable Demographic characteristics
variable_level
variables
Variables
Variables*
variables.
Variables3
VAS (0-100)
Vascular
Vascular access site†
Vascular accidents, n (%)
Vascular death
Vascular disease
Vascular disease (% of group)
Vascular Disease Indicator    No (n=6650)
Vascular disordersb
Vascular history, %
Vascular intervention
Vascular risk score — no. {%)^
Vascular risk score |
Vascular risk score*
Vascular territory #1
Vascular territory #2
Vasodilator
Vasodilator therapy
Vasoprotectives
VASP PRI-defined HPR (% patients)
vdHmTSS
VDZ n = \99
VDZ n = 394
VDZ n = 99
VDZ/PBO [n = 135]
VDZ/PBO [n = 18]
VDZ/PLA n = 36
VDZ/PLA n = 77
VDZ/VDZ [n = 269]
VDZ/VDZ [n = 39]
Vedolizumab
Vedolizumab Cohort 1 (n = 130)
Vedolizumab Cohort 1 (n = 82)
Vedolizumab Cohort 2 (n = 222)
Vedolizumab Cohort 2 (n = 258)
Vedolizumab n = 130
Vedolizumab n = 160
Vedolizumab n = 225
Vedolizumab n = 269
Vedolizumab n = 429
Vedolizumab n = 95
VEGFR (ng/ml)
Vein bypass graft stented
Vein bypass stented
Vein graft stented
Venous
Venous graft
Venous insufficiency
Ventricular tachyarrhythmias
Ventricular tachycardia or fibrillation
vents/patients
Verapamil-SR (« = 11 094)
Verapamil-SR strategy
Verapamil (n, %)
Verapamil SR
Verapamil SR (No.=3169)
Verapamil SR n=3169
Verapamil SR strategy (n = 2,922)
VerifyNow PRU-defined HPR (% patients)
versus olodaterol 5 pg
versus tiotropium 2.5 pg
versus tiotropium 5 pg
versus tiotropium 5 pg Tiotropium + olodaterol 2-5/5 pg
versus tiotropium 5 pg Tiotropium + olodaterol 2.5/5 pg
versus tiotropium+olodaterol 2.5/5 pg
Vertebral fracture and/or T score -2.0
Vertebral fracture and/or T score S -2.5
Vertebral fractures at baseline
Vertebrobasilar infarct
Very elderly patients (n - 2098)
Very g ood/ ex cellent
Very good or excellent
Very high
Very high (> 3xULN) n = 197
Very high risk
very high vs. normal
very high vs. normalb
Very severe
Very severe (GOLD 4)
Very severe (ITT) (n=334)
Very severe (ITT) (n=339)
Very severe (ITT) (n=341)
Very severe (ITT) (n=342)
Very severe (ITT) (n=447)
Very severe (ITT) (n=457)
Very severe COPD
Very severe n Z 903
Very severe, GOLD 4
Vessel size, mean (SD), mm
Vessel treated, n
VHD
VHD Event Rate/Year (n)
VI -18% (-72%, 19%)
VI -35% (-185%, 3%)
VI –7% (95% CI –35–15%)
VI    12% (-10%, 30%)
VI 1% (95% CI –13–14%)
VI 16% (95% CI 5–25%)
VI 19% (95% CI –9–40%)
VI 25 µg
VI 25 mg (n = 818)
VI 26% (-29%, 58%)
Viidagliptin 100 mg daily + glimepiride
Vilanterol, n=4118
Vildagliptin
Vildagliptin (n=137)
Vildagliptin (n=139)
Vildagliptin + metformin (VLDM)
vildagliptin 100 mg daily
Vildagliptin 100 mg daily
Vildagliptin 50 mg bid
Vildagliptin 50 mg bid N = 146
Vildagliptin 50 mg daily + glimepiride
Vildagliptin 50 mg qd
Vildagliptin 50 mg qd N = 148
Visit
Visit 1 blood pressures:
Visit 2 blood pressures:
Visit 2 DBP, mm Hg
Visit 2 LDL cholesterol strata
Visit 2 SBP, mm Hg
Vital signs, mean (SD)
Vitality
Vitamin C
Vitamin D§
Vitamin E
Vitamin K antagonist
Vitamin K antagonist (e.g. warfarin/coumarol)
Vitamin K antagonist experienced, n (%)
Vitamin K antagonist experiencedk (n=21 104)
Vitamin K antagonist naive
Vitamin K antagonists
Vitamins
VKA
VKA (n = 215)
VKA (n = 287)
VKA (n = 502)
VKA at randomization
VKA at Randomization
VKA experienced
VKA Experienced
VKA naive
VKA Naive
VKA naive, n (%)
VKA Naxve
VKA therapy
VKA, only reason
VLDL
VLDL-C
VLDL cholesterol
VLDM n = 2501
VLDM n = 422
VLDM n = 643
VLDM n = 681
VLDM n = 755
Voided volume, mL
Voiding subscore
Volume change, mm^
Volume depletion-related AEs
Volumetric BMD by QCT
Voluntary
Vomiting
Vonoprazan 10 mg n = 278
Vonoprazan 20 mg n = 271
Vora
Vorapaxar
Vorapaxar    Placebo 3-Yr. KM% rate
Vorapaxar (n = 10.080)
Vorapaxar (N = 13,225)
Vorapaxar (n = 7,223)
Vorapaxar (N=10 080)
Vorapaxar (N=2435)
Vorapaxar (N=6473 )
Vorapaxar 3-y
Vorapaxar Event Rate (n=1809), %
Vorapaxar Event Rate (n=6648), %
Vorapaxar group (n=8898)
Vorapaxar N=2255
Vorapaxar N=6203
Vorapaxar No. (3-y KM%)
Vorapaxar Placebo
Vorapaxar Placebo 3-yr%
Vorapaxar Placebo 3-yr. KM%
Vorapaxar(n=1892)
Vorapaxar(n=1892), n (%)
vs. Placebo
vs. Warfarin
VTE at day 28+
VTE/VTE-related deathsa, n/N (%)
VTE/VTE-related deathsb, n/N (%)
W
W    Event (rate)
W eight ( k g)
W est Europe
W Europe
W hite
W. Europe
Wafarin
Wafarin Event Incidence/N
Waist-hip ratio
Waist-to-hip ratio
Waist-to-hip, female
Waist-to-hip, male
Waist (cm)
Waist circumference
Waist circumference — cm
Waist circumference — cmj
Waist circumference (cm)
Waist Circumference (cm): mean ± SD
Waist circumference S102 (men) or >88 cm (women)
Waist circumference women: > 35 in (88 cm) men: > 40 in (102 cm) TC 2c 150 mg/dL
Waist circumference, (cm)
Waist circumference, cm
Waist circumference, cm (SD)
Waist circumference, cm mean (SD)
Waist circumference, cm, mean (SD)
Waist circumference, mean (SD), cm
Waist circumference, mean (SD), in
Waist circumference.
Waist/Hip < Median
Waist:hip ratio
Waisthip ratio
WaisVHip >= Median
Walk for exercise
Walk for exercise (%)
Walking
WAP4C (ng/ml)
War
WAR
Warf
Warfarin
Warfarin % (n/N)
Warfarin (%)
Warfarin (n - 5,594)
Warfarin (N = 1266)
Warfarin (N = 1426)
Warfarin (N = 1669)
Warfarin (n = 184)
Warfarin (N = 2453)
Warfarin (N = 4122)
Warfarin (N = 7036)
Warfarin (N=1558)
Warfarin (n=1685)
Warfarin (n=199)
Warfarin (n=263)
Warfarin (n=407)
Warfarin (n=6022)
Warfarin (n=670)
Warfarin (n=7023)
Warfarin (n=7036), n (%/y)
Warfarin (n=756)
Warfarin (S5% Cl)
Warfarin at enrollment
Warfarin at last follow-up
Warfarin Events/n (%/y)
Warfarin group
Warfarin Group
Warfarin Group (n = 244)
Warfarin Group (N=255)
Warfarin N = 3584
Warfarin N = 3584 n/N (%)
Warfarin N = 538
Warfarin N = 538 n/N (%)
"Warfarin n/N; rate (%)"
Warfarin n=2326
Warfarin n=3696
Warfarin, No. (%)
WC (cm)
We recorded no significant interactions for any subgroup analysis. NYHA= New York Heart Association. LVEF=left ventricular ejection fraction. '95% Cl was calculated by Cox proportional hazards model. tMedian value. Data for total cholesterol were available for 4537 patients (2266 rosuvastatin, 2271 placebo).
We recorded no significant interactions for any subgroup analysis. PUFA=polyunsaturated fatty acids. NYHA=New York Heart Association. LVEF=left ventricular ejection fraction. *95% Cl was calculated with a Cox proportional hazards model. tMedian value. Data for total cholesterol were available for 6918 patients (3467 n-3 PUFA, 3451 placebo).
Week
Week-30 changea
Week 0
Week 0 — mg/liter
Week 0 CZP 200 mg Q2W
Week 0 CZP 200 mg Q2W (N=138)
Week 0 CZP 400 mg Q4W
Week 0 CZP 400 mg Q4W (N=135)
Week 0 CZP Dose Combined
Week 0 CZP dose combined (N = 273)
Week 0 Mayo endoscopy subscorea
Week 0 Mean±SEM
Week 104
Week 108
Week 12
Week 12 - Baseline
Week 12 — mg/liter^
Week 12 FPG, mean (s.e.)
Week 12 HbA1c, mean (s.e.)
Week 12 Mean+SEM
Week 12 outcome
Week 12 Outcomes
Week 12 Overall population
Week 12 Responders, (n = 45)
Week 13
Week 14
Week 148
Week 16
Week 16 (before EE)
Week 16 (ITT Population)
Week 164
Week 18 mean 士 SD
Week 196
Week 2 CRP
Week 216
Week 24
Week 24 (non-EE responders)
Week 24 mean (SD)
Week 24 mean (SE)
Week 24 Overall population
Week 256
Week 26
Week 26 % of patients
Week 26 (geometric mean, CV)
week 26 (mean, SD)
Week 26 (mean, SD)
Week 26 (mmol/L)
Week 26 ertugliflozin 15 mg vs placebo
Week 26 ertugliflozin 15 mg vs. placebo
Week 26 ertugliflozin 5 mg vs placebo
Week 26 ertugliflozin 5 mg vs. placebo
"Week 26, % (n)"""""
Week 26, % (n)#
Week 26, % (n)# OR for CANA vs PBO (95% CI)||
Week 26, % (n)**
Week 26, % (n)^
Week 26, % (n)|| OR for CANA vs PBO (95% CI)§
Week 26, % (n)§
Week 26, % (n)1
Week 26, % (n)1 OR for CANA vs PBO (95% CI)||
Week 26, % (n)J
Week 28
Week 3
Week 30
Week 36
Week 4
Week 4 CRP
Week 44
Week 48
Week 48*
Week 48*’’
Week 52
Week 52/ET
Week 52a
Week 56
Week 56 % of patients
Week 6
Week 6 Responders, (n = 172)
Week 6 Responders, (n = 195)
Week 60
Week 78
Week 8
Week 8 CRP
Week 96
Week and
Week o (baseline) mean 士 SD
Week 26
Weekly
Weekly ISS{
Weekly ISS6
Weekly number of hives score{
Weekly number of hives score6
Weekly size of largest hives score{
WeekO Mean+SEM
Weeks
Weeks_measured
Weight
Weight— kg
Weight—kg (median)
Weight - kg
Weight - kg, Median (IQR)
Weight — kg
Weight — kg Cardiovascular history — no. (%)
Weight — no. (%)
Weight #60 kg
Weight $70.0 kg, <82.0 kg, N
Weight $82.0 kg, N
Weight (kg )
Weight (kg)
Weight (kg) (mean ± SD)
Weight (kg) BMI (kg/m2)
Weight (kg)*
Weight (kg), mean (s.d.)
Weight (kg), mean (s.e.)
Weight (kg), mean (SD)
Weight (kg), mean ± SD
Weight (kg), mean±SD
Weight (kg), Mean±SD
Weight (kg), median (IQR)
Weight (kg), median (m/n, max)
Weight (kg)十
Weight (kg)a
Weight (kg/m2) [median (25th to 75th percentile)]
Weight (kg}, median (min, max}
Weight (median [IQR]), kg
Weight (range) (kg)
Weight [kg]
Weight < 60 kg
Weight < 70.0 kg, N
Weight <60 kg
Weight <60 kg, n (%)
Weight 一kg
Weight > 60 kg
Weight > 80 kg, n(%)
WEIGHT 100+
WEIGHT 50-99
Weight Ab,%
WeIgHt Ab,%
Weight at baseline
Weight at randomization (kg)
Weight category
Weight group, no. (%)
"Weight in kg (baseline: mean (SD) [n]; wk 48 and change: mean (SE) [n])"
Weight in kg, mean (SD)
Weight in kg, median (IQR)
Weight of < 60 kg, n (%)
Weight, kg
Weight, kg (mean ± s.d.)
Weight, kg (mean 6 SD)
Weight, kg Blood pressure, mm Hg
Weight, kg Duration of PAH, n (%)
Weight, kg Mean (SD)
Weight, kg*
Weight, kg, mean (SD)
Weight, kg, mean ± SD
Weight, kg, median (25th, 75th)
Weight, kg, median (range)
Weight, kg: mean (SD)
Weight, kg1
Weight, lbs
Weight, mean (SD) (kg)
Weight, mean (SD) kg
Weight, mean (sd) lbs.
Weight, mean (SD), kg
Weight, mean (SD), kgb
Weight, mean ± SD kg
Weight, mean 6 SD kg
Weight, median (25th—75th percentiles), kg
Weight, median (interquartile range), kg
Weight, median (IQR), kg
Weight, median (SD), kg
Weight,mean(SD),kg
"Weight; mean ± SD (kg)"
"Weight^;"
WEIGHT<50
West Europe
Western
Western Europe
Western Europe (%)
Western Europe (including South Africa)
Western Europe (n = 1,908)
Western Europe / Australia
Western Europe and Australia
Western Europe and Israel
Western Europe and Lebanon
Western Europe and other
Western Europe and Other
Western Europe HR (95% Cl)
Western Europe plus other
Western Europe, Australia, New Zealand
Western Europe, Australia, New Zealand, and Middle East
Western Europe, Australia, New Zealand, Middle Eai
Western Europe, Australia, New Zealand, Middle East
Western Europe, Israel, Australia, or South Africa
Western Europe/Australia
Western Europe/Australia/Israel
Western European includinq Australia, Israel, and South Africa
Western friroce
While
While ethnic origin
White
White-cell count — x10_9/liter
White (84.4%)
White (n — 350)
White (n = 1328)
White (N = 1328)
White (n = 444)
White (n = 5,006)
White (n=1538)
White (n=6,660)
White (n=6660)
White blood cell count, cellsx103
White ethnic origin
White ethnicity
White Hispanic
White Hispanic - n (%)
White MTX (n)
White non-Hispanic
White Non-Hispanic
White non-Hispanic - n (%)
White not of Hispanic origin
White or Caucasian, n (%)
White race
White race—number (%)
White race — no. (%):
White race — no. (%):t
White race — no. (%)f
White race — no. (%)y Left ventricular ejection fraction — %
White race — no. {%)'i'
White race — no. {%)-i-
White race — no. {%)$
White race — no. {%)t
White race — no./total no. (%)$
White race — no./total no. (%)f
White race (n=21 104)
White race, %
White race, n (%)
White TCZ+MTX (n)
White, %
White, n (%)
White, n (%) Medical history, n (%)
White, n(%)
White, n/N (%)
White, No. (%)
White, non-Hispanic
White/Caucasian
White/European
White/other
Whitea
Whiteb
WHO FC II symptoms at baseline
WHO FC II symptoms at baseline1
WHO FC II symptoms at baselinef
WHO FC III symptoms at baseline
WHO functional class
WHO functional class — no. (%):c
WHO functional class II/III
WHO/IDF IFG
WHO/IDF Impaired Fasting Glucose
Whole cohort
With (n = 457)
With ACEI/ARB
With alogliptin 12.5 mg
With alogliptin 12.5 mg (n 5 203)
With alogliptin 25 mg
With alogliptin 25 mg (n 5 198)
With an SFUa
With antiplatelets
With any stent
With Aspirin (n = 1,970)
With baseline CRP level of>10 mg/liter
With baseline vertebral fracture
With Beta Blocker
With cerebrovascular disease
With CKD (4060)
With CKD intensive (N = 1836)
With CKD standard (N = 1800)
With concomitant ICS
With corticosteroid treatment < 20
With corticosteroid treatment > 20
With DES
With diabetes
With DM
With DM (N Proactive Intervention (n = 324a)
With Dyspnoea
with events (%)
with higher classes indicating greater limitations on physical activity owing to
with highest BWa
with highest HbA1cc
with ICS, n (%)
with LABA, n (%) Pretreatment
With lipid-lowering agents
With long-acting j82-agonists
with lowest BWb
with lowest HbA1cd
With metabolic syndrome
With Metabolic Syndrome
With MetS
With p blockers
With placebo
With placebo (n 5 99)
With previous surgery
With Prior MI/Stroke (n=3692)
With psoriasis (n = 495)
With psoriasis (n = 52)
With psoriasis (zi = 495)
With psoriasis (zi = 52)
with rehospitalization, urgent coronary revascularization
With revascularisation
With stent
With stent^l
With T2DM N = 182
With tamsulosin
With tiotropium
With Treatment
Withdrawals, n/N(%)
Withdrew consent
within 24 h
within 48 h
within 72 h after
within 72 h after first procedure
Within last 30 d
Without (n = 14 214)
Without ACEI/ARB
Without an SFUa
Without antiplatelets
Without Aspirin (n = 7,223)
Without baseline vertebral fracture
Without Beta Blocker
Without cerebrovascular disease
Without CKD (8114)
Without concomitant ICS
Without diabetes
Without DM
Without DM (N = 8I7*)
without DVT DVT alone
Without Dyspnoea
Without Hx of HF
without hypertension at baseline to hypertension
Without insulin or insulin-modifying therapy
Without lipid-lowering agents
Without metabolic syndrome
Without Metabolic Syndrome
Without MetS
Without p blockers
Without previous surgery
Without psoriasis (n = 18,394)
Without psoriasis (n = 2786)
Without psoriasis (zi = 18,394)
Without psoriasis (zi = 2786)
Without revascularsation
Without stent
Without T2DM N = 434
Without tamsulosin
WML load at baseline MRI
WML load at follow-up MRI
WML load at follow-up MRI stratified by baseline severity of WML load
WOMAC function score
WOMAC pain score
WOMAC score
WOMAC stiffness score
Woman
Women
Women - no. (%)
Women — no. (%)
Women (%)
Women (n (%))
Women (n = 2291), n/N (%)
Women (n=1139 vs 572)
Women (n=2291)
Women (N=2476)
Women (N=2487) Events
Women (N=2925)
Women (N=3051)
Women (n=369)
Women (n=4416)
Women < 65 years
Women > 65 years
Women Ethnic origin
Women Men
"Women T"""
Women taking estrogen
Women, %
Women, <90 cm
Women, >90 cm
women, n (%)
Women, n (%)
Women, n (%) *
Women, no. (%)
Women, No. (%)
Women/men [%]
Women/men, %
Women: <50 mg/dL (<1.30 mmol/L)
"Women; QVA149-SFC"
Womens
Worldwide Black Patients
Worldwide Non-Black Patients
Worsened
Worsening angina
Worsening Angina
Worsening heart failure
WOSCOPS
Wrist
Wrist fracture
Wssng
WT, second, median
X Cr 1.094 X age
x/n
X/n*
"X?=0-0; p=0-9"
"X?=0-l;p=0-8"
"X?=l-6;p=0-2"
X13, n (%)
"X2=0-2; p=0-7"
"X2=0-5;p=0-8"
"X2=0-l;p=0-8"
"x2=08;p=0-4"
"X2=6-6; p=0-01"
X65 years
X65, n (%)
Xanthine
Xanthines
Xanthines,b n (%)
Xanthines11
Xanthinesg
"xHo;p=o-2"
Xi=°-°6
"xi=0-3;p=0-6"
Xi=0.01
Xi=0.02
Xi=0.04
Xi=0.10
Xi=0.17
Xi=0.20
Xi=0.23
Xi=0.24
Xi=0.42
Xi=0.47
Xi=1-28
Xi=1-89
Xi=106
"Xi=2-3;p=0-l"
"Xi=2-4;p=0-l"
"Xi=2-5;p=O-l"
"Xi=2-6;p=01"
Xi=2.06
Xi=2.73
"xi=3-l;p=0-08"
Xi=4.18
"xi=l’3;P=0-3"
"Xi=o-3;p=o-6"
"Xi=o-4;p=o-5"
"xi=oo;p=o-9"
Y es
Yaa
Year-1
Year-2
Year-4
Year 1
Year 2
Year 3
Year 4
Year From Randomization
Year of publication of primary results
year, n (%)
Yearl
years (mean ± SD)
years (SD)
Years duration OA
years Male gender, n (%)
years Modified Hoehn and Yahr stage, n (%)
Years of education*
Years of education, mean (SD)
Years of follow-up, mean (SD) [maximum]
Years since diagnosis
Years since diagnosis of type 2 diabetes, n (%)
Years since diagnosis, mean
Years since last gout flare
Years since menopause
Years since MI (median,
Years since myocardial infarction
Years since PAH diagnosis
Years since PD diagnosis, mean ± SD
Years since symptom onset
Years with gout
Years with Gout
Years with gout, mean ± SD
Years with gouty arthritis
years)
years, mean (SD)
Years, mean (SD)
years, n (%) Smoking, n (%) Current
Yes
Yes '
Yes (%)
Yes (%) Weight [kg] (Interaction: p=0.37)
Yes (any)
Yes (n =481)
Yes (n, %)
Yes (n=1060)
Yes (n=1135)
Yes (n=1582)
Yes (n=160)
Yes (n=167)
Yes (n=270)
Yes (N=314)
Yes (n=362)
Yes (n=756)
Yes (n=861)
Yes (n=966)
Yes (stopped for trial)
Yes Previous revascularization
Yes vs. No
Yes(N=1418)
Yes(N=1604)
Yes(n=1731)
Yes(N=3063)
Yes(N=839)
Yes*
Yes, 4 1 y
Yes, Insulin-treated
Yes, n (%)
Yes, Non-insulin-treated
Yes, o 2 cm
Yes, r 1 y
Yes, Z 2 cm
Younger patients (aged575 years)
Younger subjects (aged <55 years)
ZE + statin
Zoledronic acid
Zoledronic acid (n = 745)
Zoledronic acid arm
Zotarolimus
Zotarolimus-eluting
Zotarolimust
zt=65
Placebo-ezetimibe 10/simvastatin 20-fenofibrate 160-ezetimibe 10/simvastatin 20/ezetimibe 160
L-dopa/carbidopa-L-dopa/carbidopa/entacapone
ARB-ARB/CCB
other-candesartan
Benazepril/hydrochlorothiazide-Benazepril/amlodipine
Atenolol-losartan
Amlodipine-amlodipine/valsartan
mycophenolate mofetil-cyclophosphamide
Atorvastatin-pravastatin
Placebo-Abatacept 30/10-Abatacept 10/10
Bivalirudin-Heparin plus GPI
Olmesartan/CCB-Olmesartan/diuretic
Comparator-linagliptin
Placebo-linagliptin
Placebo-dexlansoprazole
Placebo-carisbamate 800mg-carisbamate 1200mg
Ezetimibe/simvastatin-double dose statin-rosuvastatin
Stent/abciximab-stent/placebo
Insulin lispro mix 25/Lispro mix 50-Insulin glargine/Insulin lispro
IDegLira-Ideg-Lira
Placebo-IDegLira
IDegLira-Ideg
Budesonide-budesonide/formoterol
Placebo-Vonoprazan 10-Vonoprazan 20
Fluticasone-Fluticasone/salmeterol
Febuxostat-febuxostat/lesinurad 200-febuxostat/lesinurad 400
Telmisartan/amlodipine-telmisartan/amlodipine/hydrochlorothiazide
Chlorthalidone-amlodipine-lisinopril
Placebo-Famotidine 40- Famotidine 20
Air insulin-insulin glargine-air insulin/insulin glargine
Olmesartan 40-olmesartan 40/hydrochlorothiazide 12.5
SDC 0.5-0.9 ng/ml
SDC 1.2-2.0 ng/ml
HF symptomatic improvement
HF symptom unchanged
HF symptom worsened
CV death/HF hospitalization
Vertebral fracture
Nonvertebral fracture
LDL-C <2.6 mmol/l
LDL-c
Mortality, shock or congestive heart failure within 90 days
Main ACCORD endpoint
Fatal/nonfatal MI (excluding silent MI)
Cardiovascular death or nonfatal MI (excluding silent MI)
Cardiovascular death, nonfatal MI (excluding silent MI), or stroke
Combined efficacy and safety endpoint
Mean change from baseline BP at week 4
Median change in atheroma volume, %
Nonvertebral fractures
Clinical Vertebral Fractures
Complete clinical response at week 52
Death or MI at 6 days
Death or MI at 40 days
1-year Mortality
Net adverse clinical events at day 30
ADAS-cog
CDR-SOB
ADCS-ADL
NPI
Proportion of >=50% responder rates
LDL-C concentration
Non-HDLc concentration
HDLC- concentration
Apolipoprotein A
Apolipoprotein B
Complete ulcer healing at week 12
Major amputations at week 24
Mean percentage of nights without heartburn
new or worsening vertebral fracture at 24 months
new vertebral fracture at 24 months
Seizure reduction from baseline
HDL-c
Apolipoprotein A-I
HbA1c at week 26
Primary endpoint at 30 days
Primary endpoint at 6 months
DUAL I extension - end of trial HbA1c
DUAL IV - end of trial HbA1c
DUAL II - end of trial HbA1c
HbA1c at week 24
Proportion of days without heartburn at week 2, percentage
First severe asthma exacerbation
Change in FEV1 at week 16
Serum UA <5mg/dl by month 6
Control of sitting BP at week 8
Rate of atrial fibrillation
Combined 6-year CVD
Percentage of days without heartburn
HbA1c at week 52
BP goal at week 8
Previous use of digoxin
Cardiothoracic ratio
Retinal severity change
Serum uric acid, mg/dl
Concomitant statin use
Study protocol
Concomitant MAO-B inhibitor use
CKD at baseline
CVD, CKD
ACEi use
Beta blocker use
Nitrate use
Sirolimus eluting stent
Vessel disease
Kilip Class
Time to randomisation from symptom onset (h)
Time from symptoms onset to 1st balloon inflation (h)
Time from randomisation to 1st balloon inflation (h)
First medical contact
Stent placement
Previous MI and T2DM
Baseline peripheral artery disease
Fibrinolytic agent given
Shock risk indext
Aetiology
Baseline 6-min walk distance m
Baseline WHO functional class
Age at baseline years
Diabetes and untreated hypertension
Clinically evident vascular disease
Ethnicity, location
Alcohol intake, drinks/week
History of statin use
Low-density lipoprotein, mg/dl
High-density lipoprotein, mg/dl
Baseline BMD T score at femoral neck
Prior treatment status
Inclusion diagnosis
Modified Braunwald class
High-risk criterion
CADILLAC Score
Arterial access site
Vessels with stenosis >50%
Stent type implanted
Heparin pre-randomization
P2Y12 inhibitor loading dos
P2Y12 inhibitor maintenance
Primary management strategy
Clinical dementia rating score
Cholinesterase inhibitor use
Apolipoprotein E carrier
Prior exposure to levetiracetam
Prior exposure to carbamazepine
Prior exposure to topiramate
Prior exposure to lamotrigine
Thienopyridine use
Intent to use GP IIb/IIIa
Intent to use DTI
Troponin or CKMB value
TIMI score
Investigator-reported hypoglycaemia
Nocturnal heartburn severity
Concurrent medication
Antiepileptic drug type at baseline
Cardiogenic shock
Type of MI
Target vessel diameter
Onset of chest pain
Received PCI
ACEi or ARB pre-randomisation
ACEi or ARB post-randomisation
BB after randomisation
ACEi/ARB and BB after randomisation
Pulsed blood pressure
Admission CrCl
Admission K, mmol/l
Randomisation
NERD Grade
Asthma control
Eosinophil count (cells/microlitre)
Baseline uric acid
Disease stage
Disease severity
Hispanic or latino
Chronic heart failure class II-III
Prior MI/Stroke
Cardiovascular status
eGFR, ml/min (MDRD)
Diabetic retinopathy at baseline
Type of reflux disease
Number of symptom days per week
Cardiac surgery type
Baseline eGFR
Hiatus hernia
H. pylori infection
Hypertension severity
0.25-0.45
<0.25
<0.55
>0.55
<50
50-59
60-69
70-79
>80
<65 y
>= 65y
<2
2-3
>3 or incident vitrectomy or photocoagulation
>9.5
<9.5
Stage 1(Cockcroft-Gault)
Stage 2(Cockcroft-Gault)
Stage 3(Cockcroft-Gault)
Stage 4(Cockcroft-Gault)
Stage 1(four-variable modification of diet in kidney disease)
Stage 2(four-variable modification of diet in kidney disease)
Stage 3(four-variable modification of diet in kidney disease)
Stage 4(four-variable modification of diet in kidney disease)
< 75
> 75
< 25
25 to < 30
> 30
< 60
> 60
Western EU, Australia, New Zealand
Eastern EU
< -2.5
> -2.5
Atorvastatin 10mg
Atorvastatin 20mg
803
804
>27.2 kg/m2
<65
>65
<75
>=75
>=2
Yes, Yes
Yes, No
No, Yes
No, No
<=75
>75
II-III
0-2
>2-4
>4
<=4
<=2
>2
PCI-hospital
Non-PCI hospital/ambulance
Non-European
>70
>135 mm Hg
<80.3 mm Hg
>80.3 mm Hg
<7.3%
>7.3%
<83.79 ml/min/1.73 m2
>83.79 ml/min/1.73 m2
<4
<60
<6
6 to <13
13-24
<120
120-139
140-159
>160
<70
70-89
90-109
>110
IPAH/FPAH/drug and toxin
Repaired congenital shunt
<380
>380
III/IV
60
>60
Black, worldwide
Non-black, worldwide
Black, US
Non-black, US
0
1-7
>8
<55
>=55
>=median
Past or nonsmoker
>30
<30
>-2.0
>-2.5 to <-2.0
<-2.5
Naïve
Recent
Inadequate
>=71
<76
>=76
<26
>=26
Current non-smoker
Non-Q-wave Ml
No rest angina
Rest angina
No antianginal drug
1 antianginal drug
32 antianginal drugs
Intermediate risk
Single vessel disease
At least one drug-eluting stent
All bare metal stents
Prasugrel or ticagrelor
Non-LAD
PCI Procedure
Non PCI Procedure
Non Europe
0.5
1
2
65-74
75-84
>75years
< 60 kg
> 60 kg
<60 CrCl
3-4
5-7
< 65
> 65
< 15%
> 15%
<Mild
Mild-<Moderate
Moderate-<severe
Severe-very severe
<53
>53
<90.8
>90.8
<95mmHg
>95mmHg
Enzyme inducing
Non-enzyme inducing
>=9.0
<=65
>2.5mm
<=2.5mm
<6h
>=6h
>=65
<45
>=45
<40
>=40
<=60 ml/min
>=4
Pre-hospital
In-hospital
<=25
>25
<=8%
12-17
18-64
<8%
>8%
Russia/Ukraine/Belarus
Poor, tried previous glucocorticoid/non-LABA
Poor, tried previous glucocorticoid+LABA
Good, tried previous glucocorticoid+LABA
Good, tried previous glucocorticoid
>64
<100
>=100
<200
>=200
<300
>=300
<400
>=400
>=5mg/dl
Advanced
1.5
2.5
3
>6
<=8.5%
>8.5%
<=10
>10
Established disease
Risk factors only
Pre-mixed insulin
"Yes; Proliferative"
"Yes; Non-proliferative"
"Yes; Unknown"
Unknown/Missing
Erosive reflux disease
Gastrooesophageal reflux disease
0-1
>1,<=2
Non-CABG or combined
>90
60-89
>40
< 18.5
18.5-25.0
>25.0
< 3
3-6
<7%
<6.5%
tx
tx2
tx3
type
Amlodipione-chlorthalidone
Lisinopril-chlorthalidone
famotidine 20-famotidine 40
Placebo-famotidine 20
Placebo-famotidine 40
air insulin-air insulin/insulin glargine
Air insulin-air insulin/insulin glargine
insulin glargine-air insulin/insulin glargine
Placebo-Vonoprazan 10
Placebo-Vonoprazan 20
Febuxostat-febuxostat/lesinurad 200
Febuxostat-febuxostat/lesinurad 400
P-value2
OR_value
OR2
OR2_value
P-value3
